1	Data	N	O
2	from	N	O
3	experimental	N	O
4	studies	N	O
5	suggest	N	O
6	that	N	O
7	octreotide	N	I-MajorClaim
8	,	N	I-MajorClaim
9	the	N	I-MajorClaim
10	long	N	I-MajorClaim
11	acting	N	I-MajorClaim
12	somatostatin	N	I-MajorClaim
13	analogue	N	I-MajorClaim
14	,	N	I-MajorClaim
15	improves	N	I-MajorClaim
16	survival	N	I-MajorClaim
17	of	N	I-MajorClaim
18	animals	N	I-MajorClaim
19	with	N	I-MajorClaim
20	pancreatic	N	I-MajorClaim
21	cancer	N	I-MajorClaim
22	.	N	I-MajorClaim

23	To	N	O
24	assess	N	O
25	the	N	O
26	antitumour	N	O
27	effect	N	O
28	of	N	O
29	octreotide	N	O
30	,	N	O
31	a	N	O
32	randomized	N	O
33	trial	N	O
34	was	N	O
35	performed	N	O
36	comparing	N	O
37	octreotide	N	O
38	with	N	O
39	supportive	N	O
40	care	N	O
41	in	N	O
42	advanced	N	O
43	pancreatic	N	O
44	cancer	N	O
45	patients	N	O
46	.	N	O

47	All	N	O
48	patients	N	O
49	,	N	O
50	aged	N	O
51	59-75	N	O
52	years	N	O
53	,	N	O
54	were	N	O
55	not	N	O
56	liable	N	O
57	to	N	O
58	radical	N	O
59	surgical	N	O
60	treatment	N	O
61	and	N	O
62	were	N	O
63	not	N	O
64	submitted	N	O
65	to	N	O
66	other	N	O
67	treatments	N	O
68	(	N	O
69	chemo	N	O
70	and/or	N	O
71	radiotherapy	N	O
72	)	N	O
73	.	N	O

74	Six	N	O
75	patients	N	O
76	were	N	O
77	enrolled	N	O
78	,	N	O
79	4	N	O
80	of	N	O
81	these	N	O
82	treated	N	O
83	with	N	O
84	octreotide	N	O
85	(	N	O
86	500	N	O
87	micrograms	N	O
88	two	N	O
89	times	N	O
90	a	N	O
91	day	N	O
92	subcutaneous	N	O
93	for	N	O
94	six	N	O
95	months	N	O
96	)	N	O
97	and	N	O
98	the	N	O
99	other	N	O
100	2	N	O
101	were	N	O
102	inserted	N	O
103	a	N	O
104	control	N	O
105	group	N	O
106	.	N	O

107	The	N	I-Premise
108	patients	N	I-Premise
109	treated	N	I-Premise
110	with	N	I-Premise
111	octreotide	N	I-Premise
112	showed	N	I-Premise
113	a	N	I-Premise
114	significant	N	I-Premise
115	advantage	N	I-Premise
116	in	N	I-Premise
117	quality	N	I-Premise
118	of	N	I-Premise
119	life	N	I-Premise
120	(	N	I-Premise
121	restored	N	I-Premise
122	appetite	N	I-Premise
123	,	N	I-Premise
124	improvement	N	I-Premise
125	of	N	I-Premise
126	digestion	N	I-Premise
127	and	N	I-Premise
128	intestine	N	I-Premise
129	function	N	I-Premise
130	,	N	I-Premise
131	remission	N	I-Premise
132	of	N	I-Premise
133	abdominal	N	I-Premise
134	pain	N	I-Premise
135	and	N	I-Premise
136	preservation	N	I-Premise
137	of	N	I-Premise
138	baseline	N	I-Premise
139	body	N	I-Premise
140	weight	N	I-Premise
141	)	N	I-Premise
142	with	N	I-Premise
143	a	N	I-Premise
144	mean	N	I-Premise
145	>	N	I-Premise
146	80	N	I-Premise
147	of	N	I-Premise
148	karnofsky	N	I-Premise
149	performance	N	I-Premise
150	score	N	I-Premise
151	.	N	I-Premise

152	Monitoring	N	I-Premise
153	of	N	I-Premise
154	tumour	N	I-Premise
155	size	N	I-Premise
156	changes	N	I-Premise
157	(	N	I-Premise
158	US-TC	N	I-Premise
159	)	N	I-Premise
160	over	N	I-Premise
161	the	N	I-Premise
162	6	N	I-Premise
163	months	N	I-Premise
164	study	N	I-Premise
165	period	N	I-Premise
166	,	N	I-Premise
167	showed	N	I-Premise
168	slackened	N	I-Premise
169	neoplastic	N	I-Premise
170	growth	N	I-Premise
171	in	N	I-Premise
172	all	N	I-Premise
173	treated	N	I-Premise
174	patients	N	I-Premise
175	,	N	I-Premise
176	whereas	N	I-Premise
177	neoplasm	N	I-Premise
178	grew	N	I-Premise
179	according	N	I-Premise
180	to	N	I-Premise
181	an	N	I-Premise
182	almost	N	I-Premise
183	exponential	N	I-Premise
184	trend	N	I-Premise
185	in	N	I-Premise
186	untreated	N	I-Premise
187	patients	N	I-Premise
188	.	N	O

189	Also	N	O
190	survival	N	I-Premise
191	was	N	I-Premise
192	better	N	I-Premise
193	in	N	I-Premise
194	treated	N	I-Premise
195	patients	N	I-Premise
196	:	N	O
197	in	N	O
198	particular	N	O
199	,	N	O
200	2	N	O
201	patients	N	O
202	out	N	O
203	of	N	O
204	4	N	O
205	who	N	O
206	completed	N	O
207	the	N	O
208	study	N	O
209	underwent	N	O
210	follow-up	N	O
211	until	N	O
212	they	N	O
213	died	N	O
214	12	N	O
215	and	N	O
216	16	N	O
217	months	N	O
218	after	N	O
219	beginning	N	O
220	of	N	O
221	treatment	N	O
222	,	N	O
223	respectively	N	O
224	.	N	O

225	Karnofsky	N	I-Premise
226	performance	N	I-Premise
227	score	N	I-Premise
228	was	N	I-Premise
229	particularly	N	I-Premise
230	high	N	I-Premise
231	in	N	I-Premise
232	both	N	I-Premise
233	patients	N	I-Premise
234	.	N	I-Premise

235	This	N	O
236	supports	N	O
237	the	N	O
238	view	N	O
239	that	N	O
240	octreotide	N	I-Claim
241	is	N	I-Claim
242	endowed	N	I-Claim
243	with	N	I-Claim
244	antiproliferative	N	I-Claim
245	activity	N	I-Claim
246	.	N	I-Claim

247	In	N	O
248	conclusion	N	O
249	octreotide	N	I-Claim
250	therapy	N	I-Claim
251	seems	N	I-Claim
252	to	N	I-Claim
253	confer	N	I-Claim
254	a	N	I-Claim
255	survival	N	I-Claim
256	benefit	N	I-Claim
257	and	N	I-Claim
258	a	N	I-Claim
259	better	N	I-Claim
260	quality	N	I-Claim
261	of	N	I-Claim
262	life	N	I-Claim
263	in	N	I-Claim
264	advanced	N	I-Claim
265	pancreatic	N	I-Claim
266	tumour	N	I-Claim
267	.	N	I-Claim

268	Additional	N	O
269	studies	N	O
270	are	N	O
271	needed	N	O
272	to	N	O
273	confirm	N	O
274	these	N	O
275	results	N	O
276	and	N	O
277	to	N	O
278	clarify	N	O
279	other	N	O
280	questions	N	O
281	about	N	O
282	dose	N	O
283	and	N	O
284	somatostatin	N	O
285	receptors	N	O
286	in	N	O
287	this	N	O
288	kind	N	O
289	of	N	O
290	tumour	N	O
291	.	N	O

1	In	N	O
2	a	N	O
3	prospective	N	O
4	randomized	N	O
5	study	N	O
6	,	N	O
7	287	N	O
8	patients	N	O
9	with	N	O
10	advanced	N	O
11	non-small	N	O
12	cell	N	O
13	lung	N	O
14	cancer	N	O
15	(	N	O
16	NSCLC	N	O
17	)	N	O
18	stage	N	O
19	IIIb	N	O
20	or	N	O
21	IV	N	O
22	with	N	O
23	ECOG	N	O
24	performance	N	O
25	status	N	O
26	(	N	O
27	PS	N	O
28	)	N	O
29	0-1	N	O
30	or	N	O
31	2	N	O
32	were	N	O
33	randomly	N	O
34	assigned	N	O
35	to	N	O
36	receive	N	O
37	either	N	O
38	best	N	O
39	supportive	N	O
40	care	N	O
41	(	N	O
42	BSC	N	O
43	)	N	O
44	or	N	O
45	supportive	N	O
46	care	N	O
47	plus	N	O
48	combination	N	O
49	chemotherapy	N	O
50	(	N	O
51	IEP	N	O
52	regimen	N	O
53	:	N	O
54	ifosfamide	N	O
55	3	N	O
56	gm/m2	N	O
57	IV	N	O
58	with	N	O
59	mesna	N	O
60	uroprotection	N	O
61	,	N	O
62	epirubicin	N	O
63	60	N	O
64	mg/m2	N	O
65	IV	N	O
66	on	N	O
67	day	N	O
68	1	N	O
69	and	N	O
70	cisplatin	N	O
71	60	N	O
72	mg/m2	N	O
73	IV	N	O
74	on	N	O
75	day	N	O
76	2	N	O
77	;	N	O
78	or	N	O
79	MVP	N	O
80	regimen	N	O
81	:	N	O
82	mitomycin-C	N	O
83	8	N	O
84	mg/m2	N	O
85	,	N	O
86	cisplatin	N	O
87	100	N	O
88	mg/m2	N	O
89	IV	N	O
90	on	N	O
91	day	N	O
92	1	N	O
93	,	N	O
94	vinblastine	N	O
95	4	N	O
96	mg/m2	N	O
97	IV	N	O
98	on	N	O
99	days	N	O
100	1	N	O
101	and	N	O
102	15	N	O
103	)	N	O
104	.	N	O

105	Serial	N	O
106	assessment	N	O
107	of	N	O
108	Karnofsky	N	O
109	performance	N	O
110	status	N	O
111	(	N	O
112	KPS	N	O
113	)	N	O
114	,	N	O
115	modified	N	O
116	Functional	N	O
117	Living	N	O
118	Index-Cancer	N	O
119	(	N	O
120	T-FLIC	N	O
121	)	N	O
122	and	N	O
123	modified	N	O
124	Quality	N	O
125	of	N	O
126	Life-Index	N	O
127	(	N	O
128	T-QLI	N	O
129	)	N	O
130	were	N	O
131	used	N	O
132	to	N	O
133	estimate	N	O
134	the	N	O
135	quality	N	O
136	of	N	O
137	life	N	O
138	.	N	O

139	Interviews	N	O
140	were	N	O
141	done	N	O
142	at	N	O
143	entry	N	O
144	,	N	O
145	at	N	O
146	the	N	O
147	third	N	O
148	month	N	O
149	and	N	O
150	at	N	O
151	2	N	O
152	months	N	O
153	post	N	O
154	complete	N	O
155	treatment	N	O
156	.	N	O

157	At	N	O
158	least	N	O
159	two	N	O
160	courses	N	O
161	of	N	O
162	chemotherapy	N	O
163	were	N	O
164	considered	N	O
165	to	N	O
166	be	N	O
167	adequate	N	O
168	for	N	O
169	response	N	O
170	evaluation	N	O
171	.	N	O

172	Patients	N	O
173	were	N	O
174	treated	N	O
175	for	N	O
176	a	N	O
177	total	N	O
178	of	N	O
179	four	N	O
180	to	N	O
181	six	N	O
182	courses	N	O
183	or	N	O
184	until	N	O
185	progression	N	O
186	of	N	O
187	disease	N	O
188	.	N	O

189	Partial	N	I-Premise
190	response	N	I-Premise
191	rates	N	I-Premise
192	were	N	I-Premise
193	40	N	I-Premise
194	and	N	I-Premise
195	41.7	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	IEP	N	I-Premise
199	and	N	I-Premise
200	MVP	N	I-Premise
201	arms	N	I-Premise
202	.	N	I-Premise

203	Median	N	I-Premise
204	survival	N	I-Premise
205	durations	N	I-Premise
206	were	N	I-Premise
207	5.9	N	I-Premise
208	and	N	I-Premise
209	8.1	N	I-Premise
210	months	N	I-Premise
211	for	N	I-Premise
212	the	N	I-Premise
213	IEP	N	I-Premise
214	and	N	I-Premise
215	MVP	N	I-Premise
216	chemotherapy	N	I-Premise
217	arms	N	I-Premise
218	,	N	I-Premise
219	and	N	I-Premise
220	4.1	N	I-Premise
221	months	N	I-Premise
222	for	N	I-Premise
223	BSC	N	I-Premise
224	(	N	I-Premise
225	log-rank	N	I-Premise
226	test	N	I-Premise
227	:	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	0.0003	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	One	N	I-Premise
234	year	N	I-Premise
235	survival	N	I-Premise
236	was	N	I-Premise
237	13	N	I-Premise
238	,	N	I-Premise
239	29.8	N	I-Premise
240	and	N	I-Premise
241	39.3	N	I-Premise
242	%	N	I-Premise
243	for	N	I-Premise
244	the	N	I-Premise
245	BSC	N	I-Premise
246	,	N	I-Premise
247	IEP	N	I-Premise
248	and	N	I-Premise
249	MVP	N	I-Premise
250	regimens	N	I-Premise
251	,	N	I-Premise
252	respectively	N	I-Premise
253	.	N	I-Premise

254	Two	N	I-Premise
255	years	N	I-Premise
256	survival	N	I-Premise
257	was	N	I-Premise
258	7.8	N	I-Premise
259	,	N	I-Premise
260	6.4	N	I-Premise
261	and	N	I-Premise
262	13.1	N	I-Premise
263	%	N	I-Premise
264	for	N	I-Premise
265	the	N	I-Premise
266	BSC	N	I-Premise
267	,	N	I-Premise
268	IEP	N	I-Premise
269	and	N	I-Premise
270	MVP	N	I-Premise
271	regimens	N	I-Premise
272	,	N	I-Premise
273	respectively	N	I-Premise
274	.	N	I-Premise

275	Improvement	N	I-Premise
276	in	N	I-Premise
277	quality	N	I-Premise
278	of	N	I-Premise
279	life	N	I-Premise
280	(	N	I-Premise
281	QOL	N	I-Premise
282	)	N	I-Premise
283	scores	N	I-Premise
284	at	N	I-Premise
285	the	N	I-Premise
286	first	N	I-Premise
287	,	N	I-Premise
288	second	N	I-Premise
289	and	N	I-Premise
290	third	N	I-Premise
291	interview	N	I-Premise
292	were	N	I-Premise
293	seen	N	I-Premise
294	in	N	I-Premise
295	chemotherapy	N	I-Premise
296	arms	N	I-Premise
297	only	N	I-Premise
298	,	N	I-Premise
299	not	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	BSC	N	I-Premise
303	arm	N	I-Premise
304	.	N	I-Premise

305	We	N	O
306	conclude	N	O
307	that	N	O
308	combination	N	I-Claim
309	chemotherapy	N	I-Claim
310	improves	N	I-Claim
311	the	N	I-Claim
312	quality	N	I-Claim
313	of	N	I-Claim
314	life	N	I-Claim
315	as	N	I-Claim
316	well	N	I-Claim
317	as	N	I-Claim
318	prolonging	N	I-Claim
319	the	N	I-Claim
320	survival	N	I-Claim
321	of	N	I-Claim
322	patients	N	I-Claim
323	with	N	I-Claim
324	advanced	N	I-Claim
325	NSCLC	N	I-Claim
326	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	safety	N	O
7	of	N	O
8	a	N	O
9	slow-release	N	O
10	formulation	N	O
11	of	N	O
12	cytarabine	N	O
13	(	N	O
14	DepoCyt	N	O
15	;	N	O
16	Chiron	N	O
17	Corp	N	O
18	,	N	O
19	Emeryville	N	O
20	,	N	O
21	CA	N	O
22	,	N	O
23	and	N	O
24	Skye	N	O
25	Pharma	N	O
26	,	N	O
27	Inc	N	O
28	,	N	O
29	San	N	O
30	Diego	N	O
31	,	N	O
32	CA	N	O
33	)	N	O
34	that	N	O
35	maintains	N	O
36	cytotoxic	N	O
37	concentrations	N	O
38	of	N	O
39	cytarabine	N	O
40	(	N	O
41	ara-C	N	O
42	)	N	O
43	in	N	O
44	the	N	O
45	CSF	N	O
46	of	N	O
47	most	N	O
48	patients	N	O
49	for	N	O
50	more	N	O
51	than	N	O
52	14	N	O
53	days	N	O
54	.	N	O

55	Twenty-eight	N	O
56	patients	N	O
57	with	N	O
58	lymphoma	N	O
59	and	N	O
60	a	N	O
61	positive	N	O
62	CSF	N	O
63	cytology	N	O
64	were	N	O
65	randomized	N	O
66	to	N	O
67	receive	N	O
68	DepoCyt	N	O
69	50	N	O
70	mg	N	O
71	once	N	O
72	every	N	O
73	2	N	O
74	weeks	N	O
75	or	N	O
76	free	N	O
77	ara-C	N	O
78	50	N	O
79	mg	N	O
80	twice	N	O
81	a	N	O
82	week	N	O
83	for	N	O
84	1	N	O
85	month	N	O
86	.	N	O

87	Patients	N	O
88	whose	N	O
89	CSF	N	O
90	cytology	N	O
91	converted	N	O
92	to	N	O
93	negative	N	O
94	and	N	O
95	who	N	O
96	did	N	O
97	not	N	O
98	have	N	O
99	neurologic	N	O
100	progression	N	O
101	received	N	O
102	an	N	O
103	additional	N	O
104	3	N	O
105	months	N	O
106	of	N	O
107	consolidation	N	O
108	therapy	N	O
109	and	N	O
110	then	N	O
111	4	N	O
112	months	N	O
113	of	N	O
114	maintenance	N	O
115	therapy	N	O
116	.	N	O

117	All	N	O
118	patients	N	O
119	received	N	O
120	dexamethasone	N	O
121	4	N	O
122	mg	N	O
123	orally	N	O
124	bid	N	O
125	on	N	O
126	days	N	O
127	1	N	O
128	through	N	O
129	5	N	O
130	of	N	O
131	each	N	O
132	2-week	N	O
133	cycle	N	O
134	.	N	O

135	The	N	I-Premise
136	response	N	I-Premise
137	rate	N	I-Premise
138	was	N	I-Premise
139	71	N	I-Premise
140	%	N	I-Premise
141	for	N	I-Premise
142	DepoCyt	N	I-Premise
143	and	N	I-Premise
144	15	N	I-Premise
145	%	N	I-Premise
146	for	N	I-Premise
147	ara-C	N	I-Premise
148	on	N	I-Premise
149	an	N	I-Premise
150	intent-to-treat	N	I-Premise
151	basis	N	I-Premise
152	(	N	I-Premise
153	P	N	I-Premise
154	=.006	N	I-Premise
155	)	N	I-Premise
156	.	N	I-Premise

157	All	N	I-Premise
158	of	N	I-Premise
159	the	N	I-Premise
160	patients	N	I-Premise
161	on	N	I-Premise
162	the	N	I-Premise
163	DepoCyt	N	I-Premise
164	arm	N	I-Premise
165	but	N	I-Premise
166	only	N	I-Premise
167	53	N	I-Premise
168	%	N	I-Premise
169	of	N	I-Premise
170	those	N	I-Premise
171	on	N	I-Premise
172	the	N	I-Premise
173	ara-C	N	I-Premise
174	arm	N	I-Premise
175	were	N	I-Premise
176	able	N	I-Premise
177	to	N	I-Premise
178	complete	N	I-Premise
179	the	N	I-Premise
180	planned	N	I-Premise
181	1-month	N	I-Premise
182	induction	N	I-Premise
183	therapy	N	I-Premise
184	regimen	N	I-Premise
185	.	N	I-Premise

186	Time	N	I-Premise
187	to	N	I-Premise
188	neurologic	N	I-Premise
189	progression	N	I-Premise
190	and	N	I-Premise
191	survival	N	I-Premise
192	trend	N	I-Premise
193	in	N	I-Premise
194	favor	N	I-Premise
195	of	N	I-Premise
196	DepoCyt	N	I-Premise
197	(	N	I-Premise
198	median	N	I-Premise
199	,	N	I-Premise
200	78.5	N	I-Premise
201	v	N	I-Premise
202	42	N	I-Premise
203	days	N	I-Premise
204	and	N	I-Premise
205	99.5	N	I-Premise
206	v	N	I-Premise
207	63	N	I-Premise
208	days	N	I-Premise
209	,	N	I-Premise
210	respectively	N	I-Premise
211	;	N	I-Premise
212	P	N	I-Premise
213	>	N	I-Premise
214	.05	N	I-Premise
215	)	N	I-Premise
216	.	N	I-Premise

217	DepoCyt	N	I-Premise
218	treatment	N	I-Premise
219	was	N	I-Premise
220	associated	N	I-Premise
221	with	N	I-Premise
222	an	N	I-Premise
223	improved	N	I-Premise
224	mean	N	I-Premise
225	change	N	I-Premise
226	in	N	I-Premise
227	Karnofsky	N	I-Premise
228	performance	N	I-Premise
229	score	N	I-Premise
230	at	N	I-Premise
231	the	N	I-Premise
232	end	N	I-Premise
233	of	N	I-Premise
234	induction	N	I-Premise
235	(	N	I-Premise
236	P	N	I-Premise
237	=.041	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	The	N	I-Premise
241	major	N	I-Premise
242	adverse	N	I-Premise
243	events	N	I-Premise
244	on	N	I-Premise
245	both	N	I-Premise
246	arms	N	I-Premise
247	were	N	I-Premise
248	headache	N	I-Premise
249	and	N	I-Premise
250	arachnoiditis	N	I-Premise
251	,	N	I-Premise
252	which	N	I-Premise
253	were	N	I-Premise
254	often	N	I-Premise
255	caused	N	I-Premise
256	by	N	I-Premise
257	the	N	I-Premise
258	underlying	N	I-Premise
259	disease	N	I-Premise
260	.	N	I-Premise

261	DepoCyt	N	I-Claim
262	injected	N	I-Claim
263	once	N	I-Claim
264	every	N	I-Claim
265	2	N	I-Claim
266	weeks	N	I-Claim
267	produced	N	I-Claim
268	a	N	I-Claim
269	high	N	I-Claim
270	response	N	I-Claim
271	rate	N	I-Claim
272	and	N	I-Claim
273	a	N	I-Claim
274	better	N	I-Claim
275	quality	N	I-Claim
276	of	N	I-Claim
277	life	N	I-Claim
278	as	N	I-Claim
279	measured	N	I-Claim
280	by	N	I-Claim
281	Karnofsky	N	I-Claim
282	score	N	I-Claim
283	relative	N	I-Claim
284	to	N	I-Claim
285	that	N	I-Claim
286	produced	N	I-Claim
287	by	N	I-Claim
288	free	N	I-Claim
289	ara-C	N	I-Claim
290	injected	N	I-Claim
291	twice	N	I-Claim
292	a	N	I-Claim
293	week	N	I-Claim
294	.	N	I-Claim

1	For	N	I-Claim
2	several	N	I-Claim
3	decades	N	I-Claim
4	,	N	I-Claim
5	both	N	I-Claim
6	preoperative	N	I-Claim
7	intra-arterial	N	I-Claim
8	chemotherapy	N	I-Claim
9	and	N	I-Claim
10	preoperative	N	I-Claim
11	irradiation	N	I-Claim
12	have	N	I-Claim
13	been	N	I-Claim
14	accepted	N	I-Claim
15	treatments	N	I-Claim
16	for	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	tumors	N	I-Claim
20	of	N	I-Claim
21	the	N	I-Claim
22	head	N	I-Claim
23	and	N	I-Claim
24	neck	N	I-Claim
25	.	N	I-Claim

26	Unfortunately	N	O
27	,	N	O
28	arguments	N	O
29	have	N	O
30	often	N	O
31	been	N	O
32	put	N	O
33	forward	N	O
34	in	N	O
35	favor	N	O
36	of	N	O
37	one	N	O
38	or	N	O
39	other	N	O
40	of	N	O
41	the	N	O
42	two	N	O
43	methods	N	O
44	,	N	O
45	but	N	O
46	without	N	O
47	the	N	O
48	performance	N	O
49	of	N	O
50	an	N	O
51	objective	N	O
52	,	N	O
53	randomized	N	O
54	investigation	N	O
55	.	N	O

56	To	N	O
57	resolve	N	O
58	this	N	O
59	situation	N	O
60	,	N	O
61	the	N	O
62	authors	N	O
63	have	N	O
64	carried	N	O
65	out	N	O
66	a	N	O
67	multicenter	N	O
68	,	N	O
69	randomized	N	O
70	prospective	N	O
71	study	N	O
72	of	N	O
73	selected	N	O
74	patients	N	O
75	with	N	O
76	a	N	O
77	view	N	O
78	to	N	O
79	deciding	N	O
80	which	N	O
81	method	N	O
82	affords	N	O
83	better	N	O
84	results	N	O
85	in	N	O
86	complex	N	O
87	tumor	N	O
88	therapy	N	O
89	from	N	O
90	the	N	O
91	aspects	N	O
92	of	N	O
93	survival	N	O
94	and	N	O
95	postoperative	N	O
96	quality	N	O
97	of	N	O
98	life	N	O
99	.	N	O

100	One	N	O
101	hundred	N	O
102	thirty-one	N	O
103	patients	N	O
104	with	N	O
105	operable	N	O
106	sublingual	N	O
107	or	N	O
108	lingual	N	O
109	squamous	N	O
110	cell	N	O
111	carcinoma	N	O
112	in	N	O
113	stages	N	O
114	T2NXM0	N	O
115	to	N	O
116	T4MXM0	N	O
117	were	N	O
118	randomized	N	O
119	into	N	O
120	2	N	O
121	groups	N	O
122	:	N	O
123	1	N	O
124	group	N	O
125	participated	N	O
126	in	N	O
127	preoperative	N	O
128	chemotherapy	N	O
129	with	N	O
130	cisplatin	N	O
131	and	N	O
132	epirubicin	N	O
133	(	N	O
134	total	N	O
135	doses	N	O
136	:	N	O
137	200	N	O
138	mg	N	O
139	cisplatin	N	O
140	,	N	O
141	120	N	O
142	mg	N	O
143	epirubicin	N	O
144	)	N	O
145	via	N	O
146	the	N	O
147	external	N	O
148	carotid	N	O
149	artery	N	O
150	,	N	O
151	whereas	N	O
152	the	N	O
153	other	N	O
154	group	N	O
155	received	N	O
156	preoperative	N	O
157	radiation	N	O
158	therapy	N	O
159	(	N	O
160	46	N	O
161	grays	N	O
162	)	N	O
163	.	N	O

164	Following	N	O
165	subsequent	N	O
166	radical	N	O
167	surgery	N	O
168	,	N	O
169	the	N	O
170	patients	N	O
171	received	N	O
172	regular	N	O
173	follow-up	N	O
174	for	N	O
175	5	N	O
176	years	N	O
177	.	N	O

178	By	N	O
179	the	N	O
180	end	N	O
181	of	N	O
182	the	N	O
183	5	N	O
184	years	N	O
185	,	N	O
186	95	N	O
187	of	N	O
188	the	N	O
189	131	N	O
190	patients	N	O
191	had	N	O
192	conformed	N	O
193	to	N	O
194	the	N	O
195	protocol	N	O
196	.	N	O

197	Of	N	O
198	those	N	O
199	95	N	O
200	,	N	O
201	47	N	O
202	had	N	O
203	received	N	O
204	preoperative	N	O
205	chemotherapy	N	O
206	and	N	O
207	48	N	O
208	preoperative	N	O
209	irradiation	N	O
210	.	N	O

211	After	N	I-Premise
212	5	N	I-Premise
213	years	N	I-Premise
214	,	N	I-Premise
215	18	N	I-Premise
216	of	N	I-Premise
217	the	N	I-Premise
218	47	N	I-Premise
219	patients	N	I-Premise
220	who	N	I-Premise
221	received	N	I-Premise
222	chemotherapy	N	I-Premise
223	and	N	I-Premise
224	15	N	I-Premise
225	of	N	I-Premise
226	the	N	I-Premise
227	48	N	I-Premise
228	patients	N	I-Premise
229	who	N	I-Premise
230	received	N	I-Premise
231	irradiation	N	I-Premise
232	were	N	I-Premise
233	still	N	I-Premise
234	alive	N	I-Premise
235	and	N	I-Premise
236	tumor	N	I-Premise
237	free	N	I-Premise
238	.	N	I-Premise

239	A	N	I-Premise
240	few	N	I-Premise
241	more	N	I-Premise
242	patients	N	I-Premise
243	had	N	I-Premise
244	died	N	I-Premise
245	of	N	I-Premise
246	recurrence	N	I-Premise
247	or	N	I-Premise
248	regional	N	I-Premise
249	metastasis	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	chemotherapy	N	I-Premise
253	group	N	I-Premise
254	(	N	I-Premise
255	23	N	I-Premise
256	patients	N	I-Premise
257	)	N	I-Premise
258	than	N	I-Premise
259	in	N	I-Premise
260	the	N	I-Premise
261	irradiation	N	I-Premise
262	group	N	I-Premise
263	(	N	I-Premise
264	20	N	I-Premise
265	patients	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	Occurrence	N	I-Premise
269	of	N	I-Premise
270	a	N	I-Premise
271	second	N	I-Premise
272	carcinoma	N	I-Premise
273	was	N	I-Premise
274	3	N	I-Premise
275	times	N	I-Premise
276	as	N	I-Premise
277	frequent	N	I-Premise
278	in	N	I-Premise
279	the	N	I-Premise
280	irradiation	N	I-Premise
281	group	N	I-Premise
282	(	N	I-Premise
283	9	N	I-Premise
284	patients	N	I-Premise
285	)	N	I-Premise
286	as	N	I-Premise
287	in	N	I-Premise
288	the	N	I-Premise
289	chemotherapy	N	I-Premise
290	group	N	I-Premise
291	(	N	I-Premise
292	3	N	I-Premise
293	patients	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	Overall	N	O
297	,	N	O
298	the	N	I-Claim
299	survival	N	I-Claim
300	rates	N	I-Claim
301	were	N	I-Claim
302	by-and-large	N	I-Claim
303	the	N	I-Claim
304	same	N	I-Claim
305	for	N	I-Claim
306	the	N	I-Claim
307	two	N	I-Claim
308	groups	N	I-Claim
309	.	N	I-Claim

310	Regarding	N	I-Claim
311	postoperative	N	I-Claim
312	quality	N	I-Claim
313	of	N	I-Claim
314	life	N	I-Claim
315	,	N	I-Claim
316	the	N	I-Claim
317	chemotherapy	N	I-Claim
318	group	N	I-Claim
319	presented	N	I-Claim
320	a	N	I-Claim
321	more	N	I-Claim
322	favorable	N	I-Claim
323	picture	N	I-Claim
324	.	N	I-Claim

325	The	N	I-Claim
326	long	N	I-Claim
327	term	N	I-Claim
328	survival	N	I-Claim
329	results	N	I-Claim
330	subsequent	N	I-Claim
331	to	N	I-Claim
332	preoperative	N	I-Claim
333	intra-arterial	N	I-Claim
334	chemotherapy	N	I-Claim
335	or	N	I-Claim
336	preoperative	N	I-Claim
337	radiotherapy	N	I-Claim
338	were	N	I-Claim
339	practically	N	I-Claim
340	the	N	I-Claim
341	same	N	I-Claim
342	.	N	I-Claim

343	Regarding	N	I-Claim
344	postoperative	N	I-Claim
345	quality	N	I-Claim
346	of	N	I-Claim
347	life	N	I-Claim
348	,	N	I-Claim
349	patients	N	I-Claim
350	who	N	I-Claim
351	underwent	N	I-Claim
352	intra-arterial	N	I-Claim
353	chemotherapy	N	I-Claim
354	appeared	N	I-Claim
355	to	N	I-Claim
356	be	N	I-Claim
357	in	N	I-Claim
358	a	N	I-Claim
359	slightly	N	I-Claim
360	more	N	I-Claim
361	favorable	N	I-Claim
362	situation	N	I-Claim
363	.	N	I-Claim

364	The	N	O
365	authors	N	O
366	consider	N	O
367	it	N	O
368	important	N	O
369	to	N	O
370	stress	N	O
371	these	N	O
372	findings	N	O
373	,	N	O
374	as	N	O
375	they	N	O
376	are	N	O
377	not	N	O
378	aware	N	O
379	of	N	O
380	a	N	O
381	similar	N	O
382	randomized	N	O
383	study	N	O
384	of	N	O
385	patients	N	O
386	with	N	O
387	tumors	N	O
388	of	N	O
389	the	N	O
390	oral	N	O
391	cavity	N	O
392	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	efficacy	N	O
7	of	N	O
8	oral	N	O
9	bexarotene	N	O
10	(	N	O
11	Targretin	N	O
12	capsules	N	O
13	;	N	O
14	Ligand	N	O
15	Pharmaceuticals	N	O
16	Incorporated	N	O
17	,	N	O
18	San	N	O
19	Diego	N	O
20	,	N	O
21	Calif	N	O
22	)	N	O
23	.	N	O

24	The	N	O
25	effects	N	O
26	of	N	O
27	2	N	O
28	randomized	N	O
29	doses	N	O
30	of	N	O
31	6.5	N	O
32	mg/m	N	O
33	(	N	O
34	2	N	O
35	)	N	O
36	per	N	O
37	day	N	O
38	(	N	O
39	with	N	O
40	crossover	N	O
41	for	N	O
42	progression	N	O
43	)	N	O
44	vs	N	O
45	650	N	O
46	mg/m	N	O
47	(	N	O
48	2	N	O
49	)	N	O
50	per	N	O
51	day	N	O
52	(	N	O
53	later	N	O
54	modified	N	O
55	to	N	O
56	300	N	O
57	mg/m	N	O
58	(	N	O
59	2	N	O
60	)	N	O
61	per	N	O
62	day	N	O
63	)	N	O
64	were	N	O
65	evaluated	N	O
66	in	N	O
67	an	N	O
68	open-label	N	O
69	,	N	O
70	multicenter	N	O
71	,	N	O
72	phase	N	O
73	2	N	O
74	and	N	O
75	3	N	O
76	study	N	O
77	conducted	N	O
78	between	N	O
79	February	N	O
80	1997	N	O
81	and	N	O
82	November	N	O
83	1998	N	O
84	.	N	O

85	Eighteen	N	O
86	international	N	O
87	cutaneous	N	O
88	T-cell	N	O
89	lymphoma	N	O
90	clinics	N	O
91	at	N	O
92	academic	N	O
93	referral	N	O
94	centers	N	O
95	.	N	O

96	Fifty-eight	N	O
97	patients	N	O
98	with	N	O
99	biopsy-proven	N	O
100	stage	N	O
101	IA	N	O
102	through	N	O
103	IIA	N	O
104	cutaneous	N	O
105	T-cell	N	O
106	lymphoma	N	O
107	that	N	O
108	was	N	O
109	refractory	N	O
110	to	N	O
111	(	N	O
112	or	N	O
113	patients	N	O
114	were	N	O
115	intolerant	N	O
116	of	N	O
117	)	N	O
118	treatment	N	O
119	or	N	O
120	had	N	O
121	reached	N	O
122	at	N	O
123	least	N	O
124	a	N	O
125	6-month	N	O
126	response	N	O
127	plateau	N	O
128	under	N	O
129	at	N	O
130	least	N	O
131	2	N	O
132	forms	N	O
133	of	N	O
134	prior	N	O
135	therapy	N	O
136	(	N	O
137	median	N	O
138	of	N	O
139	3.5	N	O
140	prior	N	O
141	therapies	N	O
142	)	N	O
143	.	N	O

144	Bexarotene	N	O
145	(	N	O
146	Targretin	N	O
147	capsules	N	O
148	)	N	O
149	administered	N	O
150	once	N	O
151	daily	N	O
152	with	N	O
153	meal	N	O
154	for	N	O
155	16	N	O
156	weeks	N	O
157	or	N	O
158	longer	N	O
159	.	N	O

160	Primary	N	O
161	end	N	O
162	point	N	O
163	classification	N	O
164	of	N	O
165	overall	N	O
166	response	N	O
167	rate	N	O
168	of	N	O
169	complete	N	O
170	and	N	O
171	partial	N	O
172	remissions	N	O
173	determined	N	O
174	by	N	O
175	either	N	O
176	the	N	O
177	Physician	N	O
178	's	N	O
179	Global	N	O
180	Assessment	N	O
181	of	N	O
182	Clinical	N	O
183	Condition	N	O
184	or	N	O
185	the	N	O
186	objective	N	O
187	Composite	N	O
188	Assessment	N	O
189	of	N	O
190	Index	N	O
191	Lesion	N	O
192	Severity	N	O
193	.	N	O

194	Body	N	O
195	surface	N	O
196	area	N	O
197	,	N	O
198	time	N	O
199	to	N	O
200	response	N	O
201	,	N	O
202	duration	N	O
203	of	N	O
204	disease	N	O
205	control	N	O
206	,	N	O
207	time	N	O
208	to	N	O
209	disease	N	O
210	progression	N	O
211	,	N	O
212	individual	N	O
213	index	N	O
214	lesion	N	O
215	signs	N	O
216	and	N	O
217	symptoms	N	O
218	,	N	O
219	and	N	O
220	quality	N	O
221	of	N	O
222	life	N	O
223	parameters	N	O
224	were	N	O
225	secondary	N	O
226	outcomes	N	O
227	.	N	O

228	Responses	N	I-Premise
229	(	N	I-Premise
230	>	N	I-Premise
231	or	N	I-Premise
232	=	N	I-Premise
233	50	N	I-Premise
234	%	N	I-Premise
235	improvement	N	I-Premise
236	)	N	I-Premise
237	were	N	I-Premise
238	seen	N	I-Premise
239	in	N	I-Premise
240	3	N	I-Premise
241	(	N	I-Premise
242	20	N	I-Premise
243	%	N	I-Premise
244	)	N	I-Premise
245	of	N	I-Premise
246	15	N	I-Premise
247	patients	N	I-Premise
248	with	N	I-Premise
249	an	N	I-Premise
250	initial	N	I-Premise
251	dose	N	I-Premise
252	at	N	I-Premise
253	6.5	N	I-Premise
254	mg/m	N	I-Premise
255	(	N	I-Premise
256	2	N	I-Premise
257	)	N	I-Premise
258	per	N	I-Premise
259	day	N	I-Premise
260	(	N	I-Premise
261	95	N	I-Premise
262	%	N	I-Premise
263	confidence	N	I-Premise
264	interval	N	I-Premise
265	[	N	I-Premise
266	CI	N	I-Premise
267	]	N	I-Premise
268	,	N	I-Premise
269	0	N	I-Premise
270	%	N	I-Premise
271	-40	N	I-Premise
272	%	N	I-Premise
273	)	N	I-Premise
274	,	N	I-Premise
275	15	N	I-Premise
276	(	N	I-Premise
277	54	N	I-Premise
278	%	N	I-Premise
279	)	N	I-Premise
280	of	N	I-Premise
281	28	N	I-Premise
282	patients	N	I-Premise
283	at	N	I-Premise
284	300	N	I-Premise
285	mg/m	N	I-Premise
286	(	N	I-Premise
287	2	N	I-Premise
288	)	N	I-Premise
289	per	N	I-Premise
290	day	N	I-Premise
291	(	N	I-Premise
292	95	N	I-Premise
293	%	N	I-Premise
294	CI	N	I-Premise
295	,	N	I-Premise
296	35	N	I-Premise
297	%	N	I-Premise
298	-72	N	I-Premise
299	%	N	I-Premise
300	)	N	I-Premise
301	,	N	I-Premise
302	and	N	I-Premise
303	10	N	I-Premise
304	(	N	I-Premise
305	67	N	I-Premise
306	%	N	I-Premise
307	)	N	I-Premise
308	of	N	I-Premise
309	15	N	I-Premise
310	patients	N	I-Premise
311	at	N	I-Premise
312	above	N	I-Premise
313	300	N	I-Premise
314	mg/m	N	I-Premise
315	(	N	I-Premise
316	2	N	I-Premise
317	)	N	I-Premise
318	per	N	I-Premise
319	day	N	I-Premise
320	(	N	I-Premise
321	95	N	I-Premise
322	%	N	I-Premise
323	CI	N	I-Premise
324	,	N	I-Premise
325	43	N	I-Premise
326	%	N	I-Premise
327	-91	N	I-Premise
328	%	N	I-Premise
329	)	N	I-Premise
330	.	N	I-Premise

331	The	N	I-Premise
332	rate	N	I-Premise
333	of	N	I-Premise
334	progressive	N	I-Premise
335	disease	N	I-Premise
336	was	N	I-Premise
337	47	N	I-Premise
338	%	N	I-Premise
339	,	N	I-Premise
340	21	N	I-Premise
341	%	N	I-Premise
342	,	N	I-Premise
343	and	N	I-Premise
344	13	N	I-Premise
345	%	N	I-Premise
346	at	N	I-Premise
347	the	N	I-Premise
348	same	N	I-Premise
349	dose	N	I-Premise
350	levels	N	I-Premise
351	,	N	I-Premise
352	respectively	N	I-Premise
353	.	N	I-Premise

354	Eight	N	I-Premise
355	(	N	I-Premise
356	73	N	I-Premise
357	%	N	I-Premise
358	)	N	I-Premise
359	of	N	I-Premise
360	11	N	I-Premise
361	patients	N	I-Premise
362	crossing	N	I-Premise
363	over	N	I-Premise
364	from	N	I-Premise
365	6.5	N	I-Premise
366	mg/m	N	I-Premise
367	(	N	I-Premise
368	2	N	I-Premise
369	)	N	I-Premise
370	per	N	I-Premise
371	day	N	I-Premise
372	to	N	I-Premise
373	higher	N	I-Premise
374	doses	N	I-Premise
375	subsequently	N	I-Premise
376	responded	N	I-Premise
377	.	N	I-Premise

378	The	N	I-Premise
379	median	N	I-Premise
380	duration	N	I-Premise
381	of	N	I-Premise
382	response	N	I-Premise
383	from	N	I-Premise
384	start	N	I-Premise
385	of	N	I-Premise
386	therapy	N	I-Premise
387	could	N	I-Premise
388	not	N	I-Premise
389	be	N	I-Premise
390	estimated	N	I-Premise
391	for	N	I-Premise
392	the	N	I-Premise
393	15	N	I-Premise
394	patients	N	I-Premise
395	at	N	I-Premise
396	300	N	I-Premise
397	mg/m	N	I-Premise
398	(	N	I-Premise
399	2	N	I-Premise
400	)	N	I-Premise
401	per	N	I-Premise
402	day	N	I-Premise
403	owing	N	I-Premise
404	to	N	I-Premise
405	low	N	I-Premise
406	relapse	N	I-Premise
407	rates	N	I-Premise
408	in	N	I-Premise
409	2	N	I-Premise
410	patients	N	I-Premise
411	(	N	I-Premise
412	13	N	I-Premise
413	%	N	I-Premise
414	)	N	I-Premise
415	;	N	I-Premise
416	at	N	I-Premise
417	higher	N	I-Premise
418	doses	N	I-Premise
419	it	N	I-Premise
420	was	N	I-Premise
421	516	N	I-Premise
422	days	N	I-Premise
423	.	N	I-Premise

424	The	N	I-Premise
425	following	N	I-Premise
426	drug-related	N	I-Premise
427	adverse	N	I-Premise
428	effects	N	I-Premise
429	were	N	I-Premise
430	reversible	N	I-Premise
431	and	N	I-Premise
432	treatable	N	I-Premise
433	:	N	I-Premise
434	hypertriglyceridemia	N	I-Premise
435	(	N	I-Premise
436	46	N	I-Premise
437	patients	N	I-Premise
438	[	N	I-Premise
439	79	N	I-Premise
440	%	N	I-Premise
441	]	N	I-Premise
442	)	N	I-Premise
443	,	N	I-Premise
444	hypercholesterolemia	N	I-Premise
445	(	N	I-Premise
446	28	N	I-Premise
447	patients	N	I-Premise
448	[	N	I-Premise
449	48	N	I-Premise
450	%	N	I-Premise
451	]	N	I-Premise
452	)	N	I-Premise
453	,	N	I-Premise
454	headache	N	I-Premise
455	(	N	I-Premise
456	27	N	I-Premise
457	patients	N	I-Premise
458	[	N	I-Premise
459	47	N	I-Premise
460	%	N	I-Premise
461	]	N	I-Premise
462	)	N	I-Premise
463	,	N	I-Premise
464	central	N	I-Premise
465	hypothyroidism	N	I-Premise
466	(	N	I-Premise
467	23	N	I-Premise
468	patients	N	I-Premise
469	[	N	I-Premise
470	40	N	I-Premise
471	%	N	I-Premise
472	]	N	I-Premise
473	)	N	I-Premise
474	,	N	I-Premise
475	asthenia	N	I-Premise
476	(	N	I-Premise
477	21	N	I-Premise
478	patients	N	I-Premise
479	[	N	I-Premise
480	36	N	I-Premise
481	%	N	I-Premise
482	]	N	I-Premise
483	)	N	I-Premise
484	,	N	I-Premise
485	and	N	I-Premise
486	leukopenia	N	I-Premise
487	(	N	I-Premise
488	16	N	I-Premise
489	patients	N	I-Premise
490	[	N	I-Premise
491	28	N	I-Premise
492	%	N	I-Premise
493	]	N	I-Premise
494	)	N	I-Premise
495	.	N	I-Premise

496	No	N	I-Premise
497	cases	N	I-Premise
498	of	N	I-Premise
499	drug-related	N	I-Premise
500	neutropenic	N	I-Premise
501	fever	N	I-Premise
502	,	N	I-Premise
503	sepsis	N	I-Premise
504	,	N	I-Premise
505	or	N	I-Premise
506	death	N	I-Premise
507	occurred	N	I-Premise
508	.	N	I-Premise

509	Pancreatitis	N	I-Premise
510	occurred	N	I-Premise
511	in	N	I-Premise
512	3	N	I-Premise
513	patients	N	I-Premise
514	with	N	I-Premise
515	triglyceride	N	I-Premise
516	levels	N	I-Premise
517	higher	N	I-Premise
518	than	N	I-Premise
519	14.69	N	I-Premise
520	mmol/L	N	I-Premise
521	(	N	I-Premise
522	1300	N	I-Premise
523	mg/dL	N	I-Premise
524	)	N	I-Premise
525	,	N	I-Premise
526	all	N	I-Premise
527	of	N	I-Premise
528	whom	N	I-Premise
529	were	N	I-Premise
530	taking	N	I-Premise
531	300	N	I-Premise
532	mg/m	N	I-Premise
533	(	N	I-Premise
534	2	N	I-Premise
535	)	N	I-Premise
536	or	N	I-Premise
537	more	N	I-Premise
538	of	N	I-Premise
539	oral	N	I-Premise
540	bexarotene	N	I-Premise
541	per	N	I-Premise
542	day	N	I-Premise
543	.	N	I-Premise

544	Bexarotene	N	I-Claim
545	(	N	I-Claim
546	Targretin	N	I-Claim
547	capsules	N	I-Claim
548	)	N	I-Claim
549	(	N	I-Claim
550	the	N	I-Claim
551	first	N	I-Claim
552	retinoid	N	I-Claim
553	X	N	I-Claim
554	receptor-selective	N	I-Claim
555	rexinoid	N	I-Claim
556	)	N	I-Claim
557	was	N	I-Claim
558	well	N	I-Claim
559	tolerated	N	I-Claim
560	and	N	I-Claim
561	effective	N	I-Claim
562	as	N	I-Claim
563	an	N	I-Claim
564	oral	N	I-Claim
565	treatment	N	I-Claim
566	for	N	I-Claim
567	15	N	I-Claim
568	(	N	I-Claim
569	54	N	I-Claim
570	%	N	I-Claim
571	)	N	I-Claim
572	of	N	I-Claim
573	28	N	I-Claim
574	patients	N	I-Claim
575	with	N	I-Claim
576	refractory	N	I-Claim
577	or	N	I-Claim
578	persistent	N	I-Claim
579	early-stage	N	I-Claim
580	cutaneous	N	I-Claim
581	T-cell	N	I-Claim
582	lymphoma	N	I-Claim
583	at	N	I-Claim
584	doses	N	I-Claim
585	of	N	I-Claim
586	300	N	I-Claim
587	mg/m	N	I-Claim
588	(	N	I-Claim
589	2	N	I-Claim
590	)	N	I-Claim
591	per	N	I-Claim
592	day	N	I-Claim
593	.	N	I-Claim

594	Hypertriglyceridemia	N	I-Claim
595	and	N	I-Claim
596	hypothyroidism	N	I-Claim
597	require	N	I-Claim
598	monitoring	N	I-Claim
599	but	N	I-Claim
600	are	N	I-Claim
601	reversible	N	I-Claim
602	and	N	I-Claim
603	manageable	N	I-Claim
604	with	N	I-Claim
605	concomitant	N	I-Claim
606	medication	N	I-Claim
607	.	N	I-Claim

1	The	N	O
2	standard	N	O
3	treatment	N	O
4	for	N	O
5	patients	N	O
6	with	N	O
7	clinically	N	O
8	resectable	N	O
9	rectal	N	O
10	cancer	N	O
11	is	N	O
12	surgery	N	O
13	.	N	O

14	Postoperative	N	I-Claim
15	radiochemotherapy	N	I-Claim
16	is	N	I-Claim
17	recommended	N	I-Claim
18	for	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	advanced	N	I-Claim
22	disease	N	I-Claim
23	(	N	I-Claim
24	pT3/4	N	I-Claim
25	or	N	I-Claim
26	pN+	N	I-Claim
27	)	N	I-Claim
28	.	N	I-Claim

29	In	N	I-Claim
30	recent	N	I-Claim
31	years	N	I-Claim
32	,	N	I-Claim
33	encouraging	N	I-Claim
34	results	N	I-Claim
35	of	N	I-Claim
36	preoperative	N	I-Claim
37	radiotherapy	N	I-Claim
38	have	N	I-Claim
39	been	N	I-Claim
40	reported	N	I-Claim
41	.	N	I-Claim

42	This	N	O
43	prospective	N	O
44	randomized	N	O
45	phase-III	N	O
46	trial	N	O
47	(	N	O
48	CAO/ARO/AIO-94	N	O
49	)	N	O
50	compares	N	O
51	the	N	O
52	efficacy	N	O
53	of	N	O
54	neoadjuvant	N	O
55	radiochemotherapy	N	O
56	to	N	O
57	standard	N	O
58	postoperative	N	O
59	radiochemotherapy	N	O
60	.	N	O

61	We	N	O
62	report	N	O
63	on	N	O
64	the	N	O
65	design	N	O
66	of	N	O
67	the	N	O
68	study	N	O
69	and	N	O
70	first	N	O
71	results	N	O
72	with	N	O
73	regard	N	O
74	to	N	O
75	toxicity	N	O
76	of	N	O
77	radiochemotherapy	N	O
78	and	N	O
79	postoperative	N	O
80	morbidity	N	O
81	.	N	O

82	Patients	N	O
83	with	N	O
84	locally	N	O
85	advanced	N	O
86	operable	N	O
87	rectal	N	O
88	cancer	N	O
89	(	N	O
90	uT3/4	N	O
91	or	N	O
92	uN+	N	O
93	,	N	O
94	Mason	N	O
95	CS	N	O
96	III/IV	N	O
97	)	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	pre-	N	O
103	or	N	O
104	postoperative	N	O
105	radiochemotherapy	N	O
106	:	N	O
107	A	N	O
108	total	N	O
109	dose	N	O
110	of	N	O
111	50.4	N	O
112	Gy	N	O
113	(	N	O
114	single	N	O
115	dose	N	O
116	1.8	N	O
117	Gy	N	O
118	)	N	O
119	was	N	O
120	applied	N	O
121	to	N	O
122	the	N	O
123	tumor	N	O
124	and	N	O
125	the	N	O
126	pelvic	N	O
127	lymph	N	O
128	nodes	N	O
129	.	N	O

130	5-FU	N	O
131	(	N	O
132	1,000	N	O
133	mg/m2/d	N	O
134	)	N	O
135	was	N	O
136	administered	N	O
137	concomitantly	N	O
138	in	N	O
139	the	N	O
140	first	N	O
141	and	N	O
142	fifth	N	O
143	week	N	O
144	of	N	O
145	radiation	N	O
146	as	N	O
147	120-h	N	O
148	continuous	N	O
149	infusion	N	O
150	.	N	O

151	Four	N	O
152	additional	N	O
153	cycles	N	O
154	of	N	O
155	5-FU	N	O
156	chemotherapy	N	O
157	(	N	O
158	500	N	O
159	mg/m2/d	N	O
160	,	N	O
161	i.v	N	O
162	.	N	O

163	bolus	N	O
164	)	N	O
165	were	N	O
166	applied	N	O
167	.	N	O

168	Radiochemotherapy	N	O
169	was	N	O
170	identical	N	O
171	in	N	O
172	both	N	O
173	arms	N	O
174	except	N	O
175	for	N	O
176	a	N	O
177	small-volume	N	O
178	boost	N	O
179	of	N	O
180	5.4	N	O
181	Gy	N	O
182	in	N	O
183	the	N	O
184	postoperative	N	O
185	setting	N	O
186	.	N	O

187	Time	N	O
188	interval	N	O
189	between	N	O
190	radiochemotherapy	N	O
191	and	N	O
192	surgery	N	O
193	was	N	O
194	4-6	N	O
195	weeks	N	O
196	in	N	O
197	both	N	O
198	arms	N	O
199	.	N	O

200	Techniques	N	O
201	of	N	O
202	surgery	N	O
203	were	N	O
204	standardized	N	O
205	and	N	O
206	included	N	O
207	total	N	O
208	mesorectal	N	O
209	excision	N	O
210	.	N	O

211	In	N	O
212	addition	N	O
213	,	N	O
214	stratification	N	O
215	according	N	O
216	to	N	O
217	surgeons	N	O
218	involved	N	O
219	has	N	O
220	been	N	O
221	provided	N	O
222	for	N	O
223	.	N	O

224	Primary	N	O
225	endpoints	N	O
226	of	N	O
227	the	N	O
228	study	N	O
229	are	N	O
230	5-year	N	O
231	overall-survival	N	O
232	,	N	O
233	local	N	O
234	and	N	O
235	distant	N	O
236	control	N	O
237	,	N	O
238	secondary	N	O
239	endpoints	N	O
240	include	N	O
241	rate	N	O
242	of	N	O
243	curative	N	O
244	(	N	O
245	R0	N	O
246	)	N	O
247	resections	N	O
248	and	N	O
249	sphincter	N	O
250	saving	N	O
251	procedures	N	O
252	,	N	O
253	toxicity	N	O
254	of	N	O
255	radiochemotherapy	N	O
256	,	N	O
257	surgical	N	O
258	complications	N	O
259	and	N	O
260	quality	N	O
261	of	N	O
262	life	N	O
263	.	N	O

264	As	N	O
265	of	N	O
266	15th	N	O
267	November	N	O
268	2000	N	O
269	,	N	O
270	628	N	O
271	patients	N	O
272	were	N	O
273	randomized	N	O
274	from	N	O
275	26	N	O
276	participating	N	O
277	institutions	N	O
278	:	N	O
279	310	N	O
280	patients	N	O
281	were	N	O
282	randomized	N	O
283	to	N	O
284	postoperative	N	O
285	radiochemotherapy	N	O
286	,	N	O
287	318	N	O
288	patients	N	O
289	to	N	O
290	preoperative	N	O
291	radiochemotherapy	N	O
292	.	N	O

293	Acute	N	I-Premise
294	toxicity	N	I-Premise
295	(	N	I-Premise
296	WHO	N	I-Premise
297	)	N	I-Premise
298	of	N	I-Premise
299	radiochemotherapy	N	I-Premise
300	was	N	I-Premise
301	low	N	I-Premise
302	,	N	I-Premise
303	with	N	I-Premise
304	less	N	I-Premise
305	than	N	I-Premise
306	15	N	I-Premise
307	%	N	I-Premise
308	of	N	I-Premise
309	patients	N	I-Premise
310	experiencing	N	I-Premise
311	Grade	N	I-Premise
312	3	N	I-Premise
313	or	N	I-Premise
314	higher	N	I-Premise
315	toxicity	N	I-Premise
316	:	N	O
317	The	N	I-Premise
318	principal	N	I-Premise
319	toxicity	N	I-Premise
320	was	N	I-Premise
321	diarrhea	N	I-Premise
322	,	N	I-Premise
323	with	N	I-Premise
324	12	N	I-Premise
325	%	N	I-Premise
326	in	N	I-Premise
327	the	N	I-Premise
328	postoperative	N	I-Premise
329	radiochemotherapy	N	I-Premise
330	arm	N	I-Premise
331	and	N	I-Premise
332	10	N	I-Premise
333	%	N	I-Premise
334	in	N	I-Premise
335	the	N	I-Premise
336	preoperative	N	I-Premise
337	radiochemotherapy	N	I-Premise
338	arm	N	I-Premise
339	having	N	I-Premise
340	Grade-3	N	I-Premise
341	,	N	I-Premise
342	and	N	I-Premise
343	1	N	I-Premise
344	%	N	I-Premise
345	in	N	I-Premise
346	either	N	I-Premise
347	arm	N	I-Premise
348	having	N	I-Premise
349	Grade-4	N	I-Premise
350	diarrhea	N	I-Premise
351	.	N	I-Premise

352	Erythema	N	I-Premise
353	,	N	I-Premise
354	nausea	N	I-Premise
355	and	N	I-Premise
356	leukopenia	N	I-Premise
357	were	N	I-Premise
358	the	N	I-Premise
359	next	N	I-Premise
360	common	N	I-Premise
361	toxicities	N	I-Premise
362	,	N	I-Premise
363	with	N	I-Premise
364	less	N	I-Premise
365	than	N	I-Premise
366	3	N	I-Premise
367	%	N	I-Premise
368	of	N	I-Premise
369	patients	N	I-Premise
370	in	N	I-Premise
371	either	N	I-Premise
372	arm	N	I-Premise
373	suffering	N	I-Premise
374	Grade	N	I-Premise
375	3	N	I-Premise
376	or	N	I-Premise
377	greater	N	I-Premise
378	leukopenia	N	I-Premise
379	or	N	I-Premise
380	nausea	N	I-Premise
381	.	N	I-Premise

382	Postoperative	N	I-Premise
383	complication	N	I-Premise
384	rates	N	I-Premise
385	were	N	I-Premise
386	similar	N	I-Premise
387	in	N	I-Premise
388	both	N	I-Premise
389	arms	N	I-Premise
390	,	N	I-Premise
391	with	N	I-Premise
392	12	N	I-Premise
393	%	N	I-Premise
394	(	N	I-Premise
395	postoperative	N	I-Premise
396	radiochemotherapy	N	I-Premise
397	)	N	I-Premise
398	and	N	I-Premise
399	13	N	I-Premise
400	%	N	I-Premise
401	(	N	I-Premise
402	preoperative	N	I-Premise
403	radiochemotherapy	N	I-Premise
404	)	N	I-Premise
405	of	N	I-Premise
406	patients	N	I-Premise
407	,	N	I-Premise
408	respectively	N	I-Premise
409	,	N	I-Premise
410	suffering	N	I-Premise
411	from	N	I-Premise
412	anastomotic	N	I-Premise
413	leakage	N	I-Premise
414	,	N	I-Premise
415	4	N	I-Premise
416	%	N	I-Premise
417	(	N	I-Premise
418	postoperative	N	I-Premise
419	radiochemotherapy	N	I-Premise
420	)	N	I-Premise
421	and	N	I-Premise
422	3	N	I-Premise
423	%	N	I-Premise
424	(	N	I-Premise
425	preoperative	N	I-Premise
426	radiochemotherapy	N	I-Premise
427	)	N	I-Premise
428	from	N	I-Premise
429	postoperative	N	I-Premise
430	bleeding	N	I-Premise
431	,	N	I-Premise
432	and	N	I-Premise
433	6	N	I-Premise
434	%	N	I-Premise
435	(	N	I-Premise
436	postoperative	N	I-Premise
437	radiochemotherapy	N	I-Premise
438	)	N	I-Premise
439	and	N	I-Premise
440	5	N	I-Premise
441	%	N	I-Premise
442	(	N	I-Premise
443	preoperative	N	I-Premise
444	radiochemotherapy	N	I-Premise
445	)	N	I-Premise
446	from	N	I-Premise
447	delayed	N	I-Premise
448	wound	N	I-Premise
449	healing	N	I-Premise
450	.	N	I-Premise

451	The	N	I-Claim
452	patient	N	I-Claim
453	accrual	N	I-Claim
454	of	N	I-Claim
455	our	N	I-Claim
456	trial	N	I-Claim
457	is	N	I-Claim
458	satisfactory	N	I-Claim
459	,	N	I-Claim
460	neoadjuvant	N	I-Claim
461	radiochemotherapy	N	I-Claim
462	is	N	I-Claim
463	well	N	I-Claim
464	tolerated	N	I-Claim
465	and	N	I-Claim
466	bears	N	I-Claim
467	no	N	I-Claim
468	higher	N	I-Claim
469	risk	N	I-Claim
470	for	N	I-Claim
471	postoperative	N	I-Claim
472	morbidity	N	I-Claim
473	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	,	N	O
4	double-blind	N	O
5	,	N	O
6	placebo-controlled	N	O
7	clinical	N	O
8	trial	N	O
9	assessed	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	epoetin	N	O
14	alfa	N	O
15	on	N	O
16	transfusion	N	O
17	requirements	N	O
18	,	N	O
19	hematopoietic	N	O
20	parameters	N	O
21	,	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	(	N	O
26	QOL	N	O
27	)	N	O
28	,	N	O
29	and	N	O
30	safety	N	O
31	in	N	O
32	anemic	N	O
33	cancer	N	O
34	patients	N	O
35	receiving	N	O
36	nonplatinum	N	O
37	chemotherapy	N	O
38	.	N	O

39	The	N	O
40	study	N	O
41	also	N	O
42	explored	N	O
43	a	N	O
44	possible	N	O
45	relationship	N	O
46	between	N	O
47	increased	N	O
48	hemoglobin	N	O
49	and	N	O
50	survival	N	O
51	.	N	O

52	Three	N	O
53	hundred	N	O
54	seventy-five	N	O
55	patients	N	O
56	with	N	O
57	solid	N	O
58	or	N	O
59	nonmyeloid	N	O
60	hematologic	N	O
61	malignancies	N	O
62	and	N	O
63	hemoglobin	N	O
64	levels	N	O
65	<	N	O
66	or	N	O
67	=	N	O
68	10.5	N	O
69	g/dL	N	O
70	,	N	O
71	or	N	O
72	greater	N	O
73	than	N	O
74	10.5	N	O
75	g/dL	N	O
76	but	N	O
77	<	N	O
78	or	N	O
79	=	N	O
80	12.0	N	O
81	g/dL	N	O
82	after	N	O
83	a	N	O
84	hemoglobin	N	O
85	decrease	N	O
86	of	N	O
87	>	N	O
88	or	N	O
89	=	N	O
90	1.5	N	O
91	g/dL	N	O
92	per	N	O
93	cycle	N	O
94	since	N	O
95	starting	N	O
96	chemotherapy	N	O
97	,	N	O
98	were	N	O
99	randomized	N	O
100	2:1	N	O
101	to	N	O
102	epoetin	N	O
103	alfa	N	O
104	150	N	O
105	to	N	O
106	300	N	O
107	IU/kg	N	O
108	(	N	O
109	n	N	O
110	=	N	O
111	251	N	O
112	)	N	O
113	or	N	O
114	placebo	N	O
115	(	N	O
116	n	N	O
117	=	N	O
118	124	N	O
119	)	N	O
120	three	N	O
121	times	N	O
122	per	N	O
123	week	N	O
124	subcutaneously	N	O
125	for	N	O
126	12	N	O
127	to	N	O
128	24	N	O
129	weeks	N	O
130	.	N	O

131	The	N	O
132	primary	N	O
133	end	N	O
134	point	N	O
135	was	N	O
136	proportion	N	O
137	of	N	O
138	patients	N	O
139	transfused	N	O
140	;	N	O
141	secondary	N	O
142	end	N	O
143	points	N	O
144	were	N	O
145	change	N	O
146	in	N	O
147	hemoglobin	N	O
148	and	N	O
149	QOL	N	O
150	.	N	O

151	The	N	O
152	protocol	N	O
153	was	N	O
154	amended	N	O
155	before	N	O
156	unblinding	N	O
157	to	N	O
158	prospectively	N	O
159	collect	N	O
160	and	N	O
161	assess	N	O
162	survival	N	O
163	data	N	O
164	12	N	O
165	months	N	O
166	after	N	O
167	the	N	O
168	last	N	O
169	patient	N	O
170	completed	N	O
171	the	N	O
172	study	N	O
173	.	N	O

174	Epoetin	N	I-Premise
175	alfa	N	I-Premise
176	,	N	I-Premise
177	compared	N	I-Premise
178	with	N	I-Premise
179	placebo	N	I-Premise
180	,	N	I-Premise
181	significantly	N	I-Premise
182	decreased	N	I-Premise
183	transfusion	N	I-Premise
184	requirements	N	I-Premise
185	(	N	I-Premise
186	P	N	I-Premise
187	=.0057	N	I-Premise
188	)	N	I-Premise
189	and	N	I-Premise
190	increased	N	I-Premise
191	hemoglobin	N	I-Premise
192	(	N	I-Premise
193	P	N	I-Premise
194	<	N	I-Premise
195	.001	N	I-Premise
196	)	N	I-Premise
197	.	N	I-Premise

198	Improvement	N	I-Premise
199	of	N	I-Premise
200	all	N	I-Premise
201	primary	N	I-Premise
202	cancer-	N	I-Premise
203	and	N	I-Premise
204	anemia-specific	N	I-Premise
205	QOL	N	I-Premise
206	domains	N	I-Premise
207	,	N	I-Premise
208	including	N	I-Premise
209	energy	N	I-Premise
210	level	N	I-Premise
211	,	N	I-Premise
212	ability	N	I-Premise
213	to	N	I-Premise
214	do	N	I-Premise
215	daily	N	I-Premise
216	activities	N	I-Premise
217	,	N	I-Premise
218	and	N	I-Premise
219	fatigue	N	I-Premise
220	,	N	I-Premise
221	was	N	I-Premise
222	significantly	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	<	N	I-Premise
226	.01	N	I-Premise
227	)	N	I-Premise
228	greater	N	I-Premise
229	for	N	I-Premise
230	epoetin	N	I-Premise
231	alfa	N	I-Premise
232	versus	N	I-Premise
233	placebo	N	I-Premise
234	patients	N	I-Premise
235	.	N	I-Premise

236	Although	N	O
237	the	N	O
238	study	N	O
239	was	N	O
240	not	N	O
241	powered	N	O
242	for	N	O
243	survival	N	O
244	as	N	O
245	an	N	O
246	end	N	O
247	point	N	O
248	,	N	O
249	Kaplan-Meier	N	I-Premise
250	estimates	N	I-Premise
251	showed	N	I-Premise
252	a	N	I-Premise
253	trend	N	I-Premise
254	in	N	I-Premise
255	overall	N	I-Premise
256	survival	N	I-Premise
257	favoring	N	I-Premise
258	epoetin	N	I-Premise
259	alfa	N	I-Premise
260	(	N	I-Premise
261	P	N	I-Premise
262	=.13	N	I-Premise
263	,	N	I-Premise
264	log-rank	N	I-Premise
265	test	N	I-Premise
266	)	N	I-Premise
267	,	N	I-Premise
268	and	N	O
269	Cox	N	I-Premise
270	regression	N	I-Premise
271	analysis	N	I-Premise
272	showed	N	I-Premise
273	an	N	I-Premise
274	estimated	N	I-Premise
275	hazards	N	I-Premise
276	ratio	N	I-Premise
277	of	N	I-Premise
278	1.309	N	I-Premise
279	(	N	I-Premise
280	P	N	I-Premise
281	=.052	N	I-Premise
282	)	N	I-Premise
283	favoring	N	I-Premise
284	epoetin	N	I-Premise
285	alfa	N	I-Premise
286	.	N	I-Premise

287	Adverse	N	I-Premise
288	events	N	I-Premise
289	were	N	I-Premise
290	comparable	N	I-Premise
291	between	N	I-Premise
292	groups	N	I-Premise
293	.	N	I-Premise

294	Epoetin	N	I-Claim
295	alfa	N	I-Claim
296	safely	N	I-Claim
297	and	N	I-Claim
298	effectively	N	I-Claim
299	ameliorates	N	I-Claim
300	anemia	N	I-Claim
301	and	N	I-Claim
302	significantly	N	I-Claim
303	improves	N	I-Claim
304	QOL	N	I-Claim
305	in	N	I-Claim
306	cancer	N	I-Claim
307	patients	N	I-Claim
308	receiving	N	I-Claim
309	nonplatinum	N	I-Claim
310	chemotherapy	N	I-Claim
311	.	N	I-Claim

312	Encouraging	N	I-Claim
313	results	N	I-Claim
314	regarding	N	I-Claim
315	increased	N	I-Claim
316	survival	N	I-Claim
317	warrant	N	I-Claim
318	another	N	I-Claim
319	trial	N	I-Claim
320	designed	N	I-Claim
321	to	N	I-Claim
322	confirm	N	I-Claim
323	these	N	I-Claim
324	findings	N	I-Claim
325	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	comparatively	N	O
4	,	N	O
5	in	N	O
6	terms	N	O
7	of	N	O
8	quality-adjusted	N	O
9	survival	N	O
10	,	N	O
11	three	N	O
12	front-line	N	O
13	treatments	N	O
14	in	N	O
15	patients	N	O
16	with	N	O
17	stage	N	O
18	B-	N	O
19	or	N	O
20	C-chronic	N	O
21	lymphocytic	N	O
22	leukemia	N	O
23	(	N	O
24	CLL	N	O
25	)	N	O
26	.	N	O

27	To	N	O
28	describe	N	O
29	better	N	O
30	and	N	O
31	compare	N	O
32	the	N	O
33	survival	N	O
34	after	N	O
35	randomization	N	O
36	of	N	O
37	patients	N	O
38	from	N	O
39	the	N	O
40	CLL90	N	O
41	trial	N	O
42	that	N	O
43	randomly	N	O
44	compared	N	O
45	ChOP	N	O
46	(	N	O
47	cyclophosphamide	N	O
48	,	N	O
49	doxorubicin	N	O
50	,	N	O
51	oncovin	N	O
52	,	N	O
53	prednisone	N	O
54	)	N	O
55	,	N	O
56	CAP	N	O
57	(	N	O
58	cyclophosphamide	N	O
59	,	N	O
60	doxorubicin	N	O
61	,	N	O
62	prednisone	N	O
63	)	N	O
64	and	N	O
65	fludarabine	N	O
66	in	N	O
67	advanced	N	O
68	CLL	N	O
69	,	N	O
70	we	N	O
71	performed	N	O
72	a	N	O
73	quality-adjusted	N	O
74	survival	N	O
75	analysis	N	O
76	.	N	O

77	This	N	O
78	consisted	N	O
79	of	N	O
80	defining	N	O
81	four	N	O
82	clinical	N	O
83	states	N	O
84	(	N	O
85	toxicity	N	O
86	,	N	O
87	treatment	N	O
88	free	N	O
89	of	N	O
90	toxicity	N	O
91	,	N	O
92	no	N	O
93	treatment	N	O
94	nor	N	O
95	symptoms	N	O
96	,	N	O
97	relapse	N	O
98	)	N	O
99	,	N	O
100	then	N	O
101	summing	N	O
102	up	N	O
103	the	N	O
104	average	N	O
105	times	N	O
106	spent	N	O
107	in	N	O
108	each	N	O
109	state	N	O
110	weighted	N	O
111	by	N	O
112	utility	N	O
113	coefficients	N	O
114	that	N	O
115	reflect	N	O
116	relative	N	O
117	value	N	O
118	according	N	O
119	to	N	O
120	quality	N	O
121	of	N	O
122	life	N	O
123	.	N	O

124	The	N	O
125	resulting	N	O
126	quality-adjusted	N	O
127	time	N	O
128	without	N	O
129	symptoms	N	O
130	or	N	O
131	toxicity	N	O
132	(	N	O
133	Q-TWIST	N	O
134	)	N	O
135	was	N	O
136	compared	N	O
137	between	N	O
138	randomized	N	O
139	groups	N	O
140	,	N	O
141	and	N	O
142	sensitivity	N	O
143	(	N	O
144	threshold	N	O
145	)	N	O
146	analyses	N	O
147	to	N	O
148	the	N	O
149	choice	N	O
150	of	N	O
151	utility	N	O
152	coefficients	N	O
153	was	N	O
154	performed	N	O
155	.	N	O

156	Over	N	I-Premise
157	73	N	I-Premise
158	months	N	I-Premise
159	after	N	I-Premise
160	randomization	N	I-Premise
161	,	N	I-Premise
162	the	N	I-Premise
163	fludarabine	N	I-Premise
164	group	N	I-Premise
165	gained	N	I-Premise
166	a	N	I-Premise
167	mean	N	I-Premise
168	of	N	I-Premise
169	45	N	I-Premise
170	days	N	I-Premise
171	of	N	I-Premise
172	toxicity-free	N	I-Premise
173	survival	N	I-Premise
174	at	N	I-Premise
175	CAP	N	I-Premise
176	,	N	I-Premise
177	and	N	I-Premise
178	61	N	I-Premise
179	days	N	I-Premise
180	over	N	I-Premise
181	ChOP	N	I-Premise
182	.	N	I-Premise

183	The	N	I-Premise
184	mean	N	I-Premise
185	TWIST	N	I-Premise
186	was	N	I-Premise
187	27.05	N	I-Premise
188	months	N	I-Premise
189	with	N	I-Premise
190	CAP	N	I-Premise
191	,	N	I-Premise
192	31.5	N	I-Premise
193	months	N	I-Premise
194	with	N	I-Premise
195	ChOP	N	I-Premise
196	and	N	I-Premise
197	32.95	N	I-Premise
198	months	N	I-Premise
199	with	N	I-Premise
200	fludarabine	N	I-Premise
201	.	N	I-Premise

202	The	N	I-Premise
203	threshold	N	I-Premise
204	analyses	N	I-Premise
205	showed	N	I-Premise
206	that	N	I-Premise
207	,	N	I-Premise
208	whatever	N	I-Premise
209	the	N	I-Premise
210	utility	N	I-Premise
211	weights	N	I-Premise
212	,	N	I-Premise
213	the	N	I-Premise
214	mean	N	I-Premise
215	Q-TWIST	N	I-Premise
216	was	N	I-Premise
217	always	N	I-Premise
218	greater	N	I-Premise
219	with	N	I-Premise
220	ChOP	N	I-Premise
221	or	N	I-Premise
222	fludarabine	N	I-Premise
223	as	N	I-Premise
224	compared	N	I-Premise
225	to	N	I-Premise
226	CAP	N	I-Premise
227	.	N	I-Premise

228	Fludarabine	N	I-Claim
229	was	N	I-Claim
230	consistently	N	I-Claim
231	a	N	I-Claim
232	better	N	I-Claim
233	treatment	N	I-Claim
234	than	N	I-Claim
235	ChOP	N	I-Claim
236	,	N	I-Claim
237	except	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	unlikely	N	I-Premise
241	case	N	I-Premise
242	of	N	I-Premise
243	high	N	I-Premise
244	utility	N	I-Premise
245	weights	N	I-Premise
246	attributed	N	I-Premise
247	to	N	I-Premise
248	toxicity	N	I-Premise
249	and	N	I-Premise
250	low	N	I-Premise
251	utility	N	I-Premise
252	weights	N	I-Premise
253	attributed	N	I-Premise
254	to	N	I-Premise
255	treatment	N	I-Premise
256	.	N	I-Premise

257	Nevertheless	N	O
258	,	N	O
259	from	N	I-Premise
260	a	N	I-Premise
261	clinical	N	I-Premise
262	point	N	I-Premise
263	of	N	I-Premise
264	view	N	I-Premise
265	,	N	I-Premise
266	differences	N	I-Premise
267	between	N	I-Premise
268	ChOP	N	I-Premise
269	and	N	I-Premise
270	fludarabine	N	I-Premise
271	were	N	I-Premise
272	moderate	N	I-Premise
273	or	N	I-Premise
274	event	N	I-Premise
275	slight	N	I-Premise
276	(	N	I-Premise
277	mean	N	I-Premise
278	difference	N	I-Premise
279	in	N	I-Premise
280	TWIST	N	I-Premise
281	of	N	I-Premise
282	1.45	N	I-Premise
283	months	N	I-Premise
284	)	N	I-Premise
285	.	N	I-Premise

286	We	N	O
287	conclude	N	O
288	that	N	O
289	patients	N	I-Claim
290	with	N	I-Claim
291	advanced	N	I-Claim
292	CLL	N	I-Claim
293	have	N	I-Claim
294	a	N	I-Claim
295	moderate	N	I-Claim
296	benefit	N	I-Claim
297	in	N	I-Claim
298	terms	N	I-Claim
299	of	N	I-Claim
300	Q-TWIST	N	I-Claim
301	when	N	I-Claim
302	treated	N	I-Claim
303	with	N	I-Claim
304	fludarabine	N	I-Claim
305	over	N	I-Claim
306	ChOP	N	I-Claim
307	.	N	I-Claim

308	These	N	I-Claim
309	two	N	I-Claim
310	treatments	N	I-Claim
311	are	N	I-Claim
312	always	N	I-Claim
313	superior	N	I-Claim
314	to	N	I-Claim
315	CAP	N	I-Claim
316	.	N	I-Claim

1	Cutaneous	N	I-Claim
2	T-cell	N	I-Claim
3	lymphoma	N	I-Claim
4	(	N	I-Claim
5	CTCL	N	I-Claim
6	)	N	I-Claim
7	can	N	I-Claim
8	be	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	painful	N	I-Claim
12	,	N	I-Claim
13	pruritic	N	I-Claim
14	,	N	I-Claim
15	disfiguring	N	I-Claim
16	lesions	N	I-Claim
17	.	N	I-Claim

18	As	N	O
19	part	N	O
20	of	N	O
21	a	N	O
22	multicenter	N	O
23	,	N	O
24	randomized	N	O
25	phase	N	O
26	III	N	O
27	trial	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	heavily	N	O
32	pretreated	N	O
33	advanced	N	O
34	and/or	N	O
35	recurrent	N	O
36	CTCL	N	O
37	,	N	O
38	the	N	O
39	effects	N	O
40	of	N	O
41	an	N	O
42	interleukin-2	N	O
43	receptor-targeted	N	O
44	fusion	N	O
45	protein	N	O
46	,	N	O
47	denileukin	N	O
48	diftitox	N	O
49	(	N	O
50	DAB389IL-2	N	O
51	,	N	O
52	ONTAK	N	O
53	)	N	O
54	,	N	O
55	on	N	O
56	patient-rated	N	O
57	overall	N	O
58	quality	N	O
59	of	N	O
60	life	N	O
61	(	N	O
62	QOL	N	O
63	)	N	O
64	,	N	O
65	skin	N	O
66	appearance	N	O
67	,	N	O
68	and	N	O
69	pruritus	N	O
70	severity	N	O
71	were	N	O
72	evaluated	N	O
73	.	N	O

74	A	N	O
75	total	N	O
76	of	N	O
77	71	N	O
78	patients	N	O
79	with	N	O
80	stage	N	O
81	IB-IVA	N	O
82	CTCL	N	O
83	received	N	O
84	intravenous	N	O
85	denileukin	N	O
86	diftitox	N	O
87	9	N	O
88	microg/kg/day	N	O
89	or	N	O
90	18	N	O
91	microg/kg/day	N	O
92	over	N	O
93	15-60	N	O
94	minutes	N	O
95	for	N	O
96	5	N	O
97	consecutive	N	O
98	days	N	O
99	on	N	O
100	an	N	O
101	outpatient	N	O
102	basis	N	O
103	;	N	O
104	cycles	N	O
105	were	N	O
106	planned	N	O
107	for	N	O
108	every	N	O
109	21	N	O
110	days	N	O
111	for	N	O
112	a	N	O
113	total	N	O
114	of	N	O
115	8	N	O
116	cycles	N	O
117	over	N	O
118	6	N	O
119	months	N	O
120	.	N	O

121	Prior	N	O
122	to	N	O
123	each	N	O
124	treatment	N	O
125	cycle	N	O
126	,	N	O
127	patients	N	O
128	were	N	O
129	evaluated	N	O
130	for	N	O
131	disease	N	O
132	response	N	O
133	and	N	O
134	were	N	O
135	asked	N	O
136	to	N	O
137	self-rate	N	O
138	their	N	O
139	overall	N	O
140	QOL	N	O
141	via	N	O
142	the	N	O
143	Functional	N	O
144	Assessment	N	O
145	of	N	O
146	Cancer	N	O
147	Therapy-General	N	O
148	(	N	O
149	FACT-G	N	O
150	)	N	O
151	questionnaire	N	O
152	,	N	O
153	skin	N	O
154	appearance	N	O
155	(	N	O
156	7-point	N	O
157	scale	N	O
158	)	N	O
159	,	N	O
160	and	N	O
161	pruritus	N	O
162	severity	N	O
163	(	N	O
164	10-cm	N	O
165	visual	N	O
166	analogue	N	O
167	scale	N	O
168	)	N	O
169	.	N	O

170	Composite	N	I-Premise
171	FACT-G	N	I-Premise
172	and	N	I-Premise
173	most	N	I-Premise
174	individual	N	I-Premise
175	subscale	N	I-Premise
176	scores	N	I-Premise
177	(	N	I-Premise
178	physical	N	I-Premise
179	,	N	I-Premise
180	social/family	N	I-Premise
181	,	N	I-Premise
182	emotional	N	I-Premise
183	,	N	I-Premise
184	and	N	I-Premise
185	functional	N	I-Premise
186	well	N	I-Premise
187	being	N	I-Premise
188	)	N	I-Premise
189	in	N	I-Premise
190	documented	N	I-Premise
191	responders	N	I-Premise
192	(	N	I-Premise
193	n	N	I-Premise
194	=	N	I-Premise
195	21	N	I-Premise
196	)	N	I-Premise
197	gradually	N	I-Premise
198	increased	N	I-Premise
199	during	N	I-Premise
200	the	N	I-Premise
201	study	N	I-Premise
202	period	N	I-Premise
203	,	N	I-Premise
204	generally	N	I-Premise
205	reaching	N	I-Premise
206	statistical	N	I-Premise
207	significance	N	I-Premise
208	(	N	I-Premise
209	P	N	I-Premise
210	<	N	I-Premise
211	0.05	N	I-Premise
212	)	N	I-Premise
213	by	N	I-Premise
214	cycle	N	I-Premise
215	3	N	I-Premise
216	,	N	I-Premise
217	and	N	I-Premise
218	were	N	I-Premise
219	significantly	N	I-Premise
220	(	N	I-Premise
221	P	N	I-Premise
222	<	N	I-Premise
223	or	N	I-Premise
224	=	N	I-Premise
225	0.041	N	I-Premise
226	)	N	I-Premise
227	higher	N	I-Premise
228	than	N	I-Premise
229	the	N	I-Premise
230	scores	N	I-Premise
231	of	N	I-Premise
232	nonresponders	N	I-Premise
233	at	N	I-Premise
234	endpoint	N	I-Premise
235	.	N	I-Premise

236	Additionally	N	I-Premise
237	for	N	I-Premise
238	responders	N	I-Premise
239	,	N	I-Premise
240	assessments	N	I-Premise
241	of	N	I-Premise
242	skin	N	I-Premise
243	severity	N	I-Premise
244	and	N	I-Premise
245	pruritus	N	I-Premise
246	severity	N	I-Premise
247	showed	N	I-Premise
248	significant	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	<	N	I-Premise
252	or	N	I-Premise
253	=	N	I-Premise
254	0.05	N	I-Premise
255	)	N	I-Premise
256	improvements	N	I-Premise
257	at	N	I-Premise
258	study	N	I-Premise
259	endpoint	N	I-Premise
260	compared	N	I-Premise
261	with	N	I-Premise
262	baseline	N	I-Premise
263	.	N	I-Premise

264	Adverse	N	I-Premise
265	transfusion-related	N	I-Premise
266	events	N	I-Premise
267	(	N	I-Premise
268	eg	N	I-Premise
269	,	N	I-Premise
270	hypersensitivity	N	I-Premise
271	reactions	N	I-Premise
272	,	N	I-Premise
273	flu-like	N	I-Premise
274	syndrome	N	I-Premise
275	)	N	I-Premise
276	were	N	I-Premise
277	common	N	I-Premise
278	during	N	I-Premise
279	cycles	N	I-Premise
280	1	N	I-Premise
281	and	N	I-Premise
282	2	N	I-Premise
283	,	N	I-Premise
284	and	N	I-Premise
285	vascular-leak	N	I-Premise
286	syndrome	N	I-Premise
287	occurred	N	I-Premise
288	in	N	I-Premise
289	25	N	I-Premise
290	%	N	I-Premise
291	of	N	I-Premise
292	patients	N	I-Premise
293	.	N	I-Premise

294	Denileukin	N	I-Claim
295	diftitox	N	I-Claim
296	was	N	I-Claim
297	not	N	I-Claim
298	associated	N	I-Claim
299	with	N	I-Claim
300	any	N	I-Claim
301	clinically	N	I-Claim
302	significant	N	I-Claim
303	myelosuppression	N	I-Claim
304	.	N	I-Claim

305	Heavily	N	I-Claim
306	pretreated	N	I-Claim
307	patients	N	I-Claim
308	with	N	I-Claim
309	advanced	N	I-Claim
310	and/or	N	I-Claim
311	recurrent	N	I-Claim
312	CTCL	N	I-Claim
313	who	N	I-Claim
314	responded	N	I-Claim
315	to	N	I-Claim
316	denileukin	N	I-Claim
317	diftitox	N	I-Claim
318	therapy	N	I-Claim
319	showed	N	I-Claim
320	significant	N	I-Claim
321	improvements	N	I-Claim
322	in	N	I-Claim
323	self-rated	N	I-Claim
324	overall	N	I-Claim
325	QOL	N	I-Claim
326	,	N	I-Claim
327	skin	N	I-Claim
328	appearance	N	I-Claim
329	,	N	I-Claim
330	and	N	I-Claim
331	pruritus	N	I-Claim
332	severity	N	I-Claim
333	.	N	I-Claim

1	Low	N	I-Claim
2	anterior	N	I-Claim
3	resection	N	I-Claim
4	with	N	I-Claim
5	coloanal	N	I-Claim
6	anastomosis	N	I-Claim
7	prevents	N	I-Claim
8	a	N	I-Claim
9	definitive	N	I-Claim
10	stoma	N	I-Claim
11	in	N	I-Claim
12	patients	N	I-Claim
13	with	N	I-Claim
14	distal	N	I-Claim
15	rectal	N	I-Claim
16	cancer	N	I-Claim
17	.	N	I-Claim

18	However	N	I-Premise
19	,	N	I-Premise
20	imperative	N	I-Premise
21	stool	N	I-Premise
22	urge	N	I-Premise
23	,	N	I-Premise
24	stool	N	I-Premise
25	fragmentation	N	I-Premise
26	,	N	I-Premise
27	prolonged	N	I-Premise
28	stooling	N	I-Premise
29	sessions	N	I-Premise
30	,	N	I-Premise
31	and	N	I-Premise
32	minor	N	I-Premise
33	problems	N	I-Premise
34	of	N	I-Premise
35	incontinence	N	I-Premise
36	are	N	I-Premise
37	frequently	N	I-Premise
38	observed	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	postoperative	N	I-Premise
42	situation	N	I-Premise
43	and	N	I-Premise
44	negatively	N	I-Premise
45	affect	N	I-Premise
46	quality	N	I-Premise
47	of	N	I-Premise
48	life	N	I-Premise
49	.	N	I-Premise

50	Therefore	N	O
51	,	N	O
52	the	N	O
53	colonic	N	O
54	J-pouch	N	O
55	was	N	O
56	originally	N	O
57	constructed	N	O
58	to	N	O
59	create	N	O
60	a	N	O
61	stool	N	O
62	reservoir	N	O
63	.	N	O

64	In	N	O
65	a	N	O
66	randomized	N	O
67	,	N	O
68	prospective	N	O
69	study	N	O
70	,	N	O
71	the	N	O
72	short	N	O
73	(	N	O
74	5	N	O
75	cm	N	O
76	)	N	O
77	colonic	N	O
78	J-pouch	N	O
79	was	N	O
80	tested	N	O
81	for	N	O
82	function	N	O
83	and	N	O
84	continence	N	O
85	vs.	N	O
86	straight	N	O
87	coloanal	N	O
88	anastomosis	N	O
89	.	N	O

90	Over	N	O
91	a	N	O
92	period	N	O
93	of	N	O
94	30	N	O
95	months	N	O
96	,	N	O
97	74	N	O
98	consecutive	N	O
99	patients	N	O
100	(	N	O
101	55	N	O
102	males	N	O
103	)	N	O
104	with	N	O
105	rectal	N	O
106	cancer	N	O
107	in	N	O
108	the	N	O
109	lower	N	O
110	and	N	O
111	middle	N	O
112	third	N	O
113	of	N	O
114	the	N	O
115	rectum	N	O
116	were	N	O
117	included	N	O
118	and	N	O
119	randomized	N	O
120	into	N	O
121	two	N	O
122	groups	N	O
123	.	N	O

124	Anastomosis	N	O
125	was	N	O
126	performed	N	O
127	either	N	O
128	as	N	O
129	a	N	O
130	coloanal	N	O
131	or	N	O
132	a	N	O
133	colon-pouch-anal	N	O
134	anastomosis	N	O
135	.	N	O

136	The	N	O
137	standardized	N	O
138	surgical	N	O
139	procedure	N	O
140	included	N	O
141	mobilization	N	O
142	of	N	O
143	the	N	O
144	left	N	O
145	hemicolon	N	O
146	,	N	O
147	central	N	O
148	ligation	N	O
149	of	N	O
150	the	N	O
151	inferior	N	O
152	mesenteric	N	O
153	artery	N	O
154	and	N	O
155	vein	N	O
156	,	N	O
157	preaortal	N	O
158	lymph	N	O
159	node	N	O
160	dissection	N	O
161	,	N	O
162	autonomic	N	O
163	nerve	N	O
164	preservation	N	O
165	,	N	O
166	and	N	O
167	total	N	O
168	mesorectal	N	O
169	excision	N	O
170	.	N	O

171	The	N	O
172	anastomosis	N	O
173	was	N	O
174	performed	N	O
175	at	N	O
176	the	N	O
177	upper	N	O
178	anal	N	O
179	canal	N	O
180	or	N	O
181	at	N	O
182	the	N	O
183	intersphincteric	N	O
184	level	N	O
185	.	N	O

186	All	N	O
187	patients	N	O
188	were	N	O
189	evaluated	N	O
190	preoperatively	N	O
191	and	N	O
192	six	N	O
193	months	N	O
194	postoperatively	N	O
195	for	N	O
196	fecal	N	O
197	continence	N	O
198	,	N	O
199	including	N	O
200	sphincter	N	O
201	manometry	N	O
202	and	N	O
203	defecation	N	O
204	habits	N	O
205	.	N	O

206	In	N	O
207	addition	N	O
208	,	N	O
209	quality	N	O
210	of	N	O
211	life	N	O
212	was	N	O
213	determined	N	O
214	by	N	O
215	use	N	O
216	of	N	O
217	a	N	O
218	standardized	N	O
219	questionnaire	N	O
220	(	N	O
221	European	N	O
222	Organization	N	O
223	for	N	O
224	Research	N	O
225	and	N	O
226	Treatment	N	O
227	of	N	O
228	Cancer	N	O
229	,	N	O
230	EORTC-QLQ-C30	N	O
231	)	N	O
232	.	N	O

233	Thirty-seven	N	O
234	patients	N	O
235	were	N	O
236	randomized	N	O
237	into	N	O
238	each	N	O
239	group	N	O
240	.	N	O

241	In	N	O
242	general	N	O
243	,	N	O
244	problems	N	I-Premise
245	with	N	I-Premise
246	continence	N	I-Premise
247	for	N	I-Premise
248	liquids	N	I-Premise
249	or	N	I-Premise
250	gas	N	I-Premise
251	occurred	N	I-Premise
252	less	N	I-Premise
253	frequently	N	I-Premise
254	in	N	I-Premise
255	the	N	I-Premise
256	colonic	N	I-Premise
257	J-pouch	N	I-Premise
258	group	N	I-Premise
259	6	N	I-Premise
260	months	N	I-Premise
261	after	N	I-Premise
262	surgery	N	I-Premise
263	.	N	I-Premise

264	The	N	I-Premise
265	frequency	N	I-Premise
266	of	N	I-Premise
267	bowel	N	I-Premise
268	movements	N	I-Premise
269	was	N	I-Premise
270	lower	N	I-Premise
271	in	N	I-Premise
272	the	N	I-Premise
273	J-pouch	N	I-Premise
274	group	N	I-Premise
275	(	N	I-Premise
276	2.5	N	I-Premise
277	per	N	I-Premise
278	day	N	I-Premise
279	)	N	I-Premise
280	than	N	I-Premise
281	in	N	I-Premise
282	the	N	I-Premise
283	coloanal	N	I-Premise
284	group	N	I-Premise
285	(	N	I-Premise
286	4.7	N	I-Premise
287	per	N	I-Premise
288	day	N	I-Premise
289	)	N	I-Premise
290	.	N	I-Premise

291	Importantly	N	O
292	,	N	O
293	in	N	I-Premise
294	a	N	I-Premise
295	manometric	N	I-Premise
296	study	N	I-Premise
297	at	N	I-Premise
298	the	N	I-Premise
299	same	N	I-Premise
300	postoperative	N	I-Premise
301	point	N	I-Premise
302	,	N	I-Premise
303	neorectal	N	I-Premise
304	capacity	N	I-Premise
305	was	N	I-Premise
306	decreased	N	I-Premise
307	to	N	I-Premise
308	a	N	I-Premise
309	similar	N	I-Premise
310	degree	N	I-Premise
311	in	N	I-Premise
312	both	N	I-Premise
313	groups	N	I-Premise
314	compared	N	I-Premise
315	with	N	I-Premise
316	the	N	I-Premise
317	preoperative	N	I-Premise
318	rectal	N	I-Premise
319	volume	N	I-Premise
320	.	N	I-Premise

321	Thus	N	O
322	,	N	O
323	the	N	I-Premise
324	expected	N	I-Premise
325	and	N	I-Premise
326	postulated	N	I-Premise
327	reservoir	N	I-Premise
328	effect	N	I-Premise
329	could	N	I-Premise
330	not	N	I-Premise
331	be	N	I-Premise
332	achieved	N	I-Premise
333	by	N	I-Premise
334	forming	N	I-Premise
335	a	N	I-Premise
336	5-cm	N	I-Premise
337	colonic	N	I-Premise
338	J-pouch	N	I-Premise
339	.	N	I-Premise

340	The	N	I-Claim
341	colonic	N	I-Claim
342	J-pouch	N	I-Claim
343	was	N	I-Claim
344	superior	N	I-Claim
345	with	N	I-Claim
346	regard	N	I-Claim
347	to	N	I-Claim
348	continence	N	I-Claim
349	for	N	I-Claim
350	gas	N	I-Claim
351	and	N	I-Claim
352	liquids	N	I-Claim
353	compared	N	I-Claim
354	with	N	I-Claim
355	a	N	I-Claim
356	straight	N	I-Claim
357	coloanal	N	I-Claim
358	anastomosis	N	I-Claim
359	.	N	I-Claim

360	Furthermore	N	O
361	,	N	O
362	stool	N	I-Claim
363	frequency	N	I-Claim
364	was	N	I-Claim
365	significantly	N	I-Claim
366	lower	N	I-Claim
367	in	N	I-Claim
368	the	N	I-Claim
369	J-pouch	N	I-Claim
370	group	N	I-Claim
371	than	N	I-Claim
372	in	N	I-Claim
373	the	N	I-Claim
374	coloanal	N	I-Claim
375	reconstruction	N	I-Claim
376	group	N	I-Claim
377	.	N	I-Claim

378	However	N	O
379	,	N	O
380	because	N	I-Premise
381	neorectal	N	I-Premise
382	capacity	N	I-Premise
383	decreased	N	I-Premise
384	equally	N	I-Premise
385	in	N	I-Premise
386	both	N	I-Premise
387	groups	N	I-Premise
388	,	N	I-Premise
389	we	N	I-Claim
390	speculate	N	I-Claim
391	that	N	I-Claim
392	the	N	I-Claim
393	advantage	N	I-Claim
394	of	N	I-Claim
395	the	N	I-Claim
396	colonic	N	I-Claim
397	J-pouch	N	I-Claim
398	is	N	I-Claim
399	not	N	I-Claim
400	in	N	I-Claim
401	the	N	I-Claim
402	creation	N	I-Claim
403	of	N	I-Claim
404	a	N	I-Claim
405	larger	N	I-Claim
406	neorectal	N	I-Claim
407	reservoir	N	I-Claim
408	but	N	I-Claim
409	rather	N	I-Claim
410	may	N	I-Claim
411	be	N	I-Claim
412	related	N	I-Claim
413	to	N	I-Claim
414	decreased	N	I-Claim
415	motility	N	I-Claim
416	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	recombinant	N	O
7	human	N	O
8	erythropoietin	N	O
9	(	N	O
10	epoetin	N	O
11	beta	N	O
12	)	N	O
13	on	N	O
14	anemia	N	O
15	,	N	O
16	transfusion	N	O
17	need	N	O
18	,	N	O
19	and	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	in	N	O
27	severely	N	O
28	anemic	N	O
29	patients	N	O
30	with	N	O
31	low-grade	N	O
32	non-Hodgkin	N	O
33	's	N	O
34	lymphoma	N	O
35	(	N	O
36	NHL	N	O
37	)	N	O
38	,	N	O
39	chronic	N	O
40	lymphocytic	N	O
41	leukemia	N	O
42	(	N	O
43	CLL	N	O
44	)	N	O
45	,	N	O
46	or	N	O
47	multiple	N	O
48	myeloma	N	O
49	(	N	O
50	MM	N	O
51	)	N	O
52	.	N	O

53	Transfusion-dependent	N	O
54	patients	N	O
55	with	N	O
56	NHL	N	O
57	(	N	O
58	n	N	O
59	=	N	O
60	106	N	O
61	)	N	O
62	,	N	O
63	CLL	N	O
64	(	N	O
65	n	N	O
66	=	N	O
67	126	N	O
68	)	N	O
69	,	N	O
70	or	N	O
71	MM	N	O
72	(	N	O
73	n	N	O
74	=	N	O
75	117	N	O
76	)	N	O
77	and	N	O
78	a	N	O
79	low	N	O
80	serum	N	O
81	erythropoietin	N	O
82	concentration	N	O
83	were	N	O
84	randomized	N	O
85	to	N	O
86	receive	N	O
87	epoetin	N	O
88	beta	N	O
89	150	N	O
90	IU/kg	N	O
91	or	N	O
92	placebo	N	O
93	subcutaneously	N	O
94	three	N	O
95	times	N	O
96	a	N	O
97	week	N	O
98	for	N	O
99	16	N	O
100	weeks	N	O
101	.	N	O

102	Primary	N	O
103	efficacy	N	O
104	criteria	N	O
105	were	N	O
106	transfusion-free	N	O
107	and	N	O
108	transfusion-	N	O
109	and	N	O
110	severe	N	O
111	anemia-free	N	O
112	survival	N	O
113	(	N	O
114	hemoglobin	N	O
115	[	N	O
116	Hb	N	O
117	]	N	O
118	>	N	O
119	8.5	N	O
120	g/dL	N	O
121	)	N	O
122	between	N	O
123	weeks	N	O
124	5	N	O
125	to	N	O
126	16	N	O
127	.	N	O

128	Response	N	O
129	was	N	O
130	defined	N	O
131	as	N	O
132	an	N	O
133	increase	N	O
134	in	N	O
135	Hb	N	O
136	>	N	O
137	or	N	O
138	=	N	O
139	2	N	O
140	g/dL	N	O
141	with	N	O
142	elimination	N	O
143	of	N	O
144	transfusion	N	O
145	need	N	O
146	.	N	O

147	QOL	N	O
148	was	N	O
149	assessed	N	O
150	by	N	O
151	the	N	O
152	Functional	N	O
153	Assessment	N	O
154	of	N	O
155	Cancer	N	O
156	Therapy	N	O
157	scale	N	O
158	.	N	O

159	Transfusion-free	N	I-Premise
160	(	N	I-Premise
161	P	N	I-Premise
162	=.0012	N	I-Premise
163	)	N	I-Premise
164	survival	N	I-Premise
165	and	N	I-Premise
166	transfusion-	N	I-Premise
167	and	N	I-Premise
168	severe	N	I-Premise
169	anemia-free	N	I-Premise
170	survival	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	=.0001	N	I-Premise
174	)	N	I-Premise
175	were	N	I-Premise
176	significantly	N	I-Premise
177	greater	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	epoetin	N	I-Premise
181	beta	N	I-Premise
182	group	N	I-Premise
183	versus	N	I-Premise
184	placebo	N	I-Premise
185	(	N	I-Premise
186	Wald	N	I-Premise
187	chi	N	I-Premise
188	(	N	I-Premise
189	2	N	I-Premise
190	)	N	I-Premise
191	test	N	I-Premise
192	)	N	I-Premise
193	,	N	I-Premise
194	giving	N	I-Premise
195	a	N	I-Premise
196	relative	N	I-Premise
197	risk	N	I-Premise
198	reduction	N	I-Premise
199	of	N	I-Premise
200	43	N	I-Premise
201	%	N	I-Premise
202	and	N	I-Premise
203	51	N	I-Premise
204	%	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	.	N	I-Premise

208	The	N	I-Premise
209	response	N	I-Premise
210	rate	N	I-Premise
211	was	N	I-Premise
212	67	N	I-Premise
213	%	N	I-Premise
214	and	N	I-Premise
215	27	N	I-Premise
216	%	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	epoetin	N	I-Premise
220	beta	N	I-Premise
221	versus	N	I-Premise
222	the	N	I-Premise
223	placebo	N	I-Premise
224	group	N	I-Premise
225	,	N	I-Premise
226	respectively	N	I-Premise
227	(	N	I-Premise
228	P	N	I-Premise
229	<	N	I-Premise
230	.0001	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	After	N	I-Premise
234	12	N	I-Premise
235	and	N	I-Premise
236	16	N	I-Premise
237	weeks	N	I-Premise
238	of	N	I-Premise
239	treatment	N	I-Premise
240	,	N	I-Premise
241	QOL	N	I-Premise
242	significantly	N	I-Premise
243	improved	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	epoetin	N	I-Premise
247	beta	N	I-Premise
248	group	N	I-Premise
249	compared	N	I-Premise
250	with	N	I-Premise
251	placebo	N	I-Premise
252	(	N	I-Premise
253	P	N	I-Premise
254	<	N	I-Premise
255	.05	N	I-Premise
256	)	N	I-Premise
257	;	N	I-Premise
258	this	N	I-Premise
259	improvement	N	I-Premise
260	correlated	N	I-Premise
261	with	N	I-Premise
262	an	N	I-Premise
263	increase	N	I-Premise
264	in	N	I-Premise
265	Hb	N	I-Premise
266	concentration	N	I-Premise
267	(	N	I-Premise
268	>	N	I-Premise
269	or	N	I-Premise
270	=	N	I-Premise
271	2	N	I-Premise
272	g/dL	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	A	N	O
276	target	N	O
277	Hb	N	O
278	that	N	O
279	could	N	O
280	be	N	O
281	generally	N	O
282	recommended	N	O
283	could	N	O
284	not	N	O
285	be	N	O
286	identified	N	O
287	.	N	O

288	Many	N	I-Claim
289	severely	N	I-Claim
290	anemic	N	I-Claim
291	and	N	I-Claim
292	transfusion-dependent	N	I-Claim
293	patients	N	I-Claim
294	with	N	I-Claim
295	advanced	N	I-Claim
296	MM	N	I-Claim
297	,	N	I-Claim
298	NHL	N	I-Claim
299	,	N	I-Claim
300	and	N	I-Claim
301	CLL	N	I-Claim
302	and	N	I-Claim
303	a	N	I-Claim
304	low	N	I-Claim
305	performance	N	I-Claim
306	status	N	I-Claim
307	benefited	N	I-Claim
308	from	N	I-Claim
309	epoetin	N	I-Claim
310	therapy	N	I-Claim
311	,	N	I-Claim
312	with	N	I-Claim
313	elimination	N	I-Claim
314	of	N	I-Claim
315	severe	N	I-Claim
316	anemia	N	I-Claim
317	and	N	I-Claim
318	transfusion	N	I-Claim
319	need	N	I-Claim
320	,	N	I-Claim
321	and	N	I-Claim
322	improvement	N	I-Claim
323	in	N	I-Claim
324	QOL	N	I-Claim
325	.	N	I-Claim

1	This	N	O
2	randomised	N	O
3	trial	N	O
4	compared	N	O
5	three	N	O
6	chemotherapy	N	O
7	regimens	N	O
8	in	N	O
9	the	N	O
10	first-line	N	O
11	treatment	N	O
12	of	N	O
13	advanced	N	O
14	colorectal	N	O
15	cancer	N	O
16	,	N	O
17	in	N	O
18	terms	N	O
19	of	N	O
20	their	N	O
21	effect	N	O
22	on	N	O
23	overall	N	O
24	and	N	O
25	progression-free	N	O
26	survival	N	O
27	;	N	O
28	other	N	O
29	endpoints	N	O
30	included	N	O
31	toxicity	N	O
32	,	N	O
33	symptom	N	O
34	palliation	N	O
35	,	N	O
36	and	N	O
37	quality	N	O
38	of	N	O
39	life	N	O
40	.	N	O

41	905	N	O
42	patients	N	O
43	were	N	O
44	randomly	N	O
45	assigned	N	O
46	the	N	O
47	de	N	O
48	Gramont	N	O
49	regimen	N	O
50	(	N	O
51	n=303	N	O
52	;	N	O
53	folinic	N	O
54	acid	N	O
55	200	N	O
56	mg/m	N	O
57	(	N	O
58	2	N	O
59	)	N	O
60	,	N	O
61	fluorouracil	N	O
62	bolus	N	O
63	400	N	O
64	mg/m	N	O
65	(	N	O
66	2	N	O
67	)	N	O
68	,	N	O
69	and	N	O
70	infusion	N	O
71	600	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	on	N	O
77	days	N	O
78	1	N	O
79	and	N	O
80	2	N	O
81	,	N	O
82	repeated	N	O
83	every	N	O
84	14	N	O
85	days	N	O
86	)	N	O
87	,	N	O
88	the	N	O
89	Lokich	N	O
90	regimen	N	O
91	(	N	O
92	n=301	N	O
93	;	N	O
94	protracted	N	O
95	venous	N	O
96	infusion	N	O
97	of	N	O
98	fluorouracil	N	O
99	300	N	O
100	mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	daily	N	O
105	)	N	O
106	,	N	O
107	or	N	O
108	raltitrexed	N	O
109	(	N	O
110	n=301	N	O
111	;	N	O
112	3	N	O
113	mg/m	N	O
114	(	N	O
115	2	N	O
116	)	N	O
117	intravenously	N	O
118	every	N	O
119	21	N	O
120	days	N	O
121	)	N	O
122	.	N	O

123	Analyses	N	O
124	were	N	O
125	by	N	O
126	intention	N	O
127	to	N	O
128	treat	N	O
129	.	N	O

130	Median	N	O
131	follow-up	N	O
132	of	N	O
133	survivors	N	O
134	was	N	O
135	67	N	O
136	weeks	N	O
137	.	N	O

138	For	N	I-Premise
139	the	N	I-Premise
140	de	N	I-Premise
141	Gramont	N	I-Premise
142	,	N	I-Premise
143	Lokich	N	I-Premise
144	,	N	I-Premise
145	and	N	I-Premise
146	raltitrexed	N	I-Premise
147	groups	N	I-Premise
148	,	N	I-Premise
149	respectively	N	I-Premise
150	,	N	I-Premise
151	median	N	I-Premise
152	survival	N	I-Premise
153	was	N	I-Premise
154	294	N	I-Premise
155	,	N	I-Premise
156	302	N	I-Premise
157	,	N	I-Premise
158	and	N	I-Premise
159	266	N	I-Premise
160	days	N	I-Premise
161	.	N	I-Premise

162	The	N	I-Premise
163	hazard	N	I-Premise
164	ratios	N	I-Premise
165	for	N	I-Premise
166	overall	N	I-Premise
167	survival	N	I-Premise
168	were	N	I-Premise
169	0.88	N	I-Premise
170	(	N	I-Premise
171	95	N	I-Premise
172	%	N	I-Premise
173	CI	N	I-Premise
174	0.70-1.12	N	I-Premise
175	,	N	I-Premise
176	p=0.17	N	I-Premise
177	)	N	I-Premise
178	for	N	I-Premise
179	de	N	I-Premise
180	Gramont	N	I-Premise
181	versus	N	I-Premise
182	Lokich	N	I-Premise
183	,	N	I-Premise
184	and	N	I-Premise
185	0.99	N	I-Premise
186	(	N	I-Premise
187	0.79-1.25	N	I-Premise
188	,	N	I-Premise
189	p=0.94	N	I-Premise
190	)	N	I-Premise
191	for	N	I-Premise
192	de	N	I-Premise
193	Gramont	N	I-Premise
194	versus	N	I-Premise
195	raltitrexed	N	I-Premise
196	.	N	I-Premise

197	An	N	I-Premise
198	increase	N	I-Premise
199	in	N	I-Premise
200	treatment-related	N	I-Premise
201	deaths	N	I-Premise
202	was	N	I-Premise
203	seen	N	I-Premise
204	on	N	I-Premise
205	raltitrexed	N	I-Premise
206	(	N	I-Premise
207	de	N	I-Premise
208	Gramont	N	I-Premise
209	one	N	I-Premise
210	,	N	I-Premise
211	Lokich	N	I-Premise
212	two	N	I-Premise
213	,	N	I-Premise
214	raltitrexed	N	I-Premise
215	18	N	I-Premise
216	)	N	I-Premise
217	due	N	I-Premise
218	to	N	I-Premise
219	combined	N	I-Premise
220	gastrointestinal	N	I-Premise
221	and	N	I-Premise
222	haematological	N	I-Premise
223	toxicity	N	I-Premise
224	.	N	I-Premise

225	Patients	N	I-Premise
226	'	N	I-Premise
227	assessment	N	I-Premise
228	of	N	I-Premise
229	quality	N	I-Premise
230	of	N	I-Premise
231	life	N	I-Premise
232	showed	N	I-Premise
233	that	N	I-Premise
234	raltitrexed	N	I-Premise
235	was	N	I-Premise
236	inferior	N	I-Premise
237	to	N	I-Premise
238	the	N	I-Premise
239	fluorouracil-based	N	I-Premise
240	regimens	N	I-Premise
241	,	N	I-Premise
242	especially	N	I-Premise
243	in	N	I-Premise
244	terms	N	I-Premise
245	of	N	I-Premise
246	palliation	N	I-Premise
247	and	N	I-Premise
248	functioning	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Claim
251	deGramont	N	I-Claim
252	and	N	I-Claim
253	Lokich	N	I-Claim
254	regimens	N	I-Claim
255	were	N	I-Claim
256	similar	N	I-Claim
257	in	N	I-Claim
258	terms	N	I-Claim
259	of	N	I-Claim
260	survival	N	I-Claim
261	,	N	I-Claim
262	quality	N	I-Claim
263	of	N	I-Claim
264	life	N	I-Claim
265	,	N	I-Claim
266	and	N	I-Claim
267	response	N	I-Claim
268	rates	N	I-Claim
269	.	N	I-Claim

270	The	N	I-Claim
271	Lokich	N	I-Claim
272	regimen	N	I-Claim
273	was	N	I-Claim
274	associated	N	I-Claim
275	with	N	I-Claim
276	more	N	I-Claim
277	central	N	I-Claim
278	line	N	I-Claim
279	complications	N	I-Claim
280	and	N	I-Claim
281	hand-foot	N	I-Claim
282	syndrome	N	I-Claim
283	.	N	I-Claim

284	Raltitrexed	N	I-Claim
285	showed	N	I-Claim
286	similar	N	I-Claim
287	response	N	I-Claim
288	rates	N	I-Claim
289	and	N	I-Claim
290	overall	N	I-Claim
291	survival	N	I-Claim
292	to	N	I-Claim
293	the	N	I-Claim
294	de	N	I-Claim
295	Gramont	N	I-Claim
296	regimen	N	I-Claim
297	and	N	I-Claim
298	was	N	I-Claim
299	easier	N	I-Claim
300	to	N	I-Claim
301	administer	N	I-Claim
302	,	N	I-Claim
303	but	N	I-Claim
304	resulted	N	I-Claim
305	in	N	I-Claim
306	greater	N	I-Claim
307	toxicity	N	I-Claim
308	and	N	I-Claim
309	inferior	N	I-Claim
310	quality	N	I-Claim
311	of	N	I-Claim
312	life	N	I-Claim
313	.	N	I-Claim

1	The	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	compare	N	O
7	the	N	O
8	effects	N	O
9	of	N	O
10	treatment	N	O
11	with	N	O
12	a	N	O
13	combination	N	O
14	of	N	O
15	trastuzumab	N	O
16	(	N	O
17	Herceptin	N	O
18	;	N	O
19	Genentech	N	O
20	,	N	O
21	Inc	N	O
22	,	N	O
23	South	N	O
24	San	N	O
25	Francisco	N	O
26	,	N	O
27	CA	N	O
28	)	N	O
29	and	N	O
30	chemotherapy	N	O
31	versus	N	O
32	chemotherapy	N	O
33	alone	N	O
34	on	N	O
35	health-related	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	(	N	O
40	HRQL	N	O
41	)	N	O
42	in	N	O
43	patients	N	O
44	with	N	O
45	HER-2/neu	N	O
46	overexpressing	N	O
47	,	N	O
48	metastatic	N	O
49	breast	N	O
50	cancer	N	O
51	.	N	O

52	A	N	O
53	sample	N	O
54	of	N	O
55	400	N	O
56	patients	N	O
57	,	N	O
58	not	N	O
59	previously	N	O
60	treated	N	O
61	for	N	O
62	metastatic	N	O
63	disease	N	O
64	and	N	O
65	randomized	N	O
66	to	N	O
67	receive	N	O
68	either	N	O
69	trastuzumab	N	O
70	plus	N	O
71	chemotherapy	N	O
72	(	N	O
73	208	N	O
74	patients	N	O
75	)	N	O
76	or	N	O
77	chemotherapy	N	O
78	alone	N	O
79	(	N	O
80	192	N	O
81	patients	N	O
82	)	N	O
83	,	N	O
84	completed	N	O
85	the	N	O
86	European	N	O
87	Organization	N	O
88	for	N	O
89	Research	N	O
90	and	N	O
91	Treatment	N	O
92	Care	N	O
93	Quality	N	O
94	of	N	O
95	Life	N	O
96	Questionnaire	N	O
97	at	N	O
98	baseline	N	O
99	and	N	O
100	on	N	O
101	at	N	O
102	least	N	O
103	one	N	O
104	subsequent	N	O
105	occasion	N	O
106	at	N	O
107	8	N	O
108	,	N	O
109	20	N	O
110	,	N	O
111	32	N	O
112	,	N	O
113	44	N	O
114	,	N	O
115	and	N	O
116	56	N	O
117	weeks	N	O
118	.	N	O

119	HRQL	N	O
120	improvement	N	O
121	or	N	O
122	worsening	N	O
123	was	N	O
124	defined	N	O
125	as	N	O
126	a	N	O
127	>	N	O
128	or=	N	O
129	10-point	N	O
130	change	N	O
131	(	N	O
132	range	N	O
133	,	N	O
134	0	N	O
135	to	N	O
136	100	N	O
137	points	N	O
138	)	N	O
139	in	N	O
140	the	N	O
141	scores	N	O
142	of	N	O
143	six	N	O
144	preselected	N	O
145	domains	N	O
146	(	N	O
147	global	N	O
148	quality	N	O
149	of	N	O
150	life	N	O
151	[	N	O
152	QOL	N	O
153	]	N	O
154	,	N	O
155	physical	N	O
156	,	N	O
157	role	N	O
158	,	N	O
159	social	N	O
160	,	N	O
161	and	N	O
162	emotional	N	O
163	functioning	N	O
164	,	N	O
165	and	N	O
166	fatigue	N	O
167	)	N	O
168	.	N	O

169	Stable	N	O
170	HRQL	N	O
171	was	N	O
172	defined	N	O
173	as	N	O
174	a	N	O
175	change	N	O
176	of	N	O
177	less	N	O
178	than	N	O
179	10	N	O
180	.	N	O

181	A	N	O
182	Bonferroni	N	O
183	correction	N	O
184	was	N	O
185	applied	N	O
186	for	N	O
187	multiple	N	O
188	testing	N	O
189	.	N	O

190	After	N	I-Premise
191	completion	N	I-Premise
192	of	N	I-Premise
193	chemotherapy	N	I-Premise
194	,	N	I-Premise
195	patients	N	I-Premise
196	treated	N	I-Premise
197	with	N	I-Premise
198	trastuzumab	N	I-Premise
199	and	N	I-Premise
200	chemotherapy	N	I-Premise
201	reported	N	I-Premise
202	significant	N	I-Premise
203	improvement	N	I-Premise
204	in	N	I-Premise
205	fatigue	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	<	N	I-Premise
209	.05	N	I-Premise
210	)	N	I-Premise
211	as	N	I-Premise
212	compared	N	I-Premise
213	with	N	I-Premise
214	their	N	I-Premise
215	baseline	N	I-Premise
216	scores	N	I-Premise
217	.	N	I-Premise

218	Higher	N	I-Premise
219	proportions	N	I-Premise
220	of	N	I-Premise
221	patients	N	I-Premise
222	receiving	N	I-Premise
223	the	N	I-Premise
224	combined	N	I-Premise
225	therapy	N	I-Premise
226	achieved	N	I-Premise
227	improvement	N	I-Premise
228	in	N	I-Premise
229	global	N	I-Premise
230	QOL	N	I-Premise
231	(	N	I-Premise
232	P	N	I-Premise
233	<	N	I-Premise
234	.05	N	I-Premise
235	)	N	I-Premise
236	than	N	I-Premise
237	did	N	I-Premise
238	patients	N	I-Premise
239	treated	N	I-Premise
240	with	N	I-Premise
241	chemotherapy	N	I-Premise
242	alone	N	I-Premise
243	.	N	I-Premise

244	Higher	N	I-Premise
245	proportions	N	I-Premise
246	of	N	I-Premise
247	the	N	I-Premise
248	combined	N	I-Premise
249	therapy	N	I-Premise
250	group	N	I-Premise
251	also	N	I-Premise
252	achieved	N	I-Premise
253	improvement	N	I-Premise
254	in	N	I-Premise
255	physical	N	I-Premise
256	and	N	I-Premise
257	role	N	I-Premise
258	functioning	N	I-Premise
259	and	N	I-Premise
260	in	N	I-Premise
261	fatigue	N	I-Premise
262	as	N	I-Premise
263	compared	N	I-Premise
264	with	N	I-Premise
265	the	N	I-Premise
266	chemotherapy	N	I-Premise
267	group	N	I-Premise
268	,	N	I-Premise
269	but	N	I-Premise
270	the	N	I-Premise
271	differences	N	I-Premise
272	were	N	I-Premise
273	not	N	I-Premise
274	statistically	N	I-Premise
275	significant	N	I-Premise
276	.	N	I-Premise

277	There	N	I-Premise
278	were	N	I-Premise
279	no	N	I-Premise
280	differences	N	I-Premise
281	in	N	I-Premise
282	the	N	I-Premise
283	proportions	N	I-Premise
284	of	N	I-Premise
285	patients	N	I-Premise
286	in	N	I-Premise
287	the	N	I-Premise
288	two	N	I-Premise
289	groups	N	I-Premise
290	that	N	I-Premise
291	reported	N	I-Premise
292	worsening	N	I-Premise
293	.	N	I-Premise

294	Statistically	N	I-Claim
295	significantly	N	I-Claim
296	higher	N	I-Claim
297	proportions	N	I-Claim
298	of	N	I-Claim
299	patients	N	I-Claim
300	treated	N	I-Claim
301	with	N	I-Claim
302	a	N	I-Claim
303	combination	N	I-Claim
304	of	N	I-Claim
305	trastuzumab	N	I-Claim
306	and	N	I-Claim
307	chemotherapy	N	I-Claim
308	reported	N	I-Claim
309	improved	N	I-Claim
310	global	N	I-Claim
311	QOL	N	I-Claim
312	than	N	I-Claim
313	did	N	I-Claim
314	patients	N	I-Claim
315	treated	N	I-Claim
316	by	N	I-Claim
317	chemotherapy	N	I-Claim
318	alone	N	I-Claim
319	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	protracted	N	O
4	venous	N	O
5	infusion	N	O
6	(	N	O
7	PVI	N	O
8	)	N	O
9	fluorouracil	N	O
10	(	N	O
11	5-FU	N	O
12	)	N	O
13	with	N	O
14	PVI	N	O
15	5-FU	N	O
16	plus	N	O
17	mitomycin	N	O
18	(	N	O
19	MMC	N	O
20	)	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	advanced	N	O
25	pancreatic	N	O
26	cancer	N	O
27	in	N	O
28	a	N	O
29	multicenter	N	O
30	,	N	O
31	prospectively	N	O
32	randomized	N	O
33	study	N	O
34	.	N	O

35	Two	N	O
36	hundred	N	O
37	eight	N	O
38	patients	N	O
39	were	N	O
40	randomized	N	O
41	to	N	O
42	PVI	N	O
43	5-FU	N	O
44	(	N	O
45	300	N	O
46	mg/m	N	O
47	(	N	O
48	2	N	O
49	)	N	O
50	/d	N	O
51	for	N	O
52	a	N	O
53	maximum	N	O
54	of	N	O
55	24	N	O
56	weeks	N	O
57	)	N	O
58	or	N	O
59	PVI	N	O
60	5-FU	N	O
61	plus	N	O
62	MMC	N	O
63	(	N	O
64	7	N	O
65	mg/m	N	O
66	(	N	O
67	2	N	O
68	)	N	O
69	every	N	O
70	6	N	O
71	weeks	N	O
72	for	N	O
73	four	N	O
74	courses	N	O
75	)	N	O
76	.	N	O

77	The	N	O
78	major	N	O
79	end	N	O
80	points	N	O
81	were	N	O
82	tumor	N	O
83	response	N	O
84	,	N	O
85	survival	N	O
86	,	N	O
87	toxicity	N	O
88	,	N	O
89	and	N	O
90	quality	N	O
91	of	N	O
92	life	N	O
93	(	N	O
94	QOL	N	O
95	)	N	O
96	.	N	O

97	The	N	O
98	two	N	O
99	treatment	N	O
100	groups	N	O
101	were	N	O
102	balanced	N	O
103	for	N	O
104	baseline	N	O
105	demographic	N	O
106	factors	N	O
107	,	N	O
108	and	N	O
109	62	N	O
110	%	N	O
111	had	N	O
112	metastatic	N	O
113	disease	N	O
114	.	N	O

115	The	N	I-Premise
116	overall	N	I-Premise
117	response	N	I-Premise
118	rate	N	I-Premise
119	was	N	I-Premise
120	8.4	N	I-Premise
121	%	N	I-Premise
122	(	N	I-Premise
123	95	N	I-Premise
124	%	N	I-Premise
125	confidence	N	I-Premise
126	interval	N	I-Premise
127	[	N	I-Premise
128	CI	N	I-Premise
129	]	N	I-Premise
130	)	N	I-Premise
131	3.2	N	I-Premise
132	%	N	I-Premise
133	to	N	I-Premise
134	13.7	N	I-Premise
135	%	N	I-Premise
136	for	N	I-Premise
137	patients	N	I-Premise
138	treated	N	I-Premise
139	with	N	I-Premise
140	PVI	N	I-Premise
141	5-FU	N	I-Premise
142	alone	N	I-Premise
143	compared	N	I-Premise
144	with	N	I-Premise
145	17.6	N	I-Premise
146	%	N	I-Premise
147	;	N	I-Premise
148	95	N	I-Premise
149	%	N	I-Premise
150	CI	N	I-Premise
151	10.3	N	I-Premise
152	%	N	I-Premise
153	to	N	I-Premise
154	25.1	N	I-Premise
155	%	N	I-Premise
156	for	N	I-Premise
157	PVI	N	I-Premise
158	5-FU	N	I-Premise
159	plus	N	I-Premise
160	MMC	N	I-Premise
161	(	N	I-Premise
162	P	N	I-Premise
163	=.04	N	I-Premise
164	)	N	I-Premise
165	.	N	I-Premise

166	Median	N	I-Premise
167	failure-free	N	I-Premise
168	survival	N	I-Premise
169	was	N	I-Premise
170	2.8	N	I-Premise
171	months	N	I-Premise
172	for	N	I-Premise
173	PVI	N	I-Premise
174	5-FU	N	I-Premise
175	and	N	I-Premise
176	3.8	N	I-Premise
177	months	N	I-Premise
178	for	N	I-Premise
179	PVI	N	I-Premise
180	5-FU	N	I-Premise
181	plus	N	I-Premise
182	MMC	N	I-Premise
183	(	N	I-Premise
184	P	N	I-Premise
185	=.14	N	I-Premise
186	)	N	I-Premise
187	.	N	I-Premise

188	Median	N	I-Premise
189	survival	N	I-Premise
190	was	N	I-Premise
191	5.1	N	I-Premise
192	months	N	I-Premise
193	for	N	I-Premise
194	PVI	N	I-Premise
195	5-FU	N	I-Premise
196	and	N	I-Premise
197	6.5	N	I-Premise
198	months	N	I-Premise
199	for	N	I-Premise
200	PVI	N	I-Premise
201	5-FU	N	I-Premise
202	plus	N	I-Premise
203	MMC	N	I-Premise
204	(	N	I-Premise
205	P	N	I-Premise
206	=.34	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	Toxicities	N	I-Premise
210	in	N	I-Premise
211	both	N	I-Premise
212	arms	N	I-Premise
213	were	N	I-Premise
214	mild	N	I-Premise
215	.	N	I-Premise

216	There	N	I-Premise
217	was	N	I-Premise
218	an	N	I-Premise
219	increased	N	I-Premise
220	incidence	N	I-Premise
221	of	N	I-Premise
222	neutropenia	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	5-FU	N	I-Premise
226	plus	N	I-Premise
227	MMC	N	I-Premise
228	arm	N	I-Premise
229	(	N	I-Premise
230	P	N	I-Premise
231	<	N	I-Premise
232	.01	N	I-Premise
233	)	N	I-Premise
234	,	N	I-Premise
235	although	N	I-Premise
236	no	N	I-Premise
237	differences	N	I-Premise
238	in	N	I-Premise
239	infection	N	I-Premise
240	were	N	I-Premise
241	seen	N	I-Premise
242	.	N	I-Premise

243	No	N	I-Premise
244	patients	N	I-Premise
245	developed	N	I-Premise
246	hemolytic	N	I-Premise
247	uremic	N	I-Premise
248	syndrome	N	I-Premise
249	.	N	I-Premise

250	Global	N	I-Claim
251	QOL	N	I-Claim
252	improved	N	I-Claim
253	significantly	N	I-Claim
254	after	N	I-Claim
255	24	N	I-Claim
256	weeks	N	I-Claim
257	of	N	I-Claim
258	treatment	N	I-Claim
259	compared	N	I-Claim
260	with	N	I-Claim
261	baseline	N	I-Claim
262	for	N	I-Claim
263	patients	N	I-Claim
264	receiving	N	I-Claim
265	5-FU	N	I-Claim
266	plus	N	I-Claim
267	MMC	N	I-Claim
268	,	N	I-Claim
269	although	N	I-Premise
270	there	N	I-Premise
271	was	N	I-Premise
272	no	N	I-Premise
273	statistically	N	I-Premise
274	significant	N	I-Premise
275	difference	N	I-Premise
276	in	N	I-Premise
277	QOL	N	I-Premise
278	between	N	I-Premise
279	arms	N	I-Premise
280	.	N	I-Premise

281	PVI	N	I-Claim
282	5-FU	N	I-Claim
283	plus	N	I-Claim
284	MMC	N	I-Claim
285	resulted	N	I-Claim
286	in	N	I-Claim
287	a	N	I-Claim
288	superior	N	I-Claim
289	response	N	I-Claim
290	rate	N	I-Claim
291	in	N	I-Claim
292	comparison	N	I-Claim
293	with	N	I-Claim
294	PVI	N	I-Claim
295	5-FU	N	I-Claim
296	alone	N	I-Claim
297	in	N	I-Claim
298	advanced	N	I-Claim
299	pancreatic	N	I-Claim
300	cancer	N	I-Claim
301	,	N	I-Claim
302	but	N	I-Claim
303	this	N	I-Claim
304	did	N	I-Claim
305	not	N	I-Claim
306	translate	N	I-Claim
307	into	N	I-Claim
308	a	N	I-Claim
309	survival	N	I-Claim
310	advantage	N	I-Claim
311	.	N	I-Claim

312	These	N	I-Claim
313	results	N	I-Claim
314	emphasize	N	I-Claim
315	the	N	I-Claim
316	importance	N	I-Claim
317	of	N	I-Claim
318	chemotherapy	N	I-Claim
319	in	N	I-Claim
320	this	N	I-Claim
321	setting	N	I-Claim
322	and	N	I-Claim
323	the	N	I-Claim
324	continuing	N	I-Claim
325	value	N	I-Claim
326	of	N	I-Claim
327	the	N	I-Claim
328	fluoropyrimidines	N	I-Claim
329	in	N	I-Claim
330	pancreatic	N	I-Claim
331	cancer	N	I-Claim
332	.	N	I-Claim

1	We	N	O
2	compared	N	O
3	the	N	O
4	clinical	N	O
5	effects	N	O
6	and	N	O
7	impact	N	O
8	on	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	of	N	O
16	patients	N	O
17	who	N	O
18	received	N	O
19	a	N	O
20	3-month	N	O
21	course	N	O
22	of	N	O
23	flutamide	N	O
24	monotherapy	N	O
25	before	N	O
26	radical	N	O
27	prostatectomy	N	O
28	with	N	O
29	those	N	O
30	who	N	O
31	received	N	O
32	a	N	O
33	3-month	N	O
34	course	N	O
35	of	N	O
36	luteinizing	N	O
37	hormone-releasing	N	O
38	hormone	N	O
39	(	N	O
40	LHRH	N	O
41	)	N	O
42	agonist	N	O
43	monotherapy	N	O
44	.	N	O

45	Thirty-seven	N	O
46	patients	N	O
47	with	N	O
48	non-metastatic	N	O
49	prostate	N	O
50	cancer	N	O
51	were	N	O
52	enrolled	N	O
53	in	N	O
54	this	N	O
55	study	N	O
56	(	N	O
57	19	N	O
58	,	N	O
59	flutamide	N	O
60	;	N	O
61	18	N	O
62	,	N	O
63	LHRH	N	O
64	agonist	N	O
65	)	N	O
66	.	N	O

67	The	N	O
68	rates	N	O
69	of	N	O
70	change	N	O
71	of	N	O
72	serum	N	O
73	prostate-specific	N	O
74	antigen	N	O
75	(	N	O
76	PSA	N	O
77	)	N	O
78	and	N	O
79	testosterone	N	O
80	levels	N	O
81	,	N	O
82	downsizing	N	O
83	of	N	O
84	prostate	N	O
85	volume	N	O
86	,	N	O
87	the	N	O
88	rate	N	O
89	of	N	O
90	organ	N	O
91	confined	N	O
92	disease	N	O
93	,	N	O
94	adverse	N	O
95	effects	N	O
96	and	N	O
97	perioperative	N	O
98	scores	N	O
99	measured	N	O
100	using	N	O
101	the	N	O
102	European	N	O
103	Organization	N	O
104	for	N	O
105	Research	N	O
106	and	N	O
107	Treatment	N	O
108	of	N	O
109	Cancer	N	O
110	Prostate	N	O
111	Cancer	N	O
112	Quality	N	O
113	of	N	O
114	Life	N	O
115	Questionnaire	N	O
116	(	N	O
117	EORTC-P	N	O
118	)	N	O
119	and	N	O
120	the	N	O
121	Sapporo	N	O
122	Medical	N	O
123	University	N	O
124	Sexual	N	O
125	Function	N	O
126	Questionnaire	N	O
127	(	N	O
128	SMUF	N	O
129	)	N	O
130	were	N	O
131	analyzed	N	O
132	.	N	O

133	At	N	I-Premise
134	radical	N	I-Premise
135	prostatectomy	N	I-Premise
136	,	N	I-Premise
137	pathological	N	I-Premise
138	variables	N	I-Premise
139	were	N	I-Premise
140	not	N	I-Premise
141	significantly	N	I-Premise
142	different	N	I-Premise
143	in	N	I-Premise
144	the	N	I-Premise
145	two	N	I-Premise
146	groups	N	I-Premise
147	.	N	I-Premise

148	Serum	N	I-Premise
149	testosterone	N	I-Premise
150	level	N	I-Premise
151	was	N	I-Premise
152	significantly	N	I-Premise
153	higher	N	I-Premise
154	(	N	I-Premise
155	mean	N	I-Premise
156	359.2	N	I-Premise
157	compared	N	I-Premise
158	to	N	I-Premise
159	10.5	N	I-Premise
160	,	N	I-Premise
161	P	N	I-Premise
162	<	N	I-Premise
163	0.001	N	I-Premise
164	)	N	I-Premise
165	,	N	I-Premise
166	complete	N	I-Premise
167	response	N	I-Premise
168	rate	N	I-Premise
169	of	N	I-Premise
170	PSA	N	I-Premise
171	(	N	I-Premise
172	13	N	I-Premise
173	%	N	I-Premise
174	compared	N	I-Premise
175	to	N	I-Premise
176	57	N	I-Premise
177	%	N	I-Premise
178	,	N	I-Premise
179	P	N	I-Premise
180	=	N	I-Premise
181	0.028	N	I-Premise
182	)	N	I-Premise
183	and	N	I-Premise
184	rate	N	I-Premise
185	of	N	I-Premise
186	downsizing	N	I-Premise
187	of	N	I-Premise
188	prostate	N	I-Premise
189	volume	N	I-Premise
190	(	N	I-Premise
191	mean	N	I-Premise
192	,	N	I-Premise
193	-17.7	N	I-Premise
194	%	N	I-Premise
195	compared	N	I-Premise
196	to	N	I-Premise
197	-35.4	N	I-Premise
198	%	N	I-Premise
199	,	N	I-Premise
200	P	N	I-Premise
201	=	N	I-Premise
202	0.038	N	I-Premise
203	)	N	I-Premise
204	were	N	I-Premise
205	significantly	N	I-Premise
206	lower	N	I-Premise
207	in	N	I-Premise
208	the	N	I-Premise
209	flutamide	N	I-Premise
210	group	N	I-Premise
211	than	N	I-Premise
212	in	N	I-Premise
213	the	N	I-Premise
214	LHRH	N	I-Premise
215	group	N	I-Premise
216	.	N	I-Premise

217	After	N	I-Premise
218	neoadjuvant	N	I-Premise
219	hormone	N	I-Premise
220	therapy	N	I-Premise
221	,	N	I-Premise
222	the	N	I-Premise
223	scores	N	I-Premise
224	on	N	I-Premise
225	the	N	I-Premise
226	sexual	N	I-Premise
227	problem	N	I-Premise
228	domain	N	I-Premise
229	of	N	I-Premise
230	EORTC-P	N	I-Premise
231	(	N	I-Premise
232	P	N	I-Premise
233	=	N	I-Premise
234	0.033	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	sexual	N	I-Premise
238	desire	N	I-Premise
239	score	N	I-Premise
240	of	N	I-Premise
241	SMUF	N	I-Premise
242	(	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	0.021	N	I-Premise
246	)	N	I-Premise
247	were	N	I-Premise
248	significantly	N	I-Premise
249	higher	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	flutamide	N	I-Premise
253	group	N	I-Premise
254	than	N	I-Premise
255	in	N	I-Premise
256	the	N	I-Premise
257	LHRH	N	I-Premise
258	group	N	I-Premise
259	.	N	I-Premise

260	At	N	I-Premise
261	a	N	I-Premise
262	median	N	I-Premise
263	follow-up	N	I-Premise
264	of	N	I-Premise
265	34	N	I-Premise
266	months	N	I-Premise
267	after	N	I-Premise
268	prostatectomy	N	I-Premise
269	,	N	I-Premise
270	biochemical	N	I-Premise
271	failure-free	N	I-Premise
272	survival	N	I-Premise
273	rate	N	I-Premise
274	in	N	I-Premise
275	the	N	I-Premise
276	flutamide	N	I-Premise
277	group	N	I-Premise
278	did	N	I-Premise
279	not	N	I-Premise
280	differ	N	I-Premise
281	from	N	I-Premise
282	that	N	I-Premise
283	in	N	I-Premise
284	the	N	I-Premise
285	LHRH	N	I-Premise
286	group	N	I-Premise
287	.	N	I-Premise

288	This	N	I-Claim
289	study	N	I-Claim
290	suggests	N	I-Claim
291	that	N	I-Claim
292	flutamide	N	I-Claim
293	monotherapy	N	I-Claim
294	can	N	I-Claim
295	be	N	I-Claim
296	an	N	I-Claim
297	acceptable	N	I-Claim
298	modality	N	I-Claim
299	as	N	I-Claim
300	an	N	I-Claim
301	option	N	I-Claim
302	for	N	I-Claim
303	neoadjuvant	N	I-Claim
304	hormone	N	I-Claim
305	therapy	N	I-Claim
306	.	N	I-Claim

1	We	N	O
2	previously	N	O
3	reported	N	O
4	that	N	O
5	treatment	N	O
6	of	N	O
7	patients	N	O
8	with	N	O
9	symptomatic	N	O
10	advanced	N	O
11	non-small	N	O
12	cell	N	O
13	lung	N	O
14	cancer	N	O
15	with	N	O
16	single	N	O
17	agent	N	O
18	Gemcitabine	N	O
19	(	N	O
20	GEM	N	O
21	)	N	O
22	resulted	N	O
23	in	N	O
24	a	N	O
25	superior	N	O
26	clinical-benefit	N	O
27	response	N	O
28	rate	N	O
29	(	N	O
30	RR	N	O
31	)	N	O
32	compared	N	O
33	to	N	O
34	cisplatin-based	N	O
35	combination	N	O
36	chemotherapy	N	O
37	.	N	O

38	We	N	O
39	now	N	O
40	report	N	O
41	the	N	O
42	detailed	N	O
43	individual	N	O
44	symptom	N	O
45	control	N	O
46	analysis	N	O
47	,	N	O
48	and	N	O
49	the	N	O
50	influence	N	O
51	of	N	O
52	cisplatin-use	N	O
53	,	N	O
54	age	N	O
55	,	N	O
56	performance	N	O
57	status	N	O
58	(	N	O
59	PS	N	O
60	)	N	O
61	and	N	O
62	duration	N	O
63	of	N	O
64	treatment	N	O
65	.	N	O

66	Patients	N	O
67	received	N	O
68	either	N	O
69	GEM	N	O
70	(	N	O
71	1000	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	,	N	O
77	days	N	O
78	1	N	O
79	,	N	O
80	8	N	O
81	and	N	O
82	15	N	O
83	)	N	O
84	or	N	O
85	cisplatin	N	O
86	(	N	O
87	100	N	O
88	mg/m	N	O
89	(	N	O
90	2	N	O
91	)	N	O
92	,	N	O
93	day	N	O
94	1	N	O
95	)	N	O
96	plus	N	O
97	Vindesine	N	O
98	(	N	O
99	3	N	O
100	mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	,	N	O
105	days	N	O
106	1	N	O
107	and	N	O
108	15	N	O
109	)	N	O
110	(	N	O
111	PV	N	O
112	)	N	O
113	,	N	O
114	both	N	O
115	every	N	O
116	4	N	O
117	weeks	N	O
118	.	N	O

119	Scores	N	O
120	of	N	O
121	9	N	O
122	symptoms	N	O
123	were	N	O
124	listed	N	O
125	weekly	N	O
126	by	N	O
127	the	N	O
128	patient	N	O
129	on	N	O
130	visual	N	O
131	analogue	N	O
132	scales	N	O
133	.	N	O

134	Improvement	N	O
135	of	N	O
136	a	N	O
137	symptom	N	O
138	was	N	O
139	defined	N	O
140	as	N	O
141	2	N	O
142	consecutive	N	O
143	cycles	N	O
144	of	N	O
145	improvement	N	O
146	over	N	O
147	baseline	N	O
148	.	N	O

149	Baseline	N	O
150	symptoms	N	O
151	in	N	O
152	the	N	O
153	169	N	O
154	patients	N	O
155	were	N	O
156	well	N	O
157	balanced	N	O
158	between	N	O
159	the	N	O
160	2	N	O
161	arms	N	O
162	(	N	O
163	84	N	O
164	GEM	N	O
165	,	N	O
166	85	N	O
167	PV	N	O
168	)	N	O
169	.	N	O

170	Both	N	I-Premise
171	patients	N	I-Premise
172	with	N	I-Premise
173	objective	N	I-Premise
174	response	N	I-Premise
175	and	N	I-Premise
176	disease	N	I-Premise
177	stabilisation	N	I-Premise
178	had	N	I-Premise
179	clearly	N	I-Premise
180	better	N	I-Premise
181	symptom	N	I-Premise
182	control	N	I-Premise
183	than	N	I-Premise
184	those	N	I-Premise
185	with	N	I-Premise
186	disease	N	I-Premise
187	progression	N	I-Premise
188	.	N	I-Premise

189	Symptom	N	I-Premise
190	control	N	I-Premise
191	in	N	I-Premise
192	both	N	I-Premise
193	arms	N	I-Premise
194	was	N	I-Premise
195	similar	N	I-Premise
196	for	N	I-Premise
197	'disease-specific	N	I-Premise
198	'	N	I-Premise
199	symptoms	N	I-Premise
200	such	N	I-Premise
201	as	N	I-Premise
202	cough	N	I-Premise
203	,	N	I-Premise
204	dyspnea	N	I-Premise
205	,	N	I-Premise
206	pain	N	I-Premise
207	or	N	I-Premise
208	haemoptysis	N	I-Premise
209	.	N	I-Premise

210	Compared	N	I-Premise
211	to	N	I-Premise
212	PV	N	I-Premise
213	,	N	I-Premise
214	a	N	I-Premise
215	significantly	N	I-Premise
216	larger	N	I-Premise
217	number	N	I-Premise
218	of	N	I-Premise
219	GEM-patients	N	I-Premise
220	had	N	I-Premise
221	better	N	I-Premise
222	scores	N	I-Premise
223	for	N	I-Premise
224	'constitutional	N	I-Premise
225	'	N	I-Premise
226	items	N	I-Premise
227	such	N	I-Premise
228	as	N	I-Premise
229	anorexia	N	I-Premise
230	(	N	I-Premise
231	P=0.007	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	ability	N	I-Premise
235	to	N	I-Premise
236	carry	N	I-Premise
237	on	N	I-Premise
238	with	N	I-Premise
239	daily	N	I-Premise
240	activities	N	I-Premise
241	(	N	I-Premise
242	P=0.04	N	I-Premise
243	)	N	I-Premise
244	and	N	I-Premise
245	overall	N	I-Premise
246	impression	N	I-Premise
247	of	N	I-Premise
248	quality-of-life	N	I-Premise
249	(	N	I-Premise
250	P=0.008	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	Symptom	N	I-Premise
254	control	N	I-Premise
255	was	N	I-Premise
256	very	N	I-Premise
257	similar	N	I-Premise
258	in	N	I-Premise
259	younger	N	I-Premise
260	(	N	I-Premise
261	<	N	I-Premise
262	65	N	I-Premise
263	years	N	I-Premise
264	)	N	I-Premise
265	versus	N	I-Premise
266	older	N	I-Premise
267	(	N	I-Premise
268	>	N	I-Premise
269	/=65	N	I-Premise
270	years	N	I-Premise
271	)	N	I-Premise
272	patients	N	I-Premise
273	,	N	I-Premise
274	and	N	I-Premise
275	only	N	I-Premise
276	slightly	N	I-Premise
277	better	N	I-Premise
278	in	N	I-Premise
279	those	N	I-Premise
280	with	N	I-Premise
281	a	N	I-Premise
282	Karnofsky	N	I-Premise
283	PS	N	I-Premise
284	>	N	I-Premise
285	/=80	N	I-Premise
286	%	N	I-Premise
287	compared	N	I-Premise
288	to	N	I-Premise
289	those	N	I-Premise
290	<	N	I-Premise
291	80	N	I-Premise
292	%	N	I-Premise
293	.	N	I-Premise

294	Most	N	I-Premise
295	of	N	I-Premise
296	the	N	I-Premise
297	symptom	N	I-Premise
298	improvement	N	I-Premise
299	occurred	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	first	N	I-Premise
303	3	N	I-Premise
304	cycles	N	I-Premise
305	,	N	I-Premise
306	with	N	I-Premise
307	some	N	I-Premise
308	further	N	I-Premise
309	symptom	N	I-Premise
310	improvement	N	I-Premise
311	in	N	I-Premise
312	the	N	I-Premise
313	following	N	I-Premise
314	cycles	N	I-Premise
315	in	N	I-Premise
316	the	N	I-Premise
317	GEM-arm	N	I-Premise
318	only	N	I-Premise
319	.	N	I-Premise

320	Both	N	I-Claim
321	GEM	N	I-Claim
322	and	N	I-Claim
323	PV	N	I-Claim
324	yield	N	I-Claim
325	a	N	I-Claim
326	symptom	N	I-Claim
327	control	N	I-Claim
328	rate	N	I-Claim
329	much	N	I-Claim
330	higher	N	I-Claim
331	than	N	I-Claim
332	expected	N	I-Claim
333	by	N	I-Claim
334	the	N	I-Claim
335	objective	N	I-Claim
336	tumour	N	I-Claim
337	RR	N	I-Claim
338	.	N	I-Claim

339	GEM	N	I-Claim
340	is	N	I-Claim
341	equally	N	I-Claim
342	effective	N	I-Claim
343	in	N	I-Claim
344	controlling	N	I-Claim
345	'disease-specific	N	I-Claim
346	'	N	I-Claim
347	symptoms	N	I-Claim
348	,	N	I-Claim
349	but	N	I-Claim
350	superior	N	I-Claim
351	in	N	I-Claim
352	controlling	N	I-Claim
353	'constitutional	N	I-Claim
354	'	N	I-Claim
355	symptoms	N	I-Claim
356	.	N	I-Claim

357	Most	N	I-Premise
358	of	N	I-Premise
359	the	N	I-Premise
360	symptom	N	I-Premise
361	control	N	I-Premise
362	was	N	I-Premise
363	achieved	N	I-Premise
364	during	N	I-Premise
365	the	N	I-Premise
366	first	N	I-Premise
367	3	N	I-Premise
368	cycles	N	I-Premise
369	of	N	I-Premise
370	treatment	N	I-Premise
371	,	N	I-Premise
372	with	N	I-Premise
373	some	N	I-Premise
374	further	N	I-Premise
375	improvement	N	I-Premise
376	thereafter	N	I-Premise
377	in	N	I-Premise
378	the	N	I-Premise
379	GEM-arm	N	I-Premise
380	only	N	I-Premise
381	.	N	I-Premise

1	Androgen	N	I-Claim
2	deprivation	N	I-Claim
3	therapy	N	I-Claim
4	is	N	I-Claim
5	a	N	I-Claim
6	common	N	I-Claim
7	treatment	N	I-Claim
8	in	N	I-Claim
9	men	N	I-Claim
10	with	N	I-Claim
11	prostate	N	I-Claim
12	cancer	N	I-Claim
13	that	N	I-Claim
14	may	N	I-Claim
15	cause	N	I-Claim
16	fatigue	N	I-Claim
17	,	N	I-Claim
18	functional	N	I-Claim
19	decline	N	I-Claim
20	,	N	I-Claim
21	increased	N	I-Claim
22	body	N	I-Claim
23	fatness	N	I-Claim
24	,	N	I-Claim
25	and	N	I-Claim
26	loss	N	I-Claim
27	of	N	I-Claim
28	lean	N	I-Claim
29	body	N	I-Claim
30	tissue	N	I-Claim
31	.	N	I-Claim

32	These	N	I-Claim
33	physical	N	I-Claim
34	changes	N	I-Claim
35	can	N	I-Claim
36	negatively	N	I-Claim
37	affect	N	I-Claim
38	health-related	N	I-Claim
39	quality	N	I-Claim
40	of	N	I-Claim
41	life	N	I-Claim
42	.	N	I-Claim

43	Resistance	N	I-Claim
44	exercise	N	I-Claim
45	may	N	I-Claim
46	help	N	I-Claim
47	to	N	I-Claim
48	counter	N	I-Claim
49	some	N	I-Claim
50	of	N	I-Claim
51	these	N	I-Claim
52	side	N	I-Claim
53	effects	N	I-Claim
54	by	N	I-Claim
55	reducing	N	I-Claim
56	fatigue	N	I-Claim
57	,	N	I-Claim
58	elevating	N	I-Claim
59	mood	N	I-Claim
60	,	N	I-Claim
61	building	N	I-Claim
62	muscle	N	I-Claim
63	mass	N	I-Claim
64	,	N	I-Claim
65	and	N	I-Claim
66	reducing	N	I-Claim
67	body	N	I-Claim
68	fat	N	I-Claim
69	.	N	I-Claim

70	In	N	O
71	a	N	O
72	two-site	N	O
73	study	N	O
74	,	N	O
75	155	N	O
76	men	N	O
77	with	N	O
78	prostate	N	O
79	cancer	N	O
80	who	N	O
81	were	N	O
82	scheduled	N	O
83	to	N	O
84	receive	N	O
85	androgen	N	O
86	deprivation	N	O
87	therapy	N	O
88	for	N	O
89	at	N	O
90	least	N	O
91	3	N	O
92	months	N	O
93	after	N	O
94	recruitment	N	O
95	were	N	O
96	randomly	N	O
97	assigned	N	O
98	to	N	O
99	an	N	O
100	intervention	N	O
101	group	N	O
102	that	N	O
103	participated	N	O
104	in	N	O
105	a	N	O
106	resistance	N	O
107	exercise	N	O
108	program	N	O
109	three	N	O
110	times	N	O
111	per	N	O
112	week	N	O
113	for	N	O
114	12	N	O
115	weeks	N	O
116	(	N	O
117	82	N	O
118	men	N	O
119	)	N	O
120	or	N	O
121	to	N	O
122	a	N	O
123	waiting	N	O
124	list	N	O
125	control	N	O
126	group	N	O
127	(	N	O
128	73	N	O
129	men	N	O
130	)	N	O
131	.	N	O

132	The	N	O
133	primary	N	O
134	outcomes	N	O
135	were	N	O
136	fatigue	N	O
137	and	N	O
138	disease-specific	N	O
139	quality	N	O
140	of	N	O
141	life	N	O
142	as	N	O
143	assessed	N	O
144	by	N	O
145	self-reported	N	O
146	questionnaires	N	O
147	after	N	O
148	12	N	O
149	weeks	N	O
150	.	N	O

151	Secondary	N	O
152	outcomes	N	O
153	were	N	O
154	muscular	N	O
155	fitness	N	O
156	and	N	O
157	body	N	O
158	composition	N	O
159	.	N	O

160	Men	N	I-Premise
161	assigned	N	I-Premise
162	to	N	I-Premise
163	resistance	N	I-Premise
164	exercise	N	I-Premise
165	had	N	I-Premise
166	less	N	I-Premise
167	interference	N	I-Premise
168	from	N	I-Premise
169	fatigue	N	I-Premise
170	on	N	I-Premise
171	activities	N	I-Premise
172	of	N	I-Premise
173	daily	N	I-Premise
174	living	N	I-Premise
175	(	N	I-Premise
176	P	N	I-Premise
177	=.002	N	I-Premise
178	)	N	I-Premise
179	and	N	I-Premise
180	higher	N	I-Premise
181	quality	N	I-Premise
182	of	N	I-Premise
183	life	N	I-Premise
184	(	N	I-Premise
185	P	N	I-Premise
186	=.001	N	I-Premise
187	)	N	I-Premise
188	than	N	I-Premise
189	men	N	I-Premise
190	in	N	I-Premise
191	the	N	I-Premise
192	control	N	I-Premise
193	group	N	I-Premise
194	.	N	I-Premise

195	Men	N	I-Premise
196	in	N	I-Premise
197	the	N	I-Premise
198	intervention	N	I-Premise
199	group	N	I-Premise
200	demonstrated	N	I-Premise
201	higher	N	I-Premise
202	levels	N	I-Premise
203	of	N	I-Premise
204	upper	N	I-Premise
205	body	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	=.009	N	I-Premise
209	)	N	I-Premise
210	and	N	I-Premise
211	lower	N	I-Premise
212	body	N	I-Premise
213	(	N	I-Premise
214	P	N	I-Premise
215	<	N	I-Premise
216	.001	N	I-Premise
217	)	N	I-Premise
218	muscular	N	I-Premise
219	fitness	N	I-Premise
220	than	N	I-Premise
221	men	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	control	N	I-Premise
225	group	N	I-Premise
226	.	N	I-Premise

227	The	N	I-Premise
228	12-week	N	I-Premise
229	resistance	N	I-Premise
230	exercise	N	I-Premise
231	intervention	N	I-Premise
232	did	N	I-Premise
233	not	N	I-Premise
234	improve	N	I-Premise
235	body	N	I-Premise
236	composition	N	I-Premise
237	as	N	I-Premise
238	measured	N	I-Premise
239	by	N	I-Premise
240	changes	N	I-Premise
241	in	N	I-Premise
242	body	N	I-Premise
243	weight	N	I-Premise
244	,	N	I-Premise
245	body	N	I-Premise
246	mass	N	I-Premise
247	index	N	I-Premise
248	,	N	I-Premise
249	waist	N	I-Premise
250	circumference	N	I-Premise
251	,	N	I-Premise
252	or	N	I-Premise
253	subcutaneous	N	I-Premise
254	skinfolds	N	I-Premise
255	.	N	I-Premise

256	Resistance	N	I-Claim
257	exercise	N	I-Claim
258	reduces	N	I-Claim
259	fatigue	N	I-Claim
260	and	N	I-Claim
261	improves	N	I-Claim
262	quality	N	I-Claim
263	of	N	I-Claim
264	life	N	I-Claim
265	and	N	I-Claim
266	muscular	N	I-Claim
267	fitness	N	I-Claim
268	in	N	I-Claim
269	men	N	I-Claim
270	with	N	I-Claim
271	prostate	N	I-Claim
272	cancer	N	I-Claim
273	receiving	N	I-Claim
274	androgen	N	I-Claim
275	deprivation	N	I-Claim
276	therapy	N	I-Claim
277	.	N	I-Claim

278	This	N	I-MajorClaim
279	form	N	I-MajorClaim
280	of	N	I-MajorClaim
281	exercise	N	I-MajorClaim
282	can	N	I-MajorClaim
283	be	N	I-MajorClaim
284	an	N	I-MajorClaim
285	important	N	I-MajorClaim
286	component	N	I-MajorClaim
287	of	N	I-MajorClaim
288	supportive	N	I-MajorClaim
289	care	N	I-MajorClaim
290	for	N	I-MajorClaim
291	these	N	I-MajorClaim
292	patients	N	I-MajorClaim
293	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	exercise	N	O
7	training	N	O
8	on	N	O
9	cardiopulmonary	N	O
10	function	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	(	N	O
16	QOL	N	O
17	)	N	O
18	in	N	O
19	postmenopausal	N	O
20	breast	N	O
21	cancer	N	O
22	survivors	N	O
23	who	N	O
24	had	N	O
25	completed	N	O
26	surgery	N	O
27	,	N	O
28	radiotherapy	N	O
29	,	N	O
30	and/or	N	O
31	chemotherapy	N	O
32	with	N	O
33	or	N	O
34	without	N	O
35	current	N	O
36	hormone	N	O
37	therapy	N	O
38	use	N	O
39	.	N	O

40	Fifty-three	N	O
41	postmenopausal	N	O
42	breast	N	O
43	cancer	N	O
44	survivors	N	O
45	were	N	O
46	randomly	N	O
47	assigned	N	O
48	to	N	O
49	an	N	O
50	exercise	N	O
51	(	N	O
52	n	N	O
53	=	N	O
54	25	N	O
55	)	N	O
56	or	N	O
57	control	N	O
58	(	N	O
59	n	N	O
60	=	N	O
61	28	N	O
62	)	N	O
63	group	N	O
64	.	N	O

65	The	N	O
66	exercise	N	O
67	group	N	O
68	trained	N	O
69	on	N	O
70	cycle	N	O
71	ergometers	N	O
72	three	N	O
73	times	N	O
74	per	N	O
75	week	N	O
76	for	N	O
77	15	N	O
78	weeks	N	O
79	at	N	O
80	a	N	O
81	power	N	O
82	output	N	O
83	that	N	O
84	elicited	N	O
85	the	N	O
86	ventilatory	N	O
87	equivalent	N	O
88	for	N	O
89	carbon	N	O
90	dioxide	N	O
91	.	N	O

92	The	N	O
93	control	N	O
94	group	N	O
95	did	N	O
96	not	N	O
97	train	N	O
98	.	N	O

99	The	N	O
100	primary	N	O
101	outcomes	N	O
102	were	N	O
103	changes	N	O
104	in	N	O
105	peak	N	O
106	oxygen	N	O
107	consumption	N	O
108	and	N	O
109	overall	N	O
110	QOL	N	O
111	from	N	O
112	baseline	N	O
113	to	N	O
114	postintervention	N	O
115	.	N	O

116	Peak	N	O
117	oxygen	N	O
118	consumption	N	O
119	was	N	O
120	assessed	N	O
121	by	N	O
122	a	N	O
123	graded	N	O
124	exercise	N	O
125	test	N	O
126	using	N	O
127	gas	N	O
128	exchange	N	O
129	analysis	N	O
130	.	N	O

131	Overall	N	O
132	QOL	N	O
133	was	N	O
134	assessed	N	O
135	by	N	O
136	the	N	O
137	Functional	N	O
138	Assessment	N	O
139	of	N	O
140	Cancer	N	O
141	Therapy-Breast	N	O
142	scale	N	O
143	.	N	O

144	Fifty-two	N	O
145	participants	N	O
146	completed	N	O
147	the	N	O
148	trial	N	O
149	.	N	O

150	The	N	O
151	exercise	N	O
152	group	N	O
153	completed	N	O
154	98.4	N	O
155	%	N	O
156	of	N	O
157	the	N	O
158	exercise	N	O
159	sessions	N	O
160	.	N	O

161	Baseline	N	O
162	values	N	O
163	for	N	O
164	peak	N	O
165	oxygen	N	O
166	consumption	N	O
167	(	N	O
168	P	N	O
169	=.254	N	O
170	)	N	O
171	and	N	O
172	overall	N	O
173	QOL	N	O
174	(	N	O
175	P	N	O
176	=.286	N	O
177	)	N	O
178	did	N	O
179	not	N	O
180	differ	N	O
181	between	N	O
182	groups	N	O
183	.	N	O

184	Peak	N	I-Premise
185	oxygen	N	I-Premise
186	consumption	N	I-Premise
187	increased	N	I-Premise
188	by	N	I-Premise
189	0.24	N	I-Premise
190	L/min	N	I-Premise
191	in	N	I-Premise
192	the	N	I-Premise
193	exercise	N	I-Premise
194	group	N	I-Premise
195	,	N	I-Premise
196	whereas	N	I-Premise
197	it	N	I-Premise
198	decreased	N	I-Premise
199	by	N	I-Premise
200	0.05	N	I-Premise
201	L/min	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	control	N	I-Premise
205	group	N	I-Premise
206	(	N	I-Premise
207	mean	N	I-Premise
208	difference	N	I-Premise
209	,	N	I-Premise
210	0.29	N	I-Premise
211	L/min	N	I-Premise
212	;	N	I-Premise
213	95	N	I-Premise
214	%	N	I-Premise
215	confidence	N	I-Premise
216	interval	N	I-Premise
217	[	N	I-Premise
218	CI	N	I-Premise
219	]	N	I-Premise
220	,	N	I-Premise
221	0.18	N	I-Premise
222	to	N	I-Premise
223	0.40	N	I-Premise
224	;	N	I-Premise
225	P	N	I-Premise
226	<	N	I-Premise
227	.001	N	I-Premise
228	)	N	I-Premise
229	.	N	I-Premise

230	Overall	N	I-Premise
231	QOL	N	I-Premise
232	increased	N	I-Premise
233	by	N	I-Premise
234	9.1	N	I-Premise
235	points	N	I-Premise
236	in	N	I-Premise
237	the	N	I-Premise
238	exercise	N	I-Premise
239	group	N	I-Premise
240	compared	N	I-Premise
241	with	N	I-Premise
242	0.3	N	I-Premise
243	points	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	control	N	I-Premise
247	group	N	I-Premise
248	(	N	I-Premise
249	mean	N	I-Premise
250	difference	N	I-Premise
251	,	N	I-Premise
252	8.8	N	I-Premise
253	points	N	I-Premise
254	;	N	I-Premise
255	95	N	I-Premise
256	%	N	I-Premise
257	CI	N	I-Premise
258	,	N	I-Premise
259	3.6	N	I-Premise
260	to	N	I-Premise
261	14.0	N	I-Premise
262	;	N	I-Premise
263	P	N	I-Premise
264	=.001	N	I-Premise
265	)	N	I-Premise
266	.	N	I-Premise

267	Pearson	N	I-Premise
268	correlations	N	I-Premise
269	indicated	N	I-Premise
270	that	N	I-Premise
271	change	N	I-Premise
272	in	N	I-Premise
273	peak	N	I-Premise
274	oxygen	N	I-Premise
275	consumption	N	I-Premise
276	correlated	N	I-Premise
277	with	N	I-Premise
278	change	N	I-Premise
279	in	N	I-Premise
280	overall	N	I-Premise
281	QOL	N	I-Premise
282	(	N	I-Premise
283	r	N	I-Premise
284	=	N	I-Premise
285	0.45	N	I-Premise
286	;	N	I-Premise
287	P	N	I-Premise
288	<	N	I-Premise
289	.01	N	I-Premise
290	)	N	I-Premise
291	.	N	I-Premise

292	Exercise	N	I-Claim
293	training	N	I-Claim
294	had	N	I-Claim
295	beneficial	N	I-Claim
296	effects	N	I-Claim
297	on	N	I-Claim
298	cardiopulmonary	N	I-Claim
299	function	N	I-Claim
300	and	N	I-Claim
301	QOL	N	I-Claim
302	in	N	I-Claim
303	postmenopausal	N	I-Claim
304	breast	N	I-Claim
305	cancer	N	I-Claim
306	survivors	N	I-Claim
307	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	tolerability	N	O
7	of	N	O
8	two	N	O
9	doses	N	O
10	of	N	O
11	gefitinib	N	O
12	(	N	O
13	Iressa	N	O
14	[	N	O
15	ZD1839	N	O
16	]	N	O
17	;	N	O
18	AstraZeneca	N	O
19	,	N	O
20	Wilmington	N	O
21	,	N	O
22	DE	N	O
23	)	N	O
24	,	N	O
25	a	N	O
26	novel	N	O
27	epidermal	N	O
28	growth	N	O
29	factor	N	O
30	receptor	N	O
31	tyrosine	N	O
32	kinase	N	O
33	inhibitor	N	O
34	,	N	O
35	in	N	O
36	patients	N	O
37	with	N	O
38	pretreated	N	O
39	advanced	N	O
40	non-small-cell	N	O
41	lung	N	O
42	cancer	N	O
43	(	N	O
44	NSCLC	N	O
45	)	N	O
46	.	N	O

47	This	N	O
48	was	N	O
49	a	N	O
50	randomized	N	O
51	,	N	O
52	double-blind	N	O
53	,	N	O
54	parallel-group	N	O
55	,	N	O
56	multicenter	N	O
57	phase	N	O
58	II	N	O
59	trial	N	O
60	.	N	O

61	Two	N	O
62	hundred	N	O
63	ten	N	O
64	patients	N	O
65	with	N	O
66	advanced	N	O
67	NSCLC	N	O
68	who	N	O
69	were	N	O
70	previously	N	O
71	treated	N	O
72	with	N	O
73	one	N	O
74	or	N	O
75	two	N	O
76	chemotherapy	N	O
77	regimens	N	O
78	(	N	O
79	at	N	O
80	least	N	O
81	one	N	O
82	containing	N	O
83	platinum	N	O
84	)	N	O
85	were	N	O
86	randomly	N	O
87	assigned	N	O
88	to	N	O
89	receive	N	O
90	either	N	O
91	250-mg	N	O
92	or	N	O
93	500-mg	N	O
94	oral	N	O
95	doses	N	O
96	of	N	O
97	gefitinib	N	O
98	once	N	O
99	daily	N	O
100	.	N	O

101	Efficacy	N	I-Premise
102	was	N	I-Premise
103	similar	N	I-Premise
104	for	N	I-Premise
105	the	N	I-Premise
106	250-	N	I-Premise
107	and	N	I-Premise
108	500-mg/d	N	I-Premise
109	groups	N	I-Premise
110	.	N	I-Premise

111	Objective	N	I-Premise
112	tumor	N	I-Premise
113	response	N	I-Premise
114	rates	N	I-Premise
115	were	N	I-Premise
116	18.4	N	I-Premise
117	%	N	I-Premise
118	(	N	I-Premise
119	95	N	I-Premise
120	%	N	I-Premise
121	confidence	N	I-Premise
122	interval	N	I-Premise
123	[	N	I-Premise
124	CI	N	I-Premise
125	]	N	I-Premise
126	,	N	I-Premise
127	11.5	N	I-Premise
128	to	N	I-Premise
129	27.3	N	I-Premise
130	)	N	I-Premise
131	and	N	I-Premise
132	19.0	N	I-Premise
133	%	N	I-Premise
134	(	N	I-Premise
135	95	N	I-Premise
136	%	N	I-Premise
137	CI	N	I-Premise
138	,	N	I-Premise
139	12.1	N	I-Premise
140	to	N	I-Premise
141	27.9	N	I-Premise
142	)	N	I-Premise
143	;	N	I-Premise
144	among	N	I-Premise
145	evaluable	N	I-Premise
146	patients	N	I-Premise
147	,	N	I-Premise
148	symptom	N	I-Premise
149	improvement	N	I-Premise
150	rates	N	I-Premise
151	were	N	I-Premise
152	40.3	N	I-Premise
153	%	N	I-Premise
154	(	N	I-Premise
155	95	N	I-Premise
156	%	N	I-Premise
157	CI	N	I-Premise
158	,	N	I-Premise
159	28.5	N	I-Premise
160	to	N	I-Premise
161	53.0	N	I-Premise
162	)	N	I-Premise
163	and	N	I-Premise
164	37.0	N	I-Premise
165	%	N	I-Premise
166	(	N	I-Premise
167	95	N	I-Premise
168	%	N	I-Premise
169	CI	N	I-Premise
170	,	N	I-Premise
171	26.0	N	I-Premise
172	to	N	I-Premise
173	49.1	N	I-Premise
174	)	N	I-Premise
175	;	N	I-Premise
176	median	N	I-Premise
177	progression-free	N	I-Premise
178	survival	N	I-Premise
179	times	N	I-Premise
180	were	N	I-Premise
181	2.7	N	I-Premise
182	and	N	I-Premise
183	2.8	N	I-Premise
184	months	N	I-Premise
185	;	N	I-Premise
186	and	N	I-Premise
187	median	N	I-Premise
188	overall	N	I-Premise
189	survival	N	I-Premise
190	times	N	I-Premise
191	were	N	I-Premise
192	7.6	N	I-Premise
193	and	N	I-Premise
194	8.0	N	I-Premise
195	months	N	I-Premise
196	,	N	I-Premise
197	respectively	N	I-Premise
198	.	N	I-Premise

199	Symptom	N	I-Premise
200	improvements	N	I-Premise
201	were	N	I-Premise
202	recorded	N	I-Premise
203	for	N	I-Premise
204	69.2	N	I-Premise
205	%	N	I-Premise
206	(	N	I-Premise
207	250	N	I-Premise
208	mg/d	N	I-Premise
209	)	N	I-Premise
210	and	N	I-Premise
211	85.7	N	I-Premise
212	%	N	I-Premise
213	(	N	I-Premise
214	500	N	I-Premise
215	mg/d	N	I-Premise
216	)	N	I-Premise
217	of	N	I-Premise
218	patients	N	I-Premise
219	with	N	I-Premise
220	a	N	I-Premise
221	tumor	N	I-Premise
222	response	N	I-Premise
223	.	N	I-Premise

224	Adverse	N	I-Premise
225	events	N	I-Premise
226	(	N	I-Premise
227	AEs	N	I-Premise
228	)	N	I-Premise
229	at	N	I-Premise
230	both	N	I-Premise
231	dose	N	I-Premise
232	levels	N	I-Premise
233	were	N	I-Premise
234	generally	N	I-Premise
235	mild	N	I-Premise
236	(	N	I-Premise
237	grade	N	I-Premise
238	1	N	I-Premise
239	or	N	I-Premise
240	2	N	I-Premise
241	)	N	I-Premise
242	and	N	I-Premise
243	consisted	N	I-Premise
244	mainly	N	I-Premise
245	of	N	I-Premise
246	skin	N	I-Premise
247	reactions	N	I-Premise
248	and	N	I-Premise
249	diarrhea	N	I-Premise
250	.	N	I-Premise

251	Drug-related	N	I-Premise
252	toxicities	N	I-Premise
253	were	N	I-Premise
254	more	N	I-Premise
255	frequent	N	I-Premise
256	in	N	I-Premise
257	the	N	I-Premise
258	higher-dose	N	I-Premise
259	group	N	I-Premise
260	.	N	I-Premise

261	Withdrawal	N	I-Premise
262	due	N	I-Premise
263	to	N	I-Premise
264	drug-related	N	I-Premise
265	AEs	N	I-Premise
266	was	N	I-Premise
267	1.9	N	I-Premise
268	%	N	I-Premise
269	and	N	I-Premise
270	9.4	N	I-Premise
271	%	N	I-Premise
272	for	N	I-Premise
273	patients	N	I-Premise
274	receiving	N	I-Premise
275	gefitinib	N	I-Premise
276	250	N	I-Premise
277	and	N	I-Premise
278	500	N	I-Premise
279	mg/d	N	I-Premise
280	,	N	I-Premise
281	respectively	N	I-Premise
282	.	N	I-Premise

283	Gefitinib	N	I-Claim
284	showed	N	I-Claim
285	clinically	N	I-Claim
286	meaningful	N	I-Claim
287	antitumor	N	I-Claim
288	activity	N	I-Claim
289	and	N	I-Claim
290	provided	N	I-Claim
291	symptom	N	I-Claim
292	relief	N	I-Claim
293	as	N	I-Claim
294	second-	N	I-Claim
295	and	N	I-Claim
296	third-line	N	I-Claim
297	treatment	N	I-Claim
298	in	N	I-Claim
299	these	N	I-Claim
300	patients	N	I-Claim
301	.	N	I-Claim

302	At	N	I-Claim
303	250	N	I-Claim
304	mg/d	N	I-Claim
305	,	N	I-Claim
306	gefitinib	N	I-Claim
307	had	N	I-Claim
308	a	N	I-Claim
309	favorable	N	I-Claim
310	AE	N	I-Claim
311	profile	N	I-Claim
312	.	N	I-Claim

313	Gefitinib	N	I-Claim
314	250	N	I-Claim
315	mg/d	N	I-Claim
316	is	N	I-Claim
317	an	N	I-Claim
318	important	N	I-Claim
319	,	N	I-Claim
320	novel	N	I-Claim
321	treatment	N	I-Claim
322	option	N	I-Claim
323	for	N	I-Claim
324	patients	N	I-Claim
325	with	N	I-Claim
326	pretreated	N	I-Claim
327	advanced	N	I-Claim
328	NSCLC	N	I-Claim
329	.	N	I-Claim

1	Imatinib	N	I-Claim
2	(	N	I-Claim
3	Gleevec	N	I-Claim
4	)	N	I-Claim
5	,	N	I-Claim
6	a	N	I-Claim
7	highly	N	I-Claim
8	effective	N	I-Claim
9	specific	N	I-Claim
10	tyrosine	N	I-Claim
11	kinase	N	I-Claim
12	inhibitor	N	I-Claim
13	,	N	I-Claim
14	demonstrates	N	I-Claim
15	a	N	I-Claim
16	better	N	I-Claim
17	side	N	I-Claim
18	effect	N	I-Claim
19	profile	N	I-Claim
20	than	N	I-Claim
21	interferon-alpha	N	I-Claim
22	(	N	I-Claim
23	IFN	N	I-Claim
24	)	N	I-Claim
25	,	N	I-Claim
26	which	N	I-Claim
27	impairs	N	I-Claim
28	patients	N	I-Claim
29	'	N	I-Claim
30	quality	N	I-Claim
31	of	N	I-Claim
32	life	N	I-Claim
33	(	N	I-Claim
34	QoL	N	I-Claim
35	)	N	I-Claim
36	.	N	I-Claim

37	This	N	O
38	phase	N	O
39	III	N	O
40	international	N	O
41	study	N	O
42	evaluated	N	O
43	QoL	N	O
44	outcomes	N	O
45	in	N	O
46	1,106	N	O
47	newly	N	O
48	diagnosed	N	O
49	patients	N	O
50	with	N	O
51	chronic-phase	N	O
52	chronic	N	O
53	myeloid	N	O
54	leukemia	N	O
55	(	N	O
56	CML	N	O
57	)	N	O
58	who	N	O
59	were	N	O
60	randomized	N	O
61	to	N	O
62	receive	N	O
63	either	N	O
64	imatinib	N	O
65	400	N	O
66	mg	N	O
67	daily	N	O
68	or	N	O
69	IFN	N	O
70	up	N	O
71	to	N	O
72	5	N	O
73	MU/m	N	O
74	(	N	O
75	2	N	O
76	)	N	O
77	/d	N	O
78	with	N	O
79	cytarabine	N	O
80	(	N	O
81	Ara-C	N	O
82	)	N	O
83	20	N	O
84	mg/m	N	O
85	(	N	O
86	2	N	O
87	)	N	O
88	/d	N	O
89	added	N	O
90	for	N	O
91	10	N	O
92	days	N	O
93	every	N	O
94	month	N	O
95	(	N	O
96	IFN	N	O
97	+	N	O
98	LDAC	N	O
99	)	N	O
100	.	N	O

101	Crossover	N	O
102	to	N	O
103	the	N	O
104	other	N	O
105	treatment	N	O
106	arm	N	O
107	was	N	O
108	permitted	N	O
109	due	N	O
110	to	N	O
111	a	N	O
112	lack	N	O
113	of	N	O
114	efficacy	N	O
115	or	N	O
116	treatment	N	O
117	intolerance	N	O
118	.	N	O

119	QoL	N	O
120	was	N	O
121	assessed	N	O
122	with	N	O
123	the	N	O
124	Functional	N	O
125	Assessment	N	O
126	of	N	O
127	Cancer	N	O
128	Therapy-Biologic	N	O
129	Response	N	O
130	Modifiers	N	O
131	(	N	O
132	FACT-BRM	N	O
133	)	N	O
134	at	N	O
135	baseline	N	O
136	,	N	O
137	monthly	N	O
138	for	N	O
139	6	N	O
140	months	N	O
141	and	N	O
142	then	N	O
143	at	N	O
144	months	N	O
145	9	N	O
146	,	N	O
147	12	N	O
148	,	N	O
149	and	N	O
150	18	N	O
151	.	N	O

152	The	N	O
153	Trial	N	O
154	Outcome	N	O
155	Index	N	O
156	(	N	O
157	TOI	N	O
158	;	N	O
159	a	N	O
160	composite	N	O
161	endpoint	N	O
162	of	N	O
163	physical/functional/treatment-specific	N	O
164	subscales	N	O
165	)	N	O
166	was	N	O
167	the	N	O
168	primary	N	O
169	endpoint	N	O
170	.	N	O

171	Secondary	N	O
172	endpoints	N	O
173	measured	N	O
174	were	N	O
175	social/family	N	O
176	well-being	N	O
177	(	N	O
178	SFWB	N	O
179	)	N	O
180	and	N	O
181	emotional	N	O
182	well-being	N	O
183	(	N	O
184	EWB	N	O
185	)	N	O
186	.	N	O

187	QoL	N	O
188	was	N	O
189	analyzed	N	O
190	for	N	O
191	the	N	O
192	first	N	O
193	18	N	O
194	months	N	O
195	of	N	O
196	treatment	N	O
197	using	N	O
198	mixed	N	O
199	effects	N	O
200	growth	N	O
201	curve	N	O
202	models	N	O
203	.	N	O

204	The	N	O
205	primary	N	O
206	analyses	N	O
207	were	N	O
208	intention-to-treat	N	O
209	(	N	O
210	ITT	N	O
211	)	N	O
212	;	N	O
213	secondary	N	O
214	analyses	N	O
215	incorporated	N	O
216	crossover	N	O
217	as	N	O
218	a	N	O
219	time-dependent	N	O
220	covariate	N	O
221	.	N	O

222	A	N	O
223	total	N	O
224	of	N	O
225	1,049	N	O
226	patients	N	O
227	completed	N	O
228	at	N	O
229	least	N	O
230	one	N	O
231	QoL	N	O
232	assessment	N	O
233	.	N	O

234	Two	N	I-Premise
235	hundred	N	I-Premise
236	sixty-one	N	I-Premise
237	patients	N	I-Premise
238	(	N	I-Premise
239	50	N	I-Premise
240	%	N	I-Premise
241	)	N	I-Premise
242	crossed	N	I-Premise
243	over	N	I-Premise
244	from	N	I-Premise
245	IFN	N	I-Premise
246	to	N	I-Premise
247	imatinib	N	I-Premise
248	and	N	I-Premise
249	11	N	I-Premise
250	(	N	I-Premise
251	2	N	I-Premise
252	%	N	I-Premise
253	)	N	I-Premise
254	crossed	N	I-Premise
255	over	N	I-Premise
256	from	N	I-Premise
257	imatinib	N	I-Premise
258	to	N	I-Premise
259	IFN	N	I-Premise
260	.	N	I-Premise

261	There	N	I-Premise
262	was	N	I-Premise
263	a	N	I-Premise
264	significant	N	I-Premise
265	decline	N	I-Premise
266	in	N	I-Premise
267	TOI	N	I-Premise
268	scores	N	I-Premise
269	for	N	I-Premise
270	the	N	I-Premise
271	IFN	N	I-Premise
272	treatment	N	I-Premise
273	arm	N	I-Premise
274	compared	N	I-Premise
275	with	N	I-Premise
276	preservation	N	I-Premise
277	of	N	I-Premise
278	baseline	N	I-Premise
279	TOI	N	I-Premise
280	scores	N	I-Premise
281	in	N	I-Premise
282	the	N	I-Premise
283	imatinib	N	I-Premise
284	arm	N	I-Premise
285	(	N	I-Premise
286	P	N	I-Premise
287	<	N	I-Premise
288	.001	N	I-Premise
289	,	N	I-Premise
290	ITT	N	I-Premise
291	)	N	I-Premise
292	.	N	I-Premise

293	Mean	N	I-Premise
294	social/family	N	I-Premise
295	and	N	I-Premise
296	EWB	N	I-Premise
297	scores	N	I-Premise
298	were	N	I-Premise
299	22.8	N	I-Premise
300	and	N	I-Premise
301	19.5	N	I-Premise
302	,	N	I-Premise
303	respectively	N	I-Premise
304	,	N	I-Premise
305	for	N	I-Premise
306	imatinib	N	I-Premise
307	and	N	I-Premise
308	21.6	N	I-Premise
309	and	N	I-Premise
310	17.6	N	I-Premise
311	,	N	I-Premise
312	respectively	N	I-Premise
313	,	N	I-Premise
314	for	N	I-Premise
315	IFN	N	I-Premise
316	(	N	I-Premise
317	P	N	I-Premise
318	<	N	I-Premise
319	.001	N	I-Premise
320	,	N	I-Premise
321	ITT	N	I-Premise
322	)	N	I-Premise
323	.	N	I-Premise

324	After	N	I-Premise
325	crossing	N	I-Premise
326	over	N	I-Premise
327	from	N	I-Premise
328	IFN	N	I-Premise
329	to	N	I-Premise
330	imatinib	N	I-Premise
331	,	N	I-Premise
332	patients	N	I-Premise
333	experienced	N	I-Premise
334	a	N	I-Premise
335	significant	N	I-Premise
336	(	N	I-Premise
337	P	N	I-Premise
338	<	N	I-Premise
339	.001	N	I-Premise
340	)	N	I-Premise
341	increase	N	I-Premise
342	in	N	I-Premise
343	TOI	N	I-Premise
344	scores	N	I-Premise
345	.	N	I-Premise

346	Imatinib	N	I-Claim
347	offers	N	I-Claim
348	clear	N	I-Claim
349	QoL	N	I-Claim
350	advantages	N	I-Claim
351	over	N	I-Claim
352	IFN	N	I-Claim
353	as	N	I-Claim
354	first-line	N	I-Claim
355	treatment	N	I-Claim
356	of	N	I-Claim
357	chronic-phase	N	I-Claim
358	CML	N	I-Claim
359	.	N	I-Claim

360	In	N	O
361	addition	N	O
362	,	N	O
363	patients	N	I-Claim
364	who	N	I-Claim
365	crossed	N	I-Claim
366	over	N	I-Claim
367	to	N	I-Claim
368	imatinib	N	I-Claim
369	reported	N	I-Claim
370	higher	N	I-Claim
371	QoL	N	I-Claim
372	than	N	I-Claim
373	those	N	I-Claim
374	who	N	I-Claim
375	remained	N	I-Claim
376	on	N	I-Claim
377	IFN	N	I-Claim
378	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	docetaxel	N	O
5	plus	N	O
6	platinum	N	O
7	regimens	N	O
8	improve	N	O
9	survival	N	O
10	and	N	O
11	affect	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	(	N	O
16	QoL	N	O
17	)	N	O
18	in	N	O
19	advanced	N	O
20	non-small-cell	N	O
21	lung	N	O
22	cancer	N	O
23	(	N	O
24	NSCLC	N	O
25	)	N	O
26	compared	N	O
27	with	N	O
28	vinorelbine	N	O
29	plus	N	O
30	cisplatin	N	O
31	as	N	O
32	first-line	N	O
33	chemotherapy	N	O
34	.	N	O

35	Patients	N	O
36	(	N	O
37	n	N	O
38	=	N	O
39	1,218	N	O
40	)	N	O
41	with	N	O
42	stage	N	O
43	IIIB	N	O
44	to	N	O
45	IV	N	O
46	NSCLC	N	O
47	were	N	O
48	randomly	N	O
49	assigned	N	O
50	to	N	O
51	receive	N	O
52	docetaxel	N	O
53	75	N	O
54	mg/m2	N	O
55	and	N	O
56	cisplatin	N	O
57	75	N	O
58	mg/m2	N	O
59	every	N	O
60	3	N	O
61	weeks	N	O
62	(	N	O
63	DC	N	O
64	)	N	O
65	;	N	O
66	docetaxel	N	O
67	75	N	O
68	mg/m2	N	O
69	and	N	O
70	carboplatin	N	O
71	area	N	O
72	under	N	O
73	the	N	O
74	curve	N	O
75	of	N	O
76	6	N	O
77	mg/mL	N	O
78	*	N	O
79	min	N	O
80	every	N	O
81	3	N	O
82	weeks	N	O
83	(	N	O
84	DCb	N	O
85	)	N	O
86	;	N	O
87	or	N	O
88	vinorelbine	N	O
89	25	N	O
90	mg/m2/wk	N	O
91	and	N	O
92	cisplatin	N	O
93	100	N	O
94	mg/m2	N	O
95	every	N	O
96	4	N	O
97	weeks	N	O
98	(	N	O
99	VC	N	O
100	)	N	O
101	.	N	O

102	Patients	N	I-Premise
103	treated	N	I-Premise
104	with	N	I-Premise
105	DC	N	I-Premise
106	had	N	I-Premise
107	a	N	I-Premise
108	median	N	I-Premise
109	survival	N	I-Premise
110	of	N	I-Premise
111	11.3	N	I-Premise
112	v	N	I-Premise
113	10.1	N	I-Premise
114	months	N	I-Premise
115	for	N	I-Premise
116	VC-treated	N	I-Premise
117	patients	N	I-Premise
118	(	N	I-Premise
119	P	N	I-Premise
120	=.044	N	I-Premise
121	;	N	I-Premise
122	hazard	N	I-Premise
123	ratio	N	I-Premise
124	,	N	I-Premise
125	1.183	N	I-Premise
126	[	N	I-Premise
127	97.2	N	I-Premise
128	%	N	I-Premise
129	confidence	N	I-Premise
130	interval	N	I-Premise
131	,	N	I-Premise
132	0.989	N	I-Premise
133	to	N	I-Premise
134	1.416	N	I-Premise
135	]	N	I-Premise
136	)	N	I-Premise
137	.	N	I-Premise

138	The	N	I-Premise
139	2-year	N	I-Premise
140	survival	N	I-Premise
141	rate	N	I-Premise
142	was	N	I-Premise
143	21	N	I-Premise
144	%	N	I-Premise
145	for	N	I-Premise
146	DC-treated	N	I-Premise
147	patients	N	I-Premise
148	and	N	I-Premise
149	14	N	I-Premise
150	%	N	I-Premise
151	for	N	I-Premise
152	VC-treated	N	I-Premise
153	patients	N	I-Premise
154	.	N	I-Premise

155	Overall	N	I-Premise
156	response	N	I-Premise
157	rate	N	I-Premise
158	was	N	I-Premise
159	31.6	N	I-Premise
160	%	N	I-Premise
161	for	N	I-Premise
162	DC-treated	N	I-Premise
163	patients	N	I-Premise
164	v	N	I-Premise
165	24.5	N	I-Premise
166	%	N	I-Premise
167	for	N	I-Premise
168	VC-treated	N	I-Premise
169	patients	N	I-Premise
170	(	N	I-Premise
171	P	N	I-Premise
172	=.029	N	I-Premise
173	)	N	I-Premise
174	.	N	I-Premise

175	Median	N	I-Premise
176	survival	N	I-Premise
177	(	N	I-Premise
178	9.4	N	I-Premise
179	v	N	I-Premise
180	9.9	N	I-Premise
181	months	N	I-Premise
182	[	N	I-Premise
183	for	N	I-Premise
184	VC	N	I-Premise
185	]	N	I-Premise
186	;	N	I-Premise
187	P	N	I-Premise
188	=.657	N	I-Premise
189	;	N	I-Premise
190	hazard	N	I-Premise
191	ratio	N	I-Premise
192	,	N	I-Premise
193	1.048	N	I-Premise
194	[	N	I-Premise
195	97.2	N	I-Premise
196	confidence	N	I-Premise
197	interval	N	I-Premise
198	,	N	I-Premise
199	0.877	N	I-Premise
200	to	N	I-Premise
201	1.253	N	I-Premise
202	]	N	I-Premise
203	)	N	I-Premise
204	and	N	I-Premise
205	response	N	I-Premise
206	(	N	I-Premise
207	23.9	N	I-Premise
208	%	N	I-Premise
209	)	N	I-Premise
210	with	N	I-Premise
211	DCb	N	I-Premise
212	were	N	I-Premise
213	similar	N	I-Premise
214	to	N	I-Premise
215	those	N	I-Premise
216	results	N	I-Premise
217	for	N	I-Premise
218	VC	N	I-Premise
219	.	N	I-Premise

220	Neutropenia	N	I-Premise
221	,	N	I-Premise
222	thrombocytopenia	N	I-Premise
223	,	N	I-Premise
224	infection	N	I-Premise
225	,	N	I-Premise
226	and	N	I-Premise
227	febrile	N	I-Premise
228	neutropenia	N	I-Premise
229	were	N	I-Premise
230	similar	N	I-Premise
231	with	N	I-Premise
232	all	N	I-Premise
233	three	N	I-Premise
234	regimens	N	I-Premise
235	.	N	I-Premise

236	Grade	N	I-Premise
237	3	N	I-Premise
238	to	N	I-Premise
239	4	N	I-Premise
240	anemia	N	I-Premise
241	,	N	I-Premise
242	nausea	N	I-Premise
243	,	N	I-Premise
244	and	N	I-Premise
245	vomiting	N	I-Premise
246	were	N	I-Premise
247	more	N	I-Premise
248	common	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	<	N	I-Premise
252	.01	N	I-Premise
253	)	N	I-Premise
254	with	N	I-Premise
255	VC	N	I-Premise
256	than	N	I-Premise
257	with	N	I-Premise
258	DC	N	I-Premise
259	or	N	I-Premise
260	DCb	N	I-Premise
261	.	N	I-Premise

262	Patients	N	I-Premise
263	treated	N	I-Premise
264	with	N	I-Premise
265	either	N	I-Premise
266	docetaxel	N	I-Premise
267	regimen	N	I-Premise
268	had	N	I-Premise
269	consistently	N	I-Premise
270	improved	N	I-Premise
271	QoL	N	I-Premise
272	compared	N	I-Premise
273	with	N	I-Premise
274	VC-treated	N	I-Premise
275	patients	N	I-Premise
276	,	N	I-Premise
277	who	N	I-Premise
278	experienced	N	I-Premise
279	deterioration	N	I-Premise
280	in	N	I-Premise
281	QoL	N	I-Premise
282	.	N	I-Premise

283	DC	N	I-Claim
284	resulted	N	I-Claim
285	in	N	I-Claim
286	a	N	I-Claim
287	more	N	I-Claim
288	favorable	N	I-Claim
289	overall	N	I-Claim
290	response	N	I-Claim
291	and	N	I-Claim
292	survival	N	I-Claim
293	rate	N	I-Claim
294	than	N	I-Claim
295	VC	N	I-Claim
296	.	N	I-Claim

297	Both	N	I-Claim
298	DC	N	I-Claim
299	and	N	I-Claim
300	DCb	N	I-Claim
301	were	N	I-Claim
302	better	N	I-Claim
303	tolerated	N	I-Claim
304	and	N	I-Claim
305	provided	N	I-Claim
306	patients	N	I-Claim
307	with	N	I-Claim
308	consistently	N	I-Claim
309	improved	N	I-Claim
310	QoL	N	I-Claim
311	compared	N	I-Claim
312	with	N	I-Claim
313	VC	N	I-Claim
314	.	N	I-Claim

315	These	N	I-Claim
316	findings	N	I-Claim
317	demonstrate	N	I-Claim
318	that	N	I-Claim
319	a	N	I-Claim
320	docetaxel	N	I-Claim
321	plus	N	I-Claim
322	platinum	N	I-Claim
323	combination	N	I-Claim
324	is	N	I-Claim
325	an	N	I-Claim
326	effective	N	I-Claim
327	treatment	N	I-Claim
328	option	N	I-Claim
329	with	N	I-Claim
330	a	N	I-Claim
331	favorable	N	I-Claim
332	therapeutic	N	I-Claim
333	index	N	I-Claim
334	for	N	I-Claim
335	first-line	N	I-Claim
336	treatment	N	I-Claim
337	of	N	I-Claim
338	advanced	N	I-Claim
339	or	N	I-Claim
340	metastatic	N	I-Claim
341	NSCLC	N	I-Claim
342	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	the	N	O
5	relative	N	O
6	dose-intensity	N	O
7	of	N	O
8	cyclophosphamide	N	O
9	,	N	O
10	doxorubicin	N	O
11	,	N	O
12	vincristine	N	O
13	,	N	O
14	and	N	O
15	prednisone	N	O
16	(	N	O
17	CHOP	N	O
18	)	N	O
19	chemotherapy	N	O
20	could	N	O
21	be	N	O
22	improved	N	O
23	by	N	O
24	prophylactic	N	O
25	administration	N	O
26	of	N	O
27	granulocyte	N	O
28	colony-stimulating	N	O
29	factor	N	O
30	(	N	O
31	G-CSF	N	O
32	)	N	O
33	in	N	O
34	elderly	N	O
35	patients	N	O
36	with	N	O
37	aggressive	N	O
38	non-Hodgkin	N	O
39	's	N	O
40	lymphoma	N	O
41	(	N	O
42	NHL	N	O
43	)	N	O
44	.	N	O

45	Patients	N	O
46	aged	N	O
47	65	N	O
48	to	N	O
49	90	N	O
50	years	N	O
51	(	N	O
52	median	N	O
53	,	N	O
54	72	N	O
55	years	N	O
56	)	N	O
57	with	N	O
58	stage	N	O
59	II	N	O
60	to	N	O
61	IV	N	O
62	aggressive	N	O
63	NHL	N	O
64	were	N	O
65	randomly	N	O
66	assigned	N	O
67	to	N	O
68	receive	N	O
69	standard	N	O
70	CHOP	N	O
71	every	N	O
72	3	N	O
73	weeks	N	O
74	or	N	O
75	CHOP	N	O
76	plus	N	O
77	G-CSF	N	O
78	every	N	O
79	3	N	O
80	weeks	N	O
81	on	N	O
82	days	N	O
83	2	N	O
84	to	N	O
85	11	N	O
86	of	N	O
87	each	N	O
88	cycle	N	O
89	.	N	O

90	In	N	I-Premise
91	389	N	I-Premise
92	eligible	N	I-Premise
93	patients	N	I-Premise
94	,	N	I-Premise
95	the	N	I-Premise
96	relative	N	I-Premise
97	dose	N	I-Premise
98	intensities	N	I-Premise
99	(	N	I-Premise
100	RDIs	N	I-Premise
101	)	N	I-Premise
102	of	N	I-Premise
103	cyclophosphamide	N	I-Premise
104	(	N	I-Premise
105	median	N	I-Premise
106	,	N	I-Premise
107	96.3	N	I-Premise
108	%	N	I-Premise
109	v	N	I-Premise
110	93.9	N	I-Premise
111	%	N	I-Premise
112	;	N	I-Premise
113	P	N	I-Premise
114	=.01	N	I-Premise
115	)	N	I-Premise
116	and	N	I-Premise
117	doxorubicin	N	I-Premise
118	(	N	I-Premise
119	median	N	I-Premise
120	,	N	I-Premise
121	95.4	N	I-Premise
122	%	N	I-Premise
123	v	N	I-Premise
124	93.3	N	I-Premise
125	%	N	I-Premise
126	;	N	I-Premise
127	P	N	I-Premise
128	=.04	N	I-Premise
129	)	N	I-Premise
130	were	N	I-Premise
131	higher	N	I-Premise
132	in	N	I-Premise
133	patients	N	I-Premise
134	treated	N	I-Premise
135	with	N	I-Premise
136	CHOP	N	I-Premise
137	plus	N	I-Premise
138	G-CSF	N	I-Premise
139	.	N	I-Premise

140	The	N	I-Premise
141	complete	N	I-Premise
142	response	N	I-Premise
143	rates	N	I-Premise
144	were	N	I-Premise
145	55	N	I-Premise
146	%	N	I-Premise
147	and	N	I-Premise
148	52	N	I-Premise
149	%	N	I-Premise
150	for	N	I-Premise
151	CHOP	N	I-Premise
152	and	N	I-Premise
153	CHOP	N	I-Premise
154	plus	N	I-Premise
155	G-CSF	N	I-Premise
156	,	N	I-Premise
157	respectively	N	I-Premise
158	(	N	I-Premise
159	P	N	I-Premise
160	=.63	N	I-Premise
161	)	N	I-Premise
162	.	N	I-Premise

163	The	N	I-Premise
164	actuarial	N	I-Premise
165	overall	N	I-Premise
166	survival	N	I-Premise
167	at	N	I-Premise
168	5	N	I-Premise
169	years	N	I-Premise
170	was	N	I-Premise
171	22	N	I-Premise
172	%	N	I-Premise
173	with	N	I-Premise
174	CHOP	N	I-Premise
175	alone	N	I-Premise
176	,	N	I-Premise
177	compared	N	I-Premise
178	with	N	I-Premise
179	24	N	I-Premise
180	%	N	I-Premise
181	with	N	I-Premise
182	CHOP	N	I-Premise
183	plus	N	I-Premise
184	G-CSF	N	I-Premise
185	(	N	I-Premise
186	P	N	I-Premise
187	=.76	N	I-Premise
188	)	N	I-Premise
189	,	N	I-Premise
190	with	N	I-Premise
191	a	N	I-Premise
192	median	N	I-Premise
193	follow-up	N	I-Premise
194	of	N	I-Premise
195	33	N	I-Premise
196	months	N	I-Premise
197	.	N	I-Premise

198	Patients	N	I-Premise
199	treated	N	I-Premise
200	with	N	I-Premise
201	CHOP	N	I-Premise
202	plus	N	I-Premise
203	G-CSF	N	I-Premise
204	had	N	I-Premise
205	an	N	I-Premise
206	identical	N	I-Premise
207	incidence	N	I-Premise
208	of	N	I-Premise
209	infections	N	I-Premise
210	,	N	I-Premise
211	with	N	I-Premise
212	World	N	I-Premise
213	Health	N	I-Premise
214	Organization	N	I-Premise
215	grade	N	I-Premise
216	3	N	I-Premise
217	to	N	I-Premise
218	4	N	I-Premise
219	(	N	I-Premise
220	34	N	I-Premise
221	of	N	I-Premise
222	1,191	N	I-Premise
223	cycles	N	I-Premise
224	v	N	I-Premise
225	36	N	I-Premise
226	of	N	I-Premise
227	1,195	N	I-Premise
228	cycles	N	I-Premise
229	)	N	I-Premise
230	.	N	I-Premise

231	Only	N	I-Premise
232	the	N	I-Premise
233	cumulative	N	I-Premise
234	days	N	I-Premise
235	with	N	I-Premise
236	antibiotics	N	I-Premise
237	were	N	I-Premise
238	fewer	N	I-Premise
239	with	N	I-Premise
240	CHOP	N	I-Premise
241	plus	N	I-Premise
242	G-CSF	N	I-Premise
243	(	N	I-Premise
244	median	N	I-Premise
245	,	N	I-Premise
246	0	N	I-Premise
247	v	N	I-Premise
248	6	N	I-Premise
249	days	N	I-Premise
250	;	N	I-Premise
251	P	N	I-Premise
252	=.006	N	I-Premise
253	)	N	I-Premise
254	than	N	I-Premise
255	with	N	I-Premise
256	CHOP	N	I-Premise
257	alone	N	I-Premise
258	.	N	I-Premise

259	The	N	I-Premise
260	number	N	I-Premise
261	of	N	I-Premise
262	hospital	N	I-Premise
263	admissions	N	I-Premise
264	and	N	I-Premise
265	the	N	I-Premise
266	number	N	I-Premise
267	of	N	I-Premise
268	days	N	I-Premise
269	in	N	I-Premise
270	hospital	N	I-Premise
271	were	N	I-Premise
272	not	N	I-Premise
273	different	N	I-Premise
274	.	N	I-Premise

275	In	N	I-Claim
276	elderly	N	I-Claim
277	patients	N	I-Claim
278	,	N	I-Claim
279	G-CSF	N	I-Claim
280	improved	N	I-Claim
281	the	N	I-Claim
282	RDI	N	I-Claim
283	of	N	I-Claim
284	CHOP	N	I-Claim
285	,	N	I-Claim
286	but	N	I-Premise
287	this	N	I-Premise
288	did	N	I-Premise
289	not	N	I-Premise
290	lead	N	I-Premise
291	to	N	I-Premise
292	a	N	I-Premise
293	higher	N	I-Premise
294	complete	N	I-Premise
295	response	N	I-Premise
296	rate	N	I-Premise
297	or	N	I-Premise
298	better	N	I-Premise
299	overall	N	I-Premise
300	survival	N	I-Premise
301	.	N	I-Premise

302	G-CSF	N	I-Claim
303	did	N	I-Claim
304	not	N	I-Claim
305	prevent	N	I-Claim
306	serious	N	I-Claim
307	infections	N	I-Claim
308	.	N	I-Claim

1	The	N	O
2	standard	N	O
3	treatment	N	O
4	for	N	O
5	patients	N	O
6	with	N	O
7	clinically	N	O
8	resectable	N	O
9	rectal	N	O
10	cancer	N	O
11	is	N	O
12	surgery	N	O
13	.	N	O

14	Postoperative	N	I-Claim
15	radiochemotherapy	N	I-Claim
16	(	N	I-Claim
17	RCT	N	I-Claim
18	)	N	I-Claim
19	is	N	I-Claim
20	recommended	N	I-Claim
21	for	N	I-Claim
22	advanced	N	I-Claim
23	disease	N	I-Claim
24	(	N	I-Claim
25	pT3/4	N	I-Claim
26	or	N	I-Claim
27	pN+	N	I-Claim
28	)	N	I-Claim
29	.	N	I-Claim

30	In	N	O
31	recent	N	O
32	years	N	O
33	,	N	O
34	encouraging	N	O
35	results	N	O
36	of	N	O
37	pre-operative	N	O
38	radiotherapy	N	O
39	have	N	O
40	been	N	O
41	reported	N	O
42	.	N	O

43	This	N	O
44	prospective	N	O
45	randomized	N	O
46	phase-III-trial	N	O
47	(	N	O
48	CAO/ARO/AIO-94	N	O
49	)	N	O
50	compares	N	O
51	the	N	O
52	efficacy	N	O
53	of	N	O
54	neoadjuvant	N	O
55	RCT	N	O
56	to	N	O
57	standard	N	O
58	postoperative	N	O
59	RCT	N	O
60	.	N	O

61	We	N	O
62	report	N	O
63	on	N	O
64	the	N	O
65	design	N	O
66	of	N	O
67	the	N	O
68	study	N	O
69	and	N	O
70	first	N	O
71	results	N	O
72	with	N	O
73	regard	N	O
74	to	N	O
75	toxicity	N	O
76	of	N	O
77	RCT	N	O
78	and	N	O
79	postoperative	N	O
80	morbidity	N	O
81	.	N	O

82	Patients	N	O
83	with	N	O
84	locally	N	O
85	advanced	N	O
86	operable	N	O
87	rectal	N	O
88	cancer	N	O
89	(	N	O
90	uT3/4	N	O
91	or	N	O
92	uN+	N	O
93	,	N	O
94	Mason	N	O
95	CS	N	O
96	III/IV	N	O
97	)	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	pre	N	O
103	or	N	O
104	postoperative	N	O
105	RCT	N	O
106	:	N	O
107	A	N	O
108	total	N	O
109	dose	N	O
110	of	N	O
111	50.4	N	O
112	Gy	N	O
113	(	N	O
114	single	N	O
115	dose	N	O
116	1.8	N	O
117	Gy	N	O
118	)	N	O
119	was	N	O
120	applied	N	O
121	to	N	O
122	the	N	O
123	tumour	N	O
124	and	N	O
125	the	N	O
126	pelvic	N	O
127	lymph	N	O
128	nodes	N	O
129	.	N	O

130	5-FU	N	O
131	(	N	O
132	1000	N	O
133	mg/m2/d	N	O
134	)	N	O
135	was	N	O
136	administered	N	O
137	concomitantly	N	O
138	in	N	O
139	the	N	O
140	1th	N	O
141	and	N	O
142	5th	N	O
143	week	N	O
144	of	N	O
145	radiation	N	O
146	as	N	O
147	120	N	O
148	h-continuous	N	O
149	infusion	N	O
150	.	N	O

151	Four	N	O
152	additional	N	O
153	cycles	N	O
154	of	N	O
155	5-FU-chemotherapy	N	O
156	(	N	O
157	500	N	O
158	mg/m2/d	N	O
159	,	N	O
160	i.v.-bolus	N	O
161	)	N	O
162	were	N	O
163	applied	N	O
164	.	N	O

165	RCT	N	O
166	was	N	O
167	identical	N	O
168	in	N	O
169	both	N	O
170	arms	N	O
171	except	N	O
172	for	N	O
173	a	N	O
174	small-volume	N	O
175	boost	N	O
176	of	N	O
177	5.4	N	O
178	Gy	N	O
179	postoperatively	N	O
180	.	N	O

181	The	N	O
182	time	N	O
183	interval	N	O
184	between	N	O
185	RCT	N	O
186	and	N	O
187	surgery	N	O
188	was	N	O
189	4-6	N	O
190	weeks	N	O
191	in	N	O
192	both	N	O
193	arms	N	O
194	.	N	O

195	Techniques	N	O
196	of	N	O
197	surgery	N	O
198	were	N	O
199	standardized	N	O
200	and	N	O
201	included	N	O
202	total	N	O
203	mesorectal	N	O
204	excision	N	O
205	.	N	O

206	Primary	N	O
207	endpoints	N	O
208	of	N	O
209	the	N	O
210	study	N	O
211	are	N	O
212	5-year	N	O
213	survival	N	O
214	and	N	O
215	local	N	O
216	and	N	O
217	distant	N	O
218	control	N	O
219	.	N	O

220	Secondary	N	O
221	endpoints	N	O
222	include	N	O
223	the	N	O
224	rate	N	O
225	of	N	O
226	curative	N	O
227	(	N	O
228	R0	N	O
229	)	N	O
230	resection	N	O
231	and	N	O
232	sphincter	N	O
233	saving	N	O
234	procedures	N	O
235	,	N	O
236	toxicity	N	O
237	of	N	O
238	RCT	N	O
239	,	N	O
240	surgical	N	O
241	complications	N	O
242	and	N	O
243	quality	N	O
244	of	N	O
245	life	N	O
246	.	N	O

247	As	N	O
248	of	N	O
249	July	N	O
250	2002	N	O
251	,	N	O
252	805	N	O
253	patients	N	O
254	were	N	O
255	randomized	N	O
256	from	N	O
257	26	N	O
258	participating	N	O
259	institutions	N	O
260	.	N	O

261	Acute	N	I-Premise
262	toxicity	N	I-Premise
263	(	N	I-Premise
264	WHO	N	I-Premise
265	)	N	I-Premise
266	of	N	I-Premise
267	RCT	N	I-Premise
268	was	N	I-Premise
269	low	N	I-Premise
270	,	N	I-Premise
271	with	N	I-Premise
272	less	N	I-Premise
273	than	N	I-Premise
274	15	N	I-Premise
275	%	N	I-Premise
276	of	N	I-Premise
277	patients	N	I-Premise
278	experiencing	N	I-Premise
279	grade	N	I-Premise
280	3	N	I-Premise
281	or	N	I-Premise
282	higher	N	I-Premise
283	toxicity	N	I-Premise
284	:	N	O
285	The	N	I-Premise
286	principal	N	I-Premise
287	toxicity	N	I-Premise
288	was	N	I-Premise
289	diarrhea	N	I-Premise
290	,	N	I-Premise
291	with	N	I-Premise
292	12	N	I-Premise
293	%	N	I-Premise
294	in	N	I-Premise
295	the	N	I-Premise
296	postoperative	N	I-Premise
297	RCT-arm	N	I-Premise
298	and	N	I-Premise
299	11	N	I-Premise
300	%	N	I-Premise
301	in	N	I-Premise
302	the	N	I-Premise
303	pre-operative	N	I-Premise
304	RCT-arm	N	I-Premise
305	having	N	I-Premise
306	grade	N	I-Premise
307	3-	N	I-Premise
308	,	N	I-Premise
309	and	N	I-Premise
310	1	N	I-Premise
311	%	N	I-Premise
312	in	N	I-Premise
313	either	N	I-Premise
314	arm	N	I-Premise
315	having	N	I-Premise
316	grade	N	I-Premise
317	4-diarrhea	N	I-Premise
318	.	N	I-Premise

319	Erythema	N	I-Premise
320	,	N	I-Premise
321	nausea	N	I-Premise
322	and	N	I-Premise
323	leukopenia	N	I-Premise
324	were	N	I-Premise
325	the	N	I-Premise
326	next	N	I-Premise
327	common	N	I-Premise
328	toxicities	N	I-Premise
329	,	N	I-Premise
330	with	N	I-Premise
331	less	N	I-Premise
332	than	N	I-Premise
333	3	N	I-Premise
334	%	N	I-Premise
335	of	N	I-Premise
336	patients	N	I-Premise
337	in	N	I-Premise
338	either	N	I-Premise
339	arm	N	I-Premise
340	suffering	N	I-Premise
341	grade	N	I-Premise
342	3	N	I-Premise
343	or	N	I-Premise
344	greater	N	I-Premise
345	leukopenia	N	I-Premise
346	or	N	I-Premise
347	nausea	N	I-Premise
348	.	N	I-Premise

349	Postoperative	N	I-Premise
350	complication	N	I-Premise
351	rates	N	I-Premise
352	were	N	I-Premise
353	similar	N	I-Premise
354	in	N	I-Premise
355	both	N	I-Premise
356	arms	N	I-Premise
357	,	N	I-Premise
358	with	N	I-Premise
359	12	N	I-Premise
360	%	N	I-Premise
361	(	N	I-Premise
362	postop	N	I-Premise
363	.	N	I-Premise

364	RCT	N	I-Premise
365	)	N	I-Premise
366	and	N	I-Premise
367	12	N	I-Premise
368	%	N	I-Premise
369	(	N	I-Premise
370	pre-op	N	I-Premise
371	.	N	I-Premise

372	RCT	N	I-Premise
373	)	N	I-Premise
374	of	N	I-Premise
375	patients	N	I-Premise
376	,	N	I-Premise
377	respectively	N	I-Premise
378	,	N	I-Premise
379	suffering	N	I-Premise
380	from	N	I-Premise
381	anastomotic	N	I-Premise
382	leakage	N	I-Premise
383	,	N	I-Premise
384	3	N	I-Premise
385	%	N	I-Premise
386	(	N	I-Premise
387	postop	N	I-Premise
388	.	N	I-Premise

389	RCT	N	I-Premise
390	)	N	I-Premise
391	and	N	I-Premise
392	3	N	I-Premise
393	%	N	I-Premise
394	(	N	I-Premise
395	pre-op	N	I-Premise
396	.	N	I-Premise

397	RCT	N	I-Premise
398	)	N	I-Premise
399	from	N	I-Premise
400	postoperative	N	I-Premise
401	bleeding	N	I-Premise
402	,	N	I-Premise
403	and	N	I-Premise
404	6	N	I-Premise
405	%	N	I-Premise
406	(	N	I-Premise
407	postop	N	I-Premise
408	.	N	I-Premise

409	RCT	N	I-Premise
410	)	N	I-Premise
411	and	N	I-Premise
412	4	N	I-Premise
413	%	N	I-Premise
414	(	N	I-Premise
415	pre-op	N	I-Premise
416	.	N	I-Premise

417	RCT	N	I-Premise
418	)	N	I-Premise
419	from	N	I-Premise
420	delayed	N	I-Premise
421	wound	N	I-Premise
422	healing	N	I-Premise
423	.	N	I-Premise

424	The	N	I-Claim
425	patient	N	I-Claim
426	accrual	N	I-Claim
427	to	N	I-Claim
428	the	N	I-Claim
429	trial	N	I-Claim
430	is	N	I-Claim
431	satisfactory	N	I-Claim
432	.	N	O

433	Neoadjuvant	N	I-Claim
434	RCT	N	I-Claim
435	is	N	I-Claim
436	well	N	I-Claim
437	tolerated	N	I-Claim
438	and	N	I-Claim
439	bears	N	I-Claim
440	no	N	I-Claim
441	higher	N	I-Claim
442	risk	N	I-Claim
443	for	N	I-Claim
444	postoperative	N	I-Claim
445	morbidity	N	I-Claim
446	.	N	I-Claim

1	Research	N	I-MajorClaim
2	suggests	N	I-MajorClaim
3	that	N	I-MajorClaim
4	stress-reduction	N	I-MajorClaim
5	programs	N	I-MajorClaim
6	tailored	N	I-MajorClaim
7	to	N	I-MajorClaim
8	the	N	I-MajorClaim
9	cancer	N	I-MajorClaim
10	setting	N	I-MajorClaim
11	help	N	I-MajorClaim
12	patients	N	I-MajorClaim
13	cope	N	I-MajorClaim
14	with	N	I-MajorClaim
15	the	N	I-MajorClaim
16	effects	N	I-MajorClaim
17	of	N	I-MajorClaim
18	treatment	N	I-MajorClaim
19	and	N	I-MajorClaim
20	improve	N	I-MajorClaim
21	their	N	I-MajorClaim
22	quality	N	I-MajorClaim
23	of	N	I-MajorClaim
24	life	N	I-MajorClaim
25	.	N	I-MajorClaim

26	Yoga	N	O
27	,	N	O
28	an	N	O
29	ancient	N	O
30	Eastern	N	O
31	science	N	O
32	,	N	O
33	incorporates	N	O
34	stress-reduction	N	O
35	techniques	N	O
36	that	N	O
37	include	N	O
38	regulated	N	O
39	breathing	N	O
40	,	N	O
41	visual	N	O
42	imagery	N	O
43	,	N	O
44	and	N	O
45	meditation	N	O
46	as	N	O
47	well	N	O
48	as	N	O
49	various	N	O
50	postures	N	O
51	.	N	O

52	The	N	O
53	authors	N	O
54	examined	N	O
55	the	N	O
56	effects	N	O
57	of	N	O
58	the	N	O
59	Tibetan	N	O
60	yoga	N	O
61	(	N	O
62	TY	N	O
63	)	N	O
64	practices	N	O
65	of	N	O
66	Tsa	N	O
67	lung	N	O
68	and	N	O
69	Trul	N	O
70	khor	N	O
71	,	N	O
72	which	N	O
73	incorporate	N	O
74	controlled	N	O
75	breathing	N	O
76	and	N	O
77	visualization	N	O
78	,	N	O
79	mindfulness	N	O
80	techniques	N	O
81	,	N	O
82	and	N	O
83	low-impact	N	O
84	postures	N	O
85	in	N	O
86	patients	N	O
87	with	N	O
88	lymphoma	N	O
89	.	N	O

90	Thirty-nine	N	O
91	patients	N	O
92	with	N	O
93	lymphoma	N	O
94	who	N	O
95	were	N	O
96	undergoing	N	O
97	treatment	N	O
98	or	N	O
99	who	N	O
100	had	N	O
101	concluded	N	O
102	treatment	N	O
103	within	N	O
104	the	N	O
105	past	N	O
106	12	N	O
107	months	N	O
108	were	N	O
109	assigned	N	O
110	to	N	O
111	a	N	O
112	TY	N	O
113	group	N	O
114	or	N	O
115	to	N	O
116	a	N	O
117	wait-list	N	O
118	control	N	O
119	group	N	O
120	.	N	O

121	Patients	N	O
122	in	N	O
123	the	N	O
124	TY	N	O
125	group	N	O
126	participated	N	O
127	in	N	O
128	7	N	O
129	weekly	N	O
130	yoga	N	O
131	sessions	N	O
132	,	N	O
133	and	N	O
134	patients	N	O
135	in	N	O
136	the	N	O
137	wait-list	N	O
138	control	N	O
139	group	N	O
140	were	N	O
141	free	N	O
142	to	N	O
143	participate	N	O
144	in	N	O
145	the	N	O
146	TY	N	O
147	program	N	O
148	after	N	O
149	the	N	O
150	3-month	N	O
151	follow-up	N	O
152	assessment	N	O
153	.	N	O

154	Eighty	N	O
155	nine	N	O
156	percent	N	O
157	of	N	O
158	TY	N	O
159	participants	N	O
160	completed	N	O
161	at	N	O
162	least	N	O
163	2-3	N	O
164	three	N	O
165	yoga	N	O
166	sessions	N	O
167	,	N	O
168	and	N	O
169	58	N	O
170	%	N	O
171	completed	N	O
172	at	N	O
173	least	N	O
174	5	N	O
175	sessions	N	O
176	.	N	O

177	Patients	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	TY	N	I-Premise
181	group	N	I-Premise
182	reported	N	I-Premise
183	significantly	N	I-Premise
184	lower	N	I-Premise
185	sleep	N	I-Premise
186	disturbance	N	I-Premise
187	scores	N	I-Premise
188	during	N	I-Premise
189	follow-up	N	I-Premise
190	compared	N	I-Premise
191	with	N	I-Premise
192	patients	N	I-Premise
193	in	N	I-Premise
194	the	N	I-Premise
195	wait-list	N	I-Premise
196	control	N	I-Premise
197	group	N	I-Premise
198	(	N	I-Premise
199	5.8	N	I-Premise
200	vs.	N	I-Premise
201	8.1	N	I-Premise
202	;	N	I-Premise
203	P	N	I-Premise
204	<	N	I-Premise
205	0.004	N	I-Premise
206	)	N	I-Premise
207	.	N	I-Premise

208	This	N	I-Premise
209	included	N	I-Premise
210	better	N	I-Premise
211	subjective	N	I-Premise
212	sleep	N	I-Premise
213	quality	N	I-Premise
214	(	N	I-Premise
215	P	N	I-Premise
216	<	N	I-Premise
217	0.02	N	I-Premise
218	)	N	I-Premise
219	,	N	I-Premise
220	faster	N	I-Premise
221	sleep	N	I-Premise
222	latency	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	<	N	I-Premise
226	0.01	N	I-Premise
227	)	N	I-Premise
228	,	N	I-Premise
229	longer	N	I-Premise
230	sleep	N	I-Premise
231	duration	N	I-Premise
232	(	N	I-Premise
233	P	N	I-Premise
234	<	N	I-Premise
235	0.03	N	I-Premise
236	)	N	I-Premise
237	,	N	I-Premise
238	and	N	I-Premise
239	less	N	I-Premise
240	use	N	I-Premise
241	of	N	I-Premise
242	sleep	N	I-Premise
243	medications	N	I-Premise
244	(	N	I-Premise
245	P	N	I-Premise
246	<	N	I-Premise
247	0.02	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	There	N	I-Premise
251	were	N	I-Premise
252	no	N	I-Premise
253	significant	N	I-Premise
254	differences	N	I-Premise
255	between	N	I-Premise
256	groups	N	I-Premise
257	in	N	I-Premise
258	terms	N	I-Premise
259	of	N	I-Premise
260	intrusion	N	I-Premise
261	or	N	I-Premise
262	avoidance	N	I-Premise
263	,	N	I-Premise
264	state	N	I-Premise
265	anxiety	N	I-Premise
266	,	N	I-Premise
267	depression	N	I-Premise
268	,	N	I-Premise
269	or	N	I-Premise
270	fatigue	N	I-Premise
271	.	N	I-Premise

272	The	N	I-Claim
273	participation	N	I-Claim
274	rates	N	I-Claim
275	suggested	N	I-Claim
276	that	N	I-Claim
277	a	N	I-Claim
278	TY	N	I-Claim
279	program	N	I-Claim
280	is	N	I-Claim
281	feasible	N	I-Claim
282	for	N	I-Claim
283	patients	N	I-Claim
284	with	N	I-Claim
285	cancer	N	I-Claim
286	and	N	I-Claim
287	that	N	I-Claim
288	such	N	I-Claim
289	a	N	I-Claim
290	program	N	I-Claim
291	significantly	N	I-Claim
292	improves	N	I-Claim
293	sleep-related	N	I-Claim
294	outcomes	N	I-Claim
295	.	N	I-Claim

296	However	N	I-Premise
297	,	N	I-Premise
298	there	N	I-Premise
299	were	N	I-Premise
300	no	N	I-Premise
301	significant	N	I-Premise
302	differences	N	I-Premise
303	between	N	I-Premise
304	groups	N	I-Premise
305	for	N	I-Premise
306	the	N	I-Premise
307	other	N	I-Premise
308	outcomes	N	I-Premise
309	.	N	I-Premise

1	Recombinant	N	I-Claim
2	human	N	I-Claim
3	erythropoietin	N	I-Claim
4	(	N	I-Claim
5	r-HuEPO	N	I-Claim
6	)	N	I-Claim
7	corrects	N	I-Claim
8	cancer-related	N	I-Claim
9	anemia	N	I-Claim
10	and	N	I-Claim
11	,	N	I-Claim
12	thereby	N	I-Claim
13	,	N	I-Claim
14	improves	N	I-Claim
15	quality	N	I-Claim
16	of	N	I-Claim
17	life	N	I-Claim
18	.	N	I-Claim

19	The	N	O
20	purpose	N	O
21	of	N	O
22	the	N	O
23	present	N	O
24	study	N	O
25	was	N	O
26	to	N	O
27	measure	N	O
28	the	N	O
29	impact	N	O
30	of	N	O
31	erythropoietin	N	O
32	on	N	O
33	hemoglobin	N	O
34	and	N	O
35	mood	N	O
36	state	N	O
37	in	N	O
38	patients	N	O
39	with	N	O
40	metastatic	N	O
41	breast	N	O
42	cancer	N	O
43	and	N	O
44	mild	N	O
45	anemia	N	O
46	(	N	O
47	Hgb	N	O
48	<	N	O
49	12.0	N	O
50	g/dL	N	O
51	)	N	O
52	.	N	O

53	Women	N	O
54	were	N	O
55	randomized	N	O
56	to	N	O
57	receive	N	O
58	usual	N	O
59	care	N	O
60	(	N	O
61	G1	N	O
62	)	N	O
63	or	N	O
64	usual	N	O
65	care	N	O
66	plus	N	O
67	r-HuEPO	N	O
68	(	N	O
69	G2	N	O
70	)	N	O
71	.	N	O

72	Usual	N	O
73	care	N	O
74	included	N	O
75	transfusions	N	O
76	as	N	O
77	necessary	N	O
78	and	N	O
79	fatigue	N	O
80	education	N	O
81	.	N	O

82	R-HuEPO	N	O
83	was	N	O
84	begun	N	O
85	at	N	O
86	40,000U	N	O
87	subcutaneously	N	O
88	per	N	O
89	week	N	O
90	.	N	O

91	At	N	O
92	4	N	O
93	weeks	N	O
94	,	N	O
95	the	N	O
96	dose	N	O
97	was	N	O
98	increased	N	O
99	to	N	O
100	60,000U	N	O
101	if	N	O
102	Hgb	N	O
103	had	N	O
104	not	N	O
105	increased	N	O
106	>	N	O
107	or	N	O
108	=	N	O
109	1.0	N	O
110	g/dL	N	O
111	.	N	O

112	The	N	O
113	drug	N	O
114	was	N	O
115	discontinued	N	O
116	at	N	O
117	8	N	O
118	weeks	N	O
119	if	N	O
120	hemoglobin	N	O
121	improvement	N	O
122	was	N	O
123	<	N	O
124	1.0	N	O
125	g/dL	N	O
126	.	N	O

127	The	N	O
128	study	N	O
129	was	N	O
130	terminated	N	O
131	early	N	O
132	(	N	O
133	n	N	O
134	=	N	O
135	27	N	O
136	,	N	O
137	G1	N	O
138	=	N	O
139	13	N	O
140	,	N	O
141	G2	N	O
142	=	N	O
143	14	N	O
144	)	N	O
145	when	N	O
146	4/14	N	O
147	(	N	O
148	28.5	N	O
149	%	N	O
150	)	N	O
151	subjects	N	O
152	in	N	O
153	G2	N	O
154	developed	N	O
155	thrombotic	N	O
156	events	N	O
157	(	N	O
158	deep	N	O
159	vein	N	O
160	thrombosis	N	O
161	[	N	O
162	DVT	N	O
163	]	N	O
164	in	N	O
165	1	N	O
166	;	N	O
167	DVT	N	O
168	plus	N	O
169	pulmonary	N	O
170	embolism	N	O
171	[	N	O
172	PE	N	O
173	]	N	O
174	in	N	O
175	1	N	O
176	;	N	O
177	DVT	N	O
178	plus	N	O
179	PE	N	O
180	1	N	O
181	month	N	O
182	after	N	O
183	drug	N	O
184	discontinuation	N	O
185	in	N	O
186	1	N	O
187	;	N	O
188	and	N	O
189	brachial	N	O
190	vein	N	O
191	thrombosis	N	O
192	with	N	O
193	infected	N	O
194	Mediport	N	O
195	in	N	O
196	1	N	O
197	)	N	O
198	.	N	O

199	In	N	I-Premise
200	all	N	I-Premise
201	four	N	I-Premise
202	patients	N	I-Premise
203	,	N	I-Premise
204	Hgb	N	I-Premise
205	levels	N	I-Premise
206	were	N	I-Premise
207	normal	N	I-Premise
208	at	N	I-Premise
209	the	N	I-Premise
210	time	N	I-Premise
211	of	N	I-Premise
212	the	N	I-Premise
213	event	N	I-Premise
214	.	N	I-Premise

215	No	N	I-Premise
216	patient	N	I-Premise
217	in	N	I-Premise
218	G1	N	I-Premise
219	developed	N	I-Premise
220	a	N	I-Premise
221	thrombotic	N	I-Premise
222	event	N	I-Premise
223	.	N	I-Premise

224	There	N	I-Premise
225	were	N	I-Premise
226	no	N	I-Premise
227	significant	N	I-Premise
228	differences	N	I-Premise
229	in	N	I-Premise
230	demographic	N	I-Premise
231	characteristics	N	I-Premise
232	or	N	I-Premise
233	current	N	I-Premise
234	chemotherapy	N	I-Premise
235	regimen	N	I-Premise
236	in	N	I-Premise
237	G1	N	I-Premise
238	vs.	N	I-Premise
239	G2	N	I-Premise
240	.	N	I-Premise

241	The	N	O
242	decision	N	O
243	to	N	O
244	terminate	N	O
245	the	N	O
246	trial	N	O
247	was	N	O
248	made	N	O
249	after	N	O
250	considerable	N	O
251	deliberation	N	O
252	.	N	O

253	The	N	I-Premise
254	increased	N	I-Premise
255	incidence	N	I-Premise
256	of	N	I-Premise
257	thrombotic	N	I-Premise
258	events	N	I-Premise
259	in	N	I-Premise
260	the	N	I-Premise
261	r-HuEPO	N	I-Premise
262	(	N	I-Premise
263	G2	N	I-Premise
264	)	N	I-Premise
265	arm	N	I-Premise
266	of	N	I-Premise
267	this	N	I-Premise
268	study	N	I-Premise
269	exceeds	N	I-Premise
270	that	N	I-Premise
271	in	N	I-Premise
272	prior	N	I-Premise
273	studies	N	I-Premise
274	in	N	I-Premise
275	this	N	I-Premise
276	population	N	I-Premise
277	and	N	I-Premise
278	prior	N	I-Premise
279	r-HuEPO	N	I-Premise
280	trials	N	I-Premise
281	.	N	I-Premise

282	This	N	I-Claim
283	may	N	I-Claim
284	relate	N	I-Claim
285	to	N	I-Claim
286	the	N	I-Claim
287	administration	N	I-Claim
288	of	N	I-Claim
289	r-HuEPO	N	I-Claim
290	in	N	I-Claim
291	this	N	I-Claim
292	high-risk	N	I-Claim
293	population	N	I-Claim
294	,	N	I-Claim
295	but	N	I-Claim
296	the	N	I-Claim
297	small	N	I-Claim
298	sample	N	I-Claim
299	size	N	I-Claim
300	and	N	I-Claim
301	possible	N	I-Claim
302	predisposing	N	I-Claim
303	risk	N	I-Claim
304	factors	N	I-Claim
305	preclude	N	I-Claim
306	definitive	N	I-Claim
307	conclusions	N	I-Claim
308	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	health-related	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	(	N	O
8	HRQOL	N	O
9	)	N	O
10	in	N	O
11	patients	N	O
12	with	N	O
13	metastatic	N	O
14	breast	N	O
15	cancer	N	O
16	receiving	N	O
17	the	N	O
18	combination	N	O
19	of	N	O
20	doxorubicin	N	O
21	and	N	O
22	paclitaxel	N	O
23	(	N	O
24	AT	N	O
25	)	N	O
26	or	N	O
27	doxorubicin	N	O
28	and	N	O
29	cyclophosphamide	N	O
30	(	N	O
31	AC	N	O
32	)	N	O
33	as	N	O
34	first-line	N	O
35	chemotherapy	N	O
36	treatment	N	O
37	.	N	O

38	Eligible	N	O
39	patients	N	O
40	(	N	O
41	n	N	O
42	=	N	O
43	275	N	O
44	)	N	O
45	with	N	O
46	anthracycline-naive	N	O
47	measurable	N	O
48	metastatic	N	O
49	breast	N	O
50	cancer	N	O
51	were	N	O
52	randomly	N	O
53	assigned	N	O
54	to	N	O
55	AT	N	O
56	(	N	O
57	doxorubicin	N	O
58	60	N	O
59	mg/m	N	O
60	(	N	O
61	2	N	O
62	)	N	O
63	as	N	O
64	an	N	O
65	intravenous	N	O
66	bolus	N	O
67	plus	N	O
68	paclitaxel	N	O
69	175	N	O
70	mg/m	N	O
71	(	N	O
72	2	N	O
73	)	N	O
74	as	N	O
75	a	N	O
76	3-hour	N	O
77	infusion	N	O
78	)	N	O
79	or	N	O
80	AC	N	O
81	(	N	O
82	doxorubicin	N	O
83	60	N	O
84	mg/m	N	O
85	(	N	O
86	2	N	O
87	)	N	O
88	plus	N	O
89	cyclophosphamide	N	O
90	600	N	O
91	mg/m	N	O
92	(	N	O
93	2	N	O
94	)	N	O
95	)	N	O
96	every	N	O
97	3	N	O
98	weeks	N	O
99	for	N	O
100	a	N	O
101	maximum	N	O
102	of	N	O
103	six	N	O
104	cycles	N	O
105	.	N	O

106	Dose	N	O
107	escalation	N	O
108	of	N	O
109	paclitaxel	N	O
110	(	N	O
111	200	N	O
112	mg/m	N	O
113	(	N	O
114	2	N	O
115	)	N	O
116	)	N	O
117	and	N	O
118	cyclophosphamide	N	O
119	(	N	O
120	750	N	O
121	mg/m	N	O
122	(	N	O
123	2	N	O
124	)	N	O
125	)	N	O
126	was	N	O
127	planned	N	O
128	at	N	O
129	cycle	N	O
130	2	N	O
131	to	N	O
132	reach	N	O
133	equivalent	N	O
134	myelosuppression	N	O
135	in	N	O
136	the	N	O
137	two	N	O
138	groups	N	O
139	.	N	O

140	HRQOL	N	O
141	was	N	O
142	assessed	N	O
143	with	N	O
144	the	N	O
145	European	N	O
146	Organization	N	O
147	for	N	O
148	Research	N	O
149	and	N	O
150	Treatment	N	O
151	of	N	O
152	Cancer	N	O
153	(	N	O
154	EORTC	N	O
155	)	N	O
156	Quality	N	O
157	of	N	O
158	Life	N	O
159	Questionnaire	N	O
160	C30	N	O
161	and	N	O
162	the	N	O
163	EORTC	N	O
164	Breast	N	O
165	Module	N	O
166	at	N	O
167	baseline	N	O
168	and	N	O
169	the	N	O
170	start	N	O
171	of	N	O
172	cycles	N	O
173	2	N	O
174	,	N	O
175	4	N	O
176	,	N	O
177	and	N	O
178	6	N	O
179	,	N	O
180	and	N	O
181	3	N	O
182	months	N	O
183	after	N	O
184	the	N	O
185	last	N	O
186	cycle	N	O
187	.	N	O

188	Seventy-nine	N	O
189	percent	N	O
190	of	N	O
191	the	N	O
192	patients	N	O
193	(	N	O
194	n	N	O
195	=	N	O
196	219	N	O
197	)	N	O
198	completed	N	O
199	a	N	O
200	baseline	N	O
201	measure	N	O
202	.	N	O

203	However	N	O
204	,	N	O
205	there	N	I-Premise
206	were	N	I-Premise
207	no	N	I-Premise
208	statistically	N	I-Premise
209	significant	N	I-Premise
210	differences	N	I-Premise
211	in	N	I-Premise
212	HRQOL	N	I-Premise
213	between	N	I-Premise
214	the	N	I-Premise
215	two	N	I-Premise
216	treatment	N	I-Premise
217	groups	N	I-Premise
218	.	N	I-Premise

219	In	N	I-Premise
220	both	N	I-Premise
221	groups	N	I-Premise
222	,	N	I-Premise
223	selected	N	I-Premise
224	aspects	N	I-Premise
225	of	N	I-Premise
226	HRQOL	N	I-Premise
227	were	N	I-Premise
228	impaired	N	I-Premise
229	over	N	I-Premise
230	time	N	I-Premise
231	,	N	I-Premise
232	with	N	I-Premise
233	increased	N	I-Premise
234	fatigue	N	I-Premise
235	,	N	I-Premise
236	although	N	I-Premise
237	some	N	I-Premise
238	clinically	N	I-Premise
239	significant	N	I-Premise
240	improvements	N	I-Premise
241	in	N	I-Premise
242	emotional	N	I-Premise
243	functioning	N	I-Premise
244	were	N	I-Premise
245	seen	N	I-Premise
246	,	N	I-Premise
247	as	N	I-Premise
248	well	N	I-Premise
249	as	N	I-Premise
250	a	N	I-Premise
251	reduction	N	I-Premise
252	in	N	I-Premise
253	pain	N	I-Premise
254	over	N	I-Premise
255	time	N	I-Premise
256	.	N	I-Premise

257	Overall	N	I-Claim
258	,	N	I-Claim
259	global	N	I-Claim
260	quality	N	I-Claim
261	of	N	I-Claim
262	life	N	I-Claim
263	was	N	I-Claim
264	maintained	N	I-Claim
265	in	N	I-Claim
266	both	N	I-Claim
267	treatment	N	I-Claim
268	groups	N	I-Claim
269	.	N	I-Claim

270	This	N	I-Claim
271	information	N	I-Claim
272	is	N	I-Claim
273	important	N	I-Claim
274	when	N	I-Claim
275	advising	N	I-Claim
276	women	N	I-Claim
277	patients	N	I-Claim
278	of	N	I-Claim
279	the	N	I-Claim
280	expected	N	I-Claim
281	HRQOL	N	I-Claim
282	consequences	N	I-Claim
283	of	N	I-Claim
284	treatment	N	I-Claim
285	regimens	N	I-Claim
286	and	N	I-Claim
287	should	N	I-Claim
288	help	N	I-Claim
289	clinicians	N	I-Claim
290	and	N	I-Claim
291	their	N	I-Claim
292	patients	N	I-Claim
293	make	N	I-Claim
294	informed	N	I-Claim
295	treatment	N	I-Claim
296	decisions	N	I-Claim
297	.	N	I-Claim

1	Malnutrition	N	I-Claim
2	occurs	N	I-Claim
3	frequently	N	I-Claim
4	in	N	I-Claim
5	patients	N	I-Claim
6	with	N	I-Claim
7	cancer	N	I-Claim
8	of	N	I-Claim
9	the	N	I-Claim
10	gastrointestinal	N	I-Claim
11	(	N	I-Claim
12	GI	N	I-Claim
13	)	N	I-Claim
14	or	N	I-Claim
15	head	N	I-Claim
16	and	N	I-Claim
17	neck	N	I-Claim
18	area	N	I-Claim
19	and	N	I-Claim
20	can	N	I-Claim
21	lead	N	I-Claim
22	to	N	I-Claim
23	negative	N	I-Claim
24	outcomes	N	I-Claim
25	.	N	I-Claim

26	The	N	O
27	aim	N	O
28	of	N	O
29	this	N	O
30	study	N	O
31	is	N	O
32	to	N	O
33	determine	N	O
34	the	N	O
35	impact	N	O
36	of	N	O
37	early	N	O
38	and	N	O
39	intensive	N	O
40	nutrition	N	O
41	intervention	N	O
42	(	N	O
43	NI	N	O
44	)	N	O
45	on	N	O
46	body	N	O
47	weight	N	O
48	,	N	O
49	body	N	O
50	composition	N	O
51	,	N	O
52	nutritional	N	O
53	status	N	O
54	,	N	O
55	global	N	O
56	quality	N	O
57	of	N	O
58	life	N	O
59	(	N	O
60	QoL	N	O
61	)	N	O
62	and	N	O
63	physical	N	O
64	function	N	O
65	compared	N	O
66	to	N	O
67	usual	N	O
68	practice	N	O
69	in	N	O
70	oncology	N	O
71	outpatients	N	O
72	receiving	N	O
73	radiotherapy	N	O
74	to	N	O
75	the	N	O
76	GI	N	O
77	or	N	O
78	head	N	O
79	and	N	O
80	neck	N	O
81	area	N	O
82	.	N	O

83	Outpatients	N	O
84	commencing	N	O
85	at	N	O
86	least	N	O
87	20	N	O
88	fractions	N	O
89	of	N	O
90	radiotherapy	N	O
91	to	N	O
92	the	N	O
93	GI	N	O
94	or	N	O
95	head	N	O
96	and	N	O
97	neck	N	O
98	area	N	O
99	were	N	O
100	randomised	N	O
101	to	N	O
102	receive	N	O
103	intensive	N	O
104	,	N	O
105	individualised	N	O
106	nutrition	N	O
107	counselling	N	O
108	by	N	O
109	a	N	O
110	dietitian	N	O
111	using	N	O
112	a	N	O
113	standard	N	O
114	protocol	N	O
115	and	N	O
116	oral	N	O
117	supplements	N	O
118	if	N	O
119	required	N	O
120	,	N	O
121	or	N	O
122	the	N	O
123	usual	N	O
124	practice	N	O
125	of	N	O
126	the	N	O
127	centre	N	O
128	(	N	O
129	general	N	O
130	advice	N	O
131	and	N	O
132	nutrition	N	O
133	booklet	N	O
134	)	N	O
135	.	N	O

136	Outcome	N	O
137	parameters	N	O
138	were	N	O
139	measured	N	O
140	at	N	O
141	baseline	N	O
142	and	N	O
143	4	N	O
144	,	N	O
145	8	N	O
146	and	N	O
147	12	N	O
148	weeks	N	O
149	after	N	O
150	commencing	N	O
151	radiotherapy	N	O
152	using	N	O
153	valid	N	O
154	and	N	O
155	reliable	N	O
156	tools	N	O
157	.	N	O

158	A	N	O
159	total	N	O
160	of	N	O
161	60	N	O
162	patients	N	O
163	(	N	O
164	51	N	O
165	M	N	O
166	:	N	O
167	9	N	O
168	F	N	O
169	;	N	O
170	mean	N	O
171	age	N	O
172	61.9+/-14.0	N	O
173	years	N	O
174	)	N	O
175	were	N	O
176	randomised	N	O
177	to	N	O
178	receive	N	O
179	either	N	O
180	NI	N	O
181	(	N	O
182	n=29	N	O
183	)	N	O
184	or	N	O
185	usual	N	O
186	care	N	O
187	(	N	O
188	UC	N	O
189	)	N	O
190	(	N	O
191	n=31	N	O
192	)	N	O
193	.	N	O

194	The	N	I-Premise
195	NI	N	I-Premise
196	group	N	I-Premise
197	had	N	I-Premise
198	statistically	N	I-Premise
199	smaller	N	I-Premise
200	deteriorations	N	I-Premise
201	in	N	I-Premise
202	weight	N	I-Premise
203	(	N	I-Premise
204	P	N	I-Premise
205	<	N	I-Premise
206	0.001	N	I-Premise
207	)	N	I-Premise
208	,	N	I-Premise
209	nutritional	N	I-Premise
210	status	N	I-Premise
211	(	N	I-Premise
212	P=0.020	N	I-Premise
213	)	N	I-Premise
214	and	N	I-Premise
215	global	N	I-Premise
216	QoL	N	I-Premise
217	(	N	I-Premise
218	P=0.009	N	I-Premise
219	)	N	I-Premise
220	compared	N	I-Premise
221	with	N	I-Premise
222	those	N	I-Premise
223	receiving	N	I-Premise
224	UC	N	I-Premise
225	.	N	I-Premise

226	Clinically	N	I-Premise
227	,	N	I-Premise
228	but	N	I-Premise
229	not	N	I-Premise
230	statistically	N	I-Premise
231	significant	N	I-Premise
232	differences	N	I-Premise
233	in	N	I-Premise
234	fat-free	N	I-Premise
235	mass	N	I-Premise
236	were	N	I-Premise
237	observed	N	I-Premise
238	between	N	I-Premise
239	the	N	I-Premise
240	groups	N	I-Premise
241	(	N	I-Premise
242	P=0.195	N	I-Premise
243	)	N	I-Premise
244	.	N	I-Premise

245	Early	N	I-Claim
246	and	N	I-Claim
247	intensive	N	I-Claim
248	NI	N	I-Claim
249	appears	N	I-Claim
250	beneficial	N	I-Claim
251	in	N	I-Claim
252	terms	N	I-Claim
253	of	N	I-Claim
254	minimising	N	I-Claim
255	weight	N	I-Claim
256	loss	N	I-Claim
257	,	N	I-Claim
258	deterioration	N	I-Claim
259	in	N	I-Claim
260	nutritional	N	I-Claim
261	status	N	I-Claim
262	,	N	I-Claim
263	global	N	I-Claim
264	QoL	N	I-Claim
265	and	N	I-Claim
266	physical	N	I-Claim
267	function	N	I-Claim
268	in	N	I-Claim
269	oncology	N	I-Claim
270	outpatients	N	I-Claim
271	receiving	N	I-Claim
272	radiotherapy	N	I-Claim
273	to	N	I-Claim
274	the	N	I-Claim
275	GI	N	I-Claim
276	or	N	I-Claim
277	head	N	I-Claim
278	and	N	I-Claim
279	neck	N	I-Claim
280	area	N	I-Claim
281	.	N	I-Claim

282	Weight	N	I-Claim
283	maintenance	N	I-Claim
284	in	N	I-Claim
285	this	N	I-Claim
286	population	N	I-Claim
287	leads	N	I-Claim
288	to	N	I-Claim
289	beneficial	N	I-Claim
290	outcomes	N	I-Claim
291	and	N	I-Claim
292	suggests	N	I-Claim
293	that	N	I-Claim
294	this	N	I-Claim
295	,	N	I-Claim
296	rather	N	I-Claim
297	than	N	I-Claim
298	weight	N	I-Claim
299	gain	N	I-Claim
300	,	N	I-Claim
301	may	N	I-Claim
302	be	N	I-Claim
303	a	N	I-Claim
304	more	N	I-Claim
305	appropriate	N	I-Claim
306	aim	N	I-Claim
307	of	N	I-Claim
308	NI	N	I-Claim
309	.	N	I-Claim

1	Bone	N	I-Claim
2	metastases	N	I-Claim
3	occur	N	I-Claim
4	in	N	I-Claim
5	most	N	I-Claim
6	women	N	I-Claim
7	with	N	I-Claim
8	advanced	N	I-Claim
9	breast	N	I-Claim
10	cancer	N	I-Claim
11	and	N	I-Claim
12	can	N	I-Claim
13	lead	N	I-Claim
14	to	N	I-Claim
15	considerable	N	I-Claim
16	morbidity	N	I-Claim
17	and	N	I-Claim
18	a	N	I-Claim
19	rapid	N	I-Claim
20	deterioration	N	I-Claim
21	in	N	I-Claim
22	the	N	I-Claim
23	patient	N	I-Claim
24	's	N	I-Claim
25	quality	N	I-Claim
26	of	N	I-Claim
27	life	N	I-Claim
28	.	N	I-Claim

29	It	N	O
30	was	N	O
31	the	N	O
32	aim	N	O
33	of	N	O
34	the	N	O
35	present	N	O
36	study	N	O
37	to	N	O
38	assess	N	O
39	changes	N	O
40	in	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	and	N	O
45	bone	N	O
46	pain	N	O
47	due	N	O
48	to	N	O
49	intravenous	N	O
50	(	N	O
51	i.v	N	O
52	.	N	O

53	)	N	O
54	ibandronate	N	O
55	,	N	O
56	a	N	O
57	potent	N	O
58	third-generation	N	O
59	bisphosphonate	N	O
60	.	N	O

61	In	N	O
62	a	N	O
63	phase	N	O
64	III	N	O
65	randomised	N	O
66	,	N	O
67	double-blind	N	O
68	,	N	O
69	placebo-controlled	N	O
70	trial	N	O
71	in	N	O
72	patients	N	O
73	with	N	O
74	bone	N	O
75	metastases	N	O
76	due	N	O
77	to	N	O
78	breast	N	O
79	cancer	N	O
80	,	N	O
81	466	N	O
82	women	N	O
83	were	N	O
84	randomised	N	O
85	to	N	O
86	receive	N	O
87	placebo	N	O
88	,	N	O
89	2	N	O
90	mg	N	O
91	ibandronate	N	O
92	or	N	O
93	6	N	O
94	mg	N	O
95	ibandronate	N	O
96	for	N	O
97	up	N	O
98	to	N	O
99	96	N	O
100	weeks	N	O
101	.	N	O

102	Treatment	N	O
103	was	N	O
104	administered	N	O
105	i.v	N	O
106	.	N	O

107	at	N	O
108	3-	N	O
109	or	N	O
110	4-weekly	N	O
111	intervals	N	O
112	.	N	O

113	Clinical	N	O
114	endpoints	N	O
115	included	N	O
116	the	N	O
117	incidence	N	O
118	of	N	O
119	adverse	N	O
120	events	N	O
121	,	N	O
122	quality	N	O
123	of	N	O
124	life	N	O
125	(	N	O
126	assessed	N	O
127	using	N	O
128	the	N	O
129	European	N	O
130	Organisation	N	O
131	for	N	O
132	the	N	O
133	Research	N	O
134	and	N	O
135	Treatment	N	O
136	of	N	O
137	Cancer	N	O
138	(	N	O
139	EORTC	N	O
140	)	N	O
141	Quality	N	O
142	of	N	O
143	Life	N	O
144	Scale	N	O
145	-	N	O
146	Core	N	O
147	30	N	O
148	questionnaire	N	O
149	(	N	O
150	QLQ-C30	N	O
151	)	N	O
152	)	N	O
153	,	N	O
154	and	N	O
155	bone	N	O
156	pain	N	O
157	(	N	O
158	assessed	N	O
159	on	N	O
160	a	N	O
161	5-point	N	O
162	scale	N	O
163	from	N	O
164	0=none	N	O
165	to	N	O
166	4=intolerable	N	O
167	)	N	O
168	.	N	O

169	Ibandronate	N	I-Premise
170	was	N	I-Premise
171	generally	N	I-Premise
172	well	N	I-Premise
173	tolerated	N	I-Premise
174	.	N	I-Premise

175	Compared	N	I-Premise
176	with	N	I-Premise
177	baseline	N	I-Premise
178	measurements	N	I-Premise
179	,	N	I-Premise
180	the	N	I-Premise
181	bone	N	I-Premise
182	pain	N	I-Premise
183	score	N	I-Premise
184	was	N	I-Premise
185	increased	N	I-Premise
186	at	N	I-Premise
187	the	N	I-Premise
188	last	N	I-Premise
189	assessment	N	I-Premise
190	in	N	I-Premise
191	both	N	I-Premise
192	the	N	I-Premise
193	placebo	N	I-Premise
194	and	N	I-Premise
195	2	N	I-Premise
196	mg	N	I-Premise
197	ibandronate	N	I-Premise
198	groups	N	I-Premise
199	,	N	I-Premise
200	but	N	I-Premise
201	was	N	I-Premise
202	significantly	N	I-Premise
203	reduced	N	I-Premise
204	in	N	I-Premise
205	the	N	I-Premise
206	patients	N	I-Premise
207	receiving	N	I-Premise
208	6	N	I-Premise
209	mg	N	I-Premise
210	ibandronate	N	I-Premise
211	(	N	I-Premise
212	-0.28+/-1.11	N	I-Premise
213	,	N	I-Premise
214	P	N	I-Premise
215	<	N	I-Premise
216	0.001	N	I-Premise
217	)	N	I-Premise
218	.	N	I-Premise

219	A	N	I-Premise
220	significant	N	I-Premise
221	improvement	N	I-Premise
222	in	N	I-Premise
223	quality	N	I-Premise
224	of	N	I-Premise
225	life	N	I-Premise
226	was	N	I-Premise
227	demonstrated	N	I-Premise
228	for	N	I-Premise
229	patients	N	I-Premise
230	treated	N	I-Premise
231	with	N	I-Premise
232	ibandronate	N	I-Premise
233	(	N	I-Premise
234	P	N	I-Premise
235	<	N	I-Premise
236	0.05	N	I-Premise
237	)	N	I-Premise
238	for	N	I-Premise
239	all	N	I-Premise
240	global	N	I-Premise
241	health	N	I-Premise
242	status	N	I-Premise
243	.	N	I-Premise

244	Overall	N	I-Premise
245	,	N	I-Premise
246	at	N	I-Premise
247	the	N	I-Premise
248	last	N	I-Premise
249	assessment	N	I-Premise
250	,	N	I-Premise
251	the	N	I-Premise
252	6	N	I-Premise
253	mg	N	I-Premise
254	ibandronate	N	I-Premise
255	group	N	I-Premise
256	showed	N	I-Premise
257	significantly	N	I-Premise
258	better	N	I-Premise
259	functioning	N	I-Premise
260	compared	N	I-Premise
261	with	N	I-Premise
262	placebo	N	I-Premise
263	(	N	I-Premise
264	P	N	I-Premise
265	=	N	I-Premise
266	0.004	N	I-Premise
267	)	N	I-Premise
268	,	N	I-Premise
269	and	N	I-Premise
270	had	N	I-Premise
271	significantly	N	I-Premise
272	better	N	I-Premise
273	scores	N	I-Premise
274	on	N	I-Premise
275	the	N	I-Premise
276	domains	N	I-Premise
277	of	N	I-Premise
278	physical	N	I-Premise
279	,	N	I-Premise
280	emotional	N	I-Premise
281	,	N	I-Premise
282	and	N	I-Premise
283	social	N	I-Premise
284	functioning	N	I-Premise
285	,	N	I-Premise
286	and	N	I-Premise
287	in	N	I-Premise
288	global	N	I-Premise
289	health	N	I-Premise
290	status	N	I-Premise
291	(	N	I-Premise
292	P	N	I-Premise
293	<	N	I-Premise
294	0.05	N	I-Premise
295	)	N	I-Premise
296	.	N	I-Premise

297	Significant	N	I-Premise
298	improvements	N	I-Premise
299	in	N	I-Premise
300	the	N	I-Premise
301	symptoms	N	I-Premise
302	of	N	I-Premise
303	fatigue	N	I-Premise
304	and	N	I-Premise
305	pain	N	I-Premise
306	were	N	I-Premise
307	also	N	I-Premise
308	observed	N	I-Premise
309	in	N	I-Premise
310	the	N	I-Premise
311	6	N	I-Premise
312	mg	N	I-Premise
313	ibandronate	N	I-Premise
314	group	N	I-Premise
315	.	N	I-Premise

316	I.v	N	I-Claim
317	.	N	I-Claim

318	ibandronate	N	I-Claim
319	treatment	N	I-Claim
320	leads	N	I-Claim
321	to	N	I-Claim
322	significant	N	I-Claim
323	improvements	N	I-Claim
324	in	N	I-Claim
325	quality	N	I-Claim
326	of	N	I-Claim
327	life	N	I-Claim
328	,	N	I-Claim
329	and	N	I-Claim
330	is	N	I-Claim
331	an	N	I-Claim
332	effective	N	I-Claim
333	and	N	I-Claim
334	well-tolerated	N	I-Claim
335	palliative	N	I-Claim
336	treatment	N	I-Claim
337	in	N	I-Claim
338	patients	N	I-Claim
339	with	N	I-Claim
340	bone	N	I-Claim
341	metastases	N	I-Claim
342	due	N	I-Claim
343	to	N	I-Claim
344	breast	N	I-Claim
345	cancer	N	I-Claim
346	.	N	I-Claim

1	Advice	N	I-Claim
2	to	N	I-Claim
3	rest	N	I-Claim
4	and	N	I-Claim
5	take	N	I-Claim
6	things	N	I-Claim
7	easy	N	I-Claim
8	if	N	I-Claim
9	patients	N	I-Claim
10	become	N	I-Claim
11	fatigued	N	I-Claim
12	during	N	I-Claim
13	radiotherapy	N	I-Claim
14	may	N	I-Claim
15	be	N	I-Claim
16	detrimental	N	I-Claim
17	.	N	I-Claim

18	Aerobic	N	I-Premise
19	walking	N	I-Premise
20	improves	N	I-Premise
21	physical	N	I-Premise
22	functioning	N	I-Premise
23	and	N	I-Premise
24	has	N	I-Premise
25	been	N	I-Premise
26	an	N	I-Premise
27	intervention	N	I-Premise
28	for	N	I-Premise
29	chemotherapy-related	N	I-Premise
30	fatigue	N	I-Premise
31	.	N	I-Premise

32	A	N	O
33	prospective	N	O
34	,	N	O
35	randomized	N	O
36	,	N	O
37	controlled	N	O
38	trial	N	O
39	was	N	O
40	performed	N	O
41	to	N	O
42	determine	N	O
43	whether	N	O
44	aerobic	N	O
45	exercise	N	O
46	would	N	O
47	reduce	N	O
48	the	N	O
49	incidence	N	O
50	of	N	O
51	fatigue	N	O
52	and	N	O
53	prevent	N	O
54	deterioration	N	O
55	in	N	O
56	physical	N	O
57	functioning	N	O
58	during	N	O
59	radiotherapy	N	O
60	for	N	O
61	localized	N	O
62	prostate	N	O
63	carcinoma	N	O
64	.	N	O

65	Sixty-six	N	O
66	men	N	O
67	were	N	O
68	randomized	N	O
69	before	N	O
70	they	N	O
71	received	N	O
72	radical	N	O
73	radiotherapy	N	O
74	for	N	O
75	localized	N	O
76	prostate	N	O
77	carcinoma	N	O
78	,	N	O
79	with	N	O
80	33	N	O
81	men	N	O
82	randomized	N	O
83	to	N	O
84	an	N	O
85	exercise	N	O
86	group	N	O
87	and	N	O
88	33	N	O
89	men	N	O
90	randomized	N	O
91	to	N	O
92	a	N	O
93	control	N	O
94	group	N	O
95	.	N	O

96	Outcome	N	O
97	measures	N	O
98	were	N	O
99	fatigue	N	O
100	and	N	O
101	distance	N	O
102	walked	N	O
103	in	N	O
104	a	N	O
105	modified	N	O
106	shuttle	N	O
107	test	N	O
108	before	N	O
109	and	N	O
110	after	N	O
111	radiotherapy	N	O
112	.	N	O

113	There	N	I-Premise
114	were	N	I-Premise
115	no	N	I-Premise
116	significant	N	I-Premise
117	between	N	I-Premise
118	group	N	I-Premise
119	differences	N	I-Premise
120	noted	N	I-Premise
121	with	N	I-Premise
122	regard	N	I-Premise
123	to	N	I-Premise
124	fatigue	N	I-Premise
125	scores	N	I-Premise
126	at	N	I-Premise
127	baseline	N	I-Premise
128	(	N	I-Premise
129	P	N	I-Premise
130	=	N	I-Premise
131	0.55	N	I-Premise
132	)	N	I-Premise
133	or	N	I-Premise
134	after	N	I-Premise
135	4	N	I-Premise
136	weeks	N	I-Premise
137	of	N	I-Premise
138	radiotherapy	N	I-Premise
139	(	N	I-Premise
140	P	N	I-Premise
141	=	N	I-Premise
142	0.18	N	I-Premise
143	)	N	I-Premise
144	.	N	I-Premise

145	Men	N	I-Premise
146	in	N	I-Premise
147	the	N	I-Premise
148	control	N	I-Premise
149	group	N	I-Premise
150	had	N	I-Premise
151	significant	N	I-Premise
152	increases	N	I-Premise
153	in	N	I-Premise
154	fatigue	N	I-Premise
155	scores	N	I-Premise
156	from	N	I-Premise
157	baseline	N	I-Premise
158	to	N	I-Premise
159	the	N	I-Premise
160	end	N	I-Premise
161	of	N	I-Premise
162	radiotherapy	N	I-Premise
163	(	N	I-Premise
164	P	N	I-Premise
165	=	N	I-Premise
166	0.013	N	I-Premise
167	)	N	I-Premise
168	,	N	I-Premise
169	with	N	I-Premise
170	no	N	I-Premise
171	significant	N	I-Premise
172	increases	N	I-Premise
173	observed	N	I-Premise
174	in	N	I-Premise
175	the	N	I-Premise
176	exercise	N	I-Premise
177	group	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	=	N	I-Premise
181	0.203	N	I-Premise
182	)	N	I-Premise
183	.	N	I-Premise

184	A	N	I-Premise
185	nonsignificant	N	I-Premise
186	reduction	N	I-Premise
187	(	N	I-Premise
188	2.4	N	I-Premise
189	%	N	I-Premise
190	)	N	I-Premise
191	in	N	I-Premise
192	shuttle	N	I-Premise
193	test	N	I-Premise
194	distance	N	I-Premise
195	at	N	I-Premise
196	the	N	I-Premise
197	end	N	I-Premise
198	of	N	I-Premise
199	radiotherapy	N	I-Premise
200	was	N	I-Premise
201	observed	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	control	N	I-Premise
205	group	N	I-Premise
206	;	N	I-Premise
207	however	N	I-Premise
208	,	N	I-Premise
209	in	N	I-Premise
210	the	N	I-Premise
211	exercise	N	I-Premise
212	group	N	I-Premise
213	,	N	I-Premise
214	there	N	I-Premise
215	was	N	I-Premise
216	a	N	I-Premise
217	significant	N	I-Premise
218	increase	N	I-Premise
219	(	N	I-Premise
220	13.2	N	I-Premise
221	%	N	I-Premise
222	)	N	I-Premise
223	in	N	I-Premise
224	distance	N	I-Premise
225	walked	N	I-Premise
226	(	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	0.0003	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	Men	N	I-Premise
233	who	N	I-Premise
234	followed	N	I-Premise
235	advice	N	I-Premise
236	to	N	I-Premise
237	rest	N	I-Premise
238	and	N	I-Premise
239	take	N	I-Premise
240	things	N	I-Premise
241	easy	N	I-Premise
242	if	N	I-Premise
243	they	N	I-Premise
244	became	N	I-Premise
245	fatigued	N	I-Premise
246	demonstrated	N	I-Premise
247	a	N	I-Premise
248	slight	N	I-Premise
249	deterioration	N	I-Premise
250	in	N	I-Premise
251	physical	N	I-Premise
252	functioning	N	I-Premise
253	and	N	I-Premise
254	a	N	I-Premise
255	significant	N	I-Premise
256	increase	N	I-Premise
257	in	N	I-Premise
258	fatigue	N	I-Premise
259	at	N	I-Premise
260	the	N	I-Premise
261	end	N	I-Premise
262	of	N	I-Premise
263	radiotherapy	N	I-Premise
264	.	N	I-Premise

265	Home-based	N	I-Claim
266	,	N	I-Claim
267	moderate-intensity	N	I-Claim
268	walking	N	I-Claim
269	produced	N	I-Claim
270	a	N	I-Claim
271	significant	N	I-Claim
272	improvement	N	I-Claim
273	in	N	I-Claim
274	physical	N	I-Claim
275	functioning	N	I-Claim
276	with	N	I-Claim
277	no	N	I-Claim
278	significant	N	I-Claim
279	increase	N	I-Claim
280	in	N	I-Claim
281	fatigue	N	I-Claim
282	.	N	I-Claim

283	Improved	N	I-Claim
284	physical	N	I-Claim
285	functioning	N	I-Claim
286	may	N	I-Claim
287	be	N	I-Claim
288	necessary	N	I-Claim
289	to	N	I-Claim
290	combat	N	I-Claim
291	radiation	N	I-Claim
292	fatigue	N	I-Claim
293	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	cisplatin	N	O
5	plus	N	O
6	paclitaxel	N	O
7	(	N	O
8	C+P	N	O
9	)	N	O
10	improved	N	O
11	response	N	O
12	rate	N	O
13	,	N	O
14	progression-free	N	O
15	survival	N	O
16	(	N	O
17	PFS	N	O
18	)	N	O
19	,	N	O
20	or	N	O
21	survival	N	O
22	compared	N	O
23	with	N	O
24	cisplatin	N	O
25	alone	N	O
26	in	N	O
27	patients	N	O
28	with	N	O
29	stage	N	O
30	IVB	N	O
31	,	N	O
32	recurrent	N	O
33	,	N	O
34	or	N	O
35	persistent	N	O
36	squamous	N	O
37	cell	N	O
38	carcinoma	N	O
39	of	N	O
40	the	N	O
41	cervix	N	O
42	.	N	O

43	PATIENTS	N	O
44	AND	N	O
45	METHODS	N	O
46	Eligible	N	O
47	:	N	O
48	patients	N	O
49	with	N	O
50	measurable	N	O
51	disease	N	O
52	,	N	O
53	performance	N	O
54	status	N	O
55	(	N	O
56	PS	N	O
57	)	N	O
58	0	N	O
59	to	N	O
60	2	N	O
61	,	N	O
62	and	N	O
63	adequate	N	O
64	hematologic	N	O
65	,	N	O
66	hepatic	N	O
67	,	N	O
68	and	N	O
69	renal	N	O
70	function	N	O
71	received	N	O
72	either	N	O
73	cisplatin	N	O
74	50	N	O
75	mg/m2	N	O
76	or	N	O
77	C+P	N	O
78	(	N	O
79	cisplatin	N	O
80	50	N	O
81	mg/m2	N	O
82	plus	N	O
83	paclitaxel	N	O
84	135	N	O
85	mg/m2	N	O
86	)	N	O
87	every	N	O
88	3	N	O
89	weeks	N	O
90	for	N	O
91	six	N	O
92	cycles	N	O
93	.	N	O

94	Tumor	N	O
95	measurements	N	O
96	and	N	O
97	quality-of-life	N	O
98	(	N	O
99	QOL	N	O
100	)	N	O
101	assessments	N	O
102	were	N	O
103	obtained	N	O
104	before	N	O
105	each	N	O
106	treatment	N	O
107	cycle	N	O
108	.	N	O

109	Of	N	O
110	280	N	O
111	patients	N	O
112	entered	N	O
113	,	N	O
114	6	N	O
115	%	N	O
116	were	N	O
117	ineligible	N	O
118	.	N	O

119	Among	N	O
120	264	N	O
121	eligible	N	O
122	patients	N	O
123	,	N	O
124	134	N	O
125	received	N	O
126	cisplatin	N	O
127	and	N	O
128	130	N	O
129	received	N	O
130	C+P	N	O
131	.	N	O

132	Groups	N	O
133	were	N	O
134	well	N	O
135	matched	N	O
136	with	N	O
137	respect	N	O
138	to	N	O
139	age	N	O
140	,	N	O
141	ethnicity	N	O
142	,	N	O
143	PS	N	O
144	,	N	O
145	tumor	N	O
146	grade	N	O
147	,	N	O
148	disease	N	O
149	site	N	O
150	,	N	O
151	and	N	O
152	number	N	O
153	of	N	O
154	cycles	N	O
155	received	N	O
156	.	N	O

157	The	N	O
158	majority	N	O
159	of	N	O
160	all	N	O
161	patients	N	O
162	had	N	O
163	prior	N	O
164	radiation	N	O
165	therapy	N	O
166	(	N	O
167	cisplatin	N	O
168	,	N	O
169	92	N	O
170	%	N	O
171	;	N	O
172	C+P	N	O
173	,	N	O
174	91	N	O
175	%	N	O
176	)	N	O
177	.	N	O

178	Objective	N	I-Premise
179	responses	N	I-Premise
180	occurred	N	I-Premise
181	in	N	I-Premise
182	19	N	I-Premise
183	%	N	I-Premise
184	(	N	I-Premise
185	6	N	I-Premise
186	%	N	I-Premise
187	complete	N	I-Premise
188	plus	N	I-Premise
189	13	N	I-Premise
190	%	N	I-Premise
191	partial	N	I-Premise
192	)	N	I-Premise
193	of	N	I-Premise
194	patients	N	I-Premise
195	receiving	N	I-Premise
196	cisplatin	N	I-Premise
197	versus	N	I-Premise
198	36	N	I-Premise
199	%	N	I-Premise
200	(	N	I-Premise
201	15	N	I-Premise
202	%	N	I-Premise
203	complete	N	I-Premise
204	plus	N	I-Premise
205	21	N	I-Premise
206	%	N	I-Premise
207	partial	N	I-Premise
208	)	N	I-Premise
209	receiving	N	I-Premise
210	C+P	N	I-Premise
211	(	N	I-Premise
212	P	N	I-Premise
213	=	N	I-Premise
214	.002	N	I-Premise
215	)	N	I-Premise
216	.	N	I-Premise

217	The	N	I-Premise
218	median	N	I-Premise
219	PFS	N	I-Premise
220	was	N	I-Premise
221	2.8	N	I-Premise
222	and	N	I-Premise
223	4.8	N	I-Premise
224	months	N	I-Premise
225	,	N	I-Premise
226	respectively	N	I-Premise
227	,	N	I-Premise
228	for	N	I-Premise
229	cisplatin	N	I-Premise
230	versus	N	I-Premise
231	C+P	N	I-Premise
232	(	N	I-Premise
233	P	N	I-Premise
234	<	N	I-Premise
235	.001	N	I-Premise
236	)	N	I-Premise
237	.	N	I-Premise

238	There	N	I-Premise
239	was	N	I-Premise
240	no	N	I-Premise
241	difference	N	I-Premise
242	in	N	I-Premise
243	median	N	I-Premise
244	survival	N	I-Premise
245	(	N	I-Premise
246	8.8	N	I-Premise
247	months	N	I-Premise
248	v	N	I-Premise
249	9.7	N	I-Premise
250	months	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	Grade	N	I-Premise
254	3	N	I-Premise
255	to	N	I-Premise
256	4	N	I-Premise
257	anemia	N	I-Premise
258	and	N	I-Premise
259	neutropenia	N	I-Premise
260	were	N	I-Premise
261	more	N	I-Premise
262	common	N	I-Premise
263	in	N	I-Premise
264	the	N	I-Premise
265	combination	N	I-Premise
266	arm	N	I-Premise
267	.	N	I-Premise

268	There	N	I-Premise
269	was	N	I-Premise
270	no	N	I-Premise
271	significant	N	I-Premise
272	difference	N	I-Premise
273	in	N	I-Premise
274	QOL	N	I-Premise
275	scores	N	I-Premise
276	,	N	I-Premise
277	although	N	I-Premise
278	a	N	I-Premise
279	disproportionate	N	I-Premise
280	number	N	I-Premise
281	of	N	I-Premise
282	patients	N	I-Premise
283	(	N	I-Premise
284	cisplatin	N	I-Premise
285	,	N	I-Premise
286	n	N	I-Premise
287	=	N	I-Premise
288	50	N	I-Premise
289	;	N	I-Premise
290	C+P	N	I-Premise
291	,	N	I-Premise
292	n	N	I-Premise
293	=	N	I-Premise
294	33	N	I-Premise
295	)	N	I-Premise
296	dropped	N	I-Premise
297	out	N	I-Premise
298	of	N	I-Premise
299	the	N	I-Premise
300	QOL	N	I-Premise
301	component	N	I-Premise
302	,	N	I-Premise
303	presumably	N	I-Premise
304	because	N	I-Premise
305	of	N	I-Premise
306	increasing	N	I-Premise
307	disease	N	I-Premise
308	,	N	I-Premise
309	deteriorating	N	I-Premise
310	health	N	I-Premise
311	status	N	I-Premise
312	,	N	I-Premise
313	or	N	I-Premise
314	early	N	I-Premise
315	death	N	I-Premise
316	.	N	I-Premise

317	C+P	N	I-Claim
318	is	N	I-Claim
319	superior	N	I-Claim
320	to	N	I-Claim
321	cisplatin	N	I-Claim
322	alone	N	I-Claim
323	with	N	I-Claim
324	respect	N	I-Claim
325	to	N	I-Claim
326	response	N	I-Claim
327	rate	N	I-Claim
328	and	N	I-Claim
329	PFS	N	I-Claim
330	with	N	I-Claim
331	sustained	N	I-Claim
332	QOL	N	I-Claim
333	.	N	I-Claim

1	Metal	N	O
2	stent	N	O
3	placement	N	O
4	and	N	O
5	single	N	O
6	dose	N	O
7	brachytherapy	N	O
8	are	N	O
9	commonly	N	O
10	used	N	O
11	treatment	N	O
12	modalities	N	O
13	for	N	O
14	the	N	O
15	palliation	N	O
16	of	N	O
17	inoperable	N	O
18	oesophageal	N	O
19	carcinoma	N	O
20	.	N	O

21	We	N	O
22	investigated	N	O
23	generic	N	O
24	and	N	O
25	disease-specific	N	O
26	health-related	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	(	N	O
31	HRQoL	N	O
32	)	N	O
33	after	N	O
34	these	N	O
35	palliative	N	O
36	treatments	N	O
37	.	N	O

38	Patients	N	O
39	with	N	O
40	dysphagia	N	O
41	from	N	O
42	inoperable	N	O
43	oesophageal	N	O
44	carcinoma	N	O
45	were	N	O
46	randomised	N	O
47	to	N	O
48	placement	N	O
49	of	N	O
50	a	N	O
51	covered	N	O
52	Ultraflex	N	O
53	stent	N	O
54	(	N	O
55	n	N	O
56	=	N	O
57	108	N	O
58	)	N	O
59	or	N	O
60	single	N	O
61	dose	N	O
62	(	N	O
63	12	N	O
64	Gy	N	O
65	)	N	O
66	brachytherapy	N	O
67	(	N	O
68	n	N	O
69	=	N	O
70	101	N	O
71	)	N	O
72	.	N	O

73	We	N	O
74	obtained	N	O
75	longitudinal	N	O
76	data	N	O
77	on	N	O
78	disease-specific	N	O
79	(	N	O
80	dysphagia	N	O
81	score	N	O
82	,	N	O
83	European	N	O
84	Organisation	N	O
85	for	N	O
86	Research	N	O
87	and	N	O
88	Treatment	N	O
89	of	N	O
90	Cancer	N	O
91	(	N	O
92	EORTC	N	O
93	)	N	O
94	OES-23	N	O
95	,	N	O
96	visual	N	O
97	analogue	N	O
98	pain	N	O
99	scale	N	O
100	)	N	O
101	and	N	O
102	generic	N	O
103	(	N	O
104	EORTC	N	O
105	Quality	N	O
106	of	N	O
107	Life-Core	N	O
108	30	N	O
109	Questionnaire	N	O
110	(	N	O
111	QLQ-C30	N	O
112	)	N	O
113	,	N	O
114	Euroqol	N	O
115	(	N	O
116	EQ	N	O
117	)	N	O
118	-5D	N	O
119	)	N	O
120	HRQoL	N	O
121	at	N	O
122	monthly	N	O
123	home	N	O
124	visits	N	O
125	by	N	O
126	a	N	O
127	specially-trained	N	O
128	research	N	O
129	nurse	N	O
130	.	N	O

131	We	N	O
132	compared	N	O
133	HRQoL	N	O
134	between	N	O
135	the	N	O
136	two	N	O
137	treatments	N	O
138	and	N	O
139	analysed	N	O
140	changes	N	O
141	in	N	O
142	HRQoL	N	O
143	during	N	O
144	follow-up	N	O
145	.	N	O

146	Dysphagia	N	I-Premise
147	improved	N	I-Premise
148	more	N	I-Premise
149	rapidly	N	I-Premise
150	after	N	I-Premise
151	stent	N	I-Premise
152	placement	N	I-Premise
153	than	N	I-Premise
154	after	N	I-Premise
155	brachytherapy	N	I-Premise
156	,	N	I-Premise
157	but	N	I-Premise
158	long-term	N	I-Premise
159	relief	N	I-Premise
160	of	N	I-Premise
161	dysphagia	N	I-Premise
162	was	N	I-Premise
163	better	N	I-Premise
164	after	N	I-Premise
165	brachytherapy	N	I-Premise
166	.	N	I-Premise

167	For	N	I-Premise
168	generic	N	I-Premise
169	HRQoL	N	I-Premise
170	,	N	I-Premise
171	there	N	I-Premise
172	was	N	I-Premise
173	an	N	I-Premise
174	overall	N	I-Premise
175	significant	N	I-Premise
176	difference	N	I-Premise
177	in	N	I-Premise
178	favour	N	I-Premise
179	of	N	I-Premise
180	brachytherapy	N	I-Premise
181	on	N	I-Premise
182	four	N	I-Premise
183	out	N	I-Premise
184	of	N	I-Premise
185	five	N	I-Premise
186	functional	N	I-Premise
187	scales	N	I-Premise
188	of	N	I-Premise
189	the	N	I-Premise
190	EORTC	N	I-Premise
191	QLQ-C30	N	I-Premise
192	(	N	I-Premise
193	role	N	I-Premise
194	,	N	I-Premise
195	emotional	N	I-Premise
196	,	N	I-Premise
197	cognitive	N	I-Premise
198	and	N	I-Premise
199	social	N	I-Premise
200	)	N	I-Premise
201	(	N	I-Premise
202	P	N	I-Premise
203	<	N	I-Premise
204	0.05	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	Generic	N	I-Premise
208	HRQoL	N	I-Premise
209	deteriorated	N	I-Premise
210	over	N	I-Premise
211	time	N	I-Premise
212	on	N	I-Premise
213	all	N	I-Premise
214	functional	N	I-Premise
215	scales	N	I-Premise
216	of	N	I-Premise
217	the	N	I-Premise
218	EORTC	N	I-Premise
219	QLQ	N	I-Premise
220	C-30	N	I-Premise
221	and	N	I-Premise
222	EQ-5D	N	I-Premise
223	,	N	I-Premise
224	in	N	I-Premise
225	particular	N	I-Premise
226	physical	N	I-Premise
227	and	N	I-Premise
228	role	N	I-Premise
229	functioning	N	I-Premise
230	(	N	I-Premise
231	on	N	I-Premise
232	average	N	I-Premise
233	-23	N	I-Premise
234	and	N	I-Premise
235	-24	N	I-Premise
236	on	N	I-Premise
237	a	N	I-Premise
238	100	N	I-Premise
239	points	N	I-Premise
240	scale	N	I-Premise
241	during	N	I-Premise
242	0.5	N	I-Premise
243	years	N	I-Premise
244	of	N	I-Premise
245	follow-up	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	This	N	I-Premise
249	decline	N	I-Premise
250	was	N	I-Premise
251	more	N	I-Premise
252	pronounced	N	I-Premise
253	in	N	I-Premise
254	the	N	I-Premise
255	stent	N	I-Premise
256	group	N	I-Premise
257	.	N	I-Premise

258	Major	N	I-Premise
259	improvements	N	I-Premise
260	were	N	I-Premise
261	seen	N	I-Premise
262	on	N	I-Premise
263	the	N	I-Premise
264	dysphagia	N	I-Premise
265	and	N	I-Premise
266	eating	N	I-Premise
267	scales	N	I-Premise
268	of	N	I-Premise
269	the	N	I-Premise
270	EORTC	N	I-Premise
271	OES-23	N	I-Premise
272	,	N	I-Premise
273	in	N	I-Premise
274	contrast	N	I-Premise
275	to	N	I-Premise
276	other	N	I-Premise
277	scales	N	I-Premise
278	of	N	I-Premise
279	this	N	I-Premise
280	disease-specific	N	I-Premise
281	measure	N	I-Premise
282	,	N	I-Premise
283	which	N	I-Premise
284	remained	N	I-Premise
285	almost	N	I-Premise
286	stable	N	I-Premise
287	during	N	I-Premise
288	follow-up	N	I-Premise
289	.	N	I-Premise

290	Reported	N	I-Premise
291	levels	N	I-Premise
292	of	N	I-Premise
293	chest	N	I-Premise
294	or	N	I-Premise
295	abdominal	N	I-Premise
296	pain	N	I-Premise
297	remained	N	I-Premise
298	stable	N	I-Premise
299	during	N	I-Premise
300	follow-up	N	I-Premise
301	in	N	I-Premise
302	both	N	I-Premise
303	treatment	N	I-Premise
304	groups	N	I-Premise
305	,	N	I-Premise
306	general	N	I-Premise
307	pain	N	I-Premise
308	levels	N	I-Premise
309	increased	N	I-Premise
310	to	N	I-Premise
311	a	N	I-Premise
312	minor	N	I-Premise
313	extent	N	I-Premise
314	.	N	I-Premise

315	The	N	I-Claim
316	effects	N	I-Claim
317	of	N	I-Claim
318	single	N	I-Claim
319	dose	N	I-Claim
320	brachytherapy	N	I-Claim
321	on	N	I-Claim
322	HRQoL	N	I-Claim
323	compared	N	I-Claim
324	favourably	N	I-Claim
325	to	N	I-Claim
326	those	N	I-Claim
327	of	N	I-Claim
328	stent	N	I-Claim
329	placement	N	I-Claim
330	for	N	I-Claim
331	the	N	I-Claim
332	palliation	N	I-Claim
333	of	N	I-Claim
334	oesophageal	N	I-Claim
335	cancer	N	I-Claim
336	.	N	I-Claim

337	Future	N	I-Claim
338	studies	N	I-Claim
339	on	N	I-Claim
340	palliative	N	I-Claim
341	care	N	I-Claim
342	for	N	I-Claim
343	oesophageal	N	I-Claim
344	cancer	N	I-Claim
345	should	N	I-Claim
346	at	N	I-Claim
347	least	N	I-Claim
348	include	N	I-Claim
349	generic	N	I-Claim
350	HRQoL	N	I-Claim
351	scales	N	I-Claim
352	,	N	I-Claim
353	since	N	I-Premise
354	these	N	I-Premise
355	were	N	I-Premise
356	more	N	I-Premise
357	responsive	N	I-Premise
358	in	N	I-Premise
359	measuring	N	I-Premise
360	patients	N	I-Premise
361	'	N	I-Premise
362	functioning	N	I-Premise
363	and	N	I-Premise
364	well-being	N	I-Premise
365	during	N	I-Premise
366	follow-up	N	I-Premise
367	than	N	I-Premise
368	disease-specific	N	I-Premise
369	HRQoL	N	I-Premise
370	scales	N	I-Premise
371	.	N	I-Premise

1	The	N	O
2	objective	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QoL	N	O
15	)	N	O
16	of	N	O
17	ovarian	N	O
18	cancer	N	O
19	patients	N	O
20	treated	N	O
21	with	N	O
22	paclitaxel/carboplatin	N	O
23	(	N	O
24	TC	N	O
25	)	N	O
26	versus	N	O
27	paclitaxel/cisplatin	N	O
28	(	N	O
29	PT	N	O
30	)	N	O
31	and	N	O
32	to	N	O
33	determine	N	O
34	the	N	O
35	impact	N	O
36	of	N	O
37	treatment	N	O
38	toxicity	N	O
39	on	N	O
40	the	N	O
41	various	N	O
42	QoL	N	O
43	domains	N	O
44	.	N	O

45	In	N	O
46	this	N	O
47	phase	N	O
48	III	N	O
49	trial	N	O
50	,	N	O
51	798	N	O
52	patients	N	O
53	with	N	O
54	ovarian	N	O
55	cancer	N	O
56	stages	N	O
57	IIB-IV	N	O
58	were	N	O
59	randomly	N	O
60	assigned	N	O
61	to	N	O
62	receive	N	O
63	TC	N	O
64	or	N	O
65	PT	N	O
66	.	N	O

67	The	N	O
68	primary	N	O
69	end	N	O
70	point	N	O
71	was	N	O
72	progression-free	N	O
73	survival	N	O
74	;	N	O
75	secondary	N	O
76	end	N	O
77	points	N	O
78	included	N	O
79	toxicity	N	O
80	,	N	O
81	QoL	N	O
82	,	N	O
83	and	N	O
84	response	N	O
85	to	N	O
86	treatment	N	O
87	.	N	O

88	Patients	N	O
89	completed	N	O
90	the	N	O
91	European	N	O
92	Organisation	N	O
93	for	N	O
94	Research	N	O
95	and	N	O
96	Treatment	N	O
97	of	N	O
98	Cancer	N	O
99	QLQ-C30	N	O
100	before	N	O
101	treatment	N	O
102	,	N	O
103	within	N	O
104	3	N	O
105	days	N	O
106	before	N	O
107	the	N	O
108	second	N	O
109	and	N	O
110	the	N	O
111	fourth	N	O
112	chemotherapy	N	O
113	cycle	N	O
114	,	N	O
115	and	N	O
116	3	N	O
117	weeks	N	O
118	after	N	O
119	completion	N	O
120	of	N	O
121	chemotherapy	N	O
122	.	N	O

123	Previously	N	O
124	reported	N	O
125	data	N	O
126	showed	N	O
127	that	N	O
128	patients	N	O
129	undergoing	N	O
130	TC	N	O
131	or	N	O
132	PT	N	O
133	did	N	O
134	not	N	O
135	differ	N	O
136	in	N	O
137	progression-free	N	O
138	survival	N	O
139	and	N	O
140	overall	N	O
141	survival	N	O
142	.	N	O

143	However	N	O
144	,	N	O
145	the	N	O
146	TC	N	O
147	arm	N	O
148	was	N	O
149	superior	N	O
150	,	N	O
151	indicating	N	O
152	a	N	O
153	better	N	O
154	overall	N	O
155	QoL	N	O
156	compared	N	O
157	with	N	O
158	the	N	O
159	PT	N	O
160	arm	N	O
161	.	N	O

162	Controlling	N	O
163	for	N	O
164	toxicity	N	O
165	and	N	O
166	age	N	O
167	,	N	O
168	a	N	O
169	significant	N	O
170	treatment	N	O
171	by	N	O
172	assessment	N	O
173	time	N	O
174	interaction	N	O
175	was	N	O
176	found	N	O
177	for	N	O
178	four	N	O
179	QoL	N	O
180	functioning	N	O
181	scales	N	O
182	and	N	O
183	three	N	O
184	symptoms	N	O
185	scales	N	O
186	.	N	O

187	Patients	N	I-Premise
188	in	N	I-Premise
189	the	N	I-Premise
190	TC	N	I-Premise
191	arm	N	I-Premise
192	showed	N	I-Premise
193	better	N	I-Premise
194	means	N	I-Premise
195	scores	N	I-Premise
196	after	N	I-Premise
197	treatment	N	I-Premise
198	on	N	I-Premise
199	overall	N	I-Premise
200	QoL	N	I-Premise
201	(	N	I-Premise
202	P	N	I-Premise
203	=	N	I-Premise
204	.012	N	I-Premise
205	)	N	I-Premise
206	,	N	I-Premise
207	physical	N	I-Premise
208	functioning	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	=	N	I-Premise
212	.012	N	I-Premise
213	)	N	I-Premise
214	,	N	I-Premise
215	role	N	I-Premise
216	functioning	N	I-Premise
217	(	N	I-Premise
218	P	N	I-Premise
219	=	N	I-Premise
220	.005	N	I-Premise
221	)	N	I-Premise
222	,	N	I-Premise
223	and	N	I-Premise
224	cognitive	N	I-Premise
225	functioning	N	I-Premise
226	(	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	.024	N	I-Premise
230	)	N	I-Premise
231	,	N	I-Premise
232	compared	N	I-Premise
233	with	N	I-Premise
234	the	N	I-Premise
235	PT	N	I-Premise
236	arm	N	I-Premise
237	.	N	I-Premise

238	Concerning	N	I-Premise
239	symptom	N	I-Premise
240	experience	N	I-Premise
241	,	N	I-Premise
242	patients	N	I-Premise
243	undergoing	N	I-Premise
244	TC	N	I-Premise
245	showed	N	I-Premise
246	less	N	I-Premise
247	nausea	N	I-Premise
248	and	N	I-Premise
249	vomiting	N	I-Premise
250	(	N	I-Premise
251	P	N	I-Premise
252	<	N	I-Premise
253	.001	N	I-Premise
254	)	N	I-Premise
255	,	N	I-Premise
256	less	N	I-Premise
257	appetite	N	I-Premise
258	loss	N	I-Premise
259	(	N	I-Premise
260	P	N	I-Premise
261	<	N	I-Premise
262	.001	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	and	N	I-Premise
266	less	N	I-Premise
267	fatigue	N	I-Premise
268	(	N	I-Premise
269	P	N	I-Premise
270	=	N	I-Premise
271	.033	N	I-Premise
272	)	N	I-Premise
273	after	N	I-Premise
274	completion	N	I-Premise
275	of	N	I-Premise
276	treatment	N	I-Premise
277	compared	N	I-Premise
278	with	N	I-Premise
279	patients	N	I-Premise
280	undergoing	N	I-Premise
281	PT	N	I-Premise
282	.	N	I-Premise

283	The	N	I-Claim
284	TC	N	I-Claim
285	regimen	N	I-Claim
286	achieved	N	I-Claim
287	better	N	I-Claim
288	QoL	N	I-Claim
289	outcomes	N	I-Claim
290	compared	N	I-Claim
291	with	N	I-Claim
292	the	N	I-Claim
293	PT	N	I-Claim
294	regimen	N	I-Claim
295	.	N	I-Claim

296	Thus	N	I-Claim
297	,	N	I-Claim
298	clinicians	N	I-Claim
299	may	N	I-Claim
300	consider	N	I-Claim
301	replacing	N	I-Claim
302	cisplatin	N	I-Claim
303	with	N	I-Claim
304	carboplatin	N	I-Claim
305	when	N	I-Claim
306	treating	N	I-Claim
307	ovarian	N	I-Claim
308	cancer	N	I-Claim
309	patients	N	I-Claim
310	with	N	I-Claim
311	chemotherapy	N	I-Claim
312	.	N	I-Claim

1	The	N	O
2	primary	N	O
3	goal	N	O
4	of	N	O
5	this	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	feasibility	N	O
12	and	N	O
13	effectiveness	N	O
14	of	N	O
15	a	N	O
16	structured	N	O
17	,	N	O
18	multidisciplinary	N	O
19	intervention	N	O
20	targeted	N	O
21	to	N	O
22	maintain	N	O
23	the	N	O
24	overall	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	(	N	O
29	QOL	N	O
30	)	N	O
31	,	N	O
32	which	N	O
33	is	N	O
34	more	N	O
35	comprehensive	N	O
36	than	N	O
37	psychosocial	N	O
38	distress	N	O
39	,	N	O
40	of	N	O
41	patients	N	O
42	undergoing	N	O
43	radiation	N	O
44	therapy	N	O
45	for	N	O
46	advanced-stage	N	O
47	cancer	N	O
48	.	N	O

49	Radiation	N	O
50	therapy	N	O
51	patients	N	O
52	with	N	O
53	advanced	N	O
54	cancer	N	O
55	and	N	O
56	an	N	O
57	estimated	N	O
58	5-year	N	O
59	survival	N	O
60	rate	N	O
61	of	N	O
62	0	N	O
63	%	N	O
64	to	N	O
65	50	N	O
66	%	N	O
67	were	N	O
68	randomly	N	O
69	assigned	N	O
70	to	N	O
71	either	N	O
72	an	N	O
73	eight-session	N	O
74	structured	N	O
75	multidisciplinary	N	O
76	intervention	N	O
77	arm	N	O
78	or	N	O
79	a	N	O
80	standard	N	O
81	care	N	O
82	arm	N	O
83	.	N	O

84	The	N	O
85	eight	N	O
86	90-minute	N	O
87	sessions	N	O
88	addressed	N	O
89	the	N	O
90	five	N	O
91	domains	N	O
92	of	N	O
93	QOL	N	O
94	including	N	O
95	cognitive	N	O
96	,	N	O
97	physical	N	O
98	,	N	O
99	emotional	N	O
100	,	N	O
101	spiritual	N	O
102	,	N	O
103	and	N	O
104	social	N	O
105	functioning	N	O
106	.	N	O

107	The	N	O
108	primary	N	O
109	end	N	O
110	point	N	O
111	of	N	O
112	maintaining	N	O
113	overall	N	O
114	QOL	N	O
115	was	N	O
116	assessed	N	O
117	by	N	O
118	a	N	O
119	single-item	N	O
120	linear	N	O
121	analog	N	O
122	scale	N	O
123	(	N	O
124	Linear	N	O
125	Analog	N	O
126	Scale	N	O
127	of	N	O
128	Assessment	N	O
129	or	N	O
130	modified	N	O
131	Spitzer	N	O
132	Uniscale	N	O
133	)	N	O
134	.	N	O

135	QOL	N	O
136	was	N	O
137	assessed	N	O
138	at	N	O
139	baseline	N	O
140	,	N	O
141	week	N	O
142	4	N	O
143	(	N	O
144	end	N	O
145	of	N	O
146	multidisciplinary	N	O
147	intervention	N	O
148	)	N	O
149	,	N	O
150	week	N	O
151	8	N	O
152	,	N	O
153	and	N	O
154	week	N	O
155	27	N	O
156	.	N	O

157	Of	N	I-Premise
158	the	N	I-Premise
159	103	N	I-Premise
160	participants	N	I-Premise
161	,	N	I-Premise
162	overall	N	I-Premise
163	QOL	N	I-Premise
164	at	N	I-Premise
165	week	N	I-Premise
166	4	N	I-Premise
167	was	N	I-Premise
168	maintained	N	I-Premise
169	by	N	I-Premise
170	the	N	I-Premise
171	patients	N	I-Premise
172	in	N	I-Premise
173	the	N	I-Premise
174	intervention	N	I-Premise
175	(	N	I-Premise
176	n	N	I-Premise
177	=	N	I-Premise
178	49	N	I-Premise
179	)	N	I-Premise
180	,	N	I-Premise
181	whereas	N	I-Premise
182	QOL	N	I-Premise
183	at	N	I-Premise
184	week	N	I-Premise
185	4	N	I-Premise
186	significantly	N	I-Premise
187	decreased	N	I-Premise
188	for	N	I-Premise
189	patients	N	I-Premise
190	in	N	I-Premise
191	the	N	I-Premise
192	control	N	I-Premise
193	group	N	I-Premise
194	(	N	I-Premise
195	n	N	I-Premise
196	=	N	I-Premise
197	54	N	I-Premise
198	)	N	I-Premise
199	.	N	I-Premise

200	This	N	I-Premise
201	change	N	I-Premise
202	reflected	N	I-Premise
203	a	N	I-Premise
204	3-point	N	I-Premise
205	increase	N	I-Premise
206	from	N	I-Premise
207	baseline	N	I-Premise
208	in	N	I-Premise
209	the	N	I-Premise
210	intervention	N	I-Premise
211	group	N	I-Premise
212	and	N	I-Premise
213	a	N	I-Premise
214	9-point	N	I-Premise
215	decrease	N	I-Premise
216	from	N	I-Premise
217	baseline	N	I-Premise
218	in	N	I-Premise
219	the	N	I-Premise
220	control	N	I-Premise
221	group	N	I-Premise
222	(	N	I-Premise
223	P	N	I-Premise
224	=	N	I-Premise
225	.009	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	Intervention	N	I-Premise
229	participants	N	I-Premise
230	maintained	N	I-Premise
231	their	N	I-Premise
232	QOL	N	I-Premise
233	,	N	I-Premise
234	and	N	I-Premise
235	controls	N	I-Premise
236	gradually	N	I-Premise
237	returned	N	I-Premise
238	to	N	I-Premise
239	baseline	N	I-Premise
240	by	N	I-Premise
241	the	N	I-Premise
242	end	N	I-Premise
243	of	N	I-Premise
244	the	N	I-Premise
245	6-month	N	I-Premise
246	follow-up	N	I-Premise
247	period	N	I-Premise
248	.	N	I-Premise

249	Although	N	I-Claim
250	intervention	N	I-Claim
251	participants	N	I-Claim
252	maintained	N	I-Claim
253	and	N	I-Claim
254	actually	N	I-Claim
255	improved	N	I-Claim
256	their	N	I-Claim
257	QOL	N	I-Claim
258	during	N	I-Claim
259	radiation	N	I-Claim
260	therapy	N	I-Claim
261	,	N	I-Claim
262	control	N	I-Claim
263	participants	N	I-Claim
264	experienced	N	I-Claim
265	a	N	I-Claim
266	significant	N	I-Claim
267	decrease	N	I-Claim
268	in	N	I-Claim
269	their	N	I-Claim
270	QOL	N	I-Claim
271	.	N	O

272	Thus	N	I-Claim
273	,	N	I-Claim
274	a	N	I-Claim
275	structured	N	I-Claim
276	multidisciplinary	N	I-Claim
277	intervention	N	I-Claim
278	can	N	I-Claim
279	help	N	I-Claim
280	maintain	N	I-Claim
281	or	N	I-Claim
282	even	N	I-Claim
283	improve	N	I-Claim
284	QOL	N	I-Claim
285	in	N	I-Claim
286	patients	N	I-Claim
287	with	N	I-Claim
288	advanced	N	I-Claim
289	cancer	N	I-Claim
290	who	N	I-Claim
291	are	N	I-Claim
292	undergoing	N	I-Claim
293	cancer	N	I-Claim
294	treatment	N	I-Claim
295	.	N	I-Claim

1	Fatigue	N	I-Claim
2	has	N	I-Claim
3	a	N	I-Claim
4	significant	N	I-Claim
5	impact	N	I-Claim
6	on	N	I-Claim
7	the	N	I-Claim
8	quality	N	I-Claim
9	of	N	I-Claim
10	life	N	I-Claim
11	(	N	I-Claim
12	QOL	N	I-Claim
13	)	N	I-Claim
14	of	N	I-Claim
15	cancer	N	I-Claim
16	patients	N	I-Claim
17	.	N	I-Claim

18	Recent	N	I-Claim
19	research	N	I-Claim
20	has	N	I-Claim
21	suggested	N	I-Claim
22	that	N	I-Claim
23	physical	N	I-Claim
24	activity	N	I-Claim
25	can	N	I-Claim
26	reduce	N	I-Claim
27	fatigue	N	I-Claim
28	in	N	I-Claim
29	patients	N	I-Claim
30	receiving	N	I-Claim
31	active	N	I-Claim
32	cancer	N	I-Claim
33	treatment	N	I-Claim
34	.	N	I-Claim

35	In	N	O
36	this	N	O
37	project	N	O
38	,	N	O
39	we	N	O
40	examined	N	O
41	the	N	O
42	impact	N	O
43	that	N	O
44	participation	N	O
45	in	N	O
46	a	N	O
47	randomized	N	O
48	controlled	N	O
49	trial	N	O
50	of	N	O
51	a	N	O
52	multidisciplinary	N	O
53	intervention	N	O
54	designed	N	O
55	to	N	O
56	impact	N	O
57	overall	N	O
58	QOL	N	O
59	had	N	O
60	on	N	O
61	fatigue	N	O
62	for	N	O
63	advanced	N	O
64	cancer	N	O
65	patients	N	O
66	actively	N	O
67	receiving	N	O
68	treatment	N	O
69	.	N	O

70	Patients	N	O
71	with	N	O
72	newly	N	O
73	diagnosed	N	O
74	cancer	N	O
75	were	N	O
76	randomly	N	O
77	assigned	N	O
78	to	N	O
79	an	N	O
80	8-session	N	O
81	structured	N	O
82	multidisciplinary	N	O
83	intervention	N	O
84	or	N	O
85	a	N	O
86	standard-care	N	O
87	arm	N	O
88	at	N	O
89	the	N	O
90	beginning	N	O
91	of	N	O
92	their	N	O
93	course	N	O
94	of	N	O
95	radiotherapy	N	O
96	(	N	O
97	RT	N	O
98	)	N	O
99	designed	N	O
100	to	N	O
101	impact	N	O
102	QOL	N	O
103	.	N	O

104	Ninety-minute	N	O
105	sessions	N	O
106	were	N	O
107	led	N	O
108	by	N	O
109	either	N	O
110	a	N	O
111	psychiatrist	N	O
112	or	N	O
113	psychologist	N	O
114	,	N	O
115	collaborating	N	O
116	with	N	O
117	a	N	O
118	nurse	N	O
119	,	N	O
120	physical	N	O
121	therapist	N	O
122	,	N	O
123	chaplain	N	O
124	,	N	O
125	or	N	O
126	social	N	O
127	worker	N	O
128	,	N	O
129	depending	N	O
130	on	N	O
131	the	N	O
132	session	N	O
133	's	N	O
134	theme	N	O
135	.	N	O

136	The	N	O
137	fatigue	N	O
138	assessments	N	O
139	used	N	O
140	in	N	O
141	this	N	O
142	trial	N	O
143	included	N	O
144	the	N	O
145	Linear	N	O
146	Analogue	N	O
147	Self	N	O
148	Assessment	N	O
149	(	N	O
150	LASA	N	O
151	)	N	O
152	,	N	O
153	the	N	O
154	Profile	N	O
155	of	N	O
156	Mood	N	O
157	States	N	O
158	(	N	O
159	POMS	N	O
160	)	N	O
161	,	N	O
162	Spielberger	N	O
163	's	N	O
164	State-Trait	N	O
165	Anxiety	N	O
166	Inventory	N	O
167	(	N	O
168	STAI	N	O
169	)	N	O
170	,	N	O
171	and	N	O
172	the	N	O
173	Symptom	N	O
174	Distress	N	O
175	Scale	N	O
176	(	N	O
177	SDS	N	O
178	)	N	O
179	.	N	O

180	There	N	O
181	were	N	O
182	115	N	O
183	participants	N	O
184	enrolled	N	O
185	and	N	O
186	the	N	O
187	2	N	O
188	randomization	N	O
189	arms	N	O
190	were	N	O
191	well	N	O
192	balanced	N	O
193	in	N	O
194	terms	N	O
195	of	N	O
196	baseline	N	O
197	characteristics	N	O
198	and	N	O
199	treatment	N	O
200	received	N	O
201	except	N	O
202	for	N	O
203	increased	N	O
204	commuting	N	O
205	distance	N	O
206	for	N	O
207	the	N	O
208	patients	N	O
209	in	N	O
210	the	N	O
211	intervention	N	O
212	arm	N	O
213	(	N	O
214	P	N	O
215	=	N	O
216	0.042	N	O
217	)	N	O
218	.	N	O

219	Most	N	I-Premise
220	of	N	I-Premise
221	scores	N	I-Premise
222	indicated	N	I-Premise
223	less	N	I-Premise
224	fatigue	N	I-Premise
225	(	N	I-Premise
226	higher	N	I-Premise
227	score	N	I-Premise
228	)	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	standard	N	I-Premise
232	treatment	N	I-Premise
233	group	N	I-Premise
234	,	N	I-Premise
235	but	N	I-Premise
236	there	N	I-Premise
237	were	N	I-Premise
238	no	N	I-Premise
239	statistically	N	I-Premise
240	significant	N	I-Premise
241	differences	N	I-Premise
242	found	N	I-Premise
243	at	N	I-Premise
244	baseline	N	I-Premise
245	and	N	I-Premise
246	weeks	N	I-Premise
247	4	N	I-Premise
248	,	N	I-Premise
249	8	N	I-Premise
250	,	N	I-Premise
251	and	N	I-Premise
252	27	N	I-Premise
253	except	N	I-Premise
254	for	N	I-Premise
255	SDS	N	I-Premise
256	at	N	I-Premise
257	week	N	I-Premise
258	8	N	I-Premise
259	(	N	I-Premise
260	P	N	I-Premise
261	=	N	I-Premise
262	0.018	N	I-Premise
263	)	N	I-Premise
264	with	N	I-Premise
265	less	N	I-Premise
266	patients	N	I-Premise
267	reporting	N	I-Premise
268	significant	N	I-Premise
269	fatigue	N	I-Premise
270	in	N	I-Premise
271	the	N	I-Premise
272	standard	N	I-Premise
273	treatment	N	I-Premise
274	arm	N	I-Premise
275	.	N	I-Premise

276	For	N	I-Premise
277	the	N	I-Premise
278	entire	N	I-Premise
279	participant	N	I-Premise
280	population	N	I-Premise
281	,	N	I-Premise
282	fatigue	N	I-Premise
283	levels	N	I-Premise
284	initially	N	I-Premise
285	worsened	N	I-Premise
286	with	N	I-Premise
287	radiotherapy	N	I-Premise
288	,	N	I-Premise
289	stabilized	N	I-Premise
290	at	N	I-Premise
291	week	N	I-Premise
292	8	N	I-Premise
293	,	N	I-Premise
294	and	N	I-Premise
295	returned	N	I-Premise
296	to	N	I-Premise
297	baseline	N	I-Premise
298	by	N	I-Premise
299	week	N	I-Premise
300	27	N	I-Premise
301	.	N	I-Premise

302	Disease	N	I-Premise
303	site	N	I-Premise
304	,	N	I-Premise
305	chemotherapy	N	I-Premise
306	use	N	I-Premise
307	,	N	I-Premise
308	and	N	I-Premise
309	radiotherapy	N	I-Premise
310	dose	N	I-Premise
311	did	N	I-Premise
312	not	N	I-Premise
313	have	N	I-Premise
314	a	N	I-Premise
315	significant	N	I-Premise
316	impact	N	I-Premise
317	on	N	I-Premise
318	fatigue	N	I-Premise
319	levels	N	I-Premise
320	.	N	I-Premise

321	Radiotherapy	N	I-Premise
322	initially	N	I-Premise
323	caused	N	I-Premise
324	a	N	I-Premise
325	worsening	N	I-Premise
326	of	N	I-Premise
327	fatigue	N	I-Premise
328	but	N	I-Premise
329	with	N	I-Premise
330	time	N	I-Premise
331	fatigue	N	I-Premise
332	levels	N	I-Premise
333	returned	N	I-Premise
334	to	N	I-Premise
335	baseline	N	I-Premise
336	.	N	O

337	Clinically	N	I-Claim
338	,	N	I-Claim
339	this	N	I-Claim
340	structured	N	I-Claim
341	multidisciplinary	N	I-Claim
342	intervention	N	I-Claim
343	had	N	I-Claim
344	no	N	I-Claim
345	impact	N	I-Claim
346	on	N	I-Claim
347	fatigue	N	I-Claim
348	,	N	I-Claim
349	and	N	O
350	there	N	I-Claim
351	was	N	I-Claim
352	the	N	I-Claim
353	suggestion	N	I-Claim
354	the	N	I-Claim
355	multiple	N	I-Claim
356	sessions	N	I-Claim
357	may	N	I-Claim
358	have	N	I-Claim
359	contributed	N	I-Claim
360	to	N	I-Claim
361	worse	N	I-Claim
362	fatigue	N	I-Claim
363	during	N	I-Claim
364	active	N	I-Claim
365	cancer	N	I-Claim
366	treatment	N	I-Claim
367	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	cost-effectiveness	N	O
5	of	N	O
6	Mohs	N	O
7	micrographic	N	O
8	surgery	N	O
9	(	N	O
10	MMS	N	O
11	)	N	O
12	compared	N	O
13	with	N	O
14	the	N	O
15	surgical	N	O
16	excision	N	O
17	for	N	O
18	both	N	O
19	primary	N	O
20	and	N	O
21	recurrent	N	O
22	basal	N	O
23	cell	N	O
24	carcinoma	N	O
25	(	N	O
26	BCC	N	O
27	)	N	O
28	.	N	O

29	A	N	O
30	cost-effectiveness	N	O
31	study	N	O
32	performed	N	O
33	alongside	N	O
34	a	N	O
35	prospective	N	O
36	randomized	N	O
37	clinical	N	O
38	trial	N	O
39	in	N	O
40	which	N	O
41	MMS	N	O
42	was	N	O
43	compared	N	O
44	with	N	O
45	surgical	N	O
46	excision	N	O
47	.	N	O

48	The	N	O
49	study	N	O
50	was	N	O
51	carried	N	O
52	out	N	O
53	from	N	O
54	1999	N	O
55	to	N	O
56	2002	N	O
57	at	N	O
58	the	N	O
59	dermatology	N	O
60	outpatient	N	O
61	clinic	N	O
62	of	N	O
63	the	N	O
64	University	N	O
65	Hospital	N	O
66	Maastricht	N	O
67	,	N	O
68	Maastricht	N	O
69	,	N	O
70	The	N	O
71	Netherlands	N	O
72	.	N	O

73	A	N	O
74	total	N	O
75	of	N	O
76	408	N	O
77	primary	N	O
78	(	N	O
79	374	N	O
80	patients	N	O
81	)	N	O
82	and	N	O
83	204	N	O
84	recurrent	N	O
85	(	N	O
86	191	N	O
87	patients	N	O
88	)	N	O
89	cases	N	O
90	of	N	O
91	facial	N	O
92	BCC	N	O
93	were	N	O
94	included	N	O
95	.	N	O

96	The	N	O
97	mean	N	O
98	total	N	O
99	treatment	N	O
100	costs	N	O
101	of	N	O
102	MMS	N	O
103	and	N	O
104	surgical	N	O
105	excision	N	O
106	for	N	O
107	both	N	O
108	primary	N	O
109	and	N	O
110	recurrent	N	O
111	BCC	N	O
112	and	N	O
113	the	N	O
114	incremental	N	O
115	cost-effectiveness	N	O
116	ratio	N	O
117	,	N	O
118	calculated	N	O
119	as	N	O
120	the	N	O
121	difference	N	O
122	in	N	O
123	costs	N	O
124	between	N	O
125	MMS	N	O
126	and	N	O
127	surgical	N	O
128	excision	N	O
129	divided	N	O
130	by	N	O
131	their	N	O
132	difference	N	O
133	in	N	O
134	effectiveness	N	O
135	.	N	O

136	The	N	O
137	resulting	N	O
138	ratio	N	O
139	is	N	O
140	defined	N	O
141	as	N	O
142	the	N	O
143	incremental	N	O
144	costs	N	O
145	of	N	O
146	MMS	N	O
147	compared	N	O
148	with	N	O
149	surgical	N	O
150	excision	N	O
151	to	N	O
152	prevent	N	O
153	1	N	O
154	additional	N	O
155	recurrence	N	O
156	.	N	O

157	Compared	N	I-Premise
158	with	N	I-Premise
159	surgical	N	I-Premise
160	excision	N	I-Premise
161	,	N	I-Premise
162	the	N	I-Premise
163	total	N	I-Premise
164	treatment	N	I-Premise
165	costs	N	I-Premise
166	of	N	I-Premise
167	MMS	N	I-Premise
168	are	N	I-Premise
169	significantly	N	I-Premise
170	higher	N	I-Premise
171	(	N	I-Premise
172	cost	N	I-Premise
173	difference	N	I-Premise
174	:	N	I-Premise
175	primary	N	I-Premise
176	BCC	N	I-Premise
177	,	N	I-Premise
178	254	N	I-Premise
179	euros	N	I-Premise
180	;	N	I-Premise
181	95	N	I-Premise
182	%	N	I-Premise
183	confidence	N	I-Premise
184	interval	N	I-Premise
185	,	N	I-Premise
186	181-324	N	I-Premise
187	euros	N	I-Premise
188	;	N	I-Premise
189	recurrent	N	I-Premise
190	BCC	N	I-Premise
191	,	N	I-Premise
192	249	N	I-Premise
193	euros	N	I-Premise
194	;	N	I-Premise
195	95	N	I-Premise
196	%	N	I-Premise
197	confidence	N	I-Premise
198	interval	N	I-Premise
199	,	N	I-Premise
200	175-323	N	I-Premise
201	euros	N	I-Premise
202	)	N	I-Premise
203	.	N	I-Premise

204	For	N	I-Premise
205	primary	N	I-Premise
206	BCC	N	I-Premise
207	,	N	I-Premise
208	the	N	I-Premise
209	incremental	N	I-Premise
210	cost-effectiveness	N	I-Premise
211	ratio	N	I-Premise
212	was	N	I-Premise
213	29,231	N	I-Premise
214	euros	N	I-Premise
215	,	N	I-Premise
216	while	N	I-Premise
217	the	N	I-Premise
218	ratio	N	I-Premise
219	for	N	I-Premise
220	recurrent	N	I-Premise
221	BCC	N	I-Premise
222	amounted	N	I-Premise
223	to	N	I-Premise
224	8094	N	I-Premise
225	euros	N	I-Premise
226	.	N	I-Premise

227	The	N	I-Premise
228	acceptability	N	I-Premise
229	curves	N	I-Premise
230	showed	N	I-Premise
231	that	N	I-Premise
232	for	N	I-Premise
233	these	N	I-Premise
234	ratios	N	I-Premise
235	,	N	I-Premise
236	the	N	I-Premise
237	probability	N	I-Premise
238	of	N	I-Premise
239	MMS	N	I-Premise
240	being	N	I-Premise
241	more	N	I-Premise
242	cost-effective	N	I-Premise
243	than	N	I-Premise
244	surgical	N	I-Premise
245	excision	N	I-Premise
246	never	N	I-Premise
247	reached	N	I-Premise
248	50	N	I-Premise
249	%	N	I-Premise
250	.	N	I-Premise

251	At	N	I-Claim
252	present	N	I-Claim
253	,	N	I-Claim
254	it	N	I-Claim
255	does	N	I-Claim
256	not	N	I-Claim
257	seem	N	I-Claim
258	cost-effective	N	I-Claim
259	to	N	I-Claim
260	introduce	N	I-Claim
261	MMS	N	I-Claim
262	on	N	I-Claim
263	a	N	I-Claim
264	large	N	I-Claim
265	scale	N	I-Claim
266	for	N	I-Claim
267	both	N	I-Claim
268	primary	N	I-Claim
269	and	N	I-Claim
270	recurrent	N	I-Claim
271	BCC	N	I-Claim
272	.	N	I-Claim

273	However	N	O
274	,	N	O
275	because	N	I-Premise
276	a	N	I-Premise
277	5-year	N	I-Premise
278	period	N	I-Premise
279	is	N	I-Premise
280	normally	N	I-Premise
281	required	N	I-Premise
282	to	N	I-Premise
283	determine	N	I-Premise
284	definite	N	I-Premise
285	recurrence	N	I-Premise
286	rates	N	I-Premise
287	,	N	O
288	it	N	I-Claim
289	is	N	I-Claim
290	possible	N	I-Claim
291	that	N	I-Claim
292	MMS	N	I-Claim
293	may	N	I-Claim
294	become	N	I-Claim
295	a	N	I-Claim
296	cost-effective	N	I-Claim
297	treatment	N	I-Claim
298	for	N	I-Claim
299	recurrent	N	I-Claim
300	BCC	N	I-Claim
301	.	N	I-Claim

1	Hepatic	N	O
2	metastases	N	O
3	derive	N	O
4	most	N	O
5	of	N	O
6	their	N	O
7	blood	N	O
8	supply	N	O
9	from	N	O
10	the	N	O
11	hepatic	N	O
12	artery	N	O
13	;	N	O
14	therefore	N	O
15	,	N	O
16	for	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	hepatic	N	I-Claim
20	metastases	N	I-Claim
21	from	N	I-Claim
22	colorectal	N	I-Claim
23	cancer	N	I-Claim
24	,	N	I-Claim
25	hepatic	N	I-Claim
26	arterial	N	I-Claim
27	infusion	N	I-Claim
28	(	N	I-Claim
29	HAI	N	I-Claim
30	)	N	I-Claim
31	of	N	I-Claim
32	chemotherapy	N	I-Claim
33	may	N	I-Claim
34	improve	N	I-Claim
35	outcome	N	I-Claim
36	.	N	I-Claim

37	In	N	O
38	a	N	O
39	multi-institutional	N	O
40	trial	N	O
41	,	N	O
42	135	N	O
43	patients	N	O
44	were	N	O
45	randomly	N	O
46	assigned	N	O
47	to	N	O
48	receive	N	O
49	HAI	N	O
50	versus	N	O
51	systemic	N	O
52	bolus	N	O
53	fluorouracil	N	O
54	and	N	O
55	leucovorin	N	O
56	.	N	O

57	The	N	O
58	primary	N	O
59	end	N	O
60	point	N	O
61	was	N	O
62	survival	N	O
63	;	N	O
64	secondary	N	O
65	end	N	O
66	points	N	O
67	were	N	O
68	response	N	O
69	,	N	O
70	recurrence	N	O
71	,	N	O
72	toxicity	N	O
73	,	N	O
74	quality	N	O
75	of	N	O
76	life	N	O
77	,	N	O
78	cost	N	O
79	,	N	O
80	and	N	O
81	the	N	O
82	influence	N	O
83	of	N	O
84	molecular	N	O
85	markers	N	O
86	.	N	O

87	Overall	N	I-Premise
88	survival	N	I-Premise
89	was	N	I-Premise
90	significantly	N	I-Premise
91	longer	N	I-Premise
92	for	N	I-Premise
93	HAI	N	I-Premise
94	versus	N	I-Premise
95	systemic	N	I-Premise
96	treatment	N	I-Premise
97	(	N	I-Premise
98	median	N	I-Premise
99	,	N	I-Premise
100	24.4	N	I-Premise
101	v	N	I-Premise
102	20	N	I-Premise
103	months	N	I-Premise
104	;	N	I-Premise
105	P	N	I-Premise
106	=	N	I-Premise
107	.0034	N	I-Premise
108	)	N	I-Premise
109	,	N	I-Premise
110	as	N	I-Premise
111	were	N	I-Premise
112	response	N	I-Premise
113	rates	N	I-Premise
114	(	N	I-Premise
115	47	N	I-Premise
116	%	N	I-Premise
117	and	N	I-Premise
118	24	N	I-Premise
119	%	N	I-Premise
120	;	N	I-Premise
121	P	N	I-Premise
122	=	N	I-Premise
123	.012	N	I-Premise
124	)	N	I-Premise
125	and	N	I-Premise
126	time	N	I-Premise
127	to	N	I-Premise
128	hepatic	N	I-Premise
129	progression	N	I-Premise
130	(	N	I-Premise
131	THP	N	I-Premise
132	;	N	I-Premise
133	9.8	N	I-Premise
134	v	N	I-Premise
135	7.3	N	I-Premise
136	months	N	I-Premise
137	;	N	I-Premise
138	P	N	I-Premise
139	=	N	I-Premise
140	.034	N	I-Premise
141	)	N	I-Premise
142	.	N	I-Premise

143	Time	N	I-Premise
144	to	N	I-Premise
145	extrahepatic	N	I-Premise
146	progression	N	I-Premise
147	(	N	I-Premise
148	7.7	N	I-Premise
149	v	N	I-Premise
150	14.8	N	I-Premise
151	months	N	I-Premise
152	;	N	I-Premise
153	P	N	I-Premise
154	=	N	I-Premise
155	.029	N	I-Premise
156	)	N	I-Premise
157	was	N	I-Premise
158	significantly	N	I-Premise
159	shorter	N	I-Premise
160	in	N	I-Premise
161	the	N	I-Premise
162	HAI	N	I-Premise
163	group	N	I-Premise
164	.	N	I-Premise

165	Quality-of-life	N	I-Premise
166	measurements	N	I-Premise
167	showed	N	I-Premise
168	improved	N	I-Premise
169	physical	N	I-Premise
170	functioning	N	I-Premise
171	in	N	I-Premise
172	the	N	I-Premise
173	HAI	N	I-Premise
174	group	N	I-Premise
175	at	N	I-Premise
176	the	N	I-Premise
177	3-	N	I-Premise
178	and	N	I-Premise
179	6-month	N	I-Premise
180	follow-up	N	I-Premise
181	assessments	N	I-Premise
182	.	N	I-Premise

183	Toxicity	N	I-Premise
184	included	N	I-Premise
185	grade	N	I-Premise
186	>	N	I-Premise
187	or	N	I-Premise
188	=	N	I-Premise
189	3	N	I-Premise
190	neutropenia	N	I-Premise
191	(	N	I-Premise
192	2	N	I-Premise
193	%	N	I-Premise
194	and	N	I-Premise
195	45	N	I-Premise
196	%	N	I-Premise
197	;	N	I-Premise
198	P	N	I-Premise
199	<	N	I-Premise
200	.01	N	I-Premise
201	)	N	I-Premise
202	,	N	I-Premise
203	stomatitis	N	I-Premise
204	(	N	I-Premise
205	0	N	I-Premise
206	%	N	I-Premise
207	and	N	I-Premise
208	24	N	I-Premise
209	%	N	I-Premise
210	;	N	I-Premise
211	P	N	I-Premise
212	<	N	I-Premise
213	.01	N	I-Premise
214	)	N	I-Premise
215	,	N	I-Premise
216	and	N	I-Premise
217	bilirubin	N	I-Premise
218	elevation	N	I-Premise
219	(	N	I-Premise
220	18.6	N	I-Premise
221	%	N	I-Premise
222	and	N	I-Premise
223	0	N	I-Premise
224	;	N	I-Premise
225	P	N	I-Premise
226	<	N	I-Premise
227	.01	N	I-Premise
228	)	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	HAI	N	I-Premise
232	and	N	I-Premise
233	systemic	N	I-Premise
234	treatment	N	I-Premise
235	groups	N	I-Premise
236	,	N	I-Premise
237	respectively	N	I-Premise
238	.	N	I-Premise

239	A	N	I-Premise
240	greater	N	I-Premise
241	proportion	N	I-Premise
242	of	N	I-Premise
243	men	N	I-Premise
244	versus	N	I-Premise
245	women	N	I-Premise
246	receiving	N	I-Premise
247	HAI	N	I-Premise
248	experienced	N	I-Premise
249	biliary	N	I-Premise
250	toxicity	N	I-Premise
251	(	N	I-Premise
252	37	N	I-Premise
253	%	N	I-Premise
254	and	N	I-Premise
255	15	N	I-Premise
256	%	N	I-Premise
257	,	N	I-Premise
258	respectively	N	I-Premise
259	;	N	I-Premise
260	P	N	I-Premise
261	=	N	I-Premise
262	.05	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	For	N	I-Premise
266	HAI	N	I-Premise
267	patients	N	I-Premise
268	with	N	I-Premise
269	thymidylate	N	I-Premise
270	synthase	N	I-Premise
271	levels	N	I-Premise
272	in	N	I-Premise
273	tumor	N	I-Premise
274	less	N	I-Premise
275	than	N	I-Premise
276	or	N	I-Premise
277	>	N	I-Premise
278	or	N	I-Premise
279	=	N	I-Premise
280	4	N	I-Premise
281	,	N	I-Premise
282	the	N	I-Premise
283	median	N	I-Premise
284	survival	N	I-Premise
285	was	N	I-Premise
286	24	N	I-Premise
287	and	N	I-Premise
288	14	N	I-Premise
289	months	N	I-Premise
290	,	N	I-Premise
291	respectively	N	I-Premise
292	(	N	I-Premise
293	P	N	I-Premise
294	=	N	I-Premise
295	.17	N	I-Premise
296	)	N	I-Premise
297	.	N	I-Premise

298	HAI	N	I-Claim
299	therapy	N	I-Claim
300	increased	N	I-Claim
301	overall	N	I-Claim
302	survival	N	I-Claim
303	,	N	I-Claim
304	response	N	I-Claim
305	rate	N	I-Claim
306	,	N	I-Claim
307	THP	N	I-Claim
308	,	N	I-Claim
309	and	N	I-Claim
310	was	N	I-Claim
311	associated	N	I-Claim
312	with	N	I-Claim
313	better	N	I-Claim
314	physical	N	I-Claim
315	functioning	N	I-Claim
316	compared	N	I-Claim
317	with	N	I-Claim
318	systemic	N	I-Claim
319	therapy	N	I-Claim
320	.	N	I-Claim

321	Additional	N	I-Claim
322	studies	N	I-Claim
323	need	N	I-Claim
324	to	N	I-Claim
325	address	N	I-Claim
326	the	N	I-Claim
327	overall	N	I-Claim
328	benefit	N	I-Claim
329	and	N	I-Claim
330	cost	N	I-Claim
331	of	N	I-Claim
332	new	N	I-Claim
333	chemotherapy	N	I-Claim
334	agents	N	I-Claim
335	versus	N	I-Claim
336	HAI	N	I-Claim
337	alone	N	I-Claim
338	or	N	I-Claim
339	the	N	I-Claim
340	combination	N	I-Claim
341	of	N	I-Claim
342	HAI	N	I-Claim
343	with	N	I-Claim
344	new	N	I-Claim
345	agents	N	I-Claim
346	.	N	I-Claim

1	Morbidity	N	I-MajorClaim
2	is	N	I-MajorClaim
3	an	N	I-MajorClaim
4	important	N	I-MajorClaim
5	issue	N	I-MajorClaim
6	in	N	I-MajorClaim
7	cancer	N	I-MajorClaim
8	research	N	I-MajorClaim
9	.	N	I-MajorClaim

10	The	N	I-Claim
11	observer-based	N	I-Claim
12	toxicity	N	I-Claim
13	scoring	N	I-Claim
14	system	N	I-Claim
15	used	N	I-Claim
16	by	N	I-Claim
17	DAHANCA	N	I-Claim
18	(	N	I-Claim
19	the	N	I-Claim
20	Danish	N	I-Claim
21	head	N	I-Claim
22	and	N	I-Claim
23	neck	N	I-Claim
24	cancer	N	I-Claim
25	study	N	I-Claim
26	group	N	I-Claim
27	)	N	I-Claim
28	has	N	I-Claim
29	proved	N	I-Claim
30	itself	N	I-Claim
31	sensitive	N	I-Claim
32	to	N	I-Claim
33	differences	N	I-Claim
34	in	N	I-Claim
35	toxicity	N	I-Claim
36	in	N	I-Claim
37	a	N	I-Claim
38	large	N	I-Claim
39	randomised	N	I-Claim
40	study	N	I-Claim
41	,	N	I-Claim
42	but	N	I-Claim
43	like	N	I-Claim
44	other	N	I-Claim
45	toxicity	N	I-Claim
46	scoring	N	I-Claim
47	systems	N	I-Claim
48	it	N	I-Claim
49	has	N	I-Claim
50	not	N	I-Claim
51	been	N	I-Claim
52	formally	N	I-Claim
53	validated	N	I-Claim
54	.	N	I-Claim

55	Conversely	N	O
56	,	N	O
57	the	N	O
58	EORTC	N	O
59	quality	N	O
60	of	N	O
61	life	N	O
62	questionnaire	N	O
63	(	N	O
64	QLQ	N	O
65	)	N	O
66	has	N	O
67	been	N	O
68	validated	N	O
69	as	N	O
70	a	N	O
71	tool	N	O
72	for	N	O
73	collecting	N	O
74	information	N	O
75	about	N	O
76	the	N	O
77	consequences	N	O
78	of	N	O
79	disease	N	O
80	and	N	O
81	treatment	N	O
82	on	N	O
83	the	N	O
84	well	N	O
85	being	N	O
86	of	N	O
87	cancer	N	O
88	patients	N	O
89	.	N	O

90	The	N	O
91	purpose	N	O
92	of	N	O
93	this	N	O
94	study	N	O
95	was	N	O
96	to	N	O
97	examine	N	O
98	the	N	O
99	relationship	N	O
100	between	N	O
101	the	N	O
102	two	N	O
103	methods	N	O
104	of	N	O
105	side	N	O
106	effect	N	O
107	recording	N	O
108	.	N	O

109	One	N	O
110	hundred	N	O
111	and	N	O
112	sixteen	N	O
113	recurrence	N	O
114	free	N	O
115	patients	N	O
116	with	N	O
117	laryngeal	N	O
118	(	N	O
119	n=44	N	O
120	)	N	O
121	,	N	O
122	pharyngeal	N	O
123	(	N	O
124	n=34	N	O
125	)	N	O
126	and	N	O
127	oral	N	O
128	cavity	N	O
129	(	N	O
130	n=38	N	O
131	)	N	O
132	cancer	N	O
133	attending	N	O
134	follow-up	N	O
135	after	N	O
136	radiotherapy	N	O
137	(	N	O
138	n=83	N	O
139	)	N	O
140	or	N	O
141	surgery	N	O
142	(	N	O
143	n=33	N	O
144	)	N	O
145	completed	N	O
146	EORTC	N	O
147	C30	N	O
148	,	N	O
149	the	N	O
150	core	N	O
151	questionnaire	N	O
152	concerning	N	O
153	general	N	O
154	symptoms	N	O
155	and	N	O
156	function	N	O
157	and	N	O
158	EORTC	N	O
159	H	N	O
160	&	N	O
161	amp	N	O
162	;	N	O
163	N35	N	O
164	the	N	O
165	head	N	O
166	and	N	O
167	neck	N	O
168	specific	N	O
169	questionnaire	N	O
170	.	N	O

171	The	N	O
172	attending	N	O
173	physicians	N	O
174	in	N	O
175	the	N	O
176	follow-up	N	O
177	clinic	N	O
178	evaluated	N	O
179	and	N	O
180	recorded	N	O
181	DAHANCA	N	O
182	toxicity	N	O
183	scores	N	O
184	on	N	O
185	the	N	O
186	same	N	O
187	patients	N	O
188	.	N	O

189	The	N	I-Premise
190	DAHANCA	N	I-Premise
191	toxicity	N	I-Premise
192	scoring	N	I-Premise
193	system	N	I-Premise
194	and	N	I-Premise
195	the	N	I-Premise
196	EORTC	N	I-Premise
197	QLQ	N	I-Premise
198	correlated	N	I-Premise
199	with	N	I-Premise
200	several	N	I-Premise
201	clinical	N	I-Premise
202	endpoints	N	I-Premise
203	.	N	I-Premise

204	The	N	I-Premise
205	conceptually	N	I-Premise
206	similar	N	I-Premise
207	endpoints	N	I-Premise
208	of	N	I-Premise
209	the	N	I-Premise
210	two	N	I-Premise
211	methods	N	I-Premise
212	correlated	N	I-Premise
213	significantly	N	I-Premise
214	.	N	I-Premise

215	The	N	I-Premise
216	objective	N	I-Premise
217	endpoints	N	I-Premise
218	of	N	I-Premise
219	the	N	I-Premise
220	DAHANCA	N	I-Premise
221	scoring	N	I-Premise
222	system	N	I-Premise
223	were	N	I-Premise
224	only	N	I-Premise
225	correlated	N	I-Premise
226	with	N	I-Premise
227	quality	N	I-Premise
228	of	N	I-Premise
229	life	N	I-Premise
230	endpoints	N	I-Premise
231	to	N	I-Premise
232	a	N	I-Premise
233	very	N	I-Premise
234	low	N	I-Premise
235	degree	N	I-Premise
236	.	N	I-Premise

237	The	N	I-Premise
238	DAHANCA	N	I-Premise
239	toxicity	N	I-Premise
240	scores	N	I-Premise
241	had	N	I-Premise
242	a	N	I-Premise
243	low	N	I-Premise
244	sensitivity	N	I-Premise
245	(	N	I-Premise
246	0.48-0.74	N	I-Premise
247	)	N	I-Premise
248	in	N	I-Premise
249	detecting	N	I-Premise
250	equivalent	N	I-Premise
251	subjective	N	I-Premise
252	complaints	N	I-Premise
253	from	N	I-Premise
254	the	N	I-Premise
255	questionnaires	N	I-Premise
256	and	N	I-Premise
257	the	N	I-Premise
258	observer-based	N	I-Premise
259	scoring	N	I-Premise
260	system	N	I-Premise
261	severely	N	I-Premise
262	underestimated	N	I-Premise
263	patient	N	I-Premise
264	complaints	N	I-Premise
265	.	N	I-Premise

266	A	N	I-Premise
267	specific	N	I-Premise
268	patient	N	I-Premise
269	group	N	I-Premise
270	where	N	I-Premise
271	the	N	I-Premise
272	DAHANCA	N	I-Premise
273	score	N	I-Premise
274	had	N	I-Premise
275	a	N	I-Premise
276	higher	N	I-Premise
277	tendency	N	I-Premise
278	to	N	I-Premise
279	fail	N	I-Premise
280	could	N	I-Premise
281	not	N	I-Premise
282	be	N	I-Premise
283	detected	N	I-Premise
284	.	N	I-Premise

285	The	N	I-Claim
286	DAHANCA	N	I-Claim
287	toxicity	N	I-Claim
288	score	N	I-Claim
289	is	N	I-Claim
290	an	N	I-Claim
291	effective	N	I-Claim
292	instrument	N	I-Claim
293	in	N	I-Claim
294	assessing	N	I-Claim
295	objective	N	I-Claim
296	treatment	N	I-Claim
297	induced	N	I-Claim
298	toxicity	N	I-Claim
299	in	N	I-Claim
300	head	N	I-Claim
301	and	N	I-Claim
302	neck	N	I-Claim
303	cancer	N	I-Claim
304	patients	N	I-Claim
305	but	N	I-Claim
306	insensitive	N	I-Claim
307	and	N	I-Claim
308	non-specific	N	I-Claim
309	with	N	I-Claim
310	regard	N	I-Claim
311	to	N	I-Claim
312	patient	N	I-Claim
313	assessed	N	I-Claim
314	subjective	N	I-Claim
315	endpoints	N	I-Claim
316	.	N	I-Claim

317	This	N	I-Claim
318	weakness	N	I-Claim
319	seems	N	I-Claim
320	inherent	N	I-Claim
321	in	N	I-Claim
322	an	N	I-Claim
323	observer-based	N	I-Claim
324	scoring	N	I-Claim
325	system	N	I-Claim
326	,	N	I-Claim
327	and	N	I-Claim
328	will	N	I-Claim
329	probably	N	I-Claim
330	also	N	I-Claim
331	apply	N	I-Claim
332	to	N	I-Claim
333	newer	N	I-Claim
334	ones	N	I-Claim
335	like	N	I-Claim
336	CTCAE	N	I-Claim
337	3.0	N	I-Claim
338	.	N	I-Claim

1	Prospective	N	I-Claim
2	investigations	N	I-Claim
3	of	N	I-Claim
4	complete	N	I-Claim
5	decongestive	N	I-Claim
6	lymphatic	N	I-Claim
7	physiotherapy	N	I-Claim
8	(	N	I-Claim
9	CDPT	N	I-Claim
10	)	N	I-Claim
11	,	N	I-Claim
12	including	N	I-Claim
13	manual	N	I-Claim
14	lymphatic	N	I-Claim
15	drainage	N	I-Claim
16	(	N	I-Claim
17	MLD	N	I-Claim
18	)	N	I-Claim
19	,	N	I-Claim
20	have	N	I-Claim
21	validated	N	I-Claim
22	the	N	I-Claim
23	efficacy	N	I-Claim
24	of	N	I-Claim
25	these	N	I-Claim
26	interventions	N	I-Claim
27	for	N	I-Claim
28	the	N	I-Claim
29	initial	N	I-Claim
30	reduction	N	I-Claim
31	of	N	I-Claim
32	edema	N	I-Claim
33	and	N	I-Claim
34	long-term	N	I-Claim
35	maintenance	N	I-Claim
36	of	N	I-Claim
37	limb	N	I-Claim
38	volume	N	I-Claim
39	in	N	I-Claim
40	lymphedema	N	I-Claim
41	.	N	I-Claim

42	However	N	O
43	,	N	O
44	CDPT	N	O
45	demands	N	O
46	substantial	N	O
47	time	N	O
48	and	N	O
49	effort	N	O
50	from	N	O
51	patients	N	O
52	to	N	O
53	maintain	N	O
54	these	N	O
55	benefits	N	O
56	;	N	O
57	the	N	I-Claim
58	treatments	N	I-Claim
59	are	N	I-Claim
60	not	N	I-Claim
61	always	N	I-Claim
62	well-accepted	N	I-Claim
63	,	N	I-Claim
64	and	N	O
65	patients	N	I-Claim
66	may	N	I-Claim
67	suffer	N	I-Claim
68	from	N	I-Claim
69	a	N	I-Claim
70	deterioration	N	I-Claim
71	in	N	I-Claim
72	quality-of-life	N	I-Claim
73	or	N	I-Claim
74	a	N	I-Claim
75	time-dependent	N	I-Claim
76	loss	N	I-Claim
77	of	N	I-Claim
78	initial	N	I-Claim
79	treatment	N	I-Claim
80	benefits	N	I-Claim
81	.	N	I-Claim

82	A	N	O
83	new	N	O
84	device	N	O
85	designed	N	O
86	for	N	O
87	home	N	O
88	use	N	O
89	by	N	O
90	the	N	O
91	patient	N	O
92	,	N	O
93	the	N	O
94	Flexitouch	N	O
95	,	N	O
96	has	N	O
97	been	N	O
98	developed	N	O
99	to	N	O
100	mechanically	N	O
101	simulate	N	O
102	MLD	N	O
103	.	N	O

104	We	N	O
105	have	N	O
106	undertaken	N	O
107	a	N	O
108	prospective	N	O
109	,	N	O
110	randomized	N	O
111	,	N	O
112	crossover	N	O
113	study	N	O
114	of	N	O
115	the	N	O
116	efficacy	N	O
117	of	N	O
118	the	N	O
119	Flexitouch	N	O
120	,	N	O
121	when	N	O
122	compared	N	O
123	to	N	O
124	massage	N	O
125	,	N	O
126	in	N	O
127	the	N	O
128	self-administered	N	O
129	maintenance	N	O
130	therapy	N	O
131	of	N	O
132	lymphedema	N	O
133	.	N	O

134	A	N	O
135	prospective	N	O
136	,	N	O
137	randomized	N	O
138	,	N	O
139	crossover	N	O
140	study	N	O
141	of	N	O
142	maintenance	N	O
143	therapy	N	O
144	was	N	O
145	performed	N	O
146	in	N	O
147	10	N	O
148	patients	N	O
149	with	N	O
150	unilateral	N	O
151	breast	N	O
152	cancer-associated	N	O
153	lymphedema	N	O
154	of	N	O
155	the	N	O
156	arm	N	O
157	.	N	O

158	Each	N	O
159	observation	N	O
160	phase	N	O
161	included	N	O
162	self-administered	N	O
163	treatment	N	O
164	with	N	O
165	the	N	O
166	Flexitouch	N	O
167	or	N	O
168	massage	N	O
169	,	N	O
170	1	N	O
171	hour	N	O
172	daily	N	O
173	for	N	O
174	14	N	O
175	days	N	O
176	,	N	O
177	respectively	N	O
178	,	N	O
179	followed	N	O
180	by	N	O
181	crossover	N	O
182	to	N	O
183	the	N	O
184	alternate	N	O
185	treatment	N	O
186	phase	N	O
187	.	N	O

188	Each	N	O
189	treatment	N	O
190	phase	N	O
191	was	N	O
192	preceded	N	O
193	by	N	O
194	a	N	O
195	1	N	O
196	week	N	O
197	treatment	N	O
198	washout	N	O
199	,	N	O
200	with	N	O
201	use	N	O
202	of	N	O
203	garment	N	O
204	only	N	O
205	.	N	O

206	The	N	O
207	sequence	N	O
208	of	N	O
209	treatment	N	O
210	was	N	O
211	randomly	N	O
212	assigned	N	O
213	.	N	O

214	The	N	O
215	potential	N	O
216	impact	N	O
217	of	N	O
218	treatment	N	O
219	modality	N	O
220	on	N	O
221	quality	N	O
222	of	N	O
223	life	N	O
224	was	N	O
225	assessed	N	O
226	with	N	O
227	serial	N	O
228	administration	N	O
229	of	N	O
230	the	N	O
231	SF-36	N	O
232	.	N	O

233	Statistical	N	O
234	analysis	N	O
235	disclosed	N	O
236	that	N	O
237	the	N	O
238	order	N	O
239	of	N	O
240	treatment	N	O
241	had	N	O
242	no	N	O
243	outcome	N	O
244	influence	N	O
245	,	N	O
246	permitting	N	O
247	10	N	O
248	comparisons	N	O
249	within	N	O
250	each	N	O
251	treatment	N	O
252	group	N	O
253	.	N	O

254	Post-treatment	N	I-Premise
255	arm	N	I-Premise
256	volume	N	I-Premise
257	reduced	N	I-Premise
258	significantly	N	I-Premise
259	after	N	I-Premise
260	the	N	I-Premise
261	Flexitouch	N	I-Premise
262	,	N	I-Premise
263	but	N	I-Premise
264	not	N	I-Premise
265	after	N	I-Premise
266	self-administered	N	I-Premise
267	massage	N	I-Premise
268	.	N	I-Premise

269	The	N	I-Premise
270	patients	N	I-Premise
271	'	N	I-Premise
272	mean	N	I-Premise
273	weight	N	I-Premise
274	decreased	N	I-Premise
275	significantly	N	I-Premise
276	with	N	I-Premise
277	Flexitouch	N	I-Premise
278	use	N	I-Premise
279	,	N	I-Premise
280	but	N	I-Premise
281	not	N	I-Premise
282	with	N	I-Premise
283	massage	N	I-Premise
284	.	N	I-Premise

285	The	N	I-Premise
286	Flexitouch	N	I-Premise
287	device	N	I-Premise
288	was	N	I-Premise
289	apparently	N	I-Premise
290	well-tolerated	N	I-Premise
291	and	N	I-Premise
292	accepted	N	I-Premise
293	by	N	I-Premise
294	patients	N	I-Premise
295	.	N	I-Premise

296	Serial	N	I-Premise
297	SF-36	N	I-Premise
298	administration	N	I-Premise
299	showed	N	I-Premise
300	no	N	I-Premise
301	deterioration	N	I-Premise
302	in	N	I-Premise
303	physical	N	I-Premise
304	or	N	I-Premise
305	psychosocial	N	I-Premise
306	scores	N	I-Premise
307	compared	N	I-Premise
308	to	N	I-Premise
309	baseline	N	I-Premise
310	measurements	N	I-Premise
311	;	N	I-Premise
312	there	N	I-Premise
313	were	N	I-Premise
314	no	N	I-Premise
315	statistical	N	I-Premise
316	differences	N	I-Premise
317	in	N	I-Premise
318	scores	N	I-Premise
319	when	N	I-Premise
320	the	N	I-Premise
321	two	N	I-Premise
322	treatment	N	I-Premise
323	modalities	N	I-Premise
324	were	N	I-Premise
325	compared	N	I-Premise
326	.	N	I-Premise

327	This	N	I-Claim
328	short-term	N	I-Claim
329	prospective	N	I-Claim
330	evaluation	N	I-Claim
331	of	N	I-Claim
332	the	N	I-Claim
333	Flexitouch	N	I-Claim
334	suggests	N	I-Claim
335	that	N	I-Claim
336	the	N	I-Claim
337	device	N	I-Claim
338	may	N	I-Claim
339	provide	N	I-Claim
340	better	N	I-Claim
341	maintenance	N	I-Claim
342	edema	N	I-Claim
343	control	N	I-Claim
344	than	N	I-Claim
345	self-adiminstered	N	I-Claim
346	massage	N	I-Claim
347	in	N	I-Claim
348	breast	N	I-Claim
349	cancer-associated	N	I-Claim
350	lymphedema	N	I-Claim
351	.	N	I-Claim

352	The	N	I-Claim
353	apparent	N	I-Claim
354	ease	N	I-Claim
355	of	N	I-Claim
356	use	N	I-Claim
357	and	N	I-Claim
358	reliability	N	I-Claim
359	of	N	I-Claim
360	response	N	I-Claim
361	to	N	I-Claim
362	the	N	I-Claim
363	device	N	I-Claim
364	suggest	N	I-Claim
365	that	N	I-Claim
366	further	N	I-Claim
367	broad-scale	N	I-Claim
368	testing	N	I-Claim
369	is	N	I-Claim
370	warranted	N	I-Claim
371	.	N	I-Claim

1	Tumor	N	I-Claim
2	necrosis	N	I-Claim
3	factor-alpha	N	I-Claim
4	(	N	I-Claim
5	TNF-alpha	N	I-Claim
6	)	N	I-Claim
7	is	N	I-Claim
8	a	N	I-Claim
9	putative	N	I-Claim
10	mediator	N	I-Claim
11	of	N	I-Claim
12	the	N	I-Claim
13	cancer	N	I-Claim
14	anorexia/weight	N	I-Claim
15	loss	N	I-Claim
16	syndrome	N	I-Claim
17	.	N	I-Claim

18	The	N	O
19	current	N	O
20	study	N	O
21	was	N	O
22	designed	N	O
23	to	N	O
24	determine	N	O
25	whether	N	O
26	etanercept	N	O
27	(	N	O
28	a	N	O
29	dimeric	N	O
30	fusion	N	O
31	protein	N	O
32	consisting	N	O
33	of	N	O
34	the	N	O
35	extracellular	N	O
36	ligand-binding	N	O
37	portion	N	O
38	of	N	O
39	the	N	O
40	human	N	O
41	75-kilodalton	N	O
42	TNF	N	O
43	receptor	N	O
44	linked	N	O
45	to	N	O
46	the	N	O
47	Fc	N	O
48	portion	N	O
49	of	N	O
50	human	N	O
51	immunoglobulin	N	O
52	[	N	O
53	Ig	N	O
54	]	N	O
55	G1	N	O
56	)	N	O
57	could	N	O
58	palliate	N	O
59	this	N	O
60	syndrome	N	O
61	.	N	O

62	A	N	O
63	total	N	O
64	of	N	O
65	63	N	O
66	evaluable	N	O
67	patients	N	O
68	were	N	O
69	randomly	N	O
70	assigned	N	O
71	to	N	O
72	receive	N	O
73	either	N	O
74	etanercept	N	O
75	at	N	O
76	a	N	O
77	dose	N	O
78	of	N	O
79	25	N	O
80	mg	N	O
81	subcutaneously	N	O
82	twice	N	O
83	weekly	N	O
84	versus	N	O
85	a	N	O
86	comparably	N	O
87	administered	N	O
88	placebo	N	O
89	.	N	O

90	All	N	O
91	patients	N	O
92	had	N	O
93	an	N	O
94	incurable	N	O
95	malignancy	N	O
96	,	N	O
97	acknowledged	N	O
98	loss	N	O
99	of	N	O
100	weight	N	O
101	and/or	N	O
102	appetite	N	O
103	as	N	O
104	a	N	O
105	concern	N	O
106	,	N	O
107	and	N	O
108	reported	N	O
109	a	N	O
110	weight	N	O
111	loss	N	O
112	of	N	O
113	>	N	O
114	2.27	N	O
115	kg	N	O
116	over	N	O
117	2	N	O
118	months	N	O
119	and/or	N	O
120	a	N	O
121	daily	N	O
122	intake	N	O
123	of	N	O
124	<	N	O
125	20	N	O
126	calories/kg	N	O
127	body	N	O
128	weight	N	O
129	.	N	O

130	Over	N	I-Premise
131	time	N	I-Premise
132	,	N	I-Premise
133	weight	N	I-Premise
134	gain	N	I-Premise
135	was	N	I-Premise
136	found	N	I-Premise
137	to	N	I-Premise
138	be	N	I-Premise
139	minimal	N	I-Premise
140	in	N	I-Premise
141	both	N	I-Premise
142	treatment	N	I-Premise
143	arms	N	I-Premise
144	;	N	I-Premise
145	no	N	I-Premise
146	patient	N	I-Premise
147	gained	N	I-Premise
148	>	N	I-Premise
149	or=10	N	I-Premise
150	%	N	I-Premise
151	of	N	I-Premise
152	their	N	I-Premise
153	baseline	N	I-Premise
154	weight	N	I-Premise
155	.	N	I-Premise

156	Previously	N	I-Premise
157	validated	N	I-Premise
158	appetite	N	I-Premise
159	questionnaires	N	I-Premise
160	revealed	N	I-Premise
161	negligible	N	I-Premise
162	improvements	N	I-Premise
163	in	N	I-Premise
164	both	N	I-Premise
165	treatment	N	I-Premise
166	arms	N	I-Premise
167	.	N	I-Premise

168	The	N	I-Premise
169	median	N	I-Premise
170	survival	N	I-Premise
171	was	N	I-Premise
172	also	N	I-Premise
173	comparable	N	I-Premise
174	(	N	I-Premise
175	175	N	I-Premise
176	days	N	I-Premise
177	vs	N	I-Premise
178	148	N	I-Premise
179	days	N	I-Premise
180	in	N	I-Premise
181	etanercept-treated	N	I-Premise
182	and	N	I-Premise
183	placebo-exposed	N	I-Premise
184	patients	N	I-Premise
185	,	N	I-Premise
186	respectively	N	I-Premise
187	;	N	I-Premise
188	P	N	I-Premise
189	=	N	I-Premise
190	.82	N	I-Premise
191	)	N	I-Premise
192	.	N	I-Premise

193	Finally	N	O
194	,	N	O
195	preliminary	N	I-Premise
196	data	N	I-Premise
197	regarding	N	I-Premise
198	adverse	N	I-Premise
199	events	N	I-Premise
200	demonstrated	N	I-Premise
201	that	N	I-Premise
202	patients	N	I-Premise
203	treated	N	I-Premise
204	with	N	I-Premise
205	etanercept	N	I-Premise
206	had	N	I-Premise
207	higher	N	I-Premise
208	rates	N	I-Premise
209	of	N	I-Premise
210	neurotoxicity	N	I-Premise
211	(	N	I-Premise
212	29	N	I-Premise
213	%	N	I-Premise
214	vs	N	I-Premise
215	0	N	I-Premise
216	%	N	I-Premise
217	)	N	I-Premise
218	but	N	I-Premise
219	lower	N	I-Premise
220	rates	N	I-Premise
221	of	N	I-Premise
222	anemia	N	I-Premise
223	(	N	I-Premise
224	0	N	I-Premise
225	%	N	I-Premise
226	vs	N	I-Premise
227	19	N	I-Premise
228	%	N	I-Premise
229	)	N	I-Premise
230	and	N	I-Premise
231	thrombocytopenia	N	I-Premise
232	(	N	I-Premise
233	0	N	I-Premise
234	%	N	I-Premise
235	vs	N	I-Premise
236	14	N	I-Premise
237	%	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	Infection	N	I-Premise
241	rates	N	I-Premise
242	were	N	I-Premise
243	negligible	N	I-Premise
244	in	N	I-Premise
245	both	N	I-Premise
246	groups	N	I-Premise
247	.	N	I-Premise

248	Genotyping	N	I-Premise
249	for	N	I-Premise
250	TNF-alpha-238	N	I-Premise
251	and	N	I-Premise
252	TNF-alpha-308	N	I-Premise
253	polymorphisms	N	I-Premise
254	revealed	N	I-Premise
255	no	N	I-Premise
256	clinical	N	I-Premise
257	significance	N	I-Premise
258	for	N	I-Premise
259	these	N	I-Premise
260	genotypes	N	I-Premise
261	,	N	I-Premise
262	except	N	I-Premise
263	for	N	I-Premise
264	a	N	I-Premise
265	preliminary	N	I-Premise
266	association	N	I-Premise
267	between	N	I-Premise
268	presence	N	I-Premise
269	of	N	I-Premise
270	the	N	I-Premise
271	-238	N	I-Premise
272	G/A	N	I-Premise
273	genotype	N	I-Premise
274	and	N	I-Premise
275	relatively	N	I-Premise
276	less	N	I-Premise
277	favorable	N	I-Premise
278	survival	N	I-Premise
279	.	N	I-Premise

280	Etanercept	N	I-Claim
281	,	N	I-Claim
282	as	N	I-Claim
283	prescribed	N	I-Claim
284	in	N	I-Claim
285	the	N	I-Claim
286	current	N	I-Claim
287	trial	N	I-Claim
288	,	N	I-Claim
289	does	N	I-Claim
290	not	N	I-Claim
291	appear	N	I-Claim
292	to	N	I-Claim
293	palliate	N	I-Claim
294	the	N	I-Claim
295	cancer	N	I-Claim
296	anorexia/weight	N	I-Claim
297	loss	N	I-Claim
298	syndrome	N	I-Claim
299	in	N	I-Claim
300	patients	N	I-Claim
301	with	N	I-Claim
302	advanced	N	I-Claim
303	disease	N	I-Claim
304	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	if	N	O
4	raising	N	O
5	baseline	N	O
6	and	N	O
7	maintaining	N	O
8	hemoglobin	N	O
9	(	N	O
10	Hb	N	O
11	)	N	O
12	levels	N	O
13	with	N	O
14	red	N	O
15	blood	N	O
16	cell	N	O
17	(	N	O
18	RBC	N	O
19	)	N	O
20	transfusion	N	O
21	could	N	O
22	improve	N	O
23	the	N	O
24	outcomes	N	O
25	of	N	O
26	chemotherapy	N	O
27	for	N	O
28	advanced	N	O
29	gastric	N	O
30	cancer	N	O
31	(	N	O
32	AGC	N	O
33	)	N	O
34	.	N	O

35	Patients	N	O
36	were	N	O
37	randomized	N	O
38	to	N	O
39	receive	N	O
40	RBC	N	O
41	transfusion	N	O
42	to	N	O
43	maintain	N	O
44	their	N	O
45	Hb	N	O
46	levels	N	O
47	>	N	O
48	or=10	N	O
49	g/dl	N	O
50	(	N	O
51	arm	N	O
52	1	N	O
53	)	N	O
54	or	N	O
55	>	N	O
56	or=12	N	O
57	(	N	O
58	arm	N	O
59	2	N	O
60	)	N	O
61	before	N	O
62	the	N	O
63	start	N	O
64	of	N	O
65	their	N	O
66	5-fluorouracil-based	N	O
67	first-line	N	O
68	chemotherapy	N	O
69	.	N	O

70	Objective	N	O
71	response	N	O
72	,	N	O
73	KPS	N	O
74	and	N	O
75	quality	N	O
76	of	N	O
77	life	N	O
78	(	N	O
79	QOL	N	O
80	)	N	O
81	data	N	O
82	were	N	O
83	measured	N	O
84	.	N	O

85	For	N	O
86	87	N	O
87	patients	N	O
88	enrolled	N	O
89	,	N	O
90	mean	N	O
91	baseline	N	O
92	Hb	N	O
93	was	N	O
94	10.1	N	O
95	g/dl	N	O
96	,	N	O
97	and	N	O
98	54	N	O
99	patients	N	O
100	received	N	O
101	RBC	N	O
102	prior	N	O
103	to	N	O
104	chemotherapy	N	O
105	initiation	N	O
106	.	N	O

107	Despite	N	O
108	transfusion	N	O
109	,	N	O
110	we	N	O
111	failed	N	O
112	to	N	O
113	maintain	N	O
114	the	N	O
115	Hb	N	O
116	level	N	O
117	above	N	O
118	the	N	O
119	predefined	N	O
120	target	N	O
121	range	N	O
122	.	N	O

123	Eighteen	N	I-Premise
124	patients	N	I-Premise
125	experienced	N	I-Premise
126	brief	N	I-Premise
127	and	N	I-Premise
128	reversible	N	I-Premise
129	adverse	N	I-Premise
130	events	N	I-Premise
131	during	N	I-Premise
132	transfusion	N	I-Premise
133	,	N	I-Premise
134	including	N	I-Premise
135	two	N	I-Premise
136	patients	N	I-Premise
137	with	N	I-Premise
138	acute	N	I-Premise
139	pulmonary	N	I-Premise
140	edema	N	I-Premise
141	.	N	I-Premise

142	KPS	N	I-Premise
143	was	N	I-Premise
144	improved	N	I-Premise
145	from	N	I-Premise
146	baseline	N	I-Premise
147	to	N	I-Premise
148	post-chemotherapy	N	I-Premise
149	in	N	I-Premise
150	both	N	I-Premise
151	arms	N	I-Premise
152	.	N	I-Premise

153	QOL	N	I-Premise
154	data	N	I-Premise
155	showed	N	I-Premise
156	improvement	N	I-Premise
157	in	N	I-Premise
158	some	N	I-Premise
159	symptom	N	I-Premise
160	scores	N	I-Premise
161	,	N	I-Premise
162	but	N	I-Premise
163	there	N	I-Premise
164	was	N	I-Premise
165	no	N	I-Premise
166	difference	N	I-Premise
167	in	N	I-Premise
168	the	N	I-Premise
169	QOL	N	I-Premise
170	scores	N	I-Premise
171	between	N	I-Premise
172	the	N	I-Premise
173	two	N	I-Premise
174	arms	N	I-Premise
175	at	N	I-Premise
176	baseline	N	I-Premise
177	and	N	I-Premise
178	all	N	I-Premise
179	four	N	I-Premise
180	cycles	N	I-Premise
181	of	N	I-Premise
182	treatment	N	I-Premise
183	.	N	I-Premise

184	Similar	N	I-Premise
185	response	N	I-Premise
186	rates	N	I-Premise
187	were	N	I-Premise
188	observed	N	I-Premise
189	in	N	I-Premise
190	both	N	I-Premise
191	arms	N	I-Premise
192	(	N	I-Premise
193	arm	N	I-Premise
194	1	N	I-Premise
195	,	N	I-Premise
196	30	N	I-Premise
197	%	N	I-Premise
198	;	N	I-Premise
199	arm	N	I-Premise
200	2	N	I-Premise
201	,	N	I-Premise
202	35	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	.	N	I-Premise

206	Both	N	I-Premise
207	arms	N	I-Premise
208	showed	N	I-Premise
209	similar	N	I-Premise
210	chemotherapy	N	I-Premise
211	duration	N	I-Premise
212	(	N	I-Premise
213	3.8	N	I-Premise
214	and	N	I-Premise
215	4.1	N	I-Premise
216	months	N	I-Premise
217	,	N	I-Premise
218	respectively	N	I-Premise
219	)	N	I-Premise
220	,	N	I-Premise
221	progression-free	N	I-Premise
222	survival	N	I-Premise
223	(	N	I-Premise
224	4.0	N	I-Premise
225	and	N	I-Premise
226	4.1	N	I-Premise
227	months	N	I-Premise
228	)	N	I-Premise
229	and	N	I-Premise
230	overall	N	I-Premise
231	survival	N	I-Premise
232	(	N	I-Premise
233	9.9	N	I-Premise
234	and	N	I-Premise
235	9.3	N	I-Premise
236	months	N	I-Premise
237	)	N	I-Premise
238	.	N	I-Premise

239	Red	N	I-Claim
240	blood	N	I-Claim
241	cell	N	I-Claim
242	transfusion	N	I-Claim
243	achieving	N	I-Claim
244	Hb	N	I-Claim
245	level	N	I-Claim
246	above	N	I-Claim
247	10	N	I-Claim
248	g/dl	N	I-Claim
249	might	N	I-Claim
250	contribute	N	I-Claim
251	to	N	I-Claim
252	the	N	I-Claim
253	improvement	N	I-Claim
254	of	N	I-Claim
255	the	N	I-Claim
256	KPS	N	I-Claim
257	and	N	I-Claim
258	QOL	N	I-Claim
259	seen	N	I-Claim
260	in	N	I-Claim
261	patients	N	I-Claim
262	with	N	I-Claim
263	AGC	N	I-Claim
264	.	N	I-Claim

265	The	N	I-Claim
266	observation	N	I-Claim
267	of	N	I-Claim
268	equivalent	N	I-Claim
269	outcomes	N	I-Claim
270	at	N	I-Claim
271	the	N	I-Claim
272	two	N	I-Claim
273	target	N	I-Claim
274	Hb	N	I-Claim
275	levels	N	I-Claim
276	supports	N	I-Claim
277	the	N	I-Claim
278	feasibility	N	I-Claim
279	of	N	I-Claim
280	anemia	N	I-Claim
281	correction	N	I-Claim
282	to	N	I-Claim
283	Hb	N	I-Claim
284	10	N	I-Claim
285	g/dl	N	I-Claim
286	,	N	I-Claim
287	which	N	I-Claim
288	merits	N	I-Claim
289	further	N	I-Claim
290	evaluation	N	I-Claim
291	.	N	O

1	Colonic	N	O
2	pouches	N	O
3	have	N	O
4	been	N	O
5	used	N	O
6	for	N	O
7	20	N	O
8	years	N	O
9	to	N	O
10	provide	N	O
11	reservoir	N	O
12	function	N	O
13	after	N	O
14	reconstructive	N	O
15	proctectomy	N	O
16	for	N	O
17	rectal	N	O
18	cancer	N	O
19	.	N	O

20	More	N	I-Claim
21	recently	N	I-Claim
22	coloplasty	N	I-Claim
23	has	N	I-Claim
24	been	N	I-Claim
25	advocated	N	I-Claim
26	as	N	I-Claim
27	an	N	I-Claim
28	alternative	N	I-Claim
29	to	N	I-Claim
30	a	N	I-Claim
31	colonic	N	I-Claim
32	pouch	N	I-Claim
33	.	N	I-Claim

34	However	N	O
35	there	N	O
36	have	N	O
37	been	N	O
38	no	N	O
39	long-term	N	O
40	randomized	N	O
41	,	N	O
42	controlled	N	O
43	trials	N	O
44	to	N	O
45	compare	N	O
46	functional	N	O
47	outcomes	N	O
48	of	N	O
49	coloplasty	N	O
50	,	N	O
51	colonic	N	O
52	J-Pouch	N	O
53	(	N	O
54	JP	N	O
55	)	N	O
56	,	N	O
57	or	N	O
58	a	N	O
59	straight	N	O
60	anastomosis	N	O
61	(	N	O
62	SA	N	O
63	)	N	O
64	after	N	O
65	the	N	O
66	treatment	N	O
67	of	N	O
68	low	N	O
69	rectal	N	O
70	cancer	N	O
71	.	N	O

72	:	N	O
73	To	N	O
74	compare	N	O
75	the	N	O
76	complications	N	O
77	,	N	O
78	long-term	N	O
79	functional	N	O
80	outcome	N	O
81	,	N	O
82	and	N	O
83	quality	N	O
84	of	N	O
85	life	N	O
86	(	N	O
87	QOL	N	O
88	)	N	O
89	of	N	O
90	patients	N	O
91	undergoing	N	O
92	a	N	O
93	coloplasty	N	O
94	,	N	O
95	JP	N	O
96	,	N	O
97	or	N	O
98	an	N	O
99	SA	N	O
100	in	N	O
101	reconstruction	N	O
102	of	N	O
103	the	N	O
104	lower	N	O
105	gastrointestinal	N	O
106	tract	N	O
107	after	N	O
108	proctectomy	N	O
109	for	N	O
110	low	N	O
111	rectal	N	O
112	cancer	N	O
113	.	N	O

114	A	N	O
115	multicenter	N	O
116	study	N	O
117	enrolled	N	O
118	patients	N	O
119	with	N	O
120	low	N	O
121	rectal	N	O
122	cancer	N	O
123	,	N	O
124	who	N	O
125	were	N	O
126	randomized	N	O
127	intraoperatively	N	O
128	to	N	O
129	coloplasty	N	O
130	(	N	O
131	CP-1	N	O
132	)	N	O
133	or	N	O
134	SA	N	O
135	if	N	O
136	JP	N	O
137	was	N	O
138	not	N	O
139	feasible	N	O
140	,	N	O
141	or	N	O
142	JP	N	O
143	or	N	O
144	coloplasty	N	O
145	(	N	O
146	CP-2	N	O
147	)	N	O
148	if	N	O
149	a	N	O
150	JP	N	O
151	was	N	O
152	feasible	N	O
153	.	N	O

154	Patients	N	O
155	were	N	O
156	followed	N	O
157	for	N	O
158	24	N	O
159	months	N	O
160	with	N	O
161	SF-36	N	O
162	surveys	N	O
163	to	N	O
164	evaluate	N	O
165	the	N	O
166	QOL	N	O
167	.	N	O

168	Bowel	N	O
169	function	N	O
170	was	N	O
171	measured	N	O
172	quantitatively	N	O
173	and	N	O
174	using	N	O
175	Fecal	N	O
176	Incontinence	N	O
177	Severity	N	O
178	Index	N	O
179	(	N	O
180	FISI	N	O
181	)	N	O
182	.	N	O

183	Urinary	N	O
184	function	N	O
185	and	N	O
186	sexual	N	O
187	function	N	O
188	were	N	O
189	also	N	O
190	assessed	N	O
191	.	N	O

192	Three	N	O
193	hundred	N	O
194	sixty-four	N	O
195	patients	N	O
196	were	N	O
197	randomized	N	O
198	.	N	O

199	All	N	O
200	patients	N	O
201	were	N	O
202	evaluated	N	O
203	for	N	O
204	complications	N	O
205	and	N	O
206	recurrence	N	O
207	.	N	O

208	Mean	N	O
209	age	N	O
210	was	N	O
211	60	N	O
212	+/-12	N	O
213	years	N	O
214	,	N	O
215	71	N	O
216	%	N	O
217	were	N	O
218	male	N	O
219	.	N	O

220	Twenty-three	N	I-Premise
221	(	N	I-Premise
222	7.4	N	I-Premise
223	%	N	I-Premise
224	)	N	I-Premise
225	died	N	I-Premise
226	within	N	I-Premise
227	24	N	I-Premise
228	months	N	I-Premise
229	of	N	I-Premise
230	surgery	N	I-Premise
231	.	N	I-Premise

232	No	N	I-Premise
233	significant	N	I-Premise
234	difference	N	I-Premise
235	was	N	I-Premise
236	observed	N	I-Premise
237	in	N	I-Premise
238	the	N	I-Premise
239	complications	N	I-Premise
240	among	N	I-Premise
241	the	N	I-Premise
242	4	N	I-Premise
243	groups	N	I-Premise
244	.	N	I-Premise

245	Two	N	O
246	hundred	N	O
247	ninety-seven	N	O
248	of	N	O
249	364	N	O
250	were	N	O
251	evaluated	N	O
252	for	N	O
253	functional	N	O
254	outcome	N	O
255	at	N	O
256	24	N	O
257	months	N	O
258	.	N	O

259	There	N	I-Premise
260	was	N	I-Premise
261	no	N	I-Premise
262	difference	N	I-Premise
263	in	N	I-Premise
264	bowel	N	I-Premise
265	function	N	I-Premise
266	between	N	I-Premise
267	the	N	I-Premise
268	CP-1	N	I-Premise
269	and	N	I-Premise
270	SA	N	I-Premise
271	groups	N	I-Premise
272	.	N	I-Premise

273	JP	N	I-Premise
274	patients	N	I-Premise
275	had	N	I-Premise
276	fewer	N	I-Premise
277	bowel	N	I-Premise
278	movements	N	I-Premise
279	,	N	I-Premise
280	less	N	I-Premise
281	clustering	N	I-Premise
282	,	N	I-Premise
283	used	N	I-Premise
284	fewer	N	I-Premise
285	pads	N	I-Premise
286	and	N	I-Premise
287	had	N	I-Premise
288	a	N	I-Premise
289	lower	N	I-Premise
290	FISI	N	I-Premise
291	than	N	I-Premise
292	the	N	I-Premise
293	CP-2	N	I-Premise
294	group	N	I-Premise
295	.	N	I-Premise

296	Other	N	I-Premise
297	parameters	N	I-Premise
298	were	N	I-Premise
299	not	N	I-Premise
300	statistically	N	I-Premise
301	different	N	I-Premise
302	.	N	I-Premise

303	QOL	N	I-Premise
304	scores	N	I-Premise
305	at	N	I-Premise
306	24	N	I-Premise
307	months	N	I-Premise
308	were	N	I-Premise
309	similar	N	I-Premise
310	for	N	I-Premise
311	each	N	I-Premise
312	of	N	I-Premise
313	the	N	I-Premise
314	4	N	I-Premise
315	groups	N	I-Premise
316	.	N	I-Premise

317	In	N	I-Claim
318	patients	N	I-Claim
319	undergoing	N	I-Claim
320	a	N	I-Claim
321	restorative	N	I-Claim
322	resection	N	I-Claim
323	for	N	I-Claim
324	low	N	I-Claim
325	rectal	N	I-Claim
326	cancer	N	I-Claim
327	,	N	I-Claim
328	a	N	I-Claim
329	colonic	N	I-Claim
330	JP	N	I-Claim
331	offers	N	I-Claim
332	significant	N	I-Claim
333	advantages	N	I-Claim
334	in	N	I-Claim
335	function	N	I-Claim
336	over	N	I-Claim
337	an	N	I-Claim
338	SA	N	I-Claim
339	or	N	I-Claim
340	a	N	I-Claim
341	coloplasty	N	I-Claim
342	.	N	I-Claim

343	In	N	I-Claim
344	patients	N	I-Claim
345	who	N	I-Claim
346	can	N	I-Claim
347	not	N	I-Claim
348	have	N	I-Claim
349	a	N	I-Claim
350	pouch	N	I-Claim
351	,	N	I-Claim
352	coloplasty	N	I-Claim
353	seems	N	I-Claim
354	not	N	I-Claim
355	to	N	I-Claim
356	improve	N	I-Claim
357	the	N	I-Claim
358	bowel	N	I-Claim
359	function	N	I-Claim
360	of	N	I-Claim
361	patients	N	I-Claim
362	over	N	I-Claim
363	that	N	I-Claim
364	with	N	I-Claim
365	an	N	I-Claim
366	SA	N	I-Claim
367	.	N	I-Claim

1	Cancer-related	N	I-Claim
2	fatigue	N	I-Claim
3	is	N	I-Claim
4	the	N	I-Claim
5	most	N	I-Claim
6	disabling	N	I-Claim
7	symptom	N	I-Claim
8	experienced	N	I-Claim
9	by	N	I-Claim
10	breast	N	I-Claim
11	cancer	N	I-Claim
12	patients	N	I-Claim
13	following	N	I-Claim
14	the	N	I-Claim
15	cancer	N	I-Claim
16	treatment	N	I-Claim
17	.	N	I-Claim

18	The	N	I-Premise
19	positive	N	I-Premise
20	effects	N	I-Premise
21	of	N	I-Premise
22	physical	N	I-Premise
23	activity	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	rehabilitation	N	I-Premise
27	of	N	I-Premise
28	breast	N	I-Premise
29	cancer	N	I-Premise
30	patients	N	I-Premise
31	are	N	I-Premise
32	documented	N	I-Premise
33	in	N	I-Premise
34	several	N	I-Premise
35	studies	N	I-Premise
36	.	N	I-Premise

37	In	N	O
38	a	N	O
39	randomized	N	O
40	controlled	N	O
41	study	N	O
42	the	N	O
43	effects	N	O
44	of	N	O
45	a	N	O
46	structured	N	O
47	physical	N	O
48	training	N	O
49	program	N	O
50	on	N	O
51	fatigue	N	O
52	and	N	O
53	health-related	N	O
54	quality	N	O
55	of	N	O
56	life	N	O
57	were	N	O
58	evaluated	N	O
59	.	N	O

60	63	N	O
61	breast	N	O
62	cancer	N	O
63	patients	N	O
64	with	N	O
65	cancer-related	N	O
66	chronic	N	O
67	fatigue	N	O
68	were	N	O
69	randomized	N	O
70	at	N	O
71	the	N	O
72	beginning	N	O
73	of	N	O
74	the	N	O
75	inpatient	N	O
76	rehabilitation	N	O
77	.	N	O

78	The	N	O
79	control	N	O
80	group	N	O
81	received	N	O
82	the	N	O
83	standard	N	O
84	complex	N	O
85	rehabilitation	N	O
86	program	N	O
87	,	N	O
88	the	N	O
89	intervention	N	O
90	group	N	O
91	a	N	O
92	structured	N	O
93	physical	N	O
94	training	N	O
95	program	N	O
96	and	N	O
97	additional	N	O
98	muscle	N	O
99	strength	N	O
100	and	N	O
101	aerobic	N	O
102	exercises	N	O
103	.	N	O

104	The	N	O
105	effects	N	O
106	of	N	O
107	the	N	O
108	treatment	N	O
109	were	N	O
110	evaluated	N	O
111	by	N	O
112	questionnaires	N	O
113	at	N	O
114	the	N	O
115	start	N	O
116	of	N	O
117	rehabilitation	N	O
118	(	N	O
119	t1	N	O
120	)	N	O
121	,	N	O
122	end	N	O
123	of	N	O
124	rehabilitation	N	O
125	(	N	O
126	t2	N	O
127	)	N	O
128	,	N	O
129	and	N	O
130	3	N	O
131	months	N	O
132	after	N	O
133	t2	N	O
134	(	N	O
135	t3	N	O
136	)	N	O
137	.	N	O

138	Isometric	N	O
139	muscle	N	O
140	strength	N	O
141	and	N	O
142	aerobic	N	O
143	capacity	N	O
144	were	N	O
145	evaluated	N	O
146	at	N	O
147	t1	N	O
148	and	N	O
149	t2	N	O
150	.	N	O

151	There	N	I-Premise
152	was	N	I-Premise
153	an	N	I-Premise
154	improvement	N	I-Premise
155	of	N	I-Premise
156	muscle	N	I-Premise
157	strength	N	I-Premise
158	at	N	I-Premise
159	the	N	I-Premise
160	end	N	I-Premise
161	of	N	I-Premise
162	rehabilitation	N	I-Premise
163	for	N	I-Premise
164	both	N	I-Premise
165	groups	N	I-Premise
166	.	N	I-Premise

167	The	N	I-Premise
168	increase	N	I-Premise
169	from	N	I-Premise
170	t1	N	I-Premise
171	to	N	I-Premise
172	t2	N	I-Premise
173	was	N	I-Premise
174	significantly	N	I-Premise
175	higher	N	I-Premise
176	for	N	I-Premise
177	the	N	I-Premise
178	training	N	I-Premise
179	group	N	I-Premise
180	.	N	I-Premise

181	The	N	I-Premise
182	scores	N	I-Premise
183	for	N	I-Premise
184	global	N	I-Premise
185	quality	N	I-Premise
186	of	N	I-Premise
187	life	N	I-Premise
188	,	N	I-Premise
189	physical	N	I-Premise
190	well-being	N	I-Premise
191	,	N	I-Premise
192	and	N	I-Premise
193	functionality	N	I-Premise
194	increased	N	I-Premise
195	from	N	I-Premise
196	t1	N	I-Premise
197	to	N	I-Premise
198	t2	N	I-Premise
199	,	N	I-Premise
200	but	N	I-Premise
201	further	N	I-Premise
202	improvement	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	follow-up	N	I-Premise
206	(	N	I-Premise
207	t3	N	I-Premise
208	)	N	I-Premise
209	was	N	I-Premise
210	only	N	I-Premise
211	observed	N	I-Premise
212	in	N	I-Premise
213	the	N	I-Premise
214	training	N	I-Premise
215	group	N	I-Premise
216	.	N	I-Premise

217	The	N	I-Premise
218	cancer-related	N	I-Premise
219	fatigue	N	I-Premise
220	was	N	I-Premise
221	significantly	N	I-Premise
222	reduced	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	training	N	I-Premise
226	group	N	I-Premise
227	from	N	I-Premise
228	t1	N	I-Premise
229	to	N	I-Premise
230	t3	N	I-Premise
231	,	N	I-Premise
232	however	N	I-Premise
233	,	N	I-Premise
234	not	N	I-Premise
235	in	N	I-Premise
236	the	N	I-Premise
237	control	N	I-Premise
238	group	N	I-Premise
239	.	N	I-Premise

240	Structured	N	I-Claim
241	physical	N	I-Claim
242	training	N	I-Claim
243	programs	N	I-Claim
244	initiated	N	I-Claim
245	during	N	I-Claim
246	inpatient	N	I-Claim
247	rehabilitation	N	I-Claim
248	and	N	I-Claim
249	continuously	N	I-Claim
250	practiced	N	I-Claim
251	in	N	I-Claim
252	the	N	I-Claim
253	time	N	I-Claim
254	thereafter	N	I-Claim
255	can	N	I-Claim
256	improve	N	I-Claim
257	symptoms	N	I-Claim
258	of	N	I-Claim
259	chronic	N	I-Claim
260	fatigue	N	I-Claim
261	and	N	I-Claim
262	quality	N	I-Claim
263	of	N	I-Claim
264	life	N	I-Claim
265	in	N	I-Claim
266	breast	N	I-Claim
267	cancer	N	I-Claim
268	patients	N	I-Claim
269	.	N	I-Claim

1	Patients	N	I-Claim
2	receiving	N	I-Claim
3	chemotherapy	N	I-Claim
4	for	N	I-Claim
5	cancer	N	I-Claim
6	often	N	I-Claim
7	develop	N	I-Claim
8	anemia	N	I-Claim
9	,	N	I-Claim
10	which	N	I-Claim
11	can	N	I-Claim
12	contribute	N	I-Claim
13	to	N	I-Claim
14	increased	N	I-Claim
15	morbidity	N	I-Claim
16	and	N	I-Claim
17	reduced	N	I-Claim
18	quality	N	I-Claim
19	of	N	I-Claim
20	life	N	I-Claim
21	(	N	I-Claim
22	QOL	N	I-Claim
23	)	N	I-Claim
24	.	N	I-Claim

25	Chemotherapy-induced	N	I-Claim
26	anemia	N	I-Claim
27	can	N	I-Claim
28	be	N	I-Claim
29	successfully	N	I-Claim
30	treated	N	I-Claim
31	using	N	I-Claim
32	recombinant	N	I-Claim
33	human	N	I-Claim
34	erythropoietin	N	I-Claim
35	(	N	I-Claim
36	rHuEPO	N	I-Claim
37	)	N	I-Claim
38	.	N	I-Claim

39	To	N	O
40	demonstrate	N	O
41	the	N	O
42	effectiveness	N	O
43	of	N	O
44	once-weekly	N	O
45	(	N	O
46	QW	N	O
47	)	N	O
48	rHuEPO	N	O
49	dosing	N	O
50	to	N	O
51	effect	N	O
52	improved	N	O
53	hemoglobin	N	O
54	levels	N	O
55	,	N	O
56	decreased	N	O
57	transfusion	N	O
58	use	N	O
59	,	N	O
60	and	N	O
61	improved	N	O
62	functional	N	O
63	outcomes	N	O
64	and	N	O
65	QOL	N	O
66	in	N	O
67	pediatric	N	O
68	leukemic	N	O
69	patients	N	O
70	(	N	O
71	ALL	N	O
72	)	N	O
73	receiving	N	O
74	maintenance	N	O
75	chemotherapy	N	O
76	.	N	O

77	This	N	O
78	was	N	O
79	a	N	O
80	prospective	N	O
81	randomized	N	O
82	,	N	O
83	single-center	N	O
84	,	N	O
85	open-label	N	O
86	,	N	O
87	12-week	N	O
88	case-control	N	O
89	study	N	O
90	of	N	O
91	epoetin	N	O
92	alfa	N	O
93	in	N	O
94	pediatric	N	O
95	patients	N	O
96	with	N	O
97	acute	N	O
98	lymphoblastic	N	O
99	leukemia	N	O
100	(	N	O
101	ALL	N	O
102	)	N	O
103	in	N	O
104	remission	N	O
105	receiving	N	O
106	maintenance	N	O
107	chemotherapy	N	O
108	.	N	O

109	Sixty	N	O
110	patients	N	O
111	were	N	O
112	randomly	N	O
113	assigned	N	O
114	to	N	O
115	receive	N	O
116	either	N	O
117	epoetin	N	O
118	alfa	N	O
119	(	N	O
120	rHuEPO	N	O
121	group	N	O
122	=	N	O
123	30	N	O
124	cases	N	O
125	,	N	O
126	17	N	O
127	males	N	O
128	and	N	O
129	13	N	O
130	females	N	O
131	,	N	O
132	age	N	O
133	;	N	O
134	6.8	N	O
135	+/-	N	O
136	2.33	N	O
137	years	N	O
138	)	N	O
139	,	N	O
140	or	N	O
141	no	N	O
142	epoetin	N	O
143	alfa	N	O
144	(	N	O
145	control	N	O
146	group	N	O
147	=	N	O
148	30	N	O
149	cases	N	O
150	,	N	O
151	16	N	O
152	males	N	O
153	and	N	O
154	14	N	O
155	females	N	O
156	,	N	O
157	age	N	O
158	;	N	O
159	6.76	N	O
160	+/-	N	O
161	2.28	N	O
162	years	N	O
163	)	N	O
164	.	N	O

165	Both	N	O
166	groups	N	O
167	were	N	O
168	matched	N	O
169	as	N	O
170	regard	N	O
171	age	N	O
172	,	N	O
173	sex	N	O
174	,	N	O
175	baseline	N	O
176	Hb	N	O
177	concentration	N	O
178	,	N	O
179	remission	N	O
180	state	N	O
181	,	N	O
182	chemotherapy	N	O
183	regimen	N	O
184	,	N	O
185	numbers	N	O
186	and	N	O
187	amount	N	O
188	of	N	O
189	blood	N	O
190	transfusion	N	O
191	,	N	O
192	and	N	O
193	leukemia	N	O
194	state	N	O
195	(	N	O
196	both	N	O
197	were	N	O
198	low	N	O
199	and	N	O
200	standard	N	O
201	risk	N	O
202	)	N	O
203	.	N	O

204	Epoetin	N	O
205	alfa	N	O
206	was	N	O
207	administered	N	O
208	at	N	O
209	a	N	O
210	dose	N	O
211	of	N	O
212	450	N	O
213	IU/kg	N	O
214	,	N	O
215	once	N	O
216	weekly	N	O
217	,	N	O
218	subcutaneously	N	O
219	(	N	O
220	s.c.	N	O
221	)	N	O
222	for	N	O
223	12	N	O
224	consecutive	N	O
225	weeks	N	O
226	.	N	O

227	Endpoints	N	O
228	were	N	O
229	changes	N	O
230	in	N	O
231	hematologic	N	O
232	and	N	O
233	QOL	N	O
234	parameters	N	O
235	.	N	O

236	Among	N	I-Premise
237	the	N	I-Premise
238	30	N	I-Premise
239	patients	N	I-Premise
240	evaluable	N	I-Premise
241	for	N	I-Premise
242	hematologic	N	I-Premise
243	response	N	I-Premise
244	,	N	I-Premise
245	the	N	I-Premise
246	mean	N	I-Premise
247	increase	N	I-Premise
248	in	N	I-Premise
249	Hb	N	I-Premise
250	from	N	I-Premise
251	baseline	N	I-Premise
252	to	N	I-Premise
253	time	N	I-Premise
254	of	N	I-Premise
255	final	N	I-Premise
256	evaluation	N	I-Premise
257	was	N	I-Premise
258	3.08	N	I-Premise
259	+/-	N	I-Premise
260	1.48	N	I-Premise
261	g/dl	N	I-Premise
262	(	N	I-Premise
263	p	N	I-Premise
264	<	N	I-Premise
265	0.001	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	An	N	I-Premise
269	increase	N	I-Premise
270	in	N	I-Premise
271	Hb	N	I-Premise
272	of	N	I-Premise
273	>	N	I-Premise
274	or	N	I-Premise
275	=	N	I-Premise
276	2	N	I-Premise
277	g/dl	N	I-Premise
278	,	N	I-Premise
279	in	N	I-Premise
280	the	N	I-Premise
281	absence	N	I-Premise
282	of	N	I-Premise
283	blood	N	I-Premise
284	transfusion	N	I-Premise
285	,	N	I-Premise
286	occurred	N	I-Premise
287	in	N	I-Premise
288	70	N	I-Premise
289	%	N	I-Premise
290	of	N	I-Premise
291	patients	N	I-Premise
292	(	N	I-Premise
293	21	N	I-Premise
294	of	N	I-Premise
295	30	N	I-Premise
296	patients	N	I-Premise
297	)	N	I-Premise
298	who	N	I-Premise
299	were	N	I-Premise
300	on	N	I-Premise
301	the	N	I-Premise
302	study	N	I-Premise
303	for	N	I-Premise
304	>	N	I-Premise
305	or	N	I-Premise
306	=	N	I-Premise
307	30	N	I-Premise
308	days	N	I-Premise
309	.	N	I-Premise

310	The	N	I-Premise
311	overall	N	I-Premise
312	response	N	I-Premise
313	rate	N	I-Premise
314	(	N	I-Premise
315	Hb	N	I-Premise
316	increase	N	I-Premise
317	>	N	I-Premise
318	or	N	I-Premise
319	=	N	I-Premise
320	2	N	I-Premise
321	g/dl	N	I-Premise
322	or	N	I-Premise
323	Hb	N	I-Premise
324	>	N	I-Premise
325	or	N	I-Premise
326	=	N	I-Premise
327	12	N	I-Premise
328	g/dl	N	I-Premise
329	in	N	I-Premise
330	the	N	I-Premise
331	absence	N	I-Premise
332	of	N	I-Premise
333	blood	N	I-Premise
334	transfusion	N	I-Premise
335	)	N	I-Premise
336	was	N	I-Premise
337	90	N	I-Premise
338	%	N	I-Premise
339	(	N	I-Premise
340	27	N	I-Premise
341	of	N	I-Premise
342	30	N	I-Premise
343	patients	N	I-Premise
344	)	N	I-Premise
345	.	N	I-Premise

346	In	N	I-Premise
347	30	N	I-Premise
348	patients	N	I-Premise
349	who	N	I-Premise
350	were	N	I-Premise
351	evaluable	N	I-Premise
352	for	N	I-Premise
353	QOL	N	I-Premise
354	assessment	N	I-Premise
355	,	N	I-Premise
356	epoetin-alpha	N	I-Premise
357	therapy	N	I-Premise
358	was	N	I-Premise
359	found	N	I-Premise
360	to	N	I-Premise
361	significantly	N	I-Premise
362	(	N	I-Premise
363	p	N	I-Premise
364	<	N	I-Premise
365	0.001	N	I-Premise
366	)	N	I-Premise
367	improve	N	I-Premise
368	mean	N	I-Premise
369	cancer	N	I-Premise
370	linear	N	I-Premise
371	analog	N	I-Premise
372	scale	N	I-Premise
373	(	N	I-Premise
374	CLAS	N	I-Premise
375	)	N	I-Premise
376	scores	N	I-Premise
377	for	N	I-Premise
378	energy	N	I-Premise
379	level	N	I-Premise
380	,	N	I-Premise
381	ability	N	I-Premise
382	to	N	I-Premise
383	perform	N	I-Premise
384	daily	N	I-Premise
385	activity	N	I-Premise
386	,	N	I-Premise
387	and	N	I-Premise
388	overall	N	I-Premise
389	QOL	N	I-Premise
390	from	N	I-Premise
391	baseline	N	I-Premise
392	to	N	I-Premise
393	the	N	I-Premise
394	time	N	I-Premise
395	of	N	I-Premise
396	final	N	I-Premise
397	evaluation	N	I-Premise
398	.	N	I-Premise

399	QW	N	I-Premise
400	epoetin-alpha	N	I-Premise
401	was	N	I-Premise
402	found	N	I-Premise
403	to	N	I-Premise
404	be	N	I-Premise
405	well	N	I-Premise
406	tolerated	N	I-Premise
407	.	N	I-Premise

408	Treatment	N	I-Claim
409	with	N	I-Claim
410	QW	N	I-Claim
411	epoetin-alpha	N	I-Claim
412	was	N	I-Claim
413	found	N	I-Claim
414	to	N	I-Claim
415	increase	N	I-Claim
416	Hb	N	I-Claim
417	levels	N	I-Claim
418	,	N	I-Claim
419	decrease	N	I-Claim
420	transfusion	N	I-Claim
421	requirement	N	I-Claim
422	,	N	I-Claim
423	and	N	I-Claim
424	improve	N	I-Claim
425	functional	N	I-Claim
426	status	N	I-Claim
427	and	N	I-Claim
428	QOL	N	I-Claim
429	in	N	I-Claim
430	anemic	N	I-Claim
431	patients	N	I-Claim
432	with	N	I-Claim
433	ALL	N	I-Claim
434	in	N	I-Claim
435	maintenance	N	I-Claim
436	receiving	N	I-Claim
437	chemotherapy	N	I-Claim
438	.	N	I-Claim

439	The	N	I-Claim
440	once-weekly	N	I-Claim
441	schedule	N	I-Claim
442	is	N	I-Claim
443	convenient	N	I-Claim
444	,	N	I-Claim
445	safe	N	I-Claim
446	,	N	I-Claim
447	and	N	I-Claim
448	may	N	I-Claim
449	reduce	N	I-Claim
450	the	N	I-Claim
451	burden	N	I-Claim
452	on	N	I-Claim
453	patients	N	I-Claim
454	,	N	I-Claim
455	parents	N	I-Claim
456	,	N	I-Claim
457	and	N	I-Claim
458	their	N	I-Claim
459	caregivers	N	I-Claim
460	by	N	I-Claim
461	reducing	N	I-Claim
462	the	N	I-Claim
463	number	N	I-Claim
464	of	N	I-Claim
465	visits	N	I-Claim
466	to	N	I-Claim
467	the	N	I-Claim
468	clinic	N	I-Claim
469	.	N	I-Claim

1	This	N	O
2	study	N	O
3	sought	N	O
4	to	N	O
5	continue	N	O
6	research	N	O
7	on	N	O
8	psychosocial	N	O
9	interventions	N	O
10	for	N	O
11	patients	N	O
12	being	N	O
13	treated	N	O
14	with	N	O
15	radiation	N	O
16	therapy	N	O
17	across	N	O
18	multiple	N	O
19	centers	N	O
20	and	N	O
21	to	N	O
22	replicate	N	O
23	positive	N	O
24	findings	N	O
25	of	N	O
26	a	N	O
27	single-center	N	O
28	study	N	O
29	of	N	O
30	patients	N	O
31	being	N	O
32	treated	N	O
33	with	N	O
34	chemotherapy	N	O
35	.	N	O

36	The	N	O
37	primary	N	O
38	objective	N	O
39	of	N	O
40	this	N	O
41	study	N	O
42	was	N	O
43	to	N	O
44	determine	N	O
45	if	N	O
46	a	N	O
47	stress	N	O
48	management	N	O
49	intervention	N	O
50	was	N	O
51	effective	N	O
52	in	N	O
53	improving	N	O
54	quality	N	O
55	of	N	O
56	life	N	O
57	and	N	O
58	decreasing	N	O
59	psychological	N	O
60	distress	N	O
61	in	N	O
62	patients	N	O
63	undergoing	N	O
64	radiotherapy	N	O
65	for	N	O
66	cancer	N	O
67	.	N	O

68	A	N	O
69	total	N	O
70	of	N	O
71	310	N	O
72	patients	N	O
73	about	N	O
74	to	N	O
75	begin	N	O
76	radiotherapy	N	O
77	treatment	N	O
78	were	N	O
79	randomly	N	O
80	assigned	N	O
81	to	N	O
82	receive	N	O
83	usual	N	O
84	care	N	O
85	only	N	O
86	or	N	O
87	self-administered	N	O
88	stress	N	O
89	management	N	O
90	training	N	O
91	.	N	O

92	Quality-of-life	N	O
93	assessments	N	O
94	occurred	N	O
95	at	N	O
96	baseline	N	O
97	and	N	O
98	for	N	O
99	3	N	O
100	weeks	N	O
101	after	N	O
102	the	N	O
103	beginning	N	O
104	of	N	O
105	radiotherapy	N	O
106	treatment	N	O
107	.	N	O

108	Overall	N	I-Premise
109	,	N	I-Premise
110	patients	N	I-Premise
111	assigned	N	I-Premise
112	to	N	I-Premise
113	receive	N	I-Premise
114	stress	N	I-Premise
115	management	N	I-Premise
116	training	N	I-Premise
117	did	N	I-Premise
118	not	N	I-Premise
119	report	N	I-Premise
120	significantly	N	I-Premise
121	less	N	I-Premise
122	psychological	N	I-Premise
123	distress	N	I-Premise
124	on	N	I-Premise
125	the	N	I-Premise
126	Medical	N	I-Premise
127	Outcomes	N	I-Premise
128	Study	N	I-Premise
129	36-Item	N	I-Premise
130	Short	N	I-Premise
131	Form	N	I-Premise
132	(	N	I-Premise
133	SF-36	N	I-Premise
134	)	N	I-Premise
135	Mental	N	I-Premise
136	Component	N	I-Premise
137	Summary	N	I-Premise
138	Scale	N	I-Premise
139	than	N	I-Premise
140	did	N	I-Premise
141	those	N	I-Premise
142	assigned	N	I-Premise
143	to	N	I-Premise
144	usual	N	I-Premise
145	care	N	I-Premise
146	.	N	I-Premise

147	When	N	O
148	divided	N	O
149	into	N	O
150	subgroups	N	O
151	based	N	O
152	on	N	O
153	the	N	O
154	SF-36	N	O
155	Mental	N	O
156	Component	N	O
157	Summary	N	O
158	Scale	N	O
159	scores	N	O
160	immediately	N	O
161	after	N	O
162	their	N	O
163	first	N	O
164	radiotherapy	N	O
165	treatment	N	O
166	,	N	O
167	patients	N	I-Premise
168	with	N	I-Premise
169	above-average	N	I-Premise
170	levels	N	I-Premise
171	of	N	I-Premise
172	psychological	N	I-Premise
173	distress	N	I-Premise
174	(	N	I-Premise
175	scores	N	I-Premise
176	<	N	I-Premise
177	or	N	I-Premise
178	=	N	I-Premise
179	50	N	I-Premise
180	)	N	I-Premise
181	who	N	I-Premise
182	were	N	I-Premise
183	randomly	N	I-Premise
184	assigned	N	I-Premise
185	to	N	I-Premise
186	the	N	I-Premise
187	intervention	N	I-Premise
188	condition	N	I-Premise
189	reported	N	I-Premise
190	significant	N	I-Premise
191	improvement	N	I-Premise
192	in	N	I-Premise
193	their	N	I-Premise
194	distress	N	I-Premise
195	compared	N	I-Premise
196	with	N	I-Premise
197	those	N	I-Premise
198	assigned	N	I-Premise
199	to	N	I-Premise
200	usual	N	I-Premise
201	care	N	I-Premise
202	only	N	I-Premise
203	on	N	I-Premise
204	the	N	I-Premise
205	SF-36	N	I-Premise
206	Mental	N	I-Premise
207	Health	N	I-Premise
208	Subscale	N	I-Premise
209	and	N	I-Premise
210	the	N	I-Premise
211	Center	N	I-Premise
212	for	N	I-Premise
213	Epidemiologic	N	I-Premise
214	Studies	N	I-Premise
215	Depression	N	I-Premise
216	Scale	N	I-Premise
217	.	N	I-Premise

218	This	N	I-Claim
219	study	N	I-Claim
220	found	N	I-Claim
221	that	N	I-Claim
222	self-administered	N	I-Claim
223	stress	N	I-Claim
224	management	N	I-Claim
225	training	N	I-Claim
226	is	N	I-Claim
227	effective	N	I-Claim
228	only	N	I-Claim
229	in	N	I-Claim
230	those	N	I-Claim
231	radiotherapy	N	I-Claim
232	patients	N	I-Claim
233	with	N	I-Claim
234	initially	N	I-Claim
235	higher	N	I-Claim
236	levels	N	I-Claim
237	of	N	I-Claim
238	psychological	N	I-Claim
239	distress	N	I-Claim
240	.	N	I-Claim

241	Additional	N	I-Claim
242	research	N	I-Claim
243	should	N	I-Claim
244	examine	N	I-Claim
245	the	N	I-Claim
246	benefits	N	I-Claim
247	of	N	I-Claim
248	stress	N	I-Claim
249	management	N	I-Claim
250	training	N	I-Claim
251	targeted	N	I-Claim
252	specifically	N	I-Claim
253	to	N	I-Claim
254	patients	N	I-Claim
255	experiencing	N	I-Claim
256	heightened	N	I-Claim
257	distress	N	I-Claim
258	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	whether	N	O
4	3-month	N	O
5	administration	N	O
6	of	N	O
7	CDB-2914	N	O
8	,	N	O
9	a	N	O
10	selective	N	O
11	progesterone	N	O
12	receptor	N	O
13	modulator	N	O
14	,	N	O
15	reduces	N	O
16	leiomyoma	N	O
17	size	N	O
18	and	N	O
19	symptoms	N	O
20	.	N	O

21	Premenopausal	N	O
22	women	N	O
23	with	N	O
24	symptomatic	N	O
25	uterine	N	O
26	leiomyomata	N	O
27	were	N	O
28	randomly	N	O
29	assigned	N	O
30	to	N	O
31	CDB-2914	N	O
32	at	N	O
33	10	N	O
34	mg	N	O
35	(	N	O
36	T1	N	O
37	)	N	O
38	or	N	O
39	20	N	O
40	mg	N	O
41	(	N	O
42	T2	N	O
43	)	N	O
44	daily	N	O
45	or	N	O
46	to	N	O
47	placebo	N	O
48	(	N	O
49	PLC	N	O
50	)	N	O
51	for	N	O
52	3	N	O
53	cycles	N	O
54	or	N	O
55	90-102	N	O
56	days	N	O
57	if	N	O
58	no	N	O
59	menses	N	O
60	occurred	N	O
61	.	N	O

62	The	N	O
63	primary	N	O
64	outcome	N	O
65	was	N	O
66	leiomyoma	N	O
67	volume	N	O
68	change	N	O
69	determined	N	O
70	by	N	O
71	magnetic	N	O
72	resonance	N	O
73	imaging	N	O
74	at	N	O
75	study	N	O
76	entry	N	O
77	and	N	O
78	within	N	O
79	2	N	O
80	weeks	N	O
81	of	N	O
82	hysterectomy	N	O
83	.	N	O

84	Secondary	N	O
85	outcomes	N	O
86	included	N	O
87	the	N	O
88	proportion	N	O
89	of	N	O
90	amenorrhea	N	O
91	,	N	O
92	change	N	O
93	in	N	O
94	hemoglobin	N	O
95	and	N	O
96	hematocrit	N	O
97	,	N	O
98	ovulation	N	O
99	inhibition	N	O
100	,	N	O
101	and	N	O
102	quality-of-life	N	O
103	assessment	N	O
104	.	N	O

105	Twenty-two	N	O
106	patients	N	O
107	were	N	O
108	allocated	N	O
109	,	N	O
110	and	N	O
111	18	N	O
112	completed	N	O
113	the	N	O
114	trial	N	O
115	.	N	O

116	Age	N	O
117	and	N	O
118	body	N	O
119	mass	N	O
120	index	N	O
121	were	N	O
122	similar	N	O
123	among	N	O
124	groups	N	O
125	.	N	O

126	Leiomyoma	N	O
127	volume	N	O
128	was	N	O
129	significantly	N	O
130	reduced	N	O
131	with	N	O
132	CDB-2914	N	O
133	administration	N	O
134	(	N	O
135	PLC	N	O
136	6	N	O
137	%	N	O
138	;	N	O
139	CDB-2914	N	O
140	-29	N	O
141	%	N	O
142	;	N	O
143	P=.01	N	O
144	)	N	O
145	,	N	O
146	decreasing	N	O
147	36	N	O
148	%	N	O
149	and	N	O
150	21	N	O
151	%	N	O
152	in	N	O
153	the	N	O
154	T1	N	O
155	and	N	O
156	T2	N	O
157	groups	N	O
158	,	N	O
159	respectively	N	O
160	.	N	O

161	During	N	O
162	treatment	N	O
163	,	N	O
164	hemoglobin	N	O
165	was	N	O
166	unchanged	N	O
167	,	N	O
168	and	N	O
169	the	N	O
170	median	N	O
171	estradiol	N	O
172	was	N	O
173	greater	N	O
174	than	N	O
175	50	N	O
176	pg/mL	N	O
177	in	N	O
178	all	N	O
179	groups	N	O
180	.	N	O

181	CDB-2914	N	O
182	eliminated	N	O
183	menstrual	N	O
184	bleeding	N	O
185	and	N	O
186	inhibited	N	O
187	ovulation	N	O
188	(	N	O
189	%	N	O
190	ovulatory	N	O
191	cycles	N	O
192	:	N	O
193	CDB-2914	N	O
194	,	N	O
195	20	N	O
196	%	N	O
197	;	N	O
198	PLC	N	O
199	,	N	O
200	83	N	O
201	%	N	O
202	;	N	O
203	P=.001	N	O
204	)	N	O
205	.	N	O

206	CDB-2914	N	O
207	improved	N	O
208	the	N	O
209	concern	N	O
210	scores	N	O
211	of	N	O
212	the	N	O
213	uterine	N	O
214	leiomyoma	N	O
215	symptom	N	O
216	quality-of-life	N	O
217	subscale	N	O
218	(	N	O
219	P=.04	N	O
220	)	N	O
221	.	N	O

222	One	N	O
223	CDB-2914	N	O
224	woman	N	O
225	developed	N	O
226	endometrial	N	O
227	cystic	N	O
228	hyperplasia	N	O
229	without	N	O
230	evidence	N	O
231	of	N	O
232	atypia	N	O
233	.	N	O

234	No	N	I-Premise
235	serious	N	I-Premise
236	adverse	N	I-Premise
237	events	N	I-Premise
238	were	N	I-Premise
239	reported	N	I-Premise
240	.	N	I-Premise

241	Compared	N	I-Premise
242	with	N	I-Premise
243	PLC	N	I-Premise
244	,	N	I-Premise
245	CDB-2914	N	I-Premise
246	significantly	N	I-Premise
247	reduced	N	I-Premise
248	leiomyoma	N	I-Premise
249	volume	N	I-Premise
250	after	N	I-Premise
251	three	N	I-Premise
252	cycles	N	I-Premise
253	,	N	I-Premise
254	or	N	I-Premise
255	90-102	N	I-Premise
256	days	N	I-Premise
257	.	N	I-Premise

258	CDB-2914	N	I-Premise
259	treatment	N	I-Premise
260	resulted	N	I-Premise
261	in	N	I-Premise
262	improvements	N	I-Premise
263	in	N	I-Premise
264	the	N	I-Premise
265	concern	N	I-Premise
266	subscale	N	I-Premise
267	of	N	I-Premise
268	the	N	I-Premise
269	Uterine	N	I-Premise
270	Fibroid	N	I-Premise
271	Symptom	N	I-Premise
272	Quality	N	I-Premise
273	of	N	I-Premise
274	Life	N	I-Premise
275	assessment	N	I-Premise
276	.	N	I-Premise

277	In	N	I-Claim
278	this	N	I-Claim
279	small	N	I-Claim
280	study	N	I-Claim
281	,	N	I-Claim
282	CDB-2914	N	I-Claim
283	was	N	I-Claim
284	well-tolerated	N	I-Claim
285	without	N	I-Claim
286	serious	N	I-Claim
287	adverse	N	I-Claim
288	events	N	I-Claim
289	.	N	I-Claim

290	Thus	N	I-Claim
291	,	N	I-Claim
292	there	N	I-Claim
293	may	N	I-Claim
294	be	N	I-Claim
295	a	N	I-Claim
296	role	N	I-Claim
297	for	N	I-Claim
298	CDB-2914	N	I-Claim
299	in	N	I-Claim
300	the	N	I-Claim
301	treatment	N	I-Claim
302	of	N	I-Claim
303	leiomyomata	N	I-Claim
304	.	N	I-Claim

1	Shoulder	N	O
2	pain	N	O
3	and	N	O
4	disability	N	O
5	are	N	O
6	well	N	O
7	recognized	N	O
8	complications	N	O
9	associated	N	O
10	with	N	O
11	surgery	N	O
12	for	N	O
13	head	N	O
14	and	N	O
15	neck	N	O
16	cancer	N	O
17	.	N	O

18	This	N	O
19	study	N	O
20	was	N	O
21	designed	N	O
22	to	N	O
23	examine	N	O
24	the	N	O
25	effects	N	O
26	of	N	O
27	progressive	N	O
28	resistance	N	O
29	exercise	N	O
30	training	N	O
31	(	N	O
32	PRET	N	O
33	)	N	O
34	on	N	O
35	upper	N	O
36	extremity	N	O
37	pain	N	O
38	and	N	O
39	dysfunction	N	O
40	in	N	O
41	postsurgical	N	O
42	head	N	O
43	and	N	O
44	neck	N	O
45	cancer	N	O
46	survivors	N	O
47	.	N	O

48	Fifty-two	N	O
49	head	N	O
50	and	N	O
51	neck	N	O
52	cancer	N	O
53	survivors	N	O
54	were	N	O
55	assigned	N	O
56	randomly	N	O
57	to	N	O
58	PRET	N	O
59	(	N	O
60	n	N	O
61	=	N	O
62	27	N	O
63	)	N	O
64	or	N	O
65	a	N	O
66	standardized	N	O
67	therapeutic	N	O
68	exercise	N	O
69	protocol	N	O
70	(	N	O
71	TP	N	O
72	)	N	O
73	(	N	O
74	n	N	O
75	=	N	O
76	25	N	O
77	)	N	O
78	for	N	O
79	12	N	O
80	weeks	N	O
81	.	N	O

82	The	N	O
83	primary	N	O
84	endpoint	N	O
85	was	N	O
86	change	N	O
87	in	N	O
88	patient-rated	N	O
89	shoulder	N	O
90	pain	N	O
91	and	N	O
92	disability	N	O
93	from	N	O
94	baseline	N	O
95	to	N	O
96	postintervention	N	O
97	.	N	O

98	Secondary	N	O
99	endpoints	N	O
100	were	N	O
101	upper	N	O
102	extremity	N	O
103	strength	N	O
104	and	N	O
105	endurance	N	O
106	,	N	O
107	range	N	O
108	of	N	O
109	motion	N	O
110	,	N	O
111	fatigue	N	O
112	,	N	O
113	and	N	O
114	quality	N	O
115	of	N	O
116	life	N	O
117	.	N	O

118	Follow-up	N	O
119	assessment	N	O
120	for	N	O
121	the	N	O
122	primary	N	O
123	outcome	N	O
124	was	N	O
125	92	N	O
126	%	N	O
127	,	N	O
128	and	N	O
129	adherence	N	O
130	to	N	O
131	the	N	O
132	supervised	N	O
133	PRET	N	O
134	and	N	O
135	TP	N	O
136	programs	N	O
137	were	N	O
138	95	N	O
139	%	N	O
140	and	N	O
141	87	N	O
142	%	N	O
143	,	N	O
144	respectively	N	O
145	.	N	O

146	On	N	I-Premise
147	the	N	I-Premise
148	basis	N	I-Premise
149	of	N	I-Premise
150	intention-to-treat	N	I-Premise
151	analyses	N	I-Premise
152	,	N	I-Premise
153	PRET	N	I-Premise
154	was	N	I-Premise
155	superior	N	I-Premise
156	to	N	I-Premise
157	TP	N	I-Premise
158	for	N	I-Premise
159	improving	N	I-Premise
160	shoulder	N	I-Premise
161	pain	N	I-Premise
162	and	N	I-Premise
163	disability	N	I-Premise
164	(	N	I-Premise
165	-9.6	N	I-Premise
166	;	N	I-Premise
167	95	N	I-Premise
168	%	N	I-Premise
169	confidence	N	I-Premise
170	interval	N	I-Premise
171	[	N	I-Premise
172	95	N	I-Premise
173	%	N	I-Premise
174	CI	N	I-Premise
175	]	N	I-Premise
176	,	N	I-Premise
177	-16.4	N	I-Premise
178	to	N	I-Premise
179	-4.5	N	I-Premise
180	;	N	I-Premise
181	P	N	I-Premise
182	=	N	I-Premise
183	.001	N	I-Premise
184	)	N	I-Premise
185	,	N	I-Premise
186	upper	N	I-Premise
187	extremity	N	I-Premise
188	strength	N	I-Premise
189	(	N	I-Premise
190	+10.8	N	I-Premise
191	kg	N	I-Premise
192	;	N	I-Premise
193	95	N	I-Premise
194	%	N	I-Premise
195	CI	N	I-Premise
196	,	N	I-Premise
197	5.4-16.2	N	I-Premise
198	kg	N	I-Premise
199	;	N	I-Premise
200	P	N	I-Premise
201	<	N	I-Premise
202	.001	N	I-Premise
203	)	N	I-Premise
204	,	N	I-Premise
205	and	N	I-Premise
206	upper	N	I-Premise
207	extremity	N	I-Premise
208	endurance	N	I-Premise
209	(	N	I-Premise
210	+194	N	I-Premise
211	repetitions	N	I-Premise
212	x	N	I-Premise
213	kg	N	I-Premise
214	;	N	I-Premise
215	95	N	I-Premise
216	%	N	I-Premise
217	CI	N	I-Premise
218	,	N	I-Premise
219	10-378	N	I-Premise
220	repetitions	N	I-Premise
221	x	N	I-Premise
222	kg	N	I-Premise
223	;	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.039	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	Changes	N	I-Premise
230	in	N	I-Premise
231	neck	N	I-Premise
232	dissection	N	I-Premise
233	impairment	N	I-Premise
234	,	N	I-Premise
235	fatigue	N	I-Premise
236	,	N	I-Premise
237	and	N	I-Premise
238	quality	N	I-Premise
239	of	N	I-Premise
240	life	N	I-Premise
241	favored	N	I-Premise
242	the	N	I-Premise
243	PRET	N	I-Premise
244	group	N	I-Premise
245	but	N	I-Premise
246	did	N	I-Premise
247	not	N	I-Premise
248	reach	N	I-Premise
249	statistical	N	I-Premise
250	significance	N	I-Premise
251	.	N	I-Premise

252	The	N	I-Premise
253	PRET	N	I-Premise
254	program	N	I-Premise
255	significantly	N	I-Premise
256	reduced	N	I-Premise
257	shoulder	N	I-Premise
258	pain	N	I-Premise
259	and	N	I-Premise
260	disability	N	I-Premise
261	and	N	I-Premise
262	improved	N	I-Premise
263	upper	N	I-Premise
264	extremity	N	I-Premise
265	muscular	N	I-Premise
266	strength	N	I-Premise
267	and	N	I-Premise
268	endurance	N	I-Premise
269	in	N	I-Premise
270	head	N	I-Premise
271	and	N	I-Premise
272	neck	N	I-Premise
273	cancer	N	I-Premise
274	survivors	N	I-Premise
275	who	N	I-Premise
276	had	N	I-Premise
277	shoulder	N	I-Premise
278	dysfunction	N	I-Premise
279	because	N	I-Premise
280	of	N	I-Premise
281	spinal	N	I-Premise
282	accessory	N	I-Premise
283	nerve	N	I-Premise
284	damage	N	I-Premise
285	.	N	I-Premise

286	Clinicians	N	I-Claim
287	should	N	I-Claim
288	consider	N	I-Claim
289	the	N	I-Claim
290	addition	N	I-Claim
291	of	N	I-Claim
292	PRET	N	I-Claim
293	in	N	I-Claim
294	the	N	I-Claim
295	rehabilitation	N	I-Claim
296	of	N	I-Claim
297	postsurgical	N	I-Claim
298	head	N	I-Claim
299	and	N	I-Claim
300	neck	N	I-Claim
301	cancer	N	I-Claim
302	survivors	N	I-Claim
303	.	N	I-Claim

1	Debilitating	N	I-MajorClaim
2	hot	N	I-MajorClaim
3	flushes	N	I-MajorClaim
4	and	N	I-MajorClaim
5	sleep	N	I-MajorClaim
6	dysfunction	N	I-MajorClaim
7	often	N	I-MajorClaim
8	affect	N	I-MajorClaim
9	survivors	N	I-MajorClaim
10	of	N	I-MajorClaim
11	breast	N	I-MajorClaim
12	cancer	N	I-MajorClaim
13	,	N	I-MajorClaim
14	most	N	I-MajorClaim
15	notably	N	I-MajorClaim
16	in	N	I-MajorClaim
17	those	N	I-MajorClaim
18	taking	N	I-MajorClaim
19	anti-oestrogen	N	I-MajorClaim
20	medications	N	I-MajorClaim
21	.	N	I-MajorClaim

22	Conventional	N	I-MajorClaim
23	treatments	N	I-MajorClaim
24	have	N	I-MajorClaim
25	been	N	I-MajorClaim
26	only	N	I-MajorClaim
27	partially	N	I-MajorClaim
28	effective	N	I-MajorClaim
29	in	N	I-MajorClaim
30	diminishing	N	I-MajorClaim
31	these	N	I-MajorClaim
32	issues	N	I-MajorClaim
33	,	N	I-MajorClaim
34	and	N	I-MajorClaim
35	some	N	I-MajorClaim
36	have	N	I-MajorClaim
37	serious	N	I-MajorClaim
38	risks	N	I-MajorClaim
39	.	N	I-MajorClaim

40	We	N	O
41	did	N	O
42	a	N	O
43	pilot	N	O
44	study	N	O
45	to	N	O
46	investigate	N	O
47	our	N	O
48	hypothesis	N	O
49	that	N	O
50	stellate-ganglion	N	O
51	block	N	O
52	can	N	O
53	be	N	O
54	a	N	O
55	safe	N	O
56	and	N	O
57	effective	N	O
58	treatment	N	O
59	for	N	O
60	hot	N	O
61	flushes	N	O
62	and	N	O
63	sleep	N	O
64	dysfunction	N	O
65	in	N	O
66	this	N	O
67	patient	N	O
68	population	N	O
69	.	N	O

70	13	N	O
71	survivors	N	O
72	of	N	O
73	breast	N	O
74	cancer	N	O
75	(	N	O
76	in	N	O
77	remission	N	O
78	)	N	O
79	with	N	O
80	severe	N	O
81	hot	N	O
82	flushes	N	O
83	and	N	O
84	night	N	O
85	awakenings	N	O
86	were	N	O
87	treated	N	O
88	with	N	O
89	stellate-ganglion	N	O
90	block	N	O
91	at	N	O
92	the	N	O
93	anterolateral	N	O
94	aspect	N	O
95	of	N	O
96	the	N	O
97	C6	N	O
98	vertebra	N	O
99	on	N	O
100	the	N	O
101	right	N	O
102	side	N	O
103	under	N	O
104	fluoroscopy	N	O
105	.	N	O

106	Patients	N	O
107	recorded	N	O
108	hot	N	O
109	flushes	N	O
110	in	N	O
111	a	N	O
112	daily	N	O
113	diary	N	O
114	by	N	O
115	use	N	O
116	of	N	O
117	the	N	O
118	Hot-Flash	N	O
119	Score	N	O
120	,	N	O
121	devised	N	O
122	by	N	O
123	Sloan	N	O
124	and	N	O
125	colleagues	N	O
126	,	N	O
127	and	N	O
128	night	N	O
129	awakenings	N	O
130	by	N	O
131	use	N	O
132	of	N	O
133	the	N	O
134	Pittsburgh	N	O
135	Sleep	N	O
136	Quality	N	O
137	Index	N	O
138	.	N	O

139	Both	N	O
140	instruments	N	O
141	were	N	O
142	used	N	O
143	1	N	O
144	week	N	O
145	before	N	O
146	the	N	O
147	procedure	N	O
148	[	N	O
149	A40	N	O
150	]	N	O
151	and	N	O
152	then	N	O
153	weekly	N	O
154	after	N	O
155	the	N	O
156	procedure	N	O
157	for	N	O
158	12	N	O
159	weeks	N	O
160	.	N	O

161	We	N	O
162	used	N	O
163	the	N	O
164	generalised-estimating-equations	N	O
165	method	N	O
166	to	N	O
167	analyse	N	O
168	the	N	O
169	longitudinal	N	O
170	measurements	N	O
171	of	N	O
172	the	N	O
173	number	N	O
174	of	N	O
175	hot	N	O
176	flushes	N	O
177	and	N	O
178	night	N	O
179	awakenings	N	O
180	over	N	O
181	time	N	O
182	.	N	O

183	This	N	O
184	method	N	O
185	is	N	O
186	a	N	O
187	popular	N	O
188	approach	N	O
189	to	N	O
190	analysing	N	O
191	datasets	N	O
192	that	N	O
193	have	N	O
194	repeated	N	O
195	measures	N	O
196	from	N	O
197	the	N	O
198	same	N	O
199	person	N	O
200	,	N	O
201	and	N	O
202	is	N	O
203	robust	N	O
204	because	N	O
205	it	N	O
206	does	N	O
207	not	N	O
208	need	N	O
209	the	N	O
210	complete	N	O
211	distribution	N	O
212	of	N	O
213	the	N	O
214	outcomes	N	O
215	to	N	O
216	be	N	O
217	specified	N	O
218	.	N	O

219	This	N	O
220	trial	N	O
221	is	N	O
222	registered	N	O
223	on	N	O
224	the	N	O
225	International	N	O
226	Standard	N	O
227	Randomised	N	O
228	Controlled	N	O
229	Trial	N	O
230	Number	N	O
231	register	N	O
232	(	N	O
233	ISRCTN14318565	N	O
234	)	N	O
235	.	N	O

236	There	N	O
237	were	N	O
238	no	N	O
239	adverse	N	O
240	events	N	O
241	resulting	N	O
242	from	N	O
243	the	N	O
244	stellate-ganglion	N	O
245	block	N	O
246	,	N	O
247	although	N	O
248	patients	N	O
249	had	N	O
250	temporary	N	O
251	Horner	N	O
252	's	N	O
253	syndrome	N	O
254	indicating	N	O
255	the	N	O
256	effectiveness	N	O
257	of	N	O
258	the	N	O
259	block	N	O
260	.	N	O

261	Five	N	O
262	patients	N	O
263	had	N	O
264	only	N	O
265	one	N	O
266	stellate-ganglion	N	O
267	block	N	O
268	and	N	O
269	eight	N	O
270	had	N	O
271	two	N	O
272	stellate-ganglion	N	O
273	blocks	N	O
274	.	N	O

275	The	N	I-Premise
276	total	N	I-Premise
277	number	N	I-Premise
278	of	N	I-Premise
279	hot	N	I-Premise
280	flushes	N	I-Premise
281	decreased	N	I-Premise
282	from	N	I-Premise
283	a	N	I-Premise
284	mean	N	I-Premise
285	of	N	I-Premise
286	79.4	N	I-Premise
287	(	N	I-Premise
288	SD	N	I-Premise
289	37.4	N	I-Premise
290	)	N	I-Premise
291	per	N	I-Premise
292	week	N	I-Premise
293	before	N	I-Premise
294	the	N	I-Premise
295	procedure	N	I-Premise
296	to	N	I-Premise
297	a	N	I-Premise
298	mean	N	I-Premise
299	of	N	I-Premise
300	49.9	N	I-Premise
301	(	N	I-Premise
302	SD	N	I-Premise
303	39.9	N	I-Premise
304	)	N	I-Premise
305	per	N	I-Premise
306	week	N	I-Premise
307	during	N	I-Premise
308	the	N	I-Premise
309	first	N	I-Premise
310	2	N	I-Premise
311	weeks	N	I-Premise
312	after	N	I-Premise
313	the	N	I-Premise
314	procedure	N	I-Premise
315	(	N	I-Premise
316	p=0.0002	N	I-Premise
317	)	N	I-Premise
318	.	N	I-Premise

319	The	N	I-Premise
320	total	N	I-Premise
321	number	N	I-Premise
322	of	N	I-Premise
323	hot	N	I-Premise
324	flushes	N	I-Premise
325	continued	N	I-Premise
326	to	N	I-Premise
327	decrease	N	I-Premise
328	over	N	I-Premise
329	the	N	I-Premise
330	remaining	N	I-Premise
331	follow-up	N	I-Premise
332	period	N	I-Premise
333	(	N	I-Premise
334	weeks	N	I-Premise
335	3-12	N	I-Premise
336	)	N	I-Premise
337	,	N	I-Premise
338	and	N	I-Premise
339	stabilised	N	I-Premise
340	at	N	I-Premise
341	a	N	I-Premise
342	mean	N	I-Premise
343	of	N	I-Premise
344	8.1	N	I-Premise
345	(	N	I-Premise
346	SD	N	I-Premise
347	5.6	N	I-Premise
348	)	N	I-Premise
349	per	N	I-Premise
350	week	N	I-Premise
351	(	N	I-Premise
352	p	N	I-Premise
353	<	N	I-Premise
354	0.0001	N	I-Premise
355	)	N	I-Premise
356	.	N	I-Premise

357	The	N	I-Premise
358	number	N	I-Premise
359	of	N	I-Premise
360	very	N	I-Premise
361	severe	N	I-Premise
362	hot	N	I-Premise
363	flushes	N	I-Premise
364	was	N	I-Premise
365	decreased	N	I-Premise
366	to	N	I-Premise
367	near	N	I-Premise
368	zero	N	I-Premise
369	by	N	I-Premise
370	the	N	I-Premise
371	end	N	I-Premise
372	of	N	I-Premise
373	the	N	I-Premise
374	follow-up	N	I-Premise
375	period	N	I-Premise
376	(	N	I-Premise
377	week	N	I-Premise
378	12	N	I-Premise
379	;	N	I-Premise
380	p	N	I-Premise
381	<	N	I-Premise
382	0.0001	N	I-Premise
383	)	N	I-Premise
384	.	N	I-Premise

385	Night	N	I-Premise
386	awakenings	N	I-Premise
387	decreased	N	I-Premise
388	from	N	I-Premise
389	a	N	I-Premise
390	mean	N	I-Premise
391	of	N	I-Premise
392	19.5	N	I-Premise
393	(	N	I-Premise
394	SD	N	I-Premise
395	14.8	N	I-Premise
396	)	N	I-Premise
397	per	N	I-Premise
398	week	N	I-Premise
399	before	N	I-Premise
400	the	N	I-Premise
401	procedure	N	I-Premise
402	to	N	I-Premise
403	a	N	I-Premise
404	mean	N	I-Premise
405	of	N	I-Premise
406	7.3	N	I-Premise
407	(	N	I-Premise
408	SD	N	I-Premise
409	7.1	N	I-Premise
410	)	N	I-Premise
411	per	N	I-Premise
412	week	N	I-Premise
413	during	N	I-Premise
414	the	N	I-Premise
415	first	N	I-Premise
416	2	N	I-Premise
417	weeks	N	I-Premise
418	after	N	I-Premise
419	the	N	I-Premise
420	procedure	N	I-Premise
421	(	N	I-Premise
422	p	N	I-Premise
423	<	N	I-Premise
424	0.0001	N	I-Premise
425	)	N	I-Premise
426	.	N	I-Premise

427	The	N	I-Premise
428	total	N	I-Premise
429	number	N	I-Premise
430	of	N	I-Premise
431	night	N	I-Premise
432	awakenings	N	I-Premise
433	continued	N	I-Premise
434	to	N	I-Premise
435	decrease	N	I-Premise
436	over	N	I-Premise
437	the	N	I-Premise
438	remaining	N	I-Premise
439	follow-up	N	I-Premise
440	period	N	I-Premise
441	(	N	I-Premise
442	weeks	N	I-Premise
443	3-12	N	I-Premise
444	)	N	I-Premise
445	and	N	I-Premise
446	stabilised	N	I-Premise
447	at	N	I-Premise
448	a	N	I-Premise
449	mean	N	I-Premise
450	of	N	I-Premise
451	1.4	N	I-Premise
452	(	N	I-Premise
453	SD	N	I-Premise
454	1.2	N	I-Premise
455	)	N	I-Premise
456	per	N	I-Premise
457	week	N	I-Premise
458	(	N	I-Premise
459	p	N	I-Premise
460	<	N	I-Premise
461	0.0001	N	I-Premise
462	)	N	I-Premise
463	.	N	I-Premise

464	The	N	I-Claim
465	findings	N	I-Claim
466	of	N	I-Claim
467	this	N	I-Claim
468	study	N	I-Claim
469	suggest	N	I-Claim
470	that	N	I-Claim
471	stellate-ganglion	N	I-Claim
472	block	N	I-Claim
473	can	N	I-Claim
474	provide	N	I-Claim
475	survivors	N	I-Claim
476	of	N	I-Claim
477	breast	N	I-Claim
478	cancer	N	I-Claim
479	with	N	I-Claim
480	relief	N	I-Claim
481	from	N	I-Claim
482	hot	N	I-Claim
483	flushes	N	I-Claim
484	and	N	I-Claim
485	sleep	N	I-Claim
486	dysfunction	N	I-Claim
487	with	N	I-Claim
488	few	N	I-Claim
489	or	N	I-Claim
490	no	N	I-Claim
491	side-effects	N	I-Claim
492	.	N	I-Claim

493	Long-term	N	I-MajorClaim
494	relief	N	I-MajorClaim
495	of	N	I-MajorClaim
496	symptoms	N	I-MajorClaim
497	has	N	I-MajorClaim
498	the	N	I-MajorClaim
499	potential	N	I-MajorClaim
500	to	N	I-MajorClaim
501	improve	N	I-MajorClaim
502	overall	N	I-MajorClaim
503	quality	N	I-MajorClaim
504	of	N	I-MajorClaim
505	life	N	I-MajorClaim
506	and	N	I-MajorClaim
507	increase	N	I-MajorClaim
508	compliance	N	I-MajorClaim
509	with	N	I-MajorClaim
510	anti-oestrogen	N	I-MajorClaim
511	medications	N	I-MajorClaim
512	for	N	I-MajorClaim
513	breast	N	I-MajorClaim
514	cancer	N	I-MajorClaim
515	.	N	I-MajorClaim

1	Performance	N	O
2	status	N	O
3	(	N	O
4	PS	N	O
5	)	N	O
6	2	N	O
7	patients	N	O
8	with	N	O
9	non-small	N	O
10	cell	N	O
11	lung	N	O
12	cancer	N	O
13	(	N	O
14	NSCLC	N	O
15	)	N	O
16	experience	N	O
17	more	N	O
18	toxicity	N	O
19	,	N	O
20	lower	N	O
21	response	N	O
22	rates	N	O
23	,	N	O
24	and	N	O
25	shorter	N	O
26	survival	N	O
27	times	N	O
28	than	N	O
29	healthier	N	O
30	patients	N	O
31	treated	N	O
32	with	N	O
33	standard	N	O
34	chemotherapy	N	O
35	.	N	O

36	Paclitaxel	N	O
37	poliglumex	N	O
38	(	N	O
39	PPX	N	O
40	)	N	O
41	,	N	O
42	a	N	O
43	macromolecule	N	O
44	drug	N	O
45	conjugate	N	O
46	of	N	O
47	paclitaxel	N	O
48	and	N	O
49	polyglutamic	N	O
50	acid	N	O
51	,	N	O
52	reduces	N	O
53	systemic	N	O
54	exposure	N	O
55	to	N	O
56	peak	N	O
57	concentrations	N	O
58	of	N	O
59	free	N	O
60	paclitaxel	N	O
61	and	N	O
62	may	N	O
63	lead	N	O
64	to	N	O
65	increased	N	O
66	concentrations	N	O
67	in	N	O
68	tumors	N	O
69	due	N	O
70	to	N	O
71	enhanced	N	O
72	vascular	N	O
73	permeability	N	O
74	.	N	O

75	Chemotherapy-naive	N	O
76	PS	N	O
77	2	N	O
78	patients	N	O
79	with	N	O
80	advanced	N	O
81	NSCLC	N	O
82	were	N	O
83	randomized	N	O
84	to	N	O
85	receive	N	O
86	carboplatin	N	O
87	(	N	O
88	area	N	O
89	under	N	O
90	the	N	O
91	curve	N	O
92	=	N	O
93	6	N	O
94	)	N	O
95	and	N	O
96	either	N	O
97	PPX	N	O
98	(	N	O
99	210	N	O
100	mg/m/10	N	O
101	min	N	O
102	without	N	O
103	routine	N	O
104	steroid	N	O
105	premedication	N	O
106	)	N	O
107	or	N	O
108	paclitaxel	N	O
109	(	N	O
110	225	N	O
111	mg/m/3	N	O
112	h	N	O
113	with	N	O
114	standard	N	O
115	premedication	N	O
116	)	N	O
117	every	N	O
118	3	N	O
119	weeks	N	O
120	.	N	O

121	The	N	O
122	primary	N	O
123	end	N	O
124	point	N	O
125	was	N	O
126	overall	N	O
127	survival	N	O
128	.	N	O

129	A	N	O
130	total	N	O
131	of	N	O
132	400	N	O
133	patients	N	O
134	were	N	O
135	enrolled	N	O
136	.	N	O

137	Alopecia	N	I-Premise
138	,	N	I-Premise
139	arthralgias/myalgias	N	I-Premise
140	,	N	I-Premise
141	and	N	I-Premise
142	cardiac	N	I-Premise
143	events	N	I-Premise
144	were	N	I-Premise
145	significantly	N	I-Premise
146	less	N	I-Premise
147	frequent	N	I-Premise
148	with	N	I-Premise
149	PPX/carboplatin	N	I-Premise
150	,	N	I-Premise
151	whereas	N	I-Premise
152	grade	N	I-Premise
153	>	N	I-Premise
154	or	N	I-Premise
155	=3	N	I-Premise
156	neutropenia	N	I-Premise
157	and	N	I-Premise
158	grade	N	I-Premise
159	3	N	I-Premise
160	neuropathy	N	I-Premise
161	showed	N	I-Premise
162	a	N	I-Premise
163	trend	N	I-Premise
164	of	N	I-Premise
165	worsening	N	I-Premise
166	.	N	I-Premise

167	There	N	I-Premise
168	was	N	I-Premise
169	no	N	I-Premise
170	significant	N	I-Premise
171	difference	N	I-Premise
172	in	N	I-Premise
173	the	N	I-Premise
174	incidence	N	I-Premise
175	of	N	I-Premise
176	hypersensitivity	N	I-Premise
177	reactions	N	I-Premise
178	despite	N	I-Premise
179	the	N	I-Premise
180	absence	N	I-Premise
181	of	N	I-Premise
182	routine	N	I-Premise
183	premedication	N	I-Premise
184	in	N	I-Premise
185	the	N	I-Premise
186	PPX	N	I-Premise
187	arm	N	I-Premise
188	.	N	I-Premise

189	Overall	N	I-Premise
190	survival	N	I-Premise
191	was	N	I-Premise
192	similar	N	I-Premise
193	between	N	I-Premise
194	treatment	N	I-Premise
195	arms	N	I-Premise
196	(	N	I-Premise
197	hazard	N	I-Premise
198	ratio	N	I-Premise
199	,	N	I-Premise
200	0.97	N	I-Premise
201	;	N	I-Premise
202	log	N	I-Premise
203	rank	N	I-Premise
204	p	N	I-Premise
205	=	N	I-Premise
206	0.769	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	Median	N	I-Premise
210	and	N	I-Premise
211	1-year	N	I-Premise
212	survival	N	I-Premise
213	rates	N	I-Premise
214	were	N	I-Premise
215	7.9	N	I-Premise
216	months	N	I-Premise
217	and	N	I-Premise
218	31	N	I-Premise
219	%	N	I-Premise
220	,	N	I-Premise
221	for	N	I-Premise
222	PPX	N	I-Premise
223	versus	N	I-Premise
224	8	N	I-Premise
225	months	N	I-Premise
226	and	N	I-Premise
227	31	N	I-Premise
228	%	N	I-Premise
229	for	N	I-Premise
230	paclitaxel	N	I-Premise
231	.	N	I-Premise

232	Disease	N	O
233	control	N	O
234	rates	N	O
235	were	N	O
236	64	N	O
237	%	N	O
238	and	N	O
239	69	N	O
240	%	N	O
241	for	N	O
242	PPX	N	O
243	and	N	O
244	paclitaxel	N	O
245	,	N	O
246	respectively	N	O
247	.	N	O

248	Time	N	O
249	to	N	O
250	progression	N	O
251	was	N	O
252	similar	N	O
253	:	N	O
254	3.9	N	O
255	months	N	O
256	for	N	O
257	PPX/carboplatin	N	O
258	versus	N	O
259	4.6	N	O
260	months	N	O
261	for	N	O
262	paclitaxel/carboplatin	N	O
263	(	N	O
264	p	N	O
265	=	N	O
266	0.210	N	O
267	)	N	O
268	.	N	O

269	PPX/carboplatin	N	I-Claim
270	failed	N	I-Claim
271	to	N	I-Claim
272	provide	N	I-Claim
273	superior	N	I-Claim
274	survival	N	I-Claim
275	compared	N	I-Claim
276	with	N	I-Claim
277	paclitaxel/carboplatin	N	I-Claim
278	in	N	I-Claim
279	the	N	I-Claim
280	first-line	N	I-Claim
281	treatment	N	I-Claim
282	of	N	I-Claim
283	PS	N	I-Claim
284	2	N	I-Claim
285	patients	N	I-Claim
286	with	N	I-Claim
287	NSCLC	N	I-Claim
288	,	N	I-Claim
289	but	N	I-Claim
290	the	N	I-Claim
291	results	N	I-Claim
292	with	N	I-Claim
293	respect	N	I-Claim
294	to	N	I-Claim
295	progression-free	N	I-Claim
296	survival	N	I-Claim
297	and	N	I-Claim
298	overall	N	I-Claim
299	survival	N	I-Claim
300	were	N	I-Claim
301	comparable	N	I-Claim
302	and	N	I-Claim
303	the	N	I-Claim
304	PPX	N	I-Claim
305	regimen	N	I-Claim
306	was	N	I-Claim
307	more	N	I-Claim
308	convenient	N	I-Claim
309	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	uterine	N	O
5	artery	N	O
6	embolization	N	O
7	(	N	O
8	UAE	N	O
9	)	N	O
10	is	N	O
11	a	N	O
12	cost-effective	N	O
13	alternative	N	O
14	to	N	O
15	hysterectomy	N	O
16	for	N	O
17	patients	N	O
18	with	N	O
19	symptomatic	N	O
20	uterine	N	O
21	fibroids	N	O
22	,	N	O
23	the	N	O
24	authors	N	O
25	performed	N	O
26	an	N	O
27	economic	N	O
28	evaluation	N	O
29	alongside	N	O
30	the	N	O
31	multicenter	N	O
32	randomized	N	O
33	EMMY	N	O
34	(	N	O
35	EMbolization	N	O
36	versus	N	O
37	hysterectoMY	N	O
38	)	N	O
39	trial	N	O
40	.	N	O

41	Between	N	O
42	February	N	O
43	2002	N	O
44	and	N	O
45	February	N	O
46	2004	N	O
47	,	N	O
48	177	N	O
49	patients	N	O
50	were	N	O
51	randomized	N	O
52	to	N	O
53	undergo	N	O
54	UAE	N	O
55	(	N	O
56	n	N	O
57	=	N	O
58	88	N	O
59	)	N	O
60	or	N	O
61	hysterectomy	N	O
62	(	N	O
63	n	N	O
64	=	N	O
65	89	N	O
66	)	N	O
67	and	N	O
68	followed	N	O
69	up	N	O
70	until	N	O
71	24	N	O
72	months	N	O
73	after	N	O
74	initial	N	O
75	treatment	N	O
76	allocation	N	O
77	.	N	O

78	Conditional	N	O
79	on	N	O
80	the	N	O
81	equivalence	N	O
82	of	N	O
83	clinical	N	O
84	outcome	N	O
85	,	N	O
86	a	N	O
87	cost	N	O
88	minimization	N	O
89	analysis	N	O
90	was	N	O
91	performed	N	O
92	according	N	O
93	to	N	O
94	the	N	O
95	intention	N	O
96	to	N	O
97	treat	N	O
98	principle	N	O
99	.	N	O

100	Costs	N	O
101	included	N	O
102	health	N	O
103	care	N	O
104	costs	N	O
105	inside	N	O
106	and	N	O
107	outside	N	O
108	the	N	O
109	hospital	N	O
110	as	N	O
111	well	N	O
112	as	N	O
113	costs	N	O
114	related	N	O
115	to	N	O
116	absence	N	O
117	from	N	O
118	work	N	O
119	(	N	O
120	societal	N	O
121	perspective	N	O
122	)	N	O
123	.	N	O

124	Cumulative	N	O
125	standardized	N	O
126	costs	N	O
127	were	N	O
128	estimated	N	O
129	as	N	O
130	volumes	N	O
131	multiplied	N	O
132	with	N	O
133	prices	N	O
134	.	N	O

135	The	N	O
136	nonparametric	N	O
137	bootstrap	N	O
138	method	N	O
139	was	N	O
140	used	N	O
141	to	N	O
142	quantify	N	O
143	differences	N	O
144	in	N	O
145	mean	N	O
146	(	N	O
147	95	N	O
148	%	N	O
149	confidence	N	O
150	interval	N	O
151	[	N	O
152	CI	N	O
153	]	N	O
154	)	N	O
155	costs	N	O
156	between	N	O
157	the	N	O
158	strategies	N	O
159	.	N	O

160	In	N	O
161	total	N	O
162	,	N	O
163	81	N	O
164	patients	N	O
165	underwent	N	O
166	UAE	N	O
167	and	N	O
168	75	N	O
169	underwent	N	O
170	hysterectomy	N	O
171	.	N	O

172	In	N	O
173	the	N	O
174	UAE	N	O
175	group	N	O
176	,	N	O
177	19	N	O
178	patients	N	O
179	(	N	O
180	23	N	O
181	%	N	O
182	)	N	O
183	underwent	N	O
184	secondary	N	O
185	hysterectomies	N	O
186	.	N	O

187	The	N	I-Premise
188	mean	N	I-Premise
189	total	N	I-Premise
190	costs	N	I-Premise
191	per	N	I-Premise
192	patient	N	I-Premise
193	in	N	I-Premise
194	the	N	I-Premise
195	UAE	N	I-Premise
196	group	N	I-Premise
197	were	N	I-Premise
198	significantly	N	I-Premise
199	lower	N	I-Premise
200	than	N	I-Premise
201	those	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	hysterectomy	N	I-Premise
205	group	N	I-Premise
206	(	N	I-Premise
207	$	N	I-Premise
208	11,626	N	I-Premise
209	vs	N	I-Premise
210	$	N	I-Premise
211	18,563	N	I-Premise
212	;	N	I-Premise
213	mean	N	I-Premise
214	difference	N	I-Premise
215	,	N	I-Premise
216	-	N	I-Premise
217	$	N	I-Premise
218	6,936	N	I-Premise
219	[	N	I-Premise
220	-37	N	I-Premise
221	%	N	I-Premise
222	]	N	I-Premise
223	,	N	I-Premise
224	95	N	I-Premise
225	%	N	I-Premise
226	CI	N	I-Premise
227	:	N	I-Premise
228	-	N	I-Premise
229	$	N	I-Premise
230	9,548	N	I-Premise
231	,	N	I-Premise
232	$	N	I-Premise
233	4,281	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	The	N	I-Premise
237	direct	N	I-Premise
238	medical	N	I-Premise
239	in-hospital	N	I-Premise
240	costs	N	I-Premise
241	were	N	I-Premise
242	significantly	N	I-Premise
243	lower	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	UAE	N	I-Premise
247	group	N	I-Premise
248	:	N	I-Premise
249	$	N	I-Premise
250	6,688	N	I-Premise
251	vs	N	I-Premise
252	$	N	I-Premise
253	8,313	N	I-Premise
254	(	N	I-Premise
255	mean	N	I-Premise
256	difference	N	I-Premise
257	,	N	I-Premise
258	-	N	I-Premise
259	$	N	I-Premise
260	1,624	N	I-Premise
261	[	N	I-Premise
262	-20	N	I-Premise
263	%	N	I-Premise
264	]	N	I-Premise
265	,	N	I-Premise
266	95	N	I-Premise
267	%	N	I-Premise
268	CI	N	I-Premise
269	:	N	I-Premise
270	-	N	I-Premise
271	$	N	I-Premise
272	2,605	N	I-Premise
273	,	N	I-Premise
274	-	N	I-Premise
275	$	N	I-Premise
276	586	N	I-Premise
277	)	N	I-Premise
278	.	N	I-Premise

279	Direct	N	I-Premise
280	medical	N	I-Premise
281	out-of-hospital	N	I-Premise
282	and	N	I-Premise
283	direct	N	I-Premise
284	nonmedical	N	I-Premise
285	costs	N	I-Premise
286	were	N	I-Premise
287	low	N	I-Premise
288	in	N	I-Premise
289	both	N	I-Premise
290	groups	N	I-Premise
291	(	N	I-Premise
292	mean	N	I-Premise
293	cost	N	I-Premise
294	difference	N	I-Premise
295	,	N	I-Premise
296	$	N	I-Premise
297	156	N	I-Premise
298	in	N	I-Premise
299	favor	N	I-Premise
300	of	N	I-Premise
301	hysterectomy	N	I-Premise
302	)	N	I-Premise
303	.	N	I-Premise

304	The	N	I-Premise
305	costs	N	I-Premise
306	related	N	I-Premise
307	to	N	I-Premise
308	absence	N	I-Premise
309	from	N	I-Premise
310	work	N	I-Premise
311	differed	N	I-Premise
312	significantly	N	I-Premise
313	between	N	I-Premise
314	the	N	I-Premise
315	treatment	N	I-Premise
316	strategies	N	I-Premise
317	in	N	I-Premise
318	favor	N	I-Premise
319	of	N	I-Premise
320	UAE	N	I-Premise
321	(	N	I-Premise
322	mean	N	I-Premise
323	difference	N	I-Premise
324	,	N	I-Premise
325	-	N	I-Premise
326	$	N	I-Premise
327	5,453	N	I-Premise
328	;	N	I-Premise
329	95	N	I-Premise
330	%	N	I-Premise
331	CI	N	I-Premise
332	:	N	I-Premise
333	-	N	I-Premise
334	$	N	I-Premise
335	7,718	N	I-Premise
336	,	N	I-Premise
337	-	N	I-Premise
338	$	N	I-Premise
339	3,107	N	I-Premise
340	)	N	I-Premise
341	.	N	I-Premise

342	The	N	O
343	costs	N	O
344	of	N	O
345	absence	N	O
346	from	N	O
347	work	N	O
348	accounted	N	O
349	for	N	O
350	79	N	O
351	%	N	O
352	of	N	O
353	the	N	O
354	difference	N	O
355	in	N	O
356	total	N	O
357	costs	N	O
358	.	N	O

359	The	N	I-Premise
360	24-month	N	I-Premise
361	cumulative	N	I-Premise
362	cost	N	I-Premise
363	of	N	I-Premise
364	UAE	N	I-Premise
365	is	N	I-Premise
366	lower	N	I-Premise
367	than	N	I-Premise
368	that	N	I-Premise
369	of	N	I-Premise
370	hysterectomy	N	I-Premise
371	.	N	I-Premise

372	From	N	I-Claim
373	a	N	I-Claim
374	societal	N	I-Claim
375	economic	N	I-Claim
376	perspective	N	I-Claim
377	,	N	I-Claim
378	UAE	N	I-Claim
379	is	N	I-Claim
380	the	N	I-Claim
381	superior	N	I-Claim
382	treatment	N	I-Claim
383	strategy	N	I-Claim
384	in	N	I-Claim
385	women	N	I-Claim
386	with	N	I-Claim
387	symptomatic	N	I-Claim
388	uterine	N	I-Claim
389	fibroids	N	I-Claim
390	.	N	I-Claim

1	Persistent	N	O
2	insomnia	N	O
3	is	N	O
4	a	N	O
5	common	N	O
6	complaint	N	O
7	in	N	O
8	cancer	N	O
9	survivors	N	O
10	,	N	O
11	but	N	O
12	is	N	O
13	seldom	N	O
14	satisfactorily	N	O
15	addressed	N	O
16	.	N	O

17	The	N	O
18	adaptation	N	O
19	to	N	O
20	cancer	N	O
21	care	N	O
22	of	N	O
23	a	N	O
24	validated	N	O
25	,	N	O
26	cost-effective	N	O
27	intervention	N	O
28	may	N	O
29	offer	N	O
30	a	N	O
31	practicable	N	O
32	solution	N	O
33	.	N	O

34	The	N	O
35	aim	N	O
36	of	N	O
37	this	N	O
38	study	N	O
39	was	N	O
40	to	N	O
41	investigate	N	O
42	the	N	O
43	clinical	N	O
44	effectiveness	N	O
45	of	N	O
46	protocol-driven	N	O
47	cognitive	N	O
48	behavior	N	O
49	therapy	N	O
50	(	N	O
51	CBT	N	O
52	)	N	O
53	for	N	O
54	insomnia	N	O
55	,	N	O
56	delivered	N	O
57	by	N	O
58	oncology	N	O
59	nurses	N	O
60	.	N	O

61	Randomized	N	O
62	,	N	O
63	controlled	N	O
64	,	N	O
65	pragmatic	N	O
66	,	N	O
67	two-center	N	O
68	trial	N	O
69	of	N	O
70	CBT	N	O
71	versus	N	O
72	treatment	N	O
73	as	N	O
74	usual	N	O
75	(	N	O
76	TAU	N	O
77	)	N	O
78	in	N	O
79	150	N	O
80	patients	N	O
81	(	N	O
82	103	N	O
83	females	N	O
84	;	N	O
85	mean	N	O
86	age	N	O
87	,	N	O
88	61	N	O
89	years	N	O
90	.	N	O

91	)	N	O
92	who	N	O
93	had	N	O
94	completed	N	O
95	active	N	O
96	therapy	N	O
97	for	N	O
98	breast	N	O
99	,	N	O
100	prostate	N	O
101	,	N	O
102	colorectal	N	O
103	,	N	O
104	or	N	O
105	gynecological	N	O
106	cancer	N	O
107	.	N	O

108	The	N	O
109	study	N	O
110	conformed	N	O
111	to	N	O
112	CONSORT	N	O
113	guidelines	N	O
114	.	N	O

115	Primary	N	O
116	outcomes	N	O
117	were	N	O
118	sleep	N	O
119	diary	N	O
120	measures	N	O
121	at	N	O
122	baseline	N	O
123	,	N	O
124	post-treatment	N	O
125	,	N	O
126	and	N	O
127	6-month	N	O
128	follow-up	N	O
129	.	N	O

130	Actigraphic	N	O
131	sleep	N	O
132	,	N	O
133	health-related	N	O
134	quality	N	O
135	of	N	O
136	life	N	O
137	(	N	O
138	QOL	N	O
139	)	N	O
140	,	N	O
141	psychopathology	N	O
142	,	N	O
143	and	N	O
144	fatigue	N	O
145	were	N	O
146	secondary	N	O
147	measures	N	O
148	.	N	O

149	CBT	N	O
150	comprised	N	O
151	five	N	O
152	,	N	O
153	small	N	O
154	group	N	O
155	sessions	N	O
156	across	N	O
157	consecutive	N	O
158	weeks	N	O
159	,	N	O
160	after	N	O
161	a	N	O
162	manualized	N	O
163	protocol	N	O
164	.	N	O

165	TAU	N	O
166	represented	N	O
167	normal	N	O
168	clinical	N	O
169	practice	N	O
170	;	N	O
171	the	N	O
172	appropriate	N	O
173	control	N	O
174	for	N	O
175	a	N	O
176	clinical	N	O
177	effectiveness	N	O
178	study	N	O
179	.	N	O

180	CBT	N	I-Premise
181	was	N	I-Premise
182	associated	N	I-Premise
183	with	N	I-Premise
184	mean	N	I-Premise
185	reductions	N	I-Premise
186	in	N	I-Premise
187	wakefulness	N	I-Premise
188	of	N	I-Premise
189	55	N	I-Premise
190	minutes	N	I-Premise
191	per	N	I-Premise
192	night	N	I-Premise
193	compared	N	I-Premise
194	with	N	I-Premise
195	no	N	I-Premise
196	change	N	I-Premise
197	in	N	I-Premise
198	TAU	N	I-Premise
199	.	N	I-Premise

200	These	N	O
201	outcomes	N	O
202	were	N	O
203	sustained	N	O
204	6	N	O
205	months	N	O
206	after	N	O
207	treatment	N	O
208	.	N	O

209	Standardized	N	I-Premise
210	relative	N	I-Premise
211	effect	N	I-Premise
212	sizes	N	I-Premise
213	were	N	I-Premise
214	large	N	I-Premise
215	for	N	I-Premise
216	complaints	N	I-Premise
217	of	N	I-Premise
218	difficulty	N	I-Premise
219	initiating	N	I-Premise
220	sleep	N	I-Premise
221	,	N	I-Premise
222	waking	N	I-Premise
223	from	N	I-Premise
224	sleep	N	I-Premise
225	during	N	I-Premise
226	the	N	I-Premise
227	night	N	I-Premise
228	,	N	I-Premise
229	and	N	I-Premise
230	for	N	I-Premise
231	sleep	N	I-Premise
232	efficiency	N	I-Premise
233	(	N	I-Premise
234	percentage	N	I-Premise
235	of	N	I-Premise
236	time	N	I-Premise
237	in	N	I-Premise
238	bed	N	I-Premise
239	spent	N	I-Premise
240	asleep	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	CBT	N	I-Premise
244	was	N	I-Premise
245	associated	N	I-Premise
246	with	N	I-Premise
247	moderate	N	I-Premise
248	to	N	I-Premise
249	large	N	I-Premise
250	effect	N	I-Premise
251	sizes	N	I-Premise
252	for	N	I-Premise
253	five	N	I-Premise
254	of	N	I-Premise
255	seven	N	I-Premise
256	QOL	N	I-Premise
257	outcomes	N	I-Premise
258	,	N	I-Premise
259	including	N	I-Premise
260	significant	N	I-Premise
261	reduction	N	I-Premise
262	in	N	I-Premise
263	daytime	N	I-Premise
264	fatigue	N	I-Premise
265	.	N	I-Premise

266	There	N	I-Premise
267	was	N	I-Premise
268	no	N	I-Premise
269	significant	N	I-Premise
270	interaction	N	I-Premise
271	effect	N	I-Premise
272	between	N	I-Premise
273	any	N	I-Premise
274	of	N	I-Premise
275	these	N	I-Premise
276	outcomes	N	I-Premise
277	and	N	I-Premise
278	baseline	N	I-Premise
279	demographic	N	I-Premise
280	,	N	I-Premise
281	clinical	N	I-Premise
282	,	N	I-Premise
283	or	N	I-Premise
284	sleep	N	I-Premise
285	characteristics	N	I-Premise
286	.	N	I-Premise

287	CBT	N	I-Claim
288	for	N	I-Claim
289	insomnia	N	I-Claim
290	may	N	I-Claim
291	be	N	I-Claim
292	both	N	I-Claim
293	clinically	N	I-Claim
294	effective	N	I-Claim
295	and	N	I-Claim
296	feasible	N	I-Claim
297	to	N	I-Claim
298	deliver	N	I-Claim
299	in	N	I-Claim
300	real	N	I-Claim
301	world	N	I-Claim
302	practice	N	I-Claim
303	.	N	I-Claim

1	The	N	O
2	management	N	O
3	of	N	O
4	recurrent	N	O
5	ovarian	N	O
6	cancer	N	O
7	remains	N	O
8	controversial	N	O
9	.	N	O

10	Single-agent	N	O
11	topotecan	N	O
12	is	N	O
13	an	N	O
14	established	N	O
15	treatment	N	O
16	option	N	O
17	,	N	O
18	and	N	O
19	preliminary	N	O
20	evidence	N	O
21	suggests	N	O
22	improved	N	O
23	tumor	N	O
24	control	N	O
25	by	N	O
26	combining	N	O
27	topotecan	N	O
28	with	N	O
29	etoposide	N	O
30	or	N	O
31	gemcitabine	N	O
32	.	N	O

33	Women	N	O
34	with	N	O
35	relapsed	N	O
36	ovarian	N	O
37	cancer	N	O
38	after	N	O
39	primary	N	O
40	surgery	N	O
41	and	N	O
42	platinum-based	N	O
43	chemotherapy	N	O
44	were	N	O
45	randomly	N	O
46	assigned	N	O
47	to	N	O
48	topotecan	N	O
49	monotherapy	N	O
50	1.25	N	O
51	mg/m	N	O
52	(	N	O
53	2	N	O
54	)	N	O
55	/d	N	O
56	,	N	O
57	topotecan	N	O
58	1.0	N	O
59	mg/m	N	O
60	(	N	O
61	2	N	O
62	)	N	O
63	plus	N	O
64	oral	N	O
65	etoposide	N	O
66	50	N	O
67	mg/d	N	O
68	,	N	O
69	or	N	O
70	topotecan	N	O
71	0.5	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	/d	N	O
77	plus	N	O
78	gemcitabine	N	O
79	800	N	O
80	mg/m	N	O
81	(	N	O
82	2	N	O
83	)	N	O
84	on	N	O
85	day	N	O
86	1	N	O
87	and	N	O
88	600	N	O
89	mg/m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	on	N	O
94	day	N	O
95	8	N	O
96	every	N	O
97	3	N	O
98	weeks	N	O
99	.	N	O

100	Patients	N	O
101	were	N	O
102	stratified	N	O
103	for	N	O
104	platinum-refractory	N	O
105	and	N	O
106	platinum-sensitive	N	O
107	disease	N	O
108	according	N	O
109	to	N	O
110	a	N	O
111	recurrence-free	N	O
112	interval	N	O
113	of	N	O
114	less	N	O
115	or	N	O
116	more	N	O
117	than	N	O
118	12	N	O
119	months	N	O
120	,	N	O
121	respectively	N	O
122	.	N	O

123	The	N	O
124	primary	N	O
125	end	N	O
126	point	N	O
127	was	N	O
128	overall	N	O
129	survival	N	O
130	.	N	O

131	Secondary	N	O
132	end	N	O
133	points	N	O
134	included	N	O
135	progression-free	N	O
136	survival	N	O
137	,	N	O
138	objective	N	O
139	response	N	O
140	rates	N	O
141	,	N	O
142	toxicity	N	O
143	,	N	O
144	and	N	O
145	quality	N	O
146	of	N	O
147	life	N	O
148	(	N	O
149	as	N	O
150	measured	N	O
151	by	N	O
152	the	N	O
153	European	N	O
154	Organisation	N	O
155	for	N	O
156	Research	N	O
157	and	N	O
158	Treatment	N	O
159	of	N	O
160	Cancer	N	O
161	[	N	O
162	EORTC	N	O
163	]	N	O
164	30-item	N	O
165	Quality-of-Life	N	O
166	Questionnaire	N	O
167	)	N	O
168	.	N	O

169	The	N	O
170	trial	N	O
171	enrolled	N	O
172	502	N	O
173	patients	N	O
174	with	N	O
175	a	N	O
176	mean	N	O
177	age	N	O
178	of	N	O
179	60.5	N	O
180	years	N	O
181	(	N	O
182	+/-	N	O
183	10.2	N	O
184	years	N	O
185	)	N	O
186	,	N	O
187	208	N	O
188	of	N	O
189	whom	N	O
190	were	N	O
191	platinum	N	O
192	resistant	N	O
193	.	N	O

194	Median	N	I-Premise
195	overall	N	I-Premise
196	survival	N	I-Premise
197	was	N	I-Premise
198	17.2	N	I-Premise
199	months	N	I-Premise
200	(	N	I-Premise
201	95	N	I-Premise
202	%	N	I-Premise
203	CI	N	I-Premise
204	,	N	I-Premise
205	13.5	N	I-Premise
206	to	N	I-Premise
207	21.9	N	I-Premise
208	months	N	I-Premise
209	)	N	I-Premise
210	with	N	I-Premise
211	topotecan	N	I-Premise
212	,	N	I-Premise
213	17.8	N	I-Premise
214	months	N	I-Premise
215	(	N	I-Premise
216	95	N	I-Premise
217	%	N	I-Premise
218	CI	N	I-Premise
219	,	N	I-Premise
220	13.7	N	I-Premise
221	to	N	I-Premise
222	20.0	N	I-Premise
223	months	N	I-Premise
224	)	N	I-Premise
225	with	N	I-Premise
226	topotecan	N	I-Premise
227	plus	N	I-Premise
228	etoposide	N	I-Premise
229	(	N	I-Premise
230	log-rank	N	I-Premise
231	P	N	I-Premise
232	=	N	I-Premise
233	.7647	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	and	N	I-Premise
237	15.2	N	I-Premise
238	months	N	I-Premise
239	(	N	I-Premise
240	95	N	I-Premise
241	%	N	I-Premise
242	CI	N	I-Premise
243	,	N	I-Premise
244	11.3	N	I-Premise
245	to	N	I-Premise
246	20.9	N	I-Premise
247	months	N	I-Premise
248	)	N	I-Premise
249	with	N	I-Premise
250	topotecan	N	I-Premise
251	plus	N	I-Premise
252	gemcitabine	N	I-Premise
253	(	N	I-Premise
254	log-rank	N	I-Premise
255	P	N	I-Premise
256	=	N	I-Premise
257	.2344	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Platinum-sensitive	N	I-Premise
261	patients	N	I-Premise
262	lived	N	I-Premise
263	significantly	N	I-Premise
264	longer	N	I-Premise
265	than	N	I-Premise
266	platinum-refractory	N	I-Premise
267	patients	N	I-Premise
268	(	N	I-Premise
269	21.9	N	I-Premise
270	v	N	I-Premise
271	10.6	N	I-Premise
272	months	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	The	N	O
276	median	N	O
277	progression-free	N	O
278	survival	N	O
279	was	N	O
280	7.0	N	O
281	,	N	O
282	7.8	N	O
283	,	N	O
284	and	N	O
285	6.3	N	O
286	months	N	O
287	,	N	O
288	respectively	N	O
289	.	N	O

290	Objective	N	O
291	response	N	O
292	rates	N	O
293	were	N	O
294	27.8	N	O
295	%	N	O
296	,	N	O
297	36.1	N	O
298	%	N	O
299	,	N	O
300	and	N	O
301	31.6	N	O
302	%	N	O
303	,	N	O
304	respectively	N	O
305	.	N	O

306	Patients	N	I-Premise
307	under	N	I-Premise
308	combined	N	I-Premise
309	treatment	N	I-Premise
310	were	N	I-Premise
311	at	N	I-Premise
312	higher	N	I-Premise
313	risk	N	I-Premise
314	of	N	I-Premise
315	severe	N	I-Premise
316	thrombocytopenia	N	I-Premise
317	.	N	I-Premise

318	Nonplatinum	N	I-Claim
319	topotecan	N	I-Claim
320	combinations	N	I-Claim
321	do	N	I-Claim
322	not	N	I-Claim
323	provide	N	I-Claim
324	a	N	I-Claim
325	survival	N	I-Claim
326	advantage	N	I-Claim
327	over	N	I-Claim
328	topotecan	N	I-Claim
329	alone	N	I-Claim
330	in	N	I-Claim
331	women	N	I-Claim
332	with	N	I-Claim
333	relapsed	N	I-Claim
334	ovarian	N	I-Claim
335	cancer	N	I-Claim
336	.	N	I-Claim

1	In	N	O
2	an	N	O
3	international	N	O
4	,	N	O
5	randomized	N	O
6	phase	N	O
7	III	N	O
8	trial	N	O
9	,	N	O
10	sunitinib	N	O
11	demonstrated	N	O
12	statistically	N	O
13	significant	N	O
14	efficacy	N	O
15	over	N	O
16	interferon	N	O
17	alfa	N	O
18	(	N	O
19	IFN-alpha	N	O
20	)	N	O
21	as	N	O
22	first-line	N	O
23	therapy	N	O
24	in	N	O
25	patients	N	O
26	with	N	O
27	metastatic	N	O
28	renal	N	O
29	cell	N	O
30	carcinoma	N	O
31	(	N	O
32	mRCC	N	O
33	)	N	O
34	(	N	O
35	progression-free	N	O
36	survival	N	O
37	time	N	O
38	,	N	O
39	11	N	O
40	v	N	O
41	5	N	O
42	months	N	O
43	,	N	O
44	respectively	N	O
45	;	N	O
46	P	N	O
47	<	N	O
48	.001	N	O
49	;	N	O
50	objective	N	O
51	response	N	O
52	rate	N	O
53	,	N	O
54	31	N	O
55	%	N	O
56	v	N	O
57	6	N	O
58	%	N	O
59	,	N	O
60	respectively	N	O
61	;	N	O
62	P	N	O
63	<	N	O
64	.001	N	O
65	)	N	O
66	.	N	O

67	We	N	O
68	report	N	O
69	health-related	N	O
70	quality-of-life	N	O
71	(	N	O
72	QOL	N	O
73	)	N	O
74	results	N	O
75	from	N	O
76	this	N	O
77	trial	N	O
78	.	N	O

79	Seven	N	O
80	hundred	N	O
81	fifty	N	O
82	mRCC	N	O
83	patients	N	O
84	were	N	O
85	randomly	N	O
86	assigned	N	O
87	to	N	O
88	sunitinib	N	O
89	(	N	O
90	6-week	N	O
91	cycles	N	O
92	:	N	O
93	50	N	O
94	mg	N	O
95	orally	N	O
96	once	N	O
97	daily	N	O
98	for	N	O
99	4	N	O
100	weeks	N	O
101	,	N	O
102	followed	N	O
103	by	N	O
104	2	N	O
105	weeks	N	O
106	off	N	O
107	)	N	O
108	or	N	O
109	IFN-alpha	N	O
110	(	N	O
111	9	N	O
112	million	N	O
113	units	N	O
114	subcutaneous	N	O
115	injections	N	O
116	,	N	O
117	three	N	O
118	times	N	O
119	weekly	N	O
120	)	N	O
121	.	N	O

122	QOL	N	O
123	measures	N	O
124	included	N	O
125	the	N	O
126	Functional	N	O
127	Assessment	N	O
128	of	N	O
129	Cancer	N	O
130	Therapy-General	N	O
131	(	N	O
132	FACT-G	N	O
133	)	N	O
134	,	N	O
135	the	N	O
136	FACT-Kidney	N	O
137	Symptom	N	O
138	Index-15	N	O
139	item	N	O
140	(	N	O
141	FKSI-15	N	O
142	)	N	O
143	,	N	O
144	and	N	O
145	the	N	O
146	EuroQoL-5D	N	O
147	's	N	O
148	utility	N	O
149	score	N	O
150	(	N	O
151	EQ-5D	N	O
152	Index	N	O
153	)	N	O
154	and	N	O
155	its	N	O
156	visual	N	O
157	analog	N	O
158	scale	N	O
159	(	N	O
160	EQ-VAS	N	O
161	)	N	O
162	.	N	O

163	The	N	O
164	primary	N	O
165	QOL	N	O
166	end	N	O
167	point	N	O
168	was	N	O
169	the	N	O
170	FKSI	N	O
171	Disease-Related	N	O
172	Symptoms	N	O
173	(	N	O
174	FKSI-DRS	N	O
175	)	N	O
176	subscale	N	O
177	.	N	O

178	Higher	N	O
179	scores	N	O
180	indicated	N	O
181	better	N	O
182	outcomes	N	O
183	(	N	O
184	better	N	O
185	QOL	N	O
186	or	N	O
187	fewer	N	O
188	symptoms	N	O
189	)	N	O
190	.	N	O

191	Data	N	O
192	were	N	O
193	analyzed	N	O
194	for	N	O
195	the	N	O
196	intent-to-treat	N	O
197	population	N	O
198	using	N	O
199	mixed-effects	N	O
200	models	N	O
201	,	N	O
202	supplemented	N	O
203	with	N	O
204	pattern-mixture	N	O
205	models	N	O
206	.	N	O

207	Patients	N	I-Premise
208	receiving	N	I-Premise
209	sunitinib	N	I-Premise
210	reported	N	I-Premise
211	higher	N	I-Premise
212	FKSI-15	N	I-Premise
213	and	N	I-Premise
214	FKSI-DRS	N	I-Premise
215	scores	N	I-Premise
216	at	N	I-Premise
217	each	N	I-Premise
218	cycle	N	I-Premise
219	than	N	I-Premise
220	those	N	I-Premise
221	receiving	N	I-Premise
222	IFN-alpha	N	I-Premise
223	,	N	I-Premise
224	with	N	I-Premise
225	a	N	I-Premise
226	significant	N	I-Premise
227	difference	N	I-Premise
228	in	N	I-Premise
229	the	N	I-Premise
230	overall	N	I-Premise
231	least	N	I-Premise
232	squares	N	I-Premise
233	means	N	I-Premise
234	(	N	I-Premise
235	3.27	N	I-Premise
236	and	N	I-Premise
237	1.98	N	I-Premise
238	,	N	I-Premise
239	respectively	N	I-Premise
240	;	N	I-Premise
241	P	N	I-Premise
242	<	N	I-Premise
243	.0001	N	I-Premise
244	)	N	I-Premise
245	.	N	I-Premise

246	Similarly	N	O
247	,	N	O
248	differences	N	I-Premise
249	in	N	I-Premise
250	least	N	I-Premise
251	squares	N	I-Premise
252	means	N	I-Premise
253	for	N	I-Premise
254	FACT-G	N	I-Premise
255	(	N	I-Premise
256	and	N	I-Premise
257	all	N	I-Premise
258	subscales	N	I-Premise
259	)	N	I-Premise
260	,	N	I-Premise
261	EQ-5D	N	I-Premise
262	Index	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	EQ-VAS	N	I-Premise
266	were	N	I-Premise
267	all	N	I-Premise
268	significantly	N	I-Premise
269	favorable	N	I-Premise
270	for	N	I-Premise
271	sunitinib	N	I-Premise
272	(	N	I-Premise
273	P	N	I-Premise
274	<	N	I-Premise
275	.01	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	Per	N	O
279	pre-established	N	O
280	thresholds	N	O
281	,	N	O
282	between-treatment	N	O
283	differences	N	O
284	in	N	O
285	the	N	O
286	mean	N	O
287	scores	N	O
288	were	N	O
289	clinically	N	O
290	meaningful	N	O
291	after	N	O
292	cycle	N	O
293	4	N	O
294	for	N	O
295	FKSI-DRS	N	O
296	and	N	O
297	at	N	O
298	all	N	O
299	assessments	N	O
300	for	N	O
301	FKSI-15	N	O
302	,	N	O
303	FACT-G	N	O
304	,	N	O
305	and	N	O
306	the	N	O
307	FACT-G	N	O
308	functional	N	O
309	well-being	N	O
310	subscale	N	O
311	.	N	O

312	Sunitinib	N	I-Claim
313	provides	N	I-Claim
314	superior	N	I-Claim
315	QOL	N	I-Claim
316	compared	N	I-Claim
317	with	N	I-Claim
318	IFN-alpha	N	I-Claim
319	in	N	I-Claim
320	mRCC	N	I-Claim
321	patients	N	I-Claim
322	.	N	I-Claim

1	The	N	O
2	Medical	N	O
3	Research	N	O
4	Council	N	O
5	CR07/National	N	O
6	Cancer	N	O
7	Institute	N	O
8	of	N	O
9	Canada	N	O
10	Clinical	N	O
11	Trials	N	O
12	Group	N	O
13	C016	N	O
14	(	N	O
15	MRC	N	O
16	CR07/NCIC	N	O
17	CTG	N	O
18	C016	N	O
19	)	N	O
20	trial	N	O
21	showed	N	O
22	that	N	O
23	,	N	O
24	in	N	O
25	patients	N	O
26	with	N	O
27	operable	N	O
28	rectal	N	O
29	cancer	N	O
30	,	N	O
31	short-course	N	O
32	preoperative	N	O
33	radiotherapy	N	O
34	(	N	O
35	PRE	N	O
36	)	N	O
37	reduced	N	O
38	the	N	O
39	rate	N	O
40	of	N	O
41	local	N	O
42	recurrence	N	O
43	compared	N	O
44	with	N	O
45	surgery	N	O
46	followed	N	O
47	by	N	O
48	selective	N	O
49	postoperative	N	O
50	chemoradiotherapy	N	O
51	for	N	O
52	patients	N	O
53	with	N	O
54	a	N	O
55	positive	N	O
56	circumferential	N	O
57	resection	N	O
58	margin	N	O
59	.	N	O

60	However	N	O
61	,	N	O
62	the	N	O
63	advantages	N	O
64	of	N	O
65	giving	N	O
66	PRE	N	O
67	to	N	O
68	all	N	O
69	patients	N	O
70	needs	N	O
71	to	N	O
72	be	N	O
73	balanced	N	O
74	against	N	O
75	any	N	O
76	negative	N	O
77	impact	N	O
78	on	N	O
79	patients	N	O
80	'	N	O
81	quality	N	O
82	of	N	O
83	life	N	O
84	.	N	O

85	All	N	O
86	1,350	N	O
87	patients	N	O
88	were	N	O
89	asked	N	O
90	to	N	O
91	complete	N	O
92	the	N	O
93	Medical	N	O
94	Outcomes	N	O
95	Study	N	O
96	Short-Form	N	O
97	36-item	N	O
98	(	N	O
99	MOS	N	O
100	SF-36	N	O
101	)	N	O
102	and	N	O
103	the	N	O
104	European	N	O
105	Organisation	N	O
106	for	N	O
107	Research	N	O
108	and	N	O
109	Treatment	N	O
110	of	N	O
111	Cancer	N	O
112	Quality	N	O
113	of	N	O
114	Life	N	O
115	Questionnaire	N	O
116	Colorectal	N	O
117	38-item	N	O
118	(	N	O
119	EORTC	N	O
120	QLQ-CR38	N	O
121	)	N	O
122	questionnaires	N	O
123	.	N	O

124	A	N	O
125	priori	N	O
126	hypotheses	N	O
127	related	N	O
128	to	N	O
129	the	N	O
130	impact	N	O
131	of	N	O
132	treatment	N	O
133	on	N	O
134	sexual	N	O
135	,	N	O
136	bowel	N	O
137	,	N	O
138	and	N	O
139	physical	N	O
140	function	N	O
141	and	N	O
142	general	N	O
143	health	N	O
144	.	N	O

145	Male	N	I-Premise
146	sexual	N	I-Premise
147	dysfunction	N	I-Premise
148	was	N	I-Premise
149	significantly	N	I-Premise
150	increased	N	I-Premise
151	following	N	I-Premise
152	surgery	N	I-Premise
153	(	N	I-Premise
154	P	N	I-Premise
155	<	N	I-Premise
156	.001	N	I-Premise
157	)	N	I-Premise
158	,	N	I-Premise
159	although	N	I-Premise
160	there	N	I-Premise
161	was	N	I-Premise
162	no	N	I-Premise
163	difference	N	I-Premise
164	between	N	I-Premise
165	treatment	N	I-Premise
166	arms	N	I-Premise
167	.	N	I-Premise

168	However	N	O
169	,	N	O
170	a	N	O
171	treatment	N	O
172	difference	N	O
173	had	N	O
174	emerged	N	O
175	at	N	O
176	6	N	O
177	months	N	O
178	(	N	O
179	PRE	N	O
180	patients	N	O
181	reporting	N	O
182	significantly	N	O
183	greater	N	O
184	dysfunction	N	O
185	;	N	O
186	P	N	O
187	=	N	O
188	.004	N	O
189	)	N	O
190	,	N	O
191	which	N	O
192	persisted	N	O
193	out	N	O
194	to	N	O
195	at	N	O
196	least	N	O
197	2	N	O
198	years	N	O
199	(	N	O
200	an	N	O
201	insufficient	N	O
202	number	N	O
203	of	N	O
204	female	N	O
205	patients	N	O
206	completed	N	O
207	the	N	O
208	sexual	N	O
209	dysfunction	N	O
210	questions	N	O
211	to	N	O
212	draw	N	O
213	firm	N	O
214	conclusions	N	O
215	)	N	O
216	.	N	O

217	Both	N	I-Premise
218	treatment	N	I-Premise
219	groups	N	I-Premise
220	reported	N	I-Premise
221	similar	N	I-Premise
222	levels	N	I-Premise
223	of	N	I-Premise
224	decreased	N	I-Premise
225	physical	N	I-Premise
226	function	N	I-Premise
227	at	N	I-Premise
228	3	N	I-Premise
229	months	N	I-Premise
230	,	N	I-Premise
231	but	N	I-Premise
232	thereafter	N	I-Premise
233	it	N	I-Premise
234	returned	N	I-Premise
235	to	N	I-Premise
236	baseline	N	I-Premise
237	levels	N	I-Premise
238	.	N	I-Premise

239	There	N	I-Premise
240	was	N	I-Premise
241	no	N	I-Premise
242	evidence	N	I-Premise
243	of	N	I-Premise
244	any	N	I-Premise
245	major	N	I-Premise
246	changes	N	I-Premise
247	between	N	I-Premise
248	treatments	N	I-Premise
249	or	N	I-Premise
250	time	N	I-Premise
251	points	N	I-Premise
252	in	N	I-Premise
253	terms	N	I-Premise
254	of	N	I-Premise
255	general	N	I-Premise
256	health	N	I-Premise
257	or	N	I-Premise
258	bowel	N	I-Premise
259	function	N	I-Premise
260	,	N	I-Premise
261	but	N	I-Premise
262	exploratory	N	I-Premise
263	analysis	N	I-Premise
264	indicated	N	I-Premise
265	a	N	I-Premise
266	significant	N	I-Premise
267	(	N	I-Premise
268	P	N	I-Premise
269	=	N	I-Premise
270	.006	N	I-Premise
271	at	N	I-Premise
272	2	N	I-Premise
273	years	N	I-Premise
274	)	N	I-Premise
275	increase	N	I-Premise
276	in	N	I-Premise
277	the	N	I-Premise
278	level	N	I-Premise
279	of	N	I-Premise
280	fecal	N	I-Premise
281	incontinence	N	I-Premise
282	with	N	I-Premise
283	PRE	N	I-Premise
284	.	N	I-Premise

285	These	N	I-Claim
286	results	N	I-Claim
287	from	N	I-Claim
288	a	N	I-Claim
289	large	N	I-Claim
290	randomized	N	I-Claim
291	trial	N	I-Claim
292	using	N	I-Claim
293	validated	N	I-Claim
294	patient-completed	N	I-Claim
295	questionnaires	N	I-Claim
296	show	N	I-Claim
297	that	N	I-Claim
298	,	N	I-Claim
299	for	N	I-Claim
300	males	N	I-Claim
301	,	N	I-Claim
302	the	N	I-Claim
303	main	N	I-Claim
304	adverse	N	I-Claim
305	effect	N	I-Claim
306	was	N	I-Claim
307	sexual	N	I-Claim
308	dysfunction	N	I-Claim
309	,	N	I-Claim
310	and	N	I-Claim
311	the	N	I-Claim
312	main	N	I-Claim
313	cause	N	I-Claim
314	of	N	I-Claim
315	this	N	I-Claim
316	was	N	I-Claim
317	surgery	N	I-Claim
318	,	N	I-Claim
319	but	N	O
320	that	N	O
321	PRE	N	I-Claim
322	also	N	I-Claim
323	affected	N	I-Claim
324	sexual	N	I-Claim
325	and	N	I-Claim
326	some	N	I-Claim
327	aspects	N	I-Claim
328	of	N	I-Claim
329	bowel	N	I-Claim
330	functioning	N	I-Claim
331	.	N	I-Claim

1	Patients	N	O
2	receiving	N	O
3	chemoradiation	N	O
4	for	N	O
5	cervical	N	O
6	cancer	N	O
7	are	N	O
8	at	N	O
9	risk	N	O
10	for	N	O
11	distress	N	O
12	,	N	O
13	chemoradiation-related	N	O
14	side-effects	N	O
15	,	N	O
16	and	N	O
17	immunosuppression	N	O
18	.	N	O

19	This	N	O
20	prospective	N	O
21	randomized	N	O
22	clinical	N	O
23	trial	N	O
24	examined	N	O
25	effects	N	O
26	of	N	O
27	a	N	O
28	complementary	N	O
29	therapy	N	O
30	,	N	O
31	Healing	N	O
32	Touch	N	O
33	(	N	O
34	HT	N	O
35	)	N	O
36	,	N	O
37	versus	N	O
38	relaxation	N	O
39	training	N	O
40	(	N	O
41	RT	N	O
42	)	N	O
43	and	N	O
44	usual	N	O
45	care	N	O
46	(	N	O
47	UC	N	O
48	)	N	O
49	for	N	O
50	(	N	O
51	1	N	O
52	)	N	O
53	supporting	N	O
54	cellular	N	O
55	immunity	N	O
56	,	N	O
57	(	N	O
58	2	N	O
59	)	N	O
60	improving	N	O
61	mood	N	O
62	and	N	O
63	quality	N	O
64	of	N	O
65	life	N	O
66	(	N	O
67	QOL	N	O
68	)	N	O
69	,	N	O
70	and	N	O
71	(	N	O
72	3	N	O
73	)	N	O
74	reducing	N	O
75	treatment-associated	N	O
76	toxicities	N	O
77	and	N	O
78	treatment	N	O
79	delay	N	O
80	in	N	O
81	cervical	N	O
82	cancer	N	O
83	patients	N	O
84	receiving	N	O
85	chemoradiation	N	O
86	.	N	O

87	Sixty	N	O
88	women	N	O
89	with	N	O
90	stages	N	O
91	IB1	N	O
92	to	N	O
93	IVA	N	O
94	cervical	N	O
95	cancer	N	O
96	were	N	O
97	randomly	N	O
98	assigned	N	O
99	to	N	O
100	receive	N	O
101	UC	N	O
102	or	N	O
103	4	N	O
104	×/weekly	N	O
105	individual	N	O
106	sessions	N	O
107	of	N	O
108	either	N	O
109	HT	N	O
110	or	N	O
111	RT	N	O
112	immediately	N	O
113	following	N	O
114	radiation	N	O
115	during	N	O
116	their	N	O
117	6-week	N	O
118	chemoradiation	N	O
119	treatment	N	O
120	.	N	O

121	Patients	N	O
122	completed	N	O
123	psychosocial	N	O
124	assessments	N	O
125	and	N	O
126	blood	N	O
127	sampling	N	O
128	before	N	O
129	chemoradiation	N	O
130	at	N	O
131	baseline	N	O
132	,	N	O
133	weeks	N	O
134	4	N	O
135	and	N	O
136	6	N	O
137	.	N	O

138	Multilevel	N	O
139	regression	N	O
140	analyses	N	O
141	using	N	O
142	orthogonal	N	O
143	contrasts	N	O
144	tested	N	O
145	for	N	O
146	differences	N	O
147	between	N	O
148	treatment	N	O
149	conditions	N	O
150	over	N	O
151	time	N	O
152	.	N	O

153	HT	N	I-Premise
154	patients	N	I-Premise
155	had	N	I-Premise
156	a	N	I-Premise
157	minimal	N	I-Premise
158	decrease	N	I-Premise
159	in	N	I-Premise
160	natural	N	I-Premise
161	killer	N	I-Premise
162	cell	N	I-Premise
163	cytotoxicity	N	I-Premise
164	(	N	I-Premise
165	NKCC	N	I-Premise
166	)	N	I-Premise
167	over	N	I-Premise
168	the	N	I-Premise
169	course	N	I-Premise
170	of	N	I-Premise
171	treatment	N	I-Premise
172	whereas	N	I-Premise
173	NKCC	N	I-Premise
174	of	N	I-Premise
175	RT	N	I-Premise
176	and	N	I-Premise
177	UC	N	I-Premise
178	patients	N	I-Premise
179	declined	N	I-Premise
180	sharply	N	I-Premise
181	during	N	I-Premise
182	chemoradiation	N	I-Premise
183	(	N	I-Premise
184	group	N	I-Premise
185	by	N	I-Premise
186	time	N	I-Premise
187	interaction	N	I-Premise
188	:	N	I-Premise
189	p	N	I-Premise
190	=	N	I-Premise
191	0.018	N	I-Premise
192	)	N	I-Premise
193	.	N	I-Premise

194	HT	N	I-Premise
195	patients	N	I-Premise
196	showed	N	I-Premise
197	greater	N	I-Premise
198	decreases	N	I-Premise
199	in	N	I-Premise
200	two	N	I-Premise
201	different	N	I-Premise
202	indicators	N	I-Premise
203	of	N	I-Premise
204	depressed	N	I-Premise
205	mood	N	I-Premise
206	(	N	I-Premise
207	CES-D	N	I-Premise
208	depressed	N	I-Premise
209	mood	N	I-Premise
210	subscale	N	I-Premise
211	and	N	I-Premise
212	POMS	N	I-Premise
213	depression	N	I-Premise
214	scale	N	I-Premise
215	)	N	I-Premise
216	compared	N	I-Premise
217	to	N	I-Premise
218	RT	N	I-Premise
219	and	N	I-Premise
220	UC	N	I-Premise
221	(	N	I-Premise
222	group	N	I-Premise
223	by	N	I-Premise
224	time	N	I-Premise
225	interactions	N	I-Premise
226	:	N	I-Premise
227	p	N	I-Premise
228	<	N	I-Premise
229	0.05	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	No	N	I-Premise
233	between	N	I-Premise
234	group	N	I-Premise
235	differences	N	I-Premise
236	were	N	I-Premise
237	observed	N	I-Premise
238	in	N	I-Premise
239	QOL	N	I-Premise
240	,	N	I-Premise
241	treatment	N	I-Premise
242	delay	N	I-Premise
243	,	N	I-Premise
244	or	N	I-Premise
245	clinically-rated	N	I-Premise
246	toxicities	N	I-Premise
247	.	N	I-Premise

248	HT	N	I-Claim
249	may	N	I-Claim
250	benefit	N	I-Claim
251	cervical	N	I-Claim
252	cancer	N	I-Claim
253	patients	N	I-Claim
254	by	N	I-Claim
255	moderating	N	I-Claim
256	effects	N	I-Claim
257	of	N	I-Claim
258	chemoradiation	N	I-Claim
259	on	N	I-Claim
260	depressed	N	I-Claim
261	mood	N	I-Claim
262	and	N	I-Claim
263	cellular	N	I-Claim
264	immunity	N	I-Claim
265	.	N	I-Claim

266	Effects	N	I-Claim
267	of	N	I-Claim
268	HT	N	I-Claim
269	on	N	I-Claim
270	toxicities	N	I-Claim
271	,	N	I-Claim
272	treatment	N	I-Claim
273	delay	N	I-Claim
274	,	N	I-Claim
275	QOL	N	I-Claim
276	,	N	I-Claim
277	and	N	I-Claim
278	fatigue	N	I-Claim
279	were	N	I-Claim
280	not	N	I-Claim
281	observed	N	I-Claim
282	.	N	I-Claim

283	Long-term	N	O
284	clinical	N	O
285	implications	N	O
286	of	N	O
287	findings	N	O
288	are	N	O
289	not	N	O
290	known	N	O
291	.	N	O

1	Fatigue	N	O
2	is	N	O
3	one	N	O
4	of	N	O
5	the	N	O
6	most	N	O
7	common	N	O
8	symptoms	N	O
9	experienced	N	O
10	by	N	O
11	patients	N	O
12	with	N	O
13	cancer	N	O
14	.	N	O

15	This	N	O
16	trial	N	O
17	was	N	O
18	developed	N	O
19	to	N	O
20	evaluate	N	O
21	the	N	O
22	efficacy	N	O
23	of	N	O
24	long-acting	N	O
25	methylphenidate	N	O
26	for	N	O
27	improving	N	O
28	cancer-related	N	O
29	fatigue	N	O
30	and	N	O
31	to	N	O
32	assess	N	O
33	its	N	O
34	toxicities	N	O
35	.	N	O

36	Adults	N	O
37	with	N	O
38	cancer	N	O
39	were	N	O
40	randomly	N	O
41	assigned	N	O
42	in	N	O
43	a	N	O
44	double-blinded	N	O
45	manner	N	O
46	to	N	O
47	receive	N	O
48	methylphenidate	N	O
49	(	N	O
50	target	N	O
51	dose	N	O
52	,	N	O
53	54	N	O
54	mg/d	N	O
55	)	N	O
56	or	N	O
57	placebo	N	O
58	for	N	O
59	4	N	O
60	weeks	N	O
61	.	N	O

62	The	N	O
63	Brief	N	O
64	Fatigue	N	O
65	Inventory	N	O
66	was	N	O
67	the	N	O
68	primary	N	O
69	outcome	N	O
70	measure	N	O
71	,	N	O
72	while	N	O
73	secondary	N	O
74	outcome	N	O
75	measures	N	O
76	included	N	O
77	a	N	O
78	Symptom	N	O
79	Experience	N	O
80	Diary	N	O
81	(	N	O
82	SED	N	O
83	)	N	O
84	,	N	O
85	the	N	O
86	Short	N	O
87	Form-36	N	O
88	(	N	O
89	SF-36	N	O
90	)	N	O
91	Vitality	N	O
92	Subscale	N	O
93	,	N	O
94	a	N	O
95	linear	N	O
96	analog	N	O
97	self-assessment	N	O
98	,	N	O
99	the	N	O
100	Pittsburgh	N	O
101	Sleep	N	O
102	Quality	N	O
103	Index	N	O
104	,	N	O
105	and	N	O
106	the	N	O
107	Subject	N	O
108	Global	N	O
109	Impression	N	O
110	of	N	O
111	Change	N	O
112	.	N	O

113	In	N	O
114	total	N	O
115	,	N	O
116	148	N	O
117	patients	N	O
118	were	N	O
119	enrolled	N	O
120	.	N	O

121	Using	N	I-Premise
122	an	N	I-Premise
123	area	N	I-Premise
124	under	N	I-Premise
125	the	N	I-Premise
126	serum	N	I-Premise
127	concentration-time	N	I-Premise
128	curve	N	I-Premise
129	analysis	N	I-Premise
130	,	N	I-Premise
131	there	N	I-Premise
132	was	N	I-Premise
133	no	N	I-Premise
134	evidence	N	I-Premise
135	that	N	I-Premise
136	methylphenidate	N	I-Premise
137	,	N	I-Premise
138	as	N	I-Premise
139	compared	N	I-Premise
140	with	N	I-Premise
141	placebo	N	I-Premise
142	,	N	I-Premise
143	improved	N	I-Premise
144	the	N	I-Premise
145	primary	N	I-Premise
146	end	N	I-Premise
147	point	N	I-Premise
148	of	N	I-Premise
149	cancer-related	N	I-Premise
150	fatigue	N	I-Premise
151	in	N	I-Premise
152	this	N	I-Premise
153	patient	N	I-Premise
154	population	N	I-Premise
155	(	N	I-Premise
156	P	N	I-Premise
157	=	N	I-Premise
158	.35	N	I-Premise
159	)	N	I-Premise
160	.	N	I-Premise

161	Comparisons	N	I-Premise
162	of	N	I-Premise
163	secondary	N	I-Premise
164	end	N	I-Premise
165	points	N	I-Premise
166	,	N	I-Premise
167	including	N	I-Premise
168	clinically	N	I-Premise
169	significant	N	I-Premise
170	changes	N	I-Premise
171	in	N	I-Premise
172	quality-of-life	N	I-Premise
173	variables	N	I-Premise
174	and	N	I-Premise
175	cancer-related	N	I-Premise
176	fatigue	N	I-Premise
177	change	N	I-Premise
178	from	N	I-Premise
179	baseline	N	I-Premise
180	,	N	I-Premise
181	were	N	I-Premise
182	similarly	N	I-Premise
183	negative	N	I-Premise
184	.	N	I-Premise

185	However	N	I-Premise
186	,	N	I-Premise
187	a	N	I-Premise
188	subset	N	I-Premise
189	analysis	N	I-Premise
190	suggested	N	I-Premise
191	that	N	I-Premise
192	patients	N	I-Premise
193	with	N	I-Premise
194	more	N	I-Premise
195	severe	N	I-Premise
196	fatigue	N	I-Premise
197	and/or	N	I-Premise
198	with	N	I-Premise
199	more	N	I-Premise
200	advanced	N	I-Premise
201	disease	N	I-Premise
202	did	N	I-Premise
203	have	N	I-Premise
204	some	N	I-Premise
205	fatigue	N	I-Premise
206	improvement	N	I-Premise
207	with	N	I-Premise
208	methylphenidate	N	I-Premise
209	(	N	I-Premise
210	eg	N	I-Premise
211	,	N	I-Premise
212	in	N	I-Premise
213	patients	N	I-Premise
214	with	N	I-Premise
215	stage	N	I-Premise
216	III	N	I-Premise
217	or	N	I-Premise
218	IV	N	I-Premise
219	disease	N	I-Premise
220	,	N	I-Premise
221	the	N	I-Premise
222	mean	N	I-Premise
223	improvement	N	I-Premise
224	in	N	I-Premise
225	usual	N	I-Premise
226	fatigue	N	I-Premise
227	was	N	I-Premise
228	19.7	N	I-Premise
229	with	N	I-Premise
230	methylphenidate	N	I-Premise
231	v	N	I-Premise
232	2.1	N	I-Premise
233	with	N	I-Premise
234	placebo	N	I-Premise
235	;	N	I-Premise
236	P	N	I-Premise
237	=	N	I-Premise
238	.02	N	I-Premise
239	)	N	I-Premise
240	.	N	I-Premise

241	There	N	I-Premise
242	was	N	I-Premise
243	a	N	I-Premise
244	significant	N	I-Premise
245	difference	N	I-Premise
246	in	N	I-Premise
247	self-reported	N	I-Premise
248	toxicities	N	I-Premise
249	(	N	I-Premise
250	SED	N	I-Premise
251	)	N	I-Premise
252	,	N	I-Premise
253	with	N	I-Premise
254	increased	N	I-Premise
255	levels	N	I-Premise
256	of	N	I-Premise
257	nervousness	N	I-Premise
258	and	N	I-Premise
259	appetite	N	I-Premise
260	loss	N	I-Premise
261	in	N	I-Premise
262	the	N	I-Premise
263	methylphenidate	N	I-Premise
264	arm	N	I-Premise
265	.	N	I-Premise

266	This	N	I-Claim
267	clinical	N	I-Claim
268	trial	N	I-Claim
269	was	N	I-Claim
270	unable	N	I-Claim
271	to	N	I-Claim
272	support	N	I-Claim
273	the	N	I-Claim
274	primary	N	I-Claim
275	prestudy	N	I-Claim
276	hypothesis	N	I-Claim
277	that	N	I-Claim
278	the	N	I-Claim
279	chosen	N	I-Claim
280	long-acting	N	I-Claim
281	methylphenidate	N	I-Claim
282	product	N	I-Claim
283	would	N	I-Claim
284	decrease	N	I-Claim
285	cancer-related	N	I-Claim
286	fatigue	N	I-Claim
287	.	N	I-Claim

1	The	N	O
2	Australian	N	O
3	and	N	O
4	New	N	O
5	Zealand	N	O
6	Germ	N	O
7	Cell	N	O
8	Trials	N	O
9	Group	N	O
10	conducted	N	O
11	a	N	O
12	multicenter	N	O
13	randomized	N	O
14	phase	N	O
15	III	N	O
16	trial	N	O
17	in	N	O
18	men	N	O
19	with	N	O
20	good-prognosis	N	O
21	germ	N	O
22	cell	N	O
23	tumors	N	O
24	of	N	O
25	two	N	O
26	standard	N	O
27	chemotherapy	N	O
28	regimens	N	O
29	that	N	O
30	contained	N	O
31	bleomycin	N	O
32	,	N	O
33	etoposide	N	O
34	,	N	O
35	and	N	O
36	cisplatin	N	O
37	but	N	O
38	differed	N	O
39	in	N	O
40	the	N	O
41	scheduling	N	O
42	and	N	O
43	total	N	O
44	dose	N	O
45	of	N	O
46	cisplatin	N	O
47	,	N	O
48	the	N	O
49	total	N	O
50	dose	N	O
51	of	N	O
52	bleomycin	N	O
53	,	N	O
54	and	N	O
55	the	N	O
56	scheduling	N	O
57	and	N	O
58	dose	N	O
59	intensity	N	O
60	of	N	O
61	etoposide	N	O
62	.	N	O

63	The	N	O
64	trial	N	O
65	was	N	O
66	stopped	N	O
67	early	N	O
68	at	N	O
69	a	N	O
70	median	N	O
71	follow-up	N	O
72	of	N	O
73	33	N	O
74	months	N	O
75	after	N	O
76	a	N	O
77	planned	N	O
78	interim	N	O
79	analysis	N	O
80	found	N	O
81	a	N	O
82	survival	N	O
83	benefit	N	O
84	for	N	O
85	the	N	O
86	more	N	O
87	dose-intense	N	O
88	regimen	N	O
89	.	N	O

90	The	N	O
91	aim	N	O
92	of	N	O
93	this	N	O
94	analysis	N	O
95	was	N	O
96	to	N	O
97	determine	N	O
98	if	N	O
99	this	N	O
100	survival	N	O
101	benefit	N	O
102	was	N	O
103	maintained	N	O
104	with	N	O
105	long-term	N	O
106	follow-up	N	O
107	.	N	O

108	Between	N	O
109	February	N	O
110	1994	N	O
111	and	N	O
112	April	N	O
113	2000	N	O
114	,	N	O
115	166	N	O
116	men	N	O
117	with	N	O
118	good-prognosis	N	O
119	metastatic	N	O
120	germ	N	O
121	cell	N	O
122	tumors	N	O
123	defined	N	O
124	by	N	O
125	modified	N	O
126	Memorial	N	O
127	Sloan-Kettering	N	O
128	criteria	N	O
129	were	N	O
130	randomly	N	O
131	assigned	N	O
132	to	N	O
133	receive	N	O
134	3B	N	O
135	(	N	O
136	90	N	O
137	)	N	O
138	E	N	O
139	(	N	O
140	500	N	O
141	)	N	O
142	P	N	O
143	(	N	O
144	three	N	O
145	cycles	N	O
146	,	N	O
147	repeated	N	O
148	every	N	O
149	21	N	O
150	days	N	O
151	,	N	O
152	of	N	O
153	30	N	O
154	kU	N	O
155	bleomycin	N	O
156	on	N	O
157	days	N	O
158	1	N	O
159	,	N	O
160	8	N	O
161	,	N	O
162	and	N	O
163	15	N	O
164	;	N	O
165	100	N	O
166	mg/m	N	O
167	(	N	O
168	2	N	O
169	)	N	O
170	etoposide	N	O
171	on	N	O
172	days	N	O
173	1-5	N	O
174	;	N	O
175	and	N	O
176	20	N	O
177	mg/m	N	O
178	(	N	O
179	2	N	O
180	)	N	O
181	cisplatin	N	O
182	on	N	O
183	days	N	O
184	1-5	N	O
185	;	N	O
186	n	N	O
187	=	N	O
188	83	N	O
189	)	N	O
190	or	N	O
191	4B	N	O
192	(	N	O
193	30	N	O
194	)	N	O
195	E	N	O
196	(	N	O
197	360	N	O
198	)	N	O
199	P	N	O
200	(	N	O
201	four	N	O
202	cycles	N	O
203	,	N	O
204	repeated	N	O
205	every	N	O
206	21	N	O
207	days	N	O
208	,	N	O
209	of	N	O
210	30	N	O
211	kU	N	O
212	bleomycin	N	O
213	on	N	O
214	day	N	O
215	1	N	O
216	,	N	O
217	120	N	O
218	mg/m	N	O
219	(	N	O
220	2	N	O
221	)	N	O
222	etoposide	N	O
223	on	N	O
224	days	N	O
225	1-3	N	O
226	,	N	O
227	and	N	O
228	100	N	O
229	mg/m	N	O
230	(	N	O
231	2	N	O
232	)	N	O
233	cisplatin	N	O
234	on	N	O
235	day	N	O
236	1	N	O
237	;	N	O
238	n	N	O
239	=	N	O
240	83	N	O
241	)	N	O
242	.	N	O

243	Endpoints	N	O
244	included	N	O
245	overall	N	O
246	survival	N	O
247	,	N	O
248	progression-free	N	O
249	survival	N	O
250	,	N	O
251	and	N	O
252	quality	N	O
253	of	N	O
254	life	N	O
255	and	N	O
256	side	N	O
257	effects	N	O
258	,	N	O
259	which	N	O
260	were	N	O
261	assessed	N	O
262	using	N	O
263	the	N	O
264	Spitzer	N	O
265	Quality	N	O
266	of	N	O
267	Life	N	O
268	Index	N	O
269	and	N	O
270	the	N	O
271	GLQ-8	N	O
272	,	N	O
273	respectively	N	O
274	,	N	O
275	before	N	O
276	random	N	O
277	assignment	N	O
278	and	N	O
279	during	N	O
280	and	N	O
281	after	N	O
282	treatment	N	O
283	.	N	O

284	All	N	O
285	analyses	N	O
286	were	N	O
287	by	N	O
288	intention	N	O
289	to	N	O
290	treat	N	O
291	.	N	O

292	All	N	O
293	P	N	O
294	values	N	O
295	are	N	O
296	two-sided	N	O
297	.	N	O

298	The	N	O
299	median	N	O
300	follow-up	N	O
301	was	N	O
302	8.5	N	O
303	years	N	O
304	.	N	O

305	All	N	O
306	but	N	O
307	five	N	O
308	survivors	N	O
309	(	N	O
310	3	N	O
311	%	N	O
312	)	N	O
313	were	N	O
314	followed	N	O
315	up	N	O
316	for	N	O
317	at	N	O
318	least	N	O
319	5	N	O
320	years	N	O
321	.	N	O

322	Overall	N	I-Premise
323	survival	N	I-Premise
324	remained	N	I-Premise
325	better	N	I-Premise
326	in	N	I-Premise
327	those	N	I-Premise
328	assigned	N	I-Premise
329	to	N	I-Premise
330	3B	N	I-Premise
331	(	N	I-Premise
332	90	N	I-Premise
333	)	N	I-Premise
334	E	N	I-Premise
335	(	N	I-Premise
336	500	N	I-Premise
337	)	N	I-Premise
338	P	N	I-Premise
339	than	N	I-Premise
340	in	N	I-Premise
341	those	N	I-Premise
342	assigned	N	I-Premise
343	to	N	I-Premise
344	4B	N	I-Premise
345	(	N	I-Premise
346	30	N	I-Premise
347	)	N	I-Premise
348	E	N	I-Premise
349	(	N	I-Premise
350	360	N	I-Premise
351	)	N	I-Premise
352	P	N	I-Premise
353	(	N	I-Premise
354	8-year	N	I-Premise
355	survival	N	I-Premise
356	:	N	I-Premise
357	92	N	I-Premise
358	%	N	I-Premise
359	vs	N	I-Premise
360	83	N	I-Premise
361	%	N	I-Premise
362	;	N	I-Premise
363	hazard	N	I-Premise
364	ratio	N	I-Premise
365	of	N	I-Premise
366	death	N	I-Premise
367	=	N	I-Premise
368	0.38	N	I-Premise
369	,	N	I-Premise
370	95	N	I-Premise
371	%	N	I-Premise
372	confidence	N	I-Premise
373	interval	N	I-Premise
374	=	N	I-Premise
375	0.15	N	I-Premise
376	to	N	I-Premise
377	0.97	N	I-Premise
378	,	N	I-Premise
379	P	N	I-Premise
380	=	N	I-Premise
381	.037	N	I-Premise
382	)	N	I-Premise
383	.	N	I-Premise

384	Progression-free	N	I-Premise
385	survival	N	I-Premise
386	favored	N	I-Premise
387	3B	N	I-Premise
388	(	N	I-Premise
389	90	N	I-Premise
390	)	N	I-Premise
391	E	N	I-Premise
392	(	N	I-Premise
393	500	N	I-Premise
394	)	N	I-Premise
395	P	N	I-Premise
396	but	N	I-Premise
397	was	N	I-Premise
398	not	N	I-Premise
399	statistically	N	I-Premise
400	significantly	N	I-Premise
401	different	N	I-Premise
402	between	N	I-Premise
403	the	N	I-Premise
404	treatment	N	I-Premise
405	groups	N	I-Premise
406	(	N	I-Premise
407	8-year	N	I-Premise
408	progression-free	N	I-Premise
409	survival	N	I-Premise
410	,	N	I-Premise
411	3B	N	I-Premise
412	(	N	I-Premise
413	90	N	I-Premise
414	)	N	I-Premise
415	E	N	I-Premise
416	(	N	I-Premise
417	500	N	I-Premise
418	)	N	I-Premise
419	P	N	I-Premise
420	vs	N	I-Premise
421	4B	N	I-Premise
422	(	N	I-Premise
423	30	N	I-Premise
424	)	N	I-Premise
425	E	N	I-Premise
426	(	N	I-Premise
427	360	N	I-Premise
428	)	N	I-Premise
429	P	N	I-Premise
430	:	N	I-Premise
431	86	N	I-Premise
432	%	N	I-Premise
433	vs	N	I-Premise
434	79	N	I-Premise
435	%	N	I-Premise
436	;	N	I-Premise
437	hazard	N	I-Premise
438	ratio	N	I-Premise
439	of	N	I-Premise
440	progression	N	I-Premise
441	=	N	I-Premise
442	0.6	N	I-Premise
443	,	N	I-Premise
444	95	N	I-Premise
445	%	N	I-Premise
446	confidence	N	I-Premise
447	interval	N	I-Premise
448	=	N	I-Premise
449	0.3	N	I-Premise
450	to	N	I-Premise
451	1.1	N	I-Premise
452	,	N	I-Premise
453	P	N	I-Premise
454	=	N	I-Premise
455	.15	N	I-Premise
456	)	N	I-Premise
457	.	N	I-Premise

458	At	N	I-Claim
459	the	N	I-Claim
460	end	N	I-Claim
461	of	N	I-Claim
462	treatment	N	I-Claim
463	,	N	I-Claim
464	average	N	I-Claim
465	scores	N	I-Claim
466	for	N	I-Claim
467	most	N	I-Claim
468	side	N	I-Claim
469	effect	N	I-Claim
470	scales	N	I-Claim
471	favored	N	I-Claim
472	3B	N	I-Claim
473	(	N	I-Claim
474	90	N	I-Claim
475	)	N	I-Claim
476	E	N	I-Claim
477	(	N	I-Claim
478	500	N	I-Claim
479	)	N	I-Claim
480	P.	N	I-Claim
481	After	N	I-Premise
482	the	N	I-Premise
483	completion	N	I-Premise
484	of	N	I-Premise
485	treatment	N	I-Premise
486	,	N	I-Premise
487	average	N	I-Premise
488	GLQ-8	N	I-Premise
489	scores	N	I-Premise
490	for	N	I-Premise
491	numbness	N	I-Premise
492	(	N	I-Premise
493	P	N	I-Premise
494	=	N	I-Premise
495	.003	N	I-Premise
496	)	N	I-Premise
497	and	N	I-Premise
498	hair	N	I-Premise
499	loss	N	I-Premise
500	(	N	I-Premise
501	P	N	I-Premise
502	=	N	I-Premise
503	.04	N	I-Premise
504	)	N	I-Premise
505	and	N	I-Premise
506	the	N	I-Premise
507	Spitzer	N	I-Premise
508	Quality	N	I-Premise
509	of	N	I-Premise
510	Life	N	I-Premise
511	Index	N	I-Premise
512	(	N	I-Premise
513	P	N	I-Premise
514	=	N	I-Premise
515	.05	N	I-Premise
516	)	N	I-Premise
517	favored	N	I-Premise
518	3B	N	I-Premise
519	(	N	I-Premise
520	90	N	I-Premise
521	)	N	I-Premise
522	E	N	I-Premise
523	(	N	I-Premise
524	500	N	I-Premise
525	)	N	I-Premise
526	P.	N	I-Premise
527	The	N	I-Claim
528	survival	N	I-Claim
529	benefit	N	I-Claim
530	of	N	I-Claim
531	3B	N	I-Claim
532	(	N	I-Claim
533	90	N	I-Claim
534	)	N	I-Claim
535	E	N	I-Claim
536	(	N	I-Claim
537	500	N	I-Claim
538	)	N	I-Claim
539	P	N	I-Claim
540	over	N	I-Claim
541	4B	N	I-Claim
542	(	N	I-Claim
543	30	N	I-Claim
544	)	N	I-Claim
545	E	N	I-Claim
546	(	N	I-Claim
547	360	N	I-Claim
548	)	N	I-Claim
549	P	N	I-Claim
550	was	N	I-Claim
551	maintained	N	I-Claim
552	with	N	I-Claim
553	long-term	N	I-Claim
554	follow-up	N	I-Claim
555	.	N	I-Claim

1	Research	N	O
2	suggests	N	O
3	that	N	O
4	cancer	N	O
5	rehabilitation	N	O
6	reduces	N	O
7	fatigue	N	O
8	in	N	O
9	survivors	N	O
10	of	N	O
11	cancer	N	O
12	.	N	O

13	To	N	O
14	date	N	O
15	,	N	O
16	it	N	O
17	is	N	O
18	unclear	N	O
19	what	N	O
20	type	N	O
21	of	N	O
22	rehabilitation	N	O
23	is	N	O
24	most	N	O
25	beneficial	N	O
26	.	N	O

27	This	N	O
28	randomized	N	O
29	controlled	N	O
30	trial	N	O
31	compared	N	O
32	the	N	O
33	effect	N	O
34	on	N	O
35	cancer-related	N	O
36	fatigue	N	O
37	of	N	O
38	physical	N	O
39	training	N	O
40	combined	N	O
41	with	N	O
42	cognitive	N	O
43	behavioral	N	O
44	therapy	N	O
45	with	N	O
46	physical	N	O
47	training	N	O
48	alone	N	O
49	and	N	O
50	with	N	O
51	no	N	O
52	intervention	N	O
53	.	N	O

54	In	N	O
55	this	N	O
56	multicenter	N	O
57	randomized	N	O
58	controlled	N	O
59	trial	N	O
60	,	N	O
61	147	N	O
62	survivors	N	O
63	of	N	O
64	cancer	N	O
65	were	N	O
66	randomly	N	O
67	assigned	N	O
68	to	N	O
69	a	N	O
70	group	N	O
71	that	N	O
72	received	N	O
73	physical	N	O
74	training	N	O
75	combined	N	O
76	with	N	O
77	cognitive-behavioral	N	O
78	therapy	N	O
79	(	N	O
80	PT+CBT	N	O
81	group	N	O
82	,	N	O
83	n=76	N	O
84	)	N	O
85	or	N	O
86	to	N	O
87	a	N	O
88	group	N	O
89	that	N	O
90	received	N	O
91	physical	N	O
92	training	N	O
93	alone	N	O
94	(	N	O
95	PT	N	O
96	group	N	O
97	,	N	O
98	n=71	N	O
99	)	N	O
100	.	N	O

101	In	N	O
102	addition	N	O
103	,	N	O
104	a	N	O
105	nonintervention	N	O
106	control	N	O
107	group	N	O
108	(	N	O
109	WLC	N	O
110	group	N	O
111	)	N	O
112	consisting	N	O
113	of	N	O
114	62	N	O
115	survivors	N	O
116	of	N	O
117	cancer	N	O
118	who	N	O
119	were	N	O
120	on	N	O
121	the	N	O
122	waiting	N	O
123	lists	N	O
124	of	N	O
125	rehabilitation	N	O
126	centers	N	O
127	elsewhere	N	O
128	was	N	O
129	included	N	O
130	.	N	O

131	The	N	O
132	study	N	O
133	was	N	O
134	conducted	N	O
135	at	N	O
136	4	N	O
137	rehabilitation	N	O
138	centers	N	O
139	in	N	O
140	the	N	O
141	Netherlands	N	O
142	.	N	O

143	All	N	O
144	patients	N	O
145	were	N	O
146	survivors	N	O
147	of	N	O
148	cancer	N	O
149	.	N	O

150	Physical	N	O
151	training	N	O
152	consisting	N	O
153	of	N	O
154	2	N	O
155	hours	N	O
156	of	N	O
157	individual	N	O
158	training	N	O
159	and	N	O
160	group	N	O
161	sports	N	O
162	took	N	O
163	place	N	O
164	twice	N	O
165	weekly	N	O
166	,	N	O
167	and	N	O
168	cognitive-behavioral	N	O
169	therapy	N	O
170	took	N	O
171	place	N	O
172	once	N	O
173	weekly	N	O
174	for	N	O
175	2	N	O
176	hours	N	O
177	.	N	O

178	Fatigue	N	O
179	was	N	O
180	assessed	N	O
181	with	N	O
182	the	N	O
183	Multidimensional	N	O
184	Fatigue	N	O
185	Inventory	N	O
186	before	N	O
187	and	N	O
188	immediately	N	O
189	after	N	O
190	intervention	N	O
191	(	N	O
192	12	N	O
193	weeks	N	O
194	after	N	O
195	enrollment	N	O
196	)	N	O
197	.	N	O

198	The	N	O
199	WLC	N	O
200	group	N	O
201	completed	N	O
202	questionnaires	N	O
203	at	N	O
204	the	N	O
205	same	N	O
206	time	N	O
207	points	N	O
208	.	N	O

209	Baseline	N	O
210	fatigue	N	O
211	did	N	O
212	not	N	O
213	differ	N	O
214	significantly	N	O
215	among	N	O
216	the	N	O
217	3	N	O
218	groups	N	O
219	.	N	O

220	Over	N	I-Premise
221	time	N	I-Premise
222	,	N	I-Premise
223	levels	N	I-Premise
224	of	N	I-Premise
225	fatigue	N	I-Premise
226	significantly	N	I-Premise
227	decreased	N	I-Premise
228	in	N	I-Premise
229	all	N	I-Premise
230	domains	N	I-Premise
231	in	N	I-Premise
232	all	N	I-Premise
233	groups	N	I-Premise
234	,	N	I-Premise
235	except	N	I-Premise
236	in	N	I-Premise
237	mental	N	I-Premise
238	fatigue	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	WLC	N	I-Premise
242	group	N	I-Premise
243	.	N	I-Premise

244	Analyses	N	I-Premise
245	of	N	I-Premise
246	variance	N	I-Premise
247	of	N	I-Premise
248	postintervention	N	I-Premise
249	fatigue	N	I-Premise
250	showed	N	I-Premise
251	statistically	N	I-Premise
252	significant	N	I-Premise
253	group	N	I-Premise
254	effects	N	I-Premise
255	on	N	I-Premise
256	general	N	I-Premise
257	fatigue	N	I-Premise
258	,	N	I-Premise
259	on	N	I-Premise
260	physical	N	I-Premise
261	and	N	I-Premise
262	mental	N	I-Premise
263	fatigue	N	I-Premise
264	,	N	I-Premise
265	and	N	I-Premise
266	on	N	I-Premise
267	reduced	N	I-Premise
268	activation	N	I-Premise
269	but	N	I-Premise
270	not	N	I-Premise
271	on	N	I-Premise
272	reduced	N	I-Premise
273	motivation	N	I-Premise
274	.	N	I-Premise

275	Compared	N	I-Premise
276	with	N	I-Premise
277	the	N	I-Premise
278	WLC	N	I-Premise
279	group	N	I-Premise
280	,	N	I-Premise
281	the	N	I-Premise
282	PT	N	I-Premise
283	group	N	I-Premise
284	reported	N	I-Premise
285	significantly	N	I-Premise
286	greater	N	I-Premise
287	decline	N	I-Premise
288	in	N	I-Premise
289	4	N	I-Premise
290	domains	N	I-Premise
291	of	N	I-Premise
292	fatigue	N	I-Premise
293	,	N	I-Premise
294	whereas	N	I-Premise
295	the	N	I-Premise
296	PT+CBT	N	I-Premise
297	group	N	I-Premise
298	reported	N	I-Premise
299	significantly	N	I-Premise
300	greater	N	I-Premise
301	decline	N	I-Premise
302	in	N	I-Premise
303	physical	N	I-Premise
304	fatigue	N	I-Premise
305	only	N	I-Premise
306	.	N	I-Premise

307	No	N	I-Premise
308	significant	N	I-Premise
309	differences	N	I-Premise
310	in	N	I-Premise
311	decline	N	I-Premise
312	in	N	I-Premise
313	fatigue	N	I-Premise
314	were	N	I-Premise
315	found	N	I-Premise
316	between	N	I-Premise
317	the	N	I-Premise
318	PT+CBT	N	I-Premise
319	and	N	I-Premise
320	PT	N	I-Premise
321	groups	N	I-Premise
322	.	N	I-Premise

323	Physical	N	I-Premise
324	training	N	I-Premise
325	combined	N	I-Premise
326	with	N	I-Premise
327	cognitive-behavioral	N	I-Premise
328	therapy	N	I-Premise
329	and	N	I-Premise
330	physical	N	I-Premise
331	training	N	I-Premise
332	alone	N	I-Premise
333	had	N	I-Premise
334	significant	N	I-Premise
335	and	N	I-Premise
336	beneficial	N	I-Premise
337	effects	N	I-Premise
338	on	N	I-Premise
339	fatigue	N	I-Premise
340	compared	N	I-Premise
341	with	N	I-Premise
342	no	N	I-Premise
343	intervention	N	I-Premise
344	.	N	I-Premise

345	Physical	N	I-Claim
346	training	N	I-Claim
347	was	N	I-Claim
348	equally	N	I-Claim
349	effective	N	I-Claim
350	as	N	I-Claim
351	or	N	I-Claim
352	more	N	I-Claim
353	effective	N	I-Claim
354	than	N	I-Claim
355	physical	N	I-Claim
356	training	N	I-Claim
357	combined	N	I-Claim
358	with	N	I-Claim
359	cognitive-behavioral	N	I-Claim
360	therapy	N	I-Claim
361	in	N	I-Claim
362	reducing	N	I-Claim
363	cancer-related	N	I-Claim
364	fatigue	N	I-Claim
365	,	N	I-Claim
366	suggesting	N	O
367	that	N	O
368	cognitive-behavioral	N	I-Claim
369	therapy	N	I-Claim
370	did	N	I-Claim
371	not	N	I-Claim
372	have	N	I-Claim
373	additional	N	I-Claim
374	beneficial	N	I-Claim
375	effects	N	I-Claim
376	beyond	N	I-Claim
377	the	N	I-Claim
378	benefits	N	I-Claim
379	of	N	I-Claim
380	physical	N	I-Claim
381	training	N	I-Claim
382	.	N	I-Claim

1	Sentinel	N	O
2	lymph	N	O
3	node	N	O
4	resection	N	O
5	(	N	O
6	SNR	N	O
7	)	N	O
8	may	N	O
9	reduce	N	O
10	morbidity	N	O
11	while	N	O
12	providing	N	O
13	the	N	O
14	same	N	O
15	clinical	N	O
16	utility	N	O
17	as	N	O
18	conventional	N	O
19	axillary	N	O
20	dissection	N	O
21	(	N	O
22	AD	N	O
23	)	N	O
24	.	N	O

25	National	N	O
26	Surgical	N	O
27	Adjuvant	N	O
28	Breast	N	O
29	and	N	O
30	Bowel	N	O
31	Project	N	O
32	(	N	O
33	NSABP	N	O
34	)	N	O
35	B-32	N	O
36	is	N	O
37	a	N	O
38	randomized	N	O
39	phase	N	O
40	III	N	O
41	trial	N	O
42	comparing	N	O
43	SNR	N	O
44	immediately	N	O
45	followed	N	O
46	by	N	O
47	AD	N	O
48	(	N	O
49	SNAD	N	O
50	)	N	O
51	to	N	O
52	SNR	N	O
53	and	N	O
54	subsequent	N	O
55	AD	N	O
56	if	N	O
57	SN	N	O
58	is	N	O
59	positive	N	O
60	.	N	O

61	We	N	O
62	report	N	O
63	the	N	O
64	definitive	N	O
65	patient-reported	N	O
66	outcomes	N	O
67	(	N	O
68	PRO	N	O
69	)	N	O
70	comparisons	N	O
71	.	N	O

72	Eligible	N	O
73	patients	N	O
74	had	N	O
75	clinically	N	O
76	node-negative	N	O
77	,	N	O
78	operable	N	O
79	invasive	N	O
80	breast	N	O
81	cancer	N	O
82	.	N	O

83	The	N	O
84	PRO	N	O
85	substudy	N	O
86	included	N	O
87	all	N	O
88	SN-negative	N	O
89	participants	N	O
90	enrolled	N	O
91	May	N	O
92	2001	N	O
93	to	N	O
94	February	N	O
95	2004	N	O
96	at	N	O
97	community	N	O
98	institutions	N	O
99	in	N	O
100	the	N	O
101	United	N	O
102	States	N	O
103	(	N	O
104	n	N	O
105	=	N	O
106	749	N	O
107	;	N	O
108	78	N	O
109	%	N	O
110	age	N	O
111	>	N	O
112	or	N	O
113	=	N	O
114	50	N	O
115	;	N	O
116	87	N	O
117	%	N	O
118	clinical	N	O
119	tumor	N	O
120	size	N	O
121	<	N	O
122	or	N	O
123	=	N	O
124	2.0	N	O
125	cm	N	O
126	;	N	O
127	84	N	O
128	%	N	O
129	lumpectomy	N	O
130	;	N	O
131	87	N	O
132	%	N	O
133	white	N	O
134	)	N	O
135	.	N	O

136	They	N	O
137	completed	N	O
138	questionnaires	N	O
139	presurgery	N	O
140	,	N	O
141	1	N	O
142	and	N	O
143	2	N	O
144	to	N	O
145	3	N	O
146	weeks	N	O
147	postoperatively	N	O
148	,	N	O
149	and	N	O
150	every	N	O
151	6	N	O
152	months	N	O
153	through	N	O
154	year	N	O
155	3	N	O
156	.	N	O

157	Arm	N	O
158	symptoms	N	O
159	,	N	O
160	arm	N	O
161	use	N	O
162	avoidance	N	O
163	,	N	O
164	activity	N	O
165	limitations	N	O
166	,	N	O
167	and	N	O
168	quality	N	O
169	of	N	O
170	life	N	O
171	(	N	O
172	QOL	N	O
173	)	N	O
174	were	N	O
175	compared	N	O
176	with	N	O
177	intent-to-treat	N	O
178	two-sample	N	O
179	t-tests	N	O
180	and	N	O
181	repeated	N	O
182	measures	N	O
183	analyses	N	O
184	.	N	O

185	Arm	N	I-Premise
186	symptoms	N	I-Premise
187	were	N	I-Premise
188	significantly	N	I-Premise
189	more	N	I-Premise
190	bothersome	N	I-Premise
191	for	N	I-Premise
192	SNAD	N	I-Premise
193	compared	N	I-Premise
194	with	N	I-Premise
195	SNR	N	I-Premise
196	patients	N	I-Premise
197	at	N	I-Premise
198	6	N	I-Premise
199	months	N	I-Premise
200	(	N	I-Premise
201	mean	N	I-Premise
202	,	N	I-Premise
203	4.8	N	I-Premise
204	v	N	I-Premise
205	3.0	N	I-Premise
206	;	N	I-Premise
207	P	N	I-Premise
208	<	N	I-Premise
209	.001	N	I-Premise
210	)	N	I-Premise
211	and	N	I-Premise
212	at	N	I-Premise
213	12	N	I-Premise
214	months	N	I-Premise
215	(	N	I-Premise
216	3.6	N	I-Premise
217	v	N	I-Premise
218	2.5	N	I-Premise
219	;	N	I-Premise
220	P	N	I-Premise
221	=	N	I-Premise
222	.006	N	I-Premise
223	)	N	I-Premise
224	.	N	I-Premise

225	Longitudinally	N	I-Premise
226	,	N	I-Premise
227	SNAD	N	I-Premise
228	patients	N	I-Premise
229	were	N	I-Premise
230	more	N	I-Premise
231	likely	N	I-Premise
232	to	N	I-Premise
233	experience	N	I-Premise
234	ipsilateral	N	I-Premise
235	arm	N	I-Premise
236	and	N	I-Premise
237	breast	N	I-Premise
238	symptoms	N	I-Premise
239	,	N	I-Premise
240	restricted	N	I-Premise
241	work	N	I-Premise
242	and	N	I-Premise
243	social	N	I-Premise
244	activity	N	I-Premise
245	,	N	I-Premise
246	and	N	I-Premise
247	impaired	N	I-Premise
248	QOL	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	<	N	I-Premise
252	or	N	I-Premise
253	=	N	I-Premise
254	.002	N	I-Premise
255	all	N	I-Premise
256	items	N	I-Premise
257	)	N	I-Premise
258	.	N	I-Premise

259	From	N	I-Premise
260	12	N	I-Premise
261	to	N	I-Premise
262	36	N	I-Premise
263	months	N	I-Premise
264	,	N	I-Premise
265	fewer	N	I-Premise
266	than	N	I-Premise
267	15	N	I-Premise
268	%	N	I-Premise
269	of	N	I-Premise
270	either	N	I-Premise
271	SNAD	N	I-Premise
272	or	N	I-Premise
273	SNR	N	I-Premise
274	patients	N	I-Premise
275	reported	N	I-Premise
276	moderate	N	I-Premise
277	or	N	I-Premise
278	greater	N	I-Premise
279	severity	N	I-Premise
280	of	N	I-Premise
281	any	N	I-Premise
282	given	N	I-Premise
283	symptom	N	I-Premise
284	or	N	I-Premise
285	activity	N	I-Premise
286	limitation	N	I-Premise
287	.	N	I-Premise

288	Arm	N	I-Claim
289	morbidity	N	I-Claim
290	was	N	I-Claim
291	greater	N	I-Claim
292	with	N	I-Claim
293	SNAD	N	I-Claim
294	than	N	I-Claim
295	with	N	I-Claim
296	SNR	N	I-Claim
297	.	N	I-Claim

298	Despite	N	O
299	considerable	N	O
300	fears	N	O
301	about	N	O
302	complications	N	O
303	from	N	O
304	AD	N	O
305	for	N	O
306	breast	N	O
307	cancer	N	O
308	,	N	O
309	this	N	I-Claim
310	study	N	I-Claim
311	demonstrates	N	I-Claim
312	that	N	I-Claim
313	initial	N	I-Claim
314	problems	N	I-Claim
315	with	N	I-Claim
316	either	N	I-Claim
317	surgery	N	I-Claim
318	resolve	N	I-Claim
319	over	N	I-Claim
320	time	N	I-Claim
321	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	effects	N	O
11	on	N	O
12	health-related	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	HRQOL	N	O
18	)	N	O
19	of	N	O
20	two	N	O
21	treatment	N	O
22	regimens	N	O
23	in	N	O
24	the	N	O
25	TEX	N	O
26	trial	N	O
27	during	N	O
28	9	N	O
29	month	N	O
30	from	N	O
31	random	N	O
32	assignment	N	O
33	,	N	O
34	with	N	O
35	emphasis	N	O
36	on	N	O
37	the	N	O
38	2-	N	O
39	and	N	O
40	9-months	N	O
41	assessments	N	O
42	.	N	O

43	A	N	O
44	total	N	O
45	of	N	O
46	287	N	O
47	patients	N	O
48	were	N	O
49	randomized	N	O
50	to	N	O
51	treatment	N	O
52	in	N	O
53	3-week	N	O
54	cycles	N	O
55	with	N	O
56	either	N	O
57	epirubicin	N	O
58	plus	N	O
59	paclitaxel	N	O
60	(	N	O
61	ET	N	O
62	,	N	O
63	143	N	O
64	patients	N	O
65	)	N	O
66	,	N	O
67	or	N	O
68	epirubicin	N	O
69	,	N	O
70	paclitaxel	N	O
71	and	N	O
72	capecitabine	N	O
73	(	N	O
74	TEX	N	O
75	,	N	O
76	144	N	O
77	patients	N	O
78	)	N	O
79	.	N	O

80	HRQOL	N	O
81	was	N	O
82	assessed	N	O
83	by	N	O
84	the	N	O
85	EORTC-QLQ	N	O
86	C30	N	O
87	and	N	O
88	EORTC	N	O
89	QLQ-BR23	N	O
90	questionnaires	N	O
91	at	N	O
92	five	N	O
93	points	N	O
94	during	N	O
95	9	N	O
96	months	N	O
97	.	N	O

98	A	N	O
99	total	N	O
100	of	N	O
101	252	N	O
102	(	N	O
103	88	N	O
104	%	N	O
105	)	N	O
106	completed	N	O
107	questionnaires	N	O
108	before	N	O
109	randomization	N	O
110	.	N	O

111	Response	N	O
112	rate	N	O
113	for	N	O
114	the	N	O
115	following	N	O
116	assessments	N	O
117	was	N	O
118	>	N	O
119	75	N	O
120	%	N	O
121	.	N	O

122	There	N	I-Premise
123	were	N	I-Premise
124	no	N	I-Premise
125	statistically	N	I-Premise
126	significant	N	I-Premise
127	differences	N	I-Premise
128	between	N	I-Premise
129	the	N	I-Premise
130	TEX	N	I-Premise
131	group	N	I-Premise
132	and	N	I-Premise
133	the	N	I-Premise
134	ET	N	I-Premise
135	group	N	I-Premise
136	on	N	I-Premise
137	any	N	I-Premise
138	of	N	I-Premise
139	the	N	I-Premise
140	subscales	N	I-Premise
141	2	N	I-Premise
142	months	N	I-Premise
143	after	N	I-Premise
144	randomization	N	I-Premise
145	.	N	I-Premise

146	Small	N	I-Premise
147	clinical	N	I-Premise
148	differences	N	I-Premise
149	(	N	I-Premise
150	5-10	N	I-Premise
151	points	N	I-Premise
152	)	N	I-Premise
153	in	N	I-Premise
154	favor	N	I-Premise
155	of	N	I-Premise
156	the	N	I-Premise
157	ET	N	I-Premise
158	group	N	I-Premise
159	were	N	I-Premise
160	found	N	I-Premise
161	for	N	I-Premise
162	global	N	I-Premise
163	quality	N	I-Premise
164	of	N	I-Premise
165	life	N	I-Premise
166	,	N	I-Premise
167	role	N	I-Premise
168	functioning	N	I-Premise
169	,	N	I-Premise
170	social	N	I-Premise
171	functioning	N	I-Premise
172	,	N	I-Premise
173	and	N	I-Premise
174	insomnia	N	I-Premise
175	.	N	I-Premise

176	At	N	I-Premise
177	the	N	I-Premise
178	9-months	N	I-Premise
179	assessment	N	I-Premise
180	,	N	I-Premise
181	the	N	I-Premise
182	TEX	N	I-Premise
183	group	N	I-Premise
184	scored	N	I-Premise
185	statistically	N	I-Premise
186	significantly	N	I-Premise
187	higher	N	I-Premise
188	on	N	I-Premise
189	global	N	I-Premise
190	quality	N	I-Premise
191	of	N	I-Premise
192	life	N	I-Premise
193	and	N	I-Premise
194	physical	N	I-Premise
195	functioning	N	I-Premise
196	.	N	I-Premise

197	Small	N	I-Premise
198	clinically	N	I-Premise
199	significant	N	I-Premise
200	differences	N	I-Premise
201	were	N	I-Premise
202	found	N	I-Premise
203	for	N	I-Premise
204	global	N	I-Premise
205	quality	N	I-Premise
206	of	N	I-Premise
207	life	N	I-Premise
208	,	N	I-Premise
209	physical	N	I-Premise
210	functioning	N	I-Premise
211	,	N	I-Premise
212	role	N	I-Premise
213	functioning	N	I-Premise
214	,	N	I-Premise
215	emotional	N	I-Premise
216	functioning	N	I-Premise
217	,	N	I-Premise
218	dyspnoea	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	insomnia	N	I-Premise
222	,	N	I-Premise
223	all	N	I-Premise
224	in	N	I-Premise
225	favour	N	I-Premise
226	of	N	I-Premise
227	the	N	I-Premise
228	TEX	N	I-Premise
229	group	N	I-Premise
230	.	N	I-Premise

231	At	N	I-Claim
232	the	N	I-Claim
233	2-months	N	I-Claim
234	assessment	N	I-Claim
235	,	N	I-Claim
236	when	N	I-Claim
237	side-effects	N	I-Claim
238	of	N	I-Claim
239	chemotherapy	N	I-Claim
240	were	N	I-Claim
241	present	N	I-Claim
242	,	N	I-Claim
243	patients	N	I-Claim
244	in	N	I-Claim
245	the	N	I-Claim
246	TEX	N	I-Claim
247	group	N	I-Claim
248	appeared	N	I-Claim
249	to	N	I-Claim
250	fare	N	I-Claim
251	a	N	I-Claim
252	bit	N	I-Claim
253	worse	N	I-Claim
254	than	N	I-Claim
255	those	N	I-Claim
256	receiving	N	I-Claim
257	ET	N	I-Claim
258	.	N	I-Claim

259	However	N	O
260	,	N	O
261	after	N	I-Claim
262	9	N	I-Claim
263	months	N	I-Claim
264	,	N	I-Claim
265	when	N	I-Claim
266	the	N	I-Claim
267	patients	N	I-Claim
268	had	N	I-Claim
269	adapted	N	I-Claim
270	to	N	I-Claim
271	treatment	N	I-Claim
272	,	N	I-Claim
273	the	N	I-Claim
274	TEX	N	I-Claim
275	group	N	I-Claim
276	seemed	N	I-Claim
277	to	N	I-Claim
278	have	N	I-Claim
279	a	N	I-Claim
280	slightly	N	I-Claim
281	better	N	I-Claim
282	quality	N	I-Claim
283	of	N	I-Claim
284	life	N	I-Claim
285	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	clinical	N	O
5	effectiveness	N	O
6	of	N	O
7	a	N	O
8	topical	N	O
9	application	N	O
10	of	N	O
11	Xiaozheng	N	O
12	Zhitong	N	O
13	:	N	O
14	Paste	N	O
15	(	N	O
16	,	N	O
17	XZP	N	O
18	)	N	O
19	in	N	O
20	alleviating	N	O
21	the	N	O
22	cancerous	N	O
23	pain	N	O
24	of	N	O
25	patients	N	O
26	with	N	O
27	middle/late	N	O
28	stage	N	O
29	cancer	N	O
30	By	N	O
31	:	N	O
32	adopting	N	O
33	a	N	O
34	random	N	O
35	number	N	O
36	table	N	O
37	,	N	O
38	124	N	O
39	patients	N	O
40	enrolled	N	O
41	were	N	O
42	randomized	N	O
43	into	N	O
44	the	N	O
45	treatment	N	O
46	group	N	O
47	(	N	O
48	64	N	O
49	patients	N	O
50	)	N	O
51	and	N	O
52	the	N	O
53	control	N	O
54	group	N	O
55	(	N	O
56	60	N	O
57	patients	N	O
58	)	N	O
59	.	N	O

60	In	N	O
61	addition	N	O
62	to	N	O
63	the	N	O
64	basic	N	O
65	therapy	N	O
66	[	N	O
67	including	N	O
68	the	N	O
69	three-ladder	N	O
70	(	N	O
71	3L	N	O
72	)	N	O
73	analgesia	N	O
74	]	N	O
75	used	N	O
76	in	N	O
77	both	N	O
78	groups	N	O
79	,	N	O
80	topical	N	O
81	application	N	O
82	of	N	O
83	XZP	N	O
84	was	N	O
85	given	N	O
86	to	N	O
87	patients	N	O
88	in	N	O
89	the	N	O
90	treatment	N	O
91	group	N	O
92	for	N	O
93	pain	N	O
94	alleviation	N	O
95	.	N	O

96	The	N	O
97	analgesic	N	O
98	efficacy	N	O
99	was	N	O
100	recorded	N	O
101	in	N	O
102	terms	N	O
103	of	N	O
104	pain	N	O
105	intensity	N	O
106	,	N	O
107	analgesia	N	O
108	initiating	N	O
109	time	N	O
110	and	N	O
111	sustaining	N	O
112	time	N	O
113	,	N	O
114	and	N	O
115	the	N	O
116	optimal	N	O
117	analgesic	N	O
118	effect	N	O
119	revealing	N	O
120	time	N	O
121	.	N	O

122	Meanwhile	N	O
123	,	N	O
124	the	N	O
125	quality	N	O
126	of	N	O
127	life	N	O
128	(	N	O
129	QOL	N	O
130	)	N	O
131	and	N	O
132	adverse	N	O
133	reactions	N	O
134	that	N	O
135	occurred	N	O
136	in	N	O
137	patients	N	O
138	were	N	O
139	recorded	N	O
140	as	N	O
141	well	N	O
142	.	N	O

143	The	N	I-Premise
144	total	N	I-Premise
145	effective	N	I-Premise
146	rate	N	I-Premise
147	in	N	I-Premise
148	the	N	I-Premise
149	treatment	N	I-Premise
150	group	N	I-Premise
151	was	N	I-Premise
152	:	N	I-Premise
153	84.38	N	I-Premise
154	%	N	I-Premise
155	(	N	I-Premise
156	54/64	N	I-Premise
157	)	N	I-Premise
158	,	N	I-Premise
159	and	N	I-Premise
160	in	N	I-Premise
161	the	N	I-Premise
162	control	N	I-Premise
163	group	N	I-Premise
164	it	N	I-Premise
165	was	N	I-Premise
166	88.33	N	I-Premise
167	%	N	I-Premise
168	(	N	I-Premise
169	53/60	N	I-Premise
170	)	N	I-Premise
171	,	N	I-Premise
172	showing	N	I-Premise
173	no	N	I-Premise
174	significant	N	I-Premise
175	difference	N	I-Premise
176	between	N	I-Premise
177	them	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	>	N	I-Premise
181	0.05	N	I-Premise
182	)	N	I-Premise
183	,	N	I-Premise
184	but	N	I-Premise
185	the	N	I-Premise
186	analgesia	N	I-Premise
187	initiating	N	I-Premise
188	time	N	I-Premise
189	and	N	I-Premise
190	the	N	I-Premise
191	optimal	N	I-Premise
192	analgesia	N	I-Premise
193	effect	N	I-Premise
194	revealing	N	I-Premise
195	time	N	I-Premise
196	in	N	I-Premise
197	the	N	I-Premise
198	treatment	N	I-Premise
199	group	N	I-Premise
200	were	N	I-Premise
201	significantly	N	I-Premise
202	shorter	N	I-Premise
203	(	N	I-Premise
204	both	N	I-Premise
205	P	N	I-Premise
206	<	N	I-Premise
207	0.01	N	I-Premise
208	)	N	I-Premise
209	.	N	I-Premise

210	Moreover	N	O
211	,	N	O
212	XZP	N	I-Premise
213	was	N	I-Premise
214	better	N	I-Premise
215	in	N	I-Premise
216	improving	N	I-Premise
217	patients	N	I-Premise
218	'	N	I-Premise
219	QOL	N	I-Premise
220	,	N	I-Premise
221	showing	N	I-Premise
222	more	N	I-Premise
223	significant	N	I-Premise
224	improvements	N	I-Premise
225	in	N	I-Premise
226	the	N	I-Premise
227	treatment	N	I-Premise
228	group	N	I-Premise
229	than	N	I-Premise
230	those	N	I-Premise
231	in	N	I-Premise
232	the	N	I-Premise
233	control	N	I-Premise
234	group	N	I-Premise
235	in	N	I-Premise
236	aspects	N	I-Premise
237	of	N	I-Premise
238	mental	N	I-Premise
239	condition	N	I-Premise
240	,	N	I-Premise
241	walking	N	I-Premise
242	capacity	N	I-Premise
243	,	N	I-Premise
244	working	N	I-Premise
245	capacity	N	I-Premise
246	,	N	I-Premise
247	social	N	I-Premise
248	acceptability	N	I-Premise
249	,	N	I-Premise
250	sleep	N	I-Premise
251	and	N	I-Premise
252	joy	N	I-Premise
253	of	N	I-Premise
254	living	N	I-Premise
255	(	N	I-Premise
256	P	N	I-Premise
257	<	N	I-Premise
258	0.05	N	I-Premise
259	or	N	I-Premise
260	P	N	I-Premise
261	<	N	I-Premise
262	0.01	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	Lower	N	I-Premise
266	incidence	N	I-Premise
267	of	N	I-Premise
268	adverse	N	I-Premise
269	reactions	N	I-Premise
270	,	N	I-Premise
271	such	N	I-Premise
272	as	N	I-Premise
273	nausea	N	I-Premise
274	,	N	I-Premise
275	vomiting	N	I-Premise
276	,	N	I-Premise
277	mouth	N	I-Premise
278	dryness	N	I-Premise
279	,	N	I-Premise
280	dizziness	N	I-Premise
281	,	N	I-Premise
282	etc.	N	I-Premise
283	,	N	I-Premise
284	especially	N	I-Premise
285	constipation	N	I-Premise
286	,	N	I-Premise
287	was	N	I-Premise
288	noted	N	I-Premise
289	in	N	I-Premise
290	the	N	I-Premise
291	treatment	N	I-Premise
292	group	N	I-Premise
293	(	N	I-Premise
294	P	N	I-Premise
295	<	N	I-Premise
296	0.05	N	I-Premise
297	or	N	I-Premise
298	P	N	I-Premise
299	<	N	I-Premise
300	0.01	N	I-Premise
301	)	N	I-Premise
302	.	N	I-Premise

303	Applying	N	I-Claim
304	an	N	I-Claim
305	external	N	I-Claim
306	compress	N	I-Claim
307	:	N	I-Claim
308	of	N	I-Claim
309	XZP	N	I-Claim
310	showed	N	I-Claim
311	a	N	I-Claim
312	synergistic	N	I-Claim
313	action	N	I-Claim
314	with	N	I-Claim
315	3L	N	I-Claim
316	analgesia	N	I-Claim
317	for	N	I-Claim
318	shortening	N	I-Claim
319	the	N	I-Claim
320	initiating	N	I-Claim
321	time	N	I-Claim
322	and	N	I-Claim
323	the	N	I-Claim
324	optimal	N	I-Claim
325	effect	N	I-Claim
326	revealing	N	I-Claim
327	time	N	I-Claim
328	,	N	I-Claim
329	and	N	I-Claim
330	could	N	I-Claim
331	evidently	N	I-Claim
332	enhance	N	I-Claim
333	patients	N	I-Claim
334	'	N	I-Claim
335	QOL	N	I-Claim
336	with	N	I-Claim
337	fewer	N	I-Claim
338	adverse	N	I-Claim
339	reactions	N	I-Claim
340	.	N	I-Claim

1	One	N	O
2	attempt	N	O
3	to	N	O
4	improve	N	O
5	long-term	N	O
6	survival	N	O
7	in	N	O
8	patients	N	O
9	with	N	O
10	advanced	N	O
11	ovarian	N	O
12	cancer	N	O
13	was	N	O
14	thought	N	O
15	to	N	O
16	be	N	O
17	the	N	O
18	addition	N	O
19	of	N	O
20	more	N	O
21	non-cross-resistant	N	O
22	drugs	N	O
23	to	N	O
24	platinum-paclitaxel	N	O
25	combination	N	O
26	regimens	N	O
27	.	N	O

28	Gemcitabine	N	O
29	was	N	O
30	among	N	O
31	the	N	O
32	candidates	N	O
33	for	N	O
34	a	N	O
35	third	N	O
36	drug	N	O
37	.	N	O

38	We	N	O
39	performed	N	O
40	a	N	O
41	prospective	N	O
42	,	N	O
43	randomized	N	O
44	,	N	O
45	phase	N	O
46	III	N	O
47	,	N	O
48	intergroup	N	O
49	trial	N	O
50	to	N	O
51	compare	N	O
52	carboplatin	N	O
53	plus	N	O
54	paclitaxel	N	O
55	(	N	O
56	TC	N	O
57	;	N	O
58	area	N	O
59	under	N	O
60	the	N	O
61	curve	N	O
62	[	N	O
63	AUC	N	O
64	]	N	O
65	5	N	O
66	and	N	O
67	175	N	O
68	mg/m	N	O
69	(	N	O
70	2	N	O
71	)	N	O
72	,	N	O
73	respectively	N	O
74	)	N	O
75	with	N	O
76	the	N	O
77	same	N	O
78	combination	N	O
79	and	N	O
80	additional	N	O
81	gemcitabine	N	O
82	800	N	O
83	mg/m	N	O
84	(	N	O
85	2	N	O
86	)	N	O
87	on	N	O
88	days	N	O
89	1	N	O
90	and	N	O
91	8	N	O
92	(	N	O
93	TCG	N	O
94	)	N	O
95	in	N	O
96	previously	N	O
97	untreated	N	O
98	patients	N	O
99	with	N	O
100	advanced	N	O
101	epithelial	N	O
102	ovarian	N	O
103	cancer	N	O
104	.	N	O

105	TC	N	O
106	was	N	O
107	administered	N	O
108	intravenously	N	O
109	(	N	O
110	IV	N	O
111	)	N	O
112	on	N	O
113	day	N	O
114	1	N	O
115	every	N	O
116	21	N	O
117	days	N	O
118	for	N	O
119	a	N	O
120	planned	N	O
121	minimum	N	O
122	of	N	O
123	six	N	O
124	courses	N	O
125	.	N	O

126	Gemcitabine	N	O
127	was	N	O
128	administered	N	O
129	by	N	O
130	IV	N	O
131	on	N	O
132	days	N	O
133	1	N	O
134	and	N	O
135	8	N	O
136	of	N	O
137	each	N	O
138	cycle	N	O
139	in	N	O
140	the	N	O
141	TCG	N	O
142	arm	N	O
143	.	N	O

144	Between	N	O
145	2002	N	O
146	and	N	O
147	2004	N	O
148	,	N	O
149	1,742	N	O
150	patients	N	O
151	were	N	O
152	randomly	N	O
153	assigned	N	O
154	;	N	O
155	882	N	O
156	and	N	O
157	860	N	O
158	patients	N	O
159	received	N	O
160	TC	N	O
161	and	N	O
162	TCG	N	O
163	,	N	O
164	respectively	N	O
165	.	N	O

166	Grades	N	I-Premise
167	3	N	I-Premise
168	to	N	I-Premise
169	4	N	I-Premise
170	hematologic	N	I-Premise
171	toxicity	N	I-Premise
172	and	N	I-Premise
173	fatigue	N	I-Premise
174	occurred	N	I-Premise
175	more	N	I-Premise
176	frequently	N	I-Premise
177	in	N	I-Premise
178	the	N	I-Premise
179	TCG	N	I-Premise
180	arm	N	I-Premise
181	.	N	I-Premise

182	Accordingly	N	O
183	,	N	O
184	quality-of-life	N	I-Claim
185	analysis	N	I-Claim
186	during	N	I-Claim
187	chemotherapy	N	I-Claim
188	showed	N	I-Claim
189	a	N	I-Claim
190	disadvantage	N	I-Claim
191	in	N	I-Claim
192	the	N	I-Claim
193	TCG	N	I-Claim
194	arm	N	I-Claim
195	.	N	I-Claim

196	Although	N	I-Premise
197	objective	N	I-Premise
198	response	N	I-Premise
199	was	N	I-Premise
200	slightly	N	I-Premise
201	higher	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	TCG	N	I-Premise
205	arm	N	I-Premise
206	,	N	I-Premise
207	this	N	I-Premise
208	did	N	I-Premise
209	not	N	I-Premise
210	translate	N	I-Premise
211	into	N	I-Premise
212	improved	N	I-Premise
213	progression-free	N	I-Premise
214	survival	N	I-Premise
215	(	N	I-Premise
216	PFS	N	I-Premise
217	)	N	I-Premise
218	or	N	I-Premise
219	overall	N	I-Premise
220	survival	N	I-Premise
221	(	N	I-Premise
222	OS	N	I-Premise
223	)	N	I-Premise
224	.	N	I-Premise

225	Median	N	I-Premise
226	PFS	N	I-Premise
227	was	N	I-Premise
228	17.8	N	I-Premise
229	months	N	I-Premise
230	for	N	I-Premise
231	the	N	I-Premise
232	TCG	N	I-Premise
233	arm	N	I-Premise
234	and	N	I-Premise
235	19.3	N	I-Premise
236	months	N	I-Premise
237	for	N	I-Premise
238	the	N	I-Premise
239	TC	N	I-Premise
240	arm	N	I-Premise
241	(	N	I-Premise
242	hazard	N	I-Premise
243	ratio	N	I-Premise
244	[	N	I-Premise
245	HR	N	I-Premise
246	]	N	I-Premise
247	,	N	I-Premise
248	1.18	N	I-Premise
249	;	N	I-Premise
250	95	N	I-Premise
251	%	N	I-Premise
252	CI	N	I-Premise
253	,	N	I-Premise
254	1.06	N	I-Premise
255	to	N	I-Premise
256	1.32	N	I-Premise
257	;	N	I-Premise
258	P	N	I-Premise
259	=	N	I-Premise
260	.0044	N	I-Premise
261	)	N	I-Premise
262	.	N	I-Premise

263	Median	N	I-Premise
264	OS	N	I-Premise
265	was	N	I-Premise
266	49.5	N	I-Premise
267	for	N	I-Premise
268	the	N	I-Premise
269	TCG	N	I-Premise
270	arm	N	I-Premise
271	and	N	I-Premise
272	51.5	N	I-Premise
273	months	N	I-Premise
274	for	N	I-Premise
275	the	N	I-Premise
276	TC	N	I-Premise
277	arm	N	I-Premise
278	(	N	I-Premise
279	HR	N	I-Premise
280	,	N	I-Premise
281	1.05	N	I-Premise
282	;	N	I-Premise
283	95	N	I-Premise
284	%	N	I-Premise
285	CI	N	I-Premise
286	,	N	I-Premise
287	0.91	N	I-Premise
288	to	N	I-Premise
289	1.20	N	I-Premise
290	;	N	I-Premise
291	P	N	I-Premise
292	=	N	I-Premise
293	.5106	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	The	N	I-Claim
297	addition	N	I-Claim
298	of	N	I-Claim
299	gemcitabine	N	I-Claim
300	to	N	I-Claim
301	carboplatin	N	I-Claim
302	plus	N	I-Claim
303	paclitaxel	N	I-Claim
304	increased	N	I-Claim
305	treatment	N	I-Claim
306	burden	N	I-Claim
307	,	N	I-Claim
308	reduced	N	I-Claim
309	PFS	N	I-Claim
310	time	N	I-Claim
311	,	N	I-Claim
312	and	N	I-Claim
313	did	N	I-Claim
314	not	N	I-Claim
315	improve	N	I-Claim
316	OS	N	I-Claim
317	in	N	I-Claim
318	patients	N	I-Claim
319	with	N	I-Claim
320	advanced	N	I-Claim
321	epithelial	N	I-Claim
322	ovarian	N	I-Claim
323	cancer	N	I-Claim
324	.	N	I-Claim

325	Therefore	N	I-MajorClaim
326	,	N	I-MajorClaim
327	we	N	I-MajorClaim
328	recommend	N	I-MajorClaim
329	no	N	I-MajorClaim
330	additional	N	I-MajorClaim
331	clinical	N	I-MajorClaim
332	use	N	I-MajorClaim
333	of	N	I-MajorClaim
334	TCG	N	I-MajorClaim
335	in	N	I-MajorClaim
336	this	N	I-MajorClaim
337	population	N	I-MajorClaim
338	.	N	I-MajorClaim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	economic	N	O
7	efficiency	N	O
8	of	N	O
9	a	N	O
10	multimedia	N	O
11	,	N	O
12	multimodal	N	O
13	physical	N	O
14	activity	N	O
15	program	N	O
16	for	N	O
17	women	N	O
18	undergoing	N	O
19	adjuvant	N	O
20	therapy	N	O
21	following	N	O
22	surgery	N	O
23	for	N	O
24	breast	N	O
25	cancer	N	O
26	.	N	O

27	We	N	O
28	conducted	N	O
29	a	N	O
30	randomized	N	O
31	trial	N	O
32	with	N	O
33	concurrent	N	O
34	incremental	N	O
35	cost-effectiveness	N	O
36	analysis	N	O
37	and	N	O
38	blinded	N	O
39	baseline	N	O
40	,	N	O
41	3	N	O
42	,	N	O
43	6	N	O
44	and	N	O
45	12-month	N	O
46	follow-up	N	O
47	assessments	N	O
48	amongst	N	O
49	women	N	O
50	undergoing	N	O
51	adjuvant	N	O
52	therapy	N	O
53	following	N	O
54	surgery	N	O
55	for	N	O
56	breast	N	O
57	cancer	N	O
58	(	N	O
59	n	N	O
60	=	N	O
61	89	N	O
62	)	N	O
63	.	N	O

64	The	N	O
65	intervention	N	O
66	was	N	O
67	a	N	O
68	multimedia	N	O
69	,	N	O
70	multimodal	N	O
71	exercise	N	O
72	program	N	O
73	comprising	N	O
74	strength	N	O
75	,	N	O
76	balance	N	O
77	and	N	O
78	endurance	N	O
79	training	N	O
80	elements	N	O
81	.	N	O

82	The	N	O
83	control	N	O
84	was	N	O
85	sham	N	O
86	flexibility	N	O
87	and	N	O
88	relaxation	N	O
89	program	N	O
90	delivered	N	O
91	using	N	O
92	similar	N	O
93	materials	N	O
94	.	N	O

95	The	N	O
96	primary	N	O
97	outcome	N	O
98	was	N	O
99	health-related	N	O
100	quality	N	O
101	of	N	O
102	life	N	O
103	(	N	O
104	EQ-5D	N	O
105	&	N	O
106	amp	N	O
107	;	N	O
108	VAS	N	O
109	,	N	O
110	EORTC	N	O
111	C30	N	O
112	,	N	O
113	BR23	N	O
114	)	N	O
115	.	N	O

116	Economic	N	O
117	outcomes	N	O
118	included	N	O
119	direct	N	O
120	health	N	O
121	care	N	O
122	costs	N	O
123	and	N	O
124	productivity	N	O
125	gains	N	O
126	and	N	O
127	losses	N	O
128	.	N	O

129	Participants	N	I-Premise
130	in	N	I-Premise
131	the	N	I-Premise
132	intervention	N	I-Premise
133	group	N	I-Premise
134	demonstrated	N	I-Premise
135	greater	N	I-Premise
136	improvement	N	I-Premise
137	in	N	I-Premise
138	health-related	N	I-Premise
139	quality	N	I-Premise
140	of	N	I-Premise
141	life	N	I-Premise
142	between	N	I-Premise
143	baseline	N	I-Premise
144	and	N	I-Premise
145	the	N	I-Premise
146	3-month	N	I-Premise
147	assessment	N	I-Premise
148	[	N	I-Premise
149	mean	N	I-Premise
150	(	N	I-Premise
151	sd	N	I-Premise
152	)	N	I-Premise
153	EQ-5D	N	I-Premise
154	VAS	N	I-Premise
155	(	N	I-Premise
156	0-100	N	I-Premise
157	)	N	I-Premise
158	baseline	N	I-Premise
159	:	N	I-Premise
160	72.6	N	I-Premise
161	(	N	I-Premise
162	15.6	N	I-Premise
163	)	N	I-Premise
164	,	N	I-Premise
165	3	N	I-Premise
166	month	N	I-Premise
167	:	N	I-Premise
168	80.6	N	I-Premise
169	(	N	I-Premise
170	11.6	N	I-Premise
171	)	N	I-Premise
172	]	N	I-Premise
173	when	N	I-Premise
174	compared	N	I-Premise
175	to	N	I-Premise
176	control	N	I-Premise
177	group	N	I-Premise
178	participants	N	I-Premise
179	[	N	I-Premise
180	baseline	N	I-Premise
181	:	N	I-Premise
182	77.5	N	I-Premise
183	(	N	I-Premise
184	13.5	N	I-Premise
185	)	N	I-Premise
186	,	N	I-Premise
187	3	N	I-Premise
188	month	N	I-Premise
189	:	N	I-Premise
190	74.1	N	I-Premise
191	(	N	I-Premise
192	20.6	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	P	N	I-Premise
196	=	N	I-Premise
197	0.006	N	I-Premise
198	]	N	I-Premise
199	and	N	I-Premise
200	also	N	I-Premise
201	improved	N	I-Premise
202	more	N	I-Premise
203	in	N	I-Premise
204	terms	N	I-Premise
205	of	N	I-Premise
206	physical	N	I-Premise
207	function	N	I-Premise
208	[	N	I-Premise
209	mean	N	I-Premise
210	(	N	I-Premise
211	sd	N	I-Premise
212	)	N	I-Premise
213	EORTC	N	I-Premise
214	C30	N	I-Premise
215	physical	N	I-Premise
216	function	N	I-Premise
217	scale	N	I-Premise
218	intervention	N	I-Premise
219	(	N	I-Premise
220	0-100	N	I-Premise
221	)	N	I-Premise
222	baseline	N	I-Premise
223	:	N	I-Premise
224	84.9	N	I-Premise
225	(	N	I-Premise
226	14.8	N	I-Premise
227	)	N	I-Premise
228	,	N	I-Premise
229	3	N	I-Premise
230	month	N	I-Premise
231	:	N	I-Premise
232	86.9	N	I-Premise
233	(	N	I-Premise
234	10.7	N	I-Premise
235	)	N	I-Premise
236	,	N	I-Premise
237	control	N	I-Premise
238	baseline	N	I-Premise
239	:	N	I-Premise
240	91.3	N	I-Premise
241	(	N	I-Premise
242	9.6	N	I-Premise
243	)	N	I-Premise
244	,	N	I-Premise
245	3	N	I-Premise
246	month	N	I-Premise
247	:	N	I-Premise
248	86.7	N	I-Premise
249	(	N	I-Premise
250	14.9	N	I-Premise
251	)	N	I-Premise
252	,	N	I-Premise
253	P	N	I-Premise
254	=	N	I-Premise
255	0.02	N	I-Premise
256	]	N	I-Premise
257	.	N	I-Premise

258	These	N	O
259	improvements	N	O
260	were	N	O
261	not	N	O
262	sustained	N	O
263	beyond	N	O
264	this	N	O
265	point	N	O
266	.	N	O

267	Upper	N	I-Premise
268	limb	N	I-Premise
269	volumes	N	I-Premise
270	were	N	I-Premise
271	also	N	I-Premise
272	lower	N	I-Premise
273	amongst	N	I-Premise
274	intervention	N	I-Premise
275	group	N	I-Premise
276	participants	N	I-Premise
277	.	N	I-Premise

278	However	N	O
279	,	N	O
280	there	N	I-Premise
281	was	N	I-Premise
282	low	N	I-Premise
283	probability	N	I-Premise
284	that	N	I-Premise
285	the	N	I-Premise
286	intervention	N	I-Premise
287	would	N	I-Premise
288	be	N	I-Premise
289	both	N	I-Premise
290	less	N	I-Premise
291	costly	N	I-Premise
292	and	N	I-Premise
293	more	N	I-Premise
294	effective	N	I-Premise
295	than	N	I-Premise
296	the	N	I-Premise
297	control	N	I-Premise
298	condition	N	I-Premise
299	(	N	I-Premise
300	range	N	I-Premise
301	probability	N	I-Premise
302	=	N	I-Premise
303	0.05-50.02	N	I-Premise
304	%	N	I-Premise
305	depending	N	I-Premise
306	on	N	I-Premise
307	approach	N	I-Premise
308	)	N	I-Premise
309	.	N	I-Premise

310	Provision	N	I-Claim
311	of	N	I-Claim
312	multimodal	N	I-Claim
313	exercise	N	I-Claim
314	programs	N	I-Claim
315	will	N	I-Claim
316	improve	N	I-Claim
317	the	N	I-Claim
318	short-term	N	I-Claim
319	health	N	I-Claim
320	of	N	I-Claim
321	women	N	I-Claim
322	undergoing	N	I-Claim
323	adjuvant	N	I-Claim
324	therapy	N	I-Claim
325	for	N	I-Claim
326	breast	N	I-Claim
327	cancer	N	I-Claim
328	but	N	I-Claim
329	are	N	I-Claim
330	of	N	I-Claim
331	questionable	N	I-Claim
332	economic	N	I-Claim
333	efficiency	N	I-Claim
334	.	N	I-Claim

1	Quality	N	O
2	of	N	O
3	life	N	O
4	is	N	O
5	an	N	O
6	important	N	O
7	outcome	N	O
8	measure	N	O
9	in	N	O
10	the	N	O
11	care	N	O
12	of	N	O
13	patients	N	O
14	with	N	O
15	cancer	N	O
16	.	N	O

17	We	N	O
18	developed	N	O
19	a	N	O
20	new	N	O
21	scoring	N	O
22	system	N	O
23	specifically	N	O
24	for	N	O
25	the	N	O
26	evaluation	N	O
27	of	N	O
28	patients	N	O
29	with	N	O
30	upper	N	O
31	gastrointestinal	N	O
32	cancer	N	O
33	and	N	O
34	postoperative	N	O
35	gastrointestinal	N	O
36	dysfunction	N	O
37	.	N	O

38	This	N	O
39	study	N	O
40	was	N	O
41	undertaken	N	O
42	to	N	O
43	evaluate	N	O
44	the	N	O
45	scoring	N	O
46	system	N	O
47	's	N	O
48	validity	N	O
49	in	N	O
50	comparing	N	O
51	outcomes	N	O
52	after	N	O
53	gastric	N	O
54	resection	N	O
55	.	N	O

56	Patients	N	O
57	with	N	O
58	gastric	N	O
59	cancer	N	O
60	,	N	O
61	3	N	O
62	months	N	O
63	to	N	O
64	3	N	O
65	years	N	O
66	postoperatively	N	O
67	,	N	O
68	were	N	O
69	surveyed	N	O
70	using	N	O
71	the	N	O
72	survey	N	O
73	instrument	N	O
74	.	N	O

75	Postoperative	N	O
76	dysfunction	N	O
77	scores	N	O
78	and	N	O
79	the	N	O
80	status	N	O
81	of	N	O
82	resuming	N	O
83	activities	N	O
84	of	N	O
85	daily	N	O
86	living	N	O
87	were	N	O
88	compared	N	O
89	with	N	O
90	the	N	O
91	surgical	N	O
92	procedure	N	O
93	performed	N	O
94	by	N	O
95	analysis	N	O
96	of	N	O
97	variance	N	O
98	and	N	O
99	multiple-comparison	N	O
100	techniques	N	O
101	.	N	O

102	Of	N	O
103	211	N	O
104	patients	N	O
105	surveyed	N	O
106	,	N	O
107	165	N	O
108	(	N	O
109	119	N	O
110	men	N	O
111	,	N	O
112	46	N	O
113	women	N	O
114	;	N	O
115	mean	N	O
116	age	N	O
117	,	N	O
118	65.1	N	O
119	±	N	O
120	10.5	N	O
121	years	N	O
122	)	N	O
123	responded	N	O
124	.	N	O

125	Procedures	N	O
126	included	N	O
127	distal	N	O
128	gastrectomy	N	O
129	in	N	O
130	100	N	O
131	,	N	O
132	total	N	O
133	gastrectomy	N	O
134	in	N	O
135	57	N	O
136	,	N	O
137	and	N	O
138	pylorus-preserving	N	O
139	gastrectomy	N	O
140	in	N	O
141	8	N	O
142	.	N	O

143	The	N	O
144	overall	N	O
145	dysfunction	N	O
146	score	N	O
147	was	N	O
148	61.8	N	O
149	±	N	O
150	15.5	N	O
151	.	N	O

152	The	N	I-Premise
153	dysfunction	N	I-Premise
154	score	N	I-Premise
155	was	N	I-Premise
156	58.9	N	I-Premise
157	±	N	I-Premise
158	15.0	N	I-Premise
159	after	N	I-Premise
160	distal	N	I-Premise
161	gastrectomy	N	I-Premise
162	,	N	I-Premise
163	66.8	N	I-Premise
164	±	N	I-Premise
165	14.1	N	I-Premise
166	after	N	I-Premise
167	total	N	I-Premise
168	gastrectomy	N	I-Premise
169	,	N	I-Premise
170	and	N	I-Premise
171	62.4	N	I-Premise
172	±	N	I-Premise
173	21.6	N	I-Premise
174	after	N	I-Premise
175	pylorus-preserving	N	I-Premise
176	gastrectomy	N	I-Premise
177	.	N	I-Premise

178	These	N	I-Premise
179	values	N	I-Premise
180	differed	N	I-Premise
181	significantly	N	I-Premise
182	among	N	I-Premise
183	the	N	I-Premise
184	groups	N	I-Premise
185	(	N	I-Premise
186	P	N	I-Premise
187	=	N	I-Premise
188	.007	N	I-Premise
189	)	N	I-Premise
190	.	N	I-Premise

191	Dysfunction	N	I-Premise
192	scores	N	I-Premise
193	according	N	I-Premise
194	to	N	I-Premise
195	postoperative	N	I-Premise
196	activity	N	I-Premise
197	status	N	I-Premise
198	were	N	I-Premise
199	49.1	N	I-Premise
200	±	N	I-Premise
201	15.6	N	I-Premise
202	in	N	I-Premise
203	71	N	I-Premise
204	patients	N	I-Premise
205	who	N	I-Premise
206	resumed	N	I-Premise
207	their	N	I-Premise
208	activities	N	I-Premise
209	,	N	I-Premise
210	56.9	N	I-Premise
211	±	N	I-Premise
212	15.7	N	I-Premise
213	in	N	I-Premise
214	39	N	I-Premise
215	patients	N	I-Premise
216	with	N	I-Premise
217	reduced	N	I-Premise
218	activities	N	I-Premise
219	,	N	I-Premise
220	57.3	N	I-Premise
221	±	N	I-Premise
222	8.8	N	I-Premise
223	in	N	I-Premise
224	15	N	I-Premise
225	patients	N	I-Premise
226	with	N	I-Premise
227	minimal	N	I-Premise
228	activities	N	I-Premise
229	,	N	I-Premise
230	and	N	I-Premise
231	63.3	N	I-Premise
232	±	N	I-Premise
233	11.8	N	I-Premise
234	(	N	I-Premise
235	P	N	I-Premise
236	<	N	I-Premise
237	.05	N	I-Premise
238	)	N	I-Premise
239	in	N	I-Premise
240	16	N	I-Premise
241	patients	N	I-Premise
242	who	N	I-Premise
243	did	N	I-Premise
244	not	N	I-Premise
245	resume	N	I-Premise
246	activities	N	I-Premise
247	because	N	I-Premise
248	of	N	I-Premise
249	poor	N	I-Premise
250	physical	N	I-Premise
251	condition	N	I-Premise
252	.	N	I-Premise

253	This	N	I-Claim
254	scoring	N	I-Claim
255	system	N	I-Claim
256	for	N	I-Claim
257	postoperative	N	I-Claim
258	gastrointestinal	N	I-Claim
259	dysfunction	N	I-Claim
260	provides	N	I-Claim
261	an	N	I-Claim
262	objective	N	I-Claim
263	measure	N	I-Claim
264	of	N	I-Claim
265	dysfunction	N	I-Claim
266	related	N	I-Claim
267	to	N	I-Claim
268	specific	N	I-Claim
269	surgical	N	I-Claim
270	procedures	N	I-Claim
271	and	N	I-Claim
272	correlates	N	I-Claim
273	with	N	I-Claim
274	activities	N	I-Claim
275	of	N	I-Claim
276	daily	N	I-Claim
277	living	N	I-Claim
278	in	N	I-Claim
279	the	N	I-Claim
280	postoperative	N	I-Claim
281	period	N	I-Claim
282	.	N	I-Claim

1	Previous	N	O
2	studies	N	O
3	have	N	O
4	demonstrated	N	O
5	that	N	O
6	both	N	O
7	anastrozole	N	O
8	and	N	O
9	letrozole	N	O
10	are	N	O
11	well	N	O
12	tolerated	N	O
13	.	N	O

14	Letrozole	N	O
15	suppresses	N	O
16	estrogen	N	O
17	to	N	O
18	a	N	O
19	greater	N	O
20	degree	N	O
21	than	N	O
22	anastrozole	N	O
23	in	N	O
24	the	N	O
25	serum	N	O
26	and	N	O
27	breast	N	O
28	tumor	N	O
29	.	N	O

30	Concerns	N	O
31	have	N	O
32	been	N	O
33	raised	N	O
34	that	N	O
35	greater	N	O
36	potency	N	O
37	may	N	O
38	adversely	N	O
39	affect	N	O
40	patients	N	O
41	'	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	(	N	O
46	QOL	N	O
47	)	N	O
48	.	N	O

49	One	N	O
50	hundred	N	O
51	eighty-one	N	O
52	postmenopausal	N	O
53	women	N	O
54	with	N	O
55	invasive	N	O
56	estrogen	N	O
57	receptor-positive	N	O
58	breast	N	O
59	cancers	N	O
60	were	N	O
61	randomized	N	O
62	to	N	O
63	receive	N	O
64	either	N	O
65	12	N	O
66	weeks	N	O
67	of	N	O
68	letrozole	N	O
69	followed	N	O
70	by	N	O
71	12	N	O
72	weeks	N	O
73	of	N	O
74	anastrozole	N	O
75	or	N	O
76	the	N	O
77	reverse	N	O
78	sequence	N	O
79	.	N	O

80	One	N	O
81	hundred	N	O
82	and	N	O
83	six	N	O
84	received	N	O
85	immediate	N	O
86	adjuvant	N	O
87	aromatase	N	O
88	inhibitors	N	O
89	(	N	O
90	AIs	N	O
91	)	N	O
92	following	N	O
93	surgery	N	O
94	,	N	O
95	and	N	O
96	75	N	O
97	received	N	O
98	extended	N	O
99	adjuvant	N	O
100	therapy	N	O
101	.	N	O

102	The	N	O
103	Functional	N	O
104	Assessment	N	O
105	of	N	O
106	Cancer	N	O
107	Therapy	N	O
108	Endocrine	N	O
109	Subscale	N	O
110	(	N	O
111	FACT-B-ES	N	O
112	)	N	O
113	QOL	N	O
114	questionnaires	N	O
115	were	N	O
116	completed	N	O
117	to	N	O
118	assess	N	O
119	QOL	N	O
120	on	N	O
121	each	N	O
122	drug	N	O
123	.	N	O

124	Additional	N	O
125	side-effect	N	O
126	profiles	N	O
127	were	N	O
128	collected	N	O
129	.	N	O

130	Each	N	O
131	patient	N	O
132	completed	N	O
133	a	N	O
134	patient	N	O
135	preference	N	O
136	form	N	O
137	.	N	O

138	Twenty-one	N	O
139	patients	N	O
140	withdrew	N	O
141	before	N	O
142	study	N	O
143	end	N	O
144	,	N	O
145	10/179	N	O
146	(	N	O
147	5.6	N	O
148	%	N	O
149	)	N	O
150	while	N	O
151	taking	N	O
152	letrozole	N	O
153	and	N	O
154	4/173	N	O
155	(	N	O
156	2.3	N	O
157	%	N	O
158	)	N	O
159	while	N	O
160	taking	N	O
161	anastrozole	N	O
162	(	N	O
163	P	N	O
164	=	N	O
165	0.12	N	O
166	)	N	O
167	.	N	O

168	Tamoxifen-naïve	N	I-Premise
169	patients	N	I-Premise
170	had	N	I-Premise
171	a	N	I-Premise
172	higher	N	I-Premise
173	mean	N	I-Premise
174	ES	N	I-Premise
175	(	N	I-Premise
176	endocrine	N	I-Premise
177	symptoms	N	I-Premise
178	subscale	N	I-Premise
179	)	N	I-Premise
180	score	N	I-Premise
181	at	N	I-Premise
182	entry	N	I-Premise
183	versus	N	I-Premise
184	those	N	I-Premise
185	having	N	I-Premise
186	extended	N	I-Premise
187	therapy	N	I-Premise
188	(	N	I-Premise
189	66.0	N	I-Premise
190	vs.	N	I-Premise
191	61.9	N	I-Premise
192	;	N	I-Premise
193	P	N	I-Premise
194	=	N	I-Premise
195	0.001	N	I-Premise
196	)	N	I-Premise
197	.	N	I-Premise

198	There	N	I-Premise
199	was	N	I-Premise
200	no	N	I-Premise
201	significant	N	I-Premise
202	change	N	I-Premise
203	in	N	I-Premise
204	FACT-B-ES	N	I-Premise
205	(	N	I-Premise
206	overall	N	I-Premise
207	)	N	I-Premise
208	scores	N	I-Premise
209	or	N	I-Premise
210	ES	N	I-Premise
211	scores	N	I-Premise
212	while	N	I-Premise
213	patients	N	I-Premise
214	were	N	I-Premise
215	taking	N	I-Premise
216	anastrozole	N	I-Premise
217	or	N	I-Premise
218	letrozole	N	I-Premise
219	and	N	I-Premise
220	no	N	I-Premise
221	significant	N	I-Premise
222	differences	N	I-Premise
223	between	N	I-Premise
224	drugs	N	I-Premise
225	.	N	I-Premise

226	Nearly	N	I-Premise
227	80	N	I-Premise
228	%	N	I-Premise
229	of	N	I-Premise
230	patients	N	I-Premise
231	reported	N	I-Premise
232	one	N	I-Premise
233	or	N	I-Premise
234	more	N	I-Premise
235	side	N	I-Premise
236	effects	N	I-Premise
237	with	N	I-Premise
238	either	N	I-Premise
239	agent	N	I-Premise
240	.	N	I-Premise

241	No	N	I-Premise
242	differences	N	I-Premise
243	in	N	I-Premise
244	frequency	N	I-Premise
245	,	N	I-Premise
246	grade	N	I-Premise
247	,	N	I-Premise
248	or	N	I-Premise
249	range	N	I-Premise
250	of	N	I-Premise
251	side	N	I-Premise
252	effects	N	I-Premise
253	were	N	I-Premise
254	seen	N	I-Premise
255	between	N	I-Premise
256	drugs	N	I-Premise
257	.	N	I-Premise

258	Of	N	O
259	160	N	O
260	patients	N	O
261	,	N	O
262	49	N	O
263	(	N	O
264	30.6	N	O
265	%	N	O
266	)	N	O
267	preferred	N	O
268	letrozole	N	O
269	,	N	O
270	57	N	O
271	(	N	O
272	35.6	N	O
273	%	N	O
274	)	N	O
275	preferred	N	O
276	anastrozole	N	O
277	,	N	O
278	and	N	O
279	54	N	O
280	(	N	O
281	33.8	N	O
282	%	N	O
283	)	N	O
284	had	N	O
285	no	N	O
286	preference	N	O
287	(	N	O
288	P	N	O
289	=	N	O
290	0.26	N	O
291	,	N	O
292	Pearson	N	O
293	's	N	O
294	Chi-squared	N	O
295	test	N	O
296	)	N	O
297	.	N	O

298	In	N	O
299	conclusion	N	O
300	,	N	O
301	both	N	I-Claim
302	AIs	N	I-Claim
303	are	N	I-Claim
304	equally	N	I-Claim
305	well	N	I-Claim
306	tolerated	N	I-Claim
307	.	N	I-Claim

308	There	N	I-Claim
309	were	N	I-Claim
310	no	N	I-Claim
311	significant	N	I-Claim
312	differences	N	I-Claim
313	in	N	I-Claim
314	QOL	N	I-Claim
315	scores	N	I-Claim
316	between	N	I-Claim
317	the	N	I-Claim
318	two	N	I-Claim
319	drugs	N	I-Claim
320	.	N	I-Claim

1	There	N	O
2	are	N	O
3	patients	N	O
4	with	N	O
5	stage	N	O
6	I-III	N	O
7	non-small	N	O
8	cell	N	O
9	lung	N	O
10	cancer	N	O
11	(	N	O
12	NSCLC	N	O
13	)	N	O
14	who	N	O
15	are	N	O
16	not	N	O
17	suitable	N	O
18	for	N	O
19	curative	N	O
20	radical	N	O
21	chemoradiation	N	O
22	therapy	N	O
23	.	N	O

24	There	N	O
25	are	N	O
26	patients	N	O
27	with	N	O
28	an	N	O
29	isolated	N	O
30	solitary	N	O
31	extracranial	N	O
32	metastasis	N	O
33	who	N	O
34	have	N	O
35	improved	N	O
36	outcomes	N	O
37	compared	N	O
38	with	N	O
39	those	N	O
40	with	N	O
41	cranial	N	O
42	or	N	O
43	multiple	N	O
44	metastases	N	O
45	.	N	O

46	Patients	N	O
47	of	N	O
48	good	N	O
49	performance	N	O
50	status	N	O
51	receiving	N	O
52	moderate	N	O
53	dose	N	O
54	radiation	N	O
55	therapy	N	O
56	have	N	O
57	improved	N	O
58	survival	N	O
59	.	N	O

60	Two	N	O
61	regimens	N	O
62	of	N	O
63	moderate	N	O
64	dose	N	O
65	chemoradiation	N	O
66	therapy	N	O
67	for	N	O
68	such	N	O
69	patients	N	O
70	were	N	O
71	compared	N	O
72	in	N	O
73	a	N	O
74	randomized	N	O
75	phase	N	O
76	II	N	O
77	trial	N	O
78	.	N	O

79	Patients	N	O
80	were	N	O
81	eligible	N	O
82	if	N	O
83	they	N	O
84	had	N	O
85	stage	N	O
86	I-IIIB	N	O
87	NSCLC	N	O
88	,	N	O
89	unsuitable	N	O
90	for	N	O
91	curative	N	O
92	therapy	N	O
93	,	N	O
94	or	N	O
95	stage	N	O
96	IV	N	O
97	with	N	O
98	a	N	O
99	PET-detected	N	O
100	extracranial	N	O
101	solitary	N	O
102	metastasis	N	O
103	.	N	O

104	Patients	N	O
105	were	N	O
106	randomized	N	O
107	to	N	O
108	the	N	O
109	following	N	O
110	groups-arm	N	O
111	A	N	O
112	:	N	O
113	40	N	O
114	Gy/20	N	O
115	fractions/4	N	O
116	weeks	N	O
117	with	N	O
118	concurrent	N	O
119	weekly	N	O
120	vinorelbine	N	O
121	25	N	O
122	mg/m	N	O
123	+	N	O
124	cisplatin	N	O
125	20	N	O
126	mg/m	N	O
127	or	N	O
128	arm	N	O
129	B	N	O
130	:	N	O
131	30	N	O
132	Gy/15	N	O
133	fractions/3	N	O
134	weeks	N	O
135	with	N	O
136	concurrent	N	O
137	weekly	N	O
138	gemcitabine	N	O
139	200	N	O
140	mg.	N	O
141	Primary	N	O
142	end	N	O
143	points	N	O
144	were	N	O
145	feasibility	N	O
146	,	N	O
147	response	N	O
148	rates	N	O
149	,	N	O
150	and	N	O
151	toxicity	N	O
152	.	N	O

153	Secondary	N	O
154	end	N	O
155	points	N	O
156	were	N	O
157	progression-free	N	O
158	survival	N	O
159	,	N	O
160	overall	N	O
161	survival	N	O
162	,	N	O
163	and	N	O
164	quality	N	O
165	of	N	O
166	life	N	O
167	.	N	O

168	Eighty-four	N	O
169	patients	N	O
170	were	N	O
171	randomized	N	O
172	.	N	O

173	Compliance	N	O
174	was	N	O
175	above	N	O
176	90	N	O
177	%	N	O
178	for	N	O
179	both	N	O
180	arms	N	O
181	.	N	O

182	The	N	I-Premise
183	overall	N	I-Premise
184	response	N	I-Premise
185	rate	N	I-Premise
186	was	N	I-Premise
187	51	N	I-Premise
188	%	N	I-Premise
189	in	N	I-Premise
190	arm	N	I-Premise
191	A	N	I-Premise
192	and	N	I-Premise
193	38	N	I-Premise
194	%	N	I-Premise
195	in	N	I-Premise
196	arm	N	I-Premise
197	B	N	I-Premise
198	(	N	I-Premise
199	p	N	I-Premise
200	=	N	I-Premise
201	0.147	N	I-Premise
202	)	N	I-Premise
203	.	N	I-Premise

204	Grade	N	I-Premise
205	3/4	N	I-Premise
206	toxicity	N	I-Premise
207	in	N	I-Premise
208	both	N	I-Premise
209	arms	N	I-Premise
210	was	N	I-Premise
211	acceptable	N	I-Premise
212	.	N	I-Premise

213	There	N	I-Premise
214	was	N	I-Premise
215	no	N	I-Premise
216	difference	N	I-Premise
217	in	N	I-Premise
218	median	N	I-Premise
219	progression-free	N	I-Premise
220	survival	N	I-Premise
221	between	N	I-Premise
222	the	N	I-Premise
223	two	N	I-Premise
224	arms	N	I-Premise
225	(	N	I-Premise
226	5.5	N	I-Premise
227	versus	N	I-Premise
228	5.0	N	I-Premise
229	months	N	I-Premise
230	,	N	I-Premise
231	p	N	I-Premise
232	=	N	I-Premise
233	0.19	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	Patients	N	I-Premise
237	in	N	I-Premise
238	arm	N	I-Premise
239	A	N	I-Premise
240	had	N	I-Premise
241	longer	N	I-Premise
242	median	N	I-Premise
243	survival	N	I-Premise
244	but	N	I-Premise
245	this	N	I-Premise
246	did	N	I-Premise
247	not	N	I-Premise
248	reach	N	I-Premise
249	statistical	N	I-Premise
250	significance	N	I-Premise
251	(	N	I-Premise
252	13.1	N	I-Premise
253	versus	N	I-Premise
254	8.3	N	I-Premise
255	months	N	I-Premise
256	,	N	I-Premise
257	p	N	I-Premise
258	=	N	I-Premise
259	0.25	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	No	N	I-Claim
263	difference	N	I-Claim
264	in	N	I-Claim
265	quality	N	I-Claim
266	of	N	I-Claim
267	life	N	I-Claim
268	was	N	I-Claim
269	observed	N	I-Claim
270	.	N	I-Claim

271	Arm	N	O
272	A	N	O
273	was	N	O
274	chosen	N	O
275	for	N	O
276	a	N	O
277	future	N	O
278	phase	N	O
279	II	N	O
280	comparison	N	O
281	with	N	O
282	radiation	N	I-Claim
283	therapy	N	I-Claim
284	alone	N	I-Claim
285	as	N	I-Claim
286	it	N	I-Claim
287	demonstrated	N	I-Claim
288	a	N	I-Claim
289	response	N	I-Claim
290	rate	N	I-Claim
291	greater	N	I-Claim
292	than	N	I-Claim
293	50	N	I-Claim
294	%	N	I-Claim
295	,	N	I-Claim
296	and	N	I-Claim
297	data	N	I-Claim
298	suggested	N	I-Claim
299	that	N	I-Claim
300	arm	N	I-Claim
301	A	N	I-Claim
302	had	N	I-Claim
303	superior	N	I-Claim
304	survival	N	I-Claim
305	to	N	I-Claim
306	arm	N	I-Claim
307	B	N	I-Claim
308	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	determine	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	a	N	O
12	mindfulness-based	N	O
13	stress-reduction	N	O
14	(	N	O
15	MBSR	N	O
16	)	N	O
17	program	N	O
18	on	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	QOL	N	O
24	)	N	O
25	and	N	O
26	psychosocial	N	O
27	outcomes	N	O
28	in	N	O
29	women	N	O
30	with	N	O
31	early-stage	N	O
32	breast	N	O
33	cancer	N	O
34	,	N	O
35	using	N	O
36	a	N	O
37	three-arm	N	O
38	randomized	N	O
39	controlled	N	O
40	clinical	N	O
41	trial	N	O
42	(	N	O
43	RCT	N	O
44	)	N	O
45	.	N	O

46	This	N	O
47	RCT	N	O
48	consisting	N	O
49	of	N	O
50	172	N	O
51	women	N	O
52	,	N	O
53	aged	N	O
54	20-65	N	O
55	with	N	O
56	stage	N	O
57	I	N	O
58	or	N	O
59	II	N	O
60	breast	N	O
61	cancer	N	O
62	consisted	N	O
63	of	N	O
64	the	N	O
65	8-week	N	O
66	MBSR	N	O
67	,	N	O
68	which	N	O
69	was	N	O
70	compared	N	O
71	to	N	O
72	a	N	O
73	nutrition	N	O
74	education	N	O
75	program	N	O
76	(	N	O
77	NEP	N	O
78	)	N	O
79	and	N	O
80	usual	N	O
81	supportive	N	O
82	care	N	O
83	(	N	O
84	UC	N	O
85	)	N	O
86	.	N	O

87	Follow-up	N	O
88	was	N	O
89	performed	N	O
90	at	N	O
91	three	N	O
92	post-intervention	N	O
93	points	N	O
94	:	N	O
95	4	N	O
96	months	N	O
97	,	N	O
98	1	N	O
99	,	N	O
100	and	N	O
101	2	N	O
102	years	N	O
103	.	N	O

104	Standardized	N	O
105	,	N	O
106	validated	N	O
107	self-administered	N	O
108	questionnaires	N	O
109	were	N	O
110	adopted	N	O
111	to	N	O
112	assess	N	O
113	psychosocial	N	O
114	variables	N	O
115	.	N	O

116	Statistical	N	O
117	analysis	N	O
118	included	N	O
119	descriptive	N	O
120	and	N	O
121	regression	N	O
122	analyses	N	O
123	incorporating	N	O
124	both	N	O
125	intention-to-treat	N	O
126	and	N	O
127	post	N	O
128	hoc	N	O
129	multivariable	N	O
130	approaches	N	O
131	of	N	O
132	the	N	O
133	163	N	O
134	women	N	O
135	with	N	O
136	complete	N	O
137	data	N	O
138	at	N	O
139	baseline	N	O
140	,	N	O
141	those	N	O
142	who	N	O
143	were	N	O
144	randomized	N	O
145	to	N	O
146	MBSR	N	O
147	experienced	N	O
148	a	N	O
149	significant	N	O
150	improvement	N	O
151	in	N	O
152	the	N	O
153	primary	N	O
154	measures	N	O
155	of	N	O
156	QOL	N	O
157	and	N	O
158	coping	N	O
159	outcomes	N	O
160	compared	N	O
161	to	N	O
162	the	N	O
163	NEP	N	O
164	,	N	O
165	UC	N	O
166	,	N	O
167	or	N	O
168	both	N	O
169	,	N	O
170	including	N	O
171	the	N	O
172	spirituality	N	O
173	subscale	N	O
174	of	N	O
175	the	N	O
176	FACT-B	N	O
177	as	N	O
178	well	N	O
179	as	N	O
180	dealing	N	O
181	with	N	O
182	illness	N	O
183	scale	N	O
184	increases	N	O
185	in	N	O
186	active	N	O
187	behavioral	N	O
188	coping	N	O
189	and	N	O
190	active	N	O
191	cognitive	N	O
192	coping	N	O
193	.	N	O

194	Secondary	N	I-Premise
195	outcome	N	I-Premise
196	improvements	N	I-Premise
197	resulting	N	I-Premise
198	in	N	I-Premise
199	significant	N	I-Premise
200	between-group	N	I-Premise
201	contrasts	N	I-Premise
202	favoring	N	I-Premise
203	the	N	I-Premise
204	MBSR	N	I-Premise
205	group	N	I-Premise
206	at	N	I-Premise
207	4	N	I-Premise
208	months	N	I-Premise
209	included	N	I-Premise
210	meaningfulness	N	I-Premise
211	,	N	I-Premise
212	depression	N	I-Premise
213	,	N	I-Premise
214	paranoid	N	I-Premise
215	ideation	N	I-Premise
216	,	N	I-Premise
217	hostility	N	I-Premise
218	,	N	I-Premise
219	anxiety	N	I-Premise
220	,	N	I-Premise
221	unhappiness	N	I-Premise
222	,	N	I-Premise
223	and	N	I-Premise
224	emotional	N	I-Premise
225	control	N	I-Premise
226	.	N	I-Premise

227	Results	N	I-Premise
228	tended	N	I-Premise
229	to	N	I-Premise
230	decline	N	I-Premise
231	at	N	I-Premise
232	12	N	I-Premise
233	months	N	I-Premise
234	and	N	I-Premise
235	even	N	I-Premise
236	more	N	I-Premise
237	at	N	I-Premise
238	24	N	I-Premise
239	months	N	I-Premise
240	,	N	I-Premise
241	though	N	I-Premise
242	at	N	I-Premise
243	all	N	I-Premise
244	times	N	I-Premise
245	,	N	I-Premise
246	they	N	I-Premise
247	were	N	I-Premise
248	as	N	I-Premise
249	robust	N	I-Premise
250	in	N	I-Premise
251	women	N	I-Premise
252	with	N	I-Premise
253	lower	N	I-Premise
254	expectation	N	I-Premise
255	of	N	I-Premise
256	effect	N	I-Premise
257	as	N	I-Premise
258	in	N	I-Premise
259	those	N	I-Premise
260	with	N	I-Premise
261	higher	N	I-Premise
262	expectation	N	I-Premise
263	.	N	I-Premise

264	The	N	I-Claim
265	MBSR	N	I-Claim
266	intervention	N	I-Claim
267	appears	N	I-Claim
268	to	N	I-Claim
269	benefit	N	I-Claim
270	psychosocial	N	I-Claim
271	adjustment	N	I-Claim
272	in	N	I-Claim
273	cancer	N	I-Claim
274	patients	N	I-Claim
275	,	N	I-Claim
276	over	N	I-Claim
277	and	N	I-Claim
278	above	N	I-Claim
279	the	N	I-Claim
280	effects	N	I-Claim
281	of	N	I-Claim
282	usual	N	I-Claim
283	care	N	I-Claim
284	or	N	I-Claim
285	a	N	I-Claim
286	credible	N	I-Claim
287	control	N	I-Claim
288	condition	N	I-Claim
289	.	N	I-Claim

290	The	N	I-MajorClaim
291	universality	N	I-MajorClaim
292	of	N	I-MajorClaim
293	effects	N	I-MajorClaim
294	across	N	I-MajorClaim
295	levels	N	I-MajorClaim
296	of	N	I-MajorClaim
297	expectation	N	I-MajorClaim
298	indicates	N	I-MajorClaim
299	a	N	I-MajorClaim
300	potential	N	I-MajorClaim
301	to	N	I-MajorClaim
302	utilize	N	I-MajorClaim
303	this	N	I-MajorClaim
304	stress	N	I-MajorClaim
305	reduction	N	I-MajorClaim
306	approach	N	I-MajorClaim
307	as	N	I-MajorClaim
308	complementary	N	I-MajorClaim
309	therapy	N	I-MajorClaim
310	in	N	I-MajorClaim
311	oncologic	N	I-MajorClaim
312	practice	N	I-MajorClaim
313	.	N	I-MajorClaim

1	The	N	O
2	efficacy	N	O
3	of	N	O
4	a	N	O
5	home-based	N	O
6	physical	N	O
7	activity	N	O
8	(	N	O
9	PA	N	O
10	)	N	O
11	intervention	N	O
12	for	N	O
13	colorectal	N	O
14	cancer	N	O
15	patients	N	O
16	versus	N	O
17	contact	N	O
18	control	N	O
19	was	N	O
20	evaluated	N	O
21	in	N	O
22	a	N	O
23	randomized	N	O
24	controlled	N	O
25	trial	N	O
26	.	N	O

27	Forty-six	N	O
28	patients	N	O
29	(	N	O
30	mean	N	O
31	age	N	O
32	=	N	O
33	57.3	N	O
34	years	N	O
35	[	N	O
36	SD	N	O
37	=	N	O
38	9.7	N	O
39	]	N	O
40	,	N	O
41	57	N	O
42	%	N	O
43	female	N	O
44	,	N	O
45	mean	N	O
46	=	N	O
47	2.99	N	O
48	years	N	O
49	post-diagnosis	N	O
50	[	N	O
51	SD	N	O
52	=	N	O
53	1.64	N	O
54	]	N	O
55	)	N	O
56	who	N	O
57	had	N	O
58	completed	N	O
59	treatment	N	O
60	for	N	O
61	stages	N	O
62	1-3	N	O
63	colorectal	N	O
64	cancer	N	O
65	were	N	O
66	randomized	N	O
67	to	N	O
68	telephone	N	O
69	counseling	N	O
70	to	N	O
71	support	N	O
72	PA	N	O
73	(	N	O
74	PA	N	O
75	group	N	O
76	,	N	O
77	n	N	O
78	=	N	O
79	20	N	O
80	)	N	O
81	or	N	O
82	contact	N	O
83	control	N	O
84	(	N	O
85	control	N	O
86	group	N	O
87	,	N	O
88	n	N	O
89	=	N	O
90	26	N	O
91	)	N	O
92	.	N	O

93	PA	N	O
94	group	N	O
95	participants	N	O
96	received	N	O
97	3	N	O
98	months	N	O
99	of	N	O
100	PA	N	O
101	counseling	N	O
102	(	N	O
103	based	N	O
104	on	N	O
105	the	N	O
106	transtheoretical	N	O
107	model	N	O
108	and	N	O
109	the	N	O
110	social	N	O
111	cognitive	N	O
112	theory	N	O
113	)	N	O
114	delivered	N	O
115	via	N	O
116	telephone	N	O
117	,	N	O
118	as	N	O
119	well	N	O
120	as	N	O
121	weekly	N	O
122	PA	N	O
123	tip	N	O
124	sheets	N	O
125	.	N	O

126	Assessments	N	O
127	of	N	O
128	PA	N	O
129	(	N	O
130	Seven-day	N	O
131	Physical	N	O
132	Activity	N	O
133	Recall	N	O
134	[	N	O
135	7-day	N	O
136	PAR	N	O
137	]	N	O
138	and	N	O
139	Community	N	O
140	Healthy	N	O
141	Activities	N	O
142	Model	N	O
143	Program	N	O
144	for	N	O
145	Seniors	N	O
146	[	N	O
147	CHAMPS	N	O
148	]	N	O
149	)	N	O
150	,	N	O
151	submaximal	N	O
152	aerobic	N	O
153	fitness	N	O
154	(	N	O
155	Treadwalk	N	O
156	test	N	O
157	)	N	O
158	,	N	O
159	motivational	N	O
160	readiness	N	O
161	for	N	O
162	PA	N	O
163	,	N	O
164	and	N	O
165	psychosocial	N	O
166	outcomes	N	O
167	were	N	O
168	conducted	N	O
169	at	N	O
170	baseline	N	O
171	,	N	O
172	3	N	O
173	,	N	O
174	6	N	O
175	,	N	O
176	and	N	O
177	12	N	O
178	months	N	O
179	post-baseline	N	O
180	.	N	O

181	Objective	N	O
182	accelerometer	N	O
183	data	N	O
184	were	N	O
185	collected	N	O
186	at	N	O
187	the	N	O
188	same	N	O
189	time	N	O
190	points	N	O
191	.	N	O

192	The	N	I-Premise
193	PA	N	I-Premise
194	group	N	I-Premise
195	reported	N	I-Premise
196	significant	N	I-Premise
197	increases	N	I-Premise
198	in	N	I-Premise
199	minutes	N	I-Premise
200	of	N	I-Premise
201	PA	N	I-Premise
202	at	N	I-Premise
203	3	N	I-Premise
204	months	N	I-Premise
205	(	N	I-Premise
206	7-day	N	I-Premise
207	PAR	N	I-Premise
208	)	N	I-Premise
209	and	N	I-Premise
210	caloric	N	I-Premise
211	expenditure	N	I-Premise
212	(	N	I-Premise
213	CHAMPS	N	I-Premise
214	)	N	I-Premise
215	compared	N	I-Premise
216	with	N	I-Premise
217	the	N	I-Premise
218	control	N	I-Premise
219	group	N	I-Premise
220	,	N	I-Premise
221	but	N	I-Premise
222	the	N	I-Premise
223	group	N	I-Premise
224	differences	N	I-Premise
225	were	N	I-Premise
226	attenuated	N	I-Premise
227	over	N	I-Premise
228	time	N	I-Premise
229	.	N	I-Premise

230	The	N	I-Premise
231	PA	N	I-Premise
232	group	N	I-Premise
233	showed	N	I-Premise
234	significant	N	I-Premise
235	improvements	N	I-Premise
236	in	N	I-Premise
237	fitness	N	I-Premise
238	at	N	I-Premise
239	3	N	I-Premise
240	,	N	I-Premise
241	6	N	I-Premise
242	,	N	I-Premise
243	and	N	I-Premise
244	12	N	I-Premise
245	months	N	I-Premise
246	versus	N	I-Premise
247	the	N	I-Premise
248	control	N	I-Premise
249	group	N	I-Premise
250	.	N	I-Premise

251	Improvements	N	I-Premise
252	in	N	I-Premise
253	motivational	N	I-Premise
254	readiness	N	I-Premise
255	for	N	I-Premise
256	PA	N	I-Premise
257	were	N	I-Premise
258	reported	N	I-Premise
259	in	N	I-Premise
260	the	N	I-Premise
261	PA	N	I-Premise
262	group	N	I-Premise
263	only	N	I-Premise
264	at	N	I-Premise
265	3	N	I-Premise
266	months	N	I-Premise
267	.	N	I-Premise

268	No	N	I-Premise
269	significant	N	I-Premise
270	group	N	I-Premise
271	differences	N	I-Premise
272	were	N	I-Premise
273	found	N	I-Premise
274	for	N	I-Premise
275	fatigue	N	I-Premise
276	,	N	I-Premise
277	self-reported	N	I-Premise
278	physical	N	I-Premise
279	functioning	N	I-Premise
280	,	N	I-Premise
281	and	N	I-Premise
282	quality	N	I-Premise
283	of	N	I-Premise
284	life	N	I-Premise
285	at	N	I-Premise
286	3	N	I-Premise
287	,	N	I-Premise
288	6	N	I-Premise
289	,	N	I-Premise
290	and	N	I-Premise
291	12	N	I-Premise
292	months	N	I-Premise
293	.	N	I-Premise

294	A	N	I-Claim
295	home-based	N	I-Claim
296	intervention	N	I-Claim
297	improved	N	I-Claim
298	survivors	N	I-Claim
299	'	N	I-Claim
300	PA	N	I-Claim
301	and	N	I-Claim
302	motivational	N	I-Claim
303	readiness	N	I-Claim
304	at	N	I-Claim
305	3	N	I-Claim
306	months	N	I-Claim
307	and	N	I-Claim
308	increased	N	I-Claim
309	submaximal	N	I-Claim
310	aerobic	N	I-Claim
311	fitness	N	I-Claim
312	at	N	I-Claim
313	3	N	I-Claim
314	,	N	I-Claim
315	6	N	I-Claim
316	,	N	I-Claim
317	and	N	I-Claim
318	12	N	I-Claim
319	months	N	I-Claim
320	.	N	I-Claim

1	Somatostatin	N	O
2	analogs	N	O
3	act	N	O
4	directly	N	O
5	on	N	O
6	breast	N	O
7	cancer	N	O
8	cells	N	O
9	and	N	O
10	indirectly	N	O
11	on	N	O
12	insulin	N	O
13	and	N	O
14	insulin-like	N	O
15	growth	N	O
16	factor	N	O
17	1	N	O
18	(	N	O
19	IGF-1	N	O
20	)	N	O
21	levels	N	O
22	.	N	O

23	This	N	O
24	trial	N	O
25	was	N	O
26	undertaken	N	O
27	to	N	O
28	assess	N	O
29	whether	N	O
30	octreotide	N	I-Claim
31	would	N	I-Claim
32	lower	N	I-Claim
33	insulin	N	I-Claim
34	and	N	I-Claim
35	IGF-1	N	I-Claim
36	levels	N	I-Claim
37	and	N	I-Claim
38	reduce	N	I-Claim
39	risk	N	I-Claim
40	of	N	I-Claim
41	breast	N	I-Claim
42	cancer	N	I-Claim
43	recurrence	N	I-Claim
44	.	N	I-Claim

45	The	N	O
46	NCIC	N	O
47	CTG	N	O
48	MA.14	N	O
49	(	N	O
50	NCIC	N	O
51	Clinical	N	O
52	Trials	N	O
53	Group	N	O
54	MA.14	N	O
55	)	N	O
56	trial	N	O
57	randomly	N	O
58	assigned	N	O
59	postmenopausal	N	O
60	women	N	O
61	to	N	O
62	5	N	O
63	years	N	O
64	of	N	O
65	tamoxifen	N	O
66	20	N	O
67	mg	N	O
68	daily	N	O
69	(	N	O
70	TAM	N	O
71	)	N	O
72	or	N	O
73	TAM	N	O
74	plus	N	O
75	2	N	O
76	years	N	O
77	of	N	O
78	octreotide	N	O
79	90	N	O
80	mg	N	O
81	depot	N	O
82	intramuscular	N	O
83	injections	N	O
84	monthly	N	O
85	(	N	O
86	TAM-OCT	N	O
87	)	N	O
88	as	N	O
89	adjuvant	N	O
90	therapy	N	O
91	.	N	O

92	The	N	O
93	primary	N	O
94	end	N	O
95	point	N	O
96	was	N	O
97	event-free	N	O
98	survival	N	O
99	(	N	O
100	EFS	N	O
101	)	N	O
102	.	N	O

103	Secondary	N	O
104	end	N	O
105	points	N	O
106	were	N	O
107	relapse-free	N	O
108	survival	N	O
109	(	N	O
110	RFS	N	O
111	)	N	O
112	,	N	O
113	overall	N	O
114	survival	N	O
115	(	N	O
116	OS	N	O
117	)	N	O
118	,	N	O
119	toxicity	N	O
120	,	N	O
121	and	N	O
122	effects	N	O
123	of	N	O
124	treatment	N	O
125	on	N	O
126	IGF	N	O
127	physiology	N	O
128	.	N	O

129	Among	N	O
130	667	N	O
131	women	N	O
132	with	N	O
133	a	N	O
134	median	N	O
135	follow-up	N	O
136	of	N	O
137	7.9	N	O
138	years	N	O
139	,	N	O
140	220	N	O
141	events	N	O
142	occurred-108	N	O
143	with	N	O
144	TAM-OCT	N	O
145	and	N	O
146	112	N	O
147	with	N	O
148	TAM	N	O
149	.	N	O

150	Adjusted	N	I-Premise
151	hazard	N	I-Premise
152	ratios	N	I-Premise
153	(	N	I-Premise
154	HRs	N	I-Premise
155	;	N	I-Premise
156	TAM-OCT	N	I-Premise
157	to	N	I-Premise
158	TAM	N	I-Premise
159	)	N	I-Premise
160	were	N	I-Premise
161	0.93	N	I-Premise
162	for	N	I-Premise
163	EFS	N	I-Premise
164	(	N	I-Premise
165	95	N	I-Premise
166	%	N	I-Premise
167	CI	N	I-Premise
168	,	N	I-Premise
169	0.71	N	I-Premise
170	to	N	I-Premise
171	1.22	N	I-Premise
172	;	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.62	N	I-Premise
176	)	N	I-Premise
177	,	N	I-Premise
178	0.84	N	I-Premise
179	for	N	I-Premise
180	RFS	N	I-Premise
181	(	N	I-Premise
182	95	N	I-Premise
183	%	N	I-Premise
184	CI	N	I-Premise
185	,	N	I-Premise
186	0.59	N	I-Premise
187	to	N	I-Premise
188	1.18	N	I-Premise
189	;	N	I-Premise
190	P	N	I-Premise
191	=	N	I-Premise
192	.31	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	and	N	I-Premise
196	0.97	N	I-Premise
197	for	N	I-Premise
198	OS	N	I-Premise
199	(	N	I-Premise
200	95	N	I-Premise
201	%	N	I-Premise
202	CI	N	I-Premise
203	,	N	I-Premise
204	0.69	N	I-Premise
205	to	N	I-Premise
206	1.37	N	I-Premise
207	;	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	.86	N	I-Premise
211	)	N	I-Premise
212	.	N	I-Premise

213	Among	N	I-Premise
214	patients	N	I-Premise
215	with	N	I-Premise
216	normal	N	I-Premise
217	baseline	N	I-Premise
218	gallbladder	N	I-Premise
219	imaging	N	I-Premise
220	,	N	I-Premise
221	cholecystectomy	N	I-Premise
222	was	N	I-Premise
223	required	N	I-Premise
224	in	N	I-Premise
225	23.0	N	I-Premise
226	%	N	I-Premise
227	of	N	I-Premise
228	those	N	I-Premise
229	receiving	N	I-Premise
230	TAM-OCT	N	I-Premise
231	but	N	I-Premise
232	in	N	I-Premise
233	only	N	I-Premise
234	1.4	N	I-Premise
235	%	N	I-Premise
236	of	N	I-Premise
237	those	N	I-Premise
238	receiving	N	I-Premise
239	TAM	N	I-Premise
240	(	N	I-Premise
241	P	N	I-Premise
242	<	N	I-Premise
243	.001	N	I-Premise
244	)	N	I-Premise
245	.	N	I-Premise

246	At	N	I-Premise
247	4	N	I-Premise
248	months	N	I-Premise
249	,	N	I-Premise
250	TAM-OCT	N	I-Premise
251	had	N	I-Premise
252	significantly	N	I-Premise
253	(	N	I-Premise
254	P	N	I-Premise
255	<	N	I-Premise
256	.001	N	I-Premise
257	)	N	I-Premise
258	lowered	N	I-Premise
259	IGF-1	N	I-Premise
260	,	N	I-Premise
261	IGF	N	I-Premise
262	binding	N	I-Premise
263	protein	N	I-Premise
264	3	N	I-Premise
265	,	N	I-Premise
266	and	N	I-Premise
267	C-peptide	N	I-Premise
268	levels	N	I-Premise
269	.	N	I-Premise

270	Older	N	I-Premise
271	age	N	I-Premise
272	(	N	I-Premise
273	P	N	I-Premise
274	=	N	I-Premise
275	.02	N	I-Premise
276	)	N	I-Premise
277	,	N	I-Premise
278	tumor	N	I-Premise
279	size	N	I-Premise
280	(	N	I-Premise
281	P	N	I-Premise
282	=	N	I-Premise
283	.001	N	I-Premise
284	)	N	I-Premise
285	,	N	I-Premise
286	nodal	N	I-Premise
287	status	N	I-Premise
288	(	N	I-Premise
289	P	N	I-Premise
290	=	N	I-Premise
291	.01	N	I-Premise
292	)	N	I-Premise
293	,	N	I-Premise
294	high	N	I-Premise
295	C-peptide	N	I-Premise
296	levels	N	I-Premise
297	(	N	I-Premise
298	P	N	I-Premise
299	<	N	I-Premise
300	.001	N	I-Premise
301	)	N	I-Premise
302	,	N	I-Premise
303	and	N	I-Premise
304	higher	N	I-Premise
305	body	N	I-Premise
306	mass	N	I-Premise
307	index	N	I-Premise
308	(	N	I-Premise
309	BMI	N	I-Premise
310	)	N	I-Premise
311	in	N	I-Premise
312	models	N	I-Premise
313	excluding	N	I-Premise
314	C-peptide	N	I-Premise
315	(	N	I-Premise
316	P	N	I-Premise
317	<	N	I-Premise
318	.001	N	I-Premise
319	)	N	I-Premise
320	were	N	I-Premise
321	associated	N	I-Premise
322	with	N	I-Premise
323	poorer	N	I-Premise
324	EFS	N	I-Premise
325	in	N	I-Premise
326	multivariate	N	I-Premise
327	analysis	N	I-Premise
328	.	N	I-Premise

329	Octreotide-related	N	O
330	changes	N	O
331	in	N	O
332	circulating	N	O
333	IGF-1	N	O
334	and	N	O
335	C-peptide	N	O
336	levels	N	O
337	were	N	O
338	statistically	N	O
339	significant	N	O
340	.	N	O

341	Octreotide	N	I-Claim
342	did	N	I-Claim
343	not	N	I-Claim
344	add	N	I-Claim
345	significant	N	I-Claim
346	clinical	N	I-Claim
347	benefit	N	I-Claim
348	.	N	I-Claim

349	High	N	I-Claim
350	C-peptide	N	I-Claim
351	levels	N	I-Claim
352	(	N	I-Claim
353	surrogate	N	I-Claim
354	for	N	I-Claim
355	insulin	N	I-Claim
356	secretion	N	I-Claim
357	rate	N	I-Claim
358	)	N	I-Claim
359	and	N	I-Claim
360	high	N	I-Claim
361	BMI	N	I-Claim
362	were	N	I-Claim
363	associated	N	I-Claim
364	with	N	I-Claim
365	poor	N	I-Claim
366	outcome	N	I-Claim
367	.	N	I-Claim

1	Both	N	O
2	Billroth	N	O
3	I	N	O
4	(	N	O
5	B-I	N	O
6	)	N	O
7	and	N	O
8	Roux-en-Y	N	O
9	(	N	O
10	R-Y	N	O
11	)	N	O
12	reconstructions	N	O
13	are	N	O
14	commonly	N	O
15	performed	N	O
16	as	N	O
17	standard	N	O
18	procedures	N	O
19	,	N	O
20	but	N	O
21	it	N	O
22	has	N	O
23	yet	N	O
24	to	N	O
25	be	N	O
26	determined	N	O
27	which	N	O
28	reconstruction	N	O
29	is	N	O
30	better	N	O
31	for	N	O
32	patients	N	O
33	.	N	O

34	A	N	O
35	randomized	N	O
36	prospective	N	O
37	phase	N	O
38	II	N	O
39	trial	N	O
40	with	N	O
41	body	N	O
42	weight	N	O
43	loss	N	O
44	at	N	O
45	1	N	O
46	year	N	O
47	after	N	O
48	surgery	N	O
49	as	N	O
50	a	N	O
51	primary	N	O
52	endpoint	N	O
53	was	N	O
54	performed	N	O
55	to	N	O
56	address	N	O
57	this	N	O
58	issue	N	O
59	.	N	O

60	The	N	O
61	current	N	O
62	report	N	O
63	delivers	N	O
64	data	N	O
65	on	N	O
66	the	N	O
67	quality	N	O
68	of	N	O
69	life	N	O
70	and	N	O
71	degree	N	O
72	of	N	O
73	postoperative	N	O
74	dysfunction	N	O
75	,	N	O
76	which	N	O
77	were	N	O
78	the	N	O
79	secondary	N	O
80	endpoints	N	O
81	of	N	O
82	this	N	O
83	study	N	O
84	.	N	O

85	Gastric	N	O
86	cancer	N	O
87	patients	N	O
88	who	N	O
89	underwent	N	O
90	distal	N	O
91	gastrectomy	N	O
92	were	N	O
93	intraoperatively	N	O
94	randomized	N	O
95	to	N	O
96	B-I	N	O
97	or	N	O
98	R-Y	N	O
99	.	N	O

100	Postsurgical	N	O
101	QOL	N	O
102	was	N	O
103	evaluated	N	O
104	using	N	O
105	the	N	O
106	EORTC	N	O
107	QLQ-C30	N	O
108	and	N	O
109	DAUGS	N	O
110	20	N	O
111	.	N	O

112	Between	N	O
113	August	N	O
114	2005	N	O
115	and	N	O
116	December	N	O
117	2008	N	O
118	,	N	O
119	332	N	O
120	patients	N	O
121	were	N	O
122	enrolled	N	O
123	in	N	O
124	a	N	O
125	randomized	N	O
126	trial	N	O
127	comparing	N	O
128	B-I	N	O
129	versus	N	O
130	R-Y	N	O
131	.	N	O

132	A	N	O
133	mail	N	O
134	survey	N	O
135	questionnaire	N	O
136	sent	N	O
137	to	N	O
138	327	N	O
139	patients	N	O
140	was	N	O
141	completed	N	O
142	by	N	O
143	268	N	O
144	(	N	O
145	86.2	N	O
146	%	N	O
147	)	N	O
148	of	N	O
149	them	N	O
150	.	N	O

151	EORTC	N	O
152	QLQ-C30	N	O
153	scores	N	O
154	were	N	O
155	as	N	O
156	follows	N	O
157	:	N	O
158	global	N	O
159	health	N	O
160	status	N	O
161	was	N	O
162	similar	N	O
163	in	N	O
164	each	N	O
165	group	N	O
166	(	N	O
167	B-I	N	O
168	73.5	N	O
169	±	N	O
170	18.8	N	O
171	,	N	O
172	R-Y	N	O
173	73.2	N	O
174	±	N	O
175	20.2	N	O
176	,	N	O
177	p	N	O
178	=	N	O
179	0.87	N	O
180	)	N	O
181	.	N	O

182	Scores	N	O
183	of	N	O
184	five	N	O
185	functional	N	O
186	scales	N	O
187	were	N	O
188	also	N	O
189	similar	N	O
190	.	N	O

191	Only	N	I-Premise
192	the	N	I-Premise
193	dyspnea	N	I-Premise
194	symptom	N	I-Premise
195	scale	N	I-Premise
196	showed	N	I-Premise
197	superior	N	I-Premise
198	results	N	I-Premise
199	for	N	I-Premise
200	R-Y	N	I-Premise
201	than	N	I-Premise
202	for	N	I-Premise
203	B-I	N	I-Premise
204	(	N	I-Premise
205	B-I	N	I-Premise
206	13.6	N	I-Premise
207	±	N	I-Premise
208	17.9	N	I-Premise
209	,	N	I-Premise
210	R-Y	N	I-Premise
211	8.6	N	I-Premise
212	±	N	I-Premise
213	16.3	N	I-Premise
214	,	N	I-Premise
215	p	N	I-Premise
216	=	N	I-Premise
217	0.02	N	I-Premise
218	)	N	I-Premise
219	.	N	I-Premise

220	With	N	I-Premise
221	respect	N	I-Premise
222	to	N	I-Premise
223	DAUGS	N	I-Premise
224	20	N	I-Premise
225	,	N	I-Premise
226	the	N	I-Premise
227	total	N	I-Premise
228	score	N	I-Premise
229	did	N	I-Premise
230	not	N	I-Premise
231	differ	N	I-Premise
232	significantly	N	I-Premise
233	between	N	I-Premise
234	the	N	I-Premise
235	R-Y	N	I-Premise
236	and	N	I-Premise
237	B-I	N	I-Premise
238	groups	N	I-Premise
239	(	N	I-Premise
240	24.8	N	I-Premise
241	vs.	N	I-Premise
242	23.6	N	I-Premise
243	,	N	I-Premise
244	p	N	I-Premise
245	=	N	I-Premise
246	0.41	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	Only	N	I-Premise
250	reflux	N	I-Premise
251	symptoms	N	I-Premise
252	were	N	I-Premise
253	significantly	N	I-Premise
254	worse	N	I-Premise
255	for	N	I-Premise
256	B-I	N	I-Premise
257	than	N	I-Premise
258	for	N	I-Premise
259	R-Y	N	I-Premise
260	(	N	I-Premise
261	0.7	N	I-Premise
262	±	N	I-Premise
263	0.6	N	I-Premise
264	vs.	N	I-Premise
265	0.5	N	I-Premise
266	±	N	I-Premise
267	0.6	N	I-Premise
268	,	N	I-Premise
269	p	N	I-Premise
270	=	N	I-Premise
271	0.01	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	The	N	I-Claim
275	B-I	N	I-Claim
276	and	N	I-Claim
277	R-Y	N	I-Claim
278	techniques	N	I-Claim
279	were	N	I-Claim
280	generally	N	I-Claim
281	equivalent	N	I-Claim
282	in	N	I-Claim
283	terms	N	I-Claim
284	of	N	I-Claim
285	postoperative	N	I-Claim
286	QOL	N	I-Claim
287	and	N	I-Claim
288	dysfunction	N	I-Claim
289	.	N	I-Claim

290	Both	N	I-MajorClaim
291	procedures	N	I-MajorClaim
292	seem	N	I-MajorClaim
293	acceptable	N	I-MajorClaim
294	as	N	I-MajorClaim
295	standard	N	I-MajorClaim
296	reconstructions	N	I-MajorClaim
297	after	N	I-MajorClaim
298	distal	N	I-MajorClaim
299	gastrectomy	N	I-MajorClaim
300	with	N	I-MajorClaim
301	regard	N	I-MajorClaim
302	to	N	I-MajorClaim
303	postoperative	N	I-MajorClaim
304	QOL	N	I-MajorClaim
305	and	N	I-MajorClaim
306	dysfunction	N	I-MajorClaim
307	.	N	I-MajorClaim

1	In	N	O
2	a	N	O
3	phase	N	O
4	3	N	O
5	trial	N	O
6	comparing	N	O
7	the	N	O
8	efficacy	N	O
9	and	N	O
10	safety	N	O
11	of	N	O
12	axitinib	N	O
13	versus	N	O
14	sorafenib	N	O
15	as	N	O
16	second-line	N	O
17	treatment	N	O
18	for	N	O
19	metastatic	N	O
20	renal	N	O
21	cell	N	O
22	carcinoma	N	O
23	,	N	O
24	patients	N	O
25	given	N	O
26	axitinib	N	O
27	had	N	O
28	a	N	O
29	longer	N	O
30	progression-free	N	O
31	survival	N	O
32	(	N	O
33	PFS	N	O
34	)	N	O
35	.	N	O

36	Here	N	O
37	,	N	O
38	we	N	O
39	report	N	O
40	overall	N	O
41	survival	N	O
42	and	N	O
43	updated	N	O
44	efficacy	N	O
45	,	N	O
46	quality	N	O
47	of	N	O
48	life	N	O
49	,	N	O
50	and	N	O
51	safety	N	O
52	results	N	O
53	.	N	O

54	Eligible	N	O
55	patients	N	O
56	had	N	O
57	clear	N	O
58	cell	N	O
59	metastatic	N	O
60	renal	N	O
61	cell	N	O
62	carcinoma	N	O
63	,	N	O
64	progressive	N	O
65	disease	N	O
66	after	N	O
67	one	N	O
68	approved	N	O
69	systemic	N	O
70	treatment	N	O
71	,	N	O
72	and	N	O
73	an	N	O
74	Eastern	N	O
75	Cooperative	N	O
76	Oncology	N	O
77	Group	N	O
78	performance	N	O
79	status	N	O
80	(	N	O
81	ECOG	N	O
82	PS	N	O
83	)	N	O
84	of	N	O
85	0-1	N	O
86	.	N	O

87	723	N	O
88	patients	N	O
89	were	N	O
90	stratified	N	O
91	by	N	O
92	ECOG	N	O
93	PS	N	O
94	and	N	O
95	previous	N	O
96	treatment	N	O
97	and	N	O
98	randomly	N	O
99	allocated	N	O
100	(	N	O
101	1:1	N	O
102	)	N	O
103	to	N	O
104	receive	N	O
105	axitinib	N	O
106	(	N	O
107	5	N	O
108	mg	N	O
109	twice	N	O
110	daily	N	O
111	;	N	O
112	n=361	N	O
113	)	N	O
114	or	N	O
115	sorafenib	N	O
116	(	N	O
117	400	N	O
118	mg	N	O
119	twice	N	O
120	daily	N	O
121	;	N	O
122	n=362	N	O
123	)	N	O
124	.	N	O

125	The	N	O
126	primary	N	O
127	endpoint	N	O
128	was	N	O
129	PFS	N	O
130	assessed	N	O
131	by	N	O
132	a	N	O
133	masked	N	O
134	,	N	O
135	independent	N	O
136	radiology	N	O
137	review	N	O
138	committee	N	O
139	.	N	O

140	We	N	O
141	assessed	N	O
142	patient-reported	N	O
143	outcomes	N	O
144	using	N	O
145	validated	N	O
146	questionnaires	N	O
147	.	N	O

148	Baseline	N	O
149	characteristics	N	O
150	and	N	O
151	development	N	O
152	of	N	O
153	hypertension	N	O
154	on	N	O
155	treatment	N	O
156	were	N	O
157	studied	N	O
158	as	N	O
159	prognostic	N	O
160	factors	N	O
161	.	N	O

162	Efficacy	N	O
163	was	N	O
164	assessed	N	O
165	in	N	O
166	the	N	O
167	intention-to-treat	N	O
168	population	N	O
169	,	N	O
170	and	N	O
171	safety	N	O
172	was	N	O
173	assessed	N	O
174	in	N	O
175	patients	N	O
176	who	N	O
177	received	N	O
178	at	N	O
179	least	N	O
180	one	N	O
181	dose	N	O
182	of	N	O
183	the	N	O
184	study	N	O
185	drug	N	O
186	.	N	O

187	Median	N	I-Premise
188	overall	N	I-Premise
189	survival	N	I-Premise
190	was	N	I-Premise
191	20.1	N	I-Premise
192	months	N	I-Premise
193	(	N	I-Premise
194	95	N	I-Premise
195	%	N	I-Premise
196	CI	N	I-Premise
197	16.7-23.4	N	I-Premise
198	)	N	I-Premise
199	with	N	I-Premise
200	axitinib	N	I-Premise
201	and	N	I-Premise
202	19.2	N	I-Premise
203	months	N	I-Premise
204	(	N	I-Premise
205	17.5-22.3	N	I-Premise
206	)	N	I-Premise
207	with	N	I-Premise
208	sorafenib	N	I-Premise
209	(	N	I-Premise
210	hazard	N	I-Premise
211	ratio	N	I-Premise
212	[	N	I-Premise
213	HR	N	I-Premise
214	]	N	I-Premise
215	0.969	N	I-Premise
216	,	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	CI	N	I-Premise
220	0.800-1.174	N	I-Premise
221	;	N	I-Premise
222	one-sided	N	I-Premise
223	p=0.3744	N	I-Premise
224	)	N	I-Premise
225	.	N	I-Premise

226	Median	N	I-Premise
227	investigator-assessed	N	I-Premise
228	PFS	N	I-Premise
229	was	N	I-Premise
230	8.3	N	I-Premise
231	months	N	I-Premise
232	(	N	I-Premise
233	95	N	I-Premise
234	%	N	I-Premise
235	CI	N	I-Premise
236	6.7-9.2	N	I-Premise
237	)	N	I-Premise
238	with	N	I-Premise
239	axitinib	N	I-Premise
240	and	N	I-Premise
241	5·7	N	I-Premise
242	months	N	I-Premise
243	(	N	I-Premise
244	4.7-6.5	N	I-Premise
245	)	N	I-Premise
246	with	N	I-Premise
247	sorafenib	N	I-Premise
248	(	N	I-Premise
249	HR	N	I-Premise
250	0.656	N	I-Premise
251	,	N	I-Premise
252	95	N	I-Premise
253	%	N	I-Premise
254	CI	N	I-Premise
255	0.552-0.779	N	I-Premise
256	;	N	I-Premise
257	one-sided	N	I-Premise
258	p	N	I-Premise
259	<	N	I-Premise
260	0.0001	N	I-Premise
261	)	N	I-Premise
262	.	N	I-Premise

263	Patient-reported	N	I-Premise
264	outcomes	N	I-Premise
265	scores	N	I-Premise
266	were	N	I-Premise
267	similar	N	I-Premise
268	in	N	I-Premise
269	the	N	I-Premise
270	treatment	N	I-Premise
271	groups	N	I-Premise
272	at	N	I-Premise
273	baseline	N	I-Premise
274	,	N	I-Premise
275	were	N	I-Premise
276	maintained	N	I-Premise
277	during	N	I-Premise
278	treatment	N	I-Premise
279	,	N	I-Premise
280	but	N	I-Premise
281	decreased	N	I-Premise
282	at	N	I-Premise
283	end-of-treatment	N	I-Premise
284	.	N	I-Premise

285	Common	N	I-Premise
286	grade	N	I-Premise
287	3	N	I-Premise
288	or	N	I-Premise
289	higher	N	I-Premise
290	treatment-related	N	I-Premise
291	adverse	N	I-Premise
292	events	N	I-Premise
293	were	N	I-Premise
294	hypertension	N	I-Premise
295	(	N	I-Premise
296	60	N	I-Premise
297	[	N	I-Premise
298	17	N	I-Premise
299	%	N	I-Premise
300	]	N	I-Premise
301	)	N	I-Premise
302	,	N	I-Premise
303	diarrhoea	N	I-Premise
304	(	N	I-Premise
305	40	N	I-Premise
306	[	N	I-Premise
307	11	N	I-Premise
308	%	N	I-Premise
309	]	N	I-Premise
310	)	N	I-Premise
311	,	N	I-Premise
312	and	N	I-Premise
313	fatigue	N	I-Premise
314	(	N	I-Premise
315	37	N	I-Premise
316	[	N	I-Premise
317	10	N	I-Premise
318	%	N	I-Premise
319	]	N	I-Premise
320	)	N	I-Premise
321	in	N	I-Premise
322	359	N	I-Premise
323	axitinib-treated	N	I-Premise
324	patients	N	I-Premise
325	and	N	I-Premise
326	hand-foot	N	I-Premise
327	syndrome	N	I-Premise
328	(	N	I-Premise
329	61	N	I-Premise
330	[	N	I-Premise
331	17	N	I-Premise
332	%	N	I-Premise
333	]	N	I-Premise
334	)	N	I-Premise
335	,	N	I-Premise
336	hypertension	N	I-Premise
337	(	N	I-Premise
338	43	N	I-Premise
339	[	N	I-Premise
340	12	N	I-Premise
341	%	N	I-Premise
342	]	N	I-Premise
343	)	N	I-Premise
344	,	N	I-Premise
345	and	N	I-Premise
346	diarrhoea	N	I-Premise
347	(	N	I-Premise
348	27	N	I-Premise
349	[	N	I-Premise
350	8	N	I-Premise
351	%	N	I-Premise
352	]	N	I-Premise
353	)	N	I-Premise
354	in	N	I-Premise
355	355	N	I-Premise
356	sorafenib-treated	N	I-Premise
357	patients	N	I-Premise
358	.	N	I-Premise

359	In	N	I-Premise
360	a	N	I-Premise
361	post-hoc	N	I-Premise
362	12-week	N	I-Premise
363	landmark	N	I-Premise
364	analysis	N	I-Premise
365	,	N	I-Premise
366	median	N	I-Premise
367	overall	N	I-Premise
368	survival	N	I-Premise
369	was	N	I-Premise
370	longer	N	I-Premise
371	in	N	I-Premise
372	patients	N	I-Premise
373	with	N	I-Premise
374	a	N	I-Premise
375	diastolic	N	I-Premise
376	blood	N	I-Premise
377	pressure	N	I-Premise
378	of	N	I-Premise
379	90	N	I-Premise
380	mm	N	I-Premise
381	Hg	N	I-Premise
382	or	N	I-Premise
383	greater	N	I-Premise
384	than	N	I-Premise
385	in	N	I-Premise
386	those	N	I-Premise
387	with	N	I-Premise
388	a	N	I-Premise
389	diastolic	N	I-Premise
390	blood	N	I-Premise
391	pressure	N	I-Premise
392	of	N	I-Premise
393	less	N	I-Premise
394	than	N	I-Premise
395	90	N	I-Premise
396	mm	N	I-Premise
397	Hg	N	I-Premise
398	:	N	I-Premise
399	20.7	N	I-Premise
400	months	N	I-Premise
401	(	N	I-Premise
402	95	N	I-Premise
403	%	N	I-Premise
404	CI	N	I-Premise
405	18.4-24.6	N	I-Premise
406	)	N	I-Premise
407	versus	N	I-Premise
408	12.9	N	I-Premise
409	months	N	I-Premise
410	(	N	I-Premise
411	10.1-20.4	N	I-Premise
412	)	N	I-Premise
413	in	N	I-Premise
414	the	N	I-Premise
415	axitinib	N	I-Premise
416	group	N	I-Premise
417	(	N	I-Premise
418	p=0.0116	N	I-Premise
419	)	N	I-Premise
420	,	N	I-Premise
421	and	N	I-Premise
422	20.2	N	I-Premise
423	months	N	I-Premise
424	(	N	I-Premise
425	17.1-32.0	N	I-Premise
426	)	N	I-Premise
427	versus	N	I-Premise
428	14.8	N	I-Premise
429	months	N	I-Premise
430	(	N	I-Premise
431	12.0-17.7	N	I-Premise
432	)	N	I-Premise
433	in	N	I-Premise
434	the	N	I-Premise
435	sorafenib	N	I-Premise
436	group	N	I-Premise
437	(	N	I-Premise
438	one-sided	N	I-Premise
439	p=0.0020	N	I-Premise
440	)	N	I-Premise
441	.	N	I-Premise

442	Although	N	O
443	overall	N	I-Claim
444	survival	N	I-Claim
445	,	N	I-Claim
446	a	N	I-Claim
447	secondary	N	I-Claim
448	endpoint	N	I-Claim
449	for	N	I-Claim
450	the	N	I-Claim
451	study	N	I-Claim
452	,	N	I-Claim
453	did	N	I-Claim
454	not	N	I-Claim
455	differ	N	I-Claim
456	between	N	I-Claim
457	the	N	I-Claim
458	two	N	I-Claim
459	groups	N	I-Claim
460	,	N	I-Claim
461	investigator-assessed	N	I-Claim
462	PFS	N	I-Claim
463	remained	N	I-Claim
464	longer	N	I-Claim
465	in	N	I-Claim
466	the	N	I-Claim
467	axitinib	N	I-Claim
468	group	N	I-Claim
469	compared	N	I-Claim
470	with	N	I-Claim
471	the	N	I-Claim
472	sorafenib	N	I-Claim
473	group	N	I-Claim
474	.	N	I-Claim

475	These	N	I-Claim
476	results	N	I-Claim
477	establish	N	I-Claim
478	axitinib	N	I-Claim
479	as	N	I-Claim
480	a	N	I-Claim
481	second-line	N	I-Claim
482	treatment	N	I-Claim
483	option	N	I-Claim
484	for	N	I-Claim
485	patients	N	I-Claim
486	with	N	I-Claim
487	metastatic	N	I-Claim
488	renal	N	I-Claim
489	cell	N	I-Claim
490	carcinoma	N	I-Claim
491	.	N	I-Claim

1	Cancer	N	O
2	treatment	N	O
3	can	N	O
4	profoundly	N	O
5	impact	N	O
6	the	N	O
7	patient	N	O
8	's	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	.	N	O

16	It	N	O
17	has	N	O
18	been	N	O
19	well	N	O
20	documented	N	O
21	that	N	O
22	there	N	O
23	are	N	O
24	gender	N	O
25	differences	N	O
26	in	N	O
27	the	N	O
28	symptoms	N	O
29	associated	N	O
30	with	N	O
31	cancer	N	O
32	treatment	N	O
33	.	N	O

34	This	N	O
35	study	N	O
36	explores	N	O
37	the	N	O
38	impact	N	O
39	of	N	O
40	gender	N	O
41	on	N	O
42	QOL	N	O
43	for	N	O
44	patients	N	O
45	with	N	O
46	newly	N	O
47	diagnosed	N	O
48	advanced	N	O
49	cancer	N	O
50	.	N	O

51	A	N	O
52	randomized	N	O
53	,	N	O
54	controlled	N	O
55	clinical	N	O
56	trial	N	O
57	in	N	O
58	patients	N	O
59	receiving	N	O
60	radiotherapy	N	O
61	for	N	O
62	advanced	N	O
63	cancer	N	O
64	demonstrated	N	O
65	maintenance	N	O
66	of	N	O
67	QOL	N	O
68	with	N	O
69	a	N	O
70	six	N	O
71	session	N	O
72	multidisciplinary	N	O
73	structured	N	O
74	intervention	N	O
75	compared	N	O
76	to	N	O
77	controls	N	O
78	.	N	O

79	This	N	O
80	current	N	O
81	study	N	O
82	reports	N	O
83	the	N	O
84	gender	N	O
85	differences	N	O
86	in	N	O
87	that	N	O
88	trial	N	O
89	.	N	O

90	Outcome	N	O
91	measures	N	O
92	included	N	O
93	the	N	O
94	functional	N	O
95	assessment	N	O
96	of	N	O
97	cancer	N	O
98	therapy-general	N	O
99	(	N	O
100	FACT-G	N	O
101	)	N	O
102	,	N	O
103	linear	N	O
104	analog	N	O
105	self-assessment	N	O
106	(	N	O
107	LASA	N	O
108	)	N	O
109	,	N	O
110	and	N	O
111	profile	N	O
112	of	N	O
113	mood	N	O
114	states	N	O
115	(	N	O
116	POMS	N	O
117	)	N	O
118	at	N	O
119	baseline	N	O
120	and	N	O
121	weeks	N	O
122	4	N	O
123	,	N	O
124	27	N	O
125	,	N	O
126	and	N	O
127	52	N	O
128	.	N	O

129	Kruskal-Wallis	N	O
130	was	N	O
131	used	N	O
132	to	N	O
133	compare	N	O
134	QOL	N	O
135	scores	N	O
136	.	N	O

137	One	N	O
138	hundred	N	O
139	thirty-one	N	O
140	patients	N	O
141	(	N	O
142	45	N	O
143	women	N	O
144	and	N	O
145	86	N	O
146	men	N	O
147	,	N	O
148	mean	N	O
149	age	N	O
150	58.7	N	O
151	)	N	O
152	participated	N	O
153	in	N	O
154	the	N	O
155	clinical	N	O
156	trial	N	O
157	.	N	O

158	At	N	I-Premise
159	week	N	I-Premise
160	4	N	I-Premise
161	postintervention	N	I-Premise
162	,	N	I-Premise
163	women	N	I-Premise
164	in	N	I-Premise
165	the	N	I-Premise
166	intervention	N	I-Premise
167	group	N	I-Premise
168	had	N	I-Premise
169	statistically	N	I-Premise
170	significant	N	I-Premise
171	improvement	N	I-Premise
172	in	N	I-Premise
173	their	N	I-Premise
174	FACT-G	N	I-Premise
175	score	N	I-Premise
176	,	N	I-Premise
177	FACT-G	N	I-Premise
178	physical	N	I-Premise
179	well-being	N	I-Premise
180	subscale	N	I-Premise
181	,	N	I-Premise
182	LASA	N	I-Premise
183	fatigue	N	I-Premise
184	,	N	I-Premise
185	POMS	N	I-Premise
186	total	N	I-Premise
187	score	N	I-Premise
188	,	N	I-Premise
189	POMS	N	I-Premise
190	fatigue-inertia	N	I-Premise
191	subscale	N	I-Premise
192	,	N	I-Premise
193	and	N	I-Premise
194	POMS	N	I-Premise
195	confusion-bewilderment	N	I-Premise
196	subscale	N	I-Premise
197	(	N	I-Premise
198	p	N	I-Premise
199	<	N	I-Premise
200	0.05	N	I-Premise
201	)	N	I-Premise
202	.	N	I-Premise

203	Men	N	I-Premise
204	receiving	N	I-Premise
205	the	N	I-Premise
206	intervention	N	I-Premise
207	had	N	I-Premise
208	a	N	I-Premise
209	smaller	N	I-Premise
210	decrease	N	I-Premise
211	in	N	I-Premise
212	FACT-G	N	I-Premise
213	score	N	I-Premise
214	compared	N	I-Premise
215	to	N	I-Premise
216	controls	N	I-Premise
217	(	N	I-Premise
218	p	N	I-Premise
219	=	N	I-Premise
220	0.048	N	I-Premise
221	)	N	I-Premise
222	and	N	I-Premise
223	also	N	I-Premise
224	worsened	N	I-Premise
225	on	N	I-Premise
226	the	N	I-Premise
227	LASA	N	I-Premise
228	financial	N	I-Premise
229	(	N	I-Premise
230	p	N	I-Premise
231	=	N	I-Premise
232	0.02	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	At	N	I-Premise
236	week	N	I-Premise
237	27	N	I-Premise
238	,	N	I-Premise
239	the	N	I-Premise
240	only	N	I-Premise
241	gender	N	I-Premise
242	difference	N	I-Premise
243	was	N	I-Premise
244	that	N	I-Premise
245	intervention	N	I-Premise
246	group	N	I-Premise
247	men	N	I-Premise
248	had	N	I-Premise
249	more	N	I-Premise
250	POMS	N	I-Premise
251	anger-hostility	N	I-Premise
252	(	N	I-Premise
253	p	N	I-Premise
254	=	N	I-Premise
255	0.009	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	By	N	I-Premise
259	week	N	I-Premise
260	52	N	I-Premise
261	,	N	I-Premise
262	there	N	I-Premise
263	were	N	I-Premise
264	no	N	I-Premise
265	statistically	N	I-Premise
266	significant	N	I-Premise
267	gender	N	I-Premise
268	differences	N	I-Premise
269	in	N	I-Premise
270	any	N	I-Premise
271	of	N	I-Premise
272	the	N	I-Premise
273	QOL	N	I-Premise
274	measures	N	I-Premise
275	.	N	I-Premise

276	Gender-based	N	I-Claim
277	differences	N	I-Claim
278	appear	N	I-Claim
279	to	N	I-Claim
280	play	N	I-Claim
281	a	N	I-Claim
282	role	N	I-Claim
283	in	N	I-Claim
284	the	N	I-Claim
285	early	N	I-Claim
286	,	N	I-Claim
287	but	N	I-Claim
288	not	N	I-Claim
289	late	N	I-Claim
290	,	N	I-Claim
291	response	N	I-Claim
292	to	N	I-Claim
293	a	N	I-Claim
294	multidisciplinary	N	I-Claim
295	intervention	N	I-Claim
296	to	N	I-Claim
297	improve	N	I-Claim
298	QOL	N	I-Claim
299	for	N	I-Claim
300	patients	N	I-Claim
301	with	N	I-Claim
302	advanced	N	I-Claim
303	cancer	N	I-Claim
304	,	N	I-Claim
305	suggesting	N	O
306	that	N	O
307	early	N	I-Claim
308	interventions	N	I-Claim
309	can	N	I-Claim
310	be	N	I-Claim
311	tailored	N	I-Claim
312	for	N	I-Claim
313	each	N	I-Claim
314	gender	N	I-Claim
315	.	N	I-Claim

1	There	N	O
2	are	N	O
3	few	N	O
4	reports	N	O
5	about	N	O
6	the	N	O
7	course	N	O
8	of	N	O
9	vestibular	N	O
10	schwannoma	N	O
11	(	N	O
12	VS	N	O
13	)	N	O
14	patients	N	O
15	following	N	O
16	gamma	N	O
17	knife	N	O
18	radiosurgery	N	O
19	(	N	O
20	GKRS	N	O
21	)	N	O
22	compared	N	O
23	with	N	O
24	the	N	O
25	course	N	O
26	following	N	O
27	conservative	N	O
28	management	N	O
29	(	N	O
30	CM	N	O
31	)	N	O
32	.	N	O

33	In	N	O
34	this	N	O
35	study	N	O
36	,	N	O
37	we	N	O
38	present	N	O
39	prospectively	N	O
40	collected	N	O
41	data	N	O
42	of	N	O
43	237	N	O
44	patients	N	O
45	with	N	O
46	unilateral	N	O
47	VS	N	O
48	extending	N	O
49	outside	N	O
50	the	N	O
51	internal	N	O
52	acoustic	N	O
53	canal	N	O
54	who	N	O
55	received	N	O
56	either	N	O
57	GKRS	N	O
58	(	N	O
59	113	N	O
60	)	N	O
61	or	N	O
62	CM	N	O
63	(	N	O
64	124	N	O
65	)	N	O
66	.	N	O

67	The	N	O
68	aim	N	O
69	was	N	O
70	to	N	O
71	measure	N	O
72	the	N	O
73	effect	N	O
74	of	N	O
75	GKRS	N	O
76	compared	N	O
77	with	N	O
78	the	N	O
79	natural	N	O
80	course	N	O
81	on	N	O
82	tumor	N	O
83	growth	N	O
84	rate	N	O
85	and	N	O
86	hearing	N	O
87	loss	N	O
88	.	N	O

89	Secondary	N	O
90	end	N	O
91	points	N	O
92	were	N	O
93	postinclusion	N	O
94	additional	N	O
95	treatment	N	O
96	,	N	O
97	quality	N	O
98	of	N	O
99	life	N	O
100	(	N	O
101	QoL	N	O
102	)	N	O
103	,	N	O
104	and	N	O
105	symptom	N	O
106	development	N	O
107	.	N	O

108	The	N	O
109	patients	N	O
110	underwent	N	O
111	magnetic	N	O
112	resonance	N	O
113	imaging	N	O
114	scans	N	O
115	,	N	O
116	clinical	N	O
117	examination	N	O
118	,	N	O
119	and	N	O
120	QoL	N	O
121	assessment	N	O
122	by	N	O
123	SF-36	N	O
124	questionnaire	N	O
125	.	N	O

126	Statistics	N	O
127	were	N	O
128	performed	N	O
129	by	N	O
130	using	N	O
131	Spearman	N	O
132	correlation	N	O
133	coefficient	N	O
134	,	N	O
135	Kaplan-Meier	N	O
136	plot	N	O
137	,	N	O
138	Poisson	N	O
139	regression	N	O
140	model	N	O
141	,	N	O
142	mixed	N	O
143	linear	N	O
144	regression	N	O
145	models	N	O
146	,	N	O
147	and	N	O
148	mixed	N	O
149	logistic	N	O
150	regression	N	O
151	models	N	O
152	.	N	O

153	Mean	N	O
154	follow-up	N	O
155	time	N	O
156	was	N	O
157	55.0	N	O
158	months	N	O
159	(	N	O
160	26.1	N	O
161	standard	N	O
162	deviation	N	O
163	,	N	O
164	range	N	O
165	10-132	N	O
166	)	N	O
167	.	N	O

168	Thirteen	N	O
169	patients	N	O
170	were	N	O
171	lost	N	O
172	to	N	O
173	follow-up	N	O
174	.	N	O

175	Serviceable	N	I-Premise
176	hearing	N	I-Premise
177	was	N	I-Premise
178	lost	N	I-Premise
179	in	N	I-Premise
180	54	N	I-Premise
181	of	N	I-Premise
182	71	N	I-Premise
183	(	N	I-Premise
184	76	N	I-Premise
185	%	N	I-Premise
186	)	N	I-Premise
187	(	N	I-Premise
188	CM	N	I-Premise
189	)	N	I-Premise
190	and	N	I-Premise
191	34	N	I-Premise
192	of	N	I-Premise
193	53	N	I-Premise
194	(	N	I-Premise
195	64	N	I-Premise
196	%	N	I-Premise
197	)	N	I-Premise
198	(	N	I-Premise
199	GKRS	N	I-Premise
200	)	N	I-Premise
201	patients	N	I-Premise
202	during	N	I-Premise
203	the	N	I-Premise
204	study	N	I-Premise
205	period	N	I-Premise
206	(	N	I-Premise
207	not	N	I-Premise
208	significant	N	I-Premise
209	,	N	I-Premise
210	log-rank	N	I-Premise
211	test	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	There	N	I-Premise
215	was	N	I-Premise
216	a	N	I-Premise
217	significant	N	I-Premise
218	reduction	N	I-Premise
219	in	N	I-Premise
220	tumor	N	I-Premise
221	volume	N	I-Premise
222	over	N	I-Premise
223	time	N	I-Premise
224	in	N	I-Premise
225	the	N	I-Premise
226	GKRS	N	I-Premise
227	group	N	I-Premise
228	.	N	I-Premise

229	The	N	I-Premise
230	need	N	I-Premise
231	for	N	I-Premise
232	treatment	N	I-Premise
233	following	N	I-Premise
234	initial	N	I-Premise
235	GKRS	N	I-Premise
236	or	N	I-Premise
237	CM	N	I-Premise
238	differed	N	I-Premise
239	at	N	I-Premise
240	highly	N	I-Premise
241	significant	N	I-Premise
242	levels	N	I-Premise
243	(	N	I-Premise
244	log-rank	N	I-Premise
245	test	N	I-Premise
246	,	N	I-Premise
247	P	N	I-Premise
248	<	N	I-Premise
249	.001	N	I-Premise
250	)	N	I-Premise
251	.	N	I-Premise

252	Symptom	N	I-Premise
253	and	N	I-Premise
254	QoL	N	I-Premise
255	development	N	I-Premise
256	did	N	I-Premise
257	not	N	I-Premise
258	differ	N	I-Premise
259	significantly	N	I-Premise
260	between	N	I-Premise
261	the	N	I-Premise
262	groups	N	I-Premise
263	.	N	I-Premise

264	In	N	I-Claim
265	VS	N	I-Claim
266	patients	N	I-Claim
267	,	N	I-Claim
268	GKRS	N	I-Claim
269	reduces	N	I-Claim
270	the	N	I-Claim
271	tumor	N	I-Claim
272	growth	N	I-Claim
273	rate	N	I-Claim
274	and	N	I-Claim
275	thereby	N	I-Claim
276	the	N	I-Claim
277	incidence	N	I-Claim
278	rate	N	I-Claim
279	of	N	I-Claim
280	new	N	I-Claim
281	treatment	N	I-Claim
282	about	N	I-Claim
283	tenfold	N	I-Claim
284	.	N	I-Claim

285	Hearing	N	I-Claim
286	is	N	I-Claim
287	lost	N	I-Claim
288	at	N	I-Claim
289	similar	N	I-Claim
290	rates	N	I-Claim
291	in	N	I-Claim
292	both	N	I-Claim
293	groups	N	I-Claim
294	.	N	I-Claim

295	Symptoms	N	I-Claim
296	and	N	I-Claim
297	QoL	N	I-Claim
298	seem	N	I-Claim
299	not	N	I-Claim
300	to	N	I-Claim
301	be	N	I-Claim
302	significantly	N	I-Claim
303	affected	N	I-Claim
304	by	N	I-Claim
305	GKRS	N	I-Claim
306	.	N	I-Claim

1	Patients	N	O
2	undergoing	N	O
3	gastrectomy	N	O
4	because	N	O
5	of	N	O
6	stomach	N	O
7	cancer	N	O
8	often	N	O
9	face	N	O
10	weight	N	O
11	loss	N	O
12	in	N	O
13	the	N	O
14	perioperational	N	O
15	period	N	O
16	,	N	O
17	which	N	O
18	can	N	O
19	lead	N	O
20	to	N	O
21	malnutrition	N	O
22	and	N	O
23	negative	N	O
24	treatment	N	O
25	outcomes	N	O
26	.	N	O

27	The	N	O
28	purpose	N	O
29	of	N	O
30	this	N	O
31	study	N	O
32	was	N	O
33	to	N	O
34	develop	N	O
35	a	N	O
36	patient	N	O
37	participation-based	N	O
38	dietary	N	O
39	intervention	N	O
40	(	N	O
41	PPDI	N	O
42	)	N	O
43	and	N	O
44	evaluate	N	O
45	its	N	O
46	effects	N	O
47	on	N	O
48	patient	N	O
49	outcomes	N	O
50	.	N	O

51	This	N	O
52	was	N	O
53	a	N	O
54	prospective	N	O
55	,	N	O
56	randomized	N	O
57	controlled	N	O
58	trial	N	O
59	in	N	O
60	which	N	O
61	the	N	O
62	patients	N	O
63	were	N	O
64	recruited	N	O
65	in	N	O
66	a	N	O
67	cancer	N	O
68	center	N	O
69	in	N	O
70	South	N	O
71	Korea	N	O
72	.	N	O

73	The	N	O
74	participants	N	O
75	(	N	O
76	N	N	O
77	=	N	O
78	56	N	O
79	)	N	O
80	,	N	O
81	who	N	O
82	underwent	N	O
83	gastrectomy	N	O
84	with	N	O
85	stomach	N	O
86	cancer	N	O
87	stage	N	O
88	I	N	O
89	to	N	O
90	III	N	O
91	,	N	O
92	were	N	O
93	randomly	N	O
94	assigned	N	O
95	into	N	O
96	either	N	O
97	the	N	O
98	experimental	N	O
99	or	N	O
100	the	N	O
101	control	N	O
102	group	N	O
103	.	N	O

104	The	N	O
105	PPDI	N	O
106	,	N	O
107	which	N	O
108	was	N	O
109	given	N	O
110	on	N	O
111	the	N	O
112	day	N	O
113	before	N	O
114	the	N	O
115	hospital	N	O
116	discharge	N	O
117	,	N	O
118	comprised	N	O
119	2	N	O
120	face-to-face	N	O
121	and	N	O
122	2	N	O
123	telephone	N	O
124	interventions	N	O
125	.	N	O

126	The	N	O
127	outcome	N	O
128	variables	N	O
129	included	N	O
130	body	N	O
131	weight	N	O
132	,	N	O
133	body	N	O
134	mass	N	O
135	index	N	O
136	,	N	O
137	muscle	N	O
138	mass	N	O
139	,	N	O
140	the	N	O
141	Patient-Generated	N	O
142	Subjective	N	O
143	Global	N	O
144	Assessment	N	O
145	,	N	O
146	Dietary	N	O
147	Symptom	N	O
148	Scale	N	O
149	,	N	O
150	Functional	N	O
151	Assessment	N	O
152	Cancer	N	O
153	Therapy-General	N	O
154	,	N	O
155	Karnofsky	N	O
156	Performance	N	O
157	Status	N	O
158	,	N	O
159	Adherence	N	O
160	to	N	O
161	Dietary	N	O
162	Guidelines	N	O
163	Scale	N	O
164	,	N	O
165	Scale	N	O
166	of	N	O
167	Dietary	N	O
168	Knowledge	N	O
169	,	N	O
170	Patient	N	O
171	Satisfaction	N	O
172	Scale	N	O
173	,	N	O
174	and	N	O
175	a	N	O
176	3-day	N	O
177	food	N	O
178	diary	N	O
179	.	N	O

180	Participants	N	I-Premise
181	in	N	I-Premise
182	the	N	I-Premise
183	PPDI	N	I-Premise
184	intervention	N	I-Premise
185	demonstrated	N	I-Premise
186	significant	N	I-Premise
187	(	N	I-Premise
188	P	N	I-Premise
189	<	N	I-Premise
190	.05	N	I-Premise
191	)	N	I-Premise
192	reductions	N	I-Premise
193	in	N	I-Premise
194	adverse	N	I-Premise
195	dietary	N	I-Premise
196	symptoms	N	I-Premise
197	and	N	I-Premise
198	significant	N	I-Premise
199	improvements	N	I-Premise
200	(	N	I-Premise
201	P	N	I-Premise
202	<	N	I-Premise
203	.05	N	I-Premise
204	)	N	I-Premise
205	in	N	I-Premise
206	functional	N	I-Premise
207	status	N	I-Premise
208	,	N	I-Premise
209	performance	N	I-Premise
210	status	N	I-Premise
211	,	N	I-Premise
212	dietary	N	I-Premise
213	intake	N	I-Premise
214	,	N	I-Premise
215	adherence	N	I-Premise
216	to	N	I-Premise
217	dietary	N	I-Premise
218	guidelines	N	I-Premise
219	,	N	I-Premise
220	dietary	N	I-Premise
221	knowledge	N	I-Premise
222	,	N	I-Premise
223	and	N	I-Premise
224	satisfaction	N	I-Premise
225	with	N	I-Premise
226	the	N	I-Premise
227	intervention	N	I-Premise
228	as	N	I-Premise
229	compared	N	I-Premise
230	with	N	I-Premise
231	the	N	I-Premise
232	control	N	I-Premise
233	group	N	I-Premise
234	over	N	I-Premise
235	time	N	I-Premise
236	.	N	I-Premise

237	The	N	I-Claim
238	PPDI	N	I-Claim
239	was	N	I-Claim
240	an	N	I-Claim
241	effective	N	I-Claim
242	dietary	N	I-Claim
243	intervention	N	I-Claim
244	for	N	I-Claim
245	patients	N	I-Claim
246	undergoing	N	I-Claim
247	a	N	I-Claim
248	gastrectomy	N	I-Claim
249	for	N	I-Claim
250	gastric	N	I-Claim
251	cancer	N	I-Claim
252	and	N	I-Claim
253	deserves	N	I-Claim
254	additional	N	I-Claim
255	study	N	I-Claim
256	in	N	I-Claim
257	other	N	I-Claim
258	populations	N	I-Claim
259	of	N	I-Claim
260	patients	N	I-Claim
261	.	N	I-Claim

262	Incorporating	N	I-MajorClaim
263	patients	N	I-MajorClaim
264	'	N	I-MajorClaim
265	perspectives	N	I-MajorClaim
266	into	N	I-MajorClaim
267	a	N	I-MajorClaim
268	dietary	N	I-MajorClaim
269	intervention	N	I-MajorClaim
270	after	N	I-MajorClaim
271	gastrectomy	N	I-MajorClaim
272	for	N	I-MajorClaim
273	gastric	N	I-MajorClaim
274	cancer	N	I-MajorClaim
275	may	N	I-MajorClaim
276	contribute	N	I-MajorClaim
277	to	N	I-MajorClaim
278	improved	N	I-MajorClaim
279	patient	N	I-MajorClaim
280	outcomes	N	I-MajorClaim
281	and	N	I-MajorClaim
282	quality	N	I-MajorClaim
283	care	N	I-MajorClaim
284	.	N	I-MajorClaim

1	There	N	O
2	will	N	O
3	be	N	O
4	a	N	O
5	detectable	N	O
6	increase	N	O
7	in	N	O
8	overall	N	O
9	survival	N	O
10	(	N	O
11	OS	N	O
12	)	N	O
13	using	N	O
14	preoperative	N	O
15	(	N	O
16	PRE	N	O
17	)	N	O
18	as	N	O
19	opposed	N	O
20	to	N	O
21	perioperative	N	O
22	(	N	O
23	PERI	N	O
24	)	N	O
25	chemotherapy	N	O
26	in	N	O
27	resectable	N	O
28	StageI-II	N	O
29	non-small-cell	N	O
30	lung	N	O
31	cancer	N	O
32	(	N	O
33	NSCLC	N	O
34	)	N	O
35	.	N	O

36	This	N	O
37	multicenter	N	O
38	,	N	O
39	open-label	N	O
40	,	N	O
41	randomised	N	O
42	trial	N	O
43	with	N	O
44	a	N	O
45	2×2	N	O
46	factorial	N	O
47	design	N	O
48	first	N	O
49	compared	N	O
50	two	N	O
51	chemotherapy	N	O
52	strategies	N	O
53	(	N	O
54	PRE	N	O
55	versus	N	O
56	PERI	N	O
57	)	N	O
58	,	N	O
59	then	N	O
60	two	N	O
61	chemotherapy	N	O
62	regimens	N	O
63	(	N	O
64	gemcitabine-cisplatin	N	O
65	[	N	O
66	GP	N	O
67	]	N	O
68	versus	N	O
69	paclitaxel-carboplatin	N	O
70	[	N	O
71	TC	N	O
72	]	N	O
73	)	N	O
74	.	N	O

75	The	N	O
76	PRE	N	O
77	group	N	O
78	received	N	O
79	two	N	O
80	preoperative	N	O
81	cycles	N	O
82	followed	N	O
83	by	N	O
84	two	N	O
85	additional	N	O
86	preoperative	N	O
87	cycles	N	O
88	,	N	O
89	while	N	O
90	the	N	O
91	PERI	N	O
92	group	N	O
93	underwent	N	O
94	two	N	O
95	preoperative	N	O
96	cycles	N	O
97	followed	N	O
98	by	N	O
99	two	N	O
100	postoperative	N	O
101	cycles	N	O
102	,	N	O
103	the	N	O
104	3rd	N	O
105	and	N	O
106	4th	N	O
107	cycles	N	O
108	being	N	O
109	given	N	O
110	only	N	O
111	to	N	O
112	responders	N	O
113	in	N	O
114	both	N	O
115	cases	N	O
116	.	N	O

117	A	N	O
118	total	N	O
119	of	N	O
120	528	N	O
121	patients	N	O
122	were	N	O
123	randomised	N	O
124	,	N	O
125	267	N	O
126	of	N	O
127	which	N	O
128	were	N	O
129	assigned	N	O
130	to	N	O
131	the	N	O
132	PRE	N	O
133	group	N	O
134	and	N	O
135	261	N	O
136	to	N	O
137	the	N	O
138	PERI	N	O
139	group	N	O
140	.	N	O

141	Three-year	N	O
142	OS	N	O
143	did	N	O
144	not	N	O
145	differ	N	O
146	between	N	O
147	the	N	O
148	two	N	O
149	groups	N	O
150	(	N	O
151	67.4	N	O
152	%	N	O
153	and	N	O
154	67.7	N	O
155	%	N	O
156	,	N	O
157	respectively	N	O
158	;	N	O
159	hazard	N	O
160	ratio	N	O
161	(	N	O
162	HR	N	O
163	)	N	O
164	=1.01	N	O
165	[	N	O
166	0.79-1.30	N	O
167	]	N	O
168	,	N	O
169	p=0.92	N	O
170	)	N	O
171	,	N	O
172	nor	N	O
173	did	N	O
174	3-year	N	O
175	disease-free	N	O
176	survival	N	O
177	,	N	O
178	response	N	O
179	rates	N	O
180	,	N	O
181	toxicity	N	O
182	,	N	O
183	or	N	O
184	postoperative	N	O
185	mortality	N	O
186	.	N	O

187	Pathological	N	I-Premise
188	complete	N	I-Premise
189	response	N	I-Premise
190	was	N	I-Premise
191	observed	N	I-Premise
192	in	N	I-Premise
193	22	N	I-Premise
194	(	N	I-Premise
195	8.2	N	I-Premise
196	%	N	I-Premise
197	)	N	I-Premise
198	and	N	I-Premise
199	16	N	I-Premise
200	patients	N	I-Premise
201	(	N	I-Premise
202	6.1	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	.	N	I-Premise

208	Although	N	I-Premise
209	quality	N	I-Premise
210	of	N	I-Premise
211	life	N	I-Premise
212	did	N	I-Premise
213	not	N	I-Premise
214	differ	N	I-Premise
215	significantly	N	I-Premise
216	,	N	I-Premise
217	chemotherapy	N	I-Premise
218	compliance	N	I-Premise
219	was	N	I-Premise
220	significantly	N	I-Premise
221	higher	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	PRE	N	I-Premise
225	group	N	I-Premise
226	.	N	I-Premise

227	The	N	I-Premise
228	proportion	N	I-Premise
229	of	N	I-Premise
230	responders	N	I-Premise
231	who	N	I-Premise
232	received	N	I-Premise
233	Cycles	N	I-Premise
234	3	N	I-Premise
235	and	N	I-Premise
236	4	N	I-Premise
237	was	N	I-Premise
238	significantly	N	I-Premise
239	higher	N	I-Premise
240	in	N	I-Premise
241	the	N	I-Premise
242	PRE	N	I-Premise
243	group	N	I-Premise
244	(	N	I-Premise
245	90.4	N	I-Premise
246	%	N	I-Premise
247	versus	N	I-Premise
248	75.2	N	I-Premise
249	%	N	I-Premise
250	,	N	I-Premise
251	p=0.001	N	I-Premise
252	)	N	I-Premise
253	.	N	I-Premise

254	In	N	I-Premise
255	responders	N	I-Premise
256	,	N	I-Premise
257	the	N	I-Premise
258	dose	N	I-Premise
259	intensity	N	I-Premise
260	of	N	I-Premise
261	Cycles	N	I-Premise
262	3	N	I-Premise
263	and	N	I-Premise
264	4	N	I-Premise
265	was	N	I-Premise
266	higher	N	I-Premise
267	in	N	I-Premise
268	the	N	I-Premise
269	PRE	N	I-Premise
270	group	N	I-Premise
271	than	N	I-Premise
272	in	N	I-Premise
273	the	N	I-Premise
274	PERI	N	I-Premise
275	group	N	I-Premise
276	(	N	I-Premise
277	mean	N	I-Premise
278	relative	N	I-Premise
279	dose	N	I-Premise
280	intensity	N	I-Premise
281	of	N	I-Premise
282	90.4	N	I-Premise
283	%	N	I-Premise
284	versus	N	I-Premise
285	82.6	N	I-Premise
286	%	N	I-Premise
287	,	N	I-Premise
288	respectively	N	I-Premise
289	;	N	I-Premise
290	p=0.0007	N	I-Premise
291	)	N	I-Premise
292	.	N	I-Premise

293	There	N	I-Premise
294	was	N	I-Premise
295	no	N	I-Premise
296	difference	N	I-Premise
297	between	N	I-Premise
298	GP	N	I-Premise
299	and	N	I-Premise
300	TC	N	I-Premise
301	in	N	I-Premise
302	3-year	N	I-Premise
303	OS	N	I-Premise
304	(	N	I-Premise
305	HR=0.97	N	I-Premise
306	[	N	I-Premise
307	95	N	I-Premise
308	%	N	I-Premise
309	confidence	N	I-Premise
310	interval	N	I-Premise
311	(	N	I-Premise
312	CI	N	I-Premise
313	)	N	I-Premise
314	:	N	I-Premise
315	0.76-1.25	N	I-Premise
316	]	N	I-Premise
317	,	N	I-Premise
318	p=0.80	N	I-Premise
319	)	N	I-Premise
320	or	N	I-Premise
321	response	N	I-Premise
322	rates	N	I-Premise
323	.	N	I-Premise

324	However	N	O
325	,	N	O
326	the	N	I-Premise
327	regimens	N	I-Premise
328	'	N	I-Premise
329	toxicity	N	I-Premise
330	profiles	N	I-Premise
331	differed	N	I-Premise
332	.	N	I-Premise

333	This	N	I-Claim
334	study	N	I-Claim
335	failed	N	I-Claim
336	to	N	I-Claim
337	demonstrate	N	I-Claim
338	any	N	I-Claim
339	difference	N	I-Claim
340	in	N	I-Claim
341	survival	N	I-Claim
342	between	N	I-Claim
343	patients	N	I-Claim
344	receiving	N	I-Claim
345	preoperative	N	I-Claim
346	and	N	I-Claim
347	perioperative	N	I-Claim
348	chemotherapy	N	I-Claim
349	in	N	I-Claim
350	early-stage	N	I-Claim
351	NSCLC	N	I-Claim
352	.	N	I-Claim

353	The	N	I-Claim
354	increase	N	I-Claim
355	from	N	I-Claim
356	two	N	I-Claim
357	to	N	I-Claim
358	four	N	I-Claim
359	preoperative	N	I-Claim
360	chemotherapy	N	I-Claim
361	cycles	N	I-Claim
362	did	N	I-Claim
363	not	N	I-Claim
364	increase	N	I-Claim
365	the	N	I-Claim
366	pathological	N	I-Claim
367	response	N	I-Claim
368	rate	N	I-Claim
369	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aims	N	O
4	to	N	O
5	evaluate	N	O
6	the	N	O
7	feasibility	N	O
8	and	N	O
9	efficacy	N	O
10	of	N	O
11	an	N	O
12	8-week	N	O
13	supervised	N	O
14	exercise	N	O
15	program	N	O
16	in	N	O
17	de-conditioned	N	O
18	cancer	N	O
19	survivors	N	O
20	within	N	O
21	2-6	N	O
22	months	N	O
23	of	N	O
24	chemotherapy	N	O
25	completion	N	O
26	.	N	O

27	Participants	N	O
28	were	N	O
29	randomly	N	O
30	assigned	N	O
31	to	N	O
32	an	N	O
33	8-week	N	O
34	,	N	O
35	twice-weekly	N	O
36	,	N	O
37	supervised	N	O
38	aerobic	N	O
39	exercise	N	O
40	training	N	O
41	regime	N	O
42	(	N	O
43	n	N	O
44	=	N	O
45	23	N	O
46	)	N	O
47	or	N	O
48	a	N	O
49	usual	N	O
50	care	N	O
51	group	N	O
52	(	N	O
53	n	N	O
54	=	N	O
55	20	N	O
56	)	N	O
57	.	N	O

58	Feasibility	N	O
59	was	N	O
60	assessed	N	O
61	by	N	O
62	recruitment	N	O
63	rate	N	O
64	,	N	O
65	program	N	O
66	adherence	N	O
67	and	N	O
68	participant	N	O
69	feedback	N	O
70	.	N	O

71	The	N	O
72	primary	N	O
73	outcome	N	O
74	was	N	O
75	aerobic	N	O
76	fitness	N	O
77	assessed	N	O
78	by	N	O
79	the	N	O
80	Modified	N	O
81	Bruce	N	O
82	fitness	N	O
83	test	N	O
84	at	N	O
85	baseline	N	O
86	(	N	O
87	0	N	O
88	weeks	N	O
89	)	N	O
90	,	N	O
91	post-intervention	N	O
92	(	N	O
93	8	N	O
94	weeks	N	O
95	)	N	O
96	and	N	O
97	at	N	O
98	3-month	N	O
99	follow-up	N	O
100	.	N	O

101	Secondary	N	O
102	outcomes	N	O
103	included	N	O
104	physical	N	O
105	activity	N	O
106	,	N	O
107	waist	N	O
108	circumference	N	O
109	,	N	O
110	fatigue	N	O
111	and	N	O
112	quality	N	O
113	of	N	O
114	life	N	O
115	.	N	O

116	The	N	O
117	recruitment	N	O
118	rate	N	O
119	was	N	O
120	81	N	O
121	%	N	O
122	and	N	O
123	adherence	N	O
124	to	N	O
125	the	N	O
126	supervised	N	O
127	exercise	N	O
128	was	N	O
129	78.3	N	O
130	%	N	O
131	.	N	O

132	Meaningful	N	I-Premise
133	differences	N	I-Premise
134	in	N	I-Premise
135	aerobic	N	I-Premise
136	fitness	N	I-Premise
137	between	N	I-Premise
138	the	N	I-Premise
139	exercise	N	I-Premise
140	and	N	I-Premise
141	usual	N	I-Premise
142	care	N	I-Premise
143	groups	N	I-Premise
144	at	N	I-Premise
145	both	N	I-Premise
146	the	N	I-Premise
147	8-week	N	I-Premise
148	[	N	I-Premise
149	mean	N	I-Premise
150	3.0	N	I-Premise
151	mL	N	I-Premise
152	kg	N	I-Premise
153	(	N	I-Premise
154	-1	N	I-Premise
155	)	N	I-Premise
156	min	N	I-Premise
157	(	N	I-Premise
158	-1	N	I-Premise
159	)	N	I-Premise
160	(	N	I-Premise
161	95	N	I-Premise
162	%	N	I-Premise
163	CI	N	I-Premise
164	-1.1-7.0	N	I-Premise
165	)	N	I-Premise
166	]	N	I-Premise
167	and	N	I-Premise
168	3-month	N	I-Premise
169	follow-up	N	I-Premise
170	[	N	I-Premise
171	2.1	N	I-Premise
172	mL	N	I-Premise
173	kg	N	I-Premise
174	(	N	I-Premise
175	-1	N	I-Premise
176	)	N	I-Premise
177	min	N	I-Premise
178	(	N	I-Premise
179	-1	N	I-Premise
180	)	N	I-Premise
181	(	N	I-Premise
182	-2.3-6.6	N	I-Premise
183	)	N	I-Premise
184	]	N	I-Premise
185	were	N	I-Premise
186	found	N	I-Premise
187	,	N	I-Premise
188	although	N	I-Premise
189	these	N	I-Premise
190	differences	N	I-Premise
191	did	N	I-Premise
192	not	N	I-Premise
193	achieve	N	I-Premise
194	statistical	N	I-Premise
195	significance	N	I-Premise
196	(	N	I-Premise
197	p	N	I-Premise
198	values	N	I-Premise
199	>	N	I-Premise
200	0.14	N	I-Premise
201	)	N	I-Premise
202	.	N	I-Premise

203	Self-reported	N	I-Premise
204	physical	N	I-Premise
205	activity	N	I-Premise
206	increased	N	I-Premise
207	in	N	I-Premise
208	the	N	I-Premise
209	exercise	N	I-Premise
210	group	N	I-Premise
211	(	N	I-Premise
212	EG	N	I-Premise
213	)	N	I-Premise
214	compared	N	I-Premise
215	to	N	I-Premise
216	the	N	I-Premise
217	usual	N	I-Premise
218	care	N	I-Premise
219	group	N	I-Premise
220	at	N	I-Premise
221	both	N	I-Premise
222	8-week	N	I-Premise
223	(	N	I-Premise
224	p	N	I-Premise
225	=	N	I-Premise
226	0.01	N	I-Premise
227	)	N	I-Premise
228	and	N	I-Premise
229	3-month	N	I-Premise
230	follow-up	N	I-Premise
231	(	N	I-Premise
232	p	N	I-Premise
233	=	N	I-Premise
234	0.03	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	significant	N	I-Premise
238	differences	N	I-Premise
239	in	N	I-Premise
240	favour	N	I-Premise
241	of	N	I-Premise
242	the	N	I-Premise
243	EG	N	I-Premise
244	were	N	I-Premise
245	found	N	I-Premise
246	for	N	I-Premise
247	physical	N	I-Premise
248	well-being	N	I-Premise
249	at	N	I-Premise
250	both	N	I-Premise
251	the	N	I-Premise
252	8-week	N	I-Premise
253	(	N	I-Premise
254	p	N	I-Premise
255	=	N	I-Premise
256	0.03	N	I-Premise
257	)	N	I-Premise
258	and	N	I-Premise
259	3-month	N	I-Premise
260	follow-up	N	I-Premise
261	(	N	I-Premise
262	p	N	I-Premise
263	=	N	I-Premise
264	0.04	N	I-Premise
265	)	N	I-Premise
266	.	N	I-Premise

267	Improvements	N	I-Premise
268	in	N	I-Premise
269	fatigue	N	I-Premise
270	(	N	I-Premise
271	p	N	I-Premise
272	=	N	I-Premise
273	0.01	N	I-Premise
274	)	N	I-Premise
275	,	N	I-Premise
276	total	N	I-Premise
277	quality	N	I-Premise
278	of	N	I-Premise
279	life	N	I-Premise
280	plus	N	I-Premise
281	fatigue	N	I-Premise
282	(	N	I-Premise
283	p	N	I-Premise
284	=	N	I-Premise
285	0.04	N	I-Premise
286	)	N	I-Premise
287	,	N	I-Premise
288	and	N	I-Premise
289	a	N	I-Premise
290	composite	N	I-Premise
291	physical	N	I-Premise
292	functioning	N	I-Premise
293	score	N	I-Premise
294	(	N	I-Premise
295	p	N	I-Premise
296	=	N	I-Premise
297	0.01	N	I-Premise
298	)	N	I-Premise
299	at	N	I-Premise
300	the	N	I-Premise
301	3-month	N	I-Premise
302	follow-up	N	I-Premise
303	were	N	I-Premise
304	also	N	I-Premise
305	found	N	I-Premise
306	.	N	I-Premise

307	The	N	I-Claim
308	PEACH	N	I-Claim
309	trial	N	I-Claim
310	suggests	N	I-Claim
311	that	N	I-Claim
312	8	N	I-Claim
313	weeks	N	I-Claim
314	of	N	I-Claim
315	supervised	N	I-Claim
316	aerobic	N	I-Claim
317	exercise	N	I-Claim
318	training	N	I-Claim
319	was	N	I-Claim
320	feasible	N	I-Claim
321	and	N	I-Claim
322	may	N	I-Claim
323	improve	N	I-Claim
324	aerobic	N	I-Claim
325	fitness	N	I-Claim
326	,	N	I-Claim
327	fatigue	N	I-Claim
328	and	N	I-Claim
329	quality	N	I-Claim
330	of	N	I-Claim
331	life	N	I-Claim
332	in	N	I-Claim
333	de-conditioned	N	I-Claim
334	cancer	N	I-Claim
335	survivors	N	I-Claim
336	during	N	I-Claim
337	the	N	I-Claim
338	early	N	I-Claim
339	survivorship	N	I-Claim
340	phase	N	I-Claim
341	.	N	I-Claim

342	Exercise	N	I-Claim
343	interventions	N	I-Claim
344	commenced	N	I-Claim
345	in	N	I-Claim
346	the	N	I-Claim
347	early	N	I-Claim
348	survivorship	N	I-Claim
349	phase	N	I-Claim
350	appear	N	I-Claim
351	safe	N	I-Claim
352	,	N	I-Claim
353	feasible	N	I-Claim
354	and	N	I-Claim
355	may	N	I-Claim
356	lead	N	I-Claim
357	to	N	I-Claim
358	improvements	N	I-Claim
359	in	N	I-Claim
360	QOL	N	I-Claim
361	and	N	I-Claim
362	fatigue	N	I-Claim
363	.	N	I-Claim

1	There	N	O
2	is	N	O
3	a	N	O
4	paucity	N	O
5	of	N	O
6	methodologically	N	O
7	robust	N	O
8	vocational	N	O
9	rehabilitation	N	O
10	(	N	O
11	VR	N	O
12	)	N	O
13	intervention	N	O
14	trials	N	O
15	.	N	O

16	This	N	O
17	study	N	O
18	assessed	N	O
19	the	N	O
20	feasibility	N	O
21	and	N	O
22	acceptability	N	O
23	of	N	O
24	a	N	O
25	VR	N	O
26	trial	N	O
27	of	N	O
28	women	N	O
29	with	N	O
30	breast	N	O
31	cancer	N	O
32	to	N	O
33	inform	N	O
34	the	N	O
35	development	N	O
36	of	N	O
37	a	N	O
38	larger	N	O
39	interventional	N	O
40	study	N	O
41	.	N	O

42	Women	N	O
43	were	N	O
44	recruited	N	O
45	in	N	O
46	Scotland	N	O
47	and	N	O
48	randomised	N	O
49	to	N	O
50	either	N	O
51	a	N	O
52	case	N	O
53	management	N	O
54	VR	N	O
55	service	N	O
56	or	N	O
57	to	N	O
58	usual	N	O
59	care	N	O
60	.	N	O

61	Data	N	O
62	were	N	O
63	collected	N	O
64	on	N	O
65	eligibility	N	O
66	,	N	O
67	recruitment	N	O
68	and	N	O
69	attrition	N	O
70	rates	N	O
71	to	N	O
72	assess	N	O
73	trial	N	O
74	feasibility	N	O
75	,	N	O
76	and	N	O
77	interviews	N	O
78	conducted	N	O
79	to	N	O
80	determine	N	O
81	trial	N	O
82	acceptability	N	O
83	.	N	O

84	Sick	N	O
85	leave	N	O
86	days	N	O
87	(	N	O
88	primary	N	O
89	outcome	N	O
90	)	N	O
91	were	N	O
92	self-reported	N	O
93	via	N	O
94	postal	N	O
95	questionnaire	N	O
96	every	N	O
97	4	N	O
98	weeks	N	O
99	during	N	O
100	the	N	O
101	first	N	O
102	6	N	O
103	months	N	O
104	post-surgery	N	O
105	and	N	O
106	at	N	O
107	12	N	O
108	months	N	O
109	.	N	O

110	Secondary	N	O
111	outcome	N	O
112	measures	N	O
113	were	N	O
114	change	N	O
115	in	N	O
116	employment	N	O
117	pattern	N	O
118	,	N	O
119	quality	N	O
120	of	N	O
121	life	N	O
122	and	N	O
123	fatigue	N	O
124	.	N	O

125	Of	N	O
126	the	N	O
127	1,114	N	O
128	women	N	O
129	assessed	N	O
130	for	N	O
131	eligibility	N	O
132	,	N	O
133	163	N	O
134	(	N	O
135	15	N	O
136	%	N	O
137	)	N	O
138	were	N	O
139	eligible	N	O
140	.	N	O

141	The	N	O
142	main	N	O
143	reason	N	O
144	for	N	O
145	ineligibility	N	O
146	was	N	O
147	age	N	O
148	(	N	O
149	>	N	O
150	65	N	O
151	years	N	O
152	,	N	O
153	n	N	O
154	=	N	O
155	637	N	O
156	,	N	O
157	67	N	O
158	%	N	O
159	)	N	O
160	.	N	O

161	Of	N	O
162	those	N	O
163	eligible	N	O
164	,	N	O
165	111	N	O
166	(	N	O
167	68	N	O
168	%	N	O
169	)	N	O
170	received	N	O
171	study	N	O
172	information	N	O
173	,	N	O
174	of	N	O
175	which	N	O
176	23	N	O
177	(	N	O
178	21	N	O
179	%	N	O
180	)	N	O
181	consented	N	O
182	to	N	O
183	participate	N	O
184	in	N	O
185	the	N	O
186	study	N	O
187	.	N	O

188	Data	N	O
189	for	N	O
190	18	N	O
191	(	N	O
192	78	N	O
193	%	N	O
194	)	N	O
195	women	N	O
196	were	N	O
197	analysed	N	O
198	(	N	O
199	intervention	N	O
200	:	N	O
201	n	N	O
202	=	N	O
203	7	N	O
204	;	N	O
205	control	N	O
206	:	N	O
207	n	N	O
208	=	N	O
209	11	N	O
210	)	N	O
211	.	N	O

212	Participants	N	I-Premise
213	in	N	I-Premise
214	the	N	I-Premise
215	intervention	N	I-Premise
216	group	N	I-Premise
217	reported	N	I-Premise
218	,	N	I-Premise
219	on	N	I-Premise
220	average	N	I-Premise
221	,	N	I-Premise
222	53	N	I-Premise
223	fewer	N	I-Premise
224	days	N	I-Premise
225	of	N	I-Premise
226	sick	N	I-Premise
227	leave	N	I-Premise
228	over	N	I-Premise
229	the	N	I-Premise
230	first	N	I-Premise
231	6	N	I-Premise
232	months	N	I-Premise
233	post-surgery	N	I-Premise
234	than	N	I-Premise
235	those	N	I-Premise
236	in	N	I-Premise
237	the	N	I-Premise
238	control	N	I-Premise
239	group	N	I-Premise
240	;	N	I-Premise
241	however	N	I-Premise
242	,	N	I-Premise
243	this	N	I-Premise
244	difference	N	I-Premise
245	was	N	I-Premise
246	not	N	I-Premise
247	statistically	N	I-Premise
248	significant	N	I-Premise
249	(	N	I-Premise
250	p	N	I-Premise
251	=	N	I-Premise
252	0.122	N	I-Premise
253	;	N	I-Premise
254	95	N	I-Premise
255	%	N	I-Premise
256	confidence	N	I-Premise
257	interval	N	I-Premise
258	-15.8	N	I-Premise
259	,	N	I-Premise
260	122.0	N	I-Premise
261	)	N	I-Premise
262	.	N	I-Premise

263	No	N	I-Premise
264	statistically	N	I-Premise
265	significant	N	I-Premise
266	differences	N	I-Premise
267	were	N	I-Premise
268	found	N	I-Premise
269	for	N	I-Premise
270	secondary	N	I-Premise
271	outcomes	N	I-Premise
272	.	N	I-Premise

273	Interviews	N	I-Premise
274	with	N	I-Premise
275	trial	N	I-Premise
276	participants	N	I-Premise
277	indicated	N	I-Premise
278	that	N	I-Premise
279	trial	N	I-Premise
280	procedures	N	I-Premise
281	,	N	I-Premise
282	including	N	I-Premise
283	recruitment	N	I-Premise
284	,	N	I-Premise
285	randomisation	N	I-Premise
286	and	N	I-Premise
287	research	N	I-Premise
288	instruments	N	I-Premise
289	,	N	I-Premise
290	were	N	I-Premise
291	acceptable	N	I-Premise
292	.	N	I-Premise

293	Conducting	N	I-Claim
294	a	N	I-Claim
295	pragmatic	N	I-Claim
296	trial	N	I-Claim
297	of	N	I-Claim
298	effectiveness	N	I-Claim
299	of	N	I-Claim
300	a	N	I-Claim
301	VR	N	I-Claim
302	intervention	N	I-Claim
303	among	N	I-Claim
304	cancer	N	I-Claim
305	survivors	N	I-Claim
306	is	N	I-Claim
307	both	N	I-Claim
308	feasible	N	I-Claim
309	and	N	I-Claim
310	acceptable	N	I-Claim
311	,	N	I-Claim
312	but	N	I-Claim
313	more	N	I-Claim
314	research	N	I-Claim
315	about	N	I-Claim
316	the	N	I-Claim
317	exact	N	I-Claim
318	components	N	I-Claim
319	of	N	I-Claim
320	a	N	I-Claim
321	VR	N	I-Claim
322	intervention	N	I-Claim
323	and	N	I-Claim
324	choice	N	I-Claim
325	of	N	I-Claim
326	outcomes	N	I-Claim
327	to	N	I-Claim
328	measure	N	I-Claim
329	effectiveness	N	I-Claim
330	is	N	I-Claim
331	required	N	I-Claim
332	.	N	I-Claim

333	VR	N	I-MajorClaim
334	to	N	I-MajorClaim
335	assist	N	I-MajorClaim
336	breast	N	I-MajorClaim
337	cancer	N	I-MajorClaim
338	patients	N	I-MajorClaim
339	in	N	I-MajorClaim
340	the	N	I-MajorClaim
341	return	N	I-MajorClaim
342	to	N	I-MajorClaim
343	work	N	I-MajorClaim
344	process	N	I-MajorClaim
345	is	N	I-MajorClaim
346	an	N	I-MajorClaim
347	important	N	I-MajorClaim
348	component	N	I-MajorClaim
349	of	N	I-MajorClaim
350	cancer	N	I-MajorClaim
351	survivorship	N	I-MajorClaim
352	plans	N	I-MajorClaim
353	.	N	I-MajorClaim

1	Capecitabine/taxane	N	O
2	combinations	N	O
3	are	N	O
4	highly	N	O
5	active	N	O
6	in	N	O
7	metastatic	N	O
8	breast	N	O
9	cancer	N	O
10	(	N	O
11	MBC	N	O
12	)	N	O
13	.	N	O

14	We	N	O
15	conducted	N	O
16	a	N	O
17	randomized	N	O
18	,	N	O
19	phase	N	O
20	III	N	O
21	,	N	O
22	noninferiority	N	O
23	trial	N	O
24	comparing	N	O
25	capecitabine	N	O
26	plus	N	O
27	paclitaxel	N	O
28	(	N	O
29	XP	N	O
30	)	N	O
31	with	N	O
32	epirubicin	N	O
33	plus	N	O
34	paclitaxel	N	O
35	(	N	O
36	EP	N	O
37	)	N	O
38	as	N	O
39	first-line	N	O
40	therapy	N	O
41	for	N	O
42	MBC	N	O
43	,	N	O
44	regarding	N	O
45	progression-free	N	O
46	survival	N	O
47	(	N	O
48	PFS	N	O
49	)	N	O
50	as	N	O
51	primary	N	O
52	efficacy	N	O
53	endpoint	N	O
54	.	N	O

55	Females	N	O
56	who	N	O
57	had	N	O
58	received	N	O
59	no	N	O
60	prior	N	O
61	chemotherapy	N	O
62	for	N	O
63	MBC	N	O
64	were	N	O
65	randomized	N	O
66	to	N	O
67	six	N	O
68	3-weekly	N	O
69	cycles	N	O
70	of	N	O
71	XP	N	O
72	(	N	O
73	capecitabine	N	O
74	1000	N	O
75	mg/m	N	O
76	(	N	O
77	2	N	O
78	)	N	O
79	b.i.d.	N	O
80	,	N	O
81	days	N	O
82	1-14	N	O
83	;	N	O
84	paclitaxel	N	O
85	175	N	O
86	mg/m	N	O
87	(	N	O
88	2	N	O
89	)	N	O
90	3-h	N	O
91	infusion	N	O
92	,	N	O
93	day	N	O
94	1	N	O
95	)	N	O
96	or	N	O
97	EP	N	O
98	(	N	O
99	epirubicin	N	O
100	60	N	O
101	mg/m	N	O
102	(	N	O
103	2	N	O
104	)	N	O
105	1-h	N	O
106	infusion	N	O
107	,	N	O
108	day	N	O
109	1	N	O
110	;	N	O
111	paclitaxel	N	O
112	as	N	O
113	above	N	O
114	)	N	O
115	.	N	O

116	Secondary	N	O
117	endpoints	N	O
118	included	N	O
119	response	N	O
120	rate	N	O
121	,	N	O
122	overall	N	O
123	survival	N	O
124	,	N	O
125	tolerability	N	O
126	,	N	O
127	and	N	O
128	quality	N	O
129	of	N	O
130	life	N	O
131	(	N	O
132	QoL	N	O
133	)	N	O
134	.	N	O

135	Each	N	O
136	arm	N	O
137	included	N	O
138	170	N	O
139	patients	N	O
140	,	N	O
141	most	N	O
142	of	N	O
143	whom	N	O
144	received	N	O
145	all	N	O
146	six	N	O
147	cycles	N	O
148	as	N	O
149	planned	N	O
150	.	N	O

151	The	N	O
152	difference	N	O
153	in	N	O
154	means	N	O
155	of	N	O
156	(	N	O
157	logarithmic	N	O
158	)	N	O
159	PFS	N	O
160	times	N	O
161	(	N	O
162	-0.205	N	O
163	)	N	O
164	did	N	O
165	not	N	O
166	meet	N	O
167	the	N	O
168	pre-defined	N	O
169	level	N	O
170	for	N	O
171	noninferiority	N	O
172	(	N	O
173	-0.186	N	O
174	)	N	O
175	.	N	O

176	However	N	O
177	,	N	O
178	PFS	N	I-Premise
179	was	N	I-Premise
180	similar	N	I-Premise
181	in	N	I-Premise
182	the	N	I-Premise
183	two	N	I-Premise
184	arms	N	I-Premise
185	[	N	I-Premise
186	HR	N	I-Premise
187	:	N	I-Premise
188	XP	N	I-Premise
189	vs.	N	I-Premise
190	EP	N	I-Premise
191	:	N	I-Premise
192	1.012	N	I-Premise
193	(	N	I-Premise
194	95	N	I-Premise
195	%	N	I-Premise
196	CI	N	I-Premise
197	0.785-1.304	N	I-Premise
198	)	N	I-Premise
199	;	N	I-Premise
200	median	N	I-Premise
201	10.4	N	I-Premise
202	months	N	I-Premise
203	XP	N	I-Premise
204	vs.	N	I-Premise
205	9.2	N	I-Premise
206	months	N	I-Premise
207	EP	N	I-Premise
208	]	N	I-Premise
209	.	N	I-Premise

210	Overall	N	I-Premise
211	survival	N	I-Premise
212	was	N	I-Premise
213	also	N	I-Premise
214	similar	N	I-Premise
215	[	N	I-Premise
216	HR	N	I-Premise
217	1.027	N	I-Premise
218	(	N	I-Premise
219	95	N	I-Premise
220	%	N	I-Premise
221	CI	N	I-Premise
222	0.740-1.424	N	I-Premise
223	)	N	I-Premise
224	;	N	I-Premise
225	median	N	I-Premise
226	22.0	N	I-Premise
227	vs.	N	I-Premise
228	26.1	N	I-Premise
229	months	N	I-Premise
230	]	N	I-Premise
231	,	N	I-Premise
232	and	N	I-Premise
233	response	N	I-Premise
234	rate	N	I-Premise
235	was	N	I-Premise
236	47	N	I-Premise
237	%	N	I-Premise
238	versus	N	I-Premise
239	42	N	I-Premise
240	%	N	I-Premise
241	.	N	I-Premise

242	Both	N	I-Premise
243	regimens	N	I-Premise
244	were	N	I-Premise
245	tolerable	N	I-Premise
246	:	N	I-Premise
247	there	N	I-Premise
248	were	N	I-Premise
249	more	N	I-Premise
250	grade	N	I-Premise
251	3/4	N	I-Premise
252	diarrhea	N	I-Premise
253	and	N	I-Premise
254	grade	N	I-Premise
255	3	N	I-Premise
256	hand-foot	N	I-Premise
257	syndromes	N	I-Premise
258	with	N	I-Premise
259	XP	N	I-Premise
260	and	N	I-Premise
261	more	N	I-Premise
262	grade	N	I-Premise
263	3/4	N	I-Premise
264	hematologic	N	I-Premise
265	toxicities	N	I-Premise
266	with	N	I-Premise
267	EP	N	I-Premise
268	.	N	I-Premise

269	There	N	I-Premise
270	were	N	I-Premise
271	no	N	I-Premise
272	major	N	I-Premise
273	differences	N	I-Premise
274	in	N	I-Premise
275	QoL	N	I-Premise
276	.	N	I-Premise

277	Although	N	I-Claim
278	,	N	I-Claim
279	noninferiority	N	I-Claim
280	of	N	I-Claim
281	XP	N	I-Claim
282	to	N	I-Claim
283	EP	N	I-Claim
284	was	N	I-Claim
285	formally	N	I-Claim
286	not	N	I-Claim
287	proven	N	I-Claim
288	,	N	I-Claim
289	first-line	N	I-Claim
290	XP	N	I-Claim
291	was	N	I-Claim
292	active	N	I-Claim
293	and	N	I-Claim
294	feasible	N	I-Claim
295	.	N	I-Claim

296	XP	N	I-Claim
297	is	N	I-Claim
298	a	N	I-Claim
299	valid	N	I-Claim
300	first-line	N	I-Claim
301	alternative	N	I-Claim
302	to	N	I-Claim
303	anthracycline/taxane	N	I-Claim
304	regimens	N	I-Claim
305	,	N	I-Claim
306	especially	N	I-Claim
307	in	N	I-Claim
308	patients	N	I-Claim
309	previously	N	I-Claim
310	treated	N	I-Claim
311	with	N	I-Claim
312	adjuvant	N	I-Claim
313	anthracyclines	N	I-Claim
314	.	N	I-Claim

1	Major	N	O
2	depressive	N	O
3	disorder	N	O
4	develops	N	O
5	in	N	O
6	up	N	O
7	to	N	O
8	half	N	O
9	the	N	O
10	patients	N	O
11	undergoing	N	O
12	treatment	N	O
13	for	N	O
14	head	N	O
15	and	N	O
16	neck	N	O
17	cancer	N	O
18	,	N	O
19	resulting	N	O
20	in	N	O
21	significant	N	O
22	morbidity	N	O
23	;	N	O
24	therefore	N	O
25	,	N	O
26	preventing	N	O
27	depression	N	O
28	during	N	O
29	cancer	N	O
30	treatment	N	O
31	may	N	O
32	be	N	O
33	of	N	O
34	great	N	O
35	benefit	N	O
36	.	N	O

37	To	N	O
38	determine	N	O
39	whether	N	O
40	prophylactic	N	O
41	use	N	O
42	of	N	O
43	the	N	O
44	antidepressant	N	O
45	escitalopram	N	O
46	oxalate	N	O
47	would	N	O
48	decrease	N	O
49	the	N	O
50	incidence	N	O
51	of	N	O
52	depression	N	O
53	in	N	O
54	patients	N	O
55	receiving	N	O
56	primary	N	O
57	therapy	N	O
58	for	N	O
59	head	N	O
60	and	N	O
61	neck	N	O
62	cancer	N	O
63	.	N	O

64	A	N	O
65	randomized	N	O
66	,	N	O
67	double-blind	N	O
68	,	N	O
69	placebo-controlled	N	O
70	trial	N	O
71	of	N	O
72	escitalopram	N	O
73	vs	N	O
74	placebo	N	O
75	was	N	O
76	conducted	N	O
77	in	N	O
78	a	N	O
79	group	N	O
80	of	N	O
81	nondepressed	N	O
82	patients	N	O
83	diagnosed	N	O
84	as	N	O
85	having	N	O
86	head	N	O
87	and	N	O
88	neck	N	O
89	cancer	N	O
90	who	N	O
91	were	N	O
92	about	N	O
93	to	N	O
94	enter	N	O
95	cancer	N	O
96	treatment	N	O
97	.	N	O

98	Patients	N	O
99	were	N	O
100	stratified	N	O
101	by	N	O
102	sex	N	O
103	,	N	O
104	site	N	O
105	,	N	O
106	stage	N	O
107	(	N	O
108	early	N	O
109	vs	N	O
110	advanced	N	O
111	)	N	O
112	,	N	O
113	and	N	O
114	primary	N	O
115	modality	N	O
116	of	N	O
117	treatment	N	O
118	(	N	O
119	radiation	N	O
120	vs	N	O
121	surgery	N	O
122	)	N	O
123	.	N	O

124	The	N	O
125	primary	N	O
126	outcome	N	O
127	measure	N	O
128	was	N	O
129	the	N	O
130	number	N	O
131	of	N	O
132	participants	N	O
133	who	N	O
134	developed	N	O
135	moderate	N	O
136	or	N	O
137	greater	N	O
138	depression	N	O
139	(	N	O
140	scores	N	O
141	on	N	O
142	the	N	O
143	Quick	N	O
144	Inventory	N	O
145	of	N	O
146	Depressive	N	O
147	Symptomology-Self	N	O
148	Rated	N	O
149	of	N	O
150	≥11	N	O
151	)	N	O
152	.	N	O

153	From	N	O
154	January	N	O
155	6	N	O
156	,	N	O
157	2008	N	O
158	,	N	O
159	to	N	O
160	December	N	O
161	28	N	O
162	,	N	O
163	2011	N	O
164	,	N	O
165	148	N	O
166	patients	N	O
167	were	N	O
168	randomized	N	O
169	.	N	O

170	Significantly	N	I-Premise
171	fewer	N	I-Premise
172	patients	N	I-Premise
173	receiving	N	I-Premise
174	escitalopram	N	I-Premise
175	developed	N	I-Premise
176	depression	N	I-Premise
177	(	N	I-Premise
178	24.6	N	I-Premise
179	%	N	I-Premise
180	in	N	I-Premise
181	the	N	I-Premise
182	placebo	N	I-Premise
183	group	N	I-Premise
184	vs	N	I-Premise
185	10.0	N	I-Premise
186	%	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	escitalopram	N	I-Premise
190	group	N	I-Premise
191	;	N	I-Premise
192	stratified	N	I-Premise
193	log-rank	N	I-Premise
194	test	N	I-Premise
195	,	N	I-Premise
196	P	N	I-Premise
197	=	N	I-Premise
198	.04	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	A	N	O
202	Cox	N	O
203	proportional	N	O
204	hazards	N	O
205	regression	N	O
206	model	N	O
207	compared	N	O
208	the	N	O
209	2	N	O
210	treatment	N	O
211	groups	N	O
212	after	N	O
213	controlling	N	O
214	for	N	O
215	age	N	O
216	,	N	O
217	baseline	N	O
218	smoking	N	O
219	status	N	O
220	,	N	O
221	and	N	O
222	stratification	N	O
223	variables	N	O
224	.	N	O

225	The	N	I-Premise
226	hazard	N	I-Premise
227	ratio	N	I-Premise
228	of	N	I-Premise
229	0.37	N	I-Premise
230	(	N	I-Premise
231	95	N	I-Premise
232	%	N	I-Premise
233	CI	N	I-Premise
234	,	N	I-Premise
235	0.14-0.96	N	I-Premise
236	)	N	I-Premise
237	demonstrated	N	I-Premise
238	an	N	I-Premise
239	advantage	N	I-Premise
240	of	N	I-Premise
241	escitalopram	N	I-Premise
242	(	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	.04	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Patients	N	I-Premise
249	undergoing	N	I-Premise
250	radiotherapy	N	I-Premise
251	as	N	I-Premise
252	the	N	I-Premise
253	initial	N	I-Premise
254	modality	N	I-Premise
255	were	N	I-Premise
256	significantly	N	I-Premise
257	more	N	I-Premise
258	likely	N	I-Premise
259	to	N	I-Premise
260	develop	N	I-Premise
261	depression	N	I-Premise
262	than	N	I-Premise
263	those	N	I-Premise
264	undergoing	N	I-Premise
265	surgery	N	I-Premise
266	(	N	I-Premise
267	radiotherapy	N	I-Premise
268	compared	N	I-Premise
269	with	N	I-Premise
270	surgery	N	I-Premise
271	group	N	I-Premise
272	;	N	I-Premise
273	hazard	N	I-Premise
274	ratio	N	I-Premise
275	,	N	I-Premise
276	3.6	N	I-Premise
277	;	N	I-Premise
278	95	N	I-Premise
279	%	N	I-Premise
280	CI	N	I-Premise
281	,	N	I-Premise
282	1.38-9.40	N	I-Premise
283	;	N	I-Premise
284	P	N	I-Premise
285	=	N	I-Premise
286	.009	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	Patients	N	I-Premise
290	in	N	I-Premise
291	the	N	I-Premise
292	escitalopram	N	I-Premise
293	group	N	I-Premise
294	who	N	I-Premise
295	completed	N	I-Premise
296	the	N	I-Premise
297	study	N	I-Premise
298	and	N	I-Premise
299	were	N	I-Premise
300	not	N	I-Premise
301	depressed	N	I-Premise
302	rated	N	I-Premise
303	their	N	I-Premise
304	overall	N	I-Premise
305	quality	N	I-Premise
306	of	N	I-Premise
307	life	N	I-Premise
308	as	N	I-Premise
309	significantly	N	I-Premise
310	better	N	I-Premise
311	for	N	I-Premise
312	3	N	I-Premise
313	consecutive	N	I-Premise
314	months	N	I-Premise
315	after	N	I-Premise
316	cessation	N	I-Premise
317	of	N	I-Premise
318	drug	N	I-Premise
319	use	N	I-Premise
320	.	N	I-Premise

321	In	N	I-Claim
322	nondepressed	N	I-Claim
323	patients	N	I-Claim
324	undergoing	N	I-Claim
325	treatment	N	I-Claim
326	for	N	I-Claim
327	head	N	I-Claim
328	and	N	I-Claim
329	neck	N	I-Claim
330	cancer	N	I-Claim
331	,	N	I-Claim
332	prophylactic	N	I-Claim
333	escitalopram	N	I-Claim
334	reduced	N	I-Claim
335	the	N	I-Claim
336	risk	N	I-Claim
337	of	N	I-Claim
338	developing	N	I-Claim
339	depression	N	I-Claim
340	by	N	I-Claim
341	more	N	I-Claim
342	than	N	I-Claim
343	50	N	I-Claim
344	%	N	I-Claim
345	.	N	I-Claim

346	In	N	I-Claim
347	nondepressed	N	I-Claim
348	patients	N	I-Claim
349	who	N	I-Claim
350	completed	N	I-Claim
351	the	N	I-Claim
352	trial	N	I-Claim
353	,	N	I-Claim
354	quality	N	I-Claim
355	of	N	I-Claim
356	life	N	I-Claim
357	was	N	I-Claim
358	also	N	I-Claim
359	significantly	N	I-Claim
360	better	N	I-Claim
361	for	N	I-Claim
362	3	N	I-Claim
363	consecutive	N	I-Claim
364	months	N	I-Claim
365	after	N	I-Claim
366	cessation	N	I-Claim
367	of	N	I-Claim
368	drug	N	I-Claim
369	use	N	I-Claim
370	in	N	I-Claim
371	the	N	I-Claim
372	escitalopram	N	I-Claim
373	group	N	I-Claim
374	.	N	I-Claim

375	These	N	I-Claim
376	findings	N	I-Claim
377	have	N	I-Claim
378	important	N	I-Claim
379	implications	N	I-Claim
380	for	N	I-Claim
381	the	N	I-Claim
382	treatment	N	I-Claim
383	of	N	I-Claim
384	patients	N	I-Claim
385	with	N	I-Claim
386	head	N	I-Claim
387	and	N	I-Claim
388	neck	N	I-Claim
389	cancer	N	I-Claim
390	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	evaluate	N	O
9	laparoscopy-assisted	N	O
10	distal	N	O
11	gastrectomy	N	O
12	(	N	O
13	LADG	N	O
14	)	N	O
15	compared	N	O
16	to	N	O
17	open	N	O
18	distal	N	O
19	gastrectomy	N	O
20	(	N	O
21	ODG	N	O
22	)	N	O
23	in	N	O
24	the	N	O
25	treatment	N	O
26	of	N	O
27	early	N	O
28	gastric	N	O
29	cancer	N	O
30	with	N	O
31	respect	N	O
32	to	N	O
33	survival	N	O
34	,	N	O
35	surgical	N	O
36	outcomes	N	O
37	,	N	O
38	complications	N	O
39	,	N	O
40	and	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	(	N	O
45	QOL	N	O
46	)	N	O
47	.	N	O

48	One	N	O
49	hundred	N	O
50	sixty-four	N	O
51	patients	N	O
52	with	N	O
53	cT1N0M0	N	O
54	and	N	O
55	cT1N1M0	N	O
56	distal	N	O
57	gastric	N	O
58	cancer	N	O
59	were	N	O
60	randomly	N	O
61	assigned	N	O
62	to	N	O
63	either	N	O
64	the	N	O
65	LADG	N	O
66	group	N	O
67	or	N	O
68	the	N	O
69	ODG	N	O
70	group	N	O
71	.	N	O

72	The	N	O
73	primary	N	O
74	end	N	O
75	point	N	O
76	was	N	O
77	the	N	O
78	5-year	N	O
79	disease-free	N	O
80	survival	N	O
81	(	N	O
82	DFS	N	O
83	)	N	O
84	rate	N	O
85	.	N	O

86	Complications	N	O
87	were	N	O
88	classified	N	O
89	using	N	O
90	the	N	O
91	accordion	N	O
92	severity	N	O
93	classification	N	O
94	of	N	O
95	postoperative	N	O
96	complications	N	O
97	scheme	N	O
98	.	N	O

99	QOL	N	O
100	was	N	O
101	measured	N	O
102	using	N	O
103	the	N	O
104	European	N	O
105	Organization	N	O
106	for	N	O
107	Research	N	O
108	and	N	O
109	Treatment	N	O
110	of	N	O
111	Cancer	N	O
112	QLQ-C30	N	O
113	and	N	O
114	QLQ-STO22	N	O
115	preoperatively	N	O
116	and	N	O
117	postoperatively	N	O
118	during	N	O
119	regular	N	O
120	follow-up	N	O
121	visits	N	O
122	.	N	O

123	This	N	O
124	trial	N	O
125	is	N	O
126	registered	N	O
127	at	N	O
128	ClinicalTrials.gov	N	O
129	.	N	O

130	The	N	O
131	median	N	O
132	(	N	O
133	range	N	O
134	)	N	O
135	follow-up	N	O
136	period	N	O
137	was	N	O
138	74.3	N	O
139	(	N	O
140	24.8-90.8	N	O
141	)	N	O
142	months	N	O
143	.	N	O

144	The	N	I-Premise
145	LADG	N	I-Premise
146	and	N	I-Premise
147	ODG	N	I-Premise
148	groups	N	I-Premise
149	showed	N	I-Premise
150	similar	N	I-Premise
151	survival	N	I-Premise
152	[	N	I-Premise
153	5-year	N	I-Premise
154	DFS	N	I-Premise
155	rate	N	I-Premise
156	:	N	I-Premise
157	98.8	N	I-Premise
158	%	N	I-Premise
159	vs.	N	I-Premise
160	97.6	N	I-Premise
161	%	N	I-Premise
162	,	N	I-Premise
163	respectively	N	I-Premise
164	(	N	I-Premise
165	P	N	I-Premise
166	=	N	I-Premise
167	0.514	N	I-Premise
168	)	N	I-Premise
169	,	N	I-Premise
170	5-year	N	I-Premise
171	overall	N	I-Premise
172	survival	N	I-Premise
173	(	N	I-Premise
174	OS	N	I-Premise
175	)	N	I-Premise
176	rate	N	I-Premise
177	:	N	I-Premise
178	97.6	N	I-Premise
179	vs.	N	I-Premise
180	96.3	N	I-Premise
181	%	N	I-Premise
182	,	N	I-Premise
183	respectively	N	I-Premise
184	(	N	I-Premise
185	P	N	I-Premise
186	=	N	I-Premise
187	0.721	N	I-Premise
188	)	N	I-Premise
189	]	N	I-Premise
190	or	N	I-Premise
191	overall	N	I-Premise
192	complication	N	I-Premise
193	rate	N	I-Premise
194	(	N	I-Premise
195	29.3	N	I-Premise
196	vs.	N	I-Premise
197	42.7	N	I-Premise
198	%	N	I-Premise
199	,	N	I-Premise
200	respectively	N	I-Premise
201	;	N	I-Premise
202	P	N	I-Premise
203	=	N	I-Premise
204	0.073	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	Mild	N	I-Premise
208	complications	N	I-Premise
209	were	N	I-Premise
210	significantly	N	I-Premise
211	less	N	I-Premise
212	frequent	N	I-Premise
213	in	N	I-Premise
214	the	N	I-Premise
215	LADG	N	I-Premise
216	group	N	I-Premise
217	than	N	I-Premise
218	in	N	I-Premise
219	the	N	I-Premise
220	ODG	N	I-Premise
221	group	N	I-Premise
222	(	N	I-Premise
223	23.2	N	I-Premise
224	vs.	N	I-Premise
225	41.5	N	I-Premise
226	%	N	I-Premise
227	;	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	0.012	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	The	N	I-Premise
234	rates	N	I-Premise
235	of	N	I-Premise
236	moderate	N	I-Premise
237	,	N	I-Premise
238	severe	N	I-Premise
239	,	N	I-Premise
240	and	N	I-Premise
241	long-term	N	I-Premise
242	complications	N	I-Premise
243	(	N	I-Premise
244	i.e.	N	I-Premise
245	,	N	I-Premise
246	31	N	I-Premise
247	days	N	I-Premise
248	to	N	I-Premise
249	5	N	I-Premise
250	years	N	I-Premise
251	after	N	I-Premise
252	surgery	N	I-Premise
253	)	N	I-Premise
254	did	N	I-Premise
255	not	N	I-Premise
256	differ	N	I-Premise
257	significantly	N	I-Premise
258	between	N	I-Premise
259	groups	N	I-Premise
260	.	N	I-Premise

261	No	N	I-Premise
262	clinically	N	I-Premise
263	meaningful	N	I-Premise
264	differences	N	I-Premise
265	were	N	I-Premise
266	detected	N	I-Premise
267	between	N	I-Premise
268	the	N	I-Premise
269	two	N	I-Premise
270	groups	N	I-Premise
271	in	N	I-Premise
272	long-term	N	I-Premise
273	QOL	N	I-Premise
274	.	N	I-Premise

275	LADG	N	I-Claim
276	showed	N	I-Claim
277	similar	N	I-Claim
278	DFS	N	I-Claim
279	and	N	I-Claim
280	OS	N	I-Claim
281	compared	N	I-Claim
282	to	N	I-Claim
283	ODG	N	I-Claim
284	in	N	I-Claim
285	treating	N	I-Claim
286	early	N	I-Claim
287	gastric	N	I-Claim
288	cancer	N	I-Claim
289	.	N	I-Claim

290	Marginal	N	I-Claim
291	benefits	N	I-Claim
292	in	N	I-Claim
293	mild	N	I-Claim
294	complications	N	I-Claim
295	were	N	I-Claim
296	observed	N	I-Claim
297	with	N	I-Claim
298	LADG	N	I-Claim
299	.	N	I-Claim

300	LADG	N	I-Claim
301	did	N	I-Claim
302	not	N	I-Claim
303	show	N	I-Claim
304	advantages	N	I-Claim
305	over	N	I-Claim
306	ODG	N	I-Claim
307	regarding	N	I-Claim
308	other	N	I-Claim
309	complications	N	I-Claim
310	and	N	I-Claim
311	long-term	N	I-Claim
312	QOL	N	I-Claim
313	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	advanced	N	O
7	practice	N	O
8	nurse	N	O
9	(	N	O
10	APN	N	O
11	)	N	O
12	-administered	N	O
13	low-level	N	O
14	laser	N	O
15	therapy	N	O
16	(	N	O
17	LLLT	N	O
18	)	N	O
19	as	N	O
20	both	N	O
21	a	N	O
22	stand-alone	N	O
23	and	N	O
24	complementary	N	O
25	treatment	N	O
26	for	N	O
27	arm	N	O
28	volume	N	O
29	,	N	O
30	symptoms	N	O
31	,	N	O
32	and	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	(	N	O
37	QOL	N	O
38	)	N	O
39	in	N	O
40	women	N	O
41	with	N	O
42	breast	N	O
43	cancer-related	N	O
44	lymphedema	N	O
45	.	N	O

46	A	N	O
47	three-group	N	O
48	,	N	O
49	pilot	N	O
50	,	N	O
51	randomized	N	O
52	clinical	N	O
53	trial	N	O
54	.	N	O

55	A	N	O
56	private	N	O
57	rehabilitation	N	O
58	practice	N	O
59	in	N	O
60	the	N	O
61	southeastern	N	O
62	United	N	O
63	States	N	O
64	.	N	O

65	46	N	O
66	breast	N	O
67	cancer	N	O
68	survivors	N	O
69	with	N	O
70	treatment-related	N	O
71	lymphedema	N	O
72	.	N	O

73	Patients	N	O
74	were	N	O
75	screened	N	O
76	for	N	O
77	eligibility	N	O
78	and	N	O
79	then	N	O
80	randomized	N	O
81	to	N	O
82	either	N	O
83	manual	N	O
84	lymphatic	N	O
85	drainage	N	O
86	(	N	O
87	MLD	N	O
88	)	N	O
89	for	N	O
90	40	N	O
91	minutes	N	O
92	,	N	O
93	LLLT	N	O
94	for	N	O
95	20	N	O
96	minutes	N	O
97	,	N	O
98	or	N	O
99	20	N	O
100	minutes	N	O
101	of	N	O
102	MLD	N	O
103	followed	N	O
104	by	N	O
105	20	N	O
106	minutes	N	O
107	of	N	O
108	LLLT	N	O
109	.	N	O

110	Compression	N	O
111	bandaging	N	O
112	was	N	O
113	applied	N	O
114	after	N	O
115	each	N	O
116	treatment	N	O
117	.	N	O

118	Data	N	O
119	were	N	O
120	collected	N	O
121	pretreatment	N	O
122	,	N	O
123	daily	N	O
124	,	N	O
125	weekly	N	O
126	,	N	O
127	and	N	O
128	at	N	O
129	the	N	O
130	end	N	O
131	of	N	O
132	treatment	N	O
133	.	N	O

134	Independent	N	O
135	variables	N	O
136	consisted	N	O
137	of	N	O
138	three	N	O
139	types	N	O
140	of	N	O
141	APN-administered	N	O
142	lymphedema	N	O
143	treatment	N	O
144	.	N	O

145	Outcome	N	O
146	variables	N	O
147	included	N	O
148	limb	N	O
149	volume	N	O
150	,	N	O
151	extracellular	N	O
152	fluid	N	O
153	,	N	O
154	psychological	N	O
155	and	N	O
156	physical	N	O
157	symptoms	N	O
158	,	N	O
159	and	N	O
160	QOL	N	O
161	.	N	O

162	No	N	I-Premise
163	statistically	N	I-Premise
164	significant	N	I-Premise
165	between-group	N	I-Premise
166	differences	N	I-Premise
167	were	N	I-Premise
168	found	N	I-Premise
169	in	N	I-Premise
170	volume	N	I-Premise
171	reduction	N	I-Premise
172	;	N	I-Premise
173	however	N	I-Premise
174	,	N	I-Premise
175	all	N	I-Premise
176	groups	N	I-Premise
177	had	N	I-Premise
178	clinically	N	I-Premise
179	and	N	I-Premise
180	statistically	N	I-Premise
181	significant	N	I-Premise
182	reduction	N	I-Premise
183	in	N	I-Premise
184	volume	N	I-Premise
185	.	N	I-Premise

186	No	N	I-Premise
187	group	N	I-Premise
188	differences	N	I-Premise
189	were	N	I-Premise
190	noted	N	I-Premise
191	in	N	I-Premise
192	psychological	N	I-Premise
193	and	N	I-Premise
194	physical	N	I-Premise
195	symptoms	N	I-Premise
196	or	N	I-Premise
197	QOL	N	I-Premise
198	;	N	I-Premise
199	however	N	I-Premise
200	,	N	I-Premise
201	treatment-related	N	I-Premise
202	improvements	N	I-Premise
203	were	N	I-Premise
204	noted	N	I-Premise
205	in	N	I-Premise
206	symptom	N	I-Premise
207	burden	N	I-Premise
208	within	N	I-Premise
209	all	N	I-Premise
210	groups	N	I-Premise
211	.	N	I-Premise

212	Skin	N	I-Premise
213	improvement	N	I-Premise
214	was	N	I-Premise
215	noted	N	I-Premise
216	in	N	I-Premise
217	each	N	I-Premise
218	group	N	I-Premise
219	that	N	I-Premise
220	received	N	I-Premise
221	LLLT	N	I-Premise
222	.	N	I-Premise

223	LLLT	N	I-Claim
224	with	N	I-Claim
225	bandaging	N	I-Claim
226	may	N	I-Claim
227	offer	N	I-Claim
228	a	N	I-Claim
229	time-saving	N	I-Claim
230	therapeutic	N	I-Claim
231	option	N	I-Claim
232	to	N	I-Claim
233	conventional	N	I-Claim
234	MLD	N	I-Claim
235	.	N	I-Claim

236	Alternatively	N	O
237	,	N	O
238	compression	N	I-Claim
239	bandaging	N	I-Claim
240	alone	N	I-Claim
241	could	N	I-Claim
242	account	N	I-Claim
243	for	N	I-Claim
244	the	N	I-Claim
245	demonstrated	N	I-Claim
246	volume	N	I-Claim
247	reduction	N	I-Claim
248	.	N	I-Claim

249	APNs	N	I-Claim
250	can	N	I-Claim
251	effectively	N	I-Claim
252	treat	N	I-Claim
253	lymphedema	N	I-Claim
254	.	N	I-Claim

255	APNs	N	O
256	in	N	O
257	private	N	O
258	healthcare	N	O
259	practices	N	O
260	can	N	O
261	serve	N	O
262	as	N	O
263	valuable	N	O
264	research	N	O
265	collaborators	N	O
266	.	N	O

267	Lasers	N	I-Claim
268	may	N	I-Claim
269	provide	N	I-Claim
270	effective	N	I-Claim
271	,	N	I-Claim
272	less	N	I-Claim
273	burdensome	N	I-Claim
274	treatment	N	I-Claim
275	for	N	I-Claim
276	lymphedema	N	I-Claim
277	.	N	I-Claim

278	APNs	N	I-Claim
279	with	N	I-Claim
280	lymphedema	N	I-Claim
281	certification	N	I-Claim
282	can	N	I-Claim
283	effectively	N	I-Claim
284	treat	N	I-Claim
285	this	N	I-Claim
286	patient	N	I-Claim
287	population	N	I-Claim
288	with	N	I-Claim
289	the	N	I-Claim
290	use	N	I-Claim
291	of	N	I-Claim
292	LLLT	N	I-Claim
293	.	N	I-Claim

294	In	N	O
295	addition	N	O
296	,	N	O
297	bioelectrical	N	I-Claim
298	impedance	N	I-Claim
299	and	N	I-Claim
300	tape	N	I-Claim
301	measurements	N	I-Claim
302	can	N	I-Claim
303	be	N	I-Claim
304	used	N	I-Claim
305	to	N	I-Claim
306	assess	N	I-Claim
307	lymphedema	N	I-Claim
308	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aims	N	O
4	to	N	O
5	describe	N	O
6	and	N	O
7	compare	N	O
8	health-related	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	HRQL	N	O
14	)	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	node-positive	N	O
19	and	N	O
20	high-risk	N	O
21	node-negative	N	O
22	HER2-positive	N	O
23	early	N	O
24	breast	N	O
25	cancer	N	O
26	receiving	N	O
27	adjuvant	N	O
28	docetaxel	N	O
29	and	N	O
30	trastuzumab-based	N	O
31	or	N	O
32	docetaxel-based	N	O
33	regimens	N	O
34	alone	N	O
35	.	N	O

36	Eligible	N	O
37	patients	N	O
38	(	N	O
39	n	N	O
40	=	N	O
41	3,222	N	O
42	)	N	O
43	were	N	O
44	randomly	N	O
45	assigned	N	O
46	to	N	O
47	either	N	O
48	four	N	O
49	cycles	N	O
50	of	N	O
51	adjuvant	N	O
52	doxorubicin	N	O
53	and	N	O
54	cyclophosphamide	N	O
55	followed	N	O
56	by	N	O
57	four	N	O
58	cycles	N	O
59	of	N	O
60	docetaxel	N	O
61	(	N	O
62	AC→T	N	O
63	)	N	O
64	or	N	O
65	one	N	O
66	of	N	O
67	two	N	O
68	trastuzumab-containing	N	O
69	regimens	N	O
70	:	N	O
71	adjuvant	N	O
72	doxorubicin	N	O
73	and	N	O
74	cyclophosphamide	N	O
75	followed	N	O
76	by	N	O
77	docetaxel	N	O
78	plus	N	O
79	trastuzumab	N	O
80	administered	N	O
81	for	N	O
82	1	N	O
83	year	N	O
84	(	N	O
85	AC→TH	N	O
86	)	N	O
87	or	N	O
88	six	N	O
89	cycles	N	O
90	of	N	O
91	docetaxel	N	O
92	plus	N	O
93	carboplatin	N	O
94	combined	N	O
95	with	N	O
96	trastuzumab	N	O
97	administered	N	O
98	for	N	O
99	1	N	O
100	year	N	O
101	(	N	O
102	TCH	N	O
103	)	N	O
104	.	N	O

105	The	N	O
106	European	N	O
107	Organization	N	O
108	for	N	O
109	Research	N	O
110	and	N	O
111	Treatment	N	O
112	of	N	O
113	Cancer	N	O
114	(	N	O
115	EORTC	N	O
116	)	N	O
117	Quality	N	O
118	of	N	O
119	Life	N	O
120	Questionnaire	N	O
121	C30	N	O
122	and	N	O
123	BR-23	N	O
124	were	N	O
125	administered	N	O
126	at	N	O
127	baseline	N	O
128	,	N	O
129	the	N	O
130	start	N	O
131	of	N	O
132	cycle	N	O
133	4	N	O
134	(	N	O
135	mid	N	O
136	)	N	O
137	,	N	O
138	and	N	O
139	the	N	O
140	end	N	O
141	of	N	O
142	chemotherapy	N	O
143	(	N	O
144	EOC	N	O
145	)	N	O
146	,	N	O
147	as	N	O
148	well	N	O
149	as	N	O
150	at	N	O
151	6	N	O
152	,	N	O
153	12	N	O
154	,	N	O
155	and	N	O
156	24	N	O
157	months	N	O
158	after	N	O
159	chemotherapy	N	O
160	.	N	O

161	Compliance	N	I-Premise
162	rates	N	I-Premise
163	for	N	I-Premise
164	the	N	I-Premise
165	EORTC	N	I-Premise
166	questionnaires	N	I-Premise
167	were	N	I-Premise
168	acceptable	N	I-Premise
169	at	N	I-Premise
170	72	N	I-Premise
171	%	N	I-Premise
172	-93	N	I-Premise
173	%	N	I-Premise
174	of	N	I-Premise
175	eligible	N	I-Premise
176	patients	N	I-Premise
177	out	N	I-Premise
178	to	N	I-Premise
179	the	N	I-Premise
180	12-month	N	I-Premise
181	assessment	N	I-Premise
182	.	N	I-Premise

183	Systemic	N	I-Premise
184	side	N	I-Premise
185	effect	N	I-Premise
186	(	N	I-Premise
187	SE	N	I-Premise
188	)	N	I-Premise
189	change	N	I-Premise
190	scores	N	I-Premise
191	were	N	I-Premise
192	significantly	N	I-Premise
193	improved	N	I-Premise
194	for	N	I-Premise
195	TCH-treated	N	I-Premise
196	patients	N	I-Premise
197	compared	N	I-Premise
198	with	N	I-Premise
199	AC→TH	N	I-Premise
200	and	N	I-Premise
201	AC→T	N	I-Premise
202	at	N	I-Premise
203	EOC	N	I-Premise
204	,	N	I-Premise
205	suggesting	N	I-Premise
206	improved	N	I-Premise
207	tolerability	N	I-Premise
208	.	N	I-Premise

209	Physical	N	I-Premise
210	functioning	N	I-Premise
211	(	N	I-Premise
212	PF	N	I-Premise
213	)	N	I-Premise
214	was	N	I-Premise
215	only	N	I-Premise
216	slightly	N	I-Premise
217	worse	N	I-Premise
218	at	N	I-Premise
219	midpoint	N	I-Premise
220	for	N	I-Premise
221	those	N	I-Premise
222	receiving	N	I-Premise
223	TCH	N	I-Premise
224	,	N	I-Premise
225	compared	N	I-Premise
226	with	N	I-Premise
227	patients	N	I-Premise
228	who	N	I-Premise
229	were	N	I-Premise
230	just	N	I-Premise
231	starting	N	I-Premise
232	on	N	I-Premise
233	taxane	N	I-Premise
234	in	N	I-Premise
235	an	N	I-Premise
236	AC→TH	N	I-Premise
237	regimen	N	I-Premise
238	,	N	I-Premise
239	but	N	I-Premise
240	was	N	I-Premise
241	otherwise	N	I-Premise
242	similar	N	I-Premise
243	between	N	I-Premise
244	arms	N	I-Premise
245	.	N	I-Premise

246	All	N	I-Claim
247	treatment	N	I-Claim
248	arms	N	I-Claim
249	recovered	N	I-Claim
250	from	N	I-Claim
251	the	N	I-Claim
252	deterioration	N	I-Claim
253	in	N	I-Claim
254	SE	N	I-Claim
255	,	N	I-Claim
256	PF	N	I-Claim
257	,	N	I-Claim
258	and	N	I-Claim
259	Global	N	I-Claim
260	Health	N	I-Claim
261	Scale	N	I-Claim
262	scores	N	I-Claim
263	by	N	I-Claim
264	1	N	I-Claim
265	year	N	I-Claim
266	and	N	I-Claim
267	median	N	I-Claim
268	future	N	I-Claim
269	perspective	N	I-Claim
270	change	N	I-Claim
271	scores	N	I-Claim
272	continued	N	I-Claim
273	to	N	I-Claim
274	improve	N	I-Claim
275	throughout	N	I-Claim
276	treatment	N	I-Claim
277	and	N	I-Claim
278	follow-up	N	I-Claim
279	.	N	I-Claim

280	HRQL	N	I-Claim
281	outcomes	N	I-Claim
282	for	N	I-Claim
283	adjuvant	N	I-Claim
284	docetaxel	N	I-Claim
285	and	N	I-Claim
286	trastuzumab-based	N	I-Claim
287	regimens	N	I-Claim
288	are	N	I-Claim
289	favorable	N	I-Claim
290	and	N	I-Claim
291	support	N	I-Claim
292	TCH	N	I-Claim
293	as	N	I-Claim
294	a	N	I-Claim
295	more	N	I-Claim
296	tolerable	N	I-Claim
297	treatment	N	I-Claim
298	option	N	I-Claim
299	.	N	I-Claim

1	Patient-reported	N	O
2	symptoms	N	O
3	and	N	O
4	health-related	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QoL	N	O
10	)	N	O
11	benefits	N	O
12	were	N	O
13	investigated	N	O
14	in	N	O
15	a	N	O
16	randomized	N	O
17	,	N	O
18	phase	N	O
19	III	N	O
20	trial	N	O
21	of	N	O
22	afatinib	N	O
23	or	N	O
24	cisplatin/pemetrexed	N	O
25	.	N	O

26	Three	N	O
27	hundred	N	O
28	forty-five	N	O
29	patients	N	O
30	with	N	O
31	advanced	N	O
32	epidermal	N	O
33	growth	N	O
34	factor	N	O
35	receptor	N	O
36	(	N	O
37	EGFR	N	O
38	)	N	O
39	mutation-positive	N	O
40	lung	N	O
41	adenocarcinoma	N	O
42	were	N	O
43	randomly	N	O
44	assigned	N	O
45	2:1	N	O
46	to	N	O
47	afatinib	N	O
48	40	N	O
49	mg	N	O
50	per	N	O
51	day	N	O
52	or	N	O
53	up	N	O
54	to	N	O
55	six	N	O
56	cycles	N	O
57	of	N	O
58	cisplatin/pemetrexed	N	O
59	.	N	O

60	Lung	N	O
61	cancer	N	O
62	symptoms	N	O
63	and	N	O
64	health-related	N	O
65	QoL	N	O
66	were	N	O
67	assessed	N	O
68	every	N	O
69	21	N	O
70	days	N	O
71	until	N	O
72	progression	N	O
73	using	N	O
74	the	N	O
75	European	N	O
76	Organisation	N	O
77	for	N	O
78	Research	N	O
79	and	N	O
80	Treatment	N	O
81	of	N	O
82	Cancer	N	O
83	Quality	N	O
84	of	N	O
85	Life	N	O
86	Questionnaire	N	O
87	C30	N	O
88	and	N	O
89	Lung	N	O
90	Cancer-13	N	O
91	questionnaires	N	O
92	.	N	O

93	Analyses	N	O
94	of	N	O
95	cough	N	O
96	,	N	O
97	dyspnea	N	O
98	,	N	O
99	and	N	O
100	pain	N	O
101	were	N	O
102	preplanned	N	O
103	,	N	O
104	including	N	O
105	percentage	N	O
106	of	N	O
107	patients	N	O
108	who	N	O
109	improved	N	O
110	on	N	O
111	therapy	N	O
112	,	N	O
113	time	N	O
114	to	N	O
115	deterioration	N	O
116	of	N	O
117	symptoms	N	O
118	,	N	O
119	and	N	O
120	change	N	O
121	in	N	O
122	symptoms	N	O
123	over	N	O
124	time	N	O
125	.	N	O

126	Questionnaire	N	O
127	compliance	N	O
128	was	N	O
129	high	N	O
130	.	N	O

131	Compared	N	I-Premise
132	with	N	I-Premise
133	chemotherapy	N	I-Premise
134	,	N	I-Premise
135	afatinib	N	I-Premise
136	significantly	N	I-Premise
137	delayed	N	I-Premise
138	the	N	I-Premise
139	time	N	I-Premise
140	to	N	I-Premise
141	deterioration	N	I-Premise
142	for	N	I-Premise
143	cough	N	I-Premise
144	(	N	I-Premise
145	hazard	N	I-Premise
146	ratio	N	I-Premise
147	[	N	I-Premise
148	HR	N	I-Premise
149	]	N	I-Premise
150	,	N	I-Premise
151	0.60	N	I-Premise
152	;	N	I-Premise
153	95	N	I-Premise
154	%	N	I-Premise
155	CI	N	I-Premise
156	,	N	I-Premise
157	0.41	N	I-Premise
158	to	N	I-Premise
159	0.87	N	I-Premise
160	;	N	I-Premise
161	P	N	I-Premise
162	=	N	I-Premise
163	.007	N	I-Premise
164	)	N	I-Premise
165	and	N	I-Premise
166	dyspnea	N	I-Premise
167	(	N	I-Premise
168	HR	N	I-Premise
169	,	N	I-Premise
170	0.68	N	I-Premise
171	;	N	I-Premise
172	95	N	I-Premise
173	%	N	I-Premise
174	CI	N	I-Premise
175	,	N	I-Premise
176	0.50	N	I-Premise
177	to	N	I-Premise
178	0.93	N	I-Premise
179	;	N	I-Premise
180	P	N	I-Premise
181	=	N	I-Premise
182	.015	N	I-Premise
183	)	N	I-Premise
184	,	N	I-Premise
185	but	N	I-Premise
186	not	N	I-Premise
187	pain	N	I-Premise
188	(	N	I-Premise
189	HR	N	I-Premise
190	,	N	I-Premise
191	0.83	N	I-Premise
192	;	N	I-Premise
193	95	N	I-Premise
194	%	N	I-Premise
195	CI	N	I-Premise
196	,	N	I-Premise
197	0.62	N	I-Premise
198	to	N	I-Premise
199	1.10	N	I-Premise
200	;	N	I-Premise
201	P	N	I-Premise
202	=	N	I-Premise
203	.19	N	I-Premise
204	)	N	I-Premise
205	.	N	I-Premise

206	More	N	I-Premise
207	patients	N	I-Premise
208	on	N	I-Premise
209	afatinib	N	I-Premise
210	(	N	I-Premise
211	64	N	I-Premise
212	%	N	I-Premise
213	)	N	I-Premise
214	versus	N	I-Premise
215	chemotherapy	N	I-Premise
216	(	N	I-Premise
217	50	N	I-Premise
218	%	N	I-Premise
219	)	N	I-Premise
220	experienced	N	I-Premise
221	improvements	N	I-Premise
222	in	N	I-Premise
223	dyspnea	N	I-Premise
224	scores	N	I-Premise
225	(	N	I-Premise
226	P	N	I-Premise
227	=	N	I-Premise
228	.010	N	I-Premise
229	)	N	I-Premise
230	.	N	I-Premise

231	Differences	N	I-Premise
232	in	N	I-Premise
233	mean	N	I-Premise
234	scores	N	I-Premise
235	over	N	I-Premise
236	time	N	I-Premise
237	significantly	N	I-Premise
238	favored	N	I-Premise
239	afatinib	N	I-Premise
240	over	N	I-Premise
241	chemotherapy	N	I-Premise
242	for	N	I-Premise
243	cough	N	I-Premise
244	(	N	I-Premise
245	P	N	I-Premise
246	<	N	I-Premise
247	.001	N	I-Premise
248	)	N	I-Premise
249	and	N	I-Premise
250	dyspnea	N	I-Premise
251	(	N	I-Premise
252	P	N	I-Premise
253	<	N	I-Premise
254	.001	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	Afatinib	N	I-Premise
258	showed	N	I-Premise
259	significantly	N	I-Premise
260	better	N	I-Premise
261	mean	N	I-Premise
262	scores	N	I-Premise
263	over	N	I-Premise
264	time	N	I-Premise
265	in	N	I-Premise
266	global	N	I-Premise
267	health	N	I-Premise
268	status/QoL	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.015	N	I-Premise
273	)	N	I-Premise
274	and	N	I-Premise
275	physical	N	I-Premise
276	(	N	I-Premise
277	P	N	I-Premise
278	<	N	I-Premise
279	.001	N	I-Premise
280	)	N	I-Premise
281	,	N	I-Premise
282	role	N	I-Premise
283	(	N	I-Premise
284	P	N	I-Premise
285	=	N	I-Premise
286	.004	N	I-Premise
287	)	N	I-Premise
288	,	N	I-Premise
289	and	N	I-Premise
290	cognitive	N	I-Premise
291	(	N	I-Premise
292	P	N	I-Premise
293	=	N	I-Premise
294	.007	N	I-Premise
295	)	N	I-Premise
296	functioning	N	I-Premise
297	compared	N	I-Premise
298	with	N	I-Premise
299	chemotherapy	N	I-Premise
300	.	N	I-Premise

301	Fatigue	N	I-Premise
302	and	N	I-Premise
303	nausea	N	I-Premise
304	were	N	I-Premise
305	worse	N	I-Premise
306	with	N	I-Premise
307	chemotherapy	N	I-Premise
308	,	N	I-Premise
309	whereas	N	I-Premise
310	diarrhea	N	I-Premise
311	,	N	I-Premise
312	dysphagia	N	I-Premise
313	,	N	I-Premise
314	and	N	I-Premise
315	sore	N	I-Premise
316	mouth	N	I-Premise
317	were	N	I-Premise
318	worse	N	I-Premise
319	with	N	I-Premise
320	afatinib	N	I-Premise
321	(	N	I-Premise
322	all	N	I-Premise
323	P	N	I-Premise
324	<	N	I-Premise
325	.01	N	I-Premise
326	)	N	I-Premise
327	.	N	I-Premise

328	In	N	I-Claim
329	patients	N	I-Claim
330	with	N	I-Claim
331	lung	N	I-Claim
332	adenocarcinoma	N	I-Claim
333	with	N	I-Claim
334	EGFR	N	I-Claim
335	mutations	N	I-Claim
336	,	N	I-Claim
337	first-line	N	I-Claim
338	afatinib	N	I-Claim
339	was	N	I-Claim
340	associated	N	I-Claim
341	with	N	I-Claim
342	better	N	I-Claim
343	control	N	I-Claim
344	of	N	I-Claim
345	cough	N	I-Claim
346	and	N	I-Claim
347	dyspnea	N	I-Claim
348	compared	N	I-Claim
349	with	N	I-Claim
350	chemotherapy	N	I-Claim
351	,	N	I-Claim
352	although	N	I-Claim
353	diarrhea	N	I-Claim
354	,	N	I-Claim
355	dysphagia	N	I-Claim
356	,	N	I-Claim
357	and	N	I-Claim
358	sore	N	I-Claim
359	mouth	N	I-Claim
360	were	N	I-Claim
361	worse	N	I-Claim
362	.	N	I-Claim

363	Global	N	I-Claim
364	health	N	I-Claim
365	status/QoL	N	I-Claim
366	was	N	I-Claim
367	also	N	I-Claim
368	improved	N	I-Claim
369	over	N	I-Claim
370	time	N	I-Claim
371	with	N	I-Claim
372	afatinib	N	I-Claim
373	compared	N	I-Claim
374	with	N	I-Claim
375	chemotherapy	N	I-Claim
376	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	health-related	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	narrow	N	O
12	gastric	N	O
13	tube	N	O
14	and	N	O
15	whole	N	O
16	stomach	N	O
17	reconstructions	N	O
18	after	N	O
19	oncologic	N	O
20	esophagectomy	N	O
21	.	N	O

22	In	N	O
23	a	N	O
24	prospective	N	O
25	randomized	N	O
26	single-center	N	O
27	study	N	O
28	from	N	O
29	2007	N	O
30	to	N	O
31	2008	N	O
32	,	N	O
33	104	N	O
34	patients	N	O
35	underwent	N	O
36	esophagectomy	N	O
37	for	N	O
38	cancer	N	O
39	.	N	O

40	To	N	O
41	assess	N	O
42	health-related	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	,	N	O
47	the	N	O
48	questionnaire	N	O
49	(	N	O
50	European	N	O
51	Organization	N	O
52	for	N	O
53	Research	N	O
54	and	N	O
55	Treatment	N	O
56	of	N	O
57	Cancer	N	O
58	Quality	N	O
59	of	N	O
60	Life	N	O
61	Questionnaire	N	O
62	Core	N	O
63	30	N	O
64	and	N	O
65	the	N	O
66	Oesophagus-Specific	N	O
67	Quality	N	O
68	of	N	O
69	Life	N	O
70	Questionnaire	N	O
71	18	N	O
72	)	N	O
73	was	N	O
74	administered	N	O
75	at	N	O
76	3	N	O
77	weeks	N	O
78	,	N	O
79	6	N	O
80	months	N	O
81	,	N	O
82	1	N	O
83	year	N	O
84	,	N	O
85	and	N	O
86	2	N	O
87	years	N	O
88	after	N	O
89	surgery	N	O
90	.	N	O

91	The	N	I-Premise
92	perioperative	N	I-Premise
93	complication	N	I-Premise
94	rate	N	I-Premise
95	was	N	I-Premise
96	26.9	N	I-Premise
97	%	N	I-Premise
98	in	N	I-Premise
99	narrow	N	I-Premise
100	gastric	N	I-Premise
101	tube	N	I-Premise
102	group	N	I-Premise
103	and	N	I-Premise
104	48.1	N	I-Premise
105	%	N	I-Premise
106	in	N	I-Premise
107	whole	N	I-Premise
108	stomach	N	I-Premise
109	group	N	I-Premise
110	(	N	I-Premise
111	P	N	I-Premise
112	=	N	I-Premise
113	0.31	N	I-Premise
114	)	N	I-Premise
115	.	N	I-Premise

116	At	N	I-Premise
117	the	N	I-Premise
118	time	N	I-Premise
119	of	N	I-Premise
120	3	N	I-Premise
121	weeks	N	I-Premise
122	after	N	I-Premise
123	surgery	N	I-Premise
124	,	N	I-Premise
125	the	N	I-Premise
126	reflux	N	I-Premise
127	and	N	I-Premise
128	dyspnea	N	I-Premise
129	scores	N	I-Premise
130	were	N	I-Premise
131	higher	N	I-Premise
132	in	N	I-Premise
133	whole	N	I-Premise
134	stomach	N	I-Premise
135	group	N	I-Premise
136	than	N	I-Premise
137	in	N	I-Premise
138	narrow	N	I-Premise
139	gastric	N	I-Premise
140	tube	N	I-Premise
141	group	N	I-Premise
142	,	N	I-Premise
143	which	N	I-Premise
144	meant	N	I-Premise
145	that	N	I-Premise
146	the	N	I-Premise
147	patients	N	I-Premise
148	in	N	I-Premise
149	whole	N	I-Premise
150	stomach	N	I-Premise
151	group	N	I-Premise
152	suffered	N	I-Premise
153	more	N	I-Premise
154	severe	N	I-Premise
155	problem	N	I-Premise
156	.	N	I-Premise

157	At	N	I-Premise
158	the	N	I-Premise
159	time	N	I-Premise
160	of	N	I-Premise
161	6	N	I-Premise
162	months	N	I-Premise
163	and	N	I-Premise
164	1	N	I-Premise
165	year	N	I-Premise
166	after	N	I-Premise
167	surgery	N	I-Premise
168	,	N	I-Premise
169	the	N	I-Premise
170	reflux	N	I-Premise
171	scores	N	I-Premise
172	were	N	I-Premise
173	lower	N	I-Premise
174	in	N	I-Premise
175	narrow	N	I-Premise
176	gastric	N	I-Premise
177	tube	N	I-Premise
178	group	N	I-Premise
179	than	N	I-Premise
180	in	N	I-Premise
181	whole	N	I-Premise
182	stomach	N	I-Premise
183	group	N	I-Premise
184	,	N	I-Premise
185	which	N	I-Premise
186	revealed	N	I-Premise
187	that	N	I-Premise
188	there	N	I-Premise
189	were	N	I-Premise
190	less	N	I-Premise
191	problems	N	I-Premise
192	of	N	I-Premise
193	reflux	N	I-Premise
194	in	N	I-Premise
195	the	N	I-Premise
196	patients	N	I-Premise
197	of	N	I-Premise
198	narrow	N	I-Premise
199	gastric	N	I-Premise
200	tube	N	I-Premise
201	group	N	I-Premise
202	;	N	I-Premise
203	meanwhile	N	O
204	,	N	O
205	the	N	I-Premise
206	score	N	I-Premise
207	of	N	I-Premise
208	physical	N	I-Premise
209	function	N	I-Premise
210	scale	N	I-Premise
211	in	N	I-Premise
212	narrow	N	I-Premise
213	gastric	N	I-Premise
214	tube	N	I-Premise
215	group	N	I-Premise
216	was	N	I-Premise
217	higher	N	I-Premise
218	conversely	N	I-Premise
219	,	N	I-Premise
220	which	N	I-Premise
221	suggested	N	I-Premise
222	that	N	I-Premise
223	the	N	I-Premise
224	patients	N	I-Premise
225	gain	N	I-Premise
226	a	N	I-Premise
227	better	N	I-Premise
228	status	N	I-Premise
229	in	N	I-Premise
230	physical	N	I-Premise
231	function	N	I-Premise
232	.	N	I-Premise

233	Nausea	N	I-Premise
234	and	N	I-Premise
235	vomiting	N	I-Premise
236	is	N	I-Premise
237	the	N	I-Premise
238	only	N	I-Premise
239	notable	N	I-Premise
240	symptom	N	I-Premise
241	that	N	I-Premise
242	was	N	I-Premise
243	worse	N	I-Premise
244	in	N	I-Premise
245	whole	N	I-Premise
246	stomach	N	I-Premise
247	group	N	I-Premise
248	at	N	I-Premise
249	the	N	I-Premise
250	time	N	I-Premise
251	of	N	I-Premise
252	2	N	I-Premise
253	years	N	I-Premise
254	after	N	I-Premise
255	surgery	N	I-Premise
256	,	N	I-Premise
257	which	N	O
258	suggested	N	O
259	that	N	O
260	patients	N	I-Claim
261	in	N	I-Claim
262	whole	N	I-Claim
263	stomach	N	I-Claim
264	group	N	I-Claim
265	suffered	N	I-Claim
266	more	N	I-Claim
267	severe	N	I-Claim
268	nausea	N	I-Claim
269	and	N	I-Claim
270	vomiting	N	I-Claim
271	.	N	I-Claim

272	Narrow	N	I-Claim
273	gastric	N	I-Claim
274	tube	N	I-Claim
275	reconstruction	N	I-Claim
276	may	N	I-Claim
277	be	N	I-Claim
278	a	N	I-Claim
279	good	N	I-Claim
280	alternative	N	I-Claim
281	choice	N	I-Claim
282	for	N	I-Claim
283	patients	N	I-Claim
284	undergoing	N	I-Claim
285	oncologic	N	I-Claim
286	esophagectomy	N	I-Claim
287	in	N	I-Claim
288	view	N	I-Claim
289	of	N	I-Claim
290	better	N	I-Claim
291	health-related	N	I-Claim
292	quality	N	I-Claim
293	of	N	I-Claim
294	life	N	I-Claim
295	after	N	I-Claim
296	the	N	I-Claim
297	surgery	N	I-Claim
298	.	N	I-Claim

1	Delirium	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	serious	N	I-MajorClaim
5	and	N	I-MajorClaim
6	common	N	I-MajorClaim
7	postoperative	N	I-MajorClaim
8	complication	N	I-MajorClaim
9	,	N	O
10	especially	N	O
11	in	N	O
12	frail	N	O
13	elderly	N	O
14	patients	N	O
15	.	N	O

16	The	N	O
17	aim	N	O
18	of	N	O
19	this	N	O
20	study	N	O
21	was	N	O
22	to	N	O
23	evaluate	N	O
24	the	N	O
25	effect	N	O
26	of	N	O
27	a	N	O
28	geriatric	N	O
29	liaison	N	O
30	intervention	N	O
31	in	N	O
32	comparison	N	O
33	with	N	O
34	standard	N	O
35	care	N	O
36	on	N	O
37	the	N	O
38	incidence	N	O
39	of	N	O
40	postoperative	N	O
41	delirium	N	O
42	in	N	O
43	frail	N	O
44	elderly	N	O
45	cancer	N	O
46	patients	N	O
47	treated	N	O
48	with	N	O
49	an	N	O
50	elective	N	O
51	surgical	N	O
52	procedure	N	O
53	for	N	O
54	a	N	O
55	solid	N	O
56	tumour	N	O
57	.	N	O

58	Patients	N	O
59	over	N	O
60	65	N	O
61	years	N	O
62	of	N	O
63	age	N	O
64	who	N	O
65	were	N	O
66	undergoing	N	O
67	elective	N	O
68	surgery	N	O
69	for	N	O
70	a	N	O
71	solid	N	O
72	tumour	N	O
73	were	N	O
74	recruited	N	O
75	to	N	O
76	a	N	O
77	multicentre	N	O
78	,	N	O
79	prospective	N	O
80	,	N	O
81	randomized	N	O
82	,	N	O
83	controlled	N	O
84	trial	N	O
85	.	N	O

86	The	N	O
87	patients	N	O
88	were	N	O
89	randomized	N	O
90	to	N	O
91	standard	N	O
92	treatment	N	O
93	versus	N	O
94	a	N	O
95	geriatric	N	O
96	liaison	N	O
97	intervention	N	O
98	.	N	O

99	The	N	O
100	intervention	N	O
101	consisted	N	O
102	of	N	O
103	a	N	O
104	preoperative	N	O
105	geriatric	N	O
106	consultation	N	O
107	,	N	O
108	an	N	O
109	individual	N	O
110	treatment	N	O
111	plan	N	O
112	targeted	N	O
113	at	N	O
114	risk	N	O
115	factors	N	O
116	for	N	O
117	delirium	N	O
118	,	N	O
119	daily	N	O
120	visits	N	O
121	by	N	O
122	a	N	O
123	geriatric	N	O
124	nurse	N	O
125	during	N	O
126	the	N	O
127	hospital	N	O
128	stay	N	O
129	and	N	O
130	advice	N	O
131	on	N	O
132	managing	N	O
133	any	N	O
134	problems	N	O
135	encountered	N	O
136	.	N	O

137	The	N	O
138	primary	N	O
139	outcome	N	O
140	was	N	O
141	the	N	O
142	incidence	N	O
143	of	N	O
144	postoperative	N	O
145	delirium	N	O
146	.	N	O

147	The	N	O
148	secondary	N	O
149	outcome	N	O
150	measures	N	O
151	were	N	O
152	the	N	O
153	severity	N	O
154	of	N	O
155	delirium	N	O
156	,	N	O
157	length	N	O
158	of	N	O
159	hospital	N	O
160	stay	N	O
161	,	N	O
162	complications	N	O
163	,	N	O
164	mortality	N	O
165	,	N	O
166	care	N	O
167	dependency	N	O
168	,	N	O
169	quality	N	O
170	of	N	O
171	life	N	O
172	,	N	O
173	return	N	O
174	to	N	O
175	an	N	O
176	independent	N	O
177	preoperative	N	O
178	living	N	O
179	situation	N	O
180	and	N	O
181	additional	N	O
182	care	N	O
183	at	N	O
184	home	N	O
185	.	N	O

186	In	N	O
187	total	N	O
188	,	N	O
189	the	N	O
190	data	N	O
191	of	N	O
192	260	N	O
193	patients	N	O
194	were	N	O
195	analysed	N	O
196	.	N	O

197	Delirium	N	I-Premise
198	occurred	N	I-Premise
199	in	N	I-Premise
200	31	N	I-Premise
201	patients	N	I-Premise
202	(	N	I-Premise
203	11.9	N	I-Premise
204	%	N	I-Premise
205	)	N	I-Premise
206	,	N	I-Premise
207	and	N	I-Premise
208	there	N	I-Premise
209	was	N	I-Premise
210	no	N	I-Premise
211	significant	N	I-Premise
212	difference	N	I-Premise
213	between	N	I-Premise
214	the	N	I-Premise
215	incidence	N	I-Premise
216	of	N	I-Premise
217	delirium	N	I-Premise
218	in	N	I-Premise
219	the	N	I-Premise
220	intervention	N	I-Premise
221	group	N	I-Premise
222	and	N	I-Premise
223	the	N	I-Premise
224	usual-care	N	I-Premise
225	group	N	I-Premise
226	(	N	I-Premise
227	9.4	N	I-Premise
228	%	N	I-Premise
229	vs.	N	I-Premise
230	14.3	N	I-Premise
231	%	N	I-Premise
232	,	N	I-Premise
233	OR	N	I-Premise
234	:	N	I-Premise
235	0.63	N	I-Premise
236	,	N	I-Premise
237	95	N	I-Premise
238	%	N	I-Premise
239	CI	N	I-Premise
240	:	N	I-Premise
241	0.29-1.35	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	Within	N	I-Claim
245	this	N	I-Claim
246	study	N	I-Claim
247	,	N	I-Claim
248	a	N	I-Claim
249	geriatric	N	I-Claim
250	liaison	N	I-Claim
251	intervention	N	I-Claim
252	based	N	I-Claim
253	on	N	I-Claim
254	frailty	N	I-Claim
255	for	N	I-Claim
256	the	N	I-Claim
257	prevention	N	I-Claim
258	of	N	I-Claim
259	postoperative	N	I-Claim
260	delirium	N	I-Claim
261	in	N	I-Claim
262	frail	N	I-Claim
263	elderly	N	I-Claim
264	cancer	N	I-Claim
265	patients	N	I-Claim
266	undergoing	N	I-Claim
267	elective	N	I-Claim
268	surgery	N	I-Claim
269	for	N	I-Claim
270	a	N	I-Claim
271	solid	N	I-Claim
272	tumour	N	I-Claim
273	has	N	I-Claim
274	not	N	I-Claim
275	proven	N	I-Claim
276	to	N	I-Claim
277	be	N	I-Claim
278	effective	N	I-Claim
279	.	N	I-Claim

1	The	N	O
2	AGO-ETC	N	O
3	trial	N	O
4	compared	N	O
5	5-year	N	O
6	relapse-free	N	O
7	survival	N	O
8	of	N	O
9	intense	N	O
10	dose-dense	N	O
11	(	N	O
12	IDD	N	O
13	)	N	O
14	sequential	N	O
15	chemotherapy	N	O
16	with	N	O
17	epirubicin	N	O
18	(	N	O
19	E	N	O
20	)	N	O
21	,	N	O
22	paclitaxel	N	O
23	(	N	O
24	T	N	O
25	)	N	O
26	,	N	O
27	and	N	O
28	cyclophosphamide	N	O
29	(	N	O
30	C	N	O
31	)	N	O
32	(	N	O
33	IDD-ETC	N	O
34	)	N	O
35	every	N	O
36	2	N	O
37	weeks	N	O
38	vs	N	O
39	conventional	N	O
40	scheduled	N	O
41	epirubicin/cyclophosphamide	N	O
42	followed	N	O
43	by	N	O
44	paclitaxel	N	O
45	(	N	O
46	EC→T	N	O
47	)	N	O
48	(	N	O
49	every	N	O
50	3	N	O
51	weeks	N	O
52	)	N	O
53	as	N	O
54	adjuvant	N	O
55	treatment	N	O
56	in	N	O
57	high-risk	N	O
58	breast	N	O
59	cancer	N	O
60	patients	N	O
61	.	N	O

62	The	N	O
63	objective	N	O
64	of	N	O
65	this	N	O
66	study	N	O
67	was	N	O
68	to	N	O
69	evaluate	N	O
70	the	N	O
71	safety	N	O
72	and	N	O
73	efficacy	N	O
74	of	N	O
75	epoetin	N	O
76	alfa	N	O
77	in	N	O
78	a	N	O
79	second	N	O
80	randomization	N	O
81	of	N	O
82	the	N	O
83	intense	N	O
84	dose-dense	N	O
85	arm	N	O
86	.	N	O

87	One	N	O
88	thousand	N	O
89	two	N	O
90	hundred	N	O
91	eighty-four	N	O
92	patients	N	O
93	were	N	O
94	enrolled	N	O
95	;	N	O
96	658	N	O
97	patients	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	the	N	O
103	IDD-ETC	N	O
104	treatment	N	O
105	group	N	O
106	.	N	O

107	Within	N	O
108	the	N	O
109	IDD-ETC	N	O
110	group	N	O
111	,	N	O
112	324	N	O
113	patients	N	O
114	were	N	O
115	further	N	O
116	randomly	N	O
117	assigned	N	O
118	to	N	O
119	the	N	O
120	epoetin	N	O
121	alfa	N	O
122	group	N	O
123	,	N	O
124	and	N	O
125	319	N	O
126	were	N	O
127	randomly	N	O
128	assigned	N	O
129	to	N	O
130	the	N	O
131	non-erythropoiesis-stimulating	N	O
132	agent	N	O
133	(	N	O
134	ESA	N	O
135	)	N	O
136	control	N	O
137	group	N	O
138	.	N	O

139	Primary	N	O
140	efficacy	N	O
141	endpoints	N	O
142	included	N	O
143	change	N	O
144	in	N	O
145	hemoglobin	N	O
146	level	N	O
147	from	N	O
148	baseline	N	O
149	to	N	O
150	Cycle	N	O
151	9	N	O
152	and	N	O
153	the	N	O
154	percentage	N	O
155	of	N	O
156	subjects	N	O
157	requiring	N	O
158	red	N	O
159	blood	N	O
160	cell	N	O
161	transfusion	N	O
162	.	N	O

163	Relapse-free	N	O
164	survival	N	O
165	,	N	O
166	overall	N	O
167	survival	N	O
168	,	N	O
169	and	N	O
170	intramammary	N	O
171	relapse	N	O
172	were	N	O
173	secondary	N	O
174	endpoints	N	O
175	estimated	N	O
176	with	N	O
177	Kaplan-Meier	N	O
178	and	N	O
179	Cox	N	O
180	regression	N	O
181	methods	N	O
182	.	N	O

183	Except	N	O
184	for	N	O
185	the	N	O
186	primary	N	O
187	hypothesis	N	O
188	,	N	O
189	all	N	O
190	statistical	N	O
191	tests	N	O
192	were	N	O
193	two-sided	N	O
194	.	N	O

195	Epoetin	N	I-Premise
196	alfa	N	I-Premise
197	avoided	N	I-Premise
198	the	N	I-Premise
199	decrease	N	I-Premise
200	in	N	I-Premise
201	hemoglobin	N	I-Premise
202	level	N	I-Premise
203	(	N	I-Premise
204	no	N	I-Premise
205	decrease	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	epoetin	N	I-Premise
209	alfa	N	I-Premise
210	group	N	I-Premise
211	vs	N	I-Premise
212	-2.20g/dL	N	I-Premise
213	change	N	I-Premise
214	for	N	I-Premise
215	the	N	I-Premise
216	control	N	I-Premise
217	group	N	I-Premise
218	;	N	I-Premise
219	P	N	I-Premise
220	<	N	I-Premise
221	.001	N	I-Premise
222	)	N	I-Premise
223	and	N	I-Premise
224	statistically	N	I-Premise
225	significantly	N	I-Premise
226	reduced	N	I-Premise
227	the	N	I-Premise
228	percentage	N	I-Premise
229	of	N	I-Premise
230	subjects	N	I-Premise
231	requiring	N	I-Premise
232	red	N	I-Premise
233	blood	N	I-Premise
234	cell	N	I-Premise
235	transfusion	N	I-Premise
236	(	N	I-Premise
237	12.8	N	I-Premise
238	%	N	I-Premise
239	vs	N	I-Premise
240	28.1	N	I-Premise
241	%	N	I-Premise
242	;	N	I-Premise
243	P	N	I-Premise
244	<	N	I-Premise
245	.0001	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	The	N	I-Premise
249	incidence	N	I-Premise
250	of	N	I-Premise
251	thrombotic	N	I-Premise
252	events	N	I-Premise
253	was	N	I-Premise
254	7	N	I-Premise
255	%	N	I-Premise
256	in	N	I-Premise
257	the	N	I-Premise
258	epoetin	N	I-Premise
259	alfa	N	I-Premise
260	arm	N	I-Premise
261	vs	N	I-Premise
262	3	N	I-Premise
263	%	N	I-Premise
264	in	N	I-Premise
265	the	N	I-Premise
266	control	N	I-Premise
267	arm	N	I-Premise
268	.	N	I-Premise

269	After	N	I-Premise
270	a	N	I-Premise
271	median	N	I-Premise
272	follow-up	N	I-Premise
273	of	N	I-Premise
274	62	N	I-Premise
275	months	N	I-Premise
276	,	N	I-Premise
277	epoetin	N	I-Premise
278	alfa	N	I-Premise
279	treatment	N	I-Premise
280	did	N	I-Premise
281	not	N	I-Premise
282	affect	N	I-Premise
283	overall	N	I-Premise
284	survival	N	I-Premise
285	,	N	I-Premise
286	relapse-free	N	I-Premise
287	survival	N	I-Premise
288	,	N	I-Premise
289	or	N	I-Premise
290	intramammary	N	I-Premise
291	relapse	N	I-Premise
292	.	N	I-Premise

293	Epoetin	N	I-Claim
294	alfa	N	I-Claim
295	resulted	N	I-Claim
296	in	N	I-Claim
297	improved	N	I-Claim
298	hemoglobin	N	I-Claim
299	levels	N	I-Claim
300	and	N	I-Claim
301	decreased	N	I-Claim
302	transfusions	N	I-Claim
303	without	N	I-Claim
304	an	N	I-Claim
305	impact	N	I-Claim
306	on	N	I-Claim
307	relapse-free	N	I-Claim
308	or	N	I-Claim
309	overall	N	I-Claim
310	survival	N	I-Claim
311	.	N	I-Claim

312	However	N	I-Claim
313	,	N	I-Claim
314	epoetin	N	I-Claim
315	alfa	N	I-Claim
316	had	N	I-Claim
317	an	N	I-Claim
318	adverse	N	I-Claim
319	effect	N	I-Claim
320	,	N	I-Claim
321	resulting	N	I-Claim
322	in	N	I-Claim
323	increased	N	I-Claim
324	thrombosis	N	I-Claim
325	.	N	I-Claim

1	Analgesia	N	I-MajorClaim
2	and	N	I-MajorClaim
3	early	N	I-MajorClaim
4	quality	N	I-MajorClaim
5	of	N	I-MajorClaim
6	recovery	N	I-MajorClaim
7	may	N	I-MajorClaim
8	be	N	I-MajorClaim
9	improved	N	I-MajorClaim
10	by	N	I-MajorClaim
11	epidural	N	I-MajorClaim
12	analgesia	N	I-MajorClaim
13	.	N	I-MajorClaim

14	We	N	O
15	aimed	N	O
16	to	N	O
17	assess	N	O
18	the	N	O
19	effect	N	O
20	of	N	O
21	receiving	N	O
22	epidural	N	O
23	analgesia	N	O
24	on	N	O
25	surgical	N	O
26	adverse	N	O
27	events	N	O
28	and	N	O
29	quality	N	O
30	of	N	O
31	life	N	O
32	after	N	O
33	laparotomy	N	O
34	for	N	O
35	endometrial	N	O
36	cancer	N	O
37	.	N	O

38	Patients	N	O
39	were	N	O
40	enrolled	N	O
41	in	N	O
42	an	N	O
43	international	N	O
44	,	N	O
45	multicentre	N	O
46	,	N	O
47	prospective	N	O
48	randomised	N	O
49	trial	N	O
50	of	N	O
51	outcomes	N	O
52	for	N	O
53	laparoscopic	N	O
54	versus	N	O
55	open	N	O
56	surgical	N	O
57	treatment	N	O
58	for	N	O
59	the	N	O
60	management	N	O
61	of	N	O
62	apparent	N	O
63	stage	N	O
64	I	N	O
65	endometrial	N	O
66	cancer	N	O
67	(	N	O
68	LACE	N	O
69	trial	N	O
70	)	N	O
71	.	N	O

72	The	N	O
73	current	N	O
74	analysis	N	O
75	focussed	N	O
76	on	N	O
77	patients	N	O
78	who	N	O
79	received	N	O
80	an	N	O
81	open	N	O
82	abdominal	N	O
83	hysterectomy	N	O
84	via	N	O
85	vertical	N	O
86	midline	N	O
87	incision	N	O
88	only	N	O
89	(	N	O
90	n=257	N	O
91	)	N	O
92	,	N	O
93	examining	N	O
94	outcomes	N	O
95	in	N	O
96	patients	N	O
97	who	N	O
98	did	N	O
99	(	N	O
100	n=108	N	O
101	)	N	O
102	and	N	O
103	did	N	O
104	not	N	O
105	(	N	O
106	n=149	N	O
107	)	N	O
108	receive	N	O
109	epidural	N	O
110	analgesia	N	O
111	.	N	O

112	Baseline	N	O
113	characteristics	N	O
114	were	N	O
115	comparable	N	O
116	between	N	O
117	patients	N	O
118	with	N	O
119	or	N	O
120	without	N	O
121	epidural	N	O
122	analgesia	N	O
123	.	N	O

124	More	N	I-Premise
125	patients	N	I-Premise
126	without	N	I-Premise
127	epidural	N	I-Premise
128	(	N	I-Premise
129	34	N	I-Premise
130	%	N	I-Premise
131	)	N	I-Premise
132	ceased	N	I-Premise
133	opioid	N	I-Premise
134	analgesia	N	I-Premise
135	3-5	N	I-Premise
136	days	N	I-Premise
137	after	N	I-Premise
138	surgery	N	I-Premise
139	compared	N	I-Premise
140	to	N	I-Premise
141	patients	N	I-Premise
142	who	N	I-Premise
143	had	N	I-Premise
144	an	N	I-Premise
145	epidural	N	I-Premise
146	(	N	I-Premise
147	7	N	I-Premise
148	%	N	I-Premise
149	;	N	I-Premise
150	p	N	I-Premise
151	<	N	I-Premise
152	0.01	N	I-Premise
153	)	N	I-Premise
154	.	N	I-Premise

155	Postoperative	N	I-Premise
156	complications	N	I-Premise
157	(	N	I-Premise
158	any	N	I-Premise
159	grade	N	I-Premise
160	)	N	I-Premise
161	occurred	N	I-Premise
162	in	N	I-Premise
163	86	N	I-Premise
164	%	N	I-Premise
165	of	N	I-Premise
166	patients	N	I-Premise
167	with	N	I-Premise
168	and	N	I-Premise
169	in	N	I-Premise
170	66	N	I-Premise
171	%	N	I-Premise
172	of	N	I-Premise
173	patients	N	I-Premise
174	without	N	I-Premise
175	an	N	I-Premise
176	epidural	N	I-Premise
177	(	N	I-Premise
178	p	N	I-Premise
179	<	N	I-Premise
180	0.01	N	I-Premise
181	)	N	I-Premise
182	but	N	O
183	there	N	I-Premise
184	was	N	I-Premise
185	no	N	I-Premise
186	difference	N	I-Premise
187	in	N	I-Premise
188	serious	N	I-Premise
189	adverse	N	I-Premise
190	events	N	I-Premise
191	(	N	I-Premise
192	p=0.19	N	I-Premise
193	)	N	I-Premise
194	.	N	I-Premise

195	Epidural	N	I-Premise
196	analgesia	N	I-Premise
197	was	N	I-Premise
198	associated	N	I-Premise
199	with	N	I-Premise
200	increased	N	I-Premise
201	length	N	I-Premise
202	of	N	I-Premise
203	stay	N	I-Premise
204	(	N	I-Premise
205	up	N	I-Premise
206	to	N	I-Premise
207	48	N	I-Premise
208	days	N	I-Premise
209	compared	N	I-Premise
210	to	N	I-Premise
211	up	N	I-Premise
212	to	N	I-Premise
213	34	N	I-Premise
214	days	N	I-Premise
215	in	N	I-Premise
216	the	N	I-Premise
217	non-epidural	N	I-Premise
218	group	N	I-Premise
219	)	N	I-Premise
220	.	N	I-Premise

221	There	N	I-Claim
222	was	N	I-Claim
223	no	N	I-Claim
224	difference	N	I-Claim
225	in	N	I-Claim
226	postoperative	N	I-Claim
227	quality	N	I-Claim
228	of	N	I-Claim
229	life	N	I-Claim
230	up	N	I-Claim
231	to	N	I-Claim
232	six	N	I-Claim
233	months	N	I-Claim
234	after	N	I-Claim
235	surgery	N	I-Claim
236	.	N	I-Claim

237	Epidural	N	I-Claim
238	analgesia	N	I-Claim
239	was	N	I-Claim
240	associated	N	I-Claim
241	with	N	I-Claim
242	an	N	I-Claim
243	increase	N	I-Claim
244	in	N	I-Claim
245	any	N	I-Claim
246	,	N	I-Claim
247	but	N	I-Claim
248	not	N	I-Claim
249	serious	N	I-Claim
250	,	N	I-Claim
251	postoperative	N	I-Claim
252	complications	N	I-Claim
253	and	N	I-Claim
254	length	N	I-Claim
255	of	N	I-Claim
256	stay	N	I-Claim
257	after	N	I-Claim
258	abdominal	N	I-Claim
259	hysterectomy	N	I-Claim
260	.	N	I-Claim

261	Randomised	N	I-MajorClaim
262	controlled	N	I-MajorClaim
263	trials	N	I-MajorClaim
264	are	N	I-MajorClaim
265	needed	N	I-MajorClaim
266	to	N	I-MajorClaim
267	examine	N	I-MajorClaim
268	the	N	I-MajorClaim
269	effect	N	I-MajorClaim
270	of	N	I-MajorClaim
271	epidural	N	I-MajorClaim
272	analgesia	N	I-MajorClaim
273	on	N	I-MajorClaim
274	surgical	N	I-MajorClaim
275	adverse	N	I-MajorClaim
276	events	N	I-MajorClaim
277	,	N	I-MajorClaim
278	especially	N	O
279	as	N	O
280	the	N	I-Claim
281	present	N	I-Claim
282	data	N	I-Claim
283	do	N	I-Claim
284	not	N	I-Claim
285	support	N	I-Claim
286	a	N	I-Claim
287	quality	N	I-Claim
288	of	N	I-Claim
289	life	N	I-Claim
290	benefit	N	I-Claim
291	with	N	I-Claim
292	epidural	N	I-Claim
293	analgesia	N	I-Claim
294	.	N	I-Claim

1	Tivozanib	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	potent	N	I-MajorClaim
5	and	N	I-MajorClaim
6	selective	N	I-MajorClaim
7	tyrosine	N	I-MajorClaim
8	kinase	N	I-MajorClaim
9	inhibitor	N	I-MajorClaim
10	of	N	I-MajorClaim
11	vascular	N	I-MajorClaim
12	endothelial	N	I-MajorClaim
13	growth	N	I-MajorClaim
14	factor	N	I-MajorClaim
15	receptor	N	I-MajorClaim
16	1	N	I-MajorClaim
17	(	N	I-MajorClaim
18	VEGFR1	N	I-MajorClaim
19	)	N	I-MajorClaim
20	,	N	I-MajorClaim
21	-2	N	I-MajorClaim
22	,	N	I-MajorClaim
23	and	N	I-MajorClaim
24	-3	N	I-MajorClaim
25	.	N	I-MajorClaim

26	This	N	O
27	phase	N	O
28	III	N	O
29	trial	N	O
30	compared	N	O
31	tivozanib	N	O
32	with	N	O
33	sorafenib	N	O
34	as	N	O
35	initial	N	O
36	targeted	N	O
37	therapy	N	O
38	in	N	O
39	patients	N	O
40	with	N	O
41	metastatic	N	O
42	renal	N	O
43	cell	N	O
44	carcinoma	N	O
45	(	N	O
46	RCC	N	O
47	)	N	O
48	.	N	O

49	Patients	N	O
50	with	N	O
51	metastatic	N	O
52	RCC	N	O
53	,	N	O
54	with	N	O
55	a	N	O
56	clear	N	O
57	cell	N	O
58	component	N	O
59	,	N	O
60	prior	N	O
61	nephrectomy	N	O
62	,	N	O
63	measurable	N	O
64	disease	N	O
65	,	N	O
66	and	N	O
67	0	N	O
68	or	N	O
69	1	N	O
70	prior	N	O
71	therapies	N	O
72	for	N	O
73	metastatic	N	O
74	RCC	N	O
75	were	N	O
76	randomly	N	O
77	assigned	N	O
78	to	N	O
79	tivozanib	N	O
80	or	N	O
81	sorafenib	N	O
82	.	N	O

83	Prior	N	O
84	VEGF-targeted	N	O
85	therapy	N	O
86	and	N	O
87	mammalian	N	O
88	target	N	O
89	of	N	O
90	rapamycin	N	O
91	inhibitor	N	O
92	were	N	O
93	not	N	O
94	permitted	N	O
95	.	N	O

96	The	N	O
97	primary	N	O
98	end	N	O
99	point	N	O
100	was	N	O
101	progression-free	N	O
102	survival	N	O
103	(	N	O
104	PFS	N	O
105	)	N	O
106	by	N	O
107	independent	N	O
108	review	N	O
109	.	N	O

110	A	N	O
111	total	N	O
112	of	N	O
113	517	N	O
114	patients	N	O
115	were	N	O
116	randomly	N	O
117	assigned	N	O
118	to	N	O
119	tivozanib	N	O
120	(	N	O
121	n	N	O
122	=	N	O
123	260	N	O
124	)	N	O
125	or	N	O
126	sorafenib	N	O
127	(	N	O
128	n	N	O
129	=	N	O
130	257	N	O
131	)	N	O
132	.	N	O

133	PFS	N	I-Premise
134	was	N	I-Premise
135	longer	N	I-Premise
136	with	N	I-Premise
137	tivozanib	N	I-Premise
138	than	N	I-Premise
139	with	N	I-Premise
140	sorafenib	N	I-Premise
141	in	N	I-Premise
142	the	N	I-Premise
143	overall	N	I-Premise
144	population	N	I-Premise
145	(	N	I-Premise
146	median	N	I-Premise
147	,	N	I-Premise
148	11.9	N	I-Premise
149	v	N	I-Premise
150	9.1	N	I-Premise
151	months	N	I-Premise
152	;	N	I-Premise
153	hazard	N	I-Premise
154	ratio	N	I-Premise
155	[	N	I-Premise
156	HR	N	I-Premise
157	]	N	I-Premise
158	,	N	I-Premise
159	0.797	N	I-Premise
160	;	N	I-Premise
161	95	N	I-Premise
162	%	N	I-Premise
163	CI	N	I-Premise
164	,	N	I-Premise
165	0.639	N	I-Premise
166	to	N	I-Premise
167	0.993	N	I-Premise
168	;	N	I-Premise
169	P	N	I-Premise
170	=	N	I-Premise
171	.042	N	I-Premise
172	)	N	I-Premise
173	.	N	I-Premise

174	One	N	O
175	hundred	N	O
176	fifty-six	N	O
177	patients	N	O
178	(	N	O
179	61	N	O
180	%	N	O
181	)	N	O
182	who	N	O
183	progressed	N	O
184	on	N	O
185	sorafenib	N	O
186	crossed	N	O
187	over	N	O
188	to	N	O
189	receive	N	O
190	tivozanib	N	O
191	.	N	O

192	The	N	I-Premise
193	final	N	I-Premise
194	overall	N	I-Premise
195	survival	N	I-Premise
196	(	N	I-Premise
197	OS	N	I-Premise
198	)	N	I-Premise
199	analysis	N	I-Premise
200	showed	N	I-Premise
201	a	N	I-Premise
202	trend	N	I-Premise
203	toward	N	I-Premise
204	longer	N	I-Premise
205	survival	N	I-Premise
206	on	N	I-Premise
207	the	N	I-Premise
208	sorafenib	N	I-Premise
209	arm	N	I-Premise
210	than	N	I-Premise
211	on	N	I-Premise
212	the	N	I-Premise
213	tivozanib	N	I-Premise
214	arm	N	I-Premise
215	(	N	I-Premise
216	median	N	I-Premise
217	,	N	I-Premise
218	29.3	N	I-Premise
219	v	N	I-Premise
220	28.8	N	I-Premise
221	months	N	I-Premise
222	;	N	I-Premise
223	HR	N	I-Premise
224	,	N	I-Premise
225	1.245	N	I-Premise
226	;	N	I-Premise
227	95	N	I-Premise
228	%	N	I-Premise
229	CI	N	I-Premise
230	,	N	I-Premise
231	0.954	N	I-Premise
232	to	N	I-Premise
233	1.624	N	I-Premise
234	;	N	I-Premise
235	P	N	I-Premise
236	=	N	I-Premise
237	.105	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	Adverse	N	I-Premise
241	events	N	I-Premise
242	(	N	I-Premise
243	AEs	N	I-Premise
244	)	N	I-Premise
245	more	N	I-Premise
246	common	N	I-Premise
247	with	N	I-Premise
248	tivozanib	N	I-Premise
249	than	N	I-Premise
250	with	N	I-Premise
251	sorafenib	N	I-Premise
252	were	N	I-Premise
253	hypertension	N	I-Premise
254	(	N	I-Premise
255	44	N	I-Premise
256	%	N	I-Premise
257	v	N	I-Premise
258	34	N	I-Premise
259	%	N	I-Premise
260	)	N	I-Premise
261	and	N	I-Premise
262	dysphonia	N	I-Premise
263	(	N	I-Premise
264	21	N	I-Premise
265	%	N	I-Premise
266	v	N	I-Premise
267	5	N	I-Premise
268	%	N	I-Premise
269	)	N	I-Premise
270	.	N	I-Premise

271	AEs	N	I-Premise
272	more	N	I-Premise
273	common	N	I-Premise
274	with	N	I-Premise
275	sorafenib	N	I-Premise
276	than	N	I-Premise
277	with	N	I-Premise
278	tivozanib	N	I-Premise
279	were	N	I-Premise
280	hand-foot	N	I-Premise
281	skin	N	I-Premise
282	reaction	N	I-Premise
283	(	N	I-Premise
284	54	N	I-Premise
285	%	N	I-Premise
286	v	N	I-Premise
287	14	N	I-Premise
288	%	N	I-Premise
289	)	N	I-Premise
290	and	N	I-Premise
291	diarrhea	N	I-Premise
292	(	N	I-Premise
293	33	N	I-Premise
294	%	N	I-Premise
295	v	N	I-Premise
296	23	N	I-Premise
297	%	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	Tivozanib	N	I-Claim
301	demonstrated	N	I-Claim
302	improved	N	I-Claim
303	PFS	N	I-Claim
304	,	N	I-Claim
305	but	N	I-Claim
306	not	N	I-Claim
307	OS	N	I-Claim
308	,	N	I-Claim
309	and	N	I-Claim
310	a	N	I-Claim
311	differentiated	N	I-Claim
312	safety	N	I-Claim
313	profile	N	I-Claim
314	,	N	I-Claim
315	compared	N	I-Claim
316	with	N	I-Claim
317	sorafenib	N	I-Claim
318	,	N	I-Claim
319	as	N	I-Claim
320	initial	N	I-Claim
321	targeted	N	I-Claim
322	therapy	N	I-Claim
323	for	N	I-Claim
324	metastatic	N	I-Claim
325	RCC	N	I-Claim
326	.	N	I-Claim

1	Non-randomised	N	O
2	studies	N	O
3	have	N	O
4	suggested	N	O
5	that	N	O
6	the	N	I-MajorClaim
7	postoperative	N	I-MajorClaim
8	complications	N	I-MajorClaim
9	of	N	I-MajorClaim
10	(	N	I-MajorClaim
11	Campos	N	I-MajorClaim
12	LS	N	I-MajorClaim
13	,	N	I-MajorClaim
14	Limberger	N	I-MajorClaim
15	LF	N	I-MajorClaim
16	,	N	I-MajorClaim
17	Stein	N	I-MajorClaim
18	AT	N	I-MajorClaim
19	,	N	I-MajorClaim
20	Kalil	N	I-MajorClaim
21	AN	N	I-MajorClaim
22	)	N	I-MajorClaim
23	laparoscopic	N	I-MajorClaim
24	radical	N	I-MajorClaim
25	hysterectomy	N	I-MajorClaim
26	are	N	I-MajorClaim
27	similar	N	I-MajorClaim
28	to	N	I-MajorClaim
29	those	N	I-MajorClaim
30	in	N	I-MajorClaim
31	abdominal	N	I-MajorClaim
32	radical	N	I-MajorClaim
33	hysterectomy	N	I-MajorClaim
34	.	N	I-MajorClaim

35	However	N	O
36	,	N	O
37	no	N	O
38	study	N	O
39	evaluating	N	O
40	postoperative	N	O
41	pain	N	O
42	comparing	N	O
43	both	N	O
44	techniques	N	O
45	has	N	O
46	been	N	O
47	published	N	O
48	thus	N	O
49	far	N	O
50	.	N	O

51	Our	N	O
52	objective	N	O
53	was	N	O
54	to	N	O
55	compare	N	O
56	pain	N	O
57	intensity	N	O
58	and	N	O
59	other	N	O
60	perioperative	N	O
61	outcomes	N	O
62	between	N	O
63	laparoscopic	N	O
64	radical	N	O
65	hysterectomy	N	O
66	(	N	O
67	LRH	N	O
68	)	N	O
69	and	N	O
70	abdominal	N	O
71	radical	N	O
72	hysterectomy	N	O
73	(	N	O
74	ARH	N	O
75	)	N	O
76	in	N	O
77	early	N	O
78	cervical	N	O
79	cancer	N	O
80	.	N	O

81	This	N	O
82	single	N	O
83	centre	N	O
84	,	N	O
85	randomised	N	O
86	,	N	O
87	controlled	N	O
88	trial	N	O
89	enrolled	N	O
90	30	N	O
91	cervical	N	O
92	cancer	N	O
93	patients	N	O
94	who	N	O
95	were	N	O
96	clinically	N	O
97	staged	N	O
98	IA2	N	O
99	with	N	O
100	lymph	N	O
101	vascular	N	O
102	invasion	N	O
103	and	N	O
104	IB	N	O
105	according	N	O
106	to	N	O
107	the	N	O
108	FIGO	N	O
109	(	N	O
110	International	N	O
111	Federation	N	O
112	of	N	O
113	Gynaecology	N	O
114	and	N	O
115	Obstetrics	N	O
116	)	N	O
117	classification	N	O
118	,	N	O
119	and	N	O
120	underwent	N	O
121	LRH	N	O
122	or	N	O
123	ARH	N	O
124	between	N	O
125	late	N	O
126	1999	N	O
127	and	N	O
128	early	N	O
129	2004	N	O
130	.	N	O

131	Postoperative	N	O
132	pain	N	O
133	,	N	O
134	as	N	O
135	measured	N	O
136	by	N	O
137	a	N	O
138	10-point	N	O
139	numerical	N	O
140	rate	N	O
141	scale	N	O
142	,	N	O
143	was	N	O
144	considered	N	O
145	the	N	O
146	primary	N	O
147	endpoint	N	O
148	.	N	O

149	Postoperative	N	O
150	pain	N	O
151	was	N	O
152	assessed	N	O
153	every	N	O
154	six	N	O
155	hours	N	O
156	during	N	O
157	a	N	O
158	patient	N	O
159	's	N	O
160	usual	N	O
161	postoperative	N	O
162	care	N	O
163	.	N	O

164	Perioperative	N	O
165	outcomes	N	O
166	were	N	O
167	also	N	O
168	registered	N	O
169	.	N	O

170	Both	N	O
171	surgical	N	O
172	techniques	N	O
173	were	N	O
174	executed	N	O
175	by	N	O
176	the	N	O
177	same	N	O
178	surgical	N	O
179	team	N	O
180	.	N	O

181	Secondary	N	O
182	outcomes	N	O
183	included	N	O
184	intraoperative	N	O
185	and	N	O
186	other	N	O
187	postoperative	N	O
188	surgicopathological	N	O
189	factors	N	O
190	and	N	O
191	5-year	N	O
192	survival	N	O
193	rates	N	O
194	.	N	O

195	IA2	N	O
196	patients	N	O
197	with	N	O
198	lymphatic	N	O
199	vascular	N	O
200	space	N	O
201	invasion	N	O
202	and	N	O
203	IB	N	O
204	cervical	N	O
205	cancer	N	O
206	patients	N	O
207	were	N	O
208	randomised	N	O
209	to	N	O
210	either	N	O
211	the	N	O
212	LRH	N	O
213	group	N	O
214	(	N	O
215	16	N	O
216	patients	N	O
217	)	N	O
218	or	N	O
219	the	N	O
220	ARH	N	O
221	group	N	O
222	(	N	O
223	14	N	O
224	patients	N	O
225	)	N	O
226	.	N	O

227	Four	N	I-Premise
228	patients	N	I-Premise
229	(	N	I-Premise
230	25	N	I-Premise
231	%	N	I-Premise
232	)	N	I-Premise
233	in	N	I-Premise
234	the	N	I-Premise
235	LRH	N	I-Premise
236	group	N	I-Premise
237	and	N	I-Premise
238	5	N	I-Premise
239	patients	N	I-Premise
240	(	N	I-Premise
241	36	N	I-Premise
242	%	N	I-Premise
243	)	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	ARH	N	I-Premise
247	group	N	I-Premise
248	presented	N	I-Premise
249	with	N	I-Premise
250	transoperative	N	I-Premise
251	or	N	I-Premise
252	serious	N	I-Premise
253	postoperative	N	I-Premise
254	complications	N	I-Premise
255	.	N	I-Premise

256	All	N	I-Premise
257	of	N	I-Premise
258	the	N	I-Premise
259	transoperative	N	I-Premise
260	complications	N	I-Premise
261	occurred	N	I-Premise
262	in	N	I-Premise
263	the	N	I-Premise
264	LRH	N	I-Premise
265	group	N	I-Premise
266	.	N	I-Premise

267	The	N	I-Premise
268	relative	N	I-Premise
269	risk	N	I-Premise
270	of	N	I-Premise
271	presenting	N	I-Premise
272	with	N	I-Premise
273	complications	N	I-Premise
274	was	N	I-Premise
275	0.70	N	I-Premise
276	;	N	I-Premise
277	CI	N	I-Premise
278	95	N	I-Premise
279	%	N	I-Premise
280	(	N	I-Premise
281	0.23-2.11	N	I-Premise
282	)	N	I-Premise
283	;	N	I-Premise
284	P	N	I-Premise
285	=	N	I-Premise
286	0.694	N	I-Premise
287	.	N	I-Premise

288	LRH	N	I-Premise
289	group	N	I-Premise
290	mean	N	I-Premise
291	pain	N	I-Premise
292	score	N	I-Premise
293	was	N	I-Premise
294	significantly	N	I-Premise
295	lower	N	I-Premise
296	than	N	I-Premise
297	ARH	N	I-Premise
298	after	N	I-Premise
299	36	N	I-Premise
300	h	N	I-Premise
301	of	N	I-Premise
302	observation	N	I-Premise
303	(	N	I-Premise
304	P	N	I-Premise
305	=	N	I-Premise
306	0.044	N	I-Premise
307	;	N	I-Premise
308	mean	N	I-Premise
309	difference	N	I-Premise
310	score	N	I-Premise
311	:	N	I-Premise
312	1.42	N	I-Premise
313	;	N	I-Premise
314	95	N	I-Premise
315	%	N	I-Premise
316	CI	N	I-Premise
317	:	N	I-Premise
318	0.04-2.80	N	I-Premise
319	)	N	I-Premise
320	.	N	I-Premise

321	The	N	O
322	survival	N	O
323	results	N	O
324	will	N	O
325	be	N	O
326	published	N	O
327	elsewhere	N	O
328	.	N	O

329	LRH	N	I-Claim
330	provided	N	I-Claim
331	lower	N	I-Claim
332	pain	N	I-Claim
333	scores	N	I-Claim
334	after	N	I-Claim
335	36	N	I-Claim
336	h	N	I-Claim
337	of	N	I-Claim
338	observation	N	I-Claim
339	in	N	I-Claim
340	this	N	I-Claim
341	series	N	I-Claim
342	.	N	I-Claim

343	The	N	I-Claim
344	perioperative	N	I-Claim
345	and	N	I-Claim
346	serious	N	I-Claim
347	postoperative	N	I-Claim
348	complications	N	I-Claim
349	ratios	N	I-Claim
350	were	N	I-Claim
351	comparable	N	I-Claim
352	between	N	I-Claim
353	the	N	I-Claim
354	groups	N	I-Claim
355	.	N	I-Claim

1	We	N	O
2	analyzed	N	O
3	the	N	O
4	long-term	N	O
5	survival	N	O
6	of	N	O
7	children	N	O
8	under	N	O
9	6	N	O
10	years	N	O
11	of	N	O
12	age	N	O
13	(	N	O
14	<	N	O
15	6	N	O
16	years	N	O
17	)	N	O
18	enrolled	N	O
19	upon	N	O
20	the	N	O
21	Children	N	O
22	's	N	O
23	Cancer	N	O
24	Group	N	O
25	(	N	O
26	CCG	N	O
27	)	N	O
28	-945	N	O
29	high-grade	N	O
30	glioma	N	O
31	(	N	O
32	HGG	N	O
33	)	N	O
34	study	N	O
35	to	N	O
36	determine	N	O
37	the	N	O
38	impact	N	O
39	of	N	O
40	intrinsic	N	O
41	biological	N	O
42	characteristics	N	O
43	as	N	O
44	well	N	O
45	as	N	O
46	treatment	N	O
47	upon	N	O
48	both	N	O
49	survival	N	O
50	and	N	O
51	quality	N	O
52	of	N	O
53	life	N	O
54	(	N	O
55	QOL	N	O
56	)	N	O
57	in	N	O
58	this	N	O
59	younger	N	O
60	age	N	O
61	population	N	O
62	.	N	O

63	Analyses	N	O
64	were	N	O
65	undertaken	N	O
66	on	N	O
67	patients	N	O
68	<	N	O
69	6	N	O
70	years	N	O
71	with	N	O
72	institutionally	N	O
73	diagnosed	N	O
74	HGG	N	O
75	enrolled	N	O
76	on	N	O
77	the	N	O
78	CCG-945	N	O
79	trial	N	O
80	.	N	O

81	Comparisons	N	O
82	of	N	O
83	survival	N	O
84	were	N	O
85	performed	N	O
86	for	N	O
87	patients	N	O
88	<	N	O
89	3	N	O
90	years	N	O
91	of	N	O
92	age	N	O
93	(	N	O
94	<	N	O
95	3	N	O
96	years	N	O
97	)	N	O
98	(	N	O
99	treated	N	O
100	with	N	O
101	intent	N	O
102	to	N	O
103	avoid	N	O
104	irradiation	N	O
105	)	N	O
106	versus	N	O
107	those	N	O
108	between	N	O
109	3	N	O
110	and	N	O
111	6	N	O
112	years	N	O
113	of	N	O
114	age	N	O
115	(	N	O
116	3-6	N	O
117	years	N	O
118	)	N	O
119	(	N	O
120	treated	N	O
121	with	N	O
122	irradiation	N	O
123	and	N	O
124	chemotherapy	N	O
125	)	N	O
126	at	N	O
127	diagnosis	N	O
128	.	N	O

129	Discordance	N	O
130	between	N	O
131	the	N	O
132	institutional	N	O
133	diagnoses	N	O
134	of	N	O
135	HGG	N	O
136	and	N	O
137	consensus-reviewed	N	O
138	diagnoses	N	O
139	led	N	O
140	us	N	O
141	to	N	O
142	perform	N	O
143	further	N	O
144	survival	N	O
145	analyses	N	O
146	for	N	O
147	both	N	O
148	groups	N	O
149	.	N	O

150	We	N	O
151	compared	N	O
152	the	N	O
153	two	N	O
154	groups	N	O
155	of	N	O
156	patients	N	O
157	for	N	O
158	biological	N	O
159	markers	N	O
160	,	N	O
161	and	N	O
162	evaluated	N	O
163	the	N	O
164	neuropsychological	N	O
165	and	N	O
166	QOL	N	O
167	outcomes	N	O
168	of	N	O
169	long-term	N	O
170	survivors	N	O
171	.	N	O

172	Patients	N	I-Premise
173	<	N	I-Premise
174	3	N	I-Premise
175	years	N	I-Premise
176	(	N	I-Premise
177	n	N	I-Premise
178	=	N	I-Premise
179	49	N	I-Premise
180	,	N	I-Premise
181	19.5	N	I-Premise
182	%	N	I-Premise
183	of	N	I-Premise
184	all	N	I-Premise
185	enrolled	N	I-Premise
186	patients	N	I-Premise
187	)	N	I-Premise
188	at	N	I-Premise
189	diagnosis	N	I-Premise
190	had	N	I-Premise
191	a	N	I-Premise
192	10-year	N	I-Premise
193	EFS	N	I-Premise
194	and	N	I-Premise
195	OS	N	I-Premise
196	of	N	I-Premise
197	29	N	I-Premise
198	±	N	I-Premise
199	6.5	N	I-Premise
200	%	N	I-Premise
201	and	N	I-Premise
202	37.5	N	I-Premise
203	±	N	I-Premise
204	7	N	I-Premise
205	%	N	I-Premise
206	,	N	I-Premise
207	respectively	N	I-Premise
208	,	N	I-Premise
209	while	N	I-Premise
210	for	N	I-Premise
211	patients	N	I-Premise
212	3-6	N	I-Premise
213	years	N	I-Premise
214	(	N	I-Premise
215	n	N	I-Premise
216	=	N	I-Premise
217	34	N	I-Premise
218	,	N	I-Premise
219	13.5	N	I-Premise
220	%	N	I-Premise
221	of	N	I-Premise
222	all	N	I-Premise
223	enrolled	N	I-Premise
224	patients	N	I-Premise
225	)	N	I-Premise
226	10-year	N	I-Premise
227	EFS	N	I-Premise
228	and	N	I-Premise
229	OS	N	I-Premise
230	were	N	I-Premise
231	35	N	I-Premise
232	±	N	I-Premise
233	8	N	I-Premise
234	%	N	I-Premise
235	and	N	I-Premise
236	36	N	I-Premise
237	±	N	I-Premise
238	8	N	I-Premise
239	%	N	I-Premise
240	,	N	I-Premise
241	respectively	N	I-Premise
242	.	N	I-Premise

243	Molecular	N	I-Premise
244	marker	N	I-Premise
245	analysis	N	I-Premise
246	showed	N	I-Premise
247	that	N	I-Premise
248	a	N	I-Premise
249	smaller	N	I-Premise
250	proportion	N	I-Premise
251	of	N	I-Premise
252	patients	N	I-Premise
253	<	N	I-Premise
254	3	N	I-Premise
255	years	N	I-Premise
256	harbored	N	I-Premise
257	TP53	N	I-Premise
258	mutations	N	I-Premise
259	(	N	I-Premise
260	P	N	I-Premise
261	=	N	I-Premise
262	0.05	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	Analysis	N	I-Premise
266	of	N	I-Premise
267	QOL	N	I-Premise
268	outcomes	N	I-Premise
269	with	N	I-Premise
270	a	N	I-Premise
271	median	N	I-Premise
272	length	N	I-Premise
273	of	N	I-Premise
274	follow-up	N	I-Premise
275	of	N	I-Premise
276	15.1	N	I-Premise
277	years	N	I-Premise
278	(	N	I-Premise
279	9.5-19.2	N	I-Premise
280	)	N	I-Premise
281	showed	N	I-Premise
282	comparable	N	I-Premise
283	results	N	I-Premise
284	.	N	I-Premise

285	QOL	N	I-Claim
286	and	N	I-Claim
287	survival	N	I-Claim
288	data	N	I-Claim
289	were	N	I-Claim
290	similar	N	I-Claim
291	for	N	I-Claim
292	the	N	I-Claim
293	two	N	I-Claim
294	groups	N	I-Claim
295	.	N	I-Claim

296	A	N	I-Claim
297	larger	N	I-Claim
298	prospective	N	I-Claim
299	study	N	I-Claim
300	is	N	I-Claim
301	justified	N	I-Claim
302	to	N	I-Claim
303	study	N	I-Claim
304	the	N	I-Claim
305	efficacy	N	I-Claim
306	of	N	I-Claim
307	chemotherapy	N	I-Claim
308	only	N	I-Claim
309	regimens	N	I-Claim
310	in	N	I-Claim
311	younger	N	I-Claim
312	children	N	I-Claim
313	.	N	I-Claim

1	Postcancer	N	I-MajorClaim
2	fatigue	N	I-MajorClaim
3	is	N	I-MajorClaim
4	a	N	I-MajorClaim
5	frequently	N	I-MajorClaim
6	occurring	N	I-MajorClaim
7	problem	N	I-MajorClaim
8	,	N	I-MajorClaim
9	impairing	N	I-MajorClaim
10	quality	N	I-MajorClaim
11	of	N	I-MajorClaim
12	life	N	I-MajorClaim
13	.	N	I-MajorClaim

14	Until	N	O
15	now	N	O
16	,	N	O
17	little	N	O
18	is	N	O
19	known	N	O
20	about	N	O
21	(	N	O
22	neuro	N	O
23	)	N	O
24	physiological	N	O
25	factors	N	O
26	determining	N	O
27	postcancer	N	O
28	fatigue	N	O
29	.	N	O

30	For	N	O
31	non-cancer	N	O
32	patients	N	O
33	with	N	O
34	chronic	N	O
35	fatigue	N	O
36	syndrome	N	O
37	,	N	O
38	certain	N	O
39	characteristics	N	O
40	of	N	O
41	brain	N	O
42	morphology	N	O
43	and	N	O
44	metabolism	N	O
45	have	N	O
46	been	N	O
47	identified	N	O
48	in	N	O
49	previous	N	O
50	studies	N	O
51	.	N	O

52	We	N	O
53	investigated	N	O
54	whether	N	O
55	these	N	O
56	volumetric	N	O
57	and	N	O
58	metabolic	N	O
59	traits	N	O
60	are	N	O
61	a	N	O
62	reflection	N	O
63	of	N	O
64	fatigue	N	O
65	in	N	O
66	general	N	O
67	and	N	O
68	thus	N	O
69	also	N	O
70	of	N	O
71	importance	N	O
72	for	N	O
73	postcancer	N	O
74	fatigue	N	O
75	.	N	O

76	Fatigued	N	O
77	patients	N	O
78	were	N	O
79	randomly	N	O
80	assigned	N	O
81	to	N	O
82	either	N	O
83	the	N	O
84	intervention	N	O
85	condition	N	O
86	(	N	O
87	cognitive	N	O
88	behavior	N	O
89	therapy	N	O
90	)	N	O
91	or	N	O
92	the	N	O
93	waiting	N	O
94	list	N	O
95	condition	N	O
96	.	N	O

97	Twenty-five	N	O
98	patients	N	O
99	in	N	O
100	the	N	O
101	intervention	N	O
102	condition	N	O
103	and	N	O
104	fourteen	N	O
105	patients	N	O
106	in	N	O
107	the	N	O
108	waiting	N	O
109	list	N	O
110	condition	N	O
111	were	N	O
112	assessed	N	O
113	twice	N	O
114	,	N	O
115	at	N	O
116	baseline	N	O
117	and	N	O
118	six	N	O
119	months	N	O
120	later	N	O
121	.	N	O

122	Baseline	N	O
123	measurements	N	O
124	of	N	O
125	20	N	O
126	fatigued	N	O
127	patients	N	O
128	were	N	O
129	compared	N	O
130	with	N	O
131	20	N	O
132	matched	N	O
133	non-fatigued	N	O
134	controls	N	O
135	.	N	O

136	All	N	O
137	participants	N	O
138	had	N	O
139	completed	N	O
140	treatment	N	O
141	of	N	O
142	a	N	O
143	malignant	N	O
144	,	N	O
145	solid	N	O
146	tumor	N	O
147	minimal	N	O
148	one	N	O
149	year	N	O
150	earlier	N	O
151	.	N	O

152	Global	N	O
153	brain	N	O
154	volumes	N	O
155	,	N	O
156	subcortical	N	O
157	brain	N	O
158	volumes	N	O
159	,	N	O
160	metabolite	N	O
161	tissue	N	O
162	concentrations	N	O
163	,	N	O
164	and	N	O
165	metabolite	N	O
166	ratios	N	O
167	were	N	O
168	primary	N	O
169	outcome	N	O
170	measures	N	O
171	.	N	O

172	Volumetric	N	O
173	and	N	O
174	metabolic	N	O
175	parameters	N	O
176	were	N	O
177	not	N	O
178	significantly	N	O
179	different	N	O
180	between	N	O
181	fatigued	N	O
182	and	N	O
183	non-fatigued	N	O
184	patients	N	O
185	.	N	O

186	Change	N	I-Premise
187	scores	N	I-Premise
188	of	N	I-Premise
189	volumetric	N	I-Premise
190	and	N	I-Premise
191	metabolic	N	I-Premise
192	parameters	N	I-Premise
193	from	N	I-Premise
194	baseline	N	I-Premise
195	to	N	I-Premise
196	follow-up	N	I-Premise
197	were	N	I-Premise
198	not	N	I-Premise
199	significantly	N	I-Premise
200	different	N	I-Premise
201	between	N	I-Premise
202	patients	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	therapy	N	I-Premise
206	and	N	I-Premise
207	the	N	I-Premise
208	waiting	N	I-Premise
209	list	N	I-Premise
210	group	N	I-Premise
211	.	N	I-Premise

212	Patients	N	I-Premise
213	in	N	I-Premise
214	the	N	I-Premise
215	therapy	N	I-Premise
216	group	N	I-Premise
217	reported	N	I-Premise
218	a	N	I-Premise
219	significant	N	I-Premise
220	larger	N	I-Premise
221	decrease	N	I-Premise
222	in	N	I-Premise
223	fatigue	N	I-Premise
224	scores	N	I-Premise
225	than	N	I-Premise
226	patients	N	I-Premise
227	in	N	I-Premise
228	the	N	I-Premise
229	waiting	N	I-Premise
230	list	N	I-Premise
231	group	N	I-Premise
232	.	N	I-Premise

233	No	N	I-Premise
234	relation	N	I-Premise
235	was	N	I-Premise
236	found	N	I-Premise
237	between	N	I-Premise
238	postcancer	N	I-Premise
239	fatigue	N	I-Premise
240	and	N	I-Premise
241	the	N	I-Premise
242	studied	N	I-Premise
243	volumetric	N	I-Premise
244	and	N	I-Premise
245	metabolic	N	I-Premise
246	markers	N	I-Premise
247	.	N	I-Premise

248	This	N	I-Claim
249	may	N	I-Claim
250	suggest	N	I-Claim
251	that	N	I-Claim
252	,	N	I-Claim
253	although	N	I-Claim
254	postcancer	N	I-Claim
255	fatigue	N	I-Claim
256	and	N	I-Claim
257	chronic	N	I-Claim
258	fatigue	N	I-Claim
259	syndrome	N	I-Claim
260	show	N	I-Claim
261	strong	N	I-Claim
262	resemblances	N	I-Claim
263	as	N	I-Claim
264	a	N	I-Claim
265	clinical	N	I-Claim
266	syndrome	N	I-Claim
267	,	N	I-Claim
268	the	N	I-Claim
269	underlying	N	I-Claim
270	physiology	N	I-Claim
271	is	N	I-Claim
272	different	N	I-Claim
273	.	N	I-Claim

1	The	N	O
2	CO.20	N	O
3	trial	N	O
4	randomized	N	O
5	patients	N	O
6	with	N	O
7	K-RAS	N	O
8	wild-type	N	O
9	,	N	O
10	chemotherapy-refractory	N	O
11	,	N	O
12	metastatic	N	O
13	colorectal	N	O
14	cancer	N	O
15	to	N	O
16	receive	N	O
17	cetuximab	N	O
18	(	N	O
19	CET	N	O
20	)	N	O
21	plus	N	O
22	brivanib	N	O
23	alaninate	N	O
24	(	N	O
25	BRIV	N	O
26	)	N	O
27	or	N	O
28	CET	N	O
29	plus	N	O
30	placebo	N	O
31	(	N	O
32	CET/placebo	N	O
33	)	N	O
34	.	N	O

35	Quality	N	O
36	of	N	O
37	life	N	O
38	(	N	O
39	QoL	N	O
40	)	N	O
41	was	N	O
42	assessed	N	O
43	using	N	O
44	the	N	O
45	European	N	O
46	Organization	N	O
47	for	N	O
48	Research	N	O
49	and	N	O
50	Treatment	N	O
51	of	N	O
52	Cancer	N	O
53	Quality	N	O
54	of	N	O
55	Life	N	O
56	Questionnaire	N	O
57	C30	N	O
58	at	N	O
59	baseline	N	O
60	and	N	O
61	at	N	O
62	2	N	O
63	,	N	O
64	4	N	O
65	,	N	O
66	6	N	O
67	,	N	O
68	8	N	O
69	,	N	O
70	12	N	O
71	,	N	O
72	16	N	O
73	,	N	O
74	and	N	O
75	24	N	O
76	weeks	N	O
77	until	N	O
78	disease	N	O
79	progression	N	O
80	.	N	O

81	Predefined	N	O
82	coprimary	N	O
83	QoL	N	O
84	endpoints	N	O
85	were	N	O
86	time	N	O
87	to	N	O
88	deterioration	N	O
89	(	N	O
90	first	N	O
91	worsening	N	O
92	from	N	O
93	baseline	N	O
94	of	N	O
95	≥	N	O
96	10	N	O
97	points	N	O
98	)	N	O
99	on	N	O
100	the	N	O
101	Physical	N	O
102	Function	N	O
103	(	N	O
104	PF	N	O
105	)	N	O
106	and	N	O
107	Global	N	O
108	(	N	O
109	GHS	N	O
110	)	N	O
111	scales	N	O
112	.	N	O

113	Of	N	O
114	750	N	O
115	randomized	N	O
116	patients	N	O
117	,	N	O
118	721	N	O
119	(	N	O
120	358	N	O
121	of	N	O
122	whom	N	O
123	received	N	O
124	CET/BRIV	N	O
125	)	N	O
126	were	N	O
127	assessable	N	O
128	for	N	O
129	QoL	N	O
130	.	N	O

131	QoL	N	O
132	compliance	N	O
133	and	N	O
134	baseline	N	O
135	PF	N	O
136	and	N	O
137	GHS	N	O
138	scores	N	O
139	did	N	O
140	not	N	O
141	differ	N	O
142	by	N	O
143	treatment	N	O
144	arm	N	O
145	.	N	O

146	The	N	I-Premise
147	median	N	I-Premise
148	time	N	I-Premise
149	to	N	I-Premise
150	deterioration	N	I-Premise
151	was	N	I-Premise
152	1.6	N	I-Premise
153	months	N	I-Premise
154	versus	N	I-Premise
155	1.1	N	I-Premise
156	months	N	I-Premise
157	for	N	I-Premise
158	GHS	N	I-Premise
159	(	N	I-Premise
160	P	N	I-Premise
161	=.02	N	I-Premise
162	)	N	I-Premise
163	and	N	I-Premise
164	5.6	N	I-Premise
165	months	N	I-Premise
166	versus	N	I-Premise
167	1.7	N	I-Premise
168	months	N	I-Premise
169	for	N	I-Premise
170	PF	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	<	N	I-Premise
174	.0001	N	I-Premise
175	)	N	I-Premise
176	favoring	N	I-Premise
177	CET/placebo	N	I-Premise
178	.	N	I-Premise

179	Secondary	N	I-Premise
180	analysis	N	I-Premise
181	favored	N	I-Premise
182	CET/placebo	N	I-Premise
183	for	N	I-Premise
184	QOL	N	I-Premise
185	response	N	I-Premise
186	on	N	I-Premise
187	the	N	I-Premise
188	PF	N	I-Premise
189	,	N	I-Premise
190	Cognitive	N	I-Premise
191	Function	N	I-Premise
192	,	N	I-Premise
193	Fatigue	N	I-Premise
194	,	N	I-Premise
195	Nausea	N	I-Premise
196	,	N	I-Premise
197	Appetite	N	I-Premise
198	,	N	I-Premise
199	and	N	I-Premise
200	Diarrhea	N	I-Premise
201	scales	N	I-Premise
202	.	N	I-Premise

203	A	N	I-Premise
204	greater	N	I-Premise
205	percentage	N	I-Premise
206	of	N	I-Premise
207	patients	N	I-Premise
208	on	N	I-Premise
209	the	N	I-Premise
210	CET/BRIV	N	I-Premise
211	arm	N	I-Premise
212	had	N	I-Premise
213	PF	N	I-Premise
214	worsening	N	I-Premise
215	at	N	I-Premise
216	6	N	I-Premise
217	weeks	N	I-Premise
218	(	N	I-Premise
219	31	N	I-Premise
220	%	N	I-Premise
221	vs	N	I-Premise
222	17	N	I-Premise
223	%	N	I-Premise
224	)	N	I-Premise
225	.	N	I-Premise

226	Clinical	N	I-Premise
227	adverse	N	I-Premise
228	events	N	I-Premise
229	of	N	I-Premise
230	≥	N	I-Premise
231	grade	N	I-Premise
232	3	N	I-Premise
233	were	N	I-Premise
234	more	N	I-Premise
235	common	N	I-Premise
236	with	N	I-Premise
237	CET/BRIV	N	I-Premise
238	than	N	I-Premise
239	with	N	I-Premise
240	CET/placebo	N	I-Premise
241	,	N	I-Premise
242	including	N	I-Premise
243	fatigue	N	I-Premise
244	(	N	I-Premise
245	25	N	I-Premise
246	%	N	I-Premise
247	vs	N	I-Premise
248	11	N	I-Premise
249	%	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	hypertension	N	I-Premise
253	,	N	I-Premise
254	rash	N	I-Premise
255	,	N	I-Premise
256	diarrhea	N	I-Premise
257	,	N	I-Premise
258	abdominal	N	I-Premise
259	pain	N	I-Premise
260	,	N	I-Premise
261	dehydration	N	I-Premise
262	,	N	I-Premise
263	and	N	I-Premise
264	anorexia	N	I-Premise
265	.	N	I-Premise

266	Compared	N	I-Claim
267	with	N	I-Claim
268	CET/placebo	N	I-Claim
269	,	N	I-Claim
270	the	N	I-Claim
271	combination	N	I-Claim
272	of	N	I-Claim
273	CET/BRIV	N	I-Claim
274	worsened	N	I-Claim
275	time	N	I-Claim
276	to	N	I-Claim
277	QoL	N	I-Claim
278	deterioration	N	I-Claim
279	for	N	I-Claim
280	patients	N	I-Claim
281	with	N	I-Claim
282	K-RAS	N	I-Claim
283	wild-type	N	I-Claim
284	,	N	I-Claim
285	chemotherapy-refractory	N	I-Claim
286	,	N	I-Claim
287	metastatic	N	I-Claim
288	colorectal	N	I-Claim
289	cancer	N	I-Claim
290	on	N	I-Claim
291	the	N	I-Claim
292	PF	N	I-Claim
293	and	N	I-Claim
294	GHS	N	I-Claim
295	scales	N	I-Claim
296	of	N	I-Claim
297	European	N	I-Claim
298	Organization	N	I-Claim
299	for	N	I-Claim
300	Research	N	I-Claim
301	and	N	I-Claim
302	Treatment	N	I-Claim
303	of	N	I-Claim
304	Cancer	N	I-Claim
305	Quality	N	I-Claim
306	of	N	I-Claim
307	Life	N	I-Claim
308	Questionnaire	N	I-Claim
309	C30	N	I-Claim
310	.	N	I-Claim

311	This	N	I-Claim
312	result	N	I-Claim
313	may	N	I-Claim
314	be	N	I-Claim
315	due	N	I-Claim
316	to	N	I-Claim
317	higher	N	I-Claim
318	rates	N	I-Claim
319	of	N	I-Claim
320	fatigue	N	I-Claim
321	and	N	I-Claim
322	gastrointestinal	N	I-Claim
323	adverse	N	I-Claim
324	events	N	I-Claim
325	.	N	I-Claim

1	Exercise	N	O
2	improves	N	O
3	physical	N	O
4	functioning	N	O
5	and	N	O
6	symptom	N	O
7	management	N	O
8	during	N	O
9	breast	N	O
10	cancer	N	O
11	chemotherapy	N	O
12	,	N	O
13	but	N	O
14	the	N	O
15	effects	N	O
16	of	N	O
17	different	N	O
18	doses	N	O
19	and	N	O
20	types	N	O
21	of	N	O
22	exercise	N	O
23	are	N	O
24	unknown	N	O
25	.	N	O

26	A	N	O
27	multicenter	N	O
28	trial	N	O
29	in	N	O
30	Canada	N	O
31	randomized	N	O
32	301	N	O
33	breast	N	O
34	cancer	N	O
35	patients	N	O
36	to	N	O
37	thrice-weekly	N	O
38	supervised	N	O
39	exercise	N	O
40	during	N	O
41	chemotherapy	N	O
42	consisting	N	O
43	of	N	O
44	either	N	O
45	a	N	O
46	standard	N	O
47	dose	N	O
48	of	N	O
49	25	N	O
50	to	N	O
51	30	N	O
52	minutes	N	O
53	of	N	O
54	aerobic	N	O
55	exercise	N	O
56	(	N	O
57	STAN	N	O
58	;	N	O
59	n	N	O
60	=	N	O
61	96	N	O
62	)	N	O
63	,	N	O
64	a	N	O
65	higher	N	O
66	dose	N	O
67	of	N	O
68	50	N	O
69	to	N	O
70	60	N	O
71	minutes	N	O
72	of	N	O
73	aerobic	N	O
74	exercise	N	O
75	(	N	O
76	HIGH	N	O
77	;	N	O
78	n	N	O
79	=	N	O
80	101	N	O
81	)	N	O
82	,	N	O
83	or	N	O
84	a	N	O
85	combined	N	O
86	dose	N	O
87	of	N	O
88	50	N	O
89	to	N	O
90	60	N	O
91	minutes	N	O
92	of	N	O
93	aerobic	N	O
94	and	N	O
95	resistance	N	O
96	exercise	N	O
97	(	N	O
98	COMB	N	O
99	;	N	O
100	n	N	O
101	=	N	O
102	104	N	O
103	)	N	O
104	.	N	O

105	The	N	O
106	primary	N	O
107	endpoint	N	O
108	was	N	O
109	physical	N	O
110	functioning	N	O
111	assessed	N	O
112	by	N	O
113	the	N	O
114	Medical	N	O
115	Outcomes	N	O
116	Survey-Short	N	O
117	Form	N	O
118	(	N	O
119	SF	N	O
120	)	N	O
121	-36	N	O
122	.	N	O

123	Secondary	N	O
124	endpoints	N	O
125	were	N	O
126	other	N	O
127	physical	N	O
128	functioning	N	O
129	scales	N	O
130	,	N	O
131	symptoms	N	O
132	,	N	O
133	fitness	N	O
134	,	N	O
135	and	N	O
136	chemotherapy	N	O
137	completion	N	O
138	.	N	O

139	All	N	O
140	statistical	N	O
141	tests	N	O
142	were	N	O
143	linear	N	O
144	mixed	N	O
145	model	N	O
146	analyses	N	O
147	,	N	O
148	and	N	O
149	the	N	O
150	P	N	O
151	values	N	O
152	were	N	O
153	two-sided	N	O
154	.	N	O

155	Follow-up	N	O
156	assessment	N	O
157	of	N	O
158	patient-reported	N	O
159	outcomes	N	O
160	was	N	O
161	99.0	N	O
162	%	N	O
163	.	N	O

164	Adjusted	N	I-Premise
165	linear	N	I-Premise
166	mixed-model	N	I-Premise
167	analyses	N	I-Premise
168	showed	N	I-Premise
169	that	N	I-Premise
170	neither	N	I-Premise
171	HIGH	N	I-Premise
172	(	N	I-Premise
173	+0.8	N	I-Premise
174	;	N	I-Premise
175	95	N	I-Premise
176	%	N	I-Premise
177	confidence	N	I-Premise
178	interval	N	I-Premise
179	[	N	I-Premise
180	CI	N	I-Premise
181	]	N	I-Premise
182	=	N	I-Premise
183	-0.8	N	I-Premise
184	to	N	I-Premise
185	2.4	N	I-Premise
186	;	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	.30	N	I-Premise
190	)	N	I-Premise
191	nor	N	I-Premise
192	COMB	N	I-Premise
193	(	N	I-Premise
194	+0.5	N	I-Premise
195	;	N	I-Premise
196	95	N	I-Premise
197	%	N	I-Premise
198	CI	N	I-Premise
199	=	N	I-Premise
200	-1.1	N	I-Premise
201	to	N	I-Premise
202	2.1	N	I-Premise
203	;	N	I-Premise
204	P	N	I-Premise
205	=	N	I-Premise
206	.52	N	I-Premise
207	]	N	I-Premise
208	were	N	I-Premise
209	superior	N	I-Premise
210	to	N	I-Premise
211	STAN	N	I-Premise
212	for	N	I-Premise
213	the	N	I-Premise
214	primary	N	I-Premise
215	outcome	N	I-Premise
216	.	N	I-Premise

217	In	N	I-Premise
218	secondary	N	I-Premise
219	analyses	N	I-Premise
220	not	N	I-Premise
221	adjusted	N	I-Premise
222	for	N	I-Premise
223	multiple	N	I-Premise
224	comparisons	N	I-Premise
225	,	N	I-Premise
226	HIGH	N	I-Premise
227	was	N	I-Premise
228	superior	N	I-Premise
229	to	N	I-Premise
230	STAN	N	I-Premise
231	for	N	I-Premise
232	the	N	I-Premise
233	SF-36	N	I-Premise
234	physical	N	I-Premise
235	component	N	I-Premise
236	summary	N	I-Premise
237	(	N	I-Premise
238	P	N	I-Premise
239	=	N	I-Premise
240	.04	N	I-Premise
241	)	N	I-Premise
242	,	N	I-Premise
243	SF-36	N	I-Premise
244	bodily	N	I-Premise
245	pain	N	I-Premise
246	(	N	I-Premise
247	P	N	I-Premise
248	=	N	I-Premise
249	.02	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	and	N	I-Premise
253	endocrine	N	I-Premise
254	symptoms	N	I-Premise
255	(	N	I-Premise
256	P	N	I-Premise
257	=	N	I-Premise
258	.02	N	I-Premise
259	)	N	I-Premise
260	.	N	I-Premise

261	COMB	N	I-Premise
262	was	N	I-Premise
263	superior	N	I-Premise
264	to	N	I-Premise
265	STAN	N	I-Premise
266	for	N	I-Premise
267	endocrine	N	I-Premise
268	symptoms	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.009	N	I-Premise
273	)	N	I-Premise
274	and	N	I-Premise
275	superior	N	I-Premise
276	to	N	I-Premise
277	STAN	N	I-Premise
278	(	N	I-Premise
279	P	N	I-Premise
280	<	N	I-Premise
281	.001	N	I-Premise
282	)	N	I-Premise
283	and	N	I-Premise
284	HIGH	N	I-Premise
285	(	N	I-Premise
286	P	N	I-Premise
287	<	N	I-Premise
288	.001	N	I-Premise
289	)	N	I-Premise
290	for	N	I-Premise
291	muscular	N	I-Premise
292	strength	N	I-Premise
293	.	N	I-Premise

294	HIGH	N	I-Premise
295	was	N	I-Premise
296	superior	N	I-Premise
297	to	N	I-Premise
298	COMB	N	I-Premise
299	for	N	I-Premise
300	the	N	I-Premise
301	SF-36	N	I-Premise
302	bodily	N	I-Premise
303	pain	N	I-Premise
304	(	N	I-Premise
305	P	N	I-Premise
306	=	N	I-Premise
307	.04	N	I-Premise
308	)	N	I-Premise
309	and	N	I-Premise
310	aerobic	N	I-Premise
311	fitness	N	I-Premise
312	(	N	I-Premise
313	P	N	I-Premise
314	=	N	I-Premise
315	.03	N	I-Premise
316	)	N	I-Premise
317	.	N	I-Premise

318	No	N	I-Premise
319	differences	N	I-Premise
320	emerged	N	I-Premise
321	for	N	I-Premise
322	body	N	I-Premise
323	composition	N	I-Premise
324	or	N	I-Premise
325	chemotherapy	N	I-Premise
326	completion	N	I-Premise
327	.	N	I-Premise

328	A	N	I-Claim
329	higher	N	I-Claim
330	volume	N	I-Claim
331	of	N	I-Claim
332	aerobic	N	I-Claim
333	or	N	I-Claim
334	combined	N	I-Claim
335	exercise	N	I-Claim
336	is	N	I-Claim
337	achievable	N	I-Claim
338	and	N	I-Claim
339	safe	N	I-Claim
340	during	N	I-Claim
341	breast	N	I-Claim
342	cancer	N	I-Claim
343	chemotherapy	N	I-Claim
344	and	N	I-Claim
345	may	N	I-Claim
346	manage	N	I-Claim
347	declines	N	I-Claim
348	in	N	I-Claim
349	physical	N	I-Claim
350	functioning	N	I-Claim
351	and	N	I-Claim
352	worsening	N	I-Claim
353	symptoms	N	I-Claim
354	better	N	I-Claim
355	than	N	I-Claim
356	standard	N	I-Claim
357	volumes	N	I-Claim
358	.	N	I-Claim

1	Intravenous	N	O
2	(	N	O
3	IV	N	O
4	)	N	O
5	granulocyte	N	O
6	colony	N	O
7	stimulating	N	O
8	factor	N	O
9	(	N	O
10	G-CSF	N	O
11	)	N	O
12	might	N	O
13	be	N	O
14	safer	N	O
15	and	N	O
16	more	N	O
17	convenient	N	O
18	than	N	O
19	subcutaneous	N	O
20	(	N	O
21	SC	N	O
22	)	N	O
23	administration	N	O
24	to	N	O
25	hospitalized	N	O
26	hemato-oncological	N	O
27	patients	N	O
28	receiving	N	O
29	chemotherapy	N	O
30	.	N	O

31	To	N	O
32	compare	N	O
33	IV	N	O
34	vs.	N	O
35	SC	N	O
36	G-CSF	N	O
37	administration	N	O
38	,	N	O
39	we	N	O
40	conducted	N	O
41	a	N	O
42	randomized	N	O
43	,	N	O
44	open-label	N	O
45	trial	N	O
46	.	N	O

47	We	N	O
48	included	N	O
49	inpatients	N	O
50	receiving	N	O
51	chemotherapy	N	O
52	for	N	O
53	acute	N	O
54	myeloid	N	O
55	leukemia	N	O
56	,	N	O
57	acute	N	O
58	lymphoblastic	N	O
59	leukemia	N	O
60	,	N	O
61	lymphoma	N	O
62	or	N	O
63	multiple	N	O
64	myeloma	N	O
65	,	N	O
66	and	N	O
67	allogeneic	N	O
68	or	N	O
69	autologous	N	O
70	hematopoietic	N	O
71	cell	N	O
72	transplantation	N	O
73	(	N	O
74	HCT	N	O
75	)	N	O
76	.	N	O

77	Patients	N	O
78	were	N	O
79	randomized	N	O
80	to	N	O
81	5	N	O
82	mcg/kg	N	O
83	single	N	O
84	daily	N	O
85	dose	N	O
86	of	N	O
87	IV	N	O
88	bolus	N	O
89	versus	N	O
90	SC	N	O
91	filgrastim	N	O
92	given	N	O
93	for	N	O
94	its	N	O
95	clinical	N	O
96	indications	N	O
97	.	N	O

98	Patients	N	O
99	were	N	O
100	crossed-over	N	O
101	to	N	O
102	the	N	O
103	alternate	N	O
104	study	N	O
105	arm	N	O
106	on	N	O
107	the	N	O
108	subsequent	N	O
109	chemotherapy	N	O
110	course	N	O
111	.	N	O

112	The	N	O
113	primary	N	O
114	outcomes	N	O
115	were	N	O
116	time	N	O
117	from	N	O
118	initiation	N	O
119	of	N	O
120	filgrastim	N	O
121	to	N	O
122	recovery	N	O
123	of	N	O
124	stable	N	O
125	neutrophil	N	O
126	count	N	O
127	of	N	O
128	>	N	O
129	500	N	O
130	cells/µL	N	O
131	and	N	O
132	a	N	O
133	composite	N	O
134	clinical	N	O
135	outcome	N	O
136	of	N	O
137	infection	N	O
138	or	N	O
139	death	N	O
140	assessed	N	O
141	for	N	O
142	the	N	O
143	first	N	O
144	course	N	O
145	post-randomization	N	O
146	.	N	O

147	The	N	O
148	study	N	O
149	was	N	O
150	stopped	N	O
151	on	N	O
152	the	N	O
153	second	N	O
154	interim	N	O
155	analysis	N	O
156	.	N	O

157	Of	N	O
158	120	N	O
159	patients	N	O
160	randomized	N	O
161	,	N	O
162	118	N	O
163	were	N	O
164	evaluated	N	O
165	in	N	O
166	the	N	O
167	first	N	O
168	treatment	N	O
169	course	N	O
170	.	N	O

171	The	N	I-Premise
172	mean	N	I-Premise
173	time	N	I-Premise
174	to	N	I-Premise
175	neutropenia	N	I-Premise
176	resolution	N	I-Premise
177	was	N	I-Premise
178	longer	N	I-Premise
179	with	N	I-Premise
180	IV	N	I-Premise
181	G-CSF	N	I-Premise
182	[	N	I-Premise
183	7.9	N	I-Premise
184	days	N	I-Premise
185	,	N	I-Premise
186	95	N	I-Premise
187	%	N	I-Premise
188	confidence	N	I-Premise
189	interval	N	I-Premise
190	(	N	I-Premise
191	CI	N	I-Premise
192	)	N	I-Premise
193	6.6-9.1	N	I-Premise
194	]	N	I-Premise
195	compared	N	I-Premise
196	with	N	I-Premise
197	SC	N	I-Premise
198	G-CSF	N	I-Premise
199	(	N	I-Premise
200	5.4	N	I-Premise
201	days	N	I-Premise
202	,	N	I-Premise
203	95	N	I-Premise
204	%	N	I-Premise
205	CI	N	I-Premise
206	4.6-6.2	N	I-Premise
207	)	N	I-Premise
208	,	N	I-Premise
209	log-rank	N	I-Premise
210	P	N	I-Premise
211	=	N	I-Premise
212	0.001	N	I-Premise
213	.	N	I-Premise

214	Longer	N	I-Premise
215	neutropenia	N	I-Premise
216	duration	N	I-Premise
217	was	N	I-Premise
218	observed	N	I-Premise
219	in	N	I-Premise
220	all	N	I-Premise
221	patient	N	I-Premise
222	subgroups	N	I-Premise
223	,	N	I-Premise
224	except	N	I-Premise
225	for	N	I-Premise
226	patients	N	I-Premise
227	undergoing	N	I-Premise
228	autologous	N	I-Premise
229	HCT	N	I-Premise
230	.	N	I-Premise

231	There	N	I-Premise
232	was	N	I-Premise
233	no	N	I-Premise
234	significant	N	I-Premise
235	difference	N	I-Premise
236	between	N	I-Premise
237	groups	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	occurrence	N	I-Premise
241	of	N	I-Premise
242	infection	N	I-Premise
243	or	N	I-Premise
244	death	N	I-Premise
245	,	N	I-Premise
246	but	N	I-Premise
247	more	N	I-Premise
248	deaths	N	I-Premise
249	were	N	I-Premise
250	observed	N	I-Premise
251	with	N	I-Premise
252	IV	N	I-Premise
253	(	N	I-Premise
254	4/57	N	I-Premise
255	,	N	I-Premise
256	7	N	I-Premise
257	%	N	I-Premise
258	)	N	I-Premise
259	versus	N	I-Premise
260	SC	N	I-Premise
261	(	N	I-Premise
262	1/61	N	I-Premise
263	,	N	I-Premise
264	1.6	N	I-Premise
265	%	N	I-Premise
266	)	N	I-Premise
267	G-CSF	N	I-Premise
268	administration	N	I-Premise
269	,	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	0.196	N	I-Premise
273	.	N	I-Premise

274	Similar	N	O
275	results	N	O
276	were	N	O
277	observed	N	O
278	when	N	O
279	all	N	O
280	158	N	O
281	courses	N	O
282	following	N	O
283	cross-over	N	O
284	were	N	O
285	analyzed	N	O
286	.	N	O

287	Patients	N	I-Claim
288	reported	N	I-Claim
289	similar	N	I-Claim
290	pain	N	I-Claim
291	and	N	I-Claim
292	satisfaction	N	I-Claim
293	scores	N	I-Claim
294	in	N	I-Claim
295	both	N	I-Claim
296	groups	N	I-Claim
297	.	N	I-Claim

298	Bolus	N	I-Claim
299	IV	N	I-Claim
300	administration	N	I-Claim
301	of	N	I-Claim
302	G-CSF	N	I-Claim
303	results	N	I-Claim
304	in	N	I-Claim
305	longer	N	I-Claim
306	neutropenia	N	I-Claim
307	duration	N	I-Claim
308	than	N	I-Claim
309	SC	N	I-Claim
310	administration	N	I-Claim
311	,	N	I-Claim
312	with	N	I-Claim
313	no	N	I-Claim
314	difference	N	I-Claim
315	in	N	I-Claim
316	clinical	N	I-Claim
317	or	N	I-Claim
318	quality-of-life	N	I-Claim
319	measures	N	I-Claim
320	.	N	I-Claim

1	Surgical	N	O
2	resection	N	O
3	enhances	N	O
4	long-term	N	O
5	survival	N	O
6	after	N	O
7	lung	N	O
8	cancer	N	O
9	,	N	O
10	but	N	O
11	survivors	N	O
12	face	N	O
13	functional	N	O
14	deficits	N	O
15	and	N	O
16	report	N	O
17	on	N	O
18	poor	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	long	N	O
23	time	N	O
24	after	N	O
25	surgery	N	O
26	.	N	O

27	This	N	O
28	study	N	O
29	evaluated	N	O
30	short	N	O
31	and	N	O
32	long-term	N	O
33	effects	N	O
34	of	N	O
35	supervised	N	O
36	group	N	O
37	exercise	N	O
38	training	N	O
39	on	N	O
40	health-related	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	and	N	O
45	physical	N	O
46	performance	N	O
47	in	N	O
48	patients	N	O
49	,	N	O
50	who	N	O
51	were	N	O
52	radically	N	O
53	operated	N	O
54	for	N	O
55	lung	N	O
56	cancer	N	O
57	.	N	O

58	A	N	O
59	randomized	N	O
60	,	N	O
61	assessor-blinded	N	O
62	,	N	O
63	controlled	N	O
64	trial	N	O
65	was	N	O
66	performed	N	O
67	on	N	O
68	78	N	O
69	patients	N	O
70	undergoing	N	O
71	lung	N	O
72	cancer	N	O
73	surgery	N	O
74	.	N	O

75	The	N	O
76	intervention	N	O
77	group	N	O
78	(	N	O
79	IG	N	O
80	,	N	O
81	n=41	N	O
82	)	N	O
83	participated	N	O
84	in	N	O
85	supervised	N	O
86	out-patient	N	O
87	exercise	N	O
88	training	N	O
89	sessions	N	O
90	,	N	O
91	one	N	O
92	hour	N	O
93	once	N	O
94	a	N	O
95	week	N	O
96	for	N	O
97	ten	N	O
98	weeks	N	O
99	.	N	O

100	The	N	O
101	sessions	N	O
102	were	N	O
103	based	N	O
104	on	N	O
105	aerobic	N	O
106	exercises	N	O
107	with	N	O
108	target	N	O
109	intensity	N	O
110	of	N	O
111	60-80	N	O
112	%	N	O
113	of	N	O
114	work	N	O
115	capacity	N	O
116	,	N	O
117	resistance	N	O
118	training	N	O
119	and	N	O
120	dyspnoea	N	O
121	management	N	O
122	.	N	O

123	The	N	O
124	control	N	O
125	group	N	O
126	(	N	O
127	CG	N	O
128	,	N	O
129	n=37	N	O
130	)	N	O
131	received	N	O
132	one	N	O
133	individual	N	O
134	instruction	N	O
135	in	N	O
136	exercise	N	O
137	training	N	O
138	.	N	O

139	Measurements	N	O
140	consisted	N	O
141	of	N	O
142	:	N	O
143	health-related	N	O
144	quality	N	O
145	of	N	O
146	life	N	O
147	(	N	O
148	SF36	N	O
149	)	N	O
150	,	N	O
151	six	N	O
152	minute	N	O
153	walk	N	O
154	test	N	O
155	(	N	O
156	6MWT	N	O
157	)	N	O
158	and	N	O
159	lung	N	O
160	function	N	O
161	(	N	O
162	spirometry	N	O
163	)	N	O
164	,	N	O
165	assessed	N	O
166	three	N	O
167	weeks	N	O
168	after	N	O
169	surgery	N	O
170	and	N	O
171	after	N	O
172	four	N	O
173	and	N	O
174	twelve	N	O
175	months	N	O
176	.	N	O

177	Both	N	O
178	groups	N	O
179	were	N	O
180	comparable	N	O
181	at	N	O
182	baseline	N	O
183	on	N	O
184	demographic	N	O
185	characteristic	N	O
186	and	N	O
187	outcome	N	O
188	values	N	O
189	.	N	O

190	We	N	I-Premise
191	found	N	I-Premise
192	a	N	I-Premise
193	statistically	N	I-Premise
194	significant	N	I-Premise
195	effect	N	I-Premise
196	after	N	I-Premise
197	four	N	I-Premise
198	months	N	I-Premise
199	in	N	I-Premise
200	the	N	I-Premise
201	bodily	N	I-Premise
202	pain	N	I-Premise
203	domain	N	I-Premise
204	of	N	I-Premise
205	SF36	N	I-Premise
206	,	N	I-Premise
207	with	N	I-Premise
208	an	N	I-Premise
209	estimated	N	I-Premise
210	mean	N	I-Premise
211	difference	N	I-Premise
212	(	N	I-Premise
213	EMD	N	I-Premise
214	)	N	I-Premise
215	of	N	I-Premise
216	15.3	N	I-Premise
217	(	N	I-Premise
218	95	N	I-Premise
219	%	N	I-Premise
220	CI:4	N	I-Premise
221	to	N	I-Premise
222	26.6	N	I-Premise
223	,	N	I-Premise
224	p=0.01	N	I-Premise
225	)	N	I-Premise
226	and	N	I-Premise
227	a	N	I-Premise
228	trend	N	I-Premise
229	in	N	I-Premise
230	favour	N	I-Premise
231	of	N	I-Premise
232	the	N	I-Premise
233	intervention	N	I-Premise
234	for	N	I-Premise
235	role	N	I-Premise
236	physical	N	I-Premise
237	functioning	N	I-Premise
238	(	N	I-Premise
239	EMD	N	I-Premise
240	12.04	N	I-Premise
241	,	N	I-Premise
242	95	N	I-Premise
243	%	N	I-Premise
244	CI	N	I-Premise
245	:	N	I-Premise
246	-1	N	I-Premise
247	to	N	I-Premise
248	25.1	N	I-Premise
249	,	N	I-Premise
250	p=0.07	N	I-Premise
251	)	N	I-Premise
252	and	N	I-Premise
253	physical	N	I-Premise
254	component	N	I-Premise
255	summary	N	I-Premise
256	(	N	I-Premise
257	EMD	N	I-Premise
258	3.76	N	I-Premise
259	,	N	I-Premise
260	95	N	I-Premise
261	%	N	I-Premise
262	CI	N	I-Premise
263	:	N	I-Premise
264	-0.1	N	I-Premise
265	to	N	I-Premise
266	7.6	N	I-Premise
267	,	N	I-Premise
268	p=0.06	N	I-Premise
269	)	N	I-Premise
270	.	N	I-Premise

271	At	N	I-Premise
272	12	N	I-Premise
273	months	N	I-Premise
274	,	N	I-Premise
275	the	N	I-Premise
276	tendency	N	I-Premise
277	was	N	I-Premise
278	reversed	N	I-Premise
279	,	N	I-Premise
280	with	N	I-Premise
281	the	N	I-Premise
282	CG	N	I-Premise
283	presenting	N	I-Premise
284	overall	N	I-Premise
285	slightly	N	I-Premise
286	better	N	I-Premise
287	measures	N	I-Premise
288	.	N	I-Premise

289	We	N	I-Claim
290	found	N	I-Claim
291	no	N	I-Claim
292	effect	N	I-Claim
293	of	N	I-Claim
294	the	N	I-Claim
295	intervention	N	I-Claim
296	on	N	I-Claim
297	6MWT	N	I-Claim
298	or	N	I-Claim
299	lung	N	I-Claim
300	volumes	N	I-Claim
301	at	N	I-Claim
302	any	N	I-Claim
303	time-point	N	I-Claim
304	.	N	I-Claim

305	Supervised	N	I-Claim
306	compared	N	I-Claim
307	to	N	I-Claim
308	unsupervised	N	I-Claim
309	exercise	N	I-Claim
310	training	N	I-Claim
311	resulted	N	I-Claim
312	in	N	I-Claim
313	no	N	I-Claim
314	improvement	N	I-Claim
315	in	N	I-Claim
316	health-related	N	I-Claim
317	quality	N	I-Claim
318	of	N	I-Claim
319	life	N	I-Claim
320	,	N	I-Claim
321	except	N	I-Claim
322	for	N	I-Claim
323	the	N	I-Claim
324	bodily	N	I-Claim
325	pain	N	I-Claim
326	domain	N	I-Claim
327	,	N	I-Claim
328	four	N	I-Claim
329	months	N	I-Claim
330	after	N	I-Claim
331	lung	N	I-Claim
332	cancer	N	I-Claim
333	surgery	N	I-Claim
334	.	N	I-Claim

335	No	N	I-Claim
336	effects	N	I-Claim
337	of	N	I-Claim
338	the	N	I-Claim
339	intervention	N	I-Claim
340	were	N	I-Claim
341	found	N	I-Claim
342	for	N	I-Claim
343	any	N	I-Claim
344	outcome	N	I-Claim
345	after	N	I-Claim
346	one	N	I-Claim
347	year	N	I-Claim
348	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	medroxyprogesterone	N	O
7	acetate	N	O
8	(	N	O
9	MPA	N	O
10	)	N	O
11	on	N	O
12	appetite	N	O
13	,	N	O
14	weight	N	O
15	,	N	O
16	and	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QL	N	O
22	)	N	O
23	in	N	O
24	patients	N	O
25	with	N	O
26	advanced-stage	N	O
27	,	N	O
28	incurable	N	O
29	,	N	O
30	non-hormone-sensitive	N	O
31	cancer	N	O
32	.	N	O

33	Two	N	O
34	hundred	N	O
35	six	N	O
36	eligible	N	O
37	patients	N	O
38	were	N	O
39	randomized	N	O
40	between	N	O
41	double-blind	N	O
42	MPA	N	O
43	500	N	O
44	mg	N	O
45	twice	N	O
46	daily	N	O
47	or	N	O
48	placebo	N	O
49	.	N	O

50	Appetite	N	O
51	(	N	O
52	0	N	O
53	to	N	O
54	10	N	O
55	numerical	N	O
56	rating	N	O
57	scale	N	O
58	)	N	O
59	,	N	O
60	weight	N	O
61	,	N	O
62	and	N	O
63	QL	N	O
64	(	N	O
65	European	N	O
66	Organization	N	O
67	for	N	O
68	Research	N	O
69	and	N	O
70	Treatment	N	O
71	of	N	O
72	Cancer	N	O
73	Quality	N	O
74	of	N	O
75	Life	N	O
76	Questionnaire	N	O
77	[	N	O
78	EORTC-QLQ-C30	N	O
79	]	N	O
80	)	N	O
81	were	N	O
82	assessed	N	O
83	before	N	O
84	the	N	O
85	start	N	O
86	of	N	O
87	treatment	N	O
88	(	N	O
89	t	N	O
90	=	N	O
91	0	N	O
92	)	N	O
93	,	N	O
94	and	N	O
95	6	N	O
96	weeks	N	O
97	(	N	O
98	t	N	O
99	=	N	O
100	6	N	O
101	)	N	O
102	and	N	O
103	12	N	O
104	weeks	N	O
105	(	N	O
106	t	N	O
107	=	N	O
108	12	N	O
109	)	N	O
110	thereafter	N	O
111	.	N	O

112	One	N	O
113	hundred	N	O
114	thirty-four	N	O
115	patients	N	O
116	(	N	O
117	68	N	O
118	MPA	N	O
119	and	N	O
120	66	N	O
121	placebo	N	O
122	)	N	O
123	were	N	O
124	assessable	N	O
125	at	N	O
126	t	N	O
127	=	N	O
128	6	N	O
129	and	N	O
130	99	N	O
131	patients	N	O
132	(	N	O
133	53	N	O
134	MPA	N	O
135	and	N	O
136	46	N	O
137	placebo	N	O
138	)	N	O
139	at	N	O
140	t	N	O
141	=	N	O
142	12	N	O
143	.	N	O

144	A	N	I-Premise
145	beneficial	N	I-Premise
146	effect	N	I-Premise
147	of	N	I-Premise
148	MPA	N	I-Premise
149	on	N	I-Premise
150	appetite	N	I-Premise
151	was	N	I-Premise
152	observed	N	I-Premise
153	after	N	I-Premise
154	both	N	I-Premise
155	6	N	I-Premise
156	weeks	N	I-Premise
157	(	N	I-Premise
158	P	N	I-Premise
159	=	N	I-Premise
160	.008	N	I-Premise
161	)	N	I-Premise
162	and	N	I-Premise
163	12	N	I-Premise
164	weeks	N	I-Premise
165	(	N	I-Premise
166	P	N	I-Premise
167	=	N	I-Premise
168	.01	N	I-Premise
169	)	N	I-Premise
170	of	N	I-Premise
171	treatment	N	I-Premise
172	.	N	I-Premise

173	After	N	I-Premise
174	12	N	I-Premise
175	weeks	N	I-Premise
176	,	N	I-Premise
177	a	N	I-Premise
178	mean	N	I-Premise
179	weight	N	I-Premise
180	gain	N	I-Premise
181	of	N	I-Premise
182	0.6	N	I-Premise
183	+/-	N	I-Premise
184	4.4	N	I-Premise
185	kg	N	I-Premise
186	was	N	I-Premise
187	seen	N	I-Premise
188	in	N	I-Premise
189	the	N	I-Premise
190	MPA	N	I-Premise
191	,	N	I-Premise
192	versus	N	I-Premise
193	an	N	I-Premise
194	ongoing	N	I-Premise
195	mean	N	I-Premise
196	weight	N	I-Premise
197	loss	N	I-Premise
198	of	N	I-Premise
199	1.4	N	I-Premise
200	+/-	N	I-Premise
201	4.6	N	I-Premise
202	kg	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	placebo	N	I-Premise
206	group	N	I-Premise
207	.	N	I-Premise

208	This	N	I-Premise
209	difference	N	I-Premise
210	of	N	I-Premise
211	2.0	N	I-Premise
212	kg	N	I-Premise
213	was	N	I-Premise
214	statistically	N	I-Premise
215	significant	N	I-Premise
216	(	N	I-Premise
217	P	N	I-Premise
218	=	N	I-Premise
219	.04	N	I-Premise
220	)	N	I-Premise
221	.	N	I-Premise

222	During	N	I-Premise
223	the	N	I-Premise
224	study	N	I-Premise
225	,	N	I-Premise
226	several	N	I-Premise
227	areas	N	I-Premise
228	of	N	I-Premise
229	QL	N	I-Premise
230	deteriorated	N	I-Premise
231	in	N	I-Premise
232	the	N	I-Premise
233	total	N	I-Premise
234	group	N	I-Premise
235	of	N	I-Premise
236	patients	N	I-Premise
237	.	N	I-Premise

238	With	N	I-Claim
239	the	N	I-Claim
240	exception	N	I-Claim
241	of	N	I-Claim
242	an	N	I-Claim
243	improvement	N	I-Claim
244	in	N	I-Claim
245	appetite	N	I-Claim
246	and	N	I-Claim
247	possible	N	I-Claim
248	also	N	I-Claim
249	a	N	I-Claim
250	reduction	N	I-Claim
251	in	N	I-Claim
252	nausea	N	I-Claim
253	and	N	I-Claim
254	vomiting	N	I-Claim
255	,	N	I-Claim
256	no	N	I-Claim
257	measurable	N	I-Claim
258	beneficial	N	I-Claim
259	effects	N	I-Claim
260	of	N	I-Claim
261	MPA	N	I-Claim
262	on	N	I-Claim
263	QL	N	I-Claim
264	could	N	I-Claim
265	be	N	I-Claim
266	demonstrated	N	I-Claim
267	.	N	I-Claim

268	The	N	I-Premise
269	side	N	I-Premise
270	effects	N	I-Premise
271	profile	N	I-Premise
272	of	N	I-Premise
273	MPA	N	I-Premise
274	was	N	I-Premise
275	favorable	N	I-Premise
276	:	N	I-Premise
277	only	N	I-Premise
278	a	N	I-Premise
279	trend	N	I-Premise
280	toward	N	I-Premise
281	an	N	I-Premise
282	increase	N	I-Premise
283	in	N	I-Premise
284	(	N	I-Premise
285	usually	N	I-Premise
286	mild	N	I-Premise
287	)	N	I-Premise
288	peripheral	N	I-Premise
289	edema	N	I-Premise
290	was	N	I-Premise
291	observed	N	I-Premise
292	.	N	I-Premise

293	In	N	I-Claim
294	weight-losing	N	I-Claim
295	,	N	I-Claim
296	advanced-stage	N	I-Claim
297	non-hormone-sensitive	N	I-Claim
298	cancer	N	I-Claim
299	patients	N	I-Claim
300	,	N	I-Claim
301	MPA	N	I-Claim
302	exhibits	N	I-Claim
303	a	N	I-Claim
304	mild	N	I-Claim
305	side	N	I-Claim
306	effects	N	I-Claim
307	profile	N	I-Claim
308	,	N	I-Claim
309	has	N	I-Claim
310	a	N	I-Claim
311	beneficial	N	I-Claim
312	effect	N	I-Claim
313	on	N	I-Claim
314	appetite	N	I-Claim
315	,	N	I-Claim
316	and	N	I-Claim
317	may	N	I-Claim
318	prevent	N	I-Claim
319	further	N	I-Claim
320	weight	N	I-Claim
321	loss	N	I-Claim
322	.	N	I-Claim

323	However	N	I-Claim
324	,	N	I-Claim
325	general	N	I-Claim
326	QL	N	I-Claim
327	in	N	I-Claim
328	the	N	I-Claim
329	present	N	I-Claim
330	study	N	I-Claim
331	was	N	I-Claim
332	not	N	I-Claim
333	measurably	N	I-Claim
334	influenced	N	I-Claim
335	by	N	I-Claim
336	MPA	N	I-Claim
337	treatment	N	I-Claim
338	.	N	I-Claim

1	Combined	N	I-MajorClaim
2	radiation	N	I-MajorClaim
3	therapy	N	I-MajorClaim
4	and	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	after	N	I-MajorClaim
7	surgery	N	I-MajorClaim
8	,	N	I-MajorClaim
9	compared	N	I-MajorClaim
10	with	N	I-MajorClaim
11	postsurgical	N	I-MajorClaim
12	radiation	N	I-MajorClaim
13	therapy	N	I-MajorClaim
14	alone	N	I-MajorClaim
15	,	N	I-MajorClaim
16	has	N	I-MajorClaim
17	been	N	I-MajorClaim
18	shown	N	I-MajorClaim
19	to	N	I-MajorClaim
20	improve	N	I-MajorClaim
21	disease-free	N	I-MajorClaim
22	survival	N	I-MajorClaim
23	and	N	I-MajorClaim
24	overall	N	I-MajorClaim
25	survival	N	I-MajorClaim
26	significantly	N	I-MajorClaim
27	among	N	I-MajorClaim
28	patients	N	I-MajorClaim
29	with	N	I-MajorClaim
30	poor-prognosis	N	I-MajorClaim
31	(	N	I-MajorClaim
32	i.e.	N	I-MajorClaim
33	,	N	I-MajorClaim
34	advanced	N	I-MajorClaim
35	stage	N	I-MajorClaim
36	disease	N	I-MajorClaim
37	or	N	I-MajorClaim
38	metastasis	N	I-MajorClaim
39	to	N	I-MajorClaim
40	regional	N	I-MajorClaim
41	lymph	N	I-MajorClaim
42	nodes	N	I-MajorClaim
43	)	N	I-MajorClaim
44	resectable	N	I-MajorClaim
45	rectal	N	I-MajorClaim
46	cancer	N	I-MajorClaim
47	.	N	I-MajorClaim

48	However	N	I-Claim
49	,	N	I-Claim
50	the	N	I-Claim
51	combined	N	I-Claim
52	therapy	N	I-Claim
53	is	N	I-Claim
54	associated	N	I-Claim
55	with	N	I-Claim
56	more	N	I-Claim
57	toxic	N	I-Claim
58	effects	N	I-Claim
59	,	N	I-Claim
60	raising	N	I-Claim
61	the	N	I-Claim
62	question	N	I-Claim
63	of	N	I-Claim
64	whether	N	I-Claim
65	the	N	I-Claim
66	benefits	N	I-Claim
67	of	N	I-Claim
68	the	N	I-Claim
69	treatment	N	I-Claim
70	justify	N	I-Claim
71	its	N	I-Claim
72	quality-of-life	N	I-Claim
73	costs	N	I-Claim
74	for	N	I-Claim
75	the	N	I-Claim
76	individual	N	I-Claim
77	patient	N	I-Claim
78	.	N	I-Claim

79	To	N	O
80	assess	N	O
81	the	N	O
82	trade-offs	N	O
83	between	N	O
84	improved	N	O
85	survival	N	O
86	and	N	O
87	increased	N	O
88	treatment	N	O
89	toxicity	N	O
90	,	N	O
91	we	N	O
92	reanalyzed	N	O
93	data	N	O
94	from	N	O
95	a	N	O
96	randomized	N	O
97	clinical	N	O
98	trial	N	O
99	that	N	O
100	compared	N	O
101	the	N	O
102	efficacy	N	O
103	of	N	O
104	combined	N	O
105	adjuvant	N	O
106	chemotherapy	N	O
107	and	N	O
108	radiation	N	O
109	therapy	N	O
110	with	N	O
111	adjuvant	N	O
112	radiation	N	O
113	therapy	N	O
114	alone	N	O
115	in	N	O
116	the	N	O
117	treatment	N	O
118	of	N	O
119	patients	N	O
120	with	N	O
121	poor-prognosis	N	O
122	resectable	N	O
123	rectal	N	O
124	cancer	N	O
125	.	N	O

126	The	N	O
127	data	N	O
128	were	N	O
129	from	N	O
130	a	N	O
131	North	N	O
132	Central	N	O
133	Cancer	N	O
134	Treatment	N	O
135	Group	N	O
136	trial	N	O
137	in	N	O
138	which	N	O
139	204	N	O
140	patients	N	O
141	with	N	O
142	poor-prognosis	N	O
143	rectal	N	O
144	cancer	N	O
145	were	N	O
146	randomly	N	O
147	assigned	N	O
148	to	N	O
149	receive	N	O
150	either	N	O
151	postoperative	N	O
152	radiation	N	O
153	therapy	N	O
154	alone	N	O
155	or	N	O
156	radiation	N	O
157	therapy	N	O
158	plus	N	O
159	fluorouracil-based	N	O
160	chemotherapy	N	O
161	.	N	O

162	A	N	O
163	quality-adjusted	N	O
164	time	N	O
165	without	N	O
166	symptoms	N	O
167	or	N	O
168	toxicity	N	O
169	(	N	O
170	Q-TWiST	N	O
171	)	N	O
172	analysis	N	O
173	was	N	O
174	used	N	O
175	to	N	O
176	account	N	O
177	for	N	O
178	freedom	N	O
179	from	N	O
180	symptomatic	N	O
181	disease	N	O
182	and	N	O
183	from	N	O
184	early	N	O
185	and	N	O
186	late	N	O
187	side	N	O
188	effects	N	O
189	of	N	O
190	treatment	N	O
191	.	N	O

192	All	N	O
193	reported	N	O
194	P	N	O
195	values	N	O
196	are	N	O
197	two-sided	N	O
198	.	N	O

199	As	N	I-Premise
200	reported	N	I-Premise
201	previously	N	I-Premise
202	,	N	I-Premise
203	the	N	I-Premise
204	combined	N	I-Premise
205	therapy	N	I-Premise
206	reduced	N	I-Premise
207	the	N	I-Premise
208	risk	N	I-Premise
209	of	N	I-Premise
210	relapse	N	I-Premise
211	by	N	I-Premise
212	34	N	I-Premise
213	%	N	I-Premise
214	(	N	I-Premise
215	95	N	I-Premise
216	%	N	I-Premise
217	confidence	N	I-Premise
218	interval	N	I-Premise
219	[	N	I-Premise
220	CI	N	I-Premise
221	]	N	I-Premise
222	=	N	I-Premise
223	12	N	I-Premise
224	%	N	I-Premise
225	-50	N	I-Premise
226	%	N	I-Premise
227	;	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	.0016	N	I-Premise
231	)	N	I-Premise
232	and	N	I-Premise
233	reduced	N	I-Premise
234	the	N	I-Premise
235	overall	N	I-Premise
236	death	N	I-Premise
237	rate	N	I-Premise
238	by	N	I-Premise
239	29	N	I-Premise
240	%	N	I-Premise
241	(	N	I-Premise
242	95	N	I-Premise
243	%	N	I-Premise
244	CI	N	I-Premise
245	=	N	I-Premise
246	7	N	I-Premise
247	%	N	I-Premise
248	-45	N	I-Premise
249	%	N	I-Premise
250	;	N	I-Premise
251	P	N	I-Premise
252	=	N	I-Premise
253	.025	N	I-Premise
254	)	N	I-Premise
255	in	N	I-Premise
256	comparison	N	I-Premise
257	with	N	I-Premise
258	adjuvant	N	I-Premise
259	radiation	N	I-Premise
260	therapy	N	I-Premise
261	alone	N	I-Premise
262	.	N	I-Premise

263	In	N	I-Premise
264	the	N	I-Premise
265	5	N	I-Premise
266	years	N	I-Premise
267	following	N	I-Premise
268	assignment	N	I-Premise
269	to	N	I-Premise
270	treatment	N	I-Premise
271	,	N	I-Premise
272	patients	N	I-Premise
273	who	N	I-Premise
274	received	N	I-Premise
275	the	N	I-Premise
276	combined	N	I-Premise
277	therapy	N	I-Premise
278	had	N	I-Premise
279	more	N	I-Premise
280	time	N	I-Premise
281	with	N	I-Premise
282	toxicity	N	I-Premise
283	(	N	I-Premise
284	3.1	N	I-Premise
285	months	N	I-Premise
286	;	N	I-Premise
287	95	N	I-Premise
288	%	N	I-Premise
289	CI	N	I-Premise
290	=	N	I-Premise
291	2.0-4.1	N	I-Premise
292	months	N	I-Premise
293	)	N	I-Premise
294	,	N	I-Premise
295	shorter	N	I-Premise
296	survival	N	I-Premise
297	after	N	I-Premise
298	relapse	N	I-Premise
299	(	N	I-Premise
300	3.6	N	I-Premise
301	months	N	I-Premise
302	less	N	I-Premise
303	;	N	I-Premise
304	95	N	I-Premise
305	%	N	I-Premise
306	CI	N	I-Premise
307	=	N	I-Premise
308	0.9-6.3	N	I-Premise
309	months	N	I-Premise
310	less	N	I-Premise
311	)	N	I-Premise
312	,	N	I-Premise
313	and	N	I-Premise
314	more	N	I-Premise
315	TWiST	N	I-Premise
316	(	N	I-Premise
317	6.1	N	I-Premise
318	months	N	I-Premise
319	;	N	I-Premise
320	95	N	I-Premise
321	%	N	I-Premise
322	CI	N	I-Premise
323	=	N	I-Premise
324	0.2-12.0	N	I-Premise
325	months	N	I-Premise
326	)	N	I-Premise
327	than	N	I-Premise
328	patients	N	I-Premise
329	who	N	I-Premise
330	received	N	I-Premise
331	adjuvant	N	I-Premise
332	radiation	N	I-Premise
333	therapy	N	I-Premise
334	alone	N	I-Premise
335	.	N	I-Premise

336	Despite	N	I-Claim
337	an	N	I-Claim
338	increase	N	I-Claim
339	in	N	I-Claim
340	the	N	I-Claim
341	amount	N	I-Claim
342	of	N	I-Claim
343	time	N	I-Claim
344	that	N	I-Claim
345	individuals	N	I-Claim
346	spent	N	I-Claim
347	with	N	I-Claim
348	early	N	I-Claim
349	and	N	I-Claim
350	late	N	I-Claim
351	toxic	N	I-Claim
352	effects	N	I-Claim
353	,	N	I-Claim
354	the	N	I-Claim
355	Q-TWiST	N	I-Claim
356	analysis	N	I-Claim
357	indicated	N	I-Claim
358	that	N	I-Claim
359	the	N	I-Claim
360	combined	N	I-Claim
361	therapy	N	I-Claim
362	conferred	N	I-Claim
363	significantly	N	I-Claim
364	greater	N	I-Claim
365	benefit	N	I-Claim
366	for	N	I-Claim
367	a	N	I-Claim
368	wide	N	I-Claim
369	range	N	I-Claim
370	of	N	I-Claim
371	patient	N	I-Claim
372	preferences	N	I-Claim
373	about	N	I-Claim
374	living	N	I-Claim
375	with	N	I-Claim
376	the	N	I-Claim
377	toxicity	N	I-Claim
378	of	N	I-Claim
379	treatment	N	I-Claim
380	or	N	I-Claim
381	the	N	I-Claim
382	symptoms	N	I-Claim
383	of	N	I-Claim
384	overt	N	I-Claim
385	disease	N	I-Claim
386	.	N	I-Claim

387	Use	N	I-Claim
388	of	N	I-Claim
389	combined	N	I-Claim
390	chemotherapy	N	I-Claim
391	and	N	I-Claim
392	radiation	N	I-Claim
393	therapy	N	I-Claim
394	as	N	I-Claim
395	an	N	I-Claim
396	adjuvant	N	I-Claim
397	to	N	I-Claim
398	surgery	N	I-Claim
399	for	N	I-Claim
400	patients	N	I-Claim
401	with	N	I-Claim
402	poor-prognosis	N	I-Claim
403	resectable	N	I-Claim
404	rectal	N	I-Claim
405	cancer	N	I-Claim
406	is	N	I-Claim
407	justified	N	I-Claim
408	,	N	I-Claim
409	since	N	I-Premise
410	the	N	I-Premise
411	improved	N	I-Premise
412	outcome	N	I-Premise
413	in	N	I-Premise
414	terms	N	I-Premise
415	of	N	I-Premise
416	delayed	N	I-Premise
417	recurrence	N	I-Premise
418	and	N	I-Premise
419	increased	N	I-Premise
420	survival	N	I-Premise
421	balances	N	I-Premise
422	the	N	I-Premise
423	time	N	I-Premise
424	spent	N	I-Premise
425	with	N	I-Premise
426	early	N	I-Premise
427	and	N	I-Premise
428	late	N	I-Premise
429	toxic	N	I-Premise
430	effects	N	I-Premise
431	.	N	I-Premise

432	The	N	I-Claim
433	Q-TWiST	N	I-Claim
434	method	N	I-Claim
435	is	N	I-Claim
436	an	N	I-Claim
437	excellent	N	I-Claim
438	way	N	I-Claim
439	to	N	I-Claim
440	compare	N	I-Claim
441	treatment	N	I-Claim
442	outcomes	N	I-Claim
443	that	N	I-Claim
444	include	N	I-Claim
445	quality-of-life	N	I-Claim
446	considerations	N	I-Claim
447	.	N	I-Claim

1	Cerebral	N	I-Claim
2	metastasis	N	I-Claim
3	is	N	I-Claim
4	a	N	I-Claim
5	common	N	I-Claim
6	oncologic	N	I-Claim
7	problem	N	I-Claim
8	that	N	I-Claim
9	occurs	N	I-Claim
10	in	N	I-Claim
11	15-30	N	I-Claim
12	%	N	I-Claim
13	of	N	I-Claim
14	cancer	N	I-Claim
15	patients	N	I-Claim
16	;	N	I-Claim
17	approximately	N	O
18	half	N	O
19	such	N	O
20	metastases	N	O
21	are	N	O
22	single	N	O
23	.	N	O

24	Previous	N	O
25	retrospective	N	O
26	studies	N	O
27	and	N	O
28	two	N	O
29	randomized	N	O
30	trials	N	O
31	reported	N	O
32	that	N	O
33	the	N	O
34	addition	N	O
35	of	N	O
36	surgical	N	O
37	extirpation	N	O
38	prior	N	O
39	to	N	O
40	radiation	N	O
41	therapy	N	O
42	increased	N	O
43	survival	N	O
44	,	N	O
45	neurologic	N	O
46	function	N	O
47	,	N	O
48	and	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	compared	N	O
53	with	N	O
54	radiation	N	O
55	alone	N	O
56	in	N	O
57	patients	N	O
58	with	N	O
59	a	N	O
60	single	N	O
61	brain	N	O
62	metastasis	N	O
63	.	N	O

64	A	N	O
65	randomized	N	O
66	controlled	N	O
67	trial	N	O
68	was	N	O
69	conducted	N	O
70	in	N	O
71	which	N	O
72	patients	N	O
73	with	N	O
74	a	N	O
75	single	N	O
76	brain	N	O
77	metastasis	N	O
78	were	N	O
79	allocated	N	O
80	to	N	O
81	undergo	N	O
82	radiation	N	O
83	alone	N	O
84	or	N	O
85	surgery	N	O
86	plus	N	O
87	radiation	N	O
88	.	N	O

89	Radiation	N	O
90	consisted	N	O
91	of	N	O
92	3000	N	O
93	centigray	N	O
94	to	N	O
95	the	N	O
96	whole	N	O
97	brain	N	O
98	in	N	O
99	10	N	O
100	fractions	N	O
101	.	N	O

102	Forty-three	N	O
103	patients	N	O
104	received	N	O
105	radiation	N	O
106	alone	N	O
107	and	N	O
108	41	N	O
109	patients	N	O
110	surgery	N	O
111	plus	N	O
112	radiation	N	O
113	.	N	O

114	All	N	O
115	but	N	O
116	two	N	O
117	of	N	O
118	the	N	O
119	study	N	O
120	patients	N	O
121	died	N	O
122	.	N	O

123	No	N	I-Premise
124	difference	N	I-Premise
125	in	N	I-Premise
126	survival	N	I-Premise
127	was	N	I-Premise
128	detected	N	I-Premise
129	between	N	I-Premise
130	the	N	I-Premise
131	groups	N	I-Premise
132	;	N	I-Premise
133	the	N	I-Premise
134	median	N	I-Premise
135	survival	N	I-Premise
136	for	N	I-Premise
137	the	N	I-Premise
138	radiation	N	I-Premise
139	group	N	I-Premise
140	was	N	I-Premise
141	6.3	N	I-Premise
142	months	N	I-Premise
143	(	N	I-Premise
144	95	N	I-Premise
145	%	N	I-Premise
146	confidence	N	I-Premise
147	interval	N	I-Premise
148	,	N	I-Premise
149	3-11.4	N	I-Premise
150	)	N	I-Premise
151	compared	N	I-Premise
152	with	N	I-Premise
153	5.6	N	I-Premise
154	months	N	I-Premise
155	for	N	I-Premise
156	the	N	I-Premise
157	surgery	N	I-Premise
158	plus	N	I-Premise
159	radiation	N	I-Premise
160	group	N	I-Premise
161	(	N	I-Premise
162	95	N	I-Premise
163	%	N	I-Premise
164	confidence	N	I-Premise
165	interval	N	I-Premise
166	,	N	I-Premise
167	3.9-7.2	N	I-Premise
168	)	N	I-Premise
169	(	N	I-Premise
170	P	N	I-Premise
171	=	N	I-Premise
172	0.24	N	I-Premise
173	)	N	I-Premise
174	.	N	I-Premise

175	Most	N	I-Premise
176	patients	N	I-Premise
177	died	N	I-Premise
178	within	N	I-Premise
179	the	N	I-Premise
180	first	N	I-Premise
181	year	N	I-Premise
182	(	N	I-Premise
183	69.8	N	I-Premise
184	%	N	I-Premise
185	in	N	I-Premise
186	the	N	I-Premise
187	radiation	N	I-Premise
188	arm	N	I-Premise
189	vs.	N	I-Premise
190	87.8	N	I-Premise
191	%	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	surgery	N	I-Premise
195	plus	N	I-Premise
196	radiation	N	I-Premise
197	arm	N	I-Premise
198	)	N	I-Premise
199	.	N	I-Premise

200	There	N	I-Premise
201	were	N	I-Premise
202	no	N	I-Premise
203	significant	N	I-Premise
204	differences	N	I-Premise
205	in	N	I-Premise
206	the	N	I-Premise
207	30-day	N	I-Premise
208	mortality	N	I-Premise
209	,	N	I-Premise
210	morbidity	N	I-Premise
211	,	N	I-Premise
212	or	N	I-Premise
213	causes	N	I-Premise
214	of	N	I-Premise
215	death	N	I-Premise
216	.	N	I-Premise

217	Extracranial	N	I-Premise
218	metastases	N	I-Premise
219	was	N	I-Premise
220	an	N	I-Premise
221	important	N	I-Premise
222	predictor	N	I-Premise
223	of	N	I-Premise
224	mortality	N	I-Premise
225	(	N	I-Premise
226	relative	N	I-Premise
227	risk	N	I-Premise
228	,	N	I-Premise
229	2.3	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	The	N	I-Premise
233	mean	N	I-Premise
234	proportion	N	I-Premise
235	of	N	I-Premise
236	days	N	I-Premise
237	that	N	I-Premise
238	the	N	I-Premise
239	Karnofsky	N	I-Premise
240	performance	N	I-Premise
241	status	N	I-Premise
242	was	N	I-Premise
243	>	N	I-Premise
244	or	N	I-Premise
245	=	N	I-Premise
246	70	N	I-Premise
247	%	N	I-Premise
248	did	N	I-Premise
249	not	N	I-Premise
250	differ	N	I-Premise
251	between	N	I-Premise
252	the	N	I-Premise
253	2	N	I-Premise
254	groups	N	I-Premise
255	.	N	I-Premise

256	This	N	I-Claim
257	trial	N	I-Claim
258	failed	N	I-Claim
259	to	N	I-Claim
260	demonstrate	N	I-Claim
261	that	N	I-Claim
262	the	N	I-Claim
263	addition	N	I-Claim
264	of	N	I-Claim
265	surgery	N	I-Claim
266	to	N	I-Claim
267	radiation	N	I-Claim
268	therapy	N	I-Claim
269	improved	N	I-Claim
270	outcome	N	I-Claim
271	of	N	I-Claim
272	patients	N	I-Claim
273	with	N	I-Claim
274	a	N	I-Claim
275	single	N	I-Claim
276	brain	N	I-Claim
277	metastasis	N	I-Claim
278	.	N	I-Claim

279	Thus	N	I-Claim
280	,	N	I-Claim
281	the	N	I-Claim
282	efficacy	N	I-Claim
283	of	N	I-Claim
284	surgery	N	I-Claim
285	plus	N	I-Claim
286	radiation	N	I-Claim
287	compared	N	I-Claim
288	with	N	I-Claim
289	radiation	N	I-Claim
290	alone	N	I-Claim
291	needs	N	I-Claim
292	to	N	I-Claim
293	be	N	I-Claim
294	addressed	N	I-Claim
295	by	N	I-Claim
296	further	N	I-Claim
297	clinical	N	I-Claim
298	trials	N	I-Claim
299	and/or	N	I-Claim
300	a	N	I-Claim
301	meta-analysis	N	I-Claim
302	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	two	N	O
4	cisplatin	N	O
5	based	N	O
6	chemotherapy	N	O
7	schedules	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	advanced	N	O
12	non-small-cell	N	O
13	lung	N	O
14	cancer	N	O
15	(	N	O
16	NSCLC	N	O
17	)	N	O
18	.	N	O

19	A	N	O
20	total	N	O
21	of	N	O
22	332	N	O
23	patients	N	O
24	with	N	O
25	advanced	N	O
26	NSCLC	N	O
27	were	N	O
28	randomized	N	O
29	to	N	O
30	receive	N	O
31	cisplatin	N	O
32	80	N	O
33	mg/m2	N	O
34	on	N	O
35	day	N	O
36	1	N	O
37	either	N	O
38	in	N	O
39	combination	N	O
40	with	N	O
41	teniposide	N	O
42	100	N	O
43	mg/m2	N	O
44	on	N	O
45	days	N	O
46	1	N	O
47	,	N	O
48	3	N	O
49	,	N	O
50	and	N	O
51	5	N	O
52	(	N	O
53	arm	N	O
54	A	N	O
55	)	N	O
56	or	N	O
57	paclitaxel	N	O
58	175	N	O
59	mg/m2	N	O
60	by	N	O
61	3-hour	N	O
62	infusion	N	O
63	on	N	O
64	day	N	O
65	1	N	O
66	(	N	O
67	arm	N	O
68	B	N	O
69	)	N	O
70	;	N	O
71	cycles	N	O
72	were	N	O
73	repeated	N	O
74	every	N	O
75	3	N	O
76	weeks	N	O
77	.	N	O

78	Fifteen	N	O
79	patients	N	O
80	were	N	O
81	ineligible	N	O
82	;	N	O
83	patient	N	O
84	characteristics	N	O
85	were	N	O
86	well	N	O
87	balanced	N	O
88	between	N	O
89	the	N	O
90	two	N	O
91	arms	N	O
92	:	N	O
93	71	N	O
94	%	N	O
95	were	N	O
96	male	N	O
97	,	N	O
98	71	N	O
99	%	N	O
100	had	N	O
101	less	N	O
102	than	N	O
103	5	N	O
104	%	N	O
105	weight	N	O
106	loss	N	O
107	,	N	O
108	89	N	O
109	%	N	O
110	had	N	O
111	a	N	O
112	World	N	O
113	Health	N	O
114	Organization	N	O
115	(	N	O
116	WHO	N	O
117	)	N	O
118	performance	N	O
119	status	N	O
120	of	N	O
121	0	N	O
122	to	N	O
123	1	N	O
124	,	N	O
125	51	N	O
126	%	N	O
127	had	N	O
128	adenocarcinoma	N	O
129	,	N	O
130	and	N	O
131	61	N	O
132	%	N	O
133	had	N	O
134	stage	N	O
135	IV	N	O
136	disease	N	O
137	.	N	O

138	Hematologic	N	I-Premise
139	toxicity	N	I-Premise
140	was	N	I-Premise
141	significantly	N	I-Premise
142	more	N	I-Premise
143	severe	N	I-Premise
144	in	N	I-Premise
145	arm	N	I-Premise
146	A	N	I-Premise
147	(	N	I-Premise
148	leukopenia	N	I-Premise
149	,	N	I-Premise
150	neutropenia	N	I-Premise
151	,	N	I-Premise
152	and	N	I-Premise
153	thrombocytopenia	N	I-Premise
154	grade	N	I-Premise
155	3	N	I-Premise
156	or	N	I-Premise
157	4	N	I-Premise
158	:	N	I-Premise
159	66	N	I-Premise
160	%	N	I-Premise
161	v	N	I-Premise
162	19	N	I-Premise
163	%	N	I-Premise
164	,	N	I-Premise
165	83	N	I-Premise
166	%	N	I-Premise
167	v	N	I-Premise
168	55	N	I-Premise
169	%	N	I-Premise
170	,	N	I-Premise
171	36	N	I-Premise
172	%	N	I-Premise
173	v	N	I-Premise
174	2	N	I-Premise
175	%	N	I-Premise
176	in	N	I-Premise
177	arms	N	I-Premise
178	A	N	I-Premise
179	and	N	I-Premise
180	B	N	I-Premise
181	,	N	I-Premise
182	respectively	N	I-Premise
183	)	N	I-Premise
184	,	N	I-Premise
185	which	N	I-Premise
186	resulted	N	I-Premise
187	in	N	I-Premise
188	more	N	I-Premise
189	febrile	N	I-Premise
190	neutropenia	N	I-Premise
191	(	N	I-Premise
192	27	N	I-Premise
193	%	N	I-Premise
194	v	N	I-Premise
195	3	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	arms	N	I-Premise
199	A	N	I-Premise
200	and	N	I-Premise
201	B	N	I-Premise
202	,	N	I-Premise
203	respectively	N	I-Premise
204	)	N	I-Premise
205	,	N	I-Premise
206	dose	N	I-Premise
207	reductions	N	I-Premise
208	,	N	I-Premise
209	and	N	I-Premise
210	treatment	N	I-Premise
211	delays	N	I-Premise
212	.	N	I-Premise

213	There	N	I-Premise
214	were	N	I-Premise
215	a	N	I-Premise
216	total	N	I-Premise
217	of	N	I-Premise
218	nine	N	I-Premise
219	toxic	N	I-Premise
220	deaths	N	I-Premise
221	,	N	I-Premise
222	six	N	I-Premise
223	due	N	I-Premise
224	to	N	I-Premise
225	neutropenic	N	I-Premise
226	sepsis	N	I-Premise
227	:	N	I-Premise
228	five	N	I-Premise
229	in	N	I-Premise
230	arm	N	I-Premise
231	A	N	I-Premise
232	and	N	I-Premise
233	one	N	I-Premise
234	in	N	I-Premise
235	arm	N	I-Premise
236	B	N	I-Premise
237	.	N	I-Premise

238	In	N	I-Premise
239	contrast	N	I-Premise
240	,	N	I-Premise
241	arthralgia/myalgia	N	I-Premise
242	(	N	I-Premise
243	grade	N	I-Premise
244	2	N	I-Premise
245	or	N	I-Premise
246	3	N	I-Premise
247	,	N	I-Premise
248	4	N	I-Premise
249	%	N	I-Premise
250	v	N	I-Premise
251	17	N	I-Premise
252	%	N	I-Premise
253	)	N	I-Premise
254	,	N	I-Premise
255	peripheral	N	I-Premise
256	neurotoxicity	N	I-Premise
257	(	N	I-Premise
258	grade	N	I-Premise
259	2	N	I-Premise
260	or	N	I-Premise
261	3	N	I-Premise
262	,	N	I-Premise
263	6	N	I-Premise
264	%	N	I-Premise
265	v	N	I-Premise
266	29	N	I-Premise
267	%	N	I-Premise
268	)	N	I-Premise
269	,	N	I-Premise
270	and	N	I-Premise
271	hypersensitivity	N	I-Premise
272	reactions	N	I-Premise
273	(	N	I-Premise
274	1	N	I-Premise
275	%	N	I-Premise
276	v	N	I-Premise
277	7	N	I-Premise
278	%	N	I-Premise
279	,	N	I-Premise
280	all	N	I-Premise
281	grades	N	I-Premise
282	)	N	I-Premise
283	were	N	I-Premise
284	significantly	N	I-Premise
285	more	N	I-Premise
286	frequent	N	I-Premise
287	in	N	I-Premise
288	arm	N	I-Premise
289	B	N	I-Premise
290	.	N	I-Premise

291	The	N	I-Claim
292	frequency	N	I-Claim
293	and	N	I-Claim
294	severity	N	I-Claim
295	of	N	I-Claim
296	other	N	I-Claim
297	toxicities	N	I-Claim
298	were	N	I-Claim
299	comparable	N	I-Claim
300	between	N	I-Claim
301	the	N	I-Claim
302	two	N	I-Claim
303	arms	N	I-Claim
304	.	N	I-Claim

305	Responses	N	I-Premise
306	were	N	I-Premise
307	one	N	I-Premise
308	complete	N	I-Premise
309	and	N	I-Premise
310	44	N	I-Premise
311	partial	N	I-Premise
312	on	N	I-Premise
313	arm	N	I-Premise
314	A	N	I-Premise
315	(	N	I-Premise
316	28	N	I-Premise
317	%	N	I-Premise
318	)	N	I-Premise
319	and	N	I-Premise
320	two	N	I-Premise
321	complete	N	I-Premise
322	and	N	I-Premise
323	61	N	I-Premise
324	partial	N	I-Premise
325	(	N	I-Premise
326	41	N	I-Premise
327	%	N	I-Premise
328	)	N	I-Premise
329	on	N	I-Premise
330	arm	N	I-Premise
331	B	N	I-Premise
332	(	N	I-Premise
333	P	N	I-Premise
334	=	N	I-Premise
335	.018	N	I-Premise
336	)	N	I-Premise
337	.	N	I-Premise

338	There	N	I-Premise
339	was	N	I-Premise
340	no	N	I-Premise
341	significant	N	I-Premise
342	difference	N	I-Premise
343	in	N	I-Premise
344	survival	N	I-Premise
345	,	N	I-Premise
346	with	N	I-Premise
347	median	N	I-Premise
348	and	N	I-Premise
349	1-year	N	I-Premise
350	survivals	N	I-Premise
351	9.9	N	I-Premise
352	versus	N	I-Premise
353	9.7	N	I-Premise
354	months	N	I-Premise
355	and	N	I-Premise
356	41	N	I-Premise
357	%	N	I-Premise
358	versus	N	I-Premise
359	43	N	I-Premise
360	%	N	I-Premise
361	,	N	I-Premise
362	respectively	N	I-Premise
363	in	N	I-Premise
364	arm	N	I-Premise
365	A	N	I-Premise
366	and	N	I-Premise
367	B.	N	I-Premise
368	Progression-free	N	I-Premise
369	survival	N	I-Premise
370	was	N	I-Premise
371	4.9	N	I-Premise
372	and	N	I-Premise
373	5.4	N	I-Premise
374	months	N	I-Premise
375	in	N	I-Premise
376	arm	N	I-Premise
377	A	N	I-Premise
378	and	N	I-Premise
379	B	N	I-Premise
380	,	N	I-Premise
381	respectively	N	I-Premise
382	.	N	I-Premise

383	Selected	N	O
384	centers	N	O
385	participated	N	O
386	in	N	O
387	a	N	O
388	quality-of-life	N	O
389	(	N	O
390	QoL	N	O
391	)	N	O
392	assessment	N	O
393	,	N	O
394	which	N	O
395	was	N	O
396	performed	N	O
397	by	N	O
398	the	N	O
399	European	N	O
400	Organization	N	O
401	for	N	O
402	Research	N	O
403	and	N	O
404	Treatment	N	O
405	of	N	O
406	Cancer	N	O
407	(	N	O
408	EORTC	N	O
409	)	N	O
410	QLQ-C30	N	O
411	and	N	O
412	LC-13	N	O
413	administered	N	O
414	at	N	O
415	baseline	N	O
416	and	N	O
417	every	N	O
418	6	N	O
419	weeks	N	O
420	thereafter	N	O
421	.	N	O

422	Arm	N	I-Premise
423	B	N	I-Premise
424	achieved	N	I-Premise
425	a	N	I-Premise
426	better	N	I-Premise
427	score	N	I-Premise
428	at	N	I-Premise
429	week	N	I-Premise
430	6	N	I-Premise
431	for	N	I-Premise
432	emotional	N	I-Premise
433	,	N	I-Premise
434	cognitive	N	I-Premise
435	and	N	I-Premise
436	social	N	I-Premise
437	functioning	N	I-Premise
438	,	N	I-Premise
439	global	N	I-Premise
440	health	N	I-Premise
441	status	N	I-Premise
442	,	N	I-Premise
443	fatigue	N	I-Premise
444	,	N	I-Premise
445	and	N	I-Premise
446	appetite	N	I-Premise
447	loss	N	I-Premise
448	,	N	I-Premise
449	which	N	I-Premise
450	was	N	I-Premise
451	lost	N	I-Premise
452	at	N	I-Premise
453	12	N	I-Premise
454	weeks	N	I-Premise
455	.	N	I-Premise

456	In	N	I-Claim
457	conclusion	N	I-Claim
458	,	N	I-Claim
459	arm	N	I-Claim
460	B	N	I-Claim
461	appears	N	I-Claim
462	superior	N	I-Claim
463	to	N	I-Claim
464	arm	N	I-Claim
465	A	N	I-Claim
466	with	N	I-Claim
467	regard	N	I-Claim
468	to	N	I-Claim
469	response	N	I-Claim
470	rate	N	I-Claim
471	,	N	I-Claim
472	side	N	I-Claim
473	effects	N	I-Claim
474	,	N	I-Claim
475	and	N	I-Claim
476	QoL	N	I-Claim
477	.	N	I-Claim

478	Although	N	I-Claim
479	survival	N	I-Claim
480	was	N	I-Claim
481	not	N	I-Claim
482	improved	N	I-Claim
483	,	N	I-Claim
484	arm	N	I-Claim
485	B	N	I-Claim
486	offers	N	I-Claim
487	a	N	I-Claim
488	better	N	I-Claim
489	palliation	N	I-Claim
490	for	N	I-Claim
491	advanced	N	I-Claim
492	NSCLC	N	I-Claim
493	patients	N	I-Claim
494	than	N	I-Claim
495	arm	N	I-Claim
496	A	N	I-Claim
497	.	N	I-Claim

1	In	N	O
2	1980	N	O
3	the	N	O
4	EORTC-BCCG	N	O
5	initiated	N	O
6	a	N	O
7	multicentre	N	O
8	randomised	N	O
9	clinical	N	O
10	trial	N	O
11	comparing	N	O
12	modified	N	O
13	radical	N	O
14	mastectomy	N	O
15	(	N	O
16	MRM	N	O
17	)	N	O
18	with	N	O
19	breast-conserving	N	O
20	therapy	N	O
21	(	N	O
22	BCT	N	O
23	)	N	O
24	in	N	O
25	stage	N	O
26	I	N	O
27	and	N	O
28	II	N	O
29	breast	N	O
30	cancer	N	O
31	.	N	O

32	The	N	O
33	main	N	O
34	endpoint	N	O
35	of	N	O
36	the	N	O
37	trial	N	O
38	was	N	O
39	survival	N	O
40	.	N	O

41	A	N	O
42	brief	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	(	N	O
47	QoL	N	O
48	)	N	O
49	questionnaire	N	O
50	consisting	N	O
51	of	N	O
52	two	N	O
53	multi-item	N	O
54	scales	N	O
55	(	N	O
56	body	N	O
57	image	N	O
58	and	N	O
59	fear	N	O
60	of	N	O
61	recurrence	N	O
62	)	N	O
63	and	N	O
64	two	N	O
65	single	N	O
66	items	N	O
67	(	N	O
68	satisfaction	N	O
69	with	N	O
70	treatment	N	O
71	and	N	O
72	cosmetic	N	O
73	result	N	O
74	)	N	O
75	was	N	O
76	included	N	O
77	in	N	O
78	the	N	O
79	trial	N	O
80	.	N	O

81	A	N	O
82	cosmetic	N	O
83	evaluation	N	O
84	of	N	O
85	the	N	O
86	breast	N	O
87	after	N	O
88	conservative	N	O
89	surgery	N	O
90	was	N	O
91	also	N	O
92	performed	N	O
93	.	N	O

94	This	N	O
95	report	N	O
96	concentrates	N	O
97	on	N	O
98	the	N	O
99	results	N	O
100	of	N	O
101	the	N	O
102	QoL	N	O
103	study	N	O
104	and	N	O
105	the	N	O
106	cosmetic	N	O
107	evaluation	N	O
108	.	N	O

109	Multitrait	N	O
110	scaling	N	O
111	analysis	N	O
112	was	N	O
113	employed	N	O
114	to	N	O
115	verify	N	O
116	the	N	O
117	hypothesised	N	O
118	scale	N	O
119	structure	N	O
120	of	N	O
121	the	N	O
122	questionnaire	N	O
123	.	N	O

124	Treatment	N	O
125	comparison	N	O
126	of	N	O
127	the	N	O
128	QoL	N	O
129	scores	N	O
130	at	N	O
131	2	N	O
132	years	N	O
133	post-treatment	N	O
134	was	N	O
135	performed	N	O
136	using	N	O
137	a	N	O
138	stratified	N	O
139	Wilcoxon	N	O
140	rank	N	O
141	sum	N	O
142	test	N	O
143	.	N	O

144	Both	N	O
145	patients	N	O
146	'	N	O
147	and	N	O
148	doctors	N	O
149	'	N	O
150	ratings	N	O
151	of	N	O
152	the	N	O
153	cosmetic	N	O
154	result	N	O
155	were	N	O
156	documented	N	O
157	on	N	O
158	the	N	O
159	clinical	N	O
160	follow-up	N	O
161	form	N	O
162	.	N	O

163	A	N	O
164	multivariate	N	O
165	analysis	N	O
166	was	N	O
167	performed	N	O
168	to	N	O
169	identify	N	O
170	which	N	O
171	factors	N	O
172	influenced	N	O
173	the	N	O
174	cosmetic	N	O
175	outcome	N	O
176	.	N	O

177	In	N	O
178	total	N	O
179	,	N	O
180	127	N	O
181	patients	N	O
182	in	N	O
183	the	N	O
184	MRM	N	O
185	arm	N	O
186	and	N	O
187	151	N	O
188	in	N	O
189	the	N	O
190	BCT	N	O
191	arm	N	O
192	completed	N	O
193	a	N	O
194	QoL	N	O
195	questionnaire	N	O
196	at	N	O
197	approximately	N	O
198	2	N	O
199	years	N	O
200	after	N	O
201	randomisation	N	O
202	(	N	O
203	months	N	O
204	25-36	N	O
205	)	N	O
206	.	N	O

207	The	N	I-Premise
208	Cronbach	N	I-Premise
209	's	N	I-Premise
210	alpha	N	I-Premise
211	coefficients	N	I-Premise
212	were	N	I-Premise
213	0.79	N	I-Premise
214	and	N	I-Premise
215	0.73	N	I-Premise
216	for	N	I-Premise
217	the	N	I-Premise
218	body	N	I-Premise
219	image	N	I-Premise
220	and	N	I-Premise
221	fear	N	I-Premise
222	of	N	I-Premise
223	recurrence	N	I-Premise
224	scales	N	I-Premise
225	,	N	I-Premise
226	respectively	N	I-Premise
227	.	N	I-Premise

228	Significant	N	I-Premise
229	benefit	N	I-Premise
230	in	N	I-Premise
231	body	N	I-Premise
232	image	N	I-Premise
233	and	N	I-Premise
234	satisfaction	N	I-Premise
235	with	N	I-Premise
236	treatment	N	I-Premise
237	was	N	I-Premise
238	observed	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	BCT	N	I-Premise
242	patients	N	I-Premise
243	.	N	I-Premise

244	No	N	I-Premise
245	significant	N	I-Premise
246	difference	N	I-Premise
247	was	N	I-Premise
248	observed	N	I-Premise
249	in	N	I-Premise
250	fear	N	I-Premise
251	of	N	I-Premise
252	recurrence	N	I-Premise
253	between	N	I-Premise
254	the	N	I-Premise
255	two	N	I-Premise
256	groups	N	I-Premise
257	.	N	I-Premise

258	Ratings	N	I-Premise
259	of	N	I-Premise
260	cosmetic	N	I-Premise
261	results	N	I-Premise
262	decreased	N	I-Premise
263	with	N	I-Premise
264	time	N	I-Premise
265	,	N	I-Premise
266	in	N	I-Premise
267	line	N	I-Premise
268	with	N	I-Premise
269	clinical	N	I-Premise
270	observations	N	I-Premise
271	of	N	I-Premise
272	long-term	N	I-Premise
273	side-effects	N	I-Premise
274	of	N	I-Premise
275	radiotherapy	N	I-Premise
276	.	N	I-Premise

277	Wide	N	I-Claim
278	excision	N	I-Claim
279	appeared	N	I-Claim
280	to	N	I-Claim
281	be	N	I-Claim
282	the	N	I-Claim
283	most	N	I-Claim
284	important	N	I-Claim
285	predictive	N	I-Claim
286	factor	N	I-Claim
287	for	N	I-Claim
288	poor	N	I-Claim
289	cosmetic	N	I-Claim
290	result	N	I-Claim
291	.	N	I-Claim

292	In	N	I-Claim
293	this	N	I-Claim
294	multicentre	N	I-Claim
295	randomised	N	I-Claim
296	study	N	I-Claim
297	,	N	I-Claim
298	BCT	N	I-Claim
299	helped	N	I-Claim
300	to	N	I-Claim
301	maintain	N	I-Claim
302	the	N	I-Claim
303	patients	N	I-Claim
304	'	N	I-Claim
305	body	N	I-Claim
306	image	N	I-Claim
307	,	N	I-Claim
308	resulted	N	I-Claim
309	in	N	I-Claim
310	higher	N	I-Claim
311	satisfaction	N	I-Claim
312	with	N	I-Claim
313	treatment	N	I-Claim
314	and	N	I-Claim
315	yielded	N	I-Claim
316	no	N	I-Claim
317	significant	N	I-Claim
318	difference	N	I-Claim
319	from	N	I-Claim
320	MRM	N	I-Claim
321	with	N	I-Claim
322	respect	N	I-Claim
323	to	N	I-Claim
324	fear	N	I-Claim
325	of	N	I-Claim
326	recurrence	N	I-Claim
327	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	tolerability	N	O
7	of	N	O
8	'Casodex	N	O
9	'	N	O
10	monotherapy	N	O
11	(	N	O
12	150	N	O
13	mg	N	O
14	daily	N	O
15	)	N	O
16	for	N	O
17	metastatic	N	O
18	and	N	O
19	locally	N	O
20	advanced	N	O
21	prostate	N	O
22	cancer	N	O
23	.	N	O

24	A	N	O
25	total	N	O
26	of	N	O
27	1,453	N	O
28	patients	N	O
29	with	N	O
30	either	N	O
31	confirmed	N	O
32	metastatic	N	O
33	disease	N	O
34	(	N	O
35	M1	N	O
36	)	N	O
37	,	N	O
38	or	N	O
39	T3/T4	N	O
40	non-metastatic	N	O
41	disease	N	O
42	with	N	O
43	elevated	N	O
44	prostate-specific	N	O
45	antigen	N	O
46	(	N	O
47	M0	N	O
48	)	N	O
49	were	N	O
50	recruited	N	O
51	into	N	O
52	one	N	O
53	of	N	O
54	two	N	O
55	identical	N	O
56	,	N	O
57	multicentre	N	O
58	,	N	O
59	randomised	N	O
60	studies	N	O
61	to	N	O
62	compare	N	O
63	'Casodex	N	O
64	'	N	O
65	150	N	O
66	mg/day	N	O
67	with	N	O
68	castration	N	O
69	.	N	O

70	The	N	O
71	protocols	N	O
72	allowed	N	O
73	for	N	O
74	combined	N	O
75	analysis	N	O
76	.	N	O

77	At	N	I-Premise
78	a	N	I-Premise
79	median	N	I-Premise
80	follow-up	N	I-Premise
81	period	N	I-Premise
82	of	N	I-Premise
83	approximately	N	I-Premise
84	100	N	I-Premise
85	weeks	N	I-Premise
86	for	N	I-Premise
87	both	N	I-Premise
88	studies	N	I-Premise
89	,	N	I-Premise
90	'Casodex	N	I-Premise
91	'	N	I-Premise
92	150	N	I-Premise
93	mg	N	I-Premise
94	was	N	I-Premise
95	found	N	I-Premise
96	to	N	I-Premise
97	be	N	I-Premise
98	less	N	I-Premise
99	effective	N	I-Premise
100	than	N	I-Premise
101	castration	N	I-Premise
102	in	N	I-Premise
103	patients	N	I-Premise
104	with	N	I-Premise
105	metastatic	N	I-Premise
106	disease	N	I-Premise
107	(	N	I-Premise
108	M1	N	I-Premise
109	)	N	I-Premise
110	at	N	I-Premise
111	entry	N	I-Premise
112	(	N	I-Premise
113	hazard	N	I-Premise
114	ratio	N	I-Premise
115	of	N	I-Premise
116	1.30	N	I-Premise
117	for	N	I-Premise
118	time	N	I-Premise
119	to	N	I-Premise
120	death	N	I-Premise
121	)	N	I-Premise
122	with	N	I-Premise
123	a	N	I-Premise
124	difference	N	I-Premise
125	in	N	I-Premise
126	median	N	I-Premise
127	survival	N	I-Premise
128	of	N	I-Premise
129	6	N	I-Premise
130	weeks	N	I-Premise
131	.	N	I-Premise

132	In	N	I-Premise
133	symptomatic	N	I-Premise
134	M1	N	I-Premise
135	patients	N	I-Premise
136	,	N	I-Premise
137	'Casodex	N	I-Premise
138	'	N	I-Premise
139	was	N	I-Premise
140	associated	N	I-Premise
141	with	N	I-Premise
142	a	N	I-Premise
143	statistically	N	I-Premise
144	significant	N	I-Premise
145	improvement	N	I-Premise
146	in	N	I-Premise
147	subjective	N	I-Premise
148	response	N	I-Premise
149	(	N	I-Premise
150	70	N	I-Premise
151	%	N	I-Premise
152	)	N	I-Premise
153	compared	N	I-Premise
154	with	N	I-Premise
155	castration	N	I-Premise
156	(	N	I-Premise
157	58	N	I-Premise
158	%	N	I-Premise
159	)	N	I-Premise
160	.	N	I-Premise

161	Analysis	N	I-Premise
162	of	N	I-Premise
163	a	N	I-Premise
164	validated	N	I-Premise
165	quality-of-life	N	I-Premise
166	questionnaire	N	I-Premise
167	proved	N	I-Premise
168	an	N	I-Premise
169	advantage	N	I-Premise
170	for	N	I-Premise
171	'Casodex	N	I-Premise
172	'	N	I-Premise
173	in	N	I-Premise
174	sexual	N	I-Premise
175	interest	N	I-Premise
176	and	N	I-Premise
177	physical	N	I-Premise
178	capacity	N	I-Premise
179	.	N	I-Premise

180	'Casodex	N	I-Premise
181	'	N	I-Premise
182	had	N	I-Premise
183	a	N	I-Premise
184	substantially	N	I-Premise
185	lower	N	I-Premise
186	incidence	N	I-Premise
187	of	N	I-Premise
188	hot	N	I-Premise
189	flushes	N	I-Premise
190	compared	N	I-Premise
191	to	N	I-Premise
192	castration	N	I-Premise
193	(	N	I-Premise
194	6-13	N	I-Premise
195	%	N	I-Premise
196	compared	N	I-Premise
197	with	N	I-Premise
198	39-44	N	I-Premise
199	%	N	I-Premise
200	)	N	I-Premise
201	and	N	I-Premise
202	the	N	I-Premise
203	most	N	I-Premise
204	commonly	N	I-Premise
205	reported	N	I-Premise
206	adverse	N	I-Premise
207	events	N	I-Premise
208	were	N	I-Premise
209	those	N	I-Premise
210	expected	N	I-Premise
211	for	N	I-Premise
212	a	N	I-Premise
213	potent	N	I-Premise
214	antiandrogen	N	I-Premise
215	.	N	I-Premise

216	However	N	O
217	,	N	O
218	in	N	I-Claim
219	patients	N	I-Claim
220	with	N	I-Claim
221	M0	N	I-Claim
222	disease	N	I-Claim
223	at	N	I-Claim
224	entry	N	I-Claim
225	,	N	I-Claim
226	the	N	I-Claim
227	data	N	I-Claim
228	are	N	I-Claim
229	still	N	I-Claim
230	immature	N	I-Claim
231	with	N	I-Claim
232	only	N	I-Claim
233	13	N	I-Claim
234	%	N	I-Claim
235	of	N	I-Claim
236	M0	N	I-Claim
237	patients	N	I-Claim
238	having	N	I-Claim
239	died	N	I-Claim
240	.	N	I-Claim

241	An	N	I-Claim
242	initial	N	I-Claim
243	analysis	N	I-Claim
244	of	N	I-Claim
245	this	N	I-Claim
246	immature	N	I-Claim
247	data	N	I-Claim
248	has	N	I-Claim
249	suggested	N	I-Claim
250	that	N	I-Claim
251	the	N	I-Claim
252	results	N	I-Claim
253	in	N	I-Claim
254	these	N	I-Claim
255	patients	N	I-Claim
256	may	N	I-Claim
257	be	N	I-Claim
258	different	N	I-Claim
259	to	N	I-Claim
260	those	N	I-Claim
261	obtained	N	I-Claim
262	in	N	I-Claim
263	patients	N	I-Claim
264	with	N	I-Claim
265	M1	N	I-Claim
266	disease	N	I-Claim
267	.	N	I-Claim

268	A	N	O
269	further	N	O
270	survival	N	O
271	analysis	N	O
272	in	N	O
273	patients	N	O
274	with	N	O
275	M0	N	O
276	disease	N	O
277	is	N	O
278	therefore	N	O
279	planned	N	O
280	when	N	O
281	the	N	O
282	data	N	O
283	are	N	O
284	more	N	O
285	mature	N	O
286	.	N	O

287	'Casodex	N	I-Claim
288	'	N	I-Claim
289	150	N	I-Claim
290	mg	N	I-Claim
291	is	N	I-Claim
292	less	N	I-Claim
293	effective	N	I-Claim
294	than	N	I-Claim
295	castration	N	I-Claim
296	in	N	I-Claim
297	patients	N	I-Claim
298	with	N	I-Claim
299	M1	N	I-Claim
300	disease	N	I-Claim
301	.	N	I-Claim

302	However	N	O
303	,	N	O
304	'Casodex	N	I-Claim
305	'	N	I-Claim
306	has	N	I-Claim
307	shown	N	I-Claim
308	a	N	I-Claim
309	benefit	N	I-Claim
310	in	N	I-Claim
311	terms	N	I-Claim
312	of	N	I-Claim
313	quality	N	I-Claim
314	of	N	I-Claim
315	life	N	I-Claim
316	and	N	I-Claim
317	subjective	N	I-Claim
318	response	N	I-Claim
319	when	N	I-Claim
320	compared	N	I-Claim
321	to	N	I-Claim
322	castration	N	I-Claim
323	and	N	I-Claim
324	has	N	I-Claim
325	an	N	I-Claim
326	acceptable	N	I-Claim
327	tolerability	N	I-Claim
328	profile	N	I-Claim
329	.	N	I-Claim

330	Thus	N	I-MajorClaim
331	'Casodex	N	I-MajorClaim
332	'	N	I-MajorClaim
333	150	N	I-MajorClaim
334	mg	N	I-MajorClaim
335	monotherapy	N	I-MajorClaim
336	is	N	I-MajorClaim
337	an	N	I-MajorClaim
338	option	N	I-MajorClaim
339	for	N	I-MajorClaim
340	patients	N	I-MajorClaim
341	with	N	I-MajorClaim
342	M1	N	I-MajorClaim
343	prostate	N	I-MajorClaim
344	cancer	N	I-MajorClaim
345	for	N	I-MajorClaim
346	whom	N	I-MajorClaim
347	surgical	N	I-MajorClaim
348	or	N	I-MajorClaim
349	medical	N	I-MajorClaim
350	castration	N	I-MajorClaim
351	is	N	I-MajorClaim
352	not	N	I-MajorClaim
353	indicated	N	I-MajorClaim
354	or	N	I-MajorClaim
355	is	N	I-MajorClaim
356	not	N	I-MajorClaim
357	acceptable	N	I-MajorClaim
358	.	N	I-MajorClaim

